
<!doctype html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>QBank: NEET PG</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <script type="text/javascript" async src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.7/latest.js?config=TeX-MML-AM_CHTML"></script>
    <script type="text/x-mathjax-config">
        MathJax.Hub.Config({
            "HTML-CSS": { preferredFont: "TeX", linebreaks: { automatic: true } },
            CommonHTML: { linebreaks: { automatic: true } },
            SVG: { linebreaks: { automatic: true } }
        });
    </script>
    <style>
        /* --- Global Styles & Variables --- */
        :root {
            --bg-color: #f4f7fa;
            --surface-color: #ffffff;
            --on-surface-color: #1c1b1f;
            --primary-color: #006494;
            --primary-variant: #004c75;
            --secondary-color: #025e73;
            --correct-color: #146c2e;
            --incorrect-color: #ba1a1a;
            --correct-bg: #c8e6c9;
            --incorrect-bg: #f8d7da;
            --border-color: #c1c7cd;
            --shadow-1: 0px 2px 4px rgba(0,0,0,0.1);
            --shadow-2: 0px 4px 12px rgba(0,0,0,0.12);
            --font-family: 'Inter', -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
            --sidebar-width: 320px;
            --category-bg: #e3f2fd;
            --subject-bg: #e8f5e9;
            --module-bg: #fff3e0;
        }

        /* --- Dark Theme Variables --- */
        body.dark-mode {
            --bg-color: #121212;
            --surface-color: #1e1e1e;
            --on-surface-color: #e0e0e0;
            --primary-color: #4fc3f7;
            --primary-variant: #29b6f6;
            --secondary-color: #4dd0e1;
            --border-color: #333;
            --correct-bg: #1b5e20;
            --incorrect-bg: #b71c1c;
            --category-bg: #1a237e;
            --subject-bg: #1b5e20;
            --module-bg: #e65100;
        }

        html, body {
            margin: 0;
            padding: 0;
            width: 100%;
            min-height: 100%;
            background-color: var(--bg-color);
            color: var(--on-surface-color);
            font-family: var(--font-family);
            font-size: 16px;
            line-height: 1.6;
            -webkit-font-smoothing: antialiased;
            -moz-osx-font-smoothing: grayscale;
            transition: background-color 0.3s ease, color 0.3s ease;
        }

        /* --- Layout --- */
        .app-container {
            display: flex;
            min-height: 100vh;
            overflow: hidden;
        }
        .sidebar {
            width: var(--sidebar-width);
            flex-shrink: 0;
            background-color: var(--surface-color);
            border-right: 1px solid var(--border-color);
            display: flex;
            flex-direction: column;
            overflow-y: auto;
            transition: transform 0.3s ease;
            box-shadow: var(--shadow-1);
        }
        .main-content {
            flex-grow: 1;
            display: flex;
            flex-direction: column;
            min-height: 0;
            overflow: hidden;
        }
        .content-area {
            flex-grow: 1;
            padding: 24px 24px 120px;
            overflow-y: auto;
            -webkit-overflow-scrolling: touch;
        }

        /* --- Header --- */
        .header {
            background-color: var(--surface-color);
            padding: 16px 24px;
            border-bottom: 1px solid var(--border-color);
            box-shadow: var(--shadow-1);
            z-index: 10;
            display: flex;
            justify-content: space-between;
            align-items: center;
            flex-wrap: wrap;
            gap: 16px;
        }
        .header h1 {
            margin: 0;
            font-size: 1.5em;
            font-weight: 700;
            color: var(--primary-color);
        }
        .header .subtitle {
            margin: 4px 0 0 0;
            font-size: 0.9em;
            color: #5f6368;
        }
        body.dark-mode .header .subtitle { color: #aaa; }
        
        .header-controls {
            display: flex;
            align-items: center;
            gap: 16px;
        }
        .theme-toggle {
            background: none;
            border: none;
            font-size: 1.2em;
            cursor: pointer;
            color: var(--on-surface-color);
            padding: 8px;
            border-radius: 50%;
            transition: background-color 0.3s ease;
        }
        .theme-toggle:hover {
            background-color: var(--bg-color);
        }

        /* --- Sidebar Navigation --- */
        .sidebar-header {
            padding: 16px;
            font-weight: 600;
            font-size: 1.1em;
            color: var(--primary-color);
            border-bottom: 1px solid var(--border-color);
            text-align: center;
            background-color: var(--primary-color);
            color: white;
        }
        .nav-list {
            list-style: none;
            padding: 0;
            margin: 0;
        }
        .nav-item {
            border-bottom: 1px solid var(--border-color);
        }
        .nav-link {
            display: flex;
            align-items: center;
            padding: 12px 16px;
            cursor: pointer;
            transition: background-color 0.2s ease;
            position: relative;
        }
        .nav-link:hover {
            background-color: var(--bg-color);
        }
        .nav-link.active {
            background-color: var(--primary-color);
            color: white;
        }
        .nav-link.active .nav-icon {
            color: white;
        }
        .nav-icon {
            margin-right: 12px;
            width: 20px;
            text-align: center;
            color: var(--primary-color);
        }
        .nav-text {
            flex-grow: 1;
            font-weight: 500;
        }
        .nav-count {
            background-color: var(--primary-color);
            color: white;
            border-radius: 12px;
            padding: 2px 8px;
            font-size: 0.8em;
            font-weight: 600;
        }
        .nav-link.active .nav-count {
            background-color: white;
            color: var(--primary-color);
        }
        .expand-icon {
            margin-left: 8px;
            transition: transform 0.2s ease;
        }
        .nav-item.expanded > .nav-link .expand-icon {
            transform: rotate(90deg);
        }
        .sub-nav {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.3s ease;
            background-color: var(--bg-color);
        }
        .nav-item.expanded > .sub-nav {
            max-height: 2000px;
        }
        .sub-nav .nav-link {
            padding-left: 48px;
            font-size: 0.95em;
        }
        .sub-nav .sub-nav .nav-link {
            padding-left: 72px;
            font-size: 0.9em;
        }
        .category-item .nav-link {
            background-color: var(--category-bg);
            font-weight: 600;
        }
        .subject-item .nav-link {
            background-color: var(--subject-bg);
        }
        .module-item .nav-link {
            background-color: var(--module-bg);
        }
        body.dark-mode .category-item .nav-link {
            background-color: var(--category-bg);
        }
        body.dark-mode .subject-item .nav-link {
            background-color: var(--subject-bg);
        }
        body.dark-mode .module-item .nav-link {
            background-color: var(--module-bg);
        }

        /* --- Breadcrumb --- */
        .breadcrumb {
            padding: 12px 24px;
            background-color: var(--surface-color);
            border-bottom: 1px solid var(--border-color);
            font-size: 0.9em;
        }
        .breadcrumb-item {
            display: inline-block;
        }
        .breadcrumb-item:not(:last-child)::after {
            content: " > ";
            margin: 0 8px;
            color: var(--primary-color);
        }

        /* --- Question Card --- */
        .card {
            background-color: var(--surface-color);
            border-radius: 12px;
            padding: 24px;
            margin-bottom: 24px;
            box-shadow: var(--shadow-1);
            transition: box-shadow 0.3s ease, transform 0.3s ease;
            border: 1px solid var(--border-color);
        }
        .card:hover {
            box-shadow: var(--shadow-2);
            transform: translateY(-2px);
        }
        .question-header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-bottom: 16px;
        }
        .question-number {
            font-weight: 700;
            font-size: 1.1em;
            color: var(--secondary-color);
        }
        .mark-review-btn {
            background: none;
            border: 1px solid var(--border-color);
            padding: 6px 12px;
            border-radius: 16px;
            cursor: pointer;
            font-size: 0.9em;
            color: var(--on-surface-color);
            transition: all 0.2s ease;
        }
        .mark-review-btn:hover {
            background-color: var(--bg-color);
        }
        .mark-review-btn.marked {
            background-color: var(--primary-color);
            color: white;
            border-color: var(--primary-color);
        }
        .question-text {
            font-size: 1.05em;
            margin-bottom: 20px;
        }
        .options-list {
            list-style: none;
            padding: 0;
            margin: 0;
        }
        .options-list li {
            border: 1px solid var(--border-color);
            border-radius: 8px;
            padding: 16px;
            margin-bottom: 12px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            align-items: flex-start;
        }
        .options-list li:hover:not(.locked) {
            border-color: var(--primary-color);
            background-color: var(--bg-color);
        }
        .options-list li .option-label {
            font-weight: 600;
            color: var(--primary-color);
            margin-right: 12px;
            min-width: 24px;
        }
        .options-list li.user-correct {
            border-color: var(--correct-color);
            background-color: var(--correct-bg);
            color: white;
        }
        .options-list li.user-incorrect {
            border-color: var(--incorrect-color);
            background-color: var(--incorrect-bg);
            color: white;
        }
        .options-list li.correct-reveal {
            border-color: var(--correct-color);
            background-color: var(--correct-bg);
            color: white;
            font-weight: 600;
            box-shadow: 0 0 8px rgba(20, 108, 46, 0.4);
        }
        .options-list li.locked {
            cursor: not-allowed;
        }
        .explanation-container {
            margin-top: 20px;
        }
        .show-explanation-btn {
            background-color: var(--primary-color);
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 20px;
            font-weight: 600;
            cursor: pointer;
            transition: background-color 0.2s ease;
        }
        .show-explanation-btn:hover {
            background-color: var(--primary-variant);
        }
        .explanation {
            margin-top: 16px;
            padding: 16px;
            background-color: var(--bg-color);
            border-left: 5px solid var(--primary-color);
            border-radius: 4px;
            display: none;
        }
        .explanation p:first-child { margin-top: 0; }
        .explanation p:last-child { margin-bottom: 0; }
        .correct-answer-label {
            font-weight: 700;
            color: var(--correct-color);
        }
        body.dark-mode .correct-answer-label { color: #81c784; }
        
        /* --- Progress Bar --- */
        .progress-container {
            width: 100%;
            height: 6px;
            background-color: var(--border-color);
            border-radius: 3px;
            overflow: hidden;
            margin-top: 8px;
        }
        .progress-bar {
            height: 100%;
            background-color: var(--primary-color);
            width: 0%;
            transition: width 0.4s ease;
        }
        
        /* --- Media & Math --- */
        .question-text img, .explanation img {
            max-width: 100%;
            height: auto;
            display: block;
            margin: 16px auto;
            border-radius: 8px;
            box-shadow: var(--shadow-1);
        }
        .MathJax_Display, .MathJax {
            overflow-x: auto;
            overflow-y: hidden;
        }

        /* --- Mobile Responsiveness --- */
        @media (max-width: 768px) {
            .header {
                padding: 12px 16px;
            }
            .header h1 { font-size: 1.2em; }
            .header-controls {
                width: 100%;
                justify-content: space-between;
            }
            .app-container {
                flex-direction: column;
                height: auto;
                min-height: 100vh;
                overflow: visible;
            }
            .sidebar {
                width: 100%;
                height: auto;
                border-right: none;
                border-bottom: 1px solid var(--border-color);
                position: fixed;
                top: 0;
                left: 0;
                z-index: 20;
                transform: translateY(-100%);
            }
            .sidebar.open {
                transform: translateY(0);
            }
            .sidebar-header {
                text-align: center;
            }
            .nav-list {
                display: flex;
                padding: 8px 16px;
                overflow-x: auto;
                -webkit-overflow-scrolling: touch;
                scrollbar-width: none;
            }
            .nav-list::-webkit-scrollbar { display: none; }
            .nav-list li {
                flex-shrink: 0;
                padding: 8px 16px;
                margin-right: 8px;
                border-radius: 16px;
                border: 1px solid var(--border-color);
                font-size: 0.9em;
                white-space: nowrap;
            }
            .nav-list li.active {
                border-color: var(--primary-color);
                background-color: var(--primary-color);
                color: white;
            }
            .main-content {
                overflow: visible;
            }
            .content-area {
                padding: 16px;
                margin-top: 60px; /* Space for mobile header */
                overflow: visible;
            }
            .card {
                padding: 16px;
            }
        }
    </style>
</head>
<body>

    <div class="app-container">
        <div class="sidebar" id="sidebar">
            <div class="sidebar-header">Course Navigation</div>
            <ul class="nav-list" id="nav-list">
                <!-- Navigation will be injected here by JS -->
            </ul>
        </div>
        <div class="main-content">
            <div class="header">
                <div>
                    <h1>QBank: NEET PG</h1>
                    <p class="subtitle">NEET PG | Total Questions: <span id="total-q-count">0</span></p>
                    <div class="progress-container"><div class="progress-bar" id="progress-bar"></div></div>
                </div>
                <div class="header-controls">
                    <button class="theme-toggle" id="theme-toggle"><i class="fas fa-moon"></i></button>
                </div>
            </div>
            <div class="breadcrumb" id="breadcrumb">
                <span class="breadcrumb-item">Home</span>
            </div>
            <div class="content-area" id="questions-container">
                <p>Please select a category, subject, or module to begin.</p>
            </div>
        </div>
    </div>

<script>
    // DATA IS INJECTED HERE BY PYTHON
    const COURSE_DATA = {"courseId": 1, "courseName": "NEET PG", "total_questions": 22635, "categories": [{"categoryId": "main", "name": "Main", "subjects": [{"subjectId": 1000005, "name": "Pharmacology", "modules": [{"moduleId": 1008532, "name": "Basic Principles of Pharmacology (Part 1)", "questions": [{"id": "1166325", "html_qtxt": "A one-year-old is brought to the ED having just ingested a large overdose of \"X\", which is a weak acid with a pKa of 4.0. It is capable of entering most tissues. On physical examination, the heart rate is 130/min, blood pressure 100/60 mm Hg, and respiratory rate 30/min. Which of the following statements about management in this case of \"X\" overdose is incorrect?<br>A. Absorption of the drug would be faster from the stomach than from the small intestine.<br>B. More of the drug would be ionised at blood pH than at stomach pH.<br>C. Urinary excretion would be accelerated by administration of NH4Cl, an acidifying agent.<br>D. Urinary excretion would be accelerated by giving NaHCO3, an alkalinising agent<br>E. Absorption of the drug would be slower from the stomach than from the small intestine.<br>F. More of the drug would be unionised at blood pH than at stomach pH.", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Given scenario of overdose of drug \"X\", need understanding of the <strong>Henderson-Hasselbalch</strong> <strong>Relationship</strong> for management.</li>\n<li>The Henderson-Hasselbalch relationship is clinically important when it is necessary to estimate or alter the partition of drugs between compartments of differing pH.</li>\n<li><strong>Statement A (Correct):</strong> Weak acids are better absorbed in the <strong>acidic stomach</strong> than in the <strong>alkaline intestine</strong> because they remain unionised at acidic pH.</li>\n<li><strong>Statement B (Correct):</strong> At <strong>blood pH</strong>, a weak acid (pKa 4.0) is mostly <strong>ionised</strong> (since pH > pKa), which is true.</li>\n<li><strong>Statement C (Incorrect): NH<sub>4</sub>Cl (acidifying urine)</strong> would favour the <strong>reabsorption</strong> (not excretion) of weak acids like drug \"X\", by increasing the proportion of the unionised form in the renal tubule. Hence, this would <strong>decrease</strong> excretion.</li>\n<li><strong>Statement D (Correct):</strong> <strong>Alkalinization</strong> of urine using <strong>NaHCO<sub>3</sub></strong> promotes the ionisation of weak acids, enhancing their excretion, a standard principle in overdose management.</li>\n<li><strong>Statement E (Incorrect): </strong>Absorption of weak acids is typically <strong>faster from the stomach</strong>, where the acidic environment favours the <strong>unionised form</strong> of the drug. Therefore, absorption would be <strong>slower from the intestine</strong> due to a higher pH.</li>\n<li><strong>Statement F (Incorrect): </strong>At <strong>blood pH (7.4)</strong>, a weak acid with <strong>pKa = 4.0</strong> will be predominantly <strong>ionised</strong>, while in <strong>stomach pH (1-2)</strong>, the drug remains mostly <strong>unionised</strong>. Therefore, more of the drug is unionised at <strong>stomach pH</strong>, not blood pH.</li>\n</ul>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li><strong>Weak acids</strong> are absorbed better in <strong>acidic environments</strong> (stomach).</li>\n<li><strong>Ionised forms</strong> of drugs are <strong>not reabsorbed</strong> and are excreted in urine.</li>\n<li><strong>Alkalinising agents</strong> (e.g., NaHCO<sub>3</sub>) enhance weak acid excretion.</li>\n<li><strong>NH<sub>4</sub>Cl</strong> acidifies urine, favouring the <strong>reabsorption</strong> of weak acids.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240309f3e3dddd-ae43-441c-a7b7-6efcfd09ae48.jpg\">", "options": ["A, B &amp; C", "A, B &amp; D", "B, C &amp; F", "C, E &amp; F"], "html_options": ["A, B & C", "A, B & D", "B, C & F", "C, E & F"], "corr_idx": 3}, {"id": "1166329", "html_qtxt": "A 32-year-old female has acute bacterial rhino-sinusitis and is to receive an oral antibiotic. She complains of a headache and fever. Blood pressure is 100/70 mm Hg, heart rate 100/min, temperature 37.8 &deg;C (100.1 F). Amoxicillin is a weak organic acid with a pKa of 2. What percentage of a given dose will be in the water-soluble form in the duodenum at a pH of 4?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>This question tests the application of the <strong>Henderson-Hasselbalch equation</strong> in predicting the <strong>ionised (water-soluble) fraction</strong> of weak acids at a given pH.</li>\n<li>Amoxicillin is a <strong>weak acid</strong> (pKa = 2). When placed in an <strong>alkaline environment</strong> like the <strong>duodenum (pH = 4)</strong>, the <strong>ionised form</strong> of the drug predominates, and this form is <strong>water-soluble</strong> but <strong>less absorbable</strong> across lipid membranes.</li>\n</ul>\n<h4>Step-by-step calculation using Henderson-Hasselbalch:</h4>\n<p>pH = pKa + log(A<sup><span style=\"font-size: xx-small;\">-</span></sup>/HA)</p>\n<p>Where:</p>\n<ul>\n<li>A<sup>-</sup> = ionised (water-soluble) form</li>\n<li>HA = unionised (lipid-soluble) form</li>\n</ul>\n<p>Substituting:</p>\n<p>4 = 2 + log(A<sup>-</sup>/HA)</p>\n<p>&rArr; log(A<sup>-</sup>/HA)= 2</p>\n<p>&rArr;A<sup>-</sup>/HA = 10&#178;=100.</p>\n<p><strong>Ionised</strong> = 100, <strong>unionised</strong> = 1.</p>\n<p>Therefore, % ionised = 100/(100+1)&times;100 =100/101&times;100 &asymp; 99%</p>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li>Weak acids are <strong>mostly ionised in alkaline pH</strong> &rarr; more water-soluble</li>\n<li>Ionised form = <strong>less membrane permeable</strong>, more <strong>excretable</strong></li>\n<li>Henderson-Hasselbalch helps predict <strong>drug ionisation</strong> at physiological pH</li>\n</ul>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906b2bf4601-b628-4d66-ae15-c70cb98943ba.png\">", "options": ["1%", "99%", "90%", "0.1%"], "html_options": ["1%", "99%", "90%", "0.1%"], "corr_idx": 1}, {"id": "1166336", "html_qtxt": "In a clinical trial, Pretamycin, a new drug, was administered intravenously to 20 volunteers, and blood samples were taken for several hours. Several inactive metabolites were found, as well as declining concentrations of Pretamycin. A graph was prepared as shown below, with the Pretamycin plasma levels plotted on the concentration (mg/hr) ordinate and time on the X axis. It was concluded that the drug has first-order kinetics. From this graph, which line best correlates with the concentration of Pretamycin?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403092ea7807c-2128-41ee-a762-332995266e36.jpg\">", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li><strong>The correct line is Z</strong>, because it displays an <strong>exponential decline</strong> in drug concentration with time, which is the hallmark of <strong>first-order elimination kinetics</strong>.</li>\r\n<li>In <strong>first-order kinetics</strong>, a <strong>constant fraction</strong> of the drug is eliminated per unit time.</li>\r\n<li>As drug concentration decreases, the <strong>rate of elimination slows</strong>, producing a <strong>curved, exponential decay</strong> on a <strong>linear scale plot</strong>.</li>\r\n<li>This results in a <strong>non-linear (concave)</strong> curve as seen in <strong>line Z</strong> on the graph.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>W (Option A):</strong> This line shows a <strong>gentle linear decline</strong>, indicating a <strong>slow and constant rate of elimination</strong>, which is more characteristic of <strong>zero-order kinetics</strong>. In zero-order kinetics, <strong>a fixed amount</strong> of drug is eliminated per unit time <strong>regardless of concentration</strong>. Therefore, it does <strong>not</strong> fit first-order behaviour.</p>\r\n<p><strong>X (Option B):</strong> This line shows a <strong>more rapid linear fall</strong> in concentration over time. This again reflects <strong>zero-order kinetics</strong>, where drug elimination is <strong>not dependent</strong> on plasma concentration. Despite the steeper slope, the <strong>linear nature</strong> of the curve makes it incompatible with first-order kinetics.</p>\r\n<p><strong>Y (Option C):</strong> Y appears to show a <strong>partially curved decline</strong>, which might seem like a transition phase or a <strong>mixed-order</strong> or <strong>non-classical</strong> elimination. However, it does not reflect the classic <strong>exponential drop</strong> required for first-order elimination and is thus <strong>not ideal</strong> for this scenario.</p>\r\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240309e9f42d0c-48ea-413b-913c-b3f7b7357187.jpg\">\r\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240309a3b9da4f-edd6-4174-85bf-36743b26b97f.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>First-order kinetics</strong>: Rate &prop; Concentration &rarr; <strong>exponential decay</strong></li>\r\n<li><strong>Zero-order kinetics</strong>: Rate = Constant &rarr; <strong>linear decline</strong></li>\r\n<li>Graphs must be interpreted using the <strong>shape of the curve</strong>, not just the slope</li>\r\n<li>Most drugs follow <strong>first-order kinetics</strong> at therapeutic doses</li>\r\n</ul>", "options": ["W", "X", "Y", "Z"], "html_options": ["W", "X", "Y", "Z"], "corr_idx": 3}, {"id": "1166339", "html_qtxt": "Mr Shah is undergoing hemodialysis 3 days per week while awaiting a kidney transplant. He takes metformin for type 2 diabetes mellitus and was previously stabilised while his kidney function was adequate at a dosage of 500 mg twice daily, given orally. The plasma concentration at this dosage with normal kidney function was found to be 1.5mg/L. He has had 6 dialysis procedures, and metformin toxicity is suspected. A blood sample now shows a metformin concentration of 4.5 mg/L. What was Mr Shah's clearance (litre/24hr) of metformin while his kidney function was normal, and no,w respectively?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<p>To calculate drug clearance (<strong>Cl</strong>) at steady state, we apply the formula:</p>\n<p><strong>Cl = Rate of Drug Input </strong> &#247; <strong>Steady State Plasma Concentration (Cp)</strong></p>\n<ul>\n<li><strong>Dose (Rate In)</strong> = 500 mg &times; 2 = <strong>1000 mg/day</strong></li>\n<li><strong>Cp (normal)</strong> = 1.5 mg/L</li>\n<li><strong>Cp (now)</strong> = 4.5 mg/L</li>\n</ul>\n<h4>Normal Kidney Function:</h4>\n<p>Cl = 1000 mg/day &#247; 1.5 mg/L = 666.67 L/day &#8776; <strong>667 L/24hr.</strong></p>\n<h4>Current (Dialysis State):</h4>\n<p>Cl = 1000 mg/day &#247; 4.5 mg/L = 222.22 L/day <strong>&asymp; 222 L/24hr</strong></p>\n<p>This reduced clearance confirms <strong>accumulation and risk of toxicity</strong>, which is consistent with <strong>renal dysfunction</strong>, as <strong>metformin is cleared unchanged in urine</strong>.</p>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li><strong>Metformin is not metabolised</strong> and is eliminated almost entirely via the <strong>kidneys</strong>.</li>\n<li><strong>Reduced renal clearance</strong> results in <strong>accumulation</strong>, leading to toxicity (e.g., lactic acidosis).</li>\n<li><strong>Dose adjustments or withdrawal</strong> are critical in <strong>renal impairment</strong>.</li>\n</ul>", "options": ["300, 100", "450, 150", "667, 222", "500, 167"], "html_options": ["300, 100", "450, 150", "667, 222", "500, 167"], "corr_idx": 2}, {"id": "1166353", "html_qtxt": "A 24-year-old female with candidiasis is given a one-time 100 mg dose of oral fluconazole. Administration of the medication results in a peak plasma concentration of 20 micro-g/mL. What is the apparent volume of drug distribution?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<p>The <strong>volume of distribution (Vd)</strong> is calculated by the formula:</p>\n<p><strong>Vd = Amount of drug in the body(mg)</strong> &#247; <strong>Plasma concentration (mg/L)</strong></p>\n<ul>\n<li><strong>Dose administered</strong> = <strong>100 mg</strong></li>\n<li><strong>Plasma concentration</strong> = 20 &micro;g/mL =<strong> 20 mg/L</strong></li>\n</ul>\n<p>Vd = 100 mg 20 mg/L = <strong>5L</strong></p>\n<p>This means fluconazole appears to distribute in a fluid volume equivalent to <strong>5 litres</strong>, which corresponds to extracellular water.</p>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li><strong>Vd</strong> helps infer the <strong>extent of tissue penetration</strong>.</li>\n<li>A <strong>low Vd</strong> suggests the drug remains in the plasma; a <strong>high Vd</strong> indicates distribution into tissues or fat.</li>\n<li>Useful in <strong>loading dose</strong> calculations and <strong>toxicity assessment.</strong></li>\n</ul>", "options": ["0.5 L", "1L", "2 L", "5 L"], "html_options": ["0.5 L", "1L", "2 L", "5 L"], "corr_idx": 3}, {"id": "1166356", "html_qtxt": "A 17-year-old woman is given a prescription of fluconazole to be taken daily (q 12 h) for 3 days. The half-life is 12 h. How long will it take for the medication to reach 90% of its final steady state level?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>Drug elimination follows <strong>first-order kinetics</strong>, where a <strong>fixed fraction</strong> of the drug is removed per unit time (in this case, per half-life).</li>\r\n<li>For most drugs eliminated by this pathway, the fraction of the drug remaining in the body after successive half-lives is:</li>\r\n<li>After 1 half-life, 50% remains</li>\r\n<li>After 2 half-lives, 25% remains</li>\r\n<li>After 3 half-lives, 12.5% remains</li>\r\n<li>After 3.3 half-lives, ~10% remains (i.e., <strong>90% eliminated</strong>)</li>\r\n<li>To calculate the time it takes for a medication to reach 90% of its final steady state, you can use the formula.</li>\r\n</ul>\r\n<p>Time to reach 90% of <strong>Steady state = (3.3) x (t1/2).</strong></p>\r\n<ul>\r\n<li>Given that the <strong>half-life (t1/2) of fluconazole</strong> is 12 hours:</li>\r\n<li>Time to Reach 90% of Steady State = (3.3) * (12 hours) = 39.6 hours</li>\r\n<li>So, it will take approximately 39.6 hours for the medication to reach 90% of its final steady-state level.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>It typically takes <strong>3 half-lives</strong> to reach <strong>90% steady-state</strong>,</li>\r\n<li><strong>4-5 half-lives</strong> are needed to reach <strong>~ 95-97% steady-state</strong>,</li>\r\n<li>This principle is crucial when determining <strong>loading dose needs</strong> or predicting time to <strong>therapeutic effect</strong>.</li>\r\n</ul>", "options": ["20h", "30h", "40h", "50h"], "html_options": ["20h", "30h", "40h", "50h"], "corr_idx": 2}, {"id": "1166360", "html_qtxt": "A 55-year-old man with chronic cardiac failure was brought to the ED because of slurred speech and inappropriate behaviour. It turns out that he has not taken his digoxin for the last 2 weeks. The physician gives 125 micrograms as the standard dose. Twenty-four hours later, his serum levels were reported to be 2 ng/mL. The target therapeutic level is 8 ng/mL. What dose of digoxin should he receive?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<p>The formula used to calculate the new dose is:</p>\r\n<p><strong>D<sub><span style=\"font-size: xx-small;\">new</span></sub>= Vd (Target level - Current level)</strong></p>\r\n<p>Where:</p>\r\n<ul>\r\n<li>Vd is the volume of distribution</li>\r\n<li>Target level is the desired therapeutic level</li>\r\n<li>The current level is the measured current level</li>\r\n</ul>\r\n<p>In this case:</p>\r\n<ul>\r\n<li>Current level = 2 ng/mL</li>\r\n<li>Target therapeutic level = 8 ng/mL</li>\r\n<li>Standard dose = 125 micrograms</li>\r\n</ul>\r\n<p>First, we need to calculate the volume of distribution (Vd):&nbsp;</p>\r\n<p>Vd = Standard dose / Current level Vd = 125 micrograms / 2 ng/mL = 62.5 L</p>\r\n<p>Now, calculate the new dose (D<sub><span style=\"font-size: xx-small;\">new</span></sub>):</p>\r\n<p style=\"padding-left: 30px;\">D<sub><span style=\"font-size: xx-small;\">new</span></sub>= Vd (Target level - Current level)</p>\r\n<p style=\"padding-left: 30px;\">                           = 62.5 L (8 ng/mL - 2 ng/mL)</p>\r\n<p style=\"padding-left: 30px;\">                           = 62.6 L x 6 ng/mL = <strong>375 ng</strong></p>\r\n<p>To express this in micrograms (since 1 microgram = 1000 ng), D<sub><span style=\"font-size: xx-small;\">new</span></sub>= 375 ng * (1 microgram / 1000 ng) = 0.375 micrograms.</p>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<p><strong>Digoxin Has a Narrow Therapeutic Window:</strong></p>\r\n<ul>\r\n<li>Target levels: <strong>8-2.0 ng/mL</strong> (but 8 ng/mL was asked hypothetically for concept testing).</li>\r\n<li>The toxicity risk is <strong>high</strong> with even modest overdose-precise dosing is crucial.</li>\r\n</ul>", "options": ["325 micrograms", "350 micrograms", "375 micrograms", "300 micrograms"], "html_options": ["325 micrograms", "350 micrograms", "375 micrograms", "300 micrograms"], "corr_idx": 2}, {"id": "1166377", "html_qtxt": "A 60-year-old man is evaluated for Infective endocarditis. He has a history of aortic valve replacement for aortic stenosis. As part of the patient's treatment, 240 mg of intravenous gentamicin is started. The pharmacy calculates that, in this patient, gentamicin has a volume of distribution of 30 L, a half-life of 4 hours, and demonstrates first-order and one-compartment kinetics. Which of the following is the most likely serum drug concentration just before the next dose, 8 hours later?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>The <strong>initial plasma concentration (C<sub>o</sub>)</strong> of the drug after a single IV dose can be calculated using:</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509061cca1480-f891-4c06-8bc9-709ca7870407.png\"><ul>\r\n<li>The drug follows <strong>first-order kinetics</strong>, meaning the plasma concentration halves every half-life. With a half-life of <strong>4 hours</strong>, the plasma levels will reduce as follows:\r\n<ul>\r\n<li>After 4 hours: 8&rarr;4&thinsp;mg/L</li>\r\n<li>After another 4 hours (total 8 hours): 4&rarr;2&thinsp;mg/L</li>\r\n<li>Hence, just before the next scheduled dose at 8 hours, the expected serum concentration = <strong>2 mg/L</strong>.</li>\r\n</ul>\r\n</li>\r\n</ul>", "options": ["0.5 mg/L", "1 mg/L", "1.5 mg/L", "2 mg/L"], "html_options": ["0.5 mg/L", "1 mg/L", "1.5 mg/L", "2 mg/L"], "corr_idx": 3}, {"id": "1166380", "html_qtxt": "While reviewing the data of phase I clinical trials, the researchers note that the newly developed drug's half-life seems to vary among the healthy volunteers. An increase in which of the following pharmacologic parameters is most likely responsible for the longer half-life seen in certain individuals?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>The half-life of a drug can be calculated using these parameters, as follows:</li>\r\n</ul>\r\n<p><strong>T<sub><span style=\"font-size: xx-small;\">1/2</span></sub>= (0.7 &times; Vd) / CL</strong></p>\r\n<ul>\r\n<li>Thus, <strong>an increase in volume of distribution (Vd)</strong> will proportionally increase the drug's half-life, assuming clearance remains constant.</li>\r\n<li>This explains why some individuals in the trial have a <strong>longer half-life</strong>: a larger Vd means the drug is more widely distributed into tissues and takes longer to be cleared from plasma.</li>\r\n<li>This is commonly seen in individuals with increased lean body mass, fat content, or altered tissue binding capacity.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Oral bioavailability (Option A):</strong> While it influences how much of the drug enters systemic circulation, it <strong>does not affect the half-life</strong>. Once in circulation, the rate of elimination (t&frac12;) is governed by clearance and Vd, not by absorption extent.</p>\r\n<p><strong>Clearance (Option C):</strong> A <strong>decrease</strong> in clearance would prolong half-life, not an increase. In this question, the half-life <strong>increased</strong> due to another factor, and <strong>clearance wasn't reduced</strong> across subjects.</p>\r\n<p><strong>Drug metabolism (Option D):</strong> Alterations in metabolism do affect half-life, but the question explicitly points to <strong>increased</strong> values of a parameter. If metabolism increased, clearance would rise and half-life would shorten, not lengthen.</p>", "options": ["Oral bioavailability", "Volume of distribution", "Clearance", "Drug metabolism"], "html_options": ["Oral bioavailability", "Volume of distribution", "Clearance", "Drug metabolism"], "corr_idx": 1}, {"id": "1166382", "html_qtxt": "A 70-year-old man is admitted with a MI with cardiac arrhythmia. A continuous intravenous infusion of lidocaine, 1.92 mg/min, is started at 8 AM. The average pharmacokinetic parameters of lidocaine are: Vd 77 L; clearance 640 mL/min; half-life 1.4 h. What is the expected steady-state plasma concentration?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>The steady-state plasma concentration, Cp<sub>ss,</sub> for a drug given by <strong>continuous IV infusion</strong> is determined by the equation:</li>\n</ul>\n<p><strong>Cp<sub>ss </sub>= Rate of infusion / Clearance</strong><strong></strong></p>\n<p>Given:</p>\n<ul>\n<li>Rate of infusion = <strong>1.92 mg/min</strong></li>\n<li>Clearance = <strong>640 mL/min</strong> or <strong>0.640 L/min</strong></li>\n</ul>\n<p><strong>Cp<sub>ss </sub>= 1.92/0.640 = 3.0 mg/L</strong></p>\n<ul>\n<li>Thus, the expected steady-state plasma concentration of lidocaine is <strong>3.0 mg/L</strong>.</li>\n</ul>", "options": ["40 mg/L", "3.0 mg/L", "0.025 mg/L", "7.2 mg/L"], "html_options": ["40 mg/L", "3.0 mg/L", "0.025 mg/L", "7.2 mg/L"], "corr_idx": 1}, {"id": "1166404", "html_qtxt": "Which of the following drugs are established inhibitors of P-glycoprotein (P-gp) drug transporters?<br>1. Cimetidine<br>2. Ethanol<br>3. Ketoconazole<br>4. Ritonavir<br>5. Verapamil<br>6. Amiodarone<br>7. Cyclosporine<br>8. Nifedipine", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>P-glycoprotein (P-gp), also known as <strong>MDR-1 (multidrug resistance protein 1)</strong>, is an ATP-dependent efflux transporter involved in limiting drug absorption in the gut, promoting biliary and renal excretion, and restricting drug entry into the brain and placenta.</li>\r\n<li><strong>Inhibition of P-gp</strong> can significantly increase the bioavailability and systemic exposure of P-gp substrates.</li>\r\n<li>According to Goodman & Gilman's, <strong>established P-gp inhibitors</strong> include:\r\n<ul>\r\n<li><strong>Verapamil</strong> (a calcium channel blocker),</li>\r\n<li><strong>Amiodarone</strong> (an antiarrhythmic),</li>\r\n<li><strong>Cyclosporine</strong> (an immunosuppressant), and</li>\r\n<li><strong>Nifedipine</strong> (a dihydropyridine calcium channel blocker).</li>\r\n</ul>\r\n</li>\r\n<li>These agents <strong>directly block P-gp efflux function</strong>, thereby increasing the intracellular concentration of P-gp substrate drugs.</li>\r\n<li>This is clinically relevant in enhancing drug bioavailability and increasing drug-drug interaction risk.</li>\r\n<li><strong>Cimetidine</strong> may affect renal drug secretion via OCTs but not directly P-gp.</li>\r\n<li><strong>Ethanol</strong> has no consistent P-gp inhibitory effect.</li>\r\n<li><strong>Ketoconazole</strong> and <strong>ritonavir</strong> are known inhibitors, but not enough to validate this as a complete answer.</li>\r\n<li><strong>Rifampicin</strong> is a P-gp inducer and not an inhibitor.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906c9c440ea-b00e-4297-a41b-cca827896cdc.png\">", "options": ["1, 2, 3, 4", "5, 6, 7, 8", "2, 4, 6, 8", "1, 3, 5, 7"], "html_options": ["1, 2, 3, 4", "5, 6, 7, 8", "2, 4, 6, 8", "1, 3, 5, 7"], "corr_idx": 1}, {"id": "1166426", "html_qtxt": "A 59-year-old man with MI is admitted for emergency percutaneous insertion of a coronary stent. Which of the following drugs might cause unexpected results based on the patient's CYP2C19 genotype?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>Clopidogrel is a <strong>prodrug</strong> that requires <strong>oxidative activation via CYP2C19</strong>, a polymorphic enzyme in the cytochrome P450 family.</li>\r\n<li>Individuals who are <strong>poor metabolizers</strong> (with two loss-of-function alleles) generate <strong>less of the active metabolite</strong>, leading to <strong>reduced platelet inhibition</strong> and, consequently, an increased risk of <strong>cardiovascular events</strong> despite therapy.</li>\r\n<li>Therefore, genetic polymorphism in <strong>CYP2C19</strong> plays a significant role in interindividual variability in <strong>clopidogrel response</strong>, which is clinically important in antiplatelet therapy after PCI.</li>\r\n</ul>\r\n<p>Explanation of other options:</p>\r\n<p><strong>Prasugrel (Option B):</strong> Although prasugrel is also a prodrug, its activation is more efficient and <strong>less dependent on CYP2C19</strong>. Therefore, <strong>poor metabolizers still achieve therapeutic levels</strong> of the active metabolite.</p>\r\n<p><strong>Ticagrelor (Option C):</strong> Ticagrelor is <strong>not a prodrug</strong>. It is <strong>active as administered</strong> and does not require metabolic activation via CYP enzymes. Thus, CYP2C19 polymorphism does <strong>not influence its effect</strong>.</p>\r\n<p><strong>Warfarin (Option D):</strong> Warfarin metabolism is affected by polymorphisms in <strong>CYP2C9</strong> and its target <strong>VKORC1</strong>, not CYP2C19. Thus, its variability in effect is unrelated to the genotype in question.</p>", "options": ["Clopidogrel", "Prasugrel", "Ticagrelor", "Warfarin"], "html_options": ["Clopidogrel", "Prasugrel", "Ticagrelor", "Warfarin"], "corr_idx": 0}, {"id": "1166428", "html_qtxt": "Which of the following drugs may inhibit the hepatic microsomal P450 responsible for warfarin metabolism?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>Amiodarone is a potent <strong>inhibitor of cytochrome P450 enzymes</strong>, particularly <strong>CYP2C9</strong>, which is the primary isoenzyme responsible for metabolising <strong>S-warfarin</strong>, the more active enantiomer of warfarin.</li>\r\n<li>Inhibition of CYP2C9 by amiodarone results in a <strong>reduction of warfarin clearance</strong>, leading to increased plasma levels and an enhanced anticoagulant effect, thereby heightening the <strong>risk of bleeding</strong>.</li>\r\n<li>This interaction is clinically significant and necessitates close <strong>INR monitoring</strong> and often a <strong>dose reduction</strong> of warfarin when used concomitantly.</li>\r\n</ul>\r\n<p><strong>Common Enzyme inhibitors:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090684b261b9-0a03-42c4-931b-b2ab94a10790.png\"><p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Ethanol (Option B)</strong> acts as a <strong>biphasic modulator</strong>; acute use may inhibit metabolism, but chronic use <strong>induces</strong> microsomal enzymes.</p>\r\n<p><strong>Phenobarbital (Option C)</strong> is a classic <strong>inducer</strong> of hepatic microsomal enzymes, including CYP2C9, leading to <strong>enhanced metabolism</strong> of warfarin and decreased anticoagulant effect.</p>\r\n<p><strong>Procainamide (Option D)</strong> is not known to significantly affect cytochrome P450-mediated metabolism of warfarin.</p>", "options": ["Amiodarone", "Ethanol", "Phenobarbital", "Procainamide"], "html_options": ["Amiodarone", "Ethanol", "Phenobarbital", "Procainamide"], "corr_idx": 0}, {"id": "1166431", "html_qtxt": "Which of the following drugs has higher first-pass metabolism but is used orally?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li><strong>Propranolol</strong> undergoes <strong>extensive first-pass hepatic metabolism</strong>, leading to a significant reduction in its bioavailability.</li>\r\n<li>However, despite this, it is administered <strong>orally</strong> because the metabolised fraction is still <strong>therapeutically active</strong>, and the required plasma levels can be achieved by appropriate dosing.</li>\r\n<li>First-pass effect refers to the metabolism of orally administered drugs in the <strong>liver</strong> and <strong>intestinal wall</strong> before reaching systemic circulation.</li>\r\n<li>Propranolol has a <strong>bioavailability of ~25%</strong>, and doses are adjusted to compensate for this.</li>\r\n<li>It is metabolised primarily by <strong>CYP2D6</strong> and <strong>CYP1A2</strong> in the liver.</li>\r\n</ul>\r\n<p><strong>Drugs and Oral Bioavailability Classification</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090650876e38-ba3f-4a86-80cf-30f3e7556ab7.png\"><p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Testosterone (Option A)</strong> has <strong>very high first-pass metabolism</strong> and is <strong>not used orally</strong> in its native form. Instead, modified formulations (e.g., testosterone undecanoate) or parenteral/transdermal routes are preferred to avoid hepatic degradation.</p>\r\n<p><strong>Lignocaine (Lidocaine (Option B))</strong>: Extensively metabolised by the liver; not suitable for oral use due to rapid first-pass metabolism. Typically given <strong>IV</strong> or via <strong>topical/infiltration routes</strong>.</p>\r\n<p><strong>Ritonavir (Option D)</strong>: Undergoes hepatic metabolism, but is primarily used as a <strong>CYP3A4 inhibitor (booster)</strong> to increase levels of co-administered drugs. It does have oral activity, but its <strong>primary use is as a pharmacokinetic enhancer</strong>, not a direct example of tolerable high first-pass metabolism.</p>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li>Drugs with <strong>high first-pass metabolism</strong> may still be used orally if:\r\n<ul>\r\n<li>The <strong>metabolites retain activity</strong></li>\r\n<li>The <strong>therapeutic window allows for dose adjustment<br /> </strong></li>\r\n</ul>\r\n</li>\r\n</ul>", "options": ["Testosterone", "Lignocaine", "Propranolol", "Ritonavir"], "html_options": ["Testosterone", "Lignocaine", "Propranolol", "Ritonavir"], "corr_idx": 2}, {"id": "1166437", "html_qtxt": "A 30-year-old man is being treated for HIV. When abacavir therapy is begun, he develops a severe skin rash. Which of the following pharmacogenomic diagnoses might explain this skin rash?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li><strong>Abacavir hypersensitivity</strong> is strongly associated with the presence of the <strong>HLA-B*5701</strong></li>\r\n<li>Individuals carrying this allele are at increased risk for severe immune-mediated skin reactions, such as <strong>Stevens-Johnson syndrome</strong> and <strong>toxic epidermal necrolysis (TEN)</strong>, as well as other forms of <strong>systemic hypersensitivity</strong>.</li>\r\n<li>Notable HLA-drug associations include:</li>\r\n<li><strong>HLA-B*1502 (Option A)</strong>: Linked to <strong>Stevens-Johnson syndrome</strong> in patients taking <strong>carbamazepine</strong>, particularly in Asian populations.</li>\r\n<li><strong>HLA-B*5801 (Option B)</strong>: Associated with severe <strong>cutaneous adverse reactions</strong> to <strong>allopurinol</strong>, including TEN.</li>\r\n<li><strong>HLA-B*5701</strong>: As above, associated with <strong>abacavir</strong> and also <strong>flucloxacillin</strong> in drug-induced liver injury.</li>\r\n<li>Genetic screening for these alleles prior to initiating therapy can significantly reduce the risk of adverse drug reactions.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>HLA-B*5901 (Option D)</strong>: This allele has no clinically established pharmacogenomic link with abacavir or any other common drug hypersensitivity reaction.</p>", "options": ["HLA-B*1502", "HLA-B*5801", "HLA-B*5701", "HLA-B*5901"], "html_options": ["HLA-B*1502", "HLA-B*5801", "HLA-B*5701", "HLA-B*5901"], "corr_idx": 2}, {"id": "1166443", "html_qtxt": "A 7-year-old child is brought to the ED with severe bruising after a fall, is given codeine with acetaminophen. Shortly after the first dose, the child became unresponsive and turned blue. Which of the following alleles might be responsible for this presentation?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li><strong>Codeine</strong> is a <strong>prodrug</strong> that requires <strong>metabolic activation by CYP2D6</strong> to form <strong>morphine</strong>, the active metabolite responsible for analgesia.</li>\r\n<li>Some individuals (including children) may carry <strong>CYP2D6 gene duplications,</strong> making them <strong>ultrarapid metabolizers</strong>, leading to <strong>excessive morphine formation</strong>, toxicity, <strong>respiratory depression</strong>, and death, even at therapeutic doses.</li>\r\n<li>In such patients, <strong>normal codeine dosing results in dangerously high plasma morphine levels</strong>, explaining the cyanosis and unresponsiveness observed.</li>\r\n</ul>\r\n<p><strong>Pharmacogenomic Variants and Associated Drug Responses:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906e1065efa-6972-409a-b17d-8a262dc1e0c3.png\">", "options": ["CYP2D6", "CYP2C19", "CYP2C9", "CYP3A4"], "html_options": ["CYP2D6", "CYP2C19", "CYP2C9", "CYP3A4"], "corr_idx": 0}, {"id": "1166450", "html_qtxt": "A 26-year-old man comes to the ED because of a 1-week history of worsening fatigue, nausea, and vomiting. The patient is on ATT. Physical examination shows right upper quadrant tenderness and scleral icterus. Laboratory studies show elevated aminotransferases. Impaired function of which of the following pharmacokinetic processes is the most likely explanation for this patient's symptoms?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>The patient on ATT is most likely receiving isoniazid, a drug known for hepatotoxicity in slow acetylators.</li>\r\n<li><strong>Acetylation</strong> is a <strong>phase II metabolic process</strong> where drugs are conjugated with an acetyl group to increase water solubility and promote excretion. Isoniazid is metabolised via <strong>N-acetyltransferase</strong> (NAT2).</li>\r\n<li>Genetic polymorphism in NAT2 results in \"slow acetylators\" who accumulate toxic metabolites, increasing the risk of drug-induced hepatitis and liver damage.</li>\r\n<li>Phase II reactions, such as acetylation, follow phase I metabolism if the intermediate is still insufficiently polar. In this case, impaired acetylation prevents effective detoxification of isoniazid intermediates.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030947722a03-dfb1-4da3-b89c-d3a613b93c18.jpg\">\r\n<p><strong>Comparison of Phase I and Phase II Drug Metabolism</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906a7bb8739-5e6c-41c5-a7c8-401cca8452fb.png\"><h3>Explanation of other options:</h3>\r\n<p><strong>Methylation (Option A)</strong> involves the addition of a methyl group and is typically associated with neurotransmitter metabolism (e.g., norepinephrine). It does not significantly contribute to the metabolism of isoniazid and is not associated with hepatotoxicity in ATT.</p>\r\n<p><strong>Sulfation</strong> <strong>(Option B) </strong>is another phase II conjugation reaction, mainly involved in detoxifying phenolic drugs. However, sulfation plays little to no role in isoniazid metabolism and isn't associated with hepatotoxic adverse effects in this context.</p>\r\n<p><strong>Oxidation (Option C)</strong> is a <strong>phase I reaction</strong> predominantly mediated by cytochrome P450 enzymes. Though oxidative metabolites can contribute to hepatotoxicity, the genetically influenced acetylation pathway is more directly implicated in this patient's scenario with ATT-induced hepatitis.</p>", "options": ["Methylation", "Sulfation", "Oxidation", "Acetylation"], "html_options": ["Methylation", "Sulfation", "Oxidation", "Acetylation"], "corr_idx": 3}, {"id": "1166459", "html_qtxt": "A 56-year-old patient is being treated with oral levofloxacin for community-acquired pneumonia. The plasma clearance of the drug is calculated as 12.0 L/h. Oral bioavailability of the drug is 50%. Sensitivity analysis of a sputum culture shows a minimal inhibitory concentration of 1 &mu;g/mL for the causative pathogen. The target plasma concentration is 2 mg/L. If the drug is administered twice per day, which of the following dosages should be administered at each dosing interval to maintain a steady state?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<p>To maintain a steady-state plasma concentration for a drug given at fixed intervals, the <strong>maintenance dose</strong> can be calculated using the following formula:</p>\n<p><strong>Maintenance Dose = (Cp&times;CL&times;T) &#247; F</strong></p>\n<p>Where:</p>\n<ul>\n<li>Cp = Target plasma concentration = <strong>2 mg/L</strong></li>\n<li>CL = Clearance = <strong>12 L/h</strong></li>\n<li>T = Dosing interval = <strong>12 hours</strong></li>\n<li>F = Oral bioavailability = <strong>0.5<br /> </strong></li>\n</ul>\n<p><strong>Maintenance Dose = (2&times;12&times;12)</strong> &#247; <strong>0.5 = 288</strong> &#247; <strong>0.5 = 576</strong></p>\n<p>Thus, <strong>576 mg</strong> should be administered <strong>every 12 hours</strong> to maintain the desired steady-state plasma concentration.</p>", "options": ["567", "576", "675", "765"], "html_options": ["567", "576", "675", "765"], "corr_idx": 1}, {"id": "1166463", "html_qtxt": "An investigator injects 7 mg of an experimental drug into an animal. The drug does not bind to plasma proteins and is eliminated unchanged in urine via first-order kinetics. Two hours later, the investigator obtains laboratory values from the animal that reveal the rate of drug elimination is 0.02 mg/min, the plasma drug concentration is 0.04 mg/mL, and the total amount of drug eliminated in urine is 5 mg. Which of the following is the best estimate of the clearance of the drug in the animal at the time of measurement?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>Clearance (CL) represents the <strong>volume of plasma cleared of a drug per unit time</strong>. When using the rate of elimination and plasma concentration, clearance is calculated as:</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509069eab482b-2983-41ae-a038-bfa067a329e7.png\"><ul>\r\n<li>This drug is <strong>not protein-bound</strong> and is <strong>excreted unchanged</strong>, meaning the clearance approximates <strong>renal clearance</strong> (like <strong>inulin</strong> in humans).</li>\r\n<li>In <strong>first-order kinetics</strong>, both plasma concentration and elimination rate vary with time, but <strong>clearance remains constant</strong>.</li>\r\n</ul>", "options": ["2 mL/min", "0.002 mL", "50 mL/min", "0.5 mL/min"], "html_options": ["2 mL/min", "0.002 mL", "50 mL/min", "0.5 mL/min"], "corr_idx": 3}, {"id": "1166469", "html_qtxt": "An investigator is studying the interaction between a new drug B and an existing drug A. The results are recorded and plotted on the graph shown. Which of the following properties of drug B best explains the observed effect on the dose-response curve of drug A?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403096c7b7323-1b33-4d08-99b5-52dc9791b7cc.jpg\">", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>A rightward parallel shift in the dose-response curve (as seen when comparing curve A to B) indicates that drug B competes with drug A for the same receptor site.</li>\r\n<li>This type of interaction is characteristic of a <strong>competitive antagonist</strong>.</li>\r\n<li>It decreases the <strong>potency</strong> of drug A, requiring a higher dose to achieve the same effect (i.e., increase in EC50), but <strong>does not alter the maximum efficacy (Emax)</strong>.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906b2132cea-8f35-463c-a32a-934b00d12e38.png\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403091851f046-dc84-45b1-b41a-3744332292be.jpg\">\r\n", "options": ["Non-competitive antagonist", "Competitive antagonist", "Inverse agonist", "Functional antagonist"], "html_options": ["Non-competitive antagonist", "Competitive antagonist", "Inverse agonist", "Functional antagonist"], "corr_idx": 1}, {"id": "1166473", "html_qtxt": "An investigator is studying the effect of a new drug on an enzyme. The drug triggers a conformational change in the shape of the enzyme, increasing its affinity to a substrate. The kinetics of the enzyme alone are labelled in the graph as N. Which of the following curves best represents the drug's effect on this enzyme?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240309c73b4d12-32e3-4279-9fcc-18de00b642aa.jpg\">", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>The graph shows a <strong>Michaelis-Menten plot</strong>.</li>\r\n<li>The curve labelled <strong>B</strong> indicates that the enzyme, under the influence of the drug, reaches <strong>half-maximal velocity (Vmax)</strong> at a <strong>lower substrate concentration</strong>, which reflects <strong>increased affinity</strong> for the substrate (i.e., a <strong>lower Km</strong>).</li>\r\n<li>The maximum velocity (Vmax) remains unchanged, suggesting that the catalytic potential is unaffected; only the <strong>binding</strong> of substrate is enhanced.</li>\r\n<li>This is characteristic of <strong>allosteric activation</strong> or <strong>positive cooperative binding</strong>.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906aaf291ab-29d2-4881-bafe-e8997fc6a484.png\">", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 1}, {"id": "1166478", "html_qtxt": "Therapy with elvitegravir, emtricitabine, and tenofovir is initiated for a 35-year-old woman with HIV-1. The physician also prescribes a new drug, cobicistat, which does not have antiretroviral activity. Which of the following is the most likely reason for prescribing cobicistat?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li>Cobicistat is not an antiretroviral drug. Instead, it is a <strong>pharmacokinetic enhancer</strong>, a <strong>potent CYP3A4 inhibitor</strong>.</li>\r\n<li>By inhibiting CYP3A4, cobicistat decreases the metabolism of <strong>elvitegravir</strong> (and other CYP3A4-metabolised antiretrovirals), leading to <strong>increased plasma levels</strong> and <strong>enhanced efficacy</strong> of those drugs.</li>\r\n<li>This is an example of <strong>potentiation</strong>, where a drug with <strong>no activity of its own</strong> increases the action of another drug by altering its <strong>pharmacokinetics</strong>.</li>\r\n</ul>\r\n<p><strong>Pharmacodynamic Interactions</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030988f1c7bd-60f0-43a7-95fc-c9d11311ddb7.jpg\">\r\n", "options": ["Potentiation", "Tachyphylaxis", "Synergism", "Additive interaction"], "html_options": ["Potentiation", "Tachyphylaxis", "Synergism", "Additive interaction"], "corr_idx": 0}, {"id": "1166482", "html_qtxt": "Sugammadex is a drug that reverses the action of rocuronium. It appears to interact directly with the rocuronium molecule and not at all with the rocuronium receptor. Which of the following terms best describes sugammadex?", "html_expl": "<p><strong>Explanation</strong>:</p>\r\n<ul>\r\n<li><strong>Sugammadex</strong> interacts directly with <strong>rocuronium</strong> and not with the <strong>rocuronium receptor</strong>.</li>\r\n<li>This type of antagonism, where the agent binds to the drug and prevents it from binding to its receptor, is termed <strong>chemical antagonism</strong>.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906e092b9a1-2269-4f31-a71d-8f70df431347.png\">", "options": ["Chemical antagonist", "Noncompetitive antagonist", "Physiologic antagonist", "Pharmacologic antagonist"], "html_options": ["Chemical antagonist", "Noncompetitive antagonist", "Physiologic antagonist", "Pharmacologic antagonist"], "corr_idx": 0}]}, {"moduleId": 1013389, "name": "Basic Principles of Pharmacology (Part 2)", "questions": [{"id": "1166485", "html_qtxt": "There is no statistically significant difference in the dose-corrected area under the curve (AUC) for the two routes of administration. Which of the following is the most likely explanation for this finding?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>High bioavailability</strong> means that a large proportion of the administered drug reaches systemic circulation in unchanged form.</li>\n<li>When the <strong>dose-corrected AUC (area under the curve)</strong> is <strong>similar</strong> for two different routes (e.g., oral and intravenous), it implies that the drug is <strong>well absorbed orally</strong> and <strong>undergoes minimal first-pass metabolism</strong>.</li>\n<li>Such drugs <strong>do not undergo significant first-pass metabolism</strong> and hence exhibit <strong>high bioavailability</strong> (close to 100%).</li>\n<li>This is a hallmark characteristic of certain drugs like <strong>isosorbide mononitrate</strong>, which bypass hepatic metabolism and display similar AUCs via both routes.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Extensive first-pass metabolism (Option B):</strong> If a drug undergoes significant first-pass metabolism, a large fraction of it is metabolised in the liver before reaching systemic circulation. This would result in a <strong>lower AUC for oral administration</strong> compared to intravenous administration, even after dose correction.</p>\n<p><strong>Low volume of distribution (Option C):</strong> The volume of distribution (Vd) refers to the extent to which a drug distributes into tissues relative to the plasma. It has no direct impact on the <strong>AUC differences between routes of administration</strong>, especially when the question is focused on absorption and systemic availability.</p>\n<p><strong>Delayed clearance (Option D):</strong> Delayed or decreased clearance means the drug is eliminated more slowly from the body, which could lead to higher plasma concentrations over time. However, clearance affects <strong>drug elimination</strong>, not <strong>bioavailability</strong>, and cannot explain why the oral and IV AUCs would be equivalent.</p>", "options": ["High bioavailability", "Extensive first-pass metabolism", "Low volume of distribution", "Delayed clearance"], "html_options": ["High bioavailability", "Extensive first-pass metabolism", "Low volume of distribution", "Delayed clearance"], "corr_idx": 0}, {"id": "1166493", "html_qtxt": "Each of the curves in the graph below may be considered a concentration-effect curve or a concentration-binding curve.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030933bb7e6f-05b3-4af1-aef0-47b5c6d795dd.jpg\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403090fe96773-3432-4ba2-9831-410d719a36b3.jpg\">", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Curve 1</strong> shows a lower maximal response compared to full agonists, indicating that the drug is a <strong>partial agonist</strong>.</li>\n<li><strong>Curve 2</strong> represents a <strong>full agonist</strong> as it produces the maximum effect by occupying all available receptors.</li>\n<li><strong>Curve 3</strong> shifts the dose-response curve to the right with no change in maximum response, typical of a <strong>competitive antagonist</strong>.</li>\n<li><strong>Curve 4</strong> shows reduced maximum response (efficacy), with little to no change in potency, typical of <strong>non-competitive antagonism</strong>.</li>\n</ul>", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 0}, {"id": "1166497", "html_qtxt": "Unfortunately, because of a calculation error, the heparin drip is running at 100 times the rate it should be running at for a 67-year-old patient with DVT. Protamine sulfate is immediately given intravenously. This agent works by which of the following mechanisms of action?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Protamine sulfate acts as a <strong>chemical antagonist</strong> to heparin.</li>\n<li>It neutralises the anticoagulant effect of heparin by forming a stable inactive complex with it through ionic binding.</li>\n<li>This interaction occurs <strong>independently of heparin's receptor</strong>, and protamine does not activate or block receptors directly. This sequestering action renders heparin <strong>incapable of binding to and activating its target</strong>, thereby reversing its effects.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090639283570-07e6-4d75-8d0e-75a1c696f6be.png\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Functional agonist (Option B):</strong> A functional agonist produces an effect by acting on a different receptor to oppose the action of the original drug. Protamine does not oppose heparin through a physiological counter-response but through direct binding.</p>\n<p><strong>Partial agonist (Option C):</strong> A partial agonist binds to the same receptor as the full agonist but elicits only a submaximal response. Protamine does not act through receptor binding or agonism.</p>\n<p><strong>Partial antagonist (Option D):</strong> This term is not standard pharmacological nomenclature. Protamine&rsquo;s action is not partial nor receptor-mediated; it is <strong>complete and direct</strong> via <strong>chemical sequestration</strong>.</p>", "options": ["Chemical antagonist", "Functional agonist", "Partial agonist", "Partial antagonist"], "html_options": ["Chemical antagonist", "Functional agonist", "Partial agonist", "Partial antagonist"], "corr_idx": 0}, {"id": "1166500", "html_qtxt": "A researcher for a pharmaceutical company is studying a new medication to treat Parkinsonism. The medication is dosed at 10 mg and causes improvement in bradykinesia and cogwheel rigidity in 99% of patients. However, 100 mg of this medication causes toxicity manifested as seizures in 1% of the population treated with this medication. What is the standard margin of safety of this medication?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>The <strong>standard margin of safety (SMS)</strong> is a measure of how much safer a drug's effective dose is compared to its toxic dose.</li>\n<li>It's calculated using the formula:\n<ul>\n<li><strong>SMS = [(LD1 / ED99) - 1] x 100</strong></li>\n</ul>\n</li>\n</ul>\n<p>In this case:</p>\n<ul>\n<li><strong>Effective dose (ED99):</strong> The dose at which the medication causes improvement in bradykinesia and cogwheel rigidity in 99% of patients is 10 mg.</li>\n<li><strong>Toxic dose (LD1):</strong> The dose that causes seizures in 1% of the population treated with this medication is 100 mg.</li>\n</ul>\n<p>Now, calculate the SMS:</p>\n<p>SMS = [(100 mg / 10 mg) - 1] x 100 = [10 - 1] x 100 = <strong>900</strong></p>\n<ul>\n<li>So, the standard margin of safety for this medication is 900.</li>\n<li>This indicates that the medication is <strong>900 times safer at the effective dose (10 mg)</strong> than its toxic dose: the dose that causes seizures (100 mg).</li>\n</ul>", "options": ["300", "500", "700", "900"], "html_options": ["300", "500", "700", "900"], "corr_idx": 3}, {"id": "1166508", "html_qtxt": "A 27-year-old woman takes phenytoin to control focal seizures. Most of the phenytoin in her blood is plasma-protein bound, and only the free fraction is pharmacologically active. The free fraction must diffuse through many barriers to reach its site of action. Many characteristics influence a drug's ability to diffuse across biological membranes. Which of the following possible drug characteristics would aid such diffusion?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>For a drug to passively diffuse across biological membranes, it must be:\n<ul>\n<li><strong>Uncharged (non-ionised)</strong></li>\n<li><strong>Non-polar (lipophilic)</strong></li>\n<li><strong>Small in molecular size </strong></li>\n</ul>\n</li>\n<li>A weak base with a pKa of 7 at a <strong>physiologic pH (7.4)</strong> will predominantly exist in the <strong>uncharged RNH<sub>2</sub> form</strong>, because the equilibrium:\n<ul>\n<li><strong>RNH<sub>3</sub><sup>+</sup> &rlhar;  RNH<sub>2</sub> + H<sup>+</sup></strong></li>\n</ul>\n</li>\n</ul>\n<p>Shifts towards RNH<sub>2</sub> as the hydrogen ion concentration [H<sup>+</sup>] decreases. This uncharged RNH<sub>2</sub> state is <strong>lipid-soluble</strong> and can readily diffuse across the lipid bilayers of cell membranes.</p>\n<p><strong>Explanation of other options:</strong></p>\n<ul>\n<li><strong>Hydrophilicity (Option A):</strong> Hydrophilic (water-soluble) drugs are polar and charged, hence <strong>do not diffuse well</strong> through lipophilic membranes.</li>\n<li><strong>Large molecular size (Option B):</strong> Large molecules have <strong>greater difficulty crossing</strong> biological membranes; smaller, non-polar molecules diffuse more easily.</li>\n<li><strong>Weak acid with pKa of 7 (Option C):</strong> At pH 7.4, a weak acid with pKa 7 would be <strong>mostly ionised</strong>, reducing its ability to cross membranes.</li>\n</ul>", "options": ["Hydrophilicity", "Large molecular size", "Weak acid with a pKa of 7", "Weak base with a pKa of 7"], "html_options": ["Hydrophilicity", "Large molecular size", "Weak acid with a pKa of 7", "Weak base with a pKa of 7"], "corr_idx": 3}, {"id": "1166512", "html_qtxt": "Within 12 hours of birth, a baby boy begins to experience temperature fluctuations, difficulty breathing, and reduced movements. Suspecting neonatal sepsis, IV gentamicin and ampicillin are started. The increased effectiveness of this combination is an example of which of the following principles?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Synergy</strong> refers to a pharmacologic interaction where the <strong>combined effect of two or more drugs is greater than the sum of their individual effects</strong>. This is not merely additive but rather <strong>amplifies the therapeutic efficacy</strong>.</li>\n<li>In this case, the combination of <strong>ampicillin</strong> (a beta-lactam antibiotic that inhibits bacterial cell wall synthesis) and <strong>gentamicin</strong> (an aminoglycoside that inhibits protein synthesis) acts synergistically against certain gram-negative bacteria.</li>\n<li>Penicillin disrupts the cell wall, enhancing gentamicin's penetration, thereby increasing its effect.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Agonism (Option A) </strong>binds to and activates receptors to produce a biological response. This does not refer to the interaction between two separate drugs.</p>\n<p><strong>Anergy (Option B)</strong> is an immunological term describing the failure of immune cells to respond to an antigen. It is unrelated to drug-drug interactions.</p>\n<p><strong>Symbiosis (Option C)</strong> describes a biological relationship between organisms, not pharmacological interactions between drugs.</p>", "options": ["Agonism", "Anergy", "Symbiosis", "Synergy"], "html_options": ["Agonism", "Anergy", "Symbiosis", "Synergy"], "corr_idx": 3}, {"id": "1166516", "html_qtxt": "A 56-year-old male presented with lethargy and confusion. Labs were ordered, revealing serum calcium of 17 mg/dL. To rapidly lower his serum calcium, you administer calcitonin. However, calcitonin alone is insufficient because it is known to rapidly and suddenly lose its effectiveness within 2 to 3 days of repeated dosing. For this reason, a bisphosphonate, which takes 2 to 3 days to become effective, is added simultaneously. What is the term for the rapid decrease in response to calcitonin?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Tachyphylaxis</strong> describes a scenario where the response to a drug rapidly decreases after continuous or repeated administration.</li>\n<li>Unlike tolerance, where the drug effect gradually diminishes over time, <strong>tachyphylaxis</strong> results in a <strong>rapid reduction in drug efficacy</strong>, often within minutes to hours, and is typically seen with drugs that have an immediate pharmacodynamic effect.</li>\n<li>In this case, <strong>calcitonin</strong> rapidly loses its ability to reduce serum calcium over time, making it ineffective unless combined with a drug (bisphosphonate) that takes longer to exert its effect.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Anaphylaxis (Option A):</strong> Anaphylaxis is a severe allergic reaction mediated by mast cells and histamine, and it leads to rapid systemic symptoms like difficulty breathing and low blood pressure. It is <strong>not related</strong> to the diminished response to a drug.</p>\n<p><strong>Prophylaxis (Option B):</strong> Prophylaxis refers to the prevention of disease through medication or vaccination, not to the rapid diminishing effect of a drug.</p>\n<p><strong>Tolerance (Option D):</strong> <strong>Tolerance</strong> is a <strong>gradual decrease</strong> in the effectiveness of a drug over time, where the dose needs to be increased to achieve the same effect. Unlike tachyphylaxis, tolerance takes longer to develop and is not as rapid.</p>", "options": ["Anaphylaxis", "Prophylaxis", "Tachyphylaxis", "Tolerance"], "html_options": ["Anaphylaxis", "Prophylaxis", "Tachyphylaxis", "Tolerance"], "corr_idx": 2}, {"id": "1166519", "html_qtxt": "A 26-year-old man presents with a single, painless ulcer on his penis. You want to treat him for syphilis with penicillin G, but his history includes an itchy rash following amoxicillin treatment as a child. What must first occur in the body for a penicillin to become allergenic?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Penicillin, by itself, is too small to act as an allergen.</li>\n<li>However, <strong>when it binds to larger molecules like proteins, it forms a complex that the immune system can recognise as foreign, triggering an allergic reaction</strong>. This binding is a critical first step in sensitisation to penicillin.</li>\n<li>In cases where patients report a penicillin allergy, it is often due to this process where the penicillin molecule binds to proteins or other larger molecules, thus being recognised as a foreign antigen.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>First-pass metabolism in the liver creates a toxic metabolite (Option A):</strong> The liver's role in metabolising penicillin is minor, and most of the drug is excreted unchanged in the urine. The metabolites formed are not known to be particularly toxic, so this is not the cause of an allergic reaction.</p>\n<p><strong>Simple exposure to penicillin can cause sensitisation, which leads to a hypersensitivity reaction in subsequent exposures (Option C).</strong> While sensitisation can occur after exposure, the key step is the binding of penicillin to a larger molecule, which makes it detectable as a foreign antigen. Penicillin alone, without this binding, cannot trigger an allergic response.</p>\n<p><strong>Penicillin is not allergenic; injection of penicillin simply causes histamine release by a mechanism not involving IgE (Option D).</strong> While penicillin can trigger histamine release, this is not the primary mechanism of penicillin allergy. The immune system&rsquo;s recognition of penicillin as a foreign antigen (via the binding process) is the true cause of allergic reactions.</p>", "options": ["First-pass metabolism in the liver creates a toxic metabolite", "It must bind to a larger molecule, resulting in a complex that the body sees as a foreign antigen", "Simple exposure to penicillin can cause sensitisation, which leads to a hypersensitivity reaction in subsequent exposures", "Penicillin is not allergenic; injection of penicillin simply causes histamine release by a  mechanism not involving IgE"], "html_options": ["First-pass metabolism in the liver creates a toxic metabolite", "It must bind to a larger molecule, resulting in a complex that the body sees as a foreign antigen", "Simple exposure to penicillin can cause sensitisation, which leads to a hypersensitivity reaction in subsequent exposures", "Penicillin is not allergenic; injection of penicillin simply causes histamine release by a  mechanism not involving IgE"], "corr_idx": 1}, {"id": "1166523", "html_qtxt": "A 43-year-old man has tried to quit smoking cigars three times in the past, but he could not go long without a cigarette. The nicotine in cigarettes stimulates many cells in the body by binding certain receptors. Which describes the response when nicotine binds its target receptor?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Nicotine binds to nicotinic cholinergic receptors, which are <strong>ligand-gated ion channels</strong>.</li>\n<li>These receptors are found on muscles at the <strong>neuromuscular junction</strong> (NM type) and in <strong>postganglionic neurons</strong> in the autonomic ganglia (NN type).</li>\n<li>When nicotine binds, the receptor opens <strong>a channel that allows positive ions (Na+ and K+) to flow through</strong>. This results in <strong>depolarisation</strong>, as the positive ions entering the cell cause a net positive charge inside the cell. The net effect is a <strong>change in membrane potential that facilitates neuronal firing.</strong></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>A channel opens, and negative ions flow into the cell (Option A):</strong> This description does not align with nicotine's mechanism of action, which involves the influx of positive ions to cause depolarisation, not the influx of negative ions.</p>\n<p><strong>Adenylyl-cyclase is activated to increase intracellular cAMP (Option C):</strong> This mechanism is related to G protein-coupled receptors, not the nicotinic receptors activated by nicotine. Nicotine activates ion channels, not the adenylyl-cyclase pathway.</p>\n<p><strong>Phospholipase C is activated to increase intracellular IP3 and DAG (Option D):</strong> This pathway is generally associated with muscarinic receptors and certain G protein-coupled receptors. Nicotinic receptors activate ion channels, not second messenger pathways.</p>", "options": ["A channel opens, and negative ions flow into the cell", "A channel opens, and positive ions flow into the cell", "Adenylyl-cyclase is activated to increase intracellular cAMP", "Phospholipase C is activated to increase intracellular IP3 and DAG."], "html_options": ["A channel opens, and negative ions flow into the cell", "A channel opens, and positive ions flow into the cell", "Adenylyl-cyclase is activated to increase intracellular cAMP", "Phospholipase C is activated to increase intracellular IP3 and DAG."], "corr_idx": 1}, {"id": "1166526", "html_qtxt": "A 6-month-old male infant is placed on midazolam per rectum once daily to treat the febrile seizure. Which of the following statements is true about this route of administration?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Rectal administration is advantageous when the <strong>oral route is not feasible</strong>, such as in cases of vomiting, seizures, or unconsciousness. This makes it particularly beneficial in pediatric emergency settings.</li>\n<li>Approximately <strong>50% of the drug absorbed from the rectum bypasses hepatic first-pass metabolism</strong> via the middle and inferior rectal veins, which drain directly into systemic circulation. This increases drug bioavailability compared to oral routes. <strong>(Option A ruled out)</strong></li>\n<li>Rectal absorption can be <strong>inconsistent,</strong> and some drugs may cause <strong>mucosal irritation</strong>, limiting widespread acceptance. Thus, while clinically useful in emergencies, it is not a universally preferred route for routine drug delivery. <strong>(Options B and C ruled out)</strong></li>\n</ul>", "options": ["Maximal biotransformation of the drug by the liver", "Rectal administration of medications is well accepted", "Rectal irritation following administration is uncommon", "Useful if the patient is unconscious or vomiting"], "html_options": ["Maximal biotransformation of the drug by the liver", "Rectal administration of medications is well accepted", "Rectal irritation following administration is uncommon", "Useful if the patient is unconscious or vomiting"], "corr_idx": 3}, {"id": "1166530", "html_qtxt": "A 78-year-old man presents with the complaint of difficulty urinating. He has difficulty starting his stream and feels his bladder is still full after he urinates. He has to get up about four times a night to urinate. The physician starts him on finasteride, which non-competitively inhibits 5 alpha-reductase. What effect does a noncompetitive inhibitor have on enzyme kinetics?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Noncompetitive inhibitors</strong> bind to a site <strong>other than the active site</strong> (i.e., allosteric site), independently of whether the substrate is bound or not.</li>\n<li>This alters the enzyme's activity by reducing the number of functional enzyme molecules without affecting the substrate binding affinity.</li>\n<li><strong>Vmax is reduced</strong>: Fewer active enzyme sites are available, limiting the maximum reaction rate.<strong>(Option D ruled out)</strong></li>\n<li><strong>Km remains unchanged</strong>: The inhibitor does not compete for the active site; thus, substrate affinity is unaffected. <strong>(Options A and C ruled out)</strong></li>\n</ul>\n<p><strong>Comparison of Enzyme Inhibition Types</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090647f3d0f6-70c8-40ff-83ac-27136ff51658.png\"><br>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509067d35175e-886e-4a79-8836-fcb86b1ef5df.png\">", "options": ["Decreases Km", "Decreases Vmax", "Increases Km", "Increases Vmax"], "html_options": ["Decreases Km", "Decreases Vmax", "Increases Km", "Increases Vmax"], "corr_idx": 1}, {"id": "1166532", "html_qtxt": "Drug A and Drug B are of equal magnitude. If Drug A and Drug B are combined, and they produce an effect that is equal in magnitude to the sum of effects when both are given individually, this would be an example of which of the following?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Additive effects</strong> refer to situations where <strong>two drugs with similar actions</strong>, when given together, <strong>produce an effect equal to the sum</strong> of their individual effects.</li>\n<li>This is common with drugs acting through the same or different mechanisms, but ultimately leading to a <strong>quantitative summation</strong> of effects.</li>\n</ul>\n<p><strong>Examples include:</strong></p>\n<ul>\n<li>Combining <strong>acetaminophen and NSAIDs</strong> for antipyresis.</li>\n<li>Use of <strong>antihypertensives</strong> like beta-blockers and ACE inhibitors.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Neutralisation (Option B):</strong> This occurs when <strong>two drugs interact chemically</strong> to form an inactive compound (e.g., chelation). It's a pharmacokinetic, not dynamic, interaction.</p>\n<p><strong>Potentiation (Option C): </strong>Potentiation occurs when <strong>one drug without intrinsic effect enhances the effect of another active drug</strong> (e.g., clavulanic acid with amoxicillin).</p>\n<p><strong>Synergism (Option D):</strong> Synergism means that the <strong>combined effect is greater than the sum</strong> of individual effects, as in the case of <strong>trimethoprim-sulfamethoxazole</strong>.</p>", "options": ["Additive effects", "Neutralisation", "Potentiation", "Synergism"], "html_options": ["Additive effects", "Neutralisation", "Potentiation", "Synergism"], "corr_idx": 0}, {"id": "1166535", "html_qtxt": "A new vasopressor in development, Drug X, is a partial agonist at alpha1-adrenergic receptors. Epinephrine is a full agonist at these same receptors. Which of the following statements is true regarding the potency of Drug X compared to epinephrine?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Potency</strong> refers to the <strong>amount of drug required to produce a given effect</strong>. It is independent of efficacy, which refers to the <strong>maximum effect</strong> a drug can achieve.</li>\n<li>Since <strong>Drug X is known only to be a partial agonist</strong>, we can infer it has <strong>lower efficacy</strong> than epinephrine (a full agonist).</li>\n<li>However, <strong>no data are provided regarding the dose-response relationship or EC<sub>50</sub> values</strong>, so <strong>we cannot conclude anything about potency</strong>.\n<ul>\n<li>Potency comparisons require <strong>concentration-response curves</strong> to determine EC<sub>50</sub>.</li>\n<li>A drug can be <strong>more potent but less efficacious</strong> (and vice versa).</li>\n<li>Acting on the <strong>same receptor</strong> does <strong>not ensure equal potency</strong>.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Drug X and epinephrine are equally potent because they act on the same receptors<br /> (Option A): </strong>Receptor binding does not imply equal potency. Potency also depends on drug-receptor affinity and intrinsic activity.</p>\n<p><strong>Epinephrine is more potent because it is a full agonist (Option C):</strong> Being a full agonist implies higher <strong>efficacy</strong>, not necessarily higher <strong>potency</strong>.</p>\n<p><strong>Epinephrine is more potent because it is an endogenous neurotransmitter (Option D):</strong> Endogenous origin has <strong>no bearing</strong> on potency unless pharmacodynamic data support it.</p>", "options": ["Drug X and epinephrine are equally potent because they act on the same receptors", "Relative potency cannot be determined from the information given", "Epinephrine is more potent because it is a full agonist", "Epinephrine is more potent because it is an endogenous neurotransmitter"], "html_options": ["Drug X and epinephrine are equally potent because they act on the same receptors", "Relative potency cannot be determined from the information given", "Epinephrine is more potent because it is a full agonist", "Epinephrine is more potent because it is an endogenous neurotransmitter"], "corr_idx": 1}, {"id": "1166546", "html_qtxt": "A 47-year-old man with schizophrenia is hospitalised for an exacerbation of baseline psychotic symptoms. He is found to be agitated and is disoriented. Haloperidol can be administered by Injection #1 or Injection #2 in the following figure. Furthermore, this injection should be given into which of the following skin layers?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240309275585e6-300f-4dcb-bcc6-ad2c5e1ddcc0.jpg\">", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Intramuscular (IM) injections</strong> like <strong>haloperidol decanoate</strong> are typically administered deep into <strong>skeletal muscle</strong>, allowing for <strong>sustained release</strong> and prolonged action, ideal for patients with poor compliance or in acute psychosis.</li>\n<li><strong>Injection #2</strong> in the image represents an <strong>IM injection</strong> technique.</li>\n<li><strong>Level D</strong> corresponds to the <strong>muscle layer</strong>.</li>\n<li>In contrast, <strong>Injection #1</strong> is subcutaneous (SC), targeting the <strong>subcutaneous fat layer</strong> (<strong>Level C</strong>), which is not preferred for depot neuroleptics like haloperidol.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509064288e6ec-a439-4d0a-97b1-94b3efc210b3.png\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Injection-1, Level-A (Option A):</strong> This targets the <strong>epidermis</strong>, used for <strong>intradermal injections</strong> (e.g., PPD test), not for deep drug depot injections.</p>\n<p><strong>Injection-2, Level-B (Option B):</strong> This is within the <strong>dermis</strong>, still too superficial for haloperidol IM use.</p>\n<p><strong>Injection-1, Level-C (Option C):</strong> This represents <strong>subcutaneous tissue</strong>, which does not provide the prolonged depot effect needed for antipsychotics.</p>", "options": ["Injection-1, Level-A", "Injection-2, Level-B", "Injection-1, Level-C", "Injection-2, Level-D"], "html_options": ["Injection-1, Level-A", "Injection-2, Level-B", "Injection-1, Level-C", "Injection-2, Level-D"], "corr_idx": 3}, {"id": "1166564", "html_qtxt": "A 52-year-old woman with an overactive bladder complains of urinary frequency, prescribes a transdermal patch containing an anticholinergic agent is prescribed. The following figure represents a picture of the patch formulation of this medication. The drug reservoir is contained in which of the following letters of the figure?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403090e85367a-38bc-41ae-abd0-0747d27ad49f.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The <strong>transdermal route</strong> provides sustained systemic delivery of drugs through the skin. In a <strong>reservoir-type patch</strong>, components are clearly structured:</li>\n<li><strong>Letter C</strong> in the image denotes the <strong>drug reservoir</strong>, which holds the active drug (often in a gel or solution).</li>\n<li>This is <strong>enclosed between the impermeable backing (B)</strong> and the <strong>rate-controlling membrane (D)</strong>.</li>\n<li><strong>Letter A</strong>: The <strong>skin</strong> Surface.</li>\n<li><strong>Letter B</strong>: <strong>Backing layer</strong>: prevents drug escape to the environment.</li>\n<li><strong>Letter D</strong>: <strong>Release membrane</strong>: controls drug flow.</li>\n<li><strong>Letter E</strong>: <strong>Adhesive layer</strong>: maintains skin contact.</li>\n<li>These patches allow <strong>steady plasma drug levels</strong>, bypass <strong>first-pass metabolism</strong>, and improve <strong>patient compliance</strong>, especially in chronic conditions like overactive bladder.</li>\n</ul>", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 2}, {"id": "1166565", "html_qtxt": "A research group wants to assess the safety and toxicity profile of a new drug. A clinical trial is conducted with 20 volunteers to estimate the maximum tolerated dose and monitor the apparent toxicity of the drug. The study design is best described as which of the following phases of a clinical trial?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Phase 1 clinical trials</strong> are conducted primarily to evaluate:\n<ul>\n<li><strong>Safety</strong></li>\n<li><strong>Tolerability</strong></li>\n<li><strong>Pharmacokinetics (ADME)</strong></li>\n<li><strong>Pharmacodynamics<br /> </strong></li>\n</ul>\n</li>\n<li>These trials typically involve <strong>20-100 healthy volunteers</strong> and are designed to identify:\n<ul>\n<li><strong>Maximum tolerated dose (MTD)</strong></li>\n<li><strong>Dose-limiting toxicities (DLTs)</strong></li>\n<li><strong>Adverse event profile</strong></li>\n</ul>\n</li>\n</ul>\n<p>Phase 1 trials are usually <strong>non-therapeutic</strong> and are essential for establishing whether the drug is safe enough for <strong>further efficacy testing</strong> in patient populations.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906749eac99-03f1-4051-992e-5e4d650fde29.png\">", "options": ["Phase 1", "Phase 2", "Phase 3", "Phase 4"], "html_options": ["Phase 1", "Phase 2", "Phase 3", "Phase 4"], "corr_idx": 0}, {"id": "1166566", "html_qtxt": "Patients taking which of the following drugs should be advised to avoid drinking grapefruit juice?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Grapefruit juice is a well-known inhibitor of the <strong>cytochrome P450 3A4 (CYP3A4)</strong> enzyme in the <strong>liver and intestinal wall</strong>. Inhibition of this enzyme leads to:\n<ul>\n<li><strong>Reduced metabolism of CYP3A4 substrates</strong></li>\n<li><strong>Increased plasma concentrations of drugs</strong></li>\n<li><strong>Potential dose-dependent toxicity</strong></li>\n</ul>\n</li>\n<li><strong>Atorvastatin</strong> is primarily metabolised by <strong>CYP3A4</strong>. Grapefruit juice can increase its bioavailability significantly, thereby increasing the risk of <strong>myopathy</strong> or <strong>rhabdomyolysis</strong>.</li>\n</ul>\n<p>Other drugs similarly affected include:</p>\n<ul>\n<li>Calcium channel blockers (e.g. felodipine)</li>\n<li>Immunosuppressants (e.g. cyclosporine)</li>\n<li>Benzodiazepines (e.g. midazolam)</li>\n</ul>\n<p><strong>Mnemonic for CYP450 Inhibitors:</strong></p>\n<p><strong>\"SICKFACES.COM Group\"</strong></p>\n<p><strong>S</strong>odium valproate <strong></p>\n<p><strong>I</strong>soniazid</p>\n<p><strong>C</strong>imetidine</p>\n<p><strong>K</strong>etoconazole</p>\n<p><strong>F</strong>luconazole</p>\n<p><strong>A</strong>miodarone</p>\n<p><strong>C</strong>hloramphenicol</p>\n<p><strong>E</strong>rythromycin / Clarithromycin</p>\n<p><strong>S</strong>ulfonamides</p>\n<p><strong>C</strong>iprofloxacin</p>\n<p><strong>O</strong>meprazole</p>\n<p><strong>M</strong>etronidazole</p>\n<p><strong>Group</strong> = Grapefruit juice</p>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Amoxicillin (Option A) </strong>is a <strong>beta-lactam antibiotic</strong> that undergoes minimal hepatic metabolism and is primarily excreted unchanged in the urine. It is not metabolised by the cytochrome P450 (CYP450) enzyme system, including CYP3A4. Therefore, grapefruit juice does not affect its pharmacokinetics.</p>\n<p><strong>Aspirin (Option B): </strong>Aspirin (acetylsalicylic acid) is hydrolysed by esterases in the plasma and liver to form salicylic acid. It does not undergo significant metabolism via CYP3A4 or other CYP450 isoforms. Thus, grapefruit juice does not affect aspirin's metabolism or toxicity.</p>\n<p><strong>Sildenafil (Option D): </strong>Sildenafil is metabolised predominantly by CYP3A4, with a minor contribution from CYP2C9. Grapefruit juice can theoretically increase sildenafil plasma concentration. However, the clinical significance is modest at therapeutic doses. While caution is advised, it is not routinely contraindicated with grapefruit juice, unlike atorvastatin</p>", "options": ["Amoxicillin", "Aspirin", "Atorvastatin", "Sildenafil"], "html_options": ["Amoxicillin", "Aspirin", "Atorvastatin", "Sildenafil"], "corr_idx": 2}, {"id": "1166568", "html_qtxt": "A 36-year-old woman received AHSCT for AML. Her transplant course is complicated by GVHD with diarrhoea, weight loss, and skin rash. She is immunosuppressed with tacrolimus 1 mg twice a day (bid) and prednisone 7.5 mg daily. She was recently admitted to the hospital with shortness of breath and a fever to 101.5 F. She has a chest computed tomography (CT) showing nodular pneumonia, and fungal organisms are seen on a transbronchial lung biopsy. The culture demonstrates Aspergillus fumigatus, and a serum galactomannan level is elevated. She is initiated on therapy with voriconazole 6 mg/kg IV. Two days after starting voriconazole, she is no longer febrile but is complaining of headaches and tremors. Her blood pressure is 160/90 mmHg, up from 110/70 mmHg on admission. On examination, she has developed 1+ pitting oedema in the lower extremities. Her creatinine has risen to 2.0 mg/dL from 1.0 mg/dL on admission. What is the most likely cause of the patient's current clinical picture?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Tacrolimus is a calcineurin inhibitor used to prevent transplant rejection. It is <strong>extensively metabolised by CYP3A4</strong>.</li>\n<li>Voriconazole is a <strong>potent CYP3A4 inhibitor</strong>, and when co-administered, <strong>inhibits tacrolimus metabolism</strong>, leading to <strong>elevated plasma levels</strong> of tacrolimus and enhanced toxicity.</li>\n<li><strong>Clinical manifestations of tacrolimus toxicity</strong> include:\n<ul>\n<li><strong>Neurotoxicity</strong>: Headaches, tremors, confusion, seizures</li>\n<li><strong>Nephrotoxicity</strong>: Acute kidney injury (&uarr; serum creatinine)</li>\n<li><strong>Hypertension</strong></li>\n<li><strong>Hyperkalemia</strong></li>\n</ul>\n</li>\n<li>In this case, the temporal association between <strong>starting voriconazole</strong> and the <strong>onset of symptoms</strong>, including <strong>renal dysfunction</strong> and <strong>neurological findings</strong>, strongly suggests <strong>tacrolimus toxicity</strong>.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Aspergillus meningitis (Option A): </strong>CNS involvement from Aspergillus is rare and presents with altered mental status, seizures. This patient is afebrile, alert, and responsive, making this <strong>less likely</strong>.</p>\n<p><strong>Congestive heart failure (Option B): </strong>There is no <strong>cardiac history</strong>, <strong>dyspnea on exertion</strong>, <strong>orthopnea</strong>, or <strong>cardiac imaging findings</strong> to support this diagnosis. BP elevation and renal dysfunction are more consistent with tacrolimus toxicity.</p>\n<p><strong>Recurrent GVHD (Option C): </strong>GVHD can involve skin, liver, GI tract, but <strong>typically does not present with hypertension or nephrotoxicity</strong>. The <strong>timing</strong> and drug interaction are more suggestive of tacrolimus toxicity.</p>", "options": ["Aspergillus meningitis", "Congestive heart failure", "Recurrent graft-versus-host disease", "Tacrolimus toxicity"], "html_options": ["Aspergillus meningitis", "Congestive heart failure", "Recurrent graft-versus-host disease", "Tacrolimus toxicity"], "corr_idx": 3}, {"id": "1166572", "html_qtxt": "A 43-year-old woman is diagnosed with pulmonary blastomycosis and is initiated on oral itraconazole therapy. All of the following could affect the bioavailability of this drug except:", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Itraconazole is a <strong>triazole antifungal</strong> used orally in the treatment of systemic fungal infections such as blastomycosis. Its <strong>bioavailability is highly variable</strong> and can be affected by <strong>multiple factors</strong>:</li>\n<li><strong>Gastric pH</strong>: The <strong>capsule form</strong> of itraconazole requires an <strong>acidic pH</strong> for dissolution and absorption. Concurrent use of antacids, H2-blockers, or proton pump inhibitors <strong>reduces its absorption</strong>. Co-administration with <strong>cola beverages (acidic)</strong> enhances bioavailability under hypochlorhydric conditions <strong>(Options A and D).</strong></li>\n<li><strong>Formulation differences</strong>: <strong>Capsule vs. solution</strong>, the <strong>solution has better and more consistent bioavailability</strong> and is less pH-dependent than the capsule form. Therefore, switching formulations changes systemic availability.<strong> (Option C)</strong></li>\n<li><strong>Oral contraceptives</strong> (estrogen/progestin combinations) <strong>do not alter gastric pH or drug formulation</strong>, and have <strong>no significant effect</strong> on the <strong>absorption</strong> or <strong>first-pass metabolism</strong> of itraconazole. Hence, this option <strong>does not influence bioavailability</strong>.</li>\n</ul>", "options": ["Co-administration with a cola beverage", "Co-administration with oral contraceptive pills", "Formulation of the drug (liquid vs. capsule)", "pH of the stomach"], "html_options": ["Co-administration with a cola beverage", "Co-administration with oral contraceptive pills", "Formulation of the drug (liquid vs. capsule)", "pH of the stomach"], "corr_idx": 1}, {"id": "1166573", "html_qtxt": "A 43-year-old presents today complaining of a new rash on his chest and axilla, which you diagnose as tinea corporis. He has a history of HIV, hypertension, coronary artery disease, atrial fibrillation, and ischemic cardiomyopathy. He is on antiretroviral therapy. You would like to prescribe a course of oral ketoconazole for therapy. You should consider dose adjustment for all of the following medicines that he is already taking, except:", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Carvedilol</strong> is predominantly metabolised by <strong>CYP2D6 and CYP2C9</strong>, and only to a minor extent by <strong>CYP3A4</strong>.</li>\n<li>Therefore, co-administration with <strong>ketoconazole</strong> (a <strong>potent CYP3A4 inhibitor</strong>) <strong>would not significantly alter its metabolism</strong> or serum levels. Hence, <strong>no dose adjustment is required</strong>.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Lovastatin (Option B):</strong> Lovastatin undergoes <strong>extensive first-pass metabolism</strong> via <strong>CYP3A4</strong>. Co-administration with ketoconazole significantly increases serum concentrations, raising the risk of <strong>statin-induced myopathy or rhabdomyolysis</strong>. Dose reduction or switching to a non-CYP3A4 statin (e.g., pravastatin) is recommended.</p>\n<p><strong>Mexiletine (Option C):</strong> Although mexiletine is metabolised mainly via <strong>CYP1A2</strong>, it is also partially metabolised via <strong>CYP3A4</strong>. Co-administration with ketoconazole may lead to <strong>slower metabolism</strong> and increased plasma levels, warranting caution or dose monitoring.</p>\n<p><strong>Ritonavir (Option D):</strong> Ritonavir is both a substrate and a potent <strong>inhibitor</strong> of <strong>CYP3A4</strong>. When combined with ketoconazole, <strong>mutual interactions</strong> occur, leading to altered levels of both agents. Caution and therapeutic drug monitoring are advised.</p>", "options": ["Carvedilol", "Lovastatin", "Mexiletine", "Ritonavir"], "html_options": ["Carvedilol", "Lovastatin", "Mexiletine", "Ritonavir"], "corr_idx": 0}, {"id": "1166577", "html_qtxt": "Which of the following sets of drug interactions and mechanisms is accurately described?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Sildenafil, a <strong>phosphodiesterase-5 (PDE5) inhibitor</strong>, elevates <strong>cyclic guanosine monophosphate (cGMP)</strong> by blocking its degradation.</li>\n<li>Nitroglycerin also elevates cGMP by <strong>stimulating guanylyl cyclase</strong> through nitric oxide release.</li>\n<li>When used together, they can cause <strong>profound vasodilation and dangerous hypotension</strong>, especially in patients with <strong>coronary artery disease</strong>. Co-prescription is contraindicated due to this <strong>synergistic hypotensive effect</strong>.</li>\n<li><strong>Ibuprofen</strong>, an NSAID, <strong>does not inhibit CYP2C9</strong> but may <strong>displace warfarin from albumin</strong>, increasing free warfarin levels. Both drugs also cause <strong>GI mucosal damage</strong>, compounding <strong>bleeding risk</strong>, but the proposed <strong>mechanism via CYP2C9 inhibition is incorrect</strong>. <strong>(Option A ruled out).</strong></li>\n<li><strong>Sotalol prolongs QT</strong> by blocking potassium channels. <strong>Furosemide does not inhibit CYP3A4</strong>; it can cause <strong>hypokalemia</strong>, which may potentiate sotalol's effect, but <strong>the mechanism described is incorrect</strong>.<strong> (Option B ruled out)</strong></li>\n<li>The interaction is <strong>accurate in terms of tacrolimus toxicity</strong>, but <strong>ritonavir</strong> is not involved in this interaction. Clarithromycin inhibits <strong>CYP3A4</strong>, not CYP2C19. Thus, the <strong>mechanism and drug pairing are inaccurate. (Option D ruled out)</strong></li>\n</ul>", "options": ["Ibuprofen and warfarin: increased risk of GI bleeding; ibuprofen inhibits CYP2C9", "Sotalol and furosemide: increased risk of QT prolongation and torsades de pointes; furosemide induced inhibition of CYP3A4", "Sildenafil and sublingual nitroglycerin: increased risk of hypotension; sildenafil inhibits the PDE-5, which inactivates cyclic guanosine monophosphate", "Ritonavir and lovastatin: increased risk of myotoxicity; ritonavir inhibition of CYP2C19"], "html_options": ["Ibuprofen and warfarin: increased risk of GI bleeding; ibuprofen inhibits CYP2C9", "Sotalol and furosemide: increased risk of QT prolongation and torsades de pointes; furosemide induced inhibition of CYP3A4", "Sildenafil and sublingual nitroglycerin: increased risk of hypotension; sildenafil inhibits the PDE-5, which inactivates cyclic guanosine monophosphate", "Ritonavir and lovastatin: increased risk of myotoxicity; ritonavir inhibition of CYP2C19"], "corr_idx": 2}, {"id": "1166580", "html_qtxt": "All of the following patients are correctly matched to the drug and dose adjustment that should be considered given their concomitant listed comorbidity, except:", "html_expl": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Sotalol</strong> is almost <strong>exclusively eliminated by the kidneys</strong>, with minimal hepatic metabolism. Hence, <strong>hepatic impairment (cirrhosis)</strong> does <strong>not</strong> warrant a dose reduction.</li>\n<li>Dose adjustment should instead be based on <strong>renal function.</strong></li>\n<li>Although <strong>meperidine</strong> is primarily metabolised by the <strong>liver</strong>, its <strong>toxic metabolite normeperidine</strong> is <strong>renally excreted</strong>. In renal impairment, normeperidine can accumulate and cause <strong>CNS toxicity</strong> (tremors, seizures). Therefore, <strong>dose reduction in renal disease is necessary</strong>. <strong>(Option B) </strong></li>\n<li><strong>Diazepam</strong> is metabolised in the liver and has a <strong>long half-life</strong>. In elderly patients, even those with normal hepatic/renal labs, <strong>increased sensitivity</strong> and <strong>altered pharmacokinetics</strong> (due to fat redistribution and reduced clearance) necessitate dose adjustment. <strong>(Option C)</strong></li>\n<li><strong>Cirrhosis impairs hepatic metabolism</strong>, leading to <strong>reduced clearance</strong> of meperidine. Additionally, <strong>altered hepatic blood flow</strong> can increase the drug&rsquo;s <strong>plasma concentration</strong>, justifying a dose reduction in cirrhotic patients. <strong>(Option D)</strong></li>\n</ul>", "options": ["A 57-year-old man with cirrhosis: reduced dose of sotalol", "A 35-year-old man with renal disease: reduced dose of meperidine", "A 97-year-old man with normal creatinine and bilirubin: reduced dose of diazepam", "A 42-year-old man with cirrhosis: reduced dose of meperidine"], "html_options": ["A 57-year-old man with cirrhosis: reduced dose of sotalol", "A 35-year-old man with renal disease: reduced dose of meperidine", "A 97-year-old man with normal creatinine and bilirubin: reduced dose of diazepam", "A 42-year-old man with cirrhosis: reduced dose of meperidine"], "corr_idx": 0}]}, {"moduleId": 1008533, "name": "Cholinergic Drugs, Anticholinergic Drugs", "questions": [{"id": "1166317", "html_qtxt": "Which of the following is the primary second messenger in the contraction of the ciliary muscles when focusing on near objects?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>IP3 </strong>is the<strong> primary second messenger</strong> in the contraction of the ciliary muscles when focusing on near objects. </p>\n<p><strong>Cholinomimetics</strong> primarily cause smooth muscle contraction through their action on M3 Gq-coupled receptors, leading to the release of intracellular calcium. This release is triggered by an increase in IP3 acting on <strong>IP3 receptors </strong>in the <strong>endoplasmic reticulum.</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906a1e80cca-ad1d-4485-98a5-dfc101800f8f.PNG\">\n<h3>Hormone Classification</h3>\n<h3>Types of Hormones</h3>\n<ul>\n<li>Insulin / Hypothalamic / Pituitary hormones</li>\n<li>These are polypeptide hormones that act via<strong> cell surface receptors</strong></li>\n</ul>\n<h3>Types of Cell Surface Receptors</h3>\n<h3>a. Tyrosine Kinase Receptors (TK): Activate Phosphatidylinositol cascade (PIG)</h3>\n<h4>b. GPCRs (G-protein Coupled Receptors): Non-PIG linked</h4>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906b05a4f4e-e821-400e-9287-e909d59c6416.PNG\">\n<h3>Steroid Hormone Receptors</h3>\n<p>Lipid-soluble &rarr; Intracellular receptors</p>\n<ul>\n<li>Cortisol &rarr; Cytoplasmic receptor</li>\n<li>Others &rarr; Nuclear receptor</li>\n</ul>", "options": ["cAMP", "DAG", "Depolarising influx of sodium ions via a channel", "IP3"], "html_options": ["cAMP", "DAG", "Depolarising influx of sodium ions via a channel", "IP3"], "corr_idx": 3}, {"id": "1166321", "html_qtxt": "Parasympathetic nerve stimulation and a slow infusion of bethanechol will each cause this.", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Parasympathetic nerve stimulation and a slow infusion of bethanechol will each cause an increase in <strong>bronchial smooth muscle tone.</strong></p>\n<ul>\n<li><strong>Bethanechol:</strong> A muscarinic receptor agonist (specifically M3), mimics parasympathetic stimulation. </li>\n<li><strong> Parasympathetic stimulation + Bethanechol</strong>: Increases bronchial smooth muscle tone (via M3 receptor activation), which causes bronchoconstriction.</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Cause ganglion cell depolarisation (Option A):</strong> Ganglion cells and the end plate contain nicotinic receptors, which are not affected by bethanechol, a direct-acting muscarinic agonist.</p>\n<p><strong>Cause vasodilation (Option B):</strong> Parasympathetic nerve stimulation does not cause vasodilation (most vessels do not receive parasympathetic innervation, even though some muscarinic receptors might be present there), so the choice is incorrect.</p>\n<p><strong>Increase heart rate (Option D):</strong> It does not increase heart rate; it typically decreases it via M2 receptors.</p>", "options": ["Cause ganglion cell depolarisation", "Cause vasodilation", "Increase bronchial smooth muscle tone", "Increase heart rate"], "html_options": ["Cause ganglion cell depolarisation", "Cause vasodilation", "Increase bronchial smooth muscle tone", "Increase heart rate"], "corr_idx": 2}, {"id": "1166328", "html_qtxt": "Actions and clinical uses of muscarinic cholinoceptor agonists include which one of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Muscarinic cholinergic receptor agonists </strong>aid in miosis and the treatment of narrow-angle glaucoma.</p>\n<ul>\n<li>Muscarinic agonists cause accommodation and cyclospasm, the opposite of paralysis of accommodation <strong>(cycloplegia)</strong>.</li>\n<li>Although not drugs of choice, in acute<strong> angle-closure glaucoma,</strong> this may result in a desirable increased outflow of the aqueous and a <strong>decrease in the intraocular pressure.</strong></li>\n<li>Muscarinic cholinergic receptor agonists may cause bronchospasm but do not affect neuromuscular transmission.</li>\n<li>Succinylcholine blocks the action of acetylcholine at the nicotinic receptor.</li>\n</ul>\n<h4>Muscarinic cholinoceptor agonists (e.g. pilocarpine, bethanechol) activate parasympathetic muscarinic receptors, leading to:</h4>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906d390eff5-5240-4895-81e9-8e3de07464a7.PNG\">\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Bronchodilation (treatment of asthma) (Option A): </strong>Muscarinic agonists cause bronchoconstriction, not bronchodilation.</p>\n<p><strong>Decreased gastrointestinal motility (treatment of diarrhoea) (Option C): </strong>They increase GI motility and would worsen diarrhoea.</p>\n<p><strong>Decreased neuromuscular transmission and relaxation of skeletal muscle (Option D): </strong>Muscarinic agonists do not act on nicotinic receptors at the neuromuscular junction.</p>", "options": ["Bronchodilation (treatment of asthma)", "Miosis (treatment of narrow-angle glaucoma)", "Decreased gastrointestinal motility (treatment of diarrhoea)", "Decreased neuromuscular transmission and relaxation of skeletal muscle (during surgical anaesthesia)"], "html_options": ["Bronchodilation (treatment of asthma)", "Miosis (treatment of narrow-angle glaucoma)", "Decreased gastrointestinal motility (treatment of diarrhoea)", "Decreased neuromuscular transmission and relaxation of skeletal muscle (during surgical anaesthesia)"], "corr_idx": 1}, {"id": "1166344", "html_qtxt": "A 76-year-old man with Alzheimer's disease is brought in with abdominal cramps, diarrhoea, diaphoresis, and muscular weakness and spasms in his extremities. He has ingested an excessive amount of medications in a suicide attempt. His temperature is 38.4&deg;C (101.1&deg;F), pulse is 51/min, respirations are 12/min and laboured, and blood pressure is 88/56 mm Hg. Treatment is initiated. Shortly after, most of his symptoms had resolved, but he continues to have muscular spasms. Administration of which of the following is the most appropriate next step in the treatment of this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with symptoms of <strong>muscarinic acetylcholine excess</strong> (e.g., diarrhoea, diaphoresis, bradycardia, bronchospasm, salivation, lacrimation, miosis) and <strong>nicotinic acetylcholine excess</strong> (e.g., muscle weakness).</p>\n<ul>\n<li>Atropine can only reverse the muscarinic effects.</li>\n<li>When taken in excess, medications for Alzheimer's disease, such as donepezil, can result in symptoms similar to those of <strong>organophosphate poisoning. </strong></li>\n<li>In such cases, <strong>pralidoxime</strong> is given to restore the activity of acetylcholinesterase, which then catalyses the breakdown of excessive acetylcholine to reverse symptoms.</li>\n<li><strong>Atropine</strong> does not act on nicotinic cholinergic receptors and thus cannot treat symptoms of neuromuscular dysfunction, for which <strong>pralidoxime </strong>is still necessary.</li>\n</ul>\n<p><strong>Pralidoxime</strong> has poor blood-brain barrier penetration and can lead to a transient worsening of acetylcholinesterase inhibition following administration, which is why atropine is typically administered first to treat CNS symptoms and prevent further acetylcholinesterase inhibition.</p>\n<p><strong>Management of </strong><strong>a patient with suspected OP poisoning:</strong></p>\n<ul>\n<li>Patient decontamination (e.g., remove clothes, wash skin)</li>\n<li>Secure airways, oxygen therapy, and ECG</li>\n<li>Measurement of erythrocyte cholinesterase activity: &darr; acetylcholinesterase activity</li>\n<li><strong>Atropine</strong></li>\n<li><strong>Oximes:</strong> Pralidoxime (2-PAM), obidoxime\n<ol>\n<li>Regenerate acetylcholinesterase by dephosphorylation</li>\n<li>Function peripherally on both muscarinic and nicotinic receptors</li>\n<li>Should only be administered after atropine due to the risk of transient worsening of acetylcholinesterase inhibition</li>\n</ol>\n</li>\n<li>Benzodiazepines (e.g., diazepam): to control organophosphate-induced seizures.</li>\n</ul>\n<p><strong>Direct-Acting Cholinomimetics</strong> (Muscarinic/Nicotinic Agonists)</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509068b3e12e8-ad8b-4499-b78b-700eae86bb77.PNG\">\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090638374175-ad7e-4e40-b898-0f56dfa0ff5d.PNG\">", "options": ["Carbachol", "Physostigmine", "Benztropine", "Pralidoxime"], "html_options": ["Carbachol", "Physostigmine", "Benztropine", "Pralidoxime"], "corr_idx": 3}, {"id": "1166363", "html_qtxt": "Which of the following is a direct-acting cholinomimetic that is lipid-soluble and is used to facilitate smoking cessation?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Varenicline</strong> is a lipid-soluble partial agonist at nicotinic receptors and is used to<strong> reduce craving for tobacco in smokers.</strong></p>\n<ul>\n<li>Side effects of this drug include <strong>abnormal dreams</strong> (most common), SJS, and erythema multiforme</li>\n</ul>\n<p><strong>Treatment for smoking cessation:</strong></p>\n<ul>\n<li>Counselling and support</li>\n<li>Varenicline (alpha-4-beta-2 nACHR partial agonist): reduces positive symptoms and prevents withdrawal</li>\n<li>Bupropion: reduces craving and withdrawal symptoms</li>\n<li>Nicotine replacement therapy (inhaler, lozenges, transdermal patch, nasal spray, gum)</li>\n</ul>", "options": ["Acetylcholine", "Bethanechol", "Neostigmine", "Varenicline"], "html_options": ["Acetylcholine", "Bethanechol", "Neostigmine", "Varenicline"], "corr_idx": 3}, {"id": "1166368", "html_qtxt": "A 3-year-old child is admitted after consuming multiple tablets. The signs suggest that the drug is a cholinomimetic with little or no vascular effect, little or no CNS effect, and a duration of action of about 2-4 h. Which of the following is the most likely cause of these effects?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Child Ingests Cholinomimetic drug </strong>and presents with signs including little or no vascular effect, little or no CNS (central nervous system) effect, and a duration of action of about 2-4 hours.</p>\n<ul>\n<li>These signs suggest the child has ingested a cholinomimetic drug primarily acting on muscarinic receptors with limited or no nicotinic receptor activity.</li>\n</ul>\n<p>So, the drug is probably<strong> pilocarpine, </strong>which is a muscarinic agonist primarily affecting the eye and salivary glands.</p>\n<ul>\n<li>Limited vascular and CNS effects.</li>\n<li>Duration of action is within 2-4 hours.</li>\n<li>Used for glaucoma and xerostomia (dry mouth).</li>\n</ul>\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Bethanechol (Option </strong><strong>A):</strong> Muscarinic agonist, primarily affects the GI and urinary tract, leading to increased tone and motility.</p>\n<ul>\n<li>Limited vascular and CNS effects.</li>\n<li>The duration of action is relatively shorter.</li>\n</ul>\n<p><strong>Neostigmine</strong><strong> (Option B):</strong> Reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at both muscarinic and nicotinic receptors.</p>\n<ul>\n<li>Used for myasthenia gravis and reversing non-depolarising neuromuscular blockers.</li>\n<li>Some CNS effects and vascular tone increase.</li>\n</ul>\n<p><strong>Physostigmine</strong><strong> (Option C):</strong> Acetylcholinesterase inhibitor, similar to neostigmine with pronounced muscarinic effects, limited nicotinic effects.</p>\n<ul>\n<li>Used to reverse anticholinergic toxicity.</li>\n<li>Has CNS effects, relatively short duration (30 minutes to 2 hours).</li>\n</ul>", "options": ["Bethanechol", "Neostigmine", "Physostigmine", "Pilocarpine"], "html_options": ["Bethanechol", "Neostigmine", "Physostigmine", "Pilocarpine"], "corr_idx": 3}, {"id": "1166387", "html_qtxt": "A 64-year-old man presents with a complaint of an urge to urinate that occurs suddenly, and he often is unable to make it to the bathroom before leaking urine. He has no incontinence with coughing or laughing. He has multiple sclerosis. Which of the following is the most appropriate pharmacotherapy for this patient's incontinence?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>In a patient with multiple sclerosis, a sudden urge to urinate that is not related to increased intra-abdominal pressure is consistent with <strong>urge incontinence due to detrusor hyperreflexia</strong> (upper motor neuron dysfunction).</p>\n<p><strong>Tolterodine</strong> is an antimuscarinic agent, selective for <strong>M3 receptors</strong> in the bladder that inhibits <strong>detrusor muscle overactivity,</strong> increases bladder capacity. First-line treatment for urge incontinence / overactive bladder and effective in <strong>neurogenic bladder, seen in MS.</strong></p>\n<ul>\n<li>In a healthy individual, bladder wall relaxation due to stimulation of &beta;3 receptors in the detrusor muscle allows storage of urine.</li>\n<li>During the storage phase, contraction of the trigone and sphincter muscles due to stimulation of &alpha;1 receptors at these sites maintains continence.</li>\n<li>Bladder wall contraction due to stimulation of M3 receptors in the detrusor muscle, and reflex inhibition of the trigone and sphincter allows for micturition to occur during the voiding phase.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906ab3b93db-6666-4155-944b-503a25a99922.PNG\">\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906cc751315-5746-4881-959b-15c0601fd885.PNG\">\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Doxazosin (Option A):</strong> Doxazosin is an &alpha;<sub>1</sub>-adrenergic antagonist that causes relaxation of the bladder neck and prostatic urethra, making it easier to void.</p>\n<ul>\n<li>It is used in the treatment of urinary retention and overflow incontinence caused by bladder outlet obstruction, such as in benign prostatic hyperplasia (BPH) or an overactive sphincter.</li>\n</ul>\n<p><strong>Bethanechol (Option B):</strong> Bethanechol is a parasympathomimetic (muscarinic agonist) that stimulates detrusor muscle contraction.</p>\n<ul>\n<li>It is used to treat urinary retention and overflow incontinence due to an underactive detrusor muscle, which may occur in multiple sclerosis patients with spinal cord lesions below the S1 level.</li>\n</ul>\n<p><strong>Midodrine (Option C):</strong> Midodrine is an &alpha;<sub>1</sub>-adrenergic agonist that increases tone in the urinary sphincter and detrusor muscle, leading to urinary retention.</p>\n<ul>\n<li>It is used in certain cases of stress incontinence caused by sphincter underactivity, such as in MS with lower spinal cord lesions (below S1).</li>\n</ul>", "options": ["Doxazosin", "Bethanechol", "Midodrine", "Tolterodine"], "html_options": ["Doxazosin", "Bethanechol", "Midodrine", "Tolterodine"], "corr_idx": 3}, {"id": "1166389", "html_qtxt": "A 28-year-old woman presents with the recent onset of weakness in her hands, diplopia, and difficulty swallowing. She has been treated for myasthenia gravis for several years. Which of the following is the best drug for distinguishing between myasthenic crisis and cholinergic crisis?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Edrophonium</strong> is the best drug for distinguishing between myasthenic crisis and cholinergic crisis. </p>\n<p>A patient with <strong>myasthenia gravis</strong> presents with worsening muscle weakness and bulbar symptoms (diplopia, dysphagia).</p>\n<p>This could be:</p>\n<ul>\n<li><strong>Myasthenic crisis</strong>: exacerbation of MG due to under-medication, stress, infection, etc.</li>\n<li><strong>Cholinergic crisis</strong>: due to excess acetylcholine (overmedication with AChE inhibitors), leading to desensitised receptors and paradoxical weakness.</li>\n</ul>\n<p><strong>Edrophonium Test (Amelorative/Tensilon Test): </strong>Short-acting acetylcholinesterase inhibitor (~10 min).</p>\n<p><strong>Mechanism:</strong> temporarily increases ACh at the neuromuscular junction.</p>\n<ul>\n<li>If muscle strength improves, &rarr; Myasthenic crisis</li>\n<li>If muscle weakness worsens, &rarr; Cholinergic crisis</li>\n</ul>\n<p>Thus, it helps differentiate between the two crises.</p>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Atropine (Option A): </strong>Muscarinic antagonist used to treat cholinergic toxicity, not a diagnostic tool.</p>\n<p><strong>Physostigmine (Option C): </strong>A tertiary amine AChE inhibitor that crosses the blood-brain barrier. Used primarily for anticholinergic toxicity, not in the diagnosis or management of myasthenia gravis.</p>\n<p><strong>Pyridostigmine (Option D): </strong>A long-acting AChE inhibitor used for maintenance therapy in myasthenia gravis. It does not have the rapid onset or short duration needed for a diagnostic challenge like edrophonium.</p>", "options": ["Atropine", "Edrophonium", "Physostigmine", "Pyridostigmine"], "html_options": ["Atropine", "Edrophonium", "Physostigmine", "Pyridostigmine"], "corr_idx": 1}, {"id": "1166391", "html_qtxt": "A 45-year-old farmer is admitted for Parathion poisoning. Which one of the following is its characteristic feature?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Parathion</strong> is an organophosphate insecticide. Its characteristic feature is that its toxicity can be partly reversed by <strong>pralidoxime (2-PAM)</strong> if administered early, before <strong>ageing</strong> occurs.</p>\n<p><strong>Mechanism of Organophosphate (OP) Toxicity & Reversal:</strong></p>\n<ul>\n<li>OPs like parathion <strong>inhibit acetylcholinesterase </strong>(AChE) by binding to the serine residue at the esteric site of the enzyme.</li>\n<li>Initially, this binding is reversible.</li>\n<li>Over time, the bond undergoes structural stabilisation, forming a covalent bond at the anionic site, a process known as<strong> \"ageing\".</strong>\n<ol>\n<li>Once ageing occurs, the enzyme is <strong>permanently inactivated.</strong></li>\n<li>The body must then synthesise new AChE, which takes time.</li>\n</ol>\n</li>\n<li><strong>Pralidoxime</strong>, an oxime, has a high affinity for the phosphorus atom in OPs and can reactivate AChE only before ageing.</li>\n<li>This is why <strong>early administration of pralidoxime</strong> is critical.</li>\n</ul>\n<p><strong>Contrast with Carbamates:</strong></p>\n<ul>\n<li><strong>Carbamates </strong>(e.g. physostigmine) bind both esteric and anionic sites.</li>\n<li>This makes oximes ineffective in carbamate poisoning.</li>\n</ul>", "options": ["If treated early, its toxicity may be partly reversed by pralidoxime", "It is less toxic to humans than malathion", "It is more persistent in the environment than DDT.", "It is poorly absorbed through the skin and lungs."], "html_options": ["If treated early, its toxicity may be partly reversed by pralidoxime", "It is less toxic to humans than malathion", "It is more persistent in the environment than DDT.", "It is poorly absorbed through the skin and lungs."], "corr_idx": 0}, {"id": "1166398", "html_qtxt": "A 38-year-old farmer has been accidentally exposed to a high concentration of a highly toxic agricultural organophosphate insecticide. What would be the sign/symptom of the condition ?<br>1. Sweating<br>2. Urination<br>3. Vomiting<br>4. Bradycardia<br>5. Mydriasis<br>6. Bronchorrhea<br>7. Hyperventilation", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Organophosphorus poisoning</strong> causes irreversible acetylcholinesterase inhibition and produces the following effects.</p>\n<p><strong>Muscarinic effects</strong></p>\n<ul>\n<li>Excess of secretions, including salivation, sweating, lacrimation, urination, defecation, and emesis. <strong>(Statements 1, 2, and 3 are true)</strong></li>\n<li>Miosis and blurred vision (Statement 5 is false)</li>\n<li>Bradycardia <strong>(Statement 4 is true)</strong></li>\n<li>Bronchospasm (Statement 7 is false)</li>\n<li>Bronchorrhea <strong>(Statement 6 is true)</strong></li>\n</ul>\n<p><strong>Nicotinic effects:</strong> Blockage at the neuromuscular junction (similar mechanism observed in succinylcholine)</p>\n<p><strong>Systemic effects</strong></p>\n<ul>\n<li>Hypoventilation</li>\n<li>Lethargy</li>\n<li>Seizures, coma</li>\n</ul>\n<p><strong>Antimuscarinic Drugs:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906f32eb57c-c5c4-4976-83d2-6fb77403757e.PNG\">", "options": ["1, 2, 3, 4, 5", "1, 2, 4, 6, 7", "1, 2, 3, 4, 6", "1, 2, 4, 5, 6"], "html_options": ["1, 2, 3, 4, 5", "1, 2, 4, 6, 7", "1, 2, 3, 4, 6", "1, 2, 4, 5, 6"], "corr_idx": 2}, {"id": "1166400", "html_qtxt": "A 40-year-old man with a history of major depression is admitted to the emergency department following a suicide attempt with a drug overdose. Which of the following signs or symptoms would be consistent with an overdose of a ganglion-blocking drug?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Tachycardia </strong>is a symptom that would be consistent with an <strong>overdose of a ganglion-blocking drug.</strong></p>\n<ul>\n<li>Ganglion blockade results in <strong>decreased blood pressure, bowel activity, and sweating.</strong></li>\n<li>Because the parasympathetic system dominates the pupil and the sinoatrial node, ganglion block causes mydriasis and tachycardia.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906cc63c834-3ea7-4a91-8c64-44aaf2f4ab58.PNG\">", "options": ["Increased blood pressure", "Increased bowel sounds", "Miosis", "Tachycardia"], "html_options": ["Increased blood pressure", "Increased bowel sounds", "Miosis", "Tachycardia"], "corr_idx": 3}, {"id": "1166402", "html_qtxt": "Several children were hospitalised with symptoms thought to be due to ingestion of food containing botulinum toxin. Which one of the following signs or symptoms is consistent with the diagnosis of botulinum poisoning?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Botulinum toxin</strong> inhibits <strong>presynaptic release of acetylcholine (ACh)</strong> at all <strong>cholinergic synapses</strong> by cleaving SNARE proteins like <strong>SNAP-25</strong>, which are essential for ACh vesicle fusion and neurotransmitter release.</p>\n<p>As a result, botulinum toxin impairs:</p>\n<ul>\n<li><strong>Somatic neuromuscular transmission</strong> &rarr; Flaccid paralysis</li>\n<li><strong>Parasympathetic activity</strong> &rarr; Mydriasis, <strong>cycloplegia</strong>, dry mouth, constipation</li>\n<li><strong>Autonomic ganglia</strong> &rarr; Hypotension, bradycardia (less prominent)</li>\n</ul>\n<p><strong>Botulinum toxin injections to relax wrinkles</strong>- this illustrates its <strong>spasmolytic</strong> effect, not spasm-inducing.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509069745eba2-5c8a-4da7-b8ce-79eca2f55f75.PNG\">\n<h3>Explanation for Other Options:</h3>\n<p><strong>Bronchospasm (Option A): </strong>This would result from <strong>cholinergic overactivity</strong>. Botulinum toxin causes <strong>bronchodilation</strong> due to parasympathetic blockade.</p>\n<p><strong>Skeletal muscle spasms (Option C): </strong>Botulinum toxin causes <strong>flaccid paralysis</strong>, not spasms. (Contrast this with tetanus toxin.)</p>\n<p><strong>Bradycardia (Option D): </strong>While autonomic blockade may cause <strong>some bradycardia</strong>, it is not as characteristic or reliable as <strong>cycloplegia</strong> for diagnosis.</p>", "options": ["Bronchospasm", "Cycloplegia", "Skeletal muscle spasms", "Bradycardia"], "html_options": ["Bronchospasm", "Cycloplegia", "Skeletal muscle spasms", "Bradycardia"], "corr_idx": 1}, {"id": "1166403", "html_qtxt": "A 27-year-old man is suspected of antimuscarinic drug overdose. Probable signs of overdose include which one of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Tachycardia</strong> is a characteristic of atropine (antimuscarinic drug) overdose.</p>\n<ul>\n<li>Bradycardia is sometimes observed after small doses.</li>\n<li>Atropine is the <strong>DOC for bradycardia.</strong></li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509068315eb9e-1d21-4d77-b2d4-5b7acd396c9c.PNG\">", "options": ["Gastrointestinal smooth muscle cramping", "Increased heart rate", "Increased gastric secretion", "Pupillary constriction"], "html_options": ["Gastrointestinal smooth muscle cramping", "Increased heart rate", "Increased gastric secretion", "Pupillary constriction"], "corr_idx": 1}, {"id": "1166406", "html_qtxt": "Which of the following is the effect of belladonna alkaloids ?<br>1. Dehydration<br>2. Hallucinations<br>3. Hypertension<br>4. Hyperthermia<br>5. Intraventricular heart block<br>6. Bradycardia<br>7. Bronchoconstriction", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Systemic Side Effects of Antimuscarinic (Belladonna Alkaloids) Drugs:</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509068f17a32d-d959-49e5-b307-d0a06e13da03.PNG\">", "options": ["1, 2, 3, 4", "2, 4, 5", "2, 5, 6", "1, 3, 4, 7"], "html_options": ["1, 2, 3, 4", "2, 4, 5", "2, 5, 6", "1, 3, 4, 7"], "corr_idx": 1}, {"id": "1166407", "html_qtxt": "Which one of the following can be blocked by atropine?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Atropine</strong> is a <strong>muscarinic receptor antagonist</strong>, meaning it <strong>b</strong>locks the actions of acetylcholine (ACh) at muscarinic receptors. It does not affect nicotinic receptors (e.g., at autonomic ganglia or neuromuscular junctions) or <strong>direct sympathetic adrenergic effects</strong>.</p>\n<p>Sweating caused by exercise is sympathetically mediated but <strong>cholinergic in mechanism</strong>.</p>\n<ul>\n<li>Eccrine sweat glands (involved in thermoregulation) are innervated by sympathetic cholinergic fibres.</li>\n<li>These fibres release <strong>ACh</strong>, which acts on <strong>muscarinic M3 receptors</strong> of sweat glands.</li>\n<li><strong>Atropine </strong>blocks these muscarinic receptors, thereby <strong>inhibiting sweating</strong>.</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Decreased blood pressure caused by hexamethonium (Option A): </strong>Hexamethonium is a ganglion blocker (nicotinic receptor antagonist at autonomic ganglia). Atropine acts postganglionically at muscarinic receptors, so it does not reverse ganglionic blockade effects like hypotension.</p>\n<p><strong>Increased blood pressure caused by nicotine (Option B): </strong>Nicotine stimulates nicotinic receptors at autonomic ganglia, leading to sympathetic discharge (&uarr; NE &rarr; vasoconstriction). Atropine does not block nicotinic receptors, hence no effect on this nicotine-induced hypertension.</p>\n<p><strong>Tachycardia caused by exercise (Option C): </strong>Exercise increases sympathetic adrenergic outflow &rarr; &beta;1 activation &rarr; &uarr; heart rate. Atropine only blocks parasympathetic vagal tone, not &beta;-adrenergic effects &rarr; no effect on sympathetic tachycardia.</p>\n<p><strong>Sweating & Autonomic Control</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906cd124fe5-3156-473a-bab4-a9503430fa96.PNG\">", "options": ["Decreased blood pressure caused by hexamethonium", "Increased blood pressure caused by nicotine", "Tachycardia caused by exercise", "Sweating caused by exercise"], "html_options": ["Decreased blood pressure caused by hexamethonium", "Increased blood pressure caused by nicotine", "Tachycardia caused by exercise", "Sweating caused by exercise"], "corr_idx": 3}, {"id": "1166409", "html_qtxt": "<p>Drug X caused a 50 mm Hg rise in mean blood pressure in the control animal, no blood pressure change in the ganglion-blocked animal, and a 75 mm Hg mean blood pressure rise in the atropine-pretreated animal. Drug X is probably a drug similar to</p>", "html_expl": "<p><strong>Explanation:</strong></p><p>Drug X causes an increase in blood pressure in the control animal but there is no increase in a ganglion blocked animal. The pressor response is increased by pretreatment with atropine, a muscarinic blocker, suggesting that compensatory vagal discharge (Parasympathetic response) is blocked by atropine thus a greater increase in Mean blood pressure (Sympathetic predominance). This shows that the response of Drug X is through <strong>autonomic ganglia which stimulates nicotinic receptors</strong> at ganglia. Among the given options Nicotine is a Ganglionic stimulant (Sympathetic stimulation leading to vasoconstriction and thus increase in Mean BP).</p><p><strong>Explanation for Incorrect Options:</strong><br><strong>Acetylcholine (Option A): </strong>Acts on muscarinic (M3 Receptors) which reduces Mean BP.</p><p><strong>Epinephrine (Option B): </strong>Epinephrine's pressor effects are produced at  receptors, not in the ganglia. It increases Systolic BP but decreases Diastolic BP and hence Mean BP only slightly increases or remains unchanged.</p><p><strong>Hexamethonium (Option C): </strong>It is a ganglion blocker and causes fall in Mean BP.</p>", "options": ["<p>Acetylcholine</p>", "<p>Epinephrine</p>", "<p>Hexamethonium</p>", "<p>Nicotine</p>"], "html_options": ["<p>Acetylcholine</p>", "<p>Epinephrine</p>", "<p>Hexamethonium</p>", "<p>Nicotine</p>"], "corr_idx": 3}, {"id": "1166410", "html_qtxt": "A 43-year-old man is presented with confusion and strange behavior. His friend reports that he was eating some wild berries that they had picked during their camping trip. His temperature is 38.7&deg;C (101.7&deg;F). Physical examination shows warm, dry skin and dry mucous membranes. His pupils are dilated and minimally reactive to light. His bowel sounds are decreased. which of the following drugs could lead to complete resolution of symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with <strong>anticholinergic toxidrome</strong> following ingestion of wild berries, likely from <strong>Atropa belladonna (deadly nightshade),</strong> which contains <strong>atropine-like alkaloids.</strong></p>\n<ul>\n<li><strong>Physostigmine</strong> is a reversible acetylcholinesterase inhibitor that crosses the blood-brain barrier (BBB).</li>\n<li>It increases<strong> acetylcholine levels both centrally and peripherally,</strong> thereby reversing CNS and peripheral symptoms of atropine toxicity.</li>\n<li>It is the drug of choice in severe<strong> anticholinergic toxicity</strong>, particularly with central manifestations like delirium.</li>\n<li>Don't confuse with <strong>Pyridostigmine</strong> as it <strong>does not cross the BBB </strong>and cannot treat CNS symptoms such as delirium from atropine overdose.</li>\n<li>Pyridostigmine is used for myasthenia gravis and prophylaxis against organophosphates.</li>\n</ul>\n<p>Key <strong>clinical features</strong> of anticholinergic syndrome:</p>\n<ul>\n<li>Hyperthermia (due to decreased sweating)</li>\n<li>Dry skin and mucous membranes</li>\n<li>Mydriasis (dilated pupils minimally reactive to light)</li>\n<li>Decreased bowel sounds</li>\n<li>Confusion, agitation, delirium</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Scopolamine (Option A):</strong> A muscarinic antagonist like atropine, which would worsen anticholinergic symptoms rather than treat them.</p>\n<p><strong>Atropine (Option B):</strong> Also a muscarinic antagonist; it is the cause of anticholinergic toxicity in this context. Not therapeutic here.</p>\n<p><strong>Neostigmine (Option D):</strong> A quaternary acetylcholinesterase inhibitor that does not cross the BBB &rarr; ineffective for central symptoms such as confusion or delirium. Used for the reversal of non-depolarising neuromuscular blockers and urinary retention.</p>", "options": ["Scopolamine", "Atropine", "Physostigmine", "Neostigmine"], "html_options": ["Scopolamine", "Atropine", "Physostigmine", "Neostigmine"], "corr_idx": 2}, {"id": "1166411", "html_qtxt": "A 38-year-old man has been admitted to the emergency department showing signs of autonomic drug toxicity. Which of the following signs would distinguish between an overdose of a ganglion blocker versus a muscarinic blocker?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Postural hypotension</strong> is a result of loss of sympathetic vasoconstrictor tone, which helps maintain blood pressure upon standing.</p>\n<ul>\n<li>This effect is characteristic of<strong> ganglion blockers,</strong> since they block sympathetic ganglia.</li>\n<li>Muscarinic blockers do not block sympathetic ganglia, so they do not typically cause postural hypotension.</li>\n</ul>\n<p>To distinguish between an overdose of a <strong>ganglion blocker</strong> and a <strong>muscarinic receptor antagonist</strong>, we need to consider which part of the autonomic nervous system is being affected:</p>\n<ul>\n<li><strong>Ganglion blockers</strong> (e.g., hexamethonium, mecamylamine) block nicotinic receptors at autonomic ganglia, inhibiting both sympathetic and parasympathetic transmission.</li>\n<li><strong>Muscarinic blockers</strong> (e.g., atropine, scopolamine) selectively inhibit parasympathetic postganglionic muscarinic receptors, sparing most sympathetic functions (except those mediated via ACh, like sweating).</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Cycloplegia (Option A):</strong> Both ganglion blockers and muscarinic antagonists can cause cycloplegia (loss of accommodation), since this is controlled by parasympathetic innervation to the ciliary muscle.</p>\n<p><strong>Dry skin in a warm environment (Option B):</strong> Seen with muscarinic blockers, due to inhibition of sympathetic cholinergic fibres to eccrine sweat glands. Ganglion blockers can also reduce sweating by blocking all autonomic output, so this sign is not distinguishing.</p>\n<p><strong>Miosis (Option C):</strong> Neither drug class typically causes miosis. Both can cause mydriasis by inhibiting parasympathetic tone to the pupillary sphincter muscle.</p>", "options": ["Cycloplegia", "Dry skin in a warm environment", "Miosis", "Postural hypotension"], "html_options": ["Cycloplegia", "Dry skin in a warm environment", "Miosis", "Postural hypotension"], "corr_idx": 3}, {"id": "1166412", "html_qtxt": "Which one of the following drugs causes vasodilation that can be blocked by atropine?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Bethanechol</strong> is a <strong>direct-acting muscarinic agonist.</strong> It stimulates muscarinic receptors on various smooth muscles, including endothelial M3 receptors in blood vessels. This leads to:</p>\n<ol>\n<li><strong>&uarr; Nitric oxide </strong>(NO) release from endothelial cells</li>\n<li><strong>&rarr; Vasodilation</strong></li>\n<li><strong>&rarr; &darr; Blood pressure</strong></li>\n</ol>\n<p>This effect can be blocked<strong> by atropine,</strong> a muscarinic antagonist, which prevents acetylcholine or muscarinic agonists from binding to M3 receptors.</p>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Benztropine (Option A): </strong>A central antimuscarinic used in Parkinson&rsquo;s disease. It does not cause vasodilation; rather, it can cause tachycardia and dry skin due to muscarinic blockade.</p>\n<p><strong>Edrophonium (Option C):</strong> A short-acting acetylcholinesterase inhibitor (AChEI) used to diagnose myasthenia gravis. It increases endogenous ACh, but since M3 endothelial receptors are not innervated, no vasodilation occurs. Also, its effect is primarily at the neuromuscular junction.</p>\n<p><strong>Neostigmine (Option D):</strong> Another AChEI, mainly acting peripherally. Like edrophonium, it increases ACh but does not cause vasodilation because endothelial M3 receptors lack direct cholinergic innervation.</p>", "options": ["Benztropine", "Bethanechol", "Edrophonium", "Neostigmine"], "html_options": ["Benztropine", "Bethanechol", "Edrophonium", "Neostigmine"], "corr_idx": 1}, {"id": "1166533", "html_qtxt": "A 19-year-old woman comes to the physician because of increased sweating for the past 6 months. She experiences severe sweating that is triggered by stressful situations and speaking in public. She is failing one of her university classes because she avoids public speaking. She has not had any fevers, chills, weight loss, or night sweats. Her temperature is 36.6&deg;C (98&deg;F). Physical examination shows moist skin in the axillae and on the palms, soles, and face. Which of the following drugs is most likely to be effective for this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Glycopyrrolate</strong> is a peripherally acting muscarinic antagonist.</p>\n<ul>\n<li>It blocks muscarinic receptors on sweat glands, thereby reducing excessive sweating.</li>\n<li>It does not cross the blood-brain barrier, so it avoids central nervous system (CNS) side effects.</li>\n<li><strong>Sweat glands</strong> (especially eccrine glands) are unique in that they are innervated by sympathetic nerves that release acetylcholine, acting on muscarinic receptors.</li>\n</ul>\n<p>This patient presents with <strong>primary focal hyperhidrosis</strong>, particularly exacerbated by emotional stimuli (e.g., public speaking), and<strong> localised to the palms, soles, axillae, and face.</strong> This type of sweating is due to overactive sympathetic cholinergic stimulation of eccrine sweat glands.</p>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Pilocarpine (Option A): </strong>A muscarinic agonist &ndash; it stimulates sweat glands, salivary glands, and other exocrine glands. This would worsen hyperhidrosis.</p>\n<p><strong>Bethanechol (Option B): </strong>Another muscarinic agonist, mainly used for urinary retention and GI hypomotility. Like pilocarpine, it would increase sweating.</p>\n<p><strong>Physostigmine (Option C):</strong> A reversible acetylcholinesterase inhibitor. Increases ACh levels &rarr; stimulates muscarinic receptors &rarr; increases sweating. Also crosses the BBB, which may cause CNS side effects (e.g., seizures).</p>", "options": ["Pilocarpine", "Bethanechol", "Physostigmine", "Glycopyrrolate"], "html_options": ["Pilocarpine", "Bethanechol", "Physostigmine", "Glycopyrrolate"], "corr_idx": 3}, {"id": "1166537", "html_qtxt": "Drugs acting on A and B<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024031935b44051-c293-44d8-befc-cd12e67f8f71.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The drugs acting on sites<strong> A and B</strong> are</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403198c688212-4fa2-4164-b7a6-8e5f25e7b691.jpg\">\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509064c4f8199-6c76-44e5-82b5-591caf7d5408.PNG\">", "options": ["A: Hemicholinium, B: Vesamicol", "A: Vesamicol, B: Hemicholinium", "A: Botulinum, B: Vesamicol", "A: Vesamicol, B: Botulinum"], "html_options": ["A: Hemicholinium, B: Vesamicol", "A: Vesamicol, B: Hemicholinium", "A: Botulinum, B: Vesamicol", "A: Vesamicol, B: Botulinum"], "corr_idx": 0}, {"id": "1166541", "html_qtxt": "A 53-year-old woman with schizophrenia managed for years with a drug, complains of a dry mouth, constipation, blurred vision, and feeling tired. Which of the following drugs was given, causing the given side effects?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>All of the given drugs <strong>have anticholinergic effects</strong>, but out of these, only <strong>Chlorpromazine is an antipsychotic drug.</strong></p>\n<p><strong>Chlorpromazine</strong> is a <strong>typical antipsychotic </strong>(low potency, first-generation) with strong antimuscarinic (anticholinergic) effects. It also has sedative properties due to histamine (H1) receptor blockade.</p>\n<p><strong>Anticholinergic side effects</strong> include:</p>\n<ul>\n<li>Dry mouth</li>\n<li>Constipation</li>\n<li>Blurred vision</li>\n<li>Urinary retention</li>\n<li>Sedation/fatigue</li>\n</ul>\n<p>Explanation for Other Options:</p>\n<p><strong>Benztropine (Option A): </strong>Anticholinergic used to treat extrapyramidal symptoms (EPS) in Parkinsonism or drug-induced dystonia. While it causes similar anticholinergic side effects, it is not used to treat schizophrenia, making it unlikely in this context.</p>\n<p><strong>Amitriptyline (Option B): </strong>A tricyclic antidepressant (TCA) with anticholinergic and antihistaminic effects. It can cause these symptoms, but it is used for depression, neuropathic pain, or migraine prophylaxis, not schizophrenia.</p>\n<p><strong>Cyclizine (Option C): </strong>An antihistamine (H1 blocker) used for motion sickness and nausea.<br /> It has mild anticholinergic properties, but again, not indicated for schizophrenia.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Drugs with Moderate to Strong Anticholinergic Effects:</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509068d1cc78d-582f-4bb8-a853-1c9da5366c04.PNG\">", "options": ["Benztropine", "Amitriptyline", "Cyclizine", "Chlorpromazine"], "html_options": ["Benztropine", "Amitriptyline", "Cyclizine", "Chlorpromazine"], "corr_idx": 3}, {"id": "1166548", "html_qtxt": "A 48-year-old woman complains of fatigue that increases throughout the day. At the end of her workday, she says her eyes feel \"heavy\" and \"droopy,\" although she does not feel particularly tired. A drug is prescribed to treat her myasthenia gravis. How does the drug work?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Myasthenia gravis</strong> is an autoimmune disorder in which <strong>autoantibodies attack nicotinic acetylcholine receptors (nAChRs) </strong>at the neuromuscular junction, leading to weakness, especially after exertion.</p>\n<ul>\n<li>The standard treatment includes <strong>acetylcholinesterase inhibitors such as pyridostigmine,</strong> which work by blocking acetylcholine degradation.</li>\n<li>This increases the amount of ACh available at the neuromuscular junction, allowing stimulation of the remaining unblocked receptors and<strong> improving muscle strength</strong>.</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Stimulates nicotinic cholinergic receptors (Option B):</strong> Drugs like nicotine directly stimulate nicotinic receptors, but pyridostigmine does not act directly on receptors; it enhances endogenous ACh action by preventing its breakdown.</p>\n<p><strong>Stimulates acetylcholine release (Option C): </strong>While increased ACh release might be beneficial, pyridostigmine does not affect ACh release. Instead, it increases synaptic ACh levels by inhibiting acetylcholinesterase.</p>\n<p><strong>Stimulates muscarinic cholinergic receptors (Option D):</strong> Drugs such as bethanechol and pilocarpine are direct muscarinic agonists, affecting organs like the bladder or eye. Pyridostigmine affects both nicotinic and muscarinic systems indirectly by increasing ACh but is not a direct muscarinic agonist.</p>", "options": ["Blocks acetylcholine degradation", "Stimulates nicotinic cholinergic receptors", "Stimulates acetylcholine release", "Stimulates muscarinic cholinergic receptors"], "html_options": ["Blocks acetylcholine degradation", "Stimulates nicotinic cholinergic receptors", "Stimulates acetylcholine release", "Stimulates muscarinic cholinergic receptors"], "corr_idx": 0}, {"id": "1166551", "html_qtxt": "A 38-year-old woman presents to the ophthalmologist for a routine eye examination. She is given intraocular pilocarpine, two drops in each eye, to dilate the eyes for the examination. Unfortunately, the eyedrops were inadvertently administered 10 drops of pilocarpine in each eye. Which of the following agents should be immediately given to the patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Pilocarpine</strong> is a direct muscarinic cholinergic agonist used in ophthalmology to induce miosis (pupil constriction) and reduce intraocular pressure. An overdose may cause excessive parasympathomimetic effects, particularly:</p>\n<ul>\n<li>Profound miosis</li>\n<li>Ciliary muscle spasm &rarr; blurred vision</li>\n<li>Headache and eye discomfort</li>\n</ul>\n<p><strong>Atropine</strong> is the treatment of choice in this setting as it acts as a competitive muscarinic receptor antagonist, reversing excessive cholinergic effects by:</p>\n<ul>\n<li>Relaxing the sphincter pupillae muscle &rarr; Mydriasis</li>\n<li>Relieving ciliary muscle spasm</li>\n<li>Restoring visual comfort</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Carbachol (Option B): </strong>Another direct cholinergic agonist-it would worsen the symptoms by further stimulating muscarinic receptors, aggravating miosis and visual discomfort.</p>\n<p><strong>Galantamine (Option C): </strong>An acetylcholinesterase inhibitor used for Alzheimer's disease. It increases central ACh levels and has no role in reversing pilocarpine effects-may even worsen symptoms if systemically absorbed.</p>\n<p><strong>Rivastigmine (Option D): </strong>Similar to galantamine, this drug also inhibits acetylcholinesterase and cannot reverse muscarinic overstimulation in the eye.</p>", "options": ["Atropine", "Carbachol", "Galantamine", "Rivastigmine"], "html_options": ["Atropine", "Carbachol", "Galantamine", "Rivastigmine"], "corr_idx": 0}, {"id": "1166556", "html_qtxt": "A 52-year-old woman with end-stage multiple sclerosis who is on prednisone and neostigmine. After examination, the patient has begun on dalfampridine. What is the most likely mechanism of action for this medication?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Dalfampridine</strong> (also known as fampridine) is a potassium channel blocker used symptomatically in <strong>multiple sclerosis.</strong> Its primary benefit is improving walking ability, particularly gait speed, by <strong>enhancing conduction in demyelinated neurons.</strong></p>\n<ul>\n<li>In MS, demyelination slows or blocks action potential conduction.</li>\n<li>Blocking potassium channels helps prolong the action potential and enhance neurotransmission in demyelinated axons.</li>\n<li>It is not a disease-modifying therapy but provides symptomatic relief (especially for ambulation).</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Calcium channel blocker (Option A):</strong> Used in hypertension and angina, not indicated in MS. Example: Nifedipine.</p>\n<p><strong>Cholinesterase inhibitor (Option B): </strong>These agents increase acetylcholine levels but do not improve MS gait symptoms. Example: Pyridostigmine, used in myasthenia gravis. Neostigmine is already being used in this patient for another indication.</p>\n<p><strong>Sodium channel blocker (Option D): </strong>Some antiepileptics and local anaesthetics block sodium channels. However, dalfampridine does not act via this mechanism.</p>", "options": ["Calcium channel blocker", "Cholinesterase inhibitor", "Potassium channel blocker", "Sodium channel blocker"], "html_options": ["Calcium channel blocker", "Cholinesterase inhibitor", "Potassium channel blocker", "Sodium channel blocker"], "corr_idx": 2}, {"id": "1166558", "html_qtxt": "A 62-year-old man has increased intraocular pressure bilaterally. You start him on a drug used to treat his open-angle glaucoma, which also happens to cross the blood-brain barrier better than other drugs in its class. Which of the following drugs is this?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Physostigmine</strong> is a <strong>reversible acetylcholinesterase inhibitor</strong> that readily crosses the blood-brain barrier due to its tertiary amine structure. It enhances cholinergic activity in the eye by promoting contraction of the ciliary muscle, thereby <strong>increasing aqueous humour drainage</strong> through the trabecular meshwork and reducing intraocular pressure.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Echothiophate (Option A): </strong>An irreversible acetylcholinesterase inhibitor used for glaucoma, but does not cross the blood-brain barrier due to its quaternary ammonium structure.</p>\n<p><strong>Neostigmine (Option B): </strong>Commonly used for postoperative urinary retention and reversal of neuromuscular blockade. It is a quaternary compound and cannot enter the CNS.</p>\n<p><strong>Pyridostigmine (Option D): </strong>Primarily prescribed for myasthenia gravis. Like neostigmine, it is a quaternary amine and therefore does not penetrate the blood-brain barrier.</p>", "options": ["Echothiophate", "Neostigmine", "Physostigmine", "Pyridostigmine"], "html_options": ["Echothiophate", "Neostigmine", "Physostigmine", "Pyridostigmine"], "corr_idx": 2}, {"id": "1166560", "html_qtxt": "A 23-year-old man presented with focal dystonia. The drugs acting at which site can be used in treatment?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024031935b44051-c293-44d8-befc-cd12e67f8f71.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509065794d9e1-f434-4bc3-ab89-cc19c31f6cb1.jpg\">\n<p>As in the illustrated diagram, <strong>C) Botulinum toxin</strong> helps to relieve focal dystonia.</p>\n<p><strong>Other </strong><strong>uses of botulinum</strong> are</p>\n<ul>\n<li>Blepharospasm</li>\n<li>Hemifacial spasm</li>\n<li>Laryngeal dysphonia</li>\n<li>Cervical dystonia</li>\n<li>Jaw-closing oromandibular dystonia</li>\n</ul>", "options": ["A", "B", "C", "None of the above"], "html_options": ["A", "B", "C", "None of the above"], "corr_idx": 2}, {"id": "1166561", "html_qtxt": "Which of the following drugs is used for the Diagnosis of bronchial hypersensitivity?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Methacholine</strong> is a muscarinic receptor agonist that is used only for diagnostic purposes, specifically in the <strong>methacholine challenge test</strong>, which assesses <strong>bronchial hyperreactivity</strong>-a hallmark of asthma.</p>\n<ul>\n<li>It acts on muscarinic receptors in the <strong>airway smooth muscle</strong>, causing <strong>bronchoconstriction</strong>.</li>\n<li>Since it is a quaternary amine, it <strong>does not cross the blood-brain barrier</strong>.</li>\n<li>The test involves inhalation of increasing concentrations of methacholine, with spirometry used to detect a drop in <strong>FEV<sub>1</sub>. </strong></li>\n<li>A significant decrease confirms bronchial hyperresponsiveness.</li>\n<li>This drug is not used therapeutically due to its potential to cause severe bronchoconstriction.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Edrophonium (Option B):</strong> A very short-acting acetylcholinesterase inhibitor used primarily in the diagnosis of <strong>myasthenia gravis</strong> (edrophonium test). It does not act on muscarinic receptors in the lungs and is not involved in bronchial reactivity testing.</p>\n<p><strong>Cevimeline (Option C):</strong> A muscarinic agonist used in <strong>Sj&ouml;gren syndrome</strong> to stimulate salivary and sweat glands. It has no application in respiratory diagnostics.</p>\n<p><strong>Bethanechol (Option D):</strong> A muscarinic agonist that increases bladder and gastrointestinal smooth muscle tone, used in <strong>postoperative ileus and urinary retention</strong>. It does not affect bronchial tone in a diagnostic setting.</p>", "options": ["Methacholine", "Edrophonium", "Cevimeline", "Bethanechol"], "html_options": ["Methacholine", "Edrophonium", "Cevimeline", "Bethanechol"], "corr_idx": 0}, {"id": "1166562", "html_qtxt": "Match the following drugs with their indication<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090613080854-039e-4be9-bf57-4be90b426fbe.PNG\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090673e4487a-0292-4561-be00-02e122221588.PNG\">", "options": ["1-c, 2-b, 3-a, 4-d", "1-c, 2-a, 3-b, 4-d", "1-d, 2-a, 3-b, 4-c", "1-c, 2-b, 3-d, 4-a"], "html_options": ["1-c, 2-b, 3-a, 4-d", "1-c, 2-a, 3-b, 4-d", "1-d, 2-a, 3-b, 4-c", "1-c, 2-b, 3-d, 4-a"], "corr_idx": 0}, {"id": "1166571", "html_qtxt": "Match the type of incontinence with pharmacotherapy of the same<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024072342044ca2-fc20-4ed4-8176-cbb2e4335d65.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509061af13d72-0134-4d60-a881-034383e878b1.PNG\">", "options": ["A-1, B-3, C-2", "A-2, B-3, C-1", "A-2, B-1, C-3", "A-3, B-1, C-2"], "html_options": ["A-1, B-3, C-2", "A-2, B-3, C-1", "A-2, B-1, C-3", "A-3, B-1, C-2"], "corr_idx": 1}, {"id": "1166576", "html_qtxt": "You're being asked to use of drug given below in your pharmacology viva.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312121caa743f-5833-49b2-9642-1e542a5190d1.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Scopolamine</strong> is a <strong>muscarinic receptor antagonist</strong> (anticholinergic) that is particularly effective in the <strong>prevention and treatment of motion sickness</strong>.</p>\n<ul>\n<li>It acts on the vestibular system by inhibiting cholinergic transmission from the vestibular nuclei to the vomiting centre in the brainstem.</li>\n<li>It is typically administered via a <strong>transdermal patch</strong> for long-lasting prophylaxis.</li>\n<li>Acetazolamide is used for mountain sickness.</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Morning sickness (Option A): </strong>This is best treated with <strong>doxylamine + pyridoxine</strong>, <strong>not scopolamine</strong>.</p>\n<p><strong>Smoking cessation (Option C): </strong>This is treated with agents like <strong>nicotine patches</strong> or <strong>varenicline</strong>.</p>\n<p><strong>Analgesia (Option D): </strong>This is not a primary use of scopolamine.</p>", "options": ["Morning sickness", "Motion sickness", "Smoking cessation", "Analgesia"], "html_options": ["Morning sickness", "Motion sickness", "Smoking cessation", "Analgesia"], "corr_idx": 1}, {"id": "1166579", "html_qtxt": "A 67-year-old man with COPD needs longer longer-acting bronchodilator, which is the ideal candidate for the same?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Tiotropium bromide</strong> is a long-acting muscarinic antagonist (LAMA) that provides sustained bronchodilation by blocking M3 receptors, thereby preventing<strong> bronchoconstriction.</strong> It is ideal for long-term maintenance therapy in COPD, particularly for grades II and above&nbsp;</p>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Ipratropium bromide (Option B):</strong> A short-acting muscarinic antagonist (SAMA) with a shorter duration, used in mild COPD or acute settings.</p>\n<p><strong>Salbutamol (Option C): </strong>A short-acting beta2 agonist (SABA), primarily used for asthma or quick relief in COPD.</p>\n<p><strong>Salmeterol (Option D):</strong> A long-acting beta2 agonist (LABA) useful in COPD, but muscarinic antagonists like tiotropium are generally preferred for long-acting bronchodilation in COPD.</p>", "options": ["Tiotropium bromide", "Ipratropium bromide", "Salbutamol", "Salmeterol"], "html_options": ["Tiotropium bromide", "Ipratropium bromide", "Salbutamol", "Salmeterol"], "corr_idx": 0}, {"id": "1166581", "html_qtxt": "Which of the following is not an indication of the drug given below?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212db7e227f-edd0-4274-8677-9834b2471e75.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Atropine</strong> is a muscarinic receptor antagonist used primarily in <strong>unstable (symptomatic) bradycardia</strong>, not in stable cases.</p>\n<ul>\n<li>In symptomatic bradycardia, it blocks vagal influence on the SA node, thereby increasing heart rate.</li>\n<li>It is <strong>not indicated</strong> in stable bradycardia, where no significant symptoms or haemodynamic compromise are present.</li>\n</ul>\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Before intubation (Option B):</strong> Atropine is used as premedication before intubation, especially in children, to reduce salivary and airway secretions.</p>\n<p><strong>Scorpion stings (Option C):</strong> Atropine is used to counteract the parasympathetic overactivity (e.g., excessive salivation, bronchorrhoea) caused by venom-induced acetylcholine release.</p>\n<p><strong>Uveitis (Option D):</strong> Atropine is used in ophthalmology to dilate the pupil and prevent synechiae formation in anterior uveitis.</p>", "options": ["Stable bradycardia", "Before intubation", "Scorpion stings", "Uveitis"], "html_options": ["Stable bradycardia", "Before intubation", "Scorpion stings", "Uveitis"], "corr_idx": 0}, {"id": "1166582", "html_qtxt": "A 75-year-old male with Alzheimer's disease has complained of multiple episodes of a strong, sudden sense of urinary urgency with incontinence. Which of the following is the ideal agent for him for this condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>In elderly patients with Alzheimer's disease, <strong>cognitive function </strong>is highly sensitive to central anticholinergic effects, which can worsen dementia symptoms.</p>\n<ul>\n<li><strong>Trospium</strong> is a <strong>quaternary ammonium compound</strong>, meaning it is hydrophilic and poorly crosses the blood-brain barrier (BBB), thus sparing the central nervous system from unwanted anticholinergic side effects.</li>\n<li>It is the preferred agent for treating <strong>urge incontinence</strong> in patients with Alzheimer's, as it reduces bladder overactivity <strong>without compromising cognition</strong>.</li>\n</ul>\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Oxybutynin (Option B):</strong> Though effective for urge incontinence, it is a tertiary amine that crosses the BBB, often associated with central side effects like confusion and sedation, especially in the elderly.</p>\n<p><strong>Tolterodine (Option C):</strong> Also a tertiary amine, it may cause CNS effects due to central cholinergic blockade, thus less ideal in Alzheimer's.</p>\n<p><strong>Solifenacin (Option D):</strong> Another tertiary amine with CNS penetration; although bladder-selective, it still poses a risk for cognitive decline in dementia patients.</p>", "options": ["Trospium", "Oxybutynin", "Tolterodine", "Solifenacin"], "html_options": ["Trospium", "Oxybutynin", "Tolterodine", "Solifenacin"], "corr_idx": 0}, {"id": "1166583", "html_qtxt": "A 30-year-old woman complains of severe bloating after undergoing abdominal surgery. She also finds it difficult to urinate. Mild cholinomimetic stimulation without vasodilation is preferred for treatment. Which agent should be preferred?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>In post-operative ileus and urinary retention, <strong>cholinomimetic agents</strong> are used to stimulate smooth muscle activity in the bladder and gastrointestinal tract.</p>\n<ul>\n<li>While both bethanechol and distigmine can help, <strong>distigmine</strong> is preferred here because it provides mild cholinergic stimulation <strong>without causing vasodilation</strong>.</li>\n<li>This is crucial in patients who are haemodynamically vulnerable post-surgery.</li>\n<li><strong>Distigmine</strong>, as an <strong>acetylcholinesterase inhibitor</strong>, increases endogenous acetylcholine levels without directly stimulating muscarinic receptors on vascular endothelium, thereby avoiding vasodilation, unlike bethanechol, which is a direct muscarinic agonist.</li>\n</ul>\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Bethanechol (Option A):</strong> A direct muscarinic agonist that stimulates GI and bladder smooth muscle but <strong>also causes vasodilation via endothelial M3 receptor activation</strong>, which is <strong>not desirable</strong> in this scenario.</p>\n<p><strong>Cevimeline (Option C):</strong> Primarily used to treat <strong>xerostomia</strong> in Sj&ouml;gren's syndrome; it acts mostly on <strong>M3 receptors in exocrine glands</strong> and has <strong>no clinical role in postoperative ileus or urinary retention</strong>.</p>\n<p><strong>Carbachol (Option D):</strong> Though a strong cholinergic agonist, it affects <strong>both muscarinic and nicotinic receptors</strong> and may cause <strong>excessive cholinergic side effects</strong>, making it unsuitable for controlled stimulation in postoperative settings.</p>", "options": ["Bethanechol", "Distigmine", "Cevimeline", "Carbachol"], "html_options": ["Bethanechol", "Distigmine", "Cevimeline", "Carbachol"], "corr_idx": 1}, {"id": "1166585", "html_qtxt": "Match the action of receptor with post-receptor mechanism<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090658814e25-8960-4c15-b0a0-a122917361e8.PNG\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509066caae2d5-e64d-4513-8879-de4307d8e869.PNG\">\n<p><strong>Cholinergic Receptors - G-Proteins, Effects, and Locations</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906f5de0392-113e-484c-8145-34a6ba525543.PNG\">", "options": ["A-1, 3, 5/ B-2, 4, 6/ C-7", "A-1, 4, 5 / B-2, 3, 6 / C-7", "A-1, 3, 5 / B-2, 4 / C-6, 7", "A-1, 3/ B-2, 4, 5/ C-6, 7"], "html_options": ["A-1, 3, 5/ B-2, 4, 6/ C-7", "A-1, 4, 5 / B-2, 3, 6 / C-7", "A-1, 3, 5 / B-2, 4 / C-6, 7", "A-1, 3/ B-2, 4, 5/ C-6, 7"], "corr_idx": 2}, {"id": "1166589", "html_qtxt": "A researcher studying a drug, \"Reserpine\", acts on an adrenergic neuron. Similar action on cholinergic neurons is seen by?", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212ac6a4894-3698-4e2a-a743-045b1117057a.jpg\">\n<p>Both <strong>Vesamicol and Reserpine</strong> act as transmitter storage and deplete it in vesicles of cholinergic and adrenergic terminals, respectively.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509064d7c1dbf-4a5f-4673-923c-b7c44fd017ee.PNG\">", "options": ["Hemicholinium", "Tetrodotoxin", "Vesamicol", "Conotoxin"], "html_options": ["Hemicholinium", "Tetrodotoxin", "Vesamicol", "Conotoxin"], "corr_idx": 2}]}, {"moduleId": 1008534, "name": "Adrenergic Drugs, Alpha1 Blockers, Beta-Blockers", "questions": [{"id": "1180684", "html_qtxt": "A 3-year-old child has been presented to the ED having swallowed 10 tablets as shown below.  Which of the following are signs of the toxicity that may occur in this child?<br>1.\t Bronchoconstriction<br>2.\t Tachycardia <br>3.\t Mydriasis<br>4.\t Renin release from the kidneys <br>5.\t Vasoconstriction of blood vessels<br>6.\t Urinary retention<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231211995344d1-2dd5-466a-81c2-aa2cb45aa253.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This clinical scenario suggests<strong> toxicity of phenylephrine</strong>, a potent, <strong>selective &alpha;1-adrenoceptor agonist</strong> drug, which is used as a nasal decongestant as an over-the-counter drug. Phenylephrine acts as a nasal decongestant by reducing hyperemia and mucosal oedema.</p>\n<p>It can also be used in</p>\n<ul>\n<li>Hypotension</li>\n<li>Rhinitis, obstructed Eustachian tubes</li>\n<li>Nasal decongestant</li>\n<li>Allergic conjunctivitis</li>\n<li>Open-angle glaucoma</li>\n<li>Ischemic priapism (high-dose intracavernosal phenylephrine injection)</li>\n</ul>\n<p>How to approach individual action in ANS:</p>\n<ol>\n<li>Bronchoconstriction by parasympathetic on M3 receptor (bronchial smooth muscle), not a-adrenoceptor</li>\n<li>Tachycardia by sympathetic on &beta;1 receptor (SA node), not &alpha;-adrenoceptor</li>\n<li><strong>Mydriasis </strong>by &alpha;1-adrenoceptor on the radial muscle of the iris. (<strong>Phenylephrine toxicity)</strong></li>\n<li>Renin release from the kidneys by sympathetic on &beta;1 receptor (JG cells), not &alpha;-adrenoceptor</li>\n<li><strong>Vasoconstriction of blood vessels</strong> by &alpha;1-adrenoceptor on vascular smooth muscle. (<strong>Phenylephrine toxicity)</strong></li>\n<li><strong>Urinary retention</strong> by &alpha;1-adrenoceptor on the urinary sphincter. (<strong>Phenylephrine toxicity)</strong></li>\n</ol>", "options": ["2, 5, 6", "3, 5, 6", "2, 3, 5", "4, 5, 6"], "html_options": ["2, 5, 6", "3, 5, 6", "2, 3, 5", "4, 5, 6"], "corr_idx": 1}, {"id": "1180699", "html_qtxt": "A 21-year-old male is brought to the ED from a college party because of a 1-hour history of a crawling sensation under his skin. He appears anxious. His temperature is 100.4 F, pulse is 110/min, respirations are 18/min, and blood pressure is 150/90 mm Hg. Physical examination shows diaphoretic skin, moist mucous membranes, and dilated pupils. Find out the site of action of the substance?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023121172503e5a-0b85-4dee-b8fb-cd4535b0eca8.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The clinical scenario of tachycardia with hypertension, mydriasis, and diaphoresis suggests <strong>sympathetic overactivity</strong> due to <strong>cocaine.</strong></p>\n<ul>\n<li>It acts by inhibiting dopamine, serotonin, and norepinephrine uptake by NET(Label D).</li>\n<li>Amphetamine is a substrate of NET but does not block it.&nbsp;</li>\n<li>In addition to features of sympathetic overactivity, acute cocaine overdose can also cause hallucinations (including tactile hallucinations such as formication) and paranoid ideation.</li>\n<li><strong>Acute cocaine overdose</strong> is treated with <strong>benzodiazepines and alpha-1 blockers </strong>(e.g., phenoxybenzamine).</li>\n<li>In the case of a suspected cocaine overdose, <strong>beta-blockers should not be used</strong> as first-line therapy because they can lead to unopposed alpha-1 receptor activation and thereby precipitate a hypertensive crisis or myocardial ischemia due to coronary vasospasm.</li>\n</ul>\n<p><strong>Direct Effects of Autonomic Nerve Activity on Organ Systems:</strong></p><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023121179ff8e27-7265-43f9-b8c9-e85928d5e887.jpg\">\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023121196547988-a13d-434a-8d8b-417794bff56f.jpg\">\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>A-Metyrosine (Option A): </strong>It is an inhibitor of the enzyme tyrosine hydroxylase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.</p>\n<p><strong>B-Reserpine/ Tetrabenazine (Option B): </strong>They cause reversible inhibition of vesicular monoamine transporter-2 (VMAT-2) &rarr; impaired packaging of monoamines (dopamine, serotonin, and norepinephrine) into presynaptic vesicles &rarr; &darr; dopamine release. It can be used in Hyperkinetic disorders like Chorea, Tardive dyskinesia, Tourette syndrome and Hypertension.</p>\n<p>(Production of reserpine has been discontinued.)</p>\n<p><strong>C-Guanethidine (Option C): </strong>It is an antihypertensive agent that acts by inhibiting selective transmission in postganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.</p>", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 3}, {"id": "1180702", "html_qtxt": "While playing in the garden, a 9-year-old boy was stung by 3 bees, and now presented to the ED for difficulty breathing for 15 minutes. When the symptoms started, his mother noticed a rash and swelling of his tongue and lips. Two years ago, he was diagnosed with asthma. What is the treatment of choice?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The child is exhibiting <strong>classic signs of anaphylaxis</strong>, a rapid onset of respiratory distress, angioedema (lip and tongue swelling), and urticarial rash following bee stings.</p>\n<ul>\n<li>The first-line and most critical treatment is intramuscular epinephrine at a <strong>1:1000 concentration</strong>, administered into the anterolateral thigh (0.5 mg/0.5 ml is injected IM).</li>\n<li>It counteracts bronchoconstriction, vasodilation, and increased vascular permeability, thereby reversing airway obstruction and hypotension.</li>\n</ul>\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Diphenhydramine (Option A)</strong>: An H1 antihistamine useful for treating urticaria and pruritus, but too slow-acting and insufficient as monotherapy in anaphylaxis.</p>\n<p><strong>IM Epinephrine 1:10000 (Option C):</strong> This concentration is used for intravenous administration in cardiac arrest, not for intramuscular use in anaphylaxis, due to the risk of serious cardiovascular complications.</p>\n<p><strong>Methylprednisolone (Option D):</strong> A corticosteroid used to prevent late-phase allergic responses, but has a delayed onset and is not suitable as initial emergency therapy.</p>", "options": ["Diphenhydramine", "IM Epinephrine 1:1000", "IM Epinephrine 1:10000", "Methylprednisolone"], "html_options": ["Diphenhydramine", "IM Epinephrine 1:1000", "IM Epinephrine 1:10000", "Methylprednisolone"], "corr_idx": 1}, {"id": "1180704", "html_qtxt": "A 56-year-old woman with a necrotic ulcer on the sole of her right foot is admitted to the ward. She has long-standing type 2 diabetes mellitus with impaired renal function. The consultant asked to get done with ophthalmoscopy for possible vascular changes. Which of the following drugs is a good choice for pupillary dilation?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>In <strong>diabetic patients</strong> undergoing ophthalmoscopy to assess for vascular changes (e.g., diabetic retinopathy), <strong>mydriasis without cycloplegia</strong> is preferred.</p>\r\n<ul>\r\n<li><strong>Phenylephrine</strong>, an &alpha;<sub>1</sub>-adrenergic agonist, causes pupillary dilation by stimulating the radial muscle of the iris without affecting the ciliary muscle, thus preserving accommodation.</li>\r\n<li>This makes it <strong>ideal for diagnostic fundoscopy</strong>, where only dilation is required, not refractive error testing.</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Pilocarpine (Option A):</strong> A muscarinic agonist that causes miosis by contracting the sphincter pupillae, which is the opposite of what's needed for ophthalmoscopy.</p>\r\n<p><strong>Norepinephrine (Option B): </strong>Although it has &alpha;<sub>1</sub>-agonist effects, it penetrates poorly through the conjunctiva and causes excessive vasoconstriction, making it unsuitable for this purpose.</p>\r\n<p><strong>Tropicamide (Option D): </strong>An antimuscarinic that causes both mydriasis and cycloplegia by blocking M<sub>3</sub> receptors. While it dilates the pupil, it also impairs accommodation, which is not necessary for ophthalmoscopy and can be inconvenient for the patient.</p>", "options": ["Pilocarpine ", "Norepinephrine", "Phenylephrine ", "Tropicamide "], "html_options": ["Pilocarpine ", "Norepinephrine", "Phenylephrine ", "Tropicamide "], "corr_idx": 2}, {"id": "1180706", "html_qtxt": "An 85-year-old man develops bilateral pedal cyanosis and begins to experience necrosis of the toes 5 days after admission to the ICU for CAP and severe hypotension. The patient has received empiric broad-spectrum antibiotics and vasopressors. All extremities are cold to the touch. Which of the following intracellular changes is most likely to occur in vascular smooth muscle as a result of this drug?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This elderly patient with septic shock has received <strong>vasopressors</strong> like <strong>norepinephrine</strong>, resulting in <strong>peripheral vasoconstriction</strong> severe enough to cause <strong>toe necrosis</strong> and <strong>cold extremities</strong>.</p>\r\n<ul>\r\n  <li>Norepinephrine primarily stimulates <strong>&alpha;<sub>1</sub>-adrenergic receptors</strong> on vascular smooth muscle, which are <strong>Gq protein-coupled receptors</strong>.</li>\r\n<li>Activation of Gq leads to <strong>phospholipase C stimulation</strong>, generating <strong>IP<sub>3</sub> and DAG</strong>, which together increase <strong>intracellular calcium</strong> and activate <strong>protein kinase C (PKC)</strong>.</li>\r\n<li>This cascade enhances <strong>vascular smooth muscle contraction</strong>, raising systemic vascular resistance, essential for maintaining blood pressure in shock, but with the risk of <strong>distal ischaemia</strong>.</li><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212142ab34a-85fa-4eb2-b200-1b4c19c83fab.jpg\">\r\n<li><strong>Alpha-1 agonists</strong> (e.g., phenylephrine, norepinephrine, midodrine) are used to treat hypotension because increased protein kinase C activity through the Gq GPCR pathway -> increases the concentration of intracellular calcium in vascular smooth muscle, which increases vascular smooth muscle contraction.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212e263641e-a7b8-499f-bde5-881bb592d071.jpg\">\r\n<p><strong>Explanation for Other Options:</strong></p>\r\n<p><strong>Increased activity of protein kinase A (Option D):</strong> Protein kinase A (PKA) is involved in the Gs and Gi GPCR pathways. Activation of the Gs protein ultimately leads to activation of protein kinase A. However, NE through alpha-1 receptors acts through the Gq GPCR pathway.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212511c39fe-861f-4fa3-bf0c-273582893504.jpg\">\r\n<p><strong>Decreased activity of myosin light-chain kinase (Option A): </strong>Decreased myosin light-chain kinase (MLCK) activity in vascular smooth muscle would cause vasodilation, a deleterious effect in this patient with septic shock. MLCK activity in muscle tissue is decreased by 3 mechanisms:</p>\r\n<ol>\r\n<li><strong>Closing L-type voltage-gated calcium</strong> channels through membrane repolarisation;</li>\r\n<li><strong>Decreasing intracellular calcium</strong> concentration through inhibition of a Gq protein-receptor coupled receptor (While NE acts through alpha-1 receptors on vascular smooth muscle, which increases intracellular calcium); and</li>\r\n<li><strong>Increasing the activity of protein kinase A</strong> through stimulation of Gs protein-coupled receptors.</li>\r\n</ol><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023121282b3aaa2-3f2e-4c88-ac9b-608b6448dd7d.jpg\">\r\n<p><strong>Increased activity of guanylate cyclase (Option C):</strong> Guanylate cyclase activity is increased in vascular smooth muscle by stimulation of ANP or BNP receptors and by drugs that increase nitric oxide concentration (nitrate drugs). Increased guanylate cyclase activity increases cGMP synthesis, which in turn activates myosin-light-chain phosphatase and causes smooth muscle relaxation. Nitroprusside is used to treat hypertensive crisis via this mechanism.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312120a9d7ab3-6840-4498-8f76-31dcb1c98424.jpg\">", "options": ["Decreased activity of myosin light-chain kinase", "Increased activity of protein kinase C", "Increased activity of guanylate cyclase", "Increased activity of protein kinase A"], "html_options": ["Decreased activity of myosin light-chain kinase", "Increased activity of protein kinase C", "Increased activity of guanylate cyclase", "Increased activity of protein kinase A"], "corr_idx": 1}, {"id": "1180707", "html_qtxt": "A 72-year-old man is brought to the hospital due to severe chest pain and shortness of breath for the last several hours. Physical examination reveals bilateral crackles and a third heart sound. ECG shows ST elevation in multiple leads. He has started on infusion as shown below. Which of the following is most likely to be increased due to the medication used in this patient?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023121232d62156-8076-469e-949a-12b1563a5a8d.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Dobutamine</strong> is a beta-adrenergic agonist with predominant activity on beta-1 receptors (B1 > B2, Inotropic effects > chronotropic effects).</p>\n<ul>\n<li>It is used for the management of refractory heart failure associated with severe left ventricular systolic dysfunction and cardiogenic shock.</li>\n</ul>\n<p><strong>Effects of Positive inotropy and chronotropy: </strong></p>\n<p>Increased cardiac contractility (potent effect) and heart rate (weaker effect), leading to increased cardiac output (improves end-organ perfusion) and decreased left ventricular filling pressures (improves pulmonary congestion/oedema)</p>\n<ul>\n<li>The strong inotropic effect of dobutamine significantly<strong> increases myocardial oxygen consumption,</strong> which can trigger or exacerbate myocardial ischemia.</li>\n<li>As such, dobutamine should <strong>not be used routinely</strong> in patients with decompensated heart failure.</li>\n<li>However, in patients with cardiogenic shock, this <strong>drawback is often outweighed by improvement in cardiac output</strong> and end-organ perfusion.</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Cardiac diastolic filling time (Option A):</strong> Dobutamine is a weak chronotropic agent that causes an increase in heart rate. This leads to a decrease in cardiac diastolic filling time.</p>\n<p><strong>Peripheral vascular resistance (Option C):</strong> In the vasculature, the beta-2 agonist effects (vasodilation) of dobutamine are somewhat stronger than its alpha-1 agonist activity (vasoconstriction), resulting in overall mild vasodilation.</p>\n<p><strong>Pulmonary capillary wedge pressure (Option D): </strong>Dobutamine causes decreased pulmonary capillary wedge pressure and left and right ventricular filling pressures due to the increased cardiac contractility.</p>", "options": ["Cardiac diastolic filling time ", "Myocardial oxygen consumption ", "Peripheral vascular resistance ", "Pulmonary capillary wedge pressure "], "html_options": ["Cardiac diastolic filling time ", "Myocardial oxygen consumption ", "Peripheral vascular resistance ", "Pulmonary capillary wedge pressure "], "corr_idx": 1}, {"id": "1180708", "html_qtxt": "Identify the incorrect pair of drugs with their predominant action GPCR pathway. <br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240807addc55da-eabc-4810-bb55-ea2af7da1e29.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Mirabegron - Gs</strong></p>\n<ul>\n<li>Mirabegron is a <strong>beta3-adrenergic receptor agonist</strong> used to treat an overactive bladder.</li>\n<li>It predominantly acts through the <strong>Gs (inhibitory) protein pathway,</strong> leading to relaxation of the detrusor smooth muscle in the bladder.</li>\n</ul>\n<p>This option is incorrect because the predominant GPCR pathway for Mirabegron is Gs, not Gi.</p>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Guanfacine - Gi</strong>:</p>\n<ul>\n<li>Guanfacine is an <strong>alpha2-adrenergic receptor</strong> agonist used to treat conditions like hypertension and attention deficit hyperactivity disorder (ADHD).</li>\n<li>It predominantly acts through the<strong> Gi (inhibitory) protein pathway</strong>, reducing cAMP levels and ultimately reducing sympathetic outflow.</li>\n</ul>\n<p><strong>Formeterol - Gs</strong>:</p>\n<ul>\n<li>Formoterol is a <strong>beta2-adrenergic receptor agonist</strong> commonly used as a bronchodilator.</li>\n<li>It primarily acts through the <strong>Gs (stimulatory) protein pathway</strong>, leading to increased intracellular cAMP levels and smooth muscle relaxation in the airways.</li>\n</ul>\n<p><strong>Midodrine - Gq</strong>:</p>\n<ul>\n<li>Midodrine is an <strong>alpha1-adrenergic receptor agonist</strong> used to treat orthostatic hypotension.</li>\n<li>It primarily acts through the <strong>Gq (phospholipase C) protein pathway,</strong> leading to increased intracellular calcium levels and vasoconstriction.</li>\n</ul>\n<p>Most of the drugs that act on ANS act through the GPCR pathway.</p><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312126e5d901a-b809-430b-b2c0-22e49573ee16.jpg\"><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023121252412875-d4c3-4402-aaba-fffdaff49310.jpg\">", "options": ["1", "2", "3", "4"], "html_options": ["1", "2", "3", "4"], "corr_idx": 1}, {"id": "1180709", "html_qtxt": "Examiner has asked you to identify the drug in viva-voice: \"When administered by intravenous bolus, the blood pressure increases. When given orally for 1 week, the blood pressure decreases.\" Whar drugs you will pick up from the table ?", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906YvRbC.png\">\n<p><strong>Clonidine</strong> is a <strong>centrally acting &alpha;<sub>2</sub>-adrenergic agonist</strong>.</p>\n<ul>\n<li>When given intravenously, it initially stimulates peripheral &alpha;<sub>2</sub>B receptors on vascular smooth muscle, causing <strong>vasoconstriction</strong> and a <strong>transient rise in blood pressure</strong>.</li>\n<li>However, with oral administration over days, clonidine accumulates in the CNS, where it <strong>activates central &alpha;<sub>2</sub> A receptors</strong>, leading to <strong>reduced sympathetic outflow</strong>, decreased norepinephrine release, and a sustained fall in blood pressure.</li>\n<li>This <strong>biphasic response,</strong> initial hypertension, followed by chronic antihypertensive action, is characteristic of clonidine.</li>\n</ul>\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Propranolol (Option A): </strong> A non-selective &beta;-blocker. It reduces heart rate and contractility and is used chronically to lower BP, but does <strong>not show an initial hypertensive spike</strong> like clonidine.</p>\n<p><strong>Tamsulosin (Option C): </strong>A selective <strong>&alpha;<sub>1</sub>A blocker</strong> used for <strong>BPH</strong>, not for systemic blood pressure control, and has <strong>no central effect</strong>.</p>\n<p><strong>Prazosin (Option D): </strong> An <strong>&alpha;<sub>1</sub> antagonist</strong> that lowers blood pressure by <strong>vasodilation</strong> without the biphasic blood pressure effect seen with clonidine.</p>", "options": ["<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212799f413f-596a-4d5c-8089-c5323a30bc74.jpg\">", "<img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; min-width:150px; max-width:150px; \"src=\"https://d1mobye7msb5bl.cloudfront.net/2NewQBImages/8646a9ef-a622-42a0-b95f-a3557ed89162.png\">", "<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212fa7204d5-714b-4285-a7e0-f55d670640d9.jpg\">", "<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312121a36ff39-afbb-4bc9-90d9-219d782fa751.jpg\">"], "html_options": ["<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212799f413f-596a-4d5c-8089-c5323a30bc74.jpg\">", "<img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; min-width:150px; max-width:150px; \"src=\"https://d1mobye7msb5bl.cloudfront.net/2NewQBImages/8646a9ef-a622-42a0-b95f-a3557ed89162.png\">", "<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212fa7204d5-714b-4285-a7e0-f55d670640d9.jpg\">", "<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312121a36ff39-afbb-4bc9-90d9-219d782fa751.jpg\">"], "corr_idx": 1}, {"id": "1180710", "html_qtxt": "A 54-year-old Mr. Green had a cardiac transplant 6 months ago. His current blood pressure is 110/70 mm Hg, and his heart rate is 100 bpm. Which of the following drugs would have the least effect on Mr Green's heart rate?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>In heart transplant recipients like Mr Green, the heart is denervated, meaning <strong>both sympathetic and parasympathetic innervation is absent.</strong></p>\r\n<ul>\r\n  <li><strong>Phenylephrine</strong> is a pure<strong> &alpha;<sub>1</sub>-adrenergic agonist,</strong> which increases systemic vascular resistance and normally leads to reflex bradycardia via vagal activation.</li>\r\n<li>However, since reflex mechanisms depend on intact vagal innervation, phenylephrine has minimal effect on heart rate in transplant patients.</li>\r\n<li>Hence, it causes the least change in heart rate among the listed drugs.</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Amphetamine (Option A):</strong> An indirect sympathomimetic that increases the release of norepinephrine from nerve terminals. Since autonomic nerve terminals are absent post-transplant, it has minimal effect, but not necessarily the least, due to possible central effects.</p>\r\n<p><strong>Nor-epinephrine (Option B):</strong> A direct &alpha;<sub>1</sub> and &beta;<sub>1</sub> agonist; increases heart rate and contractility, especially in denervated hearts where reflex buffering is absent.</p>\r\n<p><strong>Isoproterenol (Option C):</strong> A &beta;<sub>1</sub> and &beta;<sub>2</sub> agonist; strongly increases heart rate, and its effect is exaggerated in denervated hearts due to &beta;-receptor upregulation.</p>", "options": ["Amphetamine", "Nor-epinephrine ", "Isoproterenol ", "Phenylephrine"], "html_options": ["Amphetamine", "Nor-epinephrine ", "Isoproterenol ", "Phenylephrine"], "corr_idx": 3}, {"id": "1180711", "html_qtxt": "Several new drugs with autonomic actions were studied in preclinical trials in animals. Autonomic drugs X and Y were given in moderate doses as intravenous infusions. Results are shown below. Identify X, Y and Z.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312128813cc41-17da-45c8-97e7-760dcfcb9b9a.jpg\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212051a354d-8cff-469e-8cf9-000a17785612.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Drug X: Norepinephrine</strong></p>\n<ul>\n<li>Diastolic BP &rarr; Strong &alpha;<sub>1</sub> vasoconstriction</li>\n<li>Pulse pressure &rarr; Minimal change &rarr; Negligible &beta;<sub>2</sub> activity</li>\n<li>Stroke volume &rarr; Likely due to increased venous return (&alpha;-mediated venoconstriction)</li>\n<li>Heart rate &rarr; Due to baroreceptor-mediated reflex bradycardia</li>\n<li><strong>Classic profile of norepinephrine (&alpha;<sub>1</sub> > &beta;<sub>1</sub> >> &beta;<sub>2</sub>)</strong></li>\n</ul>\n<p><strong>Drug Y: Epinephrine</strong></p>\n<ul>\n<li>Diastolic BP (slight) &rarr; &beta;<sub>2</sub>-mediated vasodilation</li>\n<li>Systolic BP (marked) &rarr; &beta;<sub>1</sub> inotropy and some &alpha;<sub>1</sub> activity</li>\n<li>Heart rate &rarr; Due to &beta;<sub>1</sub> stimulation</li>\n<li>Pulse pressure &rarr; Increased</li>\n<li><strong>Balanced &alpha; + &beta; activity matches epinephrine</strong></li>\n</ul>\n<p><strong>Drug Z: Isoproterenol</strong></p>\n<ul>\n<li>Diastolic BP (marked) &rarr; Strong &beta;<sub>2</sub> vasodilation</li>\n<li>Systolic BP &rarr; Little or no change</li>\n<li>Pulse pressure &rarr; Significantly increased due to &beta;<sub>1</sub> inotropy</li>\n<li>Heart rate &rarr; Due to &beta;<sub>1</sub> chronotropy</li>\n<li><strong>Pure &beta; agonist (&beta;<sub>1</sub> = &beta;<sub>2</sub>), matches isoproterenol</strong></li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312126c839b5d-8257-4325-8072-2f5b7287990c.jpg\">", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 3}, {"id": "1180712", "html_qtxt": "A patient is being treated with -blockers for hypertension. Which of the following describes the effects of -blockers on end-diastolic volume (EDV), blood pressure (BP), contractility, heart rate (HR), and ejection time?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312120298d7a4-30fd-4bf5-9f15-892eceef7507.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Option <strong>C </strong>best describes the effects of &beta;-blockers.</p>\n<p>&beta;-Blockers <strong>decrease contractility</strong> and heart rate <strong>(resulting in decreased oxygen consumption)</strong> by inhibiting &beta;-receptors in the heart.</p>\n<ul>\n<li>A <strong>decrease in heart rate</strong> will then allow more time for diastolic filling <strong>(increasing EDV)</strong> and systolic ejection <strong>(increasing ejection time)</strong>.</li>\n<li>In addition, &beta;-blockers will decrease the secretion of renin, thus diminishing the renin-angiotensin cascade.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312122506665e-24af-4e9e-b369-02202070e1e6.jpg\">\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Option A & B:</strong> Doesn't reflect the effects of &beta;-Blockers.</p>\n<p><strong>Option D:</strong> The given combination is compatible with the effects of<strong> nitrates</strong>.</p>\n<ul>\n<li>These drugs serve to decrease the afterload on the heart by vasodilation.</li>\n<li>However, vasodilation produces a reflex increase in both contractility and heart rate.</li>\n<li>An increase in heart rate causes a decrease in EDV and ejection time.</li>\n</ul>", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 2}, {"id": "1180713", "html_qtxt": "A 50-year-old man presents with complaints of urinary retention. He has hypertension but is not compliant with treatment. BP: 160/100. On DRE: an enlarged prostate with rubbery consistency is felt. Which of the following drugs would be the most appropriate initial therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient has <strong>benign prostatic hyperplasia (BPH)</strong> and <strong>poorly controlled hypertension</strong>. The ideal drug should target both conditions.</p>\n<ul>\n<li><strong>Terazosin</strong> is a non-selective &alpha;<sub>1</sub>-adrenergic antagonist that relaxes smooth muscle in the bladder neck and prostate, improving urine flow in BPH, and also reduces peripheral vascular resistance, helping manage hypertension.</li>\n<li>Hence, it addresses both urinary retention and elevated blood pressure, making it the most appropriate initial choice.</li>\n</ul>\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Phenoxybenzamine (Option A):</strong> A non-selective, irreversible &alpha;-blocker mainly used preoperatively in pheochromocytoma to prevent hypertensive crises-not suitable for routine BPH or hypertension.</p>\n<p><strong>Tamsulosin (Option B):</strong> A selective &alpha;<sub>1</sub>A/&alpha;<sub>1</sub>D blocker that relieves BPH symptoms with minimal vascular effects, so it does not address hypertension effectively. Among alpha blockers, Prazosin has the highest risk of postural hypotension.</p>\n<p><strong>Finasteride (Option D):</strong> A 5-&alpha;-reductase inhibitor that reduces prostate size over months by decreasing DHT synthesis, but has no effect on blood pressure and is not suitable for rapid symptom relief.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212552635cc-f7c3-4c08-8f14-ab3129a6fbc0.jpg\">", "options": ["Phenoxybenzamine", "Tamsulosin", "Terazosin ", "Finasteride"], "html_options": ["Phenoxybenzamine", "Tamsulosin", "Terazosin ", "Finasteride"], "corr_idx": 2}, {"id": "1180714", "html_qtxt": "A 50-year-old man is started on a medication shown below. Which of the following sets of changes is most likely to occur in response to this drug?<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212ca7ecd8f-318d-44e7-8675-6715ebe32c5e.jpg\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212c5d923f0-d674-46a2-97ce-539ad309b13f.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Prazosin</strong> is a <strong>selective &alpha;<sub>1</sub>-adrenergic receptor antagonist</strong>. It blocks &alpha;<sub>1</sub> receptors present on vascular smooth muscle, the radial muscle of the iris, and the internal urethral sphincter.</p>\n<ul>\n<li><strong>Pupil:</strong> Prazosin can cause miosis (constriction of the pupils) in some cases, particularly when used at higher doses or in combination with other medications. It can also inhibit mydriasis (pupil dilation) caused by other drugs like phenylephrine.</li>\n<li><strong>Bladder sphincter tone:</strong> &alpha;<sub>1</sub> blockade in the <strong>internal urethral sphincter</strong> causes <strong>relaxation</strong>, improving urine flow and decreasing bladder outlet resistance.</li>\n<li><strong>Blood pressure:</strong> &alpha;<sub>1</sub> blockade in peripheral vessels leads to <strong>vasodilation</strong>, causing a <strong>decrease in systemic vascular resistance</strong> and hence <strong>lower blood pressure</strong>.</li>\n</ul>\n<p>So, prazosin leads to:</p>\n<ul>\n<li><strong>Miosis</strong></li>\n<li><strong>Decreased bladder sphincter tone</strong></li>\n<li><strong>Decreased blood pressure</strong>.</li>\n</ul>", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 0}, {"id": "1180715", "html_qtxt": "A 16-year-old boy presents to you complaining of worsening cough, shortness of breath, and wheezing. And you prescribe a shown inhaler to be used when needed. In considering the possible drug effects in this patient, you would note that this inhaler frequently causes<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212a89b4f00-b29f-4440-a593-9a401e5e62a7.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The clinical presentation of worsening cough, shortness of breath, and wheezing in a 16-year-old boy suggests <strong>asthma</strong>, for which a <strong>salbutamol inhaler (100 mcg)</strong>, a <strong>short-acting &beta;<sub>2</sub>-agonist (SABA)</strong>, has been prescribed.</p>\r\n<ul>\r\n<li><strong>Salbutamol</strong> acts by <strong>stimulating &beta;<sub>2</sub>-adrenergic receptors</strong> in bronchial smooth muscle, leading to <strong>bronchodilation</strong>, which rapidly relieves acute bronchospasm. However, stimulation of &beta;<sub>2</sub> receptors also increases <strong>cyclic AMP (cAMP)</strong> in skeletal muscles, which commonly causes <strong>tremors</strong>, especially in younger patients. This is the most frequent side effect of SABAs.</li>\r\n</ul>\r\n<p>Other important <strong>side effects of salbutamol</strong> due to &beta;<sub>2</sub>-mediated increase in cAMP include:</p>\r\n<ul>\r\n<li><strong>Tremor</strong> (most common)</li>\r\n<li><strong>Tachycardia</strong></li>\r\n<li><strong>Hyperglycaemia</strong></li>\r\n<li><strong>Hypotension</strong></li>\r\n<li><strong>Hypokalaemia</strong>, due to <strong>Na<sup>+</sup>/K<sup>+</sup>-K-ATPase activation</strong>, leading to intracellular shift of potassium, is clinically relevant, as <strong>salbutamol can be used to treat hyperkalaemia</strong>.</li>\r\n</ul>\r\n<p><strong>Tolerance (tachyphylaxis)</strong> can develop with repeated use; hence, SABAs are not recommended for maintenance therapy in asthma.</p>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Direct stimulation of renin release (Option A):</strong> This is a &beta;<sub>1</sub> effect, not &beta;<sub>2</sub>. &beta;<sub>1</sub> agonists like dobutamine stimulate renin release via the juxtaglomerular apparatus in the kidney.</p>\r\n<p><strong>Hypoglycaemia (Option B):</strong> &beta;<sub>2</sub> agonists typically cause hyperglycaemia by increasing glycogenolysis and gluconeogenesis. Hypoglycaemia is more commonly associated with insulin excess or &beta;-blockers masking its symptoms.</p>\r\n<p><strong>Vasodilation in the skin (Option D):</strong> Skin vasculature predominantly has &alpha;<sub>1</sub> receptors. Activation leads to vasoconstriction, and since &beta;<sub>2</sub> receptors are sparse in cutaneous vessels, salbutamol does not cause vasodilation in the skin.</p>", "options": ["Direct stimulation of renin release", "Hypoglycaemia ", "Skeletal muscle tremor ", "Vasodilation in the skin"], "html_options": ["Direct stimulation of renin release", "Hypoglycaemia ", "Skeletal muscle tremor ", "Vasodilation in the skin"], "corr_idx": 2}, {"id": "1180716", "html_qtxt": "A 55-year-old man comes to the physician because of episodic retrosternal chest pain and shortness of breath for the past 6 months. His symptoms occur when he takes long walks or climbs stairs, but resolve promptly with rest. He has a history of COPD. Physical examination shows mild expiratory wheezing over both lungs. Additional treatment with a beta blocker is considered. Which of the following agents should be avoided in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with <strong>chronic stable angina</strong> (exertional chest pain relieved by rest) and a background of <strong>COPD</strong>.</p>\n<ul>\n<li>Beta blockers are often added to reduce <strong>myocardial oxygen demand</strong> by lowering heart rate and contractility.</li>\n<li>However, <strong>not all beta blockers are suitable</strong> for patients with COPD.</li>\n<li><strong>Timolol </strong>is a nonselective beta blocker, meaning it blocks both <strong>&beta;<sub>1</sub> and &beta;<sub>2</sub> receptors</strong>. Blocking <strong>&beta;<sub>2</sub> receptors</strong> in bronchial smooth muscle can lead to bronchoconstriction, which can worsen respiratory symptoms in patients with underlying COPD or asthma. Hence, timolol should be <strong>avoided</strong> in this context.</li>\n</ul>\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Atenolol (A)</strong>, <strong>Bisoprolol (B)</strong>, and <strong>Metoprolol (C)</strong> are <strong>cardioselective &beta;<sub>1</sub> blockers</strong>. They primarily affect the heart with <strong>minimal &beta;<sub>2</sub> activity</strong>, making them <strong>safer choices for patients with COPD</strong> or asthma when beta blocker therapy is indicated. Among these, <strong>bisoprolol</strong> and <strong>metoprolol succinate</strong> are especially favoured for patients with coexisting heart failure or angina.</p>\n<p><strong>1. Cardioselective &beta;<sub>1</sub>-Blockers (A-M: Primarily heart, B<sub>1</sub> selective)</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906sXqo7.png\">\n<p><strong>2. Non-Cardioselective &beta;-Blockers (N&ndash;Z: Block B<sub>1</sub>, B<sub>2</sub> &plusmn; B<sub>3</sub>)</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906ZWMa1.png\">\n<p><strong>3. Exceptions & Mixed Action &beta;-Blockers</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906vxUTb.png\">", "options": ["Atenolol", "Bisoprolol", "Metoprolol", "Timolol"], "html_options": ["Atenolol", "Bisoprolol", "Metoprolol", "Timolol"], "corr_idx": 3}, {"id": "1180717", "html_qtxt": "Pharmacotherapy with carvedilol is initiated for a patient with Idiopathic recurrent atrial fibrillation. Compared to treatment with propranolol, which of the following adverse effects is most likely?<br> 1. Bradycardia<br> 2. Hyperglycemia<br> 3. Bronchospasm<br> 4. Hypotension", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Among the options,<strong> hypotension (4)</strong> is most distinctively associated with carvedilol due to its additional alpha-1 blockade. The other adverse effects are common to both or not more pronounced with carvedilol.</p>\n<ul>\n<li><strong>Carvedilol</strong> is a nonselective beta-blocker with additional alpha-1 blocking activity, whereas propranolol is a nonselective beta-blocker without alpha-blocking effects.</li>\n<li>This distinction is important when considering their adverse effect profiles.</li>\n<li>The alpha-1 blocking action of carvedilol leads to vasodilation, which can result in more pronounced hypotension compared to propranolol.</li>\n<li>Therefore, hypotension is the most likely unique adverse effect of carvedilol when compared to propranolol.</li>\n</ul>\n<p><strong>Explanation for other statements:</strong></p>\n<p><strong>Bradycardia (1): </strong>Common with all beta-blockers, including both carvedilol and propranolol. No clear increased risk with carvedilol alone.</p>\n<p><strong>Hyperglycemia (2):</strong> Both drugs can impair glucose tolerance, but carvedilol is actually associated with less metabolic disturbance than traditional nonselective beta-blockers like propranolol.</p>\n<p><strong>Bronchospasm (3):</strong> Both are nonselective beta-blockers and may induce bronchospasm, but neither is worse in this regard. Carvedilol, due to some &beta;1 selectivity at lower doses, may even pose slightly less risk in reactive airway disease in some studies (though still contraindicated).</p>", "options": ["1,2,3", "1,2,3,4", "3,4", "4 only"], "html_options": ["1,2,3", "1,2,3,4", "3,4", "4 only"], "corr_idx": 3}, {"id": "1180718", "html_qtxt": "A 70-year-old man comes to the ED because of blurry vision and headaches for the past 2 days. His temperature is 99&deg;F, pulse is 90/min, and blood pressure is 230/130 mm-Hg. Fundoscopy is shown below. A medication is given immediately. Five minutes later, his pulse is 75/min and blood pressure is 190/100 mm Hg. Which of the following drugs was most likely administered?<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212203fd927-d822-4e95-8220-ee9891a3056b.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This 70-year-old patient presents with <strong>hypertensive emergency</strong>, indicated by severely elevated blood pressure (>180/120 mmHg) and end-organ damage signs like blurry vision, retinal haemorrhages, and <strong>papilloedema on fundoscopy. </strong></p>\n<ul>\n<li>A drop in blood pressure with a concurrent decrease in heart rate five minutes after medication strongly suggests a drug that lowers both systemic vascular resistance and heart rate.</li>\n<li><strong>Labetalol </strong>is a mixed &alpha;1 and &beta; (nonselective) blocker, and is a preferred agent in hypertensive emergencies.\n<ol>\n<li><strong>&alpha;1-blockade</strong> &rarr; vasodilation &rarr; &darr; BP</li>\n<li><strong>&beta;1-blockade</strong> &rarr; &darr; HR, &darr; cardiac output, &darr; renin release</li>\n</ol>\n</li>\n</ul>\n<p>The result is a drop in both BP and HR, exactly as seen in this patient.</p>\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Hydralazine (Option B):</strong> A direct arteriolar vasodilator. It reduces systemic vascular resistance, lowering BP, but causes reflex tachycardia, not bradycardia.</p>\n<p><strong>Fenoldopam (Option C):</strong> A D1 receptor agonist used IV for hypertensive emergencies. Causes vasodilation and natriuresis, but again results in reflex tachycardia, not a decrease in heart rate.</p>\n<p><strong>Nicardipine (Option D):</strong> A dihydropyridine calcium channel blocker (DHP-CCB), which selectively dilates peripheral arterioles, lowering BP. Like the others, it causes reflex tachycardia, not bradycardia. Only non-DHP CCBs (like verapamil/diltiazem) can cause bradycardia.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>In hypertensive emergencies, a <strong>fall in both BP and HR </strong>after drug administration strongly points to a &beta;-blocking agent, especially labetalol, due to its <strong>combined &alpha;1 + &beta; blockade.</strong></p>", "options": ["Labetalol", "Hydralazine", "Fenoldopam", "Nicardipine"], "html_options": ["Labetalol", "Hydralazine", "Fenoldopam", "Nicardipine"], "corr_idx": 0}, {"id": "1180719", "html_qtxt": "A 44-year-old female with multiple comorbidities is to receive a cardioselective &beta;-blocker. Which of the following is not a contraindication for starting the therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>In patients with multiple comorbidities, careful screening is essential before starting cardioselective &beta;-blockers (like atenolol, bisoprolol, metoprolol).</p>\n<ul>\n<li>Absolute contraindications include high-grade (second- or third-degree) AV blocks, decompensated heart failure, and cardiogenic shock, as &beta;-blockers can worsen bradycardia and cardiac output.</li>\n<li><strong>First-degree AV block,</strong> however, is not an absolute contraindication.</li>\n<li>It is generally benign and may still allow for safe &beta;-blocker use, especially when the clinical benefits (e.g., in ischaemic heart disease or arrhythmias) outweigh the minimal conduction delay.</li>\n</ul><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212b556e429-60e5-4104-9ef6-8526362d6d5b.jpg\">\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Decompensated heart failure (Option B)</strong>: A contraindication because &beta;-blockers reduce myocardial contractility and can worsen acute decompensation. They are only started once the patient is stabilised.</p>\n<p><strong>Cardiogenic shock (Option C):</strong> An absolute contraindication. &beta;-blockers lower cardiac output and heart rate, which can be fatal in shock states.</p>\n<p><strong>Pregnancy (Option D):</strong> Most &beta;-blockers are contraindicated in pregnancy due to potential fetal bradycardia, growth restriction, and hypoglycaemia. Labetalol is an exception and is preferred in gestational hypertension, but it is not cardioselective.</p>", "options": ["First-degree heart block", "Decompensated heart failure", "Cardiogenic shock", "Pregnancy"], "html_options": ["First-degree heart block", "Decompensated heart failure", "Cardiogenic shock", "Pregnancy"], "corr_idx": 0}, {"id": "1180720", "html_qtxt": "A 42-year-old man with a 6-cm right adrenal tumour is going to undergo a laparoscopic surgical procedure to remove the tumour. It is anticipated that the procedure will take approximately 12 h. The patient has a history of hypertension controlled with an alpha-blocker. Which of the following agents, used intraoperatively, will provide efficacious blood pressure control for the duration of the procedure?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Nadolol, a non-selective &beta;-blocker</strong> with a long half-life (12&ndash;24 hours), is best suited for stable, sustained intraoperative &beta;-blockade, especially during prolonged procedures (like the 12-hour laparoscopic adrenalectomy described).</p>\n<ul>\n<li>It provides<strong> consistent haemodynamic control </strong>with a single intra-op dose.</li>\n<li>This patient with a 6-cm adrenal tumour and hypertension on &alpha;-blocker therapy is likely being treated for <strong>pheochromocytoma, a catecholamine-secreting tumour</strong>.</li>\n<li>During surgery, stress and tumour manipulation can trigger sudden catecholamine release, necessitating effective intraoperative blood pressure (BP) control.</li>\n<li>In pheochromocytoma, &alpha;-blockade (e.g., <strong>phenoxybenzamine pre-op or phentolamine intra-op</strong>) is initiated before &beta;-blockade to avoid unopposed &alpha;-adrenergic activity and hypertensive crisis.</li>\n<li>After &alpha;-blockade is established, <strong>&beta;-blockers</strong> are used to control tachycardia or arrhythmias, especially non-selective long-acting ones like nadolol in lengthy procedures.</li>\n</ul>\n<p><strong>Explanation for Other options:</strong></p>\n<p><strong>Acebutolol (Option A):</strong> Cardioselective &beta;1-blocker with moderate half-life (3&ndash;4 hours); not ideal for 12-hour procedures.</p>\n<p><strong>Esmolol (Option B): </strong>Very short-acting (half-life ~10 minutes). Useful for tight, moment-to-moment control but requires continuous infusion, not suitable for sustained single-dose control.</p>\n<p><strong>Metoprolol (Option C):</strong> Also cardioselective with a short half-life (3-4 hours). Not effective for single-dose control over long surgeries.</p>", "options": ["Acebutolol ", "Esmolol ", "Metoprolol ", "Nadolol "], "html_options": ["Acebutolol ", "Esmolol ", "Metoprolol ", "Nadolol "], "corr_idx": 3}, {"id": "1180721", "html_qtxt": "Patient is on a drug which used for BPH with Hypertension. Which of the following is not a possible adverse event after initiating therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Urinary retention</strong> is not a possible adverse event after initiating therapy with an <strong>&alpha;-1 adrenergic receptor antagonist.</strong></p>\n<p><strong>These &alpha;-1 adrenergic receptor antagonists</strong> are used to treat<strong> hypertension</strong> (&darr; vasoconstriction &rarr;&darr; blood pressure) as well as <strong>BPH </strong>(relaxation of bladder neck muscles &rarr;&darr; bladder outlet obstruction and easier micturition).</p>\n<p><strong>Common side effects</strong>:</p>\n<ul>\n<li>Orthostatic hypotension<strong> (Option A )</strong></li>\n<li>Retrograde ejaculation<strong> (Option B)</strong></li>\n<li>Dizziness, headache</li>\n<li>Peripheral oedema, hypotension</li>\n<li>Nausea, constipation</li>\n<li>Intraoperative floppy iris syndrome (IFIS)\n<ul>\n<li>Complication of cataract surgery characterised by iris prolapse through the surgical incision and intraoperative pupillary constriction</li>\n<li>May lead to retinal detachment and endophthalmitis</li>\n</ul>\n</li>\n<li>Increased Urinary frequency (not retention)</li>\n<li>Prazosin: priapism <strong>(Option D)</strong></li>\n</ul>", "options": ["Orthostatic hypotension", "Retrograde ejaculation", "Urinary retention", "Priapism"], "html_options": ["Orthostatic hypotension", "Retrograde ejaculation", "Urinary retention", "Priapism"], "corr_idx": 2}, {"id": "1180722", "html_qtxt": "A 20-year-old unconscious female was brought to the ED 6 hours after the ingestion of 10 tablets of an unknown drug in an attempt to die by suicide.<br> Temperature: 98.1&deg;F<br> Pulse: 41/min<br> RR: 14/min<br> BP: 88/55 mmHg<br> Oxygen saturation: 93%<br> RBS: 65 mg/dl<br> ECG shows prolonged PR intervals and narrow QRS complexes<br> In addition to securing the airway, which of the following is the most appropriate next step in management?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>In suspected &beta;-blocker overdose with cardiovascular collapse, <strong>glucagon </strong>is the specific <strong>antidote</strong> and should be administered early<strong> after stabilising the </strong>airway and breathing.</p>\n<p>Bradycardia, hypotension, hypoglycemia, and prolonged PR intervals strongly suggest severe <strong>beta-blocker intoxication</strong>.</p>\n<p><strong>Clinical features</strong></p>\n<ul>\n<li>Bradycardia/bradyarrhythmia</li>\n<li>Cardiogenic shock (hypotension; cold, clammy extremities)</li>\n<li>Hypoglycemia</li>\n<li>Hyperkalemia</li>\n<li>Wheezing (bronchoconstriction)</li>\n<li>Neurological symptoms (seizure, delirium, coma)</li>\n</ul>\n<p><strong>Treatment</strong></p>\n<ul>\n<li><strong>Secure the airways</strong></li>\n<li>Correct cardiovascular decompensation (hypotension, bradycardia, and cardiogenic shock) via IV access:\n<ol>\n<li>Fluids (saline) and vasopressors (e.g., epinephrine)</li>\n<li>Atropine: to correct bradycardia</li>\n<li>Glucagon: antidote for beta-blocker poisoning (It increases intracellular cAMP by activating adenylate cyclase, which improves cardiac contractility while bypassing the beta receptors.)</li>\n<li>Calcium salts: to improve cardiac contractility</li>\n</ol>\n</li>\n<li><strong>High-dose insulin with glucose:</strong> If cardiovascular decompensation is refractory to all of the above-mentioned agents, high-dose insulin is given for its positive inotropic effect.</li>\n<li><strong>Prevent further absorption of beta blocker:</strong> activated charcoal/gastric lavage, IV lipid emulsions (esp. useful in lipophilic beta-blocker overdose).</li>\n<li>Poisoning with hydrophilic beta blockers (e.g., atenolol, nadolol) may require hemodialysis for removal of the drug from circulation.</li>\n</ul>\n<p><strong>Explanation for other options:</strong></p>\n<p><strong>Naloxone (Option A): </strong>Used in opioid overdose (classic triad: respiratory depression, pinpoint pupils, and CNS depression). While both opioid and &beta;-blocker overdoses may cause bradycardia and hypotension, opioids usually cause hypoventilation and miosis, which are not seen here. Also, no hypothermia or severe respiratory depression is noted.</p>\n<p><strong>Hemodialysis (Option B): </strong>Considered for hydrophilic &beta;-blockers (like atenolol, nadolol) only in refractory cases after initial stabilisation fails. This is not a first-line measure, and there is no indication of renal failure or persistent shock here.</p>\n<p><strong>Activated Charcoal (Option C): </strong>Most effective within 1&ndash;2 hours of ingestion. Since the patient presents 6 hours after ingestion, charcoal is unlikely to help. Also, airway protection is critical before administering charcoal in unconscious patients due to aspiration risk.</p>", "options": ["Naloxone", "Hemodialysis", "Activated charcoal", "Glucagon"], "html_options": ["Naloxone", "Hemodialysis", "Activated charcoal", "Glucagon"], "corr_idx": 3}, {"id": "1180723", "html_qtxt": "Which of the following sentences is/are not true about hydrophilic beta-blockers?<br> 1.\tDo not cross the blood-brain-barrier. <br> 2. Require multiple doses per day. <br> 3. Metoprolol & Propranolol are hydrophilic beta-blockers.<br> 4. Safe in patient with kidney failure", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Statement 1: </strong>\"Do not cross the blood-brain-barrier\" is TRUE.</p>\n<ul>\n<li>Hydrophilic beta-blockers (e.g., atenolol, sotalol) have low lipid solubility, so they do not penetrate the CNS, resulting in fewer neuropsychiatric side effects.</li>\n</ul>\n<p><strong>Statement 2: </strong>\"Require multiple doses per day\" is TRUE.</p>\n<ul>\n<li>Due to shorter half-life and minimal hepatic metabolism, these drugs require frequent dosing (e.g., atenolol often needs twice-daily dosing).</li>\n</ul>\n<p><strong>Statement 3: </strong>\"Metoprolol & Propranolol are hydrophilic beta-blockers\" is FALSE.</p>\n<ul>\n<li>Both metoprolol and propranolol are lipophilic, meaning they undergo hepatic metabolism and cross the BBB, often causing CNS effects like fatigue or nightmares.</li>\n</ul>\n<p><strong>Statement 4:</strong> \"Safe in patient with kidney failure\" is FALSE.</p>\n<ul>\n<li>Hydrophilic beta-blockers are cleared by the kidneys, so in renal failure, there's a risk of accumulation and toxicity unless dose-adjusted. Hence, not inherently safe in renal impairment.</li>\n</ul>\n<p>So, Statements<strong> 3 and 4 </strong>are false. <strong>(Option B)</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906LhKJ8.png\">", "options": ["1 and 2", "3 and 4", "1, 2, and 3", "4 only"], "html_options": ["1 and 2", "3 and 4", "1, 2, and 3", "4 only"], "corr_idx": 1}, {"id": "1180724", "html_qtxt": "A 34-year-old woman is evaluated for migraine headaches, worse with menstrual cycles and stress. Recently, she has been having about six episodes per month. You advise her prophylactic therapy with propranolol. Which side effects of the therapy do you need to keep in mind?<br> 1.\tPsoriasis<br> 2.\tSecondary Raynaud phenomenon<br> 3.\tHyperglycemia and new-onset diabetes<br> 4.\tWeight loss<br> 5.\tIncrease HDL<br>6.\tHypertriglyceridemia", "html_expl": "<p><strong>Explanation:</strong></p>\n<ol>\n<li><strong> Psoriasis (True)<br /> </strong>Propranolol, a non-selective beta-blocker, is known to <strong>worsen or trigger psoriasis</strong> through immune modulation (neutrophil/macrophage degranulation and keratinocyte proliferation).</li>\n<li><strong> Secondary Raynaud phenomenon (True)<br /> </strong>Due to <strong>&beta;2-receptor blockade</strong> (which normally causes vasodilation), <strong>vasoconstriction</strong> of peripheral vessels occurs, leading to <strong>cold-induced pallor and cyanosis</strong> of the extremities.</li>\n<li><strong> Hyperglycemia and new-onset diabetes (True)<br /> </strong>Non-selective beta-blockers impair <strong>glycogenolysis</strong>, decrease <strong>insulin secretion</strong>, and increase <strong>insulin resistance</strong>, predisposing to <strong>hyperglycaemia</strong> and even <strong>new-onset diabetes</strong>.</li>\n<li><strong> Weight loss (False)<br /> </strong>Beta-blockers typically cause <strong>weight gain</strong>, likely due to decreased metabolic rate and exercise intolerance.</li>\n<li><strong> Increase HDL (False)<br /> </strong>Beta-blockers <strong>lower HDL</strong> and <strong>raise triglycerides</strong>, thus unfavourable for the lipid profile.</li>\n<li><strong> Hypertriglyceridemia (True)<br /> </strong>Especially seen with <strong>non-selective beta-blockers</strong>, which <strong>reduce lipolysis</strong> and <strong>impair triglyceride clearance</strong>, contributing to <strong>elevated serum triglycerides</strong>.</li>\n</ol>\n<p>So, statements <strong>1, 2, 3, and 6 </strong>are true.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023121236a28990-1e1f-4bf6-8359-4935c447a340.jpg\">", "options": ["1, 2, 3, and 4", "1, 2, 3, and 5", "1, 2, 3, and 6", "2, 3, 5, and 6"], "html_options": ["1, 2, 3, and 4", "1, 2, 3, and 5", "1, 2, 3, and 6", "2, 3, 5, and 6"], "corr_idx": 2}, {"id": "1180725", "html_qtxt": "A 44-year-old man comes to you with an abdominal ultrasound that shows an atrophic, hyper-echoic, nodular liver. An upper endoscopy is performed and shows dilated submucosal veins 2 mm in diameter with red spots on their surface in the distal oesophagus. Which of the following is the most appropriate next step in the management of this patient's oesophageal findings?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient has <strong>cirrhosis</strong> with<strong> small oesophageal varices</strong> (<5 mm) and no active bleeding, identified incidentally during endoscopy. In such cases, <strong>primary prophylaxis</strong> is warranted to prevent a first variceal bleed, which carries a high mortality risk.</p>\n<p><strong>Nadolol</strong> is a nonselective beta-blocker that decreases <strong>portal venous inflow</strong> by:</p>\n<ul>\n<li><strong>&beta;1 blockade</strong>: reduces cardiac output.</li>\n<li><strong>&beta;2 blockade</strong>: causes <strong>splanchnic vasoconstriction</strong>, reducing portal blood flow.<br /> These effects <strong>lower portal pressure</strong>, thereby reducing the <strong>risk of variceal bleeding</strong>. It is the <strong>drug of choice for primary prophylaxis</strong> in non-bleeding varices.</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Isosorbide mononitrate (IMN) (Option B)</strong>: Though it reduces portal pressure via venodilation, it has not been shown to reduce bleeding risk when used alone. Also associated with side effects like headache and hypotension. It may be used in combination with beta-blockers in some secondary prophylaxis cases, not as monotherapy in primary prophylaxis.</p>\n<p><strong>Metoprolol (Option C)</strong>: It is a &beta;1-selective blocker, affecting only the heart, not the splanchnic circulation, and therefore ineffective in reducing portal hypertension or preventing variceal bleeding.</p>\n<p><strong>Octreotide (Option D)</strong>: A somatostatin analogue used acutely in active variceal bleeding. It causes splanchnic vasoconstriction, but due to tachyphylaxis (loss of effect over time), it is not suitable for long-term prophylaxis.</p>", "options": ["Nadalol", "IMN", "Metaprolol", "Octreotide"], "html_options": ["Nadalol", "IMN", "Metaprolol", "Octreotide"], "corr_idx": 0}, {"id": "1180726", "html_qtxt": "A 29-year-old woman comes to the physician for intermittent episodes of sharp chest pain and palpitations. She appears nervous. Her pulse is 115/min and irregular, and blood pressure is 139/86 mmHg. Examination shows a fine tremor on both hands and digital swelling; the extremities are warm. Which of the following is the most appropriate next step in the management of this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient presents with tachycardia, irregular pulse (suggestive of atrial fibrillation), tremor, warm extremities, and digital swelling, all of which point to <strong>hyperthyroidism</strong> as the underlying cause.</p>\r\n<ul>\r\n<li>The most immediate step in managing symptomatic hyperthyroidism is to administer a <strong>non-selective beta-blocker, such as propranolol</strong>, which controls adrenergic symptoms (palpitations, tremor, anxiety) and reduces peripheral conversion of T4 to T3.</li>\r\n<li>This provides rapid symptomatic relief until<strong> definitive antithyroid therapy</strong> is initiated.</li>\r\n</ul>\r\n<p><strong>Explanation for Other Options:</strong></p>\r\n<p><strong>Warfarin (Option A):</strong> Although atrial fibrillation increases thromboembolic risk, anticoagulation is not immediately necessary unless the CHA<sub>2</sub>DS<sub>2</sub>-VASc score &ge; 2 or there's evidence of valvular disease. This patient's score is 1, so the focus should first be on controlling the underlying thyroid cause and arrhythmia symptoms.</p>\r\n<p><strong>Propylthiouracil (PTU) (Option C):</strong> PTU is an antithyroid drug that reduces thyroid hormone synthesis, but its effect is delayed (takes days to weeks). Symptom control must come first with a beta-blocker before initiating or in conjunction with PTU or other definitive therapies.</p>\r\n<p><strong>Amiodarone (Option D):</strong> Though effective for rhythm control, amiodarone is iodine-rich and can worsen or trigger thyroid dysfunction, especially in someone already hyperthyroid. It is not appropriate as first-line therapy in this setting.</p>\r\n<p><strong>Key Takeaway: </strong></p>\r\n<p><strong>Propranolol</strong> is the first-line treatment for immediate symptom control in hyperthyroid-induced adrenergic symptoms, including atrial fibrillation, making it the most appropriate initial management step.</p>", "options": ["Warfarin", "Propranolol", "Propylthiouracil", "Amiodarone"], "html_options": ["Warfarin", "Propranolol", "Propylthiouracil", "Amiodarone"], "corr_idx": 1}, {"id": "1180727", "html_qtxt": "A 60-year-old man comes to the physician because of tremors in both hands for the past few months. He has had difficulty buttoning his shirts and holding a cup of coffee without spilling its contents. He has noticed that his symptoms improve after a glass of whiskey. Which of the following is the most appropriate pharmacotherapy for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with a bilateral, action-induced tremor that improves with alcohol, which is characteristic of <strong>essential tremor (ET).</strong></p>\n<ul>\n<li>Essential tremor typically affects the <strong>upper limbs</strong>, becomes more prominent with goal-directed activity, and improves transiently with alcohol consumption.</li>\n<li>For patients who are functionally impaired by ET (difficulty eating, writing, dressing), treatment is warranted.</li>\n<li>The first-line pharmacotherapy is <strong>propranolol, a non-selective beta-blocker,</strong> which effectively reduces tremor amplitude by acting on <strong>&beta;2-receptors</strong> involved in <strong>muscle spindle activity.</strong></li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Alprazolam (Option A):</strong> This benzodiazepine may provide tremor relief but is considered second-line due to addiction risk, tolerance, and withdrawal complications. It is not preferred for long-term management, especially in elderly patients.</p>\n<p><strong>Levodopa (Option B):</strong> This is used to treat resting tremor in Parkinson&rsquo;s disease, not action tremor. Parkinsonian tremor is typically unilateral at onset, associated with bradykinesia and rigidity, and diminishes with voluntary movement, unlike ET.</p>\n<p><strong>Primidone (Option D): </strong>Primidone is an alternative first-line agent for ET, especially useful in patients who cannot tolerate beta-blockers, such as those with asthma or COPD. However, in this patient without such contraindications, propranolol is the preferred initial treatment.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p><strong>Essential tremor </strong>improves with alcohol and worsens with action, and <strong>propranolol</strong> is the most effective and well-tolerated first-line treatment for symptom control in <strong>functionally impaired patients.</strong></p>", "options": ["Alprazolam", "Levodopa", "Propranolol", "Primidone"], "html_options": ["Alprazolam", "Levodopa", "Propranolol", "Primidone"], "corr_idx": 2}, {"id": "1180728", "html_qtxt": "Action of drugs 'X' and 'Y' on heart rate with/without pre-treatment shown below in the table. Find out drug X and Y, respectively.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906oCmPz.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Based on the <strong>effect of pretreatment agents</strong> on heart rate responses:</p>\n<p><strong>Drug X decreases heart rate</strong> under normal conditions, but <strong>increases HR</strong> after pretreatment with <strong>hexamethonium</strong>, <strong>atropine</strong>, or <strong>phenoxybenzamine</strong>. This implies that:</p>\n<ul>\n<li><strong>Without blockers</strong>, it activates <strong>&alpha;1 receptors &rarr; vasoconstriction &rarr; &uarr; BP &rarr; reflex bradycardia</strong> via vagus.</li>\n<li><strong>Hexamethonium</strong> (a ganglion blocker) prevents this reflex by <strong>blocking autonomic ganglia</strong>, abolishing the vagal response &rarr; HR increases.</li>\n<li><strong>Atropine</strong>, a <strong>muscarinic blocker</strong>, blocks vagal tone &rarr; prevents reflex bradycardia &rarr; HR increases.</li>\n<li><strong>Phenoxybenzamine</strong>, an <strong>&alpha;-blocker</strong>, blocks vasoconstriction &rarr; no BP rise &rarr; no reflex bradycardia &rarr; HR increases.</li>\n</ul>\n<p>This fits <strong>norepinephrine</strong>, which acts on <strong>&alpha;1</strong> (vasoconstriction &rarr; reflex bradycardia) and <strong>&beta;1</strong> (direct cardiac stimulation), but reflex bradycardia dominates initially.</p>\n<p><strong>Drug Y increases HR</strong> under all conditions, and the response is <strong>unchanged</strong> with <strong>hexamethonium</strong>, <strong>atropine</strong>, or <strong>phenoxybenzamine</strong>.</p>\n<ul>\n<li>This implies it acts <strong>directly on the heart</strong>, not via reflexes or autonomic modulation.</li>\n</ul>\n<p>This is characteristic of <strong>isoproterenol</strong>, a non-selective &beta; agonist, stimulating &beta;1 (&uarr; HR, contractility) and &beta;2 (vasodilation) &rarr; fall in BP &rarr; reflex tachycardia adds to direct action.</p>\n<h3><strong>Explanation for Other Options:</strong></h3>\n<p><strong>Acetylcholine, Norepinephrine (Option A):</strong> Acetylcholine slows heart rate, but it would not show the described pattern of reflex-mediated bradycardia reversed by atropine and hexamethonium. Also, it wouldn't make sense as a \"tachycardia-only\" drug.</p>\n<p><strong>Isoproterenol, Norepinephrine (Option C):</strong> Reverses the correct sequence. Isoproterenol always increases HR and is not affected by blockers-should be Drug Y, not X.</p>\n<p><strong>Isoproterenol, Acetylcholine (Option D):</strong> Acetylcholine is parasympathomimetic and directly slows HR-this does not match the reflex pattern seen with Drug X.</p>", "options": ["Acetylcholine, Norepinephrine", "Norepinephrine, Isoproterenol", "Isoproterenol, Norepinephrine", "Isoproterenol, Acetylcholine"], "html_options": ["Acetylcholine, Norepinephrine", "Norepinephrine, Isoproterenol", "Isoproterenol, Norepinephrine", "Isoproterenol, Acetylcholine"], "corr_idx": 1}, {"id": "1180729", "html_qtxt": "A 70-year-old man with chronic myopia comes to the ophthalmologist for a regular check-up. Examination shows bilateral narrowing of peripheral visual fields, cupping of the optic discs, and elevated intraocular pressure. Gonioscopy shows no abnormalities. Which of the following first line of treatment for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient has classic signs of <strong>open-angle glaucoma</strong>, indicated by:</p>\n<ul>\n<li><strong>Progressive peripheral vision loss</strong></li>\n<li><strong>Optic disc cupping</strong></li>\n<li><strong>Elevated intraocular pressure (IOP)</strong></li>\n<li><strong>Normal gonioscopy</strong> (open anterior chamber angle)</li>\n</ul>\n<p>The <strong>first-line treatment</strong> for open-angle glaucoma is topical prostaglandin analogues like <strong>latanoprost</strong>.</p>\n<p>These drugs:</p>\n<ul>\n<li><strong>Increase uveoscleral outflow</strong> of aqueous humour</li>\n<li><strong>Effectively lower IOP</strong></li>\n<li>They are <strong>once-daily</strong>, well-tolerated, and very effective in reducing optic nerve damage progression</li>\n</ul>\n<p><strong>Side effects of latanoprost:</strong></p>\n<ul>\n<li>Iris, eyelash, and periorbital skin darkening</li>\n<li>Trichomegaly</li>\n<li>Epithelial keratopathy</li>\n<li>CME</li>\n<li>Contraindicated in uveitis/herpetic keratitis</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Timolol (Option A):</strong> A beta-blocker that decreases aqueous humour production. It's effective but generally considered second-line or adjunctive to prostaglandin analogues.</p>\n<p><strong>Acetazolamide (Option B):</strong> An oral carbonic anhydrase inhibitor used in acute or refractory cases; not first-line due to systemic side effects.</p>\n<p><strong>Apraclonidine (Option C):</strong> An alpha-2 agonist used in acute IOP elevations or as adjunctive therapy; not used as monotherapy long-term due to tachyphylaxis and allergic reactions.</p>", "options": ["Timolol", "Acetazolamide", "Apraclonidine", "Latanoprost"], "html_options": ["Timolol", "Acetazolamide", "Apraclonidine", "Latanoprost"], "corr_idx": 3}, {"id": "1180730", "html_qtxt": "Identify drugs acting on the area shown by the arrow in the given illustrated image.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212f35cd3bd-2cd6-459d-a6cd-751752d75dd2.jpg\"><br>1. Betaxolol<br>2. Brimonidine<br>3. Bimatoprost<br>4. Brinzolamide<br>5. Dipiverfine<br>6. Physostigmine<br>7. Pilocarpine", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The arrow in the image points at<strong> inner non-pigmented ciliary epithelium </strong>(NPE) cells. These cells are responsible for the production and <strong>secretion of Aqueous humour</strong>.</p>\n<ul>\n<li>Drugs acting on this site are responsible for decreasing the secretion of Aqueous humour.</li>\n<li>So, the drugs<strong> betaxolol (1), brimonidine(2), bimatoprost(3), dipiverfine(5)</strong> are the drugs acting on NPE cells.</li>\n</ul>\n<p><strong>Glaucoma:</strong></p>\n<p><strong>Glaucoma</strong> is a major cause of blindness, primarily due to increased intraocular pressure (IOP). It often responds to drug therapy, especially in the chronic form.</p>\n<p><strong>Primary manifestation: </strong>Increased IOP without initial symptoms.</p>\n<p><strong>Untreated glaucoma</strong> leads to retinal and optic nerve damage, visual field restriction, and blindness.</p>\n<p>Two major types: open-angle and closed-angle (narrow-angle) glaucoma.</p>\n<ul>\n<li><strong>Closed-angle glaucoma</strong> is associated with a shallow anterior chamber and requires emergency treatment or surgical intervention.</li>\n<li><strong>Open-angle glaucoma</strong> is a chronic condition treated primarily with medications.</li>\n<li>Strategies for open-angle glaucoma treatment: Reduce aqueous humour secretion and enhance aqueous outflow.</li>\n</ul>\n<p><strong>Drug Groups for Glaucoma Treatment:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906QaYT3.png\">\n<p>These drugs can also be classified based on <strong>decreased synthesis and increased outflow</strong> of aqueous humour.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906xM27f.png\">", "options": ["1, 2, 3, and 5", "2, 3, 6, and 7", "4, 5, 6, and 7", "1, 2, 3, and 4"], "html_options": ["1, 2, 3, and 5", "2, 3, 6, and 7", "4, 5, 6, and 7", "1, 2, 3, and 4"], "corr_idx": 0}, {"id": "1180731", "html_qtxt": "A 62-year-old woman is brought to the emergency department because of the sudden onset of severe left eye pain, blurred vision, nausea, and vomiting. She has been taking phenylephrine to control URI symptoms. Gonioscopy shows that the iris meets the cornea at an angle of 10&deg; (N = 20-45&deg;). Systemic pharmacotherapy is initiated with a drug. Which of the following additional adverse effects is most likely to occur in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient presents with acute <strong>primary angle-closure glaucoma</strong>, characterised by:</p>\n<ul>\n<li>Sudden severe eye pain, blurred vision</li>\n<li>Nausea, vomiting</li>\n<li>Narrow anterior chamber angle seen on gonioscopy (10&deg; vs normal 20-45&deg;)</li>\n</ul>\n<p>The first-line systemic therapy in acute angle-closure glaucoma is i<strong>ntravenous acetazolamide, a carbonic anhydrase inhibitor.</strong> It:</p>\n<ul>\n<li>Reduces aqueous humour production</li>\n<li>Rapidly lowers intraocular pressure</li>\n<li>However, it can cause <strong>metabolic acidosis</strong> by promoting bicarbonate loss in the urine, leading to a <strong>non-anion gap metabolic acidosis</strong>, especially with prolonged or high-dose use.</li>\n</ul>\n<p><strong>Explanation for Other Options:</strong></p>\n<p><strong>Ocular allergy (Option A):</strong> Typically associated with alpha-2 agonists like apraclonidine or brimonidine, not systemic acetazolamide.</p>\n<p><strong>Diaphoresis (Option B):</strong> Seen with cholinergic agents like pilocarpine (parasympathomimetic), which is topical, not systemic.</p>\n<p><strong>Bronchoconstriction (Option C): </strong>Occurs with topical non-selective beta blockers like timolol, not with acetazolamide.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906VjXqr.png\">", "options": ["Ocular allergy", "Diaphoresis", "Bronchoconstriction", "Metabolic acidosis"], "html_options": ["Ocular allergy", "Diaphoresis", "Bronchoconstriction", "Metabolic acidosis"], "corr_idx": 3}, {"id": "1180732", "html_qtxt": "A 70-year-old woman has been treated with eye drops for her open-angle glaucoma. At her most recent follow-up appointment, you noted peculiar side effects of the eye drop as shown below. Which of the following drugs has been prescribed to her?<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231212f210edbf-da9e-4f8a-bfda-9321a085e901.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The given picture shows<strong> trichomegaly,</strong> which is a known side effect of PGF2&alpha; analogues like Latanoprost, Travaprost and <strong>Bimatoprost.</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906NbAK5.png\">", "options": ["Bimatoprost", "Brinzolamide", "Brimonidine", "Pilocarpine"], "html_options": ["Bimatoprost", "Brinzolamide", "Brimonidine", "Pilocarpine"], "corr_idx": 0}]}, {"moduleId": 1008535, "name": "Antihypertensives and Hypolipidemic Drugs (Part 1)", "questions": [{"id": "1166319", "html_qtxt": "A 45-year-old male is presented to the ED with severe tachycardia after a drug overdose. His family reports that he has been depressed. Past history of hypertension is present. Which one of the following drugs increases the heart rate in a dose-dependent manner?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Given clinical scenario is the overdose of a drug in a hypertensive patient, which causes tachycardia, points towards a class of anti-hypertensives that cause increased heart rate.</li>\n<li>Direct vasodilators regularly increase heart rate (by reflex tachycardia), and <strong>Minoxidil</strong>, a very efficacious <strong>vasodilator</strong>, causes <strong>severe tachycardia that must be controlled with </strong><strong>&beta;-blockers.</strong></li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403082ec11603-aa6c-4915-af91-092483ff7c64.jpg\"><br>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308d8121edd-dc6f-44e1-a721-3198380fdf0e.jpg\">\n<p><strong>Captopril (ACE inhibitors) (Option A) </strong>and <strong>Losartan (ARB) (Option C)</strong> do not significantly increase heart rate as they predominantly act by inhibiting RAAS. Compensatory responses to blood pressure lowering by these drugs are minimal.</p>\n<p><strong>Hydrochlorothiazide</strong><strong> (Option B)</strong> is a thiazide diuretic, acts by inhibition of Na+-Cl- co-transporters in the early distal tubule segment, leading to diuresis. It lowers blood pressure by reducing blood volume. Compensatory responses to blood pressure lowering by diuretics are minimal.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403082720074f-a1f9-4540-ae44-a12754991fd2.jpg\">", "options": ["Captopril", "Hydrochlorothiazide", "Losartan", "Minoxidil"], "html_options": ["Captopril", "Hydrochlorothiazide", "Losartan", "Minoxidil"], "corr_idx": 3}, {"id": "1166331", "html_qtxt": "A 55-year-old man comes to the physician for the evaluation of recurrent headaches over the past 6 months. His blood pressure is 160/90 mm Hg. Treatment with losartan has begun. Which of the following is the most likely effect of his new medication?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Losartan, ARBs (Angiotensin II receptor blockers)</strong>, lead to <strong>an increase in urinary sodium excretion, decreased vessel tone, and lower levels of aldosterone.</strong> The combination of these <strong>lowers the blood pressure</strong>. Due to a loss of negative feedback regulation, treatment with <strong>ARBs typically leads to increased renin levels and increased renin activity</strong>, which in turn leads to <strong>increased levels of angiotensin II.</strong> </p>\n<p><strong>Option A:</strong> This combination of effects could be explained by treatment with ACE inhibitors (e.g., enalapril).</p>\n<ul>\n<li>It inhibits the conversion of angiotensin I to angiotensin II, resulting in low levels of angiotensin II. Angiotensin II mediates sodium reabsorption in the proximal tubule, vasoconstriction, and aldosterone release. Hence, decreased activation of angiotensin II receptors would lead to an increase in urinary sodium excretion, decreased vessel tone, and lower levels of aldosterone. The combination of these effects lowers blood pressure.</li>\n<li>Due to a loss of negative feedback regulation, treatment with ACE inhibitors would typically lead to an increase in renin levels and renin activity. </li>\n</ul>\n<p><strong>Option C:</strong> This combination of effects could be explained by treatment with aldosterone receptor antagonists (e.g., spironolactone),</p>\n<ul>\n<li>It competitively binds to aldosterone receptors in the late distal tubule and the collecting ducts, inhibiting the effects of aldosterone. Inhibition of aldosterone leads to decreased sodium reabsorption, resulting in increased urinary sodium excretion.</li>\n<li>Due to a loss of negative feedback regulation, treatment with aldosterone receptor antagonists leads to an increase in renin activity and downstream renin-angiotensin-aldosterone system (RAAS) components (i.e., angiotensin II) and aldosterone, causing an increase in vessel tone. </li>\n</ul>\n<p><strong>Option D: </strong>This combination of effects could be explained by treatment with direct renin inhibitors (e.g., aliskiren).</p>\n<ul>\n<li>Direct inhibition of renin decreases renin activity, which leads to lower levels of angiotensin II (AT II) and aldosterone. Decreased levels of AT II and aldosterone result in decreased vessel tone and decreased sodium reabsorption in the proximal tubule, resulting in increased urinary sodium excretion. </li>\n</ul>\n<p>The same combination of effects could also be explained by treatment with beta-blockers (e.g., metoprolol). Beta-blockers inhibit the production and release of renin, which leads to suppression of the downstream renin-angiotensin-aldosterone system (RAAS) components (i.e., angiotensin II and aldosterone) and, subsequently, mildly decreased vessel tone and increased urinary sodium excretion.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403082eaf1fba-c3c5-4971-af2f-22b7519d4714.jpg\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308e4766001-158f-4bfd-9fbf-571f0c40e2fe.jpg\">", "options": ["Renin activity-Increased, AT-2 level-decreased, Aldosterone level-decreased, Urinary Sodium-decreased", "Renin activity-Increased, AT-2 level-Increased, Aldosterone level-decreased, Urinary Sodium-Increased", "Renin activity-Increased, AT-2 level-Increased, Aldosterone level-Increased, Urinary Sodium-Increased", "Renin activity-decreased, AT-2 level-decreased, Aldosterone level-decreased, Urinary Sodium-Increased"], "html_options": ["Renin activity-Increased, AT-2 level-decreased, Aldosterone level-decreased, Urinary Sodium-decreased", "Renin activity-Increased, AT-2 level-Increased, Aldosterone level-decreased, Urinary Sodium-Increased", "Renin activity-Increased, AT-2 level-Increased, Aldosterone level-Increased, Urinary Sodium-Increased", "Renin activity-decreased, AT-2 level-decreased, Aldosterone level-decreased, Urinary Sodium-Increased"], "corr_idx": 1}, {"id": "1166334", "html_qtxt": "A 54-year-old man comes to you due to swelling of both legs for 2 months. His blood pressure is 145/95 mm Hg, and he was started on a new medication three months ago. Physical examination shows 2+ oedema in both lower extremities. This patient was most likely treated with which of the following drugs?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient's peripheral pitting oedema is most likely an adverse effect of treatment with <strong>amlodipine</strong>, a <strong>dihydropyridine calcium channel blocker</strong> that was initiated for treatment of his hypertension.</li>\n</ul>\n<p>Dihydropyridine calcium channel blockers such as amlodipine cause systemic vasodilation, which increases hydrostatic pressure within <strong>pre-capillary</strong> blood vessels and can lead to <strong>peripheral </strong><strong>oedema.</strong></p>\n<ul>\n<li><strong>ACE inhibitors and ARBs cause preferential vasodilation of the post-capillary blood vessels.</strong> When used in combination with calcium channel blockers (CCB), this results in a reduction of the trans-capillary pressure and significantly reduces the risk of developing CCB-related peripheral oedema. While the oedema itself is not dangerous, it may be bothersome to some patients and combination therapy with an ACEI or ARB may have prevented this from occurring.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308a02a9a44-7b1e-4cf9-89bf-43f3dd281e17.jpg\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403082fb01909-60a0-4d83-835c-0c2d51a9f2f7.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Losartan (Option A): </strong>ARBs preferentially dilate postcapillary venules, minimising increases in capillary hydrostatic pressure and rarely causing oedema.</p>\n<p><strong>Hydrochlorothiazide (Option B): </strong>Thiazide diuretics reduce intravascular volume and typically improve, rather than cause, peripheral oedema.</p>\n<p><strong>Propranolol (Option D): </strong>Nonselective &beta;-blockers may cause cold extremities but do not produce pitting oedema via hydrostatic mechanisms.</p>", "options": ["Losartan", "Hydrochlorothiazide", "Amlodipine", "Propranolol"], "html_options": ["Losartan", "Hydrochlorothiazide", "Amlodipine", "Propranolol"], "corr_idx": 2}, {"id": "1166341", "html_qtxt": "A 28-year-old woman, at 30 weeks' gestation, is admitted to the hospital for the management of elevated blood pressures. Treatment with an intravenous drug is initiated. Physical examination shows pitting oedema of both lower extremities that was not present on admission.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308e28d6e59-cd69-4e40-9c15-1f0157b7020b.jpg\"><br>This patient was given a drug that most likely acts by which of the following mechanisms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This woman has likely been treated with intravenous hydralazine, a first-line treatment for severe hypertension during pregnancy.\n<ul>\n<li>Hydralazine is a direct peripheral vasodilator that preferentially affects arteriolar smooth muscle and increases the intracellular concentration of cGMP, which reduces afterload and blood pressure.</li>\n<li>Common adverse effects of hydralazine therapy include headache (due to direct vasodilation), <strong>tachycardia </strong>(due to reflex sympathetic activation), and <strong>peripheral edema</strong>(due to increased hydrostatic pressure, retention of sodium and water, and fluid extravasation). To reduce these adverse effects, direct arteriolar vasodilators are often co-administered with a &beta;-blocker and/or a diuretic.</li>\n</ul>\n</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030870606242-1731-41f2-bf73-0f179114f479.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Inhibition of nondihydropyridine calcium channels (Option B):</strong> Targets cardiac L-type Ca<sup>2+</sup> channels and slows AV conduction, not the main mechanism for acute arteriolar vasodilation in pregnancy.</p>\n<p><strong>Inhibition of angiotensin II production (Option C):</strong> ACE inhibitors are teratogenic and contraindicated in pregnancy.</p>\n<p><strong>Activation of &alpha;-adrenergic receptors (Option D): </strong>Causes vasoconstriction and increased afterload, opposite to the required antihypertensive effect.</p>", "options": ["Increases the intracellular concentration of cGMP in smooth muscle", "Inhibition of nondihydropyridine calcium channels", "Inhibition of angiotensin II production", "Activation of an adrenergic receptor"], "html_options": ["Increases the intracellular concentration of cGMP in smooth muscle", "Inhibition of nondihydropyridine calcium channels", "Inhibition of angiotensin II production", "Activation of an adrenergic receptor"], "corr_idx": 0}, {"id": "1166342", "html_qtxt": "A 35-year-old man presents to the emergency department complaining of a cough and runny nose of 1 week's duration. While being evaluated, it is discovered that his blood pressure is 230/120 mm Hg. An antihypertensive is immediately administered. Later, he develops lactic acidosis, headache, vertigo, and confusion. Which antihypertensive was given to him?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient's presentation of confusion, headache, flushed skin and anion gap lactic acidosis is suggestive of cyanide poisoning. The flushed skin and red- colored venous blood seen in patients with cyanide toxicity are a result of impaired oxygen utilisation and increased venous oxygen saturation.</li>\n<li>This patient most likely had a hypertensive crisis, which may be due to the use of an alpha agonist used for a runny nose, treated with intravenous sodium nitroprusside.\n<ul>\n<li>Sodium nitroprusside contains cyanide groups, and patients who receive prolonged infusions or have kidney disease are at especially high risk of developing cyanide toxicity.</li>\n<li>Cyanide inhibits the electron transport chain and thereby disables aerobic metabolism, resulting in a switch to anaerobic metabolism that leads to elevated lactate levels and anion gap acidosis, causing histotoxic hypoxia. Treatment of cyanide toxicity consists of administration of oxygen, hydroxycobalamin, and sodium thiosulfate.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Enalapril (Option A): </strong>ACE inhibitor has a slower onset, lacks cyanide moieties, and does not cause lactic acidosis.</p>\n<p><strong>Labetalol (Option B):</strong> Mixed &alpha;/&beta;-blocker lowers BP without cyanide production or significant lactic acid buildup.</p>\n<p><strong>Losartan (Option C): </strong>ARB acts gradually, does not release cyanide, and is not linked to acute lactic acidosis.</p>", "options": ["Enalapril", "Labetalol", "Losartan", "Nitroprusside"], "html_options": ["Enalapril", "Labetalol", "Losartan", "Nitroprusside"], "corr_idx": 3}, {"id": "1166346", "html_qtxt": "A 65-year-old African American man presents for management of hypertension. His blood pressure is 160/90 mmHg. He has a past medical history significant for gout, which is currently in remission. Which of the following is the most appropriate initial pharmacotherapy for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient has Stage 2 hypertension and is of African American descent. According to major guidelines (JNC-8, ACC/AHA), the first-line antihypertensive agents for this demographic are either a <strong>thiazide-type diuretic</strong> or a <strong>calcium channel blocker (CCB)</strong>.</p>\n<p>However, this patient has a history of <strong>gout</strong>. Thiazide diuretics like chlorthalidone are known to <strong>increase serum uric acid levels</strong> and can precipitate a gouty attack. Therefore, a CCB like <strong>Amlodipine</strong> is the superior and safer first-line choice in this specific clinical context.</p>\n<p><strong>Initial Antihypertensive Therapy in Special Populations:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/202510253b582ca4-5035-4391-b73d-491eef152f5f.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Chlorthalidone (Option A):</strong> Although a first-line agent for this demographic, it should be avoided in a patient with a history of gout dsue to the risk of hyperuricemia.</p>\n<p><strong>Captopril (Option B): </strong>ACE inhibitors are not a recommended first-line monotherapy for hypertension in African American patients due to lower efficacy and a higher risk of angioedema.</p>\n<p><strong>Metoprolol (Option D):</strong> Beta-blockers are not a first-line agent for uncomplicated hypertension unless there is a compelling indication (e.g., post-MI, heart failure).</p>", "options": ["Chlorthalidone", "Captopril", "Amlodipine", "Metoprolol"], "html_options": ["Chlorthalidone", "Captopril", "Amlodipine", "Metoprolol"], "corr_idx": 2}, {"id": "1166347", "html_qtxt": "A 54-year-old man with diabetes presents to the clinic for a routine checkup. His blood pressure is 142/88 mm Hg. His last urinalysis showed a urine micro-albumin of 150 mcg. What is the most appropriate initial antihypertensive for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>ACE inhibitors like lisinopril are first-line in diabetic patients with microalbuminuria </strong>because they reduce efferent arteriolar resistance, lowering intraglomerular pressure and decreasing protein leakage.</li>\n<li>By blocking angiotensin II formation, lisinopril decreases glomerular hyperfiltration and slows the progression of diabetic nephropathy beyond its antihypertensive effect.</li>\n<li>Clinical guidelines recommend initiating ACE inhibitors in hypertensive diabetics with albuminuria for both blood pressure control and renal protection.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Doxazosin (Option A): </strong>Doxazosin is an &alpha;<sub>1</sub>-selective blocker used for hypertension and urinary retention in BPH but lacks specific renoprotective, antiproteinuric effects.</p>\n<p><strong>Hydrochlorothiazide (Option B): </strong>A thiazide diuretic commonly used for essential hypertension, but in early diabetic nephropathy, ACE inhibitors provide superior renal protection and reduce microalbuminuria.</p>\n<p><strong>Metoprolol (Option D):</strong> A &beta;<sub>1</sub>-selective blocker useful in CHF or CAD patients; it does not confer the renal benefits or antiproteinuric effects seen with ACE inhibition and may mask hypoglycemia.</p>", "options": ["Doxazosin", "Hydrochlorothiazide", "Lisinopril", "Metoprolol"], "html_options": ["Doxazosin", "Hydrochlorothiazide", "Lisinopril", "Metoprolol"], "corr_idx": 2}, {"id": "1166352", "html_qtxt": "A 59-year-old man with hypertension presents with lower extremity oedema. Physical examination reveals pitting oedema from the ankles to the knees bilaterally. The patient has begun on furosemide. What could be the side effects seen in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Furosemide inhibits the Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> cotransporter in the thick ascending limb of the loop of Henle, causing marked urinary loss of sodium, water, and potassium, leading to hypokalemia.</li>\n<li>Increased distal tubular sodium delivery enhances potassium secretion in the cortical collecting duct, further exacerbating potassium depletion and predisposing to muscle weakness and cardiac arrhythmias.</li>\n<li>Hypokalemia risk is dose-dependent and accentuated by concurrent use of other potassium-wasting agents (e.g., corticosteroids), necessitating routine electrolyte monitoring and replacement.</li>\n<li>Furosemide is a loop diuretic with important interactions that we must be aware of. This agent will potentiate the action of other antihypertensives, and the patient can become hypotensive.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Hypotension (Option B): </strong>Volume depletion from loop diuretics can cause hypotension, but electrolyte disturbances like hypokalemia are more consistent and clinically significant.</p>\n<p><strong>Ototoxicity (Option C): </strong>High-dose or rapid IV furosemide infusions-especially with aminoglycosides-can cause ototoxicity, but this is a less common adverse effect than hypokalemia.</p>\n<p><strong>Hypercalcemia (Option D): </strong>Loop diuretics increase calcium excretion and can cause hypocalcemia; thiazide diuretics, not loops, are associated with hypercalcemia.</p>\n<p><strong>Key Takeaways:</strong></p>\n<p><strong>GO PANDA mnemonic</strong> summarises loop diuretic adverse effects:</p>\n<p><strong>G</strong>out, <strong>O</strong>totoxicity, low <strong>P</strong>otassium, <strong>A</strong>llergy, <strong>N</strong>ephritis, <strong>D</strong>ehydration, <strong>A</strong>lkalosis.</p>", "options": ["Hypokalemia", "Hypotension", "Ototoxicity", "Hypercalcemia"], "html_options": ["Hypokalemia", "Hypotension", "Ototoxicity", "Hypercalcemia"], "corr_idx": 0}, {"id": "1166355", "html_qtxt": "A 56-year-old man with male pattern baldness and hypertension is placed on minoxidil. He has had a lack of response to antihypertensive agents, with failure to respond to calcium channel blockers and ACE inhibitors. Prolonged use of this agent can be associated with which of the following effects?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This drug causes dilation of resistance vessels (arterioles) but not of capacitance vessels (venules). Minoxidil is administered orally for the treatment of severe to malignant hypertension that is refractory to other drugs.\n<ul>\n<li>Reflex tachycardia and fluid retention may be severe and require the concomitant use of a loop diuretic and a beta-blocker.</li>\n<li>Minoxidil causes serious sodium and water retention, leading to volume overload, oedema, and congestive heart failure. Minoxidil treatment also causes hypertrichosis (the growth of body hair). This drug is used topically to treat male pattern baldness.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Baldness (Option A): </strong>Minoxidil paradoxically promotes hair growth and is used topically to treat male pattern baldness.</p>\n<p><strong>Muscular wasting (Option C): </strong>No evidence links minoxidil to muscle catabolism or wasting.</p>\n<p><strong>Uremic pericarditis (Option D):</strong> Uremic pericarditis arises from severe renal failure, not from minoxidil use.</p>", "options": ["Baldness", "Fluid Retention", "Muscular wasting", "Uremic pericarditis"], "html_options": ["Baldness", "Fluid Retention", "Muscular wasting", "Uremic pericarditis"], "corr_idx": 1}, {"id": "1166358", "html_qtxt": "A 57-year-old man is found to have a blood pressure of 150/100 mm Hg on three successive occasions. He has begun on an antihypertensive agent. After taking the first dose of the medication, he goes out to play golf and collapses on the golf course. Which one of the following drugs may be responsible for his symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Prazosin produces first-dose hypotension, presumably by blocking alpha-1 receptors. This effect is minimised by initially giving the drug in small, divided doses. Among alpha blockers, prazosin has the maximum propensity for Orthostatic hypotension because it is not selective. Tamsulosin, on the other hand, selectively blocks alpha1B - minimal risk of Ortho hypo - safe to use in the elderly with BPH.</li>\n<li>Other options do not cause first-dose hypotension.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Atenolol (Option A): </strong>A &beta;<sub>1</sub>-selective blocker that lowers heart rate and BP gradually without causing acute first-dose orthostatic hypotension.</p>\n<p><strong>Hydrochlorothiazide (Option B): </strong>A thiazide diuretic whose hypotensive effect develops over days and does not precipitate an immediate collapse.</p>\n<p><strong>Metoprolol (Option C): </strong>A &beta;<sub>1</sub>-selective blocker with a smooth onset and no characteristic first-dose syncope.</p>", "options": ["Atenolol", "Hydrochlorothiazide", "Metoprolol", "Prazosin"], "html_options": ["Atenolol", "Hydrochlorothiazide", "Metoprolol", "Prazosin"], "corr_idx": 3}, {"id": "1166361", "html_qtxt": "A 57-year-old homeless man takes an antihypertensive agent but has not been able to obtain the medication. The patient's blood pressure is 190/110 mm Hg. Which one of the following antihypertensive drugs can precipitate a hypertensive crisis following abrupt cessation of therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Increased sympathetic nervous system activity occurs if clonidine therapy is abruptly stopped after prolonged administration.Clonidine acts by alpha 2 agonism ( alpha 2 is present in the brain and is inhibitory in nature). Uncontrolled elevation in blood pressure can occur. Patients should be slowly weaned from clonidine while other antihypertensive medications are initiated.</li>\n<li>Other options do not cause increased sympathetic activity after abrupt discontinuation.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Diltiazem (Option B):</strong> A nondihydropyridine calcium-channel blocker with no associated rebound sympathetic surge on discontinuation.</p>\n<p><strong>Enalapril (Option C): </strong>An ACE inhibitor; abrupt cessation does not cause rebound hypertension, although BP may rise to baseline.</p>\n<p><strong>Losartan (Option D): </strong>An ARB; withdrawal may lead to loss of BP control but not a hyperadrenergic crisis.</p>", "options": ["Clonidine", "Diltiazem", "Enalapril", "Losartan"], "html_options": ["Clonidine", "Diltiazem", "Enalapril", "Losartan"], "corr_idx": 0}, {"id": "1166364", "html_qtxt": "In an investigational study, a newly synthesised drug is found to have antihypertensive effects. Increasing drug concentrations can cause an increase in arteriolar radius and a decrease in beta-cell insulin secretion. The mechanism of action of which of the following drugs most closely resembles the mechanism of action of the experimental drug?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The experimental agent is able to do <strong>both vasodilation and decrease the release of insulin in response to glucose. </strong>The question is which known drug has similar effects. The answer is diazoxide, a K+ channel opener with hyperglycemic effects.</li>\n<li><strong>Diazoxide </strong>is a direct-acting peripheral vasodilator that<strong> decreases both systolic and diastolic blood pressure</strong>. Specifically, diazoxide opens K channels on vascular smooth muscle, causing hyperpolarisation and vasodilation, resulting in a decrease in peripheral vascular resistance. Opening K channels on pancreatic beta cells causes hyperpolarisation and decreased calcium entry through voltage-gated calcium channels. As a result, <strong>diazoxide decreases insulin secretion in response to glucose.</strong></li>\n<li><strong>Diazoxide </strong>is the drug of choice for the medical management of insulinoma.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Atenolol (Option A):</strong> A &beta;<sub>1</sub>-selective antagonist that reduces heart rate and contractility without direct vasodilation or insulin suppression.</p>\n<p><strong>Losartan (Option C):</strong> An AT<sub>1 </sub>receptor blocker that lowers blood pressure via angiotensin II antagonism, not K<sup>+</sup>-channel opening, and does not affect insulin secretion.</p>\n<p><strong>Phentolamine (Option D):</strong> A nonselective &alpha;-adrenergic blocker causing vasodilation through &alpha;<sub>1</sub> antagonism, without ATP-sensitive K<sup>+</sup> channel involvement or impacts on &beta;-cell function.</p>", "options": ["Atenolol", "Diazoxide", "Losartan", "Phentolamine"], "html_options": ["Atenolol", "Diazoxide", "Losartan", "Phentolamine"], "corr_idx": 1}, {"id": "1166366", "html_qtxt": "A 35-year-old man comes in with flank pain. His blood pressure is 160/120 mm Hg. An ultrasound of the kidneys shows enlarged kidneys with multiple round cortical cysts of varying sizes. Which of the following drugs is most appropriate for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The patient has adult polycystic kidney disease, an autosomal dominant disorder that causes an irreversible decline in kidney function.</li>\n<li><strong>Autosomal dominant polycystic kidney disease (ADPKD)</strong> is caused by mutations of either<strong> PKD1 (encodes for polycystin-1) on chromosome 16, or PKD2 (encodes for polycystin-2) on chromosome 4. </strong>Patients with PKD1 or PKD2 defects develop <strong>renal cysts and often present with hypertension (almost 100%), hematuria, proteinuria, or renal insufficiency.</strong> Other common symptoms include flank pain due to renal haemorrhage, calculi, and urinary tract infections. Since essentially all patients with ADPKD (due to PKD1 or PKD2) defects develop renal cysts. It is essential to have an understanding of the effect of these cysts on the RAAS.</li>\n<li>The renal cysts impair perfusion of glomeruli, which triggers the secretion of renin by the juxtaglomerular complexes. The renin secretion triggers the renin/angiotensin/aldosterone system. <strong>ACE (angiotensin-converting enzyme) inhibitors, such as captopril, enalapril, and lisinopril, directly interrupt this system by blocking the conversion of angiotensin I to angiotensin II.</strong> Furthermore, the <strong>ACE inhibitors increase renal blood flow and may provide renoprotective effects to hypertensive patients with this condition.</strong> <strong>Angiotensin receptor blockers</strong>, such as <strong>candesartan</strong> and <strong>losartan</strong>, are also considered to be first-line agents for the treatment of hypertension in adult polycystic kidney disease.</li>\n<li>When treating hypertension, the drug of choice should be selected based on the underlying cause of the hypertension, the appearance of a concomitant disease state, drug-drug interactions, and whether or not one drug will help improve or treat another non-hypertensive condition. In this case, the ACE inhibitors will\n<ul>\n<li>treat the hypertension,</li>\n<li>treat the underlying cause of the hypertension,</li>\n<li>increase renal blood flow, and</li>\n<li>potentially provide a renoprotective effect</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Clonidine (Option B):</strong> Central &alpha;<sub>2</sub>-agonist lowers sympathetic tone but does not interrupt RAAS or confer renal protection in ADPKD.</p>\n<p><strong>Diltiazem (Option C):</strong> Nondihydropyridine CCB reduces BP via vasodilation but lacks specific antiproteinuric effects and RAAS blockade.</p>\n<p><strong>Hydrochlorothiazide (Option D): </strong>Thiazide diuretic reduces volume but does not target RAAS activation and is less renoprotective in cystic kidney disease.</p>", "options": ["Captopril", "Clonidine", "Diltiazem", "Hydrochlorothiazide"], "html_options": ["Captopril", "Clonidine", "Diltiazem", "Hydrochlorothiazide"], "corr_idx": 0}, {"id": "1166374", "html_qtxt": "A 78-year-old man is brought in with fatigue and exertional and nocturnal dyspnea. Bilateral rales are heard over the lung fields. Which of the following best describes the primary mechanism of the drug that would most likely improve long-term mortality in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Angiotensin II plays a central role in maladaptive cardiac remodelling and aldosterone-mediated fibrosis; ACE inhibitors (e.g., captopril) block conversion of angiotensin I to II, reducing preload, afterload, and neurohormonal activation to improve survival.</li>\n<li>ARBs (e.g., losartan) similarly decrease remodelling by antagonising AT<sub>1</sub> receptors, and aldosterone antagonists (e.g., spironolactone) plus &beta;-blockers (e.g., metoprolol, carvedilol) further attenuate neurohormonal drive, all demonstrating mortality benefit in heart failure.</li>\n<li>Large clinical trials confirm that ACE inhibitors and ARBs decrease hospitalizations and long-term mortality, whereas purely symptomatic agents do not alter disease progression.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Blockade of L-type calcium channels in heart and blood vessels (Option A):</strong> Mechanism of action of drugs such as verapamil. Calcium channel blockers are indicated for hypertension and arrhythmias, but do not affect cardiac remodelling.</p>\n<p><strong>Inhibition of cardiac Na<sup>+</sup>-K<sup>+</sup>ATPase (Option C):</strong> Digoxin produces a positive inotropic effect by increasing myocardial contractility and is used in mild to moderate heart failure and atrial fibrillation; however, it improves symptoms without a mortality benefit.</p>\n<p><strong>Inhibition of the Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> transporter in the thick ascending limb (Option D):</strong> Mechanism of loop diuretics (e.g., furosemide), which relieve oedema in CHF, cirrhosis, and renal disease but have not been shown to prevent remodelling or improve survival.</p>", "options": ["Blockade of L-type calcium channels in the heart and blood vessels", "Inhibition of angiotensin II production", "Inhibition of cardiac Na<sup>+</sup> - K<sup>+</sup> ATPase", "Inhibition of the Na<sup>+</sup>/K<sup>+</sup>/2CI<sup>-</sup>transporter in the thick ascending limb of the loop of Henle"], "html_options": ["Blockade of L-type calcium channels in the heart and blood vessels", "Inhibition of angiotensin II production", "Inhibition of cardiac Na<sup>+</sup> - K<sup>+</sup> ATPase", "Inhibition of the Na<sup>+</sup>/K<sup>+</sup>/2CI<sup>-</sup>transporter in the thick ascending limb of the loop of Henle"], "corr_idx": 1}, {"id": "1166376", "html_qtxt": "A 48-year-old man comes with blood pressure is 160/100 mm Hg despite the use of enalapril as well as an appropriate dietary and exercise program. He has had problems with asthma since childhood and has an allergy to sulfa drugs. Which of the following drugs is most appropriate for this patient?", "html_expl": "<p><strong>Explanation: </strong></p>\n<p>This patient is <strong>hypertensive despite the use of the ACE inhibitor enalapril</strong>, an appropriate diet, and an exercise program.</p>\n<p>The physician then prescribes a second antihypertensive medication. <strong>A beta blocker was likely chosen since the use of a thiazide or loop diuretic is contraindicated in this patient due to a severe sulfa allergy.</strong></p>\n<p>B1-selective antagonists are often used to control hypertension in patients, such as asthmatics, who might experience bronchoconstriction with nonselective beta antagonists (e.g propranolol). Remember that beta1 receptors predominate in the heart, while B2 receptors predominate in the lungs.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Labetalol (Option B):</strong> Mixed &alpha;/&beta; blockade can still inhibit &beta;<sub>2</sub> receptors, risking bronchospasm in asthma.</p>\n<p><strong>Nadolol (Option C):</strong> Nonselective &beta;-blocker with long half-life and significant &beta;<sub>2</sub> blockade, increasing bronchoconstriction risk.</p>\n<p><strong>Propranolol (Option D):</strong> Nonselective &beta; antagonist that blocks &beta;<sub>2</sub> receptors, contraindicated in reactive airway disease.</p>", "options": ["Atenolol", "Labetalol", "Nadolol", "Propranolol"], "html_options": ["Atenolol", "Labetalol", "Nadolol", "Propranolol"], "corr_idx": 0}, {"id": "1166378", "html_qtxt": "A 49-year-old woman comes with blood pressure of 180/100 mm Hg after instituting the non-pharmacological treatment measures. Treatment is begun with a drug that results in decreased sodium reabsorption and decreased potassium excretion from the distal segments. Which of the following is the most likely drug?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Aldosterone-mediated distal exchange: </strong>In the late distal convoluted tubule, connecting tubule, and cortical collecting duct, aldosterone increases Na<sup>+</sup> reabsorption and K<sup>+</sup> secretion. Its levels rise with angiotensin II stimulation.</p>\n<p><strong>ACE inhibition effect:</strong> Enalapril blocks conversion of angiotensin I to II, reducing aldosterone secretion. This leads to decreased distal Na<sup>+</sup> reabsorption (natriuresis) and decreased K<sup>+</sup> excretion (risk of hyperkalemia).</p>\n<p><strong>Clinical profile:</strong> Enalapril is indicated for hypertension, heart failure, diabetic nephropathy, and post-myocardial infarction management. Known adverse effects include hyperkalemia, angioedema, and chronic cough.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acetazolamide (Option A):</strong> A proximal tubular carbonic anhydrase inhibitor causing bicarbonate diuresis and metabolic acidosis, not affecting distal Na<sup>+</sup>/K<sup>+</sup> exchange.</p>\n<p><strong>Atenolol (Option B):</strong> A &beta;<sub>1</sub>-blocker that lowers blood pressure via reduced cardiac output and renin release, without directly altering distal nephron ion handling.</p>\n<p><strong>Diltiazem (Option C):</strong> A nondihydropyridine calcium-channel blocker that decreases vascular tone and heart rate but does not modulate aldosterone or distal tubular Na<sup>+</sup>/K<sup>+</sup> transport.</p>", "options": ["Acetazolamide", "Atenolol", "Dilitazem", "Enalapril"], "html_options": ["Acetazolamide", "Atenolol", "Dilitazem", "Enalapril"], "corr_idx": 3}, {"id": "1166381", "html_qtxt": "A 69-year-old man comes in with chest tightness when he walks uphill or climbs stairs. The patient is prescribed a medication that is metabolised to S-nitrosothiols in the vascular smooth muscle cells, and he reports rapid and significant symptom relief. Which of the following components of the cardiovascular system is most susceptible to the medication prescribed to this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient has stable angina pectoris and experienced rapid symptomatic relief following receipt of a nitrate.</li>\n<li><strong>Pharmacologic nitrates (eg, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) are </strong><strong>metabolised to nitric oxide and S-nitrosothiols via mitochondrial aldehyde dehydrogenase within vascular smooth muscle cells</strong>. These compounds, in turn, activate guanylate cyclase and promote the conversion of guanosine triphosphate to cyclic guanosine monophosphate (cGMP), which leads to dephosphorylation of myosin light chains and causes vascular smooth muscle relaxation.</li>\n<li><strong>Nitrates predominantly affect the large veins</strong>, where <strong>smooth muscle relaxation leads to venodilation and increased venous capacitance.</strong> Cardiac venous return (preload) is reduced, leading to a reduction in left ventricular end-diastolic volume and pressure and a consequent decrease in left ventricular wall stress. Decreased myocardial oxygen demand leads to relief of anginal symptoms.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Cardiac muscle (Option A): </strong>Cardiac myocytes do not directly relax in response to nitrates; any effect is secondary to decreased preload and afterload.</p>\n<p><strong>Large arteries (Option B):</strong> Arterial dilation occurs at higher doses, but the primary therapeutic action is venodilation.</p>\n<p><strong>Small arteries and arterioles (Option D):</strong> While nitrates can dilate arterioles, this effect is less pronounced and contributes minimally to angina relief at typical doses.</p>", "options": ["Cardiac muscle", "Large arteries", "Large veins", "Small arteries and arterioles"], "html_options": ["Cardiac muscle", "Large arteries", "Large veins", "Small arteries and arterioles"], "corr_idx": 2}, {"id": "1166383", "html_qtxt": "A 72-year-old woman with type 2 diabetes mellitus and hypertension under hydrochlorothiazide therapy comes with lab shows a serum potassium level of 4.2 mEq/L and a creatinine level of 0.8 mg/dL. Urinalysis shows albuminuria. Lisinopril therapy is initiated. The next day, the patient returns due to lightheadedness and near-syncope. Her blood pressure is 102/66 mm Hg supine and 80/45 mm Hg standing. Her pulse is 94/ min. Which of the following is most likely the major factor contributing to this patient's current symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>ACE inhibitors can cause first-dose hypotension, especially in patients with high plasma renin activity from volume depletion (e.g., hydrochlorothiazide use), leading to an exaggerated BP drop.</li>\n<li>Diuretic-induced volume depletion heightens renin release and sensitises the vasculature to angiotensin II blockade, precipitating orthostatic hypotension and syncope.</li>\n<li>Abrupt removal of angiotensin II's vasoconstrictive tone lowers peripheral resistance precipitously; starting ACE inhibitors at low doses and withholding diuretics briefly can prevent this.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Neuropathy (Option A): </strong>Autonomic neuropathy could cause orthostatic changes but would not present acutely after initiation of lisinopril.</p>\n<p><strong>Diabetic nephropathy (Option B):</strong> Albuminuria indicates nephropathy but does not directly cause sudden hypotension or syncope.</p>\n<p><strong>Unilateral renal artery stenosis (Option D):</strong> ACE inhibitors in renal stenosis can reduce GFR, but the dominant issue here is volume depletion-driven hypotension.</p>", "options": ["Neuropathy", "Diabetic nephropathy", "Diuretic therapy", "Unilateral renal artery stenosis"], "html_options": ["Neuropathy", "Diabetic nephropathy", "Diuretic therapy", "Unilateral renal artery stenosis"], "corr_idx": 2}, {"id": "1166386", "html_qtxt": "A 47-year-old woman comes with facial swelling and difficulty breathing. There is no itching or skin rash. She also began taking lisinopril 3 months ago for hypertension. Audible stridor without wheezing is present. Which of the following is the most likely mechanism responsible for this patient's symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Angioedema is a rare and potentially serious adverse effect of ACE inhibitor therapy. Symptoms typically appear within days of initiation but can also occur after weeks to years of therapy. Although angioedema can affect any tissue, it most commonly involves the tongue, lips, or eyelids. Laryngeal edema and difficulty breathing may also occur. ACE inhibitor-induced angioedema is due to bradykinin accumulation. Normally, ACE is responsible for bradykinin breakdown. ACE inhibitors prevent bradykinin degradation, leading to increased levels. Bradykinin is a potent vasodilator that ultimately increases vascular permeability, causing significant angioedema. ACE inhibitors should be discontinued in patients who develop angioedema.</li>\n<li>In non-immune-mediated mast cell degranulation, there is direct activation of mast cells independent of IgE cross-linking. These pseudoallergic reactions can be caused by chemicals, heat, and certain drugs (eg, opiates, vancomycin) and are clinically similar to hypersensitivity and allergic reactions.</li>\n</ul>", "options": ["Bradykinin accumulation", "Hereditary C1-esterase inhibitor deficiency", "lgE-dependent mast cell degranulation", "Nonimmune mediated mast cell degranulation"], "html_options": ["Bradykinin accumulation", "Hereditary C1-esterase inhibitor deficiency", "lgE-dependent mast cell degranulation", "Nonimmune mediated mast cell degranulation"], "corr_idx": 0}, {"id": "1166395", "html_qtxt": "A 43-year-old man with hypertension comes with confusion. Blood pressure is 230/120 mm Hg, and pulse is 76/min. Funduscopic examination shows bilateral papilledema. Serum creatinine is 1.4 mg/dL. The patient is started on an intravenous medication that causes arteriolar dilation, improves renal perfusion, and increases natriuresis. Repeat blood pressure an hour later is 182/92 mm Hg, with improvement of his symptoms. Which of the following agents is most likely being used in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient presents with <strong>hypertensive emergency</strong>, defined as severely elevated blood pressure with signs of <strong>acute end-organ damage,</strong> in this case, <strong>hypertensive encephalopathy</strong>, <strong>papilledema</strong>, and <strong>acute kidney injury</strong> (elevated creatinine).</p>\n<p><strong>Fenoldopam</strong> is a <strong>short-acting selective dopamine-1 (D1) receptor agonist</strong>. Stimulation of D1 receptors leads to <strong>arteriolar vasodilation</strong> by increasing intracellular cyclic AMP. This results in:</p>\n<ol>\n<li><strong>Improved renal blood flow</strong></li>\n<li><strong>Improved mesenteric blood flow</strong></li>\n<li><strong>Increased natriuresis and diuresis</strong></li>\n</ol>\n<p>These renal effects make <strong>fenoldopam especially beneficial in hypertensive emergencies associated with renal dysfunction</strong>, as it simultaneously reduces BP and enhances renal perfusion without compromising renal function.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Esmolol (Option A):</strong> A beta-1 selective blocker used primarily in <strong>aortic dissection</strong> or <strong>postoperative hypertension</strong>; it does not promote vasodilation or improve renal perfusion.</p>\n<p><strong>Hydralazine (Option C):</strong> A direct arteriolar vasodilator; associated with <strong>unpredictable BP control</strong> and <strong>reflex tachycardia</strong>; not preferred in hypertensive encephalopathy.</p>\n<p><strong>Nitroglycerin (Option D):</strong> A venodilator used in <strong>coronary ischemia or acute heart failure</strong>; it does not improve renal or mesenteric perfusion and is suboptimal in pure hypertensive emergencies.</p>", "options": ["Esmolol", "Fenoldopam", "Hydralazine", "Nitroglycerin"], "html_options": ["Esmolol", "Fenoldopam", "Hydralazine", "Nitroglycerin"], "corr_idx": 1}, {"id": "1166419", "html_qtxt": "A 68-year-old man comes to the office due to thigh and leg pain that worsens with exertion. The patient smokes 2 packs of cigarettes a day. Which of the following drugs would best provide symptomatic improvement due to direct dilation of arteries and inhibition of platelet aggregation?", "html_expl": "<p><strong>Explanation: </strong></p>\n<p>The patient has <strong>intermittent claudication</strong>, a classic symptom of <strong>peripheral arterial disease (PAD)</strong>. PAD results from atherosclerotic occlusion of lower extremity arteries and presents with exertional limb pain that resolves with rest.</p>\n<p><strong>Cilostazol</strong> is a <strong>phosphodiesterase III (PDE3) inhibitor</strong> that increases intracellular <strong>cyclic AMP (cAMP)</strong> levels in:</p>\n<ul>\n<li><strong>Platelets</strong>: increased cAMP inhibits platelet aggregation by preventing platelet shape change and granule release.</li>\n<li><strong>Vascular smooth muscle</strong>: elevated cAMP causes <strong>arteriolar vasodilation</strong>, improving blood flow.</li>\n</ul>\n<p>Together, these effects improve walking distance and reduce claudication symptoms. Cilostazol is the <strong>only drug approved specifically for symptomatic relief in PAD</strong>, alongside a <strong>graded exercise program</strong>.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Abciximab (Option A):</strong> A glycoprotein IIb/IIIa receptor antagonist; inhibits final common pathway of platelet aggregation but has no vasodilator effect. Used primarily in ACS and PCI settings.</p>\n<p><strong>Aspirin (Option B):</strong> Irreversibly inhibits COX-1 &rarr; &darr; thromboxane A2 synthesis &rarr; inhibits platelet aggregation; <strong>no vasodilator activity</strong>, does not improve claudication symptoms.</p>\n<p><strong>Heparin (Option D):</strong> Activates antithrombin III &rarr; inhibits thrombin and factor Xa; anticoagulant effect useful in DVT/PE but not in chronic PAD or claudication management.</p>", "options": ["Abciximab", "Aspirin", "Cilostazol", "Heparin"], "html_options": ["Abciximab", "Aspirin", "Cilostazol", "Heparin"], "corr_idx": 2}, {"id": "1166420", "html_qtxt": "A 45-year-old woman was found obtunded in her apartment. She is hypotensive and bradycardic. Intravenous glucagon is administered, and her condition improves. Which of the following intracellular changes is most likely responsible for the improvement in her condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient has most likely overdosed on beta blocker medications. Beta blocker overdose causes diffuse non-selective blockade of peripheral beta adrenergic receptors, causing depression of myocardial contractility, bradycardia, and varying degrees of AV block. The result is a low cardiac output state.</p>\n<p>Glucagon is the drug of choice for beta-blocker overdose. Glucagon acts on G protein-coupled receptors, increasing intracellular CAMP and thus increasing the release of intracellular calcium during muscle contraction. This increases heart rate and cardiac contractility. Improvements in heart rate and blood pressure may be observed within minutes.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Synaptic release of glutamate (Option A): </strong>Irrelevant to glucagon's cardiovascular effects and beta-blocker overdose.</p>\n<p><strong>Decreased cAMP in vascular smooth muscle (Option B): </strong>Would exacerbate hypotension by reducing vasoconstriction, opposite to the clinical improvement seen.</p>\n<p><strong>Decreased DAG in vascular smooth muscle (Option C): </strong>Not involved in glucagon's mechanism, which principally elevates cAMP rather than altering DAG/PKC pathways.</p>", "options": ["Synaptic release of glutamate", "Decreased cAMP in vascular smooth muscle", "Decreased DAG in vascular smooth muscle", "Increased cAMP in cardiac myocytes"], "html_options": ["Synaptic release of glutamate", "Decreased cAMP in vascular smooth muscle", "Decreased DAG in vascular smooth muscle", "Increased cAMP in cardiac myocytes"], "corr_idx": 3}]}, {"moduleId": 1013388, "name": "Antihypertensives and Hypolipidemic Drugs (Part 2)", "questions": [{"id": "1166424", "html_qtxt": "A 65-year-old male is given an intravenous infusion of an agent that increases peripheral vascular resistance, increases systolic blood pressure, decreases pulse pressure, and decreases heart rate. Which of the following agents is being described?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Phenylephrine </strong>is a selective &alpha;<sub>1</sub>-adrenergic agonist that produces marked arterial vasoconstriction, raising systemic vascular resistance and systolic blood pressure.</p>\r\n<p>The abrupt rise in blood pressure activates baroreceptors, increasing vagal tone, which reduces heart rate and stroke volume, leading to a narrowed pulse pressure.</p>\r\n<p>Reflex bradycardia and increased afterload are characteristic of pure &alpha;<sub>1</sub>-agonism, distinguishing phenylephrine from mixed or &beta;-selective adrenergic agents.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Dobutamine (Option B): </strong>A &beta;<sub>1</sub>-agonist that increases heart rate, contractility, and cardiac output, with minimal vasoconstriction and often a drop in peripheral resistance.</p>\r\n<p><strong>Isoproterenol (Option C):</strong> A nonselective &beta;-agonist that lowers peripheral resistance, increases heart rate and pulse pressure, and does not cause reflex bradycardia.</p>\r\n<p><strong>Epinephrine (Option D):</strong> A mixed &alpha;/&beta;-agonist whose effects vary with dose; typically increases heart rate and pulse pressure at low to moderate doses and does not produce isolated &alpha;<sub>1</sub>-mediated reflex bradycardia.</p>", "options": ["Phenylephrine", "Dobutamine", "Isoproterenol", "Epinephrine"], "html_options": ["Phenylephrine", "Dobutamine", "Isoproterenol", "Epinephrine"], "corr_idx": 0}, {"id": "1166425", "html_qtxt": "A 50-year-old man presents with dizziness and confusion. He had an episode of chest pain and took several tablets of nitroglycerin. His current medications include tadalafil for erectile dysfunction. His blood pressure is 50/20 mmHg, and his heart rate is 120 beats/min. Which of the following cellular changes is most likely responsible for this patient's symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Nitroglycerin is converted to nitric oxide in vascular smooth muscle, activating guanylate cyclase to increase cGMP and induce vasodilation, lowering blood pressure.</p>\r\n<p>Tadalafil inhibits phosphodiesterase-5, preventing cGMP degradation and compounding the rise in intracellular cGMP.</p>\r\n<p>The synergy of increased cGMP synthesis (from nitrates) and reduced breakdown (from PDE5 inhibition) leads to profound hypotension, reflex tachycardia, and cerebral hypoperfusion, causing dizziness and confusion.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Gs protein phosphorylation (Option A): </strong>Gs-PKA signalling is not central to nitrate-PDE5 inhibitor interactions.</p>\r\n<p><strong>Tyrosine kinase overactivity (Option C):</strong> Irrelevant to the NO-cGMP pathway and vascular smooth muscle relaxation here.</p>\r\n<p><strong>Enhanced phospholipid metabolism (Option D): </strong>Does not underlie nitrate or PDE5 inhibitor-induced vasodilation.</p>", "options": ["Gs protein phosphorylation", "Cyclic GMP accumulation", "Tyrosine kinase overactivity", "Enhanced phospholipid metabolism"], "html_options": ["Gs protein phosphorylation", "Cyclic GMP accumulation", "Tyrosine kinase overactivity", "Enhanced phospholipid metabolism"], "corr_idx": 1}, {"id": "1166430", "html_qtxt": "A 64-year-old man has been treated with lisinopril for the past 5 years. His medical history is significant for type 2 diabetes mellitus, coronary artery disease with stable angina, and moderately increased albuminuria. Blood pressure is 150/90 mm Hg, and pulse is 70/min. Serum laboratory results are as follows:<br>Sodium=138 mEq/L<br>Potassium= 5.3 mEq/L<br>Chloride= 104 mEq/L<br>Bicarbonate= 24 mEq/L<br>Calcium 9.5 mg/dL<br>Creatinine=1.0 mg/dL<br>Which of the following medications should be avoided in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>ACE inhibitors (e.g., lisinopril) block the conversion of angiotensin I to II, decreasing systemic vascular tone, reducing aldosterone secretion, and lowering blood pressure.</p>\r\n<p>Reduced aldosterone levels cause increased sodium excretion and potassium retention, leading to hyperkalemia; this risk is greatest in patients with renal insufficiency or those taking potassium-sparing diuretics or drugs that decrease GFR (e.g., NSAIDs).</p>\r\n<p>Eplerenone, a mineralocorticoid receptor antagonist, further impairs aldosterone's action, exacerbating potassium retention and risking severe hyperkalemia when used with an ACE inhibitor; thus, it should be avoided in this patient with baseline mild hyperkalemia.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Amlodipine (Option A):</strong> A dihydropyridine CCB that does not affect aldosterone or potassium handling; safe in hyperkalemia.</p>\r\n<p><strong>Diltiazem (Option B):</strong> A nondihydropyridine CCB without RAAS interaction or potassium-sparing effects; does not raise serum potassium.</p>\r\n<p><strong>Furosemide (Option D): </strong>A loop diuretic that increases renal potassium excretion; may help correct hyperkalemia.</p>", "options": ["Amlodipine", "Diltiazem", "Eplerenone", "Furosemide"], "html_options": ["Amlodipine", "Diltiazem", "Eplerenone", "Furosemide"], "corr_idx": 2}, {"id": "1166432", "html_qtxt": "A 26-year-old man with chest discomfort occurs with climbing stairs. Family history includes an uncle who died suddenly at the age of 35 years. Apical impulse is strong and sustained. He has a soft crescendo-decrescendo systolic murmur at the apex and left sternal border while supine that becomes quite pronounced when he stands up. Which of the following medications should be avoided while treating this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient's presentation, family history of premature sudden death, and systolic murmur that accentuates with standing from a supine position is consistent with hypertrophic cardiomyopathy.</li>\r\n<li>Patients with HM have dynamic left ventricular outflow tract (LVOT) obstruction that worsens with decreased left ventricular (LV) volume (as can be caused by decreased preload and/or reduced systemic vascular resistance). As such, medications that generally should be avoided in patients with hypertrophic cardiomyopathy include:\r\n<ul>\r\n<li>Vasodilators (eg, dihydropyridine calcium channel blockers, nitroglycerin, and ACE inhibitors) decrease systemic vascular resistance, leading to decreased afterload and lower LV volumes.</li>\r\n<li>Diuretics decrease LV venous filling (preload) and also result in greater outflow obstruction.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Disopyramide (Option A):</strong> A negative inotrope that decreases contractility and reduces LVOT gradient, beneficial in HCM.</p>\r\n<p><strong>Metoprolol (Option C):</strong> A &beta;<sub>1</sub>-blocker that lowers heart rate and contractility, improves diastolic filling, and reduces obstruction in HCM.</p>\r\n<p><strong>Verapamil (Option D):</strong> A nondihydropyridine calcium-channel blocker that decreases contractility and heart rate, improving left ventricular filling and reducing obstruction.</p>", "options": ["Disopyramide", "Isosorbide dinitrate", "Metoprolol", "Verapamil"], "html_options": ["Disopyramide", "Isosorbide dinitrate", "Metoprolol", "Verapamil"], "corr_idx": 1}, {"id": "1166434", "html_qtxt": "A 56-year-old female presents with a chronic cough. She says that the cough is dry and affects the quality of her life significantly. She denies chest pain, hemoptysis and shortness of breath. Her past medical history is significant for long-standing hypertension, diabetes and myocardial infarction experienced two months ago. Which of the following is the best next step in the management of this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>A chronic, dry cough in a patient on cardiovascular medications, especially without other respiratory signs, raises suspicion for drug-induced cough, most commonly from ACE inhibitors prescribed for hypertension or post-MI management.</p>\r\n<p>Reviewing current medications is essential to identify agents (e.g., lisinopril, enalapril) that impair bradykinin breakdown and provoke persistent cough; recognising this allows targeted intervention.</p>\r\n<p>If an offending drug is found, substituting with an alternative antihypertensive (such as an ARB) can alleviate cough and improve quality of life while maintaining cardiovascular protection.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Careful review of family history (Option A):</strong> Family history is irrelevant to a new drug-related cough.</p>\r\n<p><strong>Careful review of past allergic episodes (Option B):</strong> No signs of allergic reaction (rash, itching), making hypersensitivity unlikely.</p>\r\n<p><strong>Careful review of diet and physical activity (Option D):</strong> Lifestyle factors do not explain a persistent dry cough in this context.</p>", "options": ["Careful review of family history", "Careful review of past allergic episodes", "Careful review of current medications", "Careful review of diet and physical activity"], "html_options": ["Careful review of family history", "Careful review of past allergic episodes", "Careful review of current medications", "Careful review of diet and physical activity"], "corr_idx": 2}, {"id": "1166435", "html_qtxt": "A 46-year-old man is diagnosed with resistant hypertension. He agrees to enrol in a trial of a new long-acting medication that causes selective direct relaxation of the smooth muscle of arterioles but does not affect the veins. Which of the following adverse effects is most likely to be caused by the drug during the clinical trial?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Selective arteriolar vasodilators (e.g., hydralazine, minoxidil) reduce systemic vascular resistance, triggering baroreceptor-mediated sympathetic activation that increases heart rate, contractility, and cardiac output.</p>\r\n<p>Sympathetic stimulation of the renin-angiotensin-aldosterone system follows, causing enhanced sodium and water reabsorption in the kidney and resulting in volume expansion and peripheral oedema.</p>\r\n<p>These compensatory sodium and fluid retention effects limit the long-term antihypertensive efficacy of arteriolar-selective vasodilators unless combined with diuretics.</p>", "options": ["Angioedema", "Cold extremities", "Persistent cough", "Sodium and fluid retention"], "html_options": ["Angioedema", "Cold extremities", "Persistent cough", "Sodium and fluid retention"], "corr_idx": 3}, {"id": "1166436", "html_qtxt": "A 57-year-old male is admitted due to muscle pain, fatigue and dark urine. Current medications include metoprolol, atorvastatin, and aspirin. Laboratory evaluation reveals that he is in acute renal failure. The addition of which of the following medications is most likely to have precipitated this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Statin-induced myopathy can progress to rhabdomyolysis, with myoglobinuria causing tubular obstruction, oxidative injury, and acute renal failure.</strong></p>\r\n<ul>\r\n<li>Statins are very effective agents in the reduction of LDL cholesterol. Serious side effects of statins include myopathy and hepatitis.</li>\r\n<li><strong>Myopathy</strong> is a rare complication of statin use, clinically defined as muscle pain with serum creatine kinase over 10 times the upper limit of normal. With the exception of pravastatin, <strong>the statin drugs (simvastatin, lovastatin, atorvastatin) are metabolised by the liver CYP3A4.</strong></li>\r\n<li><strong>Erythromycin inhibits CYP3A4. Thus, concurrent use of erythromycin with these drugs causes increased serum levels of statins, which is in turn associated with increased risk for myopathy.</strong> Other macrolides, such as clarithromycin, also inhibit CYP3A4. Azithromycin, however, does not have a significant effect on CYP3A4. Other inhibitors of cytochrome CYP3A4 include ketoconazole, cyclosporine, HIV protease inhibitors, and grapefruit juice. <strong>If a patient is on an agent that inhibits CYP3A4, pravastatin is the statin of choice.</strong></li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Phenytoin (Option B): </strong>As a CYP3A4 inducer, phenytoin accelerates statin metabolism, lowering systemic statin exposure and reducing myopathy risk; it does not cause rhabdomyolysis but carries its own CNS and bone density side effects.</p>\r\n<p><strong>Griseofulvin (Option C): </strong>A moderate CYP3A4 inducer used for dermatophyte infections; it increases hepatic clearance of co-administered drugs, including statins, thereby decreasing their toxicity potential rather than provoking muscle injury.</p>\r\n<p><strong>Phenobarbitone (Option D): </strong>A broad-spectrum CYP inducer that upregulates multiple isoforms (including CYP3A4), enhancing statin metabolism and reducing the risk of rhabdomyolysis; its main adverse effects involve sedation and dependence, not acute muscle breakdown.</p>", "options": ["Erythromycin", "Phenytoin", "Griseofulvin", "Phenobarbitone"], "html_options": ["Erythromycin", "Phenytoin", "Griseofulvin", "Phenobarbitone"], "corr_idx": 0}, {"id": "1166439", "html_qtxt": "A 48-year-old man with hypercholesterolemia comes for follow-up with a current LDL level of 190 mg/dL. Which of the following should be obtained before starting statin therapy in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Statin mechanism & hepatotoxicity:</strong> Statins inhibit HMG-CoA reductase, reducing cholesterol synthesis. They can cause reversible hepatocellular injury (H in the \"HMG\" mnemonic: Hepatitis), so baseline AST/ALT measurements are essential for safety and future comparison.</p>\r\n<p><strong>Statins adverse effects:</strong> <strong>HMG </strong>&rarr; <strong>H</strong>epatitis, <strong>M</strong>yopathy (most common), <strong>G</strong> (Hyper<strong>g</strong>lycemia and <strong>G</strong>ravid contraindication).</p>\r\n<p><strong>Myopathy risk factors:</strong> Myopathy is the most frequent serious statin side effect; combining statins with fibrates further increases this risk. Niacin, once used for hypercholesterolemia, caused frank diabetes rather than mild hyperglycemia seen with statins.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Apolipoprotein-B level (Option A): </strong>Useful for risk assessment but not required before statin initiation.</p>\r\n<p><strong>Complete blood count (Option B): </strong>Unrelated to statin safety monitoring.</p>\r\n<p><strong>Lipoprotein lipase activity assay (Option C): </strong>Not indicated for guiding statin therapy.</p>", "options": ["Apolipoprotein-B level", "Complete blood count", "Lipoprotein lipase activity assay", "Liver transaminase levels"], "html_options": ["Apolipoprotein-B level", "Complete blood count", "Lipoprotein lipase activity assay", "Liver transaminase levels"], "corr_idx": 3}, {"id": "1166441", "html_qtxt": "A 68-year-old man has achy pain in his thigh that is not related to activity. The patient has tried warm compresses. Physical examination shows diffuse tenderness in the proximal muscles of the upper and lower extremities. Serum creatine kinase activity is elevated. Which of the following drug combinations is most likely responsible for this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Statins (eg, atorvastatin) are the first-line therapy for most patients with hypercholesterolemia and are useful in primary and secondary prevention of acute coronary events.</p>\r\n<p><strong>Statins inhibit HMG-CoA reductase, the enzyme responsible for the rate-limiting step in the synthesis of cholesterol.</strong> Statins lower total cholesterol, LDL, and triglyceride levels. The primary side effects of statins include <strong>myopathy and hepatitis</strong>.</p>\r\n<p><strong>Fibrate interaction</strong>: Gemfibrozil inhibits hepatic uptake and glucuronidation of statins, markedly raising statin plasma levels and precipitating severe myopathy or rhabdomyolysis with elevated CK.</p>\r\n<p>Rhabdomyolysis leads to myoglobinuria, which can obstruct renal tubules and cause acute kidney injury, explaining this patient's presentation.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Atorvastatin and cholestyramine (Option A):</strong> Cholestyramine acts in the gut to bind bile acids without affecting statin metabolism, so myopathy risk remains at baseline.</p>\r\n<p><strong>Atorvastatin and ezetimibe (Option B): </strong>Ezetimibe reduces intestinal cholesterol absorption but does not interfere significantly with statin clearance; only a slight increase in myopathy risk.</p>\r\n<p><strong>Gemfibrozil and ezetimibe (Option D):</strong> No statin present-this combination may cause GI side effects or elevated liver enzymes, but not statin-related myopathy.</p>", "options": ["Atorvastatin and cholestyramine", "Atorvastatin and ezetimibe", "Atorvastatin and gemfibrozil", "Gerfibrozil and ezetimibe"], "html_options": ["Atorvastatin and cholestyramine", "Atorvastatin and ezetimibe", "Atorvastatin and gemfibrozil", "Gerfibrozil and ezetimibe"], "corr_idx": 2}, {"id": "1166442", "html_qtxt": "A 55-year-old man with recurrent episodes of retrosternal chest pain. He is given a sublingual tablet and reports rapid relief of the pain. This drug most likely improved this patient's symptoms by causing which of the following hemodynamic changes?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>In chronic stable angina, sublingual nitroglycerin relieves pain primarily by <strong>reducing preload</strong>, which lowers left ventricular end-diastolic volume (LVEDV) and wall stress.</p>\r\n<p>Nitroglycerin is metabolised to nitric oxide in smooth muscle, increasing cGMP and causing direct relaxation of vascular smooth muscle.</p>\r\n<p>This leads to venodilation (predominant), decreasing venous return and LVEDV, and thereby reducing myocardial oxygen demand.</p>\r\n<p>Nitrates also produce a modest reduction in afterload via arterial dilation and mild coronary artery dilation to relieve vasospasm, but these effects are secondary to preload reduction.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Decrease in arteriolar resistance (Option A): </strong>Afterload reduction is modest with nitrates and not the primary mechanism for acute angina relief.</p>\r\n<p><strong>Increase in coronary blood flow (Option C): </strong>Coronary dilation is mild and often insufficient to markedly increase net flow in stable atherosclerotic vessels.</p>\r\n<p><strong>Increase in coronary perfusion pressure (Option D):</strong> Systemic vasodilation can lower perfusion pressure; preload reduction remains the key benefit.</p>", "options": ["Decrease in arteriolar resistance", "Decrease in left ventricular end-diastolic volume", "Increase in coronary blood flow", "Increase in coronary perfusion pressure"], "html_options": ["Decrease in arteriolar resistance", "Decrease in left ventricular end-diastolic volume", "Increase in coronary blood flow", "Increase in coronary perfusion pressure"], "corr_idx": 1}, {"id": "1166448", "html_qtxt": "A 53-year-old man comes in with shortness of breath and chest tightness. Blood pressure is 200/110 mm Hg, and pulse is 90/min and regular. Lung examination reveals bibasilar crackles. Nitroglycerin infusion is started and results in significant symptomatic improvement. Which of the following intracellular events is most likely responsible for the beneficial effects of this patient's treatment?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>In acute pulmonary oedema from hypertensive emergency, intravenous nitrates (e.g., nitroglycerin, sodium nitroprusside) rapidly improve acute heart failure by reducing both preload and afterload via direct vascular smooth muscle relaxation.</p>\r\n<p>Nitrates are converted in smooth muscle cells to nitric oxide, which activates guanylate cyclase and increases conversion of GTP to cGMP. Elevated cGMP lowers intracellular Ca<sup>2+</sup>, dampening myosin light-chain kinase activity, and activates myosin light-chain phosphatase.</p>\r\n<p>Activation of myosin light-chain phosphatase leads to <strong>myosin light-chain dephosphorylation</strong>, causing smooth muscle relaxation and the rapid hemodynamic improvement seen in this patient.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Calcium release from sarcoplasmic reticulum (Option A):</strong> Would increase cytosolic Ca<sup>2+</sup> and promote contraction, opposite to vasodilation.</p>\r\n<p><strong>Enhanced cyclic mononucleotide degradation (Option B):</strong> Increased phosphodiesterase activity would lower cGMP, negating nitrate effects and causing vasoconstriction.</p>\r\n<p><strong>Tyrosine kinase activation (Option C):</strong> Involved in growth factor signalling, not the acute vasodilatory mechanism of nitrates.</p>", "options": ["Calcium release from the sarcoplasmic reticulum", "Enhanced cyclic mononucleotide degradation", "Tyrosine kinase activation", "Myosin dephosphorylation"], "html_options": ["Calcium release from the sarcoplasmic reticulum", "Enhanced cyclic mononucleotide degradation", "Tyrosine kinase activation", "Myosin dephosphorylation"], "corr_idx": 3}, {"id": "1166451", "html_qtxt": "A 60-year-old male is diagnosed with exertional angina. His treatment regimen includes metoprolol, isosorbide dinitrate and aspirin. He takes isosorbide dinitrate early in the morning and again in the afternoon, but he does not take an evening dose. Such a pattern of drug administration is intended to decrease which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Continuous nitrate exposure leads to tachyphylaxis, where the vasculature becomes less responsive to nitric oxide and the antianginal effect wanes over time due to decreased NO bioavailability and compensatory mechanisms.</p>\r\n<p>Incorporating a daily nitrate-free interval, typically overnight when cardiac workload is lowest, restores vascular sensitivity and maintains therapeutic efficacy.</p>\r\n<p>This cyclic dosing prevents sustained enzyme inactivation and receptor desensitisation underlying nitrate tolerance, ensuring predictable hemodynamic and symptomatic relief.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Pharmacokinetic drug interaction (Option A):</strong> Altering the dosing schedule does not affect the absorption, metabolism, or elimination of nitrates.</p>\r\n<p><strong>Pharmacodynamic drug antagonism (Option B):</strong> There is no direct antagonistic interaction between nitrates and his other medications that necessitates intermittent dosing to avoid antagonism.</p>\r\n<p><strong>Withdrawal symptoms (Option D):</strong> Nitrates do not produce rebound phenomena or withdrawal syndromes; the primary issue is loss of efficacy from tolerance.</p>", "options": ["Pharmacokinetic drug interaction", "Pharmacodynamic drug antagonism", "Tolerance development", "Withdrawal symptoms"], "html_options": ["Pharmacokinetic drug interaction", "Pharmacodynamic drug antagonism", "Tolerance development", "Withdrawal symptoms"], "corr_idx": 2}, {"id": "1166453", "html_qtxt": "A 62-year-old man with hypertension has had to discontinue several medications due to side effects such as dizziness, palpitations, and headaches. Currently, he takes ramipril and chlorthalidone and is tolerating them well. ECG shows sinus bradycardia (55/min) with PR interval prolongation (280 msec). Which of the following medications would be most effective for lowering this patient's blood pressure without worsening his ECG abnormalities?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Calcium channel blockers are frequently used in the treatment of several cardiovascular disorders, including hypertension, angina pectoris, and certain cardiac arrhythmias. They inhibit the L-type calcium channel on vascular smooth muscle and cardiac cells and are divided into 2 major categories based on their predominant actions:\r\n<ul>\r\n<li><strong>Dihydropyridines (nifedipine, amlodipine, felodipine)</strong> primarily affect arterial smooth muscle, causing vasodilation with <strong>little or no effect on cardiac conduction or contractility.</strong></li>\r\n<li><strong>Nondihydropyridines (verapamil, diltiazem)</strong> affect the myocardium, slowing heart rate (negative chronotropic effect) and reducing contractility (negative inotropic effect). <strong>(Option A & D)</strong></li>\r\n<li>This patient's ECG shows sinus bradycardia (rate <60/min) with first-degree atrioventricular (AV) block (PR interval >200 msec). Of the choices above, nifedipine is the most appropriate agent to manage hypertension as it has minimal effect on cardiac conduction. Dihydropyridines can cause reflex tachycardia in response to peripheral vasodilation and are therefore useful in hypertensive patients with resting bradycardia.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Metoprolol</strong> is a &beta;<sub>1-</sub>selective blocker that reduces heart rate and AV conduction, contraindicated in symptomatic bradycardia and AV block.<strong> (Option B)</strong></p>", "options": ["Diltiazem", "Metoprolol", "Nifedipine", "Verapamil"], "html_options": ["Diltiazem", "Metoprolol", "Nifedipine", "Verapamil"], "corr_idx": 2}, {"id": "1166455", "html_qtxt": "A 53-year-old obese man with past history of acute myocardial infarction is on metoprolol and low-dose aspirin. His total serum cholesterol level is 155 mg/dL, with an HDL level of 27 mg/dL and a triglyceride level of 92 mg/dL. Which of the following lipid-lowering agents would be most effective for preventing future cardiovascular events in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Patients with low high-density lipoprotein (HDL) levels (men <40 mg/dL, women <50 mg/dL) are at increased risk for cardiovascular disease. HDL is involved in reverse cholesterol transport; it helps to remove cholesterol from peripheral tissues and transports it to the liver for metabolism. This is accomplished through 2 different pathways. In the direct pathway, HDL delivers cholesterol esters directly to the liver via a scavenger receptor (SCARB1) on the hepatocyte cell membrane. In the indirect pathway, the cholesterol in HDL is transferred to low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) by the cholesterol ester transfer protein.</li>\r\n<li>Nonpharmacologic measures such as exercise, weight loss, and smoking cessation help to raise HDL levels and have significant cardiovascular benefits. In contrast, the use of medications to raise HDL levels does not improve cardiovascular outcomes. Pharmacologic treatment of patients with low HDL levels should focus on lowering LDL cholesterol with HMG-CoA reductase inhibitors (statins), as these are the most effective lipid-lowering drugs for preventing cardiovascular events. Statins are indicated for secondary prevention in all patients with known atherosclerotic cardiovascular disease, regardless of baseline lipid levels.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Cationic exchange resin (Option A):</strong> Cholestyramine modestly lowers LDL by binding bile acids but lacks the robust mortality benefit seen with statins.</p>\r\n<p><strong>Essential fatty acids (Option C):</strong> Omega-3 fatty acids reduce triglycerides but have not been shown to decrease major adverse cardiovascular events when added to statins.</p>\r\n<p><strong>Pharmacologic vitamin (Option D):</strong> Niacin raises HDL but outcome trials failed to show improved cardiovascular outcomes, and it carries adverse effects (flushing, hyperglycemia).</p>", "options": ["Cationic exchange resin", "Enzyme inhibitor", "Essential fatty acids", "Pharmacologic vitamin"], "html_options": ["Cationic exchange resin", "Enzyme inhibitor", "Essential fatty acids", "Pharmacologic vitamin"], "corr_idx": 1}, {"id": "1166465", "html_qtxt": "A 36-year-old man comes for a regular check-up. His lab report is shown below.<br>Total cholesterol 290 mg/dL<br>HDL = 45 mg/dL<br>LDL =110 mg/dL<br>Triglycerides = 675 mg/dL<br>He has started on fenofibrate therapy. This medication is most likely to help the patient by which of the following mechanisms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient has a moderately elevated (>500 mg/dL) triglyceride level, which is associated with an increased risk of cardiovascular disease. Lifestyle modifications (increased aerobic exercise, decreased alcohol and total caloric intake) can decrease triglycerides, but moderate (or worse) hypertriglyceridemia usually requires pharmacologic therapy. Lipoprotein lipase (LPL) hydrolyses triglycerides in chylomicrons and VLDL to release free fatty acids, which can be used for energy or converted back to triglycerides for storage in adipose tissue. It also facilitates the transfer of triglycerides from these lipoproteins to HDL.</li>\r\n<li>Fibrates (eg, gemfibrozil, fenofibrate) activate peroxisome proliferator-activated receptor alpha (PPAR-&alpha;), which leads to decreased hepatic VLDL production and increased LPL activity. Fish oil supplements containing high concentrations of omega-3 fatty acids also decrease VLDL production and inhibit the synthesis of apolipoprotein B as well. These supplements lower triglycerides and can be used as an alternate treatment for patients with moderate hypertriglyceridemia.</li>\r\n<li>Triglycerides do not add to cardiovascular morbidity rather, at high levels are a risk factor for Pancreatitis. It is Cholesterol, LDL, involved in CVS morbidity. Therefore, fibrates are not added for CVS benefit</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Blocking intestinal cholesterol absorption (Option A): </strong>The Mechanism of ezetimibe, which lowers LDL but has minimal impact on triglycerides or VLDL.</p>\r\n<p><strong>Decreasing hepatic cholesterol synthesis (Option B): </strong>Mechanism of statins (HMG-CoA reductase inhibitors), which primarily reduce LDL and only modestly lower triglycerides.</p>\r\n<p><strong>Inhibiting LDL receptor degradation (Option C): </strong>Mechanism of PCSK9 inhibitors, which increase LDL receptor recycling to lower LDL cholesterol, not VLDL or triglycerides.</p>", "options": ["Blocking intestinal cholesterol absorption", "Decreasing hepatic cholesterol synthesis", "Inhibiting LDL receptor degradation", "Reducing hepatic VLDL production"], "html_options": ["Blocking intestinal cholesterol absorption", "Decreasing hepatic cholesterol synthesis", "Inhibiting LDL receptor degradation", "Reducing hepatic VLDL production"], "corr_idx": 3}, {"id": "1166467", "html_qtxt": "A 43-year-old woman comes with occasional chest discomfort as a midline pressure or squeezing sensation that lasts 10 minutes and is accompanied by diaphoresis. The patient has no history of hypertension or diabetes mellitus but is an active smoker. Ambulatory ECG monitoring shows transient ST-segment elevations in leads I, aVL, and V1-V4 during an episode of chest pain at night. Which of the following would most likely provoke this patient's chest pain?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This presentation - nocturnal chest pain with transient ST elevations in a smoker, strongly suggests <strong>Prinzmetal (variant) angina</strong> caused by coronary artery vasospasm. Provocative testing is required to confirm the diagnosis.</li>\r\n<li><strong>Dihydroergotamine</strong>, an ergot alkaloid, induces coronary smooth muscle constriction by agonising serotonin and &alpha;-adrenergic receptors, reproducibly triggering the patient's characteristic vasospastic episodes in a controlled setting.</li>\r\n<li>Smoking exacerbates endothelial dysfunction, increasing vasospasm susceptibility; a positive provocation test with dihydroergotamine guides targeted therapy (e.g., nitrates, calcium-channel blockers).</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Amlodipine (Option A):</strong> A dihydropyridine CCB that prevents vasospasm and is used therapeutically in variant angina, not diagnostically.</p>\r\n<p><strong>Morphine (Option C):</strong> An opioid analgesic that relieves ischemic chest pain via venodilation but does not provoke coronary spasm.</p>\r\n<p><strong>Phentolamine (Option D):</strong> A nonselective &alpha;-blocker that causes vasodilation, counterproductive for inducing vasospasm in diagnostic testing.</p>", "options": ["Amlodipine", "Dihydroergotamine", "Morphine", "Phentolamine"], "html_options": ["Amlodipine", "Dihydroergotamine", "Morphine", "Phentolamine"], "corr_idx": 1}, {"id": "1166470", "html_qtxt": "A 65-year-old man with known CAD comes with exertional chest tightness. The patient underwent coronary artery bypass graft surgery 3 years ago for progressive angina. You discuss about adding isosorbide dinitrate to his current therapy, but the patient is concerned about adverse effects. Which of the following is most likely to occur in this patient with the add-on therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li><strong>Nitrates are frequently used for symptomatic relief in patients with chronic stable angina. </strong>The anti-ischemic effect of nitrates is mediated by systemic vasodilation (predominantly venodilation) with a decrease in left ventricular end-diastolic volume and wall stress, resulting in decreased myocardial oxygen demand and relief of angina symptoms.</li>\r\n<li>The main adverse effects seen with nitrate therapy include <strong>headaches, cutaneous flushing, lightheadedness, hypotension, and reflex tachycardia.</strong></li>\r\n<li><strong>Nitrates must be avoided in patients with hypertrophic cardiomyopathy</strong> (due to increased outflow tract obstruction), right ventricular infarction (due to reduction in preload, impairing cardiac output), and those on phosphodiesterase inhibitors (synergism increases the risk of severe hypotension).</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Cold extremities (Option A):</strong> Seen with &beta;-blockers (peripheral vasoconstriction), not with vasodilatory nitrates.</p>\r\n<p><strong>Constipation (Option B):</strong> Associated with nondihydropyridine CCBs (e.g., verapamil), not nitrates.</p>\r\n<p><strong>Nocturnal wheezing (Option C):</strong> Reflects bronchospasm, unrelated to nitrate therapy.</p>", "options": ["Cold extremities", "Constipation", "Nocturnal wheezing", "Throbbing headaches"], "html_options": ["Cold extremities", "Constipation", "Nocturnal wheezing", "Throbbing headaches"], "corr_idx": 3}, {"id": "1166472", "html_qtxt": "A 45-year-old man has also been started on high-intensity atorvastatin therapy, along with antiplatelet therapy and appropriate medications to control blood pressure. Four weeks later, the patient's total cholesterol level is 140 mg/dL, down from 200 mg/dL before discharge. Which of the following has most likely increased as a result of the therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>HMG-CoA reductase inhibitors block the rate-limiting step in hepatic cholesterol synthesis, lowering intracellular cholesterol stores and prompting a compensatory upregulation of LDL receptors on hepatocyte surfaces.</li>\r\n<li>Increased LDL receptor density enhances the clearance of circulating LDL particles, accounting for the 20-50% reduction in serum cholesterol seen with high-intensity statin therapy.</li>\r\n<li>Beyond lipid lowering, statins exert anti-inflammatory effects, improve endothelial function, and stabilise atherosclerotic plaques, contributing to their superior efficacy in reducing acute coronary events.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>ApoB-100 concentration (Option A): </strong>ApoB-100 levels fall as LDL clearance increases; statins do not raise ApoB-100.</p>\r\n<p><strong>Biliary excretion of cholesterol (Option B): </strong>While statins may modestly affect cholesterol excretion, their primary action is receptor-mediated LDL uptake.</p>\r\n<p><strong>Plasma free fatty acids (Option D): </strong>Statins have minimal direct effects on free fatty acid levels.</p>", "options": ["ApoB-100 concentration", "Biliary excretion of cholesterol", "LDL receptor density", "Plasma free fatty acids"], "html_options": ["ApoB-100 concentration", "Biliary excretion of cholesterol", "LDL receptor density", "Plasma free fatty acids"], "corr_idx": 2}, {"id": "1166474", "html_qtxt": "A 75-year-old woman comes with sudden-onset right arm weakness and difficulty speaking, which completely resolved within 20 minutes. She takes amlodipine and rosuvastatin. Carotid Doppler reveals mild left common carotid artery stenosis. If the patient is started on an additional medication that is indicated for her condition, which of the following adverse effects is most likely to occur?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient, with hypertension, hypercholesterolemia, and sudden-onset neurologic deficits (eg, right arm weakness, difficulty speaking) that fully resolved within minutes, most likely had a transient ischemic attack (TIA). In addition to optimal blood pressure control and statin therapy, low-dose aspirin is commonly used to prevent ischemic stroke in patients with TIA.</li>\r\n<li>It works by irreversibly acetylating/inhibiting the cyclooxygenase (COX) enzymes. At low doses, aspirin predominantly inhibits COX-1, preventing platelet synthesis of thromboxane A2, which impairs platelet aggregation and reduces vasoconstriction. At least 2 distinct COX-1-dependent mechanisms contribute to the increased risk of upper gastrointestinal bleeding associated with aspirin therapy: Inhibition of platelet aggregation and impairment of prostaglandin-dependent Gl mucosal protection. The risk of upper Gl bleeding increases with higher doses but is increased 2- to 3-fold even with low-dose aspirin. Proton pump inhibitors can help reduce the risk of upper GI bleeding in patients taking aspirin.</li>\r\n</ul>", "options": ["Gastrointestinal bleeding", "Hyperpnea and vertigo", "Orthostatic hypotension", "Urinary bladder cancer"], "html_options": ["Gastrointestinal bleeding", "Hyperpnea and vertigo", "Orthostatic hypotension", "Urinary bladder cancer"], "corr_idx": 0}, {"id": "1166476", "html_qtxt": "A 75-year-old man with chronic stable angina is on sublingual nitroglycerin on an as-needed basis. While discussing a plan to start isosorbide dinitrate therapy, the patient becomes concerned about the high dose of oral isosorbide dinitrate compared to sublingual nitroglycerin. Which of the following is the most likely reason for using a high dose of oral nitrate?", "html_expl": "<p><strong>Explanation: </strong></p>\r\n<ul>\r\n<li>This patient's presentation - <strong>hypertension, hypercholesterolemia, and a transient neurologic deficit</strong> resolving within minutes is diagnostic of a<strong> transient ischemic attack</strong> <strong>(TIA).</strong> In addition to optimal blood pressure control and statin therapy, <strong>low-dose aspirin is indicated for the secondary prevention of ischemic stroke.</strong></li>\r\n<li>Aspirin works by irreversibly acetylating cyclooxygenase (COX) enzymes. At low doses, it predominantly inhibits COX-1 in platelets, preventing thromboxane A<sub>2</sub> synthesis, which impairs platelet aggregation and reduces vasoconstriction.</li>\r\n<li>Two COX-1-dependent mechanisms underlie aspirin-associated upper gastrointestinal bleeding: inhibition of platelet plug formation and reduction of protective prostaglandins in the gastric mucosa. <strong>Even low-dose aspirin increases GI bleeding risk two- to threefold, and this risk escalates with higher doses. Proton-pump inhibitors can be co-prescribed to mitigate this risk.</strong></li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Hyperpnea and vertigo (Option B):</strong> Features of salicylate overdose at toxic levels, not seen with low-dose aspirin.</p>\r\n<p><strong>Orthostatic hypotension (Option C): </strong>Related to antihypertensives (e.g., amlodipine, diuretics), not aspirin.</p>\r\n<p><strong>Urinary bladder cancer (Option D): </strong>Associated with cyclophosphamide or specific aromatic amines; not a recognised risk of aspirin.</p>", "options": ["Drug tolerance prevention", "High first-pass metabolism", "High serum protein binding", "High volume of distribution"], "html_options": ["Drug tolerance prevention", "High first-pass metabolism", "High serum protein binding", "High volume of distribution"], "corr_idx": 0}, {"id": "1166477", "html_qtxt": "A 60-year-old man with diabetic kidney disease and hypertension is treated with lisinopril but stopped a week ago due to a dry, nagging cough. Which of the following is the best treatment for this patient's hypertension?", "html_expl": "<p><strong>Explanation: </strong></p>\r\n<ul>\r\n<li>Diabetes impairs autoregulation of glomerular blood flow, raising intraglomerular pressure and risking progressive injury; ACE inhibitors (e.g., lisinopril) protect by dilating the efferent arteriole, lowering glomerular pressure.</li>\r\n<li>ACE normally degrades bradykinin and substance P; ACE inhibition raises their levels and causes a nonproductive cough-an adverse effect not shared by ARBs.</li>\r\n<li>Angiotensin II receptor blockers (e.g., valsartan) replicate the hemodynamic and renoprotective benefits of ACE inhibitors without increasing bradykinin, making them ideal for patients intolerant of ACE-inhibitor cough.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Diltiazem (Option A):</strong> A nondihydropyridine CCB that lowers systemic BP but does not preferentially reduce efferent arteriolar tone or confer specific renoprotection in diabetic nephropathy.</p>\r\n<p><strong>Hydralazine (Option B):</strong> A direct arteriolar vasodilator that can trigger reflex tachycardia and fluid retention, lacking the RAAS-mediated renoprotective effect.</p>\r\n<p><strong>Ramipril (Option C): </strong>Another ACE inhibitor that would continue to provoke cough via bradykinin accumulation.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<p>In diabetic kidney disease, RAAS blockade that spares bradykinin (ARBs) maintains efferent arteriolar dilation and renoprotection without causing cough.</p>\r\n<p>Valsartan is the ARB of choice for hypertension in patients intolerant to ACE inhibitors due to cough.</p>", "options": ["Diltiazem", "Hydralazine", "Ramipril", "Valsartan"], "html_options": ["Diltiazem", "Hydralazine", "Ramipril", "Valsartan"], "corr_idx": 3}]}, {"moduleId": 1008536, "name": "Heart Failure Management   & Anti-Arrhythmic Drugs", "questions": [{"id": "1179695", "html_qtxt": "Which of the following drugs is correctly paired with its ECG effects?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Antiarrhythmics are classified based on their electrophysiological effect on the myocardium. </p>\r\n<p>GROUP 1 ANTIARRHYTHMICS (SODIUM CHANNEL BLOCKERS)</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403084c9ec994-8253-43f3-973e-505eb6001030.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403081e21009a-d6a9-4a54-a0ed-ae757444bca2.jpg\">\r\n<p><strong>GROUP 2 ANTIARRHYTHMICS (BETA BLOCKERS)</strong></p>\r\n<p><strong>Propranolol</strong> and <strong>esmolol</strong> are prototypic anti-arrhythmic &beta;-blockers. Their mechanism in arrhythmias is primarily <em>cardiac &beta;-adrenoceptor blockade and reduction in cAMP</em>, which results in a modest reduction of both sodium and calcium currents and the suppression of abnormal pacemakers. The AV node is particularly sensitive to &beta;-blockers, and the PR interval is usually prolonged.</p>\r\n<p>Esmolol, a very short-acting &beta; blocker for intravenous administration, is used exclusively in acute arrhythmias. Propranolol and metoprolol are commonly used chronically to prevent arrhythmias in patients who have had a myocardial infarction.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308b68ee4a2-ed1c-4c5d-8073-5e3ba4d5dec5.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403083dad37b2-d8ed-4235-bca4-fe49470c1398.jpg\">\r\n<p><strong>GROUP 3 ANTIARRHYTHMICS (POTASSIUM IK CHANNEL BLOCKERS)</strong></p>\r\n<ul>\r\n<li>Dofetilide and ibutilide are typical group 3 drugs.</li>\r\n<li>Sotalol is a group 3 antiarrhythmic (not group 2, even if it's a beta blocker)</li>\r\n<li>Amiodarone is useful in most types of arrhythmias and is considered the most efficacious of all anti-arrhythmic drugs. This may be because it has a broad spectrum of action: It blocks sodium, calcium, and potassium channels and &beta;-adrenoceptors.</li>\r\n<li>Dronedarone, an amiodarone analogue, is also approved. Dronedarone does not appear to be as efficacious as amiodarone but may be less toxic.</li>\r\n</ul>\r\n<p><strong>GROUP 4 ANTIARRHYTHMICS (CALCIUM L-TYPE CHANNEL BLOCKERS)</strong></p>\r\n<p>Verapamil is the prototype. Diltiazem is also an effective anti-arrhythmic drug.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308a4bce076-238f-4bce-a27f-ea50a36f34fd.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403081b3d9ff5-b245-48e1-9165-bb728fb27052.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308a3d0dcc1-de11-450a-81f8-642bf49eba2b.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Quinidine (Option A): </strong>As a Class 1A agent, quinidine blocks Na+ and K+channels to slow conduction (&uarr;QRS) and prolong repolarisation (&uarr;QT); it does not decrease the QT interval, and its antimuscarinic action tends to lengthen PR.</p>\r\n<p><strong>Verapamil (Option C): </strong>A Class 4 nondihydropyridine CCB that reduces AV nodal conduction and prolongs the PR interval; it does not decrease PR.</p>\r\n<p><strong>Lidocaine (Option D): </strong>A Class 1B agent with minimal effect on normal ventricular conduction, so it does not significantly change QRS or PR intervals on the ECG.</p>", "options": ["Quinidine: Increased PR and decreased QT interval", "Flecainide: Increased QRS interval", "Verapamil: Decreased PR interval", "Lidocaine: Decreased QRS and PR interval"], "html_options": ["Quinidine: Increased PR and decreased QT interval", "Flecainide: Increased QRS interval", "Verapamil: Decreased PR interval", "Lidocaine: Decreased QRS and PR interval"], "corr_idx": 1}, {"id": "1179697", "html_qtxt": "The dotted line represents an action potential following the infusion of the pharmacological agent into cardiomyocytes. The results shown in the graph are most likely caused by which of the following agents?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905fbed1b51-8fd1-460a-a3c9-a53294e5d79b.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The graph shows a ventricular action potential<strong>. The drug changes the duration of the rapid upstroke of the action potential (phase O) without significantly changing the overall duration of the action potential. It shows the effect of class IC antiarrhythmics. It acts by slowly opening voltage-gated sodium channels and decreases the slope of</strong> <strong>phase 0 while still</strong><strong>maintaining the AP duration.</strong> Class IC antiarrhythmics also exhibit use dependence, further decreasing the slope as heart rate increases.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308000dfcdd-4407-4bda-b87f-99cca430bc63.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Verapamil (Option A): </strong>A Class 4 L-type Ca<sup>2+</sup> channel blocker that reduces AV nodal conduction and affects the plateau phase in pacemaker cells, not the fast Na<sup>+</sup>- dependent phase 0 in ventricular myocytes.</p>\n<p><strong>Lidocaine (Option B): </strong>A Class 1B agent that slightly reduces phase 0 slope and shortens action-potential duration, which would produce a briefer AP, unlike the unchanged duration observed.</p>\n<p><strong>Quinidine (Option D): </strong>A Class 1A drug that decreases phase 0 slope but prolongs action-potential duration and the QT interval, so it would lengthen rather than maintain the AP duration.</p>", "options": ["Verapamil", "Lidocaine", "Flecainide", "Quinidine"], "html_options": ["Verapamil", "Lidocaine", "Flecainide", "Quinidine"], "corr_idx": 2}, {"id": "1179726", "html_qtxt": "A 60-year-old man with COPD comes to you with palpitations and dizziness for 1 week. Her pulse is 75/min and regular, BP is 3.110/80 mm-Hg. An ECG is shown. What is the first line of therapy for her?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403088f6f6bd2-ace4-45eb-b749-2cdff2b02d0a.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient's symptoms and ECG findings <strong>(narrow QRS complexes</strong> with an atrial rate of 240/min in a sawtooth pattern) are most consistent with <strong>atrial flutter</strong>.</p>\r\n<p>A mainstay of the treatment of<strong> stable atrial flutter is to normalise the ventricular heart rate (rate control). </strong></p>\r\n<p>However, consider rhythm control in the following patient groups:</p>\r\n<ul>\r\n<li>Failure of rate control strategy to control symptoms or achieve target heart rate (80bpm)</li>\r\n<li>New-onset Atrial Flutter</li>\r\n<li>Acute illness that precipitated Atrial flutter</li>\r\n<li>Other: tachycardia-induced cardiomyopathy, pregnancy, patient preference, younger patients</li>\r\n</ul>\r\n<p>Drugs used for <strong>rate control include beta-blockers</strong> (e.g., esmolol, propranolol, metoprolol) and non-DHP CCBs (e.g., diltiazem, verapamil). <strong>Verapamil is commonly used as first-line therapy for rate control for atrial flutter, particularly in patients with COPD, as beta blockers are to be avoided in them. (Option B)</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308a3bb0360-5eb1-4ef9-8d38-b1d8b8fa2d92.jpg\">\r\n<p>Flecainide (Option C) is a Class 1C antiarrhythmic with selective, state-dependent Na<sup>+</sup> channel block that markedly slows conduction velocity in atrial and ventricular tissue. Primarily used for refractory supraventricular and ventricular arrhythmias due to its proarrhythmic potential and CNS toxicity.</p>\r\n<p><strong>Amiodarone (Option D)</strong> is a broad-spectrum agent (Class III with additional Class I, II, and IV effects) that prolongs action potentials and refractory periods. Reserved for refractory arrhythmias due to toxicities including thyroid dysfunction, pulmonary fibrosis, corneal deposits, optic neuropathy, and rare torsades de pointes.</p>\r\n", "options": ["Verapamil", "Propranolol", "Flecainide", "Amiodarone"], "html_options": ["Verapamil", "Propranolol", "Flecainide", "Amiodarone"], "corr_idx": 0}, {"id": "1179727", "html_qtxt": "A 68-year-old woman comes to the ED with chest pain radiating to the left shoulder. Her ECG reveals ventricular tachycardia with ST-segment elevation. Trop C levels are markedly increased. A diagnosis of myocardial infarction is made. Her arrhythmia will probably be treated initially with", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Given the clinical scenario of chest pain with <strong>ST-segment elevation and Trop C elevation</strong> suggests myocardial damage, complicated by ventricular tachycardia, a common cause of death in MI patients in the first 24 hours.</p>\n<p>Lidocaine is a Class IB antiarrhythmic of choice for acute ventricular arrhythmias, especially VT, in the setting of myocardial infarction, because it preferentially targets ischemic myocardial cells and has a rapid onset when given intravenously.</p>\n<p><strong>Lidocaine is also useful in digoxin-induced arrhythmias</strong>. After recovery from the acute phase of a myocardial infarction, &beta; blockers are used for 2 years or more to prevent sudden death arrhythmia. Procainamide or amiodarone are used as alternative drugs in this situation.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Adenosine (Option A):</strong> Markedly slows or blocks AV nodal conduction by increasing IK and reducing Ca<sup>2+</sup> current; the drug of choice for AV-nodal reentrant tachycardias due to its low toxicity profile, but <strong>ineffective in ventricular arrhythmias</strong>.</p>\n<p><strong>Digoxin (Option B):</strong> Reduces AV nodal conduction velocity and increases its refractory period to control ventricular rate in atrial flutter/fibrillation; <strong>not indicated for ventricular tachycardia</strong>.</p>\n<p><strong>Quinidine (Option D):</strong> A Class IA agent used for PSVT (AVNRT/AVRT) and ectopic SVTs; side effects include cinchonism (headache, vertigo, tinnitus), cardiac depression, gastrointestinal upset, and immune-mediated thrombocytopenia. It is <strong>less preferred for acute VT</strong> post-MI.</p>", "options": ["Adenosine", "Digoxin", "Lidocaine", "Quinidine"], "html_options": ["Adenosine", "Digoxin", "Lidocaine", "Quinidine"], "corr_idx": 2}, {"id": "1179728", "html_qtxt": "A 32-year-old man comes to the ED, says it feels like \"my heart is racing\", along with palpitations. Blood pressure is 120/80 mm Hg, and pulse is 164/min. ECG is shown below. Treatment is initiated with a medication, which leads to the resolution of the symptom but is accompanied by short-lived flushing, burning in the chest, and shortness of breath. Which of the following medications was used to treat this patient's condition?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308a36404e4-7638-45a5-8d5f-fa570989bf5b.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Given a clinical scenario of palpitation and given ECG (Typically narrow QRS complexes, Regular rhythm and P wave is typically not visible), consistent with <strong>paroxysmal supraventricular tachycardia (PSVT</strong>).</p>\n<ul>\n<li><strong>Adenosine is the first-line agent for acute termination of AV nodal-dependent PSVT. </strong>It hyperpolarises AV nodal cells by increasing IK and reducing Ca<sup>2+</sup> current, abruptly blocking conduction and interrupting the reentrant circuit.</li>\n<li>Its extremely rapid onset and very short half-life (<10 seconds) allow for quick restoration of sinus rhythm with minimal prolonged effects.</li>\n<li>Transient adverse effects like flushing, chest burning (bronchospasm), hypotension, and brief high-grade AV block occur due to adenosine's vasodilatory and bronchoconstrictive actions but resolve quickly.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308e57cbcf5-7448-4df8-8888-f2d362e7664a.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Amiodarone (Option B):</strong> A broad-spectrum Class III agent reserved for refractory or life-threatening ventricular and atrial arrhythmias; slow onset and significant long-term toxicities (thyroid, pulmonary, hepatic).</p>\n<p><strong>Digoxin (Option C): </strong>Slows AV nodal conduction by enhancing vagal tone, used for rate control in atrial fibrillation/flutter; onset is too slow for acute PSVT termination and carries the risk of toxicity.</p>\n<p><strong>Ibutilide (Option D):</strong> A Class III drug used for pharmacologic cardioversion of atrial fibrillation/flutter; can induce torsades de pointes and is not indicated for PSVT.</p>", "options": ["Adenosine", "Amiodarone", "Digoxin", "Ibutilide"], "html_options": ["Adenosine", "Amiodarone", "Digoxin", "Ibutilide"], "corr_idx": 0}, {"id": "1179729", "html_qtxt": "A 70-year-old female presents to the ED with a racing heartbeat. She is subsequently placed on a continuous ECG monitor, and an irregular rhythm is seen. The diagnosis of atrial fibrillation is made. She has started on an amiodarone drip. What side effects should you be aware of when starting amiodarone?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Amiodarone has several well-known side effects, including pulmonary fibrosis, hepatotoxicity, and thyroid imbalances.</strong> For this reason, <strong>pulmonary function tests, liver function tests, and thyroid function tests</strong> should be monitored while taking amiodarone.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403089e518b2f-93b9-42b5-8203-c90f88938b01.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308eaa19aaf-b854-4b64-ac14-e8729fdaa6b5.jpg\">\r\n<p><strong>Blurry yellow vision (Option A):</strong> A hallmark of digoxin toxicity due to xanthopsia. Amiodarone may cause corneal micro-deposits leading to visual halos, but it does not produce true yellow vision.</p>\r\n<p><strong>Impotence (Option B):</strong> Erectile dysfunction is not associated with amiodarone; drugs more commonly linked to impotence include certain &beta;-blockers and thiazide diuretics. Lupus-like syndromes characterised by malar rash and anti-histone antibodies are seen with hydralazine, procainamide, and isoniazid (SHIP), not with amiodarone.</p>\r\n<p><strong>Prolongation of AV refractory period (Option C):</strong> Characteristic of Class IC agents (e.g., flecainide, propafenone), which potently block Na<sup>+</sup>channels; amiodarone's AV effects stem from its broad, multichannel actions but do not manifest primarily as AV refractory prolongation.</p>", "options": ["Blurry yellow vision", "Impotence", "Prolongation of the AV refractory period", "Pulmonary fibrosis"], "html_options": ["Blurry yellow vision", "Impotence", "Prolongation of the AV refractory period", "Pulmonary fibrosis"], "corr_idx": 3}, {"id": "1179730", "html_qtxt": "A 48-year-old male took an overdose and manifested severe acute procainamide toxicity with markedly long QT, which of the following should be given immediately?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Concentrated sodium lactate alkalinises the serum</strong>, increasing the <strong>extracellular sodium gradient</strong> and <strong>enhancing sodium current to overcome procainamide's Na<sup>+</sup> channel blockade, thereby shortening the QT interval.</strong></p>\n<p>Alkalinization also reduces procainamide-receptor binding affinity in cardiac tissue, displacing the drug from Na<sup>+</sup> channels and restoring normal conduction.</p>\n<p>This targeted therapy is preferred in acute Class IA antiarrhythmic overdose; pressor sympathomimetics (e.g., norepinephrine) may be added if hypotension persists after lactate infusion.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>EDTA (Option A):</strong> A chelating agent for heavy-metal poisoning; has no effect on procainamide toxicity or QT prolongation.</p>\n<p><strong>Nitroprusside (Option B):</strong> A powerful arteriolar and venous vasodilator used in hypertensive emergencies; would exacerbate hypotension in this overdose scenario.</p>\n<p><strong>Potassium chloride (Option C):</strong> Raising serum K<sup>+</sup> worsens repolarisation abnormalities and further prolongs the QT interval, increasing the risk of torsades de pointes.</p>", "options": ["EDTA", "Nitroprusside", "Potassium chloride", "Sodium lactate"], "html_options": ["EDTA", "Nitroprusside", "Potassium chloride", "Sodium lactate"], "corr_idx": 3}, {"id": "1179731", "html_qtxt": "A 75-year-old man with COPD and chronic heart failure presents to you for follow-up. The patient takes multiple medications for these problems. Which of the following strategies may prove to have additional benefit in the treatment of this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>NSAIDs exacerbate heart failure</strong> by <strong>promoting sodium and water retention</strong>, blunting diuretic efficacy, and <strong>reducing renal perfusion via prostaglandin inhibition</strong>. Discontinuation improves volume status and renal function.</p>\r\n<p>Chronic HF is typically managed by</p>\r\n<ul>\r\n<li>A reduction in physical activity</li>\r\n<li>Low dietary intake of sodium (<1500 mg/d)</li>\r\n<li>Treatment of comorbid conditions</li>\r\n<li>Judicious use of diuretics, inhibitors of the renin-angiotensin system, and inotropic agents.</li>\r\n</ul>\r\n<p><strong>Drugs that may precipitate or exacerbate HF, such as NSAIDs, alcohol, calcium channel blockers, high-dose beta-blockers, and some antiarrhythmic drugs, should be avoided if possible.</strong></p>\r\n<p>Patients with HF complain of dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, fatigue, and dependent oedema.</p>\r\n<ol>\r\n<li>Vigorous exercise in this deconditioned patient may worsen heart function. <strong>(Option A)</strong></li>\r\n<li>Use of calcium channel blockers at high doses can worsen heart failure. <strong>(Option B)</strong></li>\r\n<li>Use of beta-blockers at high doses can worsen heart failure. <strong>(Option D)</strong></li>\r\n</ol>", "options": ["Exercise program involving running", "Use of calcium channel blockers at high doses", "Stopping the use of NSAIDs", "Use of beta-blockers at high doses"], "html_options": ["Exercise program involving running", "Use of calcium channel blockers at high doses", "Stopping the use of NSAIDs", "Use of beta-blockers at high doses"], "corr_idx": 2}, {"id": "1179732", "html_qtxt": "A 62-year-old man who is a chronic smoker with chronic congestive heart failure presents for follow-up. He is currently taking captopril and hydrochlorothiazide. Which of the following changes would be increased as a result of this therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Captopril (an ACE inhibitor) and hydrochlorothiazide reduce afterload </strong>(via decreased vascular resistance) <strong>and preload</strong> (via venodilation and diuresis), <strong>which together increase cardiac output and alleviate congestive symptoms.</strong></p>\r\n<p>ACE inhibitors and thiazides may improve the clinical signs of heart failure. As such, patients may have some improvement in how they feel and may be able to ambulate without as much exertion.</p>\r\n<p><strong>ACE inhibitors decrease vascular resistance, venous tone, and blood pressure</strong>. These drugs reduce preload and afterload, resulting in an increased cardiac output. ACE inhibitors also blunt the usual angiotensin II-mediated increase in epinephrine and aldosterone seen in HF.</p>\r\n<p>ACE inhibitors improve clinical signs and symptoms in patients also receiving thiazide or loop diuretics and/or digoxin.</p>\r\n<ul>\r\n<li>Vascular resistance will decrease in patients taking an ACE inhibitor. <strong>(Option A)</strong></li>\r\n<li>Venous tone will decrease in patients taking an ACE inhibitor. <strong>(Option B)</strong></li>\r\n<li>Jugular venous distension is a clinical sign that may improve with an ACE inhibitor. <strong>(Option C)</strong></li>\r\n</ul>", "options": ["Vascular resistance", "Venous tone", "Venous distension of the jugular vein", "Exercise tolerance"], "html_options": ["Vascular resistance", "Venous tone", "Venous distension of the jugular vein", "Exercise tolerance"], "corr_idx": 3}, {"id": "1179735", "html_qtxt": "A 51-year-old man with congestive heart failure and hypertension comes for follow-up. His current medications include digoxin and a calcium channel blocker. Serum electrolytes and a complete blood count are drawn. Which of the following blood indicators is most important to follow in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Digoxin toxicity is one of the most commonly encountered adverse drug reactions.</strong> Side effects often can be managed by discontinuing cardiac glycoside therapy, determining serum <strong>potassium levels </strong>(decreased K+ increases the potential for cardiotoxicity), and, if indicated, giving potassium supplements.</p>\n<p><strong>Treatment of digitalis toxicity includes several steps, as follows.</strong></p>\n<ul>\n<li><strong>Correction of potassium or magnesium deficiency </strong>- Correction of potassium deficiency (caused, eg, by diuretic use) is useful in chronic digitalis intoxication. Mild toxicity may often be managed by omitting 1 or 2 doses of digitalis and giving oral or parenteral K+ supplements. Severe acute intoxication (as in suicidal overdoses) usually causes marked hyperkalemia and should not be treated with supplemental potassium.</li>\n<li><strong>Anti-arrhythmic drugs</strong> - Anti-arrhythmic drugs may be useful if increased automaticity is prominent and does not respond to normalisation of serum potassium. Agents that do not severely impair cardiac contractility (eg, lidocaine or phenytoin) are in favour, but drugs such as propranolol have also been used successfully. Severe acute digitalis overdose usually causes marked inhibition of all cardiac pacemakers, and an electronic pacemaker may be required. Anti-arrhythmic drugs are dangerous in such patients.</li>\n<li><strong>Digoxin antibodies</strong> - Digoxin antibodies (Fab fragments; Digibind ) are extremely effective and should always be used if other therapies appear to be failing. They are effective for poisoning with several cardiac glycosides in addition to digoxin and may save patients who would otherwise die.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Bicarbonate (Option A):</strong> Acid-base status can influence electrolyte shifts, but is not directly implicated in digoxin toxicity management.</p>\n<p><strong>Chloride (Option B):</strong> Serum Cl<sup>-</sup> rarely affects digoxin pharmacodynamics or toxicity risk.</p>\n<p><strong>Sodium (Option C):</strong> While Na<sup>+</sup> gradients drive digoxin's mechanism, daily serum sodium fluctuations are less predictive of toxicity than K<sup>+</sup> levels.</p>", "options": ["Bicarbonate ", "Chloride ", "Sodium", "Potassium "], "html_options": ["Bicarbonate ", "Chloride ", "Sodium", "Potassium "], "corr_idx": 3}, {"id": "1179738", "html_qtxt": "A 48-year-old man presents to the emergency department with an arrhythmia. He has been receiving digoxin for 4 weeks. Which one of the following is most likely to contribute to the arrhythmogenic effect of digoxin?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Chronic digoxin intoxication leads to Na<sup>+</sup>/K<sup>+</sup>-ATPase inhibition</strong>, causing a modest rise in intracellular Na<sup>+</sup> that impairs the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (NCX), resulting in Ca<sup>2+</sup> overload within cardiomyocytes.</p>\n<p>This elevated intracellular Ca<sup>2+</sup> is sequestered in the sarcoplasmic reticulum and can precipitate delayed afterdepolarizations and abnormal automaticity, directly triggering arrhythmias.</p>\n<p>Calcium overload underlies the extension of digoxin's therapeutic inotropy into toxic arrhythmogenesis, particularly in settings of hypokalemia or renal impairment.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403081cab8640-e314-414e-a309-fc7e79e3613b.jpg\">\n<p>Various types of arrhythmias can manifest depending on the site of predominance.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Increased parasympathetic discharge (Option A):</strong> Digoxin does enhance vagal tone, slowing AV nodal conduction, but this effect is not proarrhythmic; it actually can help control ventricular rate in atrial arrhythmias.</p>\n<p><strong>Decreased intracellular ATP (Option C):</strong> Inhibition of Na<sup>+</sup>/K<sup>+</sup>- ATPase by digoxin does not reduce ATP levels; rather, increased Ca<span style=\"font-size: xx-small;\"><sup>2+</sup> </span> cycling can actually elevate energy demand and ATP turnover.</p>\n<p><strong>Increased extracellular potassium (Option D):</strong> Hyperkalemia antagonises digoxin binding to its receptor, reducing toxicity; thus, higher extracellular K<sup>+</sup> is protective against arrhythmias.</p>", "options": ["Increased parasympathetic discharge", "Increased intracellular calcium", "Decreased intracellular ATP", "Increased extracellular potassium"], "html_options": ["Increased parasympathetic discharge", "Increased intracellular calcium", "Decreased intracellular ATP", "Increased extracellular potassium"], "corr_idx": 1}, {"id": "1179741", "html_qtxt": "A 62-year-old woman develops acute severe heart failure with marked pulmonary oedema, but no evidence of peripheral oedema. She has been admitted to the ICU for LVMI. Which one of the following drugs would be most useful?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Acute severe congestive failure with pulmonary oedema often requires a vasodilator</strong> that reduces intravascular pressures in the lungs.<strong> Furosemide has such vasodilating actions in the context of acute failure in addition to its diuretic effect.</strong> Pulmonary oedema also involves a shift of fluid from the intravascular compartment to the lungs.</p>\r\n<p>Current clinical evidence suggests that acute heart failure should be treated with a loop diuretic; if severe, a prompt-acting positive inotropic agent such as a &beta; agonist or phosphodiesterase inhibitor, and vasodilators should be used as required to optimise filling pressures and blood pressure.</p>\r\n<p><strong>Chronic failure is best treated with diuretics </strong>(often a loop agent plus spironolactone) plus an <strong>ACE inhibitor and, if tolerated, a &beta; blocker.</strong> <strong>Digitalis may be helpful if systolic dysfunction is prominent</strong>. <strong>Nesiritide,</strong> a recombinant form of <strong>brain natriuretic peptide (BNP)</strong>, has <strong>vasodilating and diuretic properties</strong> and has been heavily promoted for <strong>use in acute failure. </strong></p>\r\n<p>A newer combination drug, <strong>sacubitril/valsartan</strong>, combines the actions of increased endogenous BNP with those of the angiotensin receptor blocker valsartan.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Digoxin (Option A):</strong> Provides symptomatic relief and modest hospitalisation reduction but does not improve survival in chronic heart failure.</p>\r\n<p><strong>Furosemide (Option B):</strong> A loop diuretic that relieves congestion but has no demonstrated mortality benefit.</p>\r\n<p><strong>Nitroprusside (Option C): </strong>An acute vasodilator used in hypertensive emergencies and acute decompensation; it does not alter long-term survival.</p>", "options": ["Digoxin", "Furosemide ", "Propranolol ", "Spironolactone"], "html_options": ["Digoxin", "Furosemide ", "Propranolol ", "Spironolactone"], "corr_idx": 1}, {"id": "1179749", "html_qtxt": "A 77-year-old man has chronic heart failure. Which one of the following drugs has been shown to reduce mortality?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Clinical trials (e.g., RALES) have demonstrated that adding the aldosterone antagonist spironolactone to standard therapy significantly reduces mortality and hospitalisations in patients with severe chronic heart failure.</p>\r\n<p>Spironolactone blocks detrimental aldosterone effects (myocardial fibrosis, vascular remodelling, and sodium retention), providing long-term survival benefits beyond symptomatic relief.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308964a4d34-2617-4078-98af-2b6661540a22.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Digoxin (Option A):</strong> Improves symptoms and reduces hospitalisations but <strong>does not</strong> confer a mortality benefit in chronic heart failure.</p>\r\n<p><strong>Furosemide (Option B):</strong> A loop diuretic that alleviates volume overload and improves symptoms, yet has <strong>no demonstrated</strong> impact on long-term survival.</p>\r\n<p><strong>Nitroprusside (Option C):</strong> An acute vasodilator used for decompensated heart failure and hypertensive emergencies; it provides symptomatic relief but <strong>does not</strong> improve chronic survival.</p>", "options": ["Digoxin", "Furosemide ", "Nitroprusside ", "Spironolactone"], "html_options": ["Digoxin", "Furosemide ", "Nitroprusside ", "Spironolactone"], "corr_idx": 3}, {"id": "1179752", "html_qtxt": "A 6-year-old child collapses while playing. He has sinus arrest and a ventricular rate of 35 bpm. An empty bottle of his uncle's digoxin was found where he was playing. Which of the following is the drug of choice in treating a severe overdose of digoxin?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>The drug of choice in severe, massive overdose with any cardiac glycoside is digoxin antibody</strong>,<strong> DigiBind</strong>. The other drugs listed are used in moderate overdosage associated with increased automaticity.</p>\r\n<p>Treatment of digitalis toxicity includes several steps, as follows.</p>\r\n<ul>\r\n<li><strong>Correction of potassium or magnesium deficiency</strong>- Correction of potassium deficiency (caused, eg, by diuretic use) is useful in chronic digitalis intoxication. Mild toxicity may often be managed by omitting 1 or 2 doses of digitalis and giving oral or parenteral K+ supplements. Severe acute intoxication (as in suicidal overdoses) usually causes marked hyperkalemia and should not be treated with supplemental potassium.</li>\r\n<li><strong>Anti-arrhythmic drugs</strong>-Anti-arrhythmic drugs may be useful if increased automaticity is prominent and does not respond to normalisation of serum potassium. Agents that do not severely impair cardiac contractility (eg, lidocaine or phenytoin) are favoured, but drugs such as propranolol have also been used successfully. Severe acute digitalis overdose usually causes marked inhibition of all cardiac pacemakers, and an electronic pacemaker may be required. Anti-arrhythmic drugs are dangerous in such patients.</li>\r\n<li><strong>Digoxin antibodies</strong>-Digoxin antibodies (Fab fragments; Digi bind) are extremely effective and should always be used if other therapies appear to be failing. They are effective for poisoning with several cardiac glycosides in addition to digoxin and may save patients who would otherwise die.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Lidocaine infusion (Option B): </strong>A Class IB antiarrhythmic effective for treating ventricular arrhythmias in moderate digitalis toxicity, but it does not remove the toxin itself.</p>\r\n<p><strong>Phenytoin (Option C): </strong>Can suppress digitalis-induced ventricular ectopy by stabilising membrane excitability, yet it is an adjunct for arrhythmia control, not the definitive antidote.</p>\r\n<p><strong>Potassium (Option D): </strong>Oral or IV K<sup>+</sup>corrects hypokalemia in chronic toxicity but is contraindicated in severe acute overdose, where hyperkalemia is common and would worsen outcomes.</p>", "options": ["Digi bind", "Lidocaine infusion", "Phenytoin  ", "Potassium "], "html_options": ["Digi bind", "Lidocaine infusion", "Phenytoin  ", "Potassium "], "corr_idx": 0}, {"id": "1179754", "html_qtxt": "A 78-year-old man with systolic heart failure comes to you for worsening shortness of breath at rest for 3 days. As a part of treatment, he is given a derivative of a hormone that acts by altering guanylate cyclase activity. This drug has been found to reduce pulmonary capillary wedge pressure and causes systemic hypotension as an adverse effect. The drug is most likely a derivative of which of the following hormones?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient's acute decompensated CHF was treated with <strong>nesiritide, a recombinant BNP derivative.</strong> Although rarely used today due to cost and hypotension risk, nesiritide remains an option for refractory acute heart failure.</p>\r\n<p><strong>BNP analogues bind natriuretic peptide receptor-A</strong> (a membrane guanylate cyclase), <strong>increasing cGMP in vascular smooth muscle to produce rapid venous and arterial vasodilation</strong>, thereby lowering PCWP and improving pulmonary congestion.</p>\r\n<p>The systemic hypotension observed is a predictable consequence of potent cGMP-mediated vasodilation. Blood pressure must be monitored closely during infusion.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Prostacyclin (Option A):</strong> A PGI<sub><span style=\"font-size: xx-small;\">2</span></sub> analogue that causes vasodilation and inhibits platelet aggregation via a GPCR-cAMP pathway; used in pulmonary arterial hypertension but does <strong>not</strong> act through guanylate cyclase nor reduce PCWP in acute CHF.</p>\r\n<p><strong>Aldosterone (Option B):</strong> Signals via nuclear receptors to promote sodium retention and fibrosis; aldosterone antagonists (spironolactone/eplerenone) improve chronic CHF survival but are <strong>not</strong> used acutely and <strong>do not modulate</strong> guanylate cyclase.</p>\r\n<p><strong>Antidiuretic hormone (Option C):</strong> Acts on V1 (PLC) and V2 (cAMP) receptors to regulate water balance and vasoconstriction; vasopressin antagonists (e.g., tolvaptan) affect volume but do <strong>not</strong> engage guanylate cyclase for vasodilation.</p>", "options": ["Prostacyclin", "Aldosterone", "Antidiuretic hormone", "Brain natriuretic peptide"], "html_options": ["Prostacyclin", "Aldosterone", "Antidiuretic hormone", "Brain natriuretic peptide"], "corr_idx": 3}, {"id": "1179756", "html_qtxt": "A 65-year-old woman with chronic CHF. All of the following drugs should be avoided except?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Amlodipine</strong>, a dihydropyridine calcium-channel blocker, causes arterial vasodilation with minimal negative inotropic effect, and <strong>does not significantly worsen left ventricular function in CHF.</strong></p>\r\n<p>Unlike nondihydropyridines, dihydropyridines have little impact on cardiac contractility or conduction, making amlodipine the only safe CCB in decompensated or chronic heart failure.</p>\r\n<p>Trials have shown that amlodipine does not increase mortality or hospitalisation rates in CHF when used appropriately for comorbid hypertension or angina.</p>\r\n<p><strong>Drugs that may worsen CHF</strong></p>\r\n<ul>\r\n<li>Most antiarrhythmic agents</li>\r\n<li>Calcium channel blockers (except amlodipine) <strong>(Option C)</strong></li>\r\n<li>NSAIDs <strong>(Option A)</strong></li>\r\n<li>Thiazolidinediones (e.g., pioglitazone) <strong>(Option B)</strong></li>\r\n<li>Inhalation anesthetics</li>\r\n<li>Cautious selection of antidepressants due to numerous interactions and adverse effects when used with HF drugs (SSRIs may be used judiciously)</li>\r\n</ul>", "options": ["Ibuprofen", "Pioglitazone", "Verapamil", "Amlodipine"], "html_options": ["Ibuprofen", "Pioglitazone", "Verapamil", "Amlodipine"], "corr_idx": 3}, {"id": "1179758", "html_qtxt": "A 78-year-old woman presents with increasing shortness of breath for 3 months. She underwent an emergency PCI for myocardial infarction 12 months ago. At the time of discharge, EDV was 300 mL, and ejection fraction was 58%. She admits to rarely taking her medication as she usually feels well and has no symptoms. Current Echocardiography shows left ventricular dilation and an end-diastolic volume of 390 mL; Ejection fraction is 35%. Which of the following is most likely to have prevented this patient's worsening of ventricular function?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient's progressive dyspnea, reduced EF, and LV dilation reflect unhindered post-MI cardiac remodelling due to lack of neurohormonal blockade.</p>\r\n<p>Enalapril, an ACE inhibitor, blocks angiotensin II formation, reducing preload and afterload, which slows the rate of LV dilation and limits adverse remodelling after MI.</p>\r\n<p>Early and sustained ACE-inhibitor therapy post-MI preserves ventricular geometry, maintains EF, and improves long-term clinical outcomes.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Atorvastatin (Option B):</strong> Lowers LDL and stabilises plaques but does not directly inhibit post-MI ventricular remodelling.</p>\r\n<p><strong>Abciximab (Option C):</strong> A glycoprotein IIb/IIIa inhibitor used acutely during PCI to prevent thrombosis; it does not affect chronic remodelling.</p>\r\n<p><strong>Nifedipine (Option D):</strong> A dihydropyridine CCB that can worsen systolic function and has no role in preventing post-MI remodelling.</p>", "options": ["Enalapril", "Atorvastatin", "Abciximab", "Nifedipine"], "html_options": ["Enalapril", "Atorvastatin", "Abciximab", "Nifedipine"], "corr_idx": 0}, {"id": "1179764", "html_qtxt": "Match the following mechanism with its drug used in heart failure.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403083d2c811e-cf88-4a6f-b0f2-823923bab17c.jpg\">", "html_expl": "<p><strong>Explanation for answer:</strong></p>\n<ul>\n<li><strong>Captopril, </strong>as an ACE inhibitor, lowers angiotensin II, <strong>reducing both preload and afterload </strong>and <strong>preventing post-MI ventricular remodelling.</strong></li>\n<li><strong>Carvedilol's</strong> &beta;-blockade plus &alpha;<sub>1</sub>-blockade <strong>decreases afterload and attenuates neurohormonal remodelling.</strong></li>\n<li>By antagonising aldosterone, <strong>spironolactone</strong> <strong>reduces sodium/water retention (preload) and, indirectly, vascular resistance (afterload).</strong></li>\n<li><strong>Milrinone </strong>is A PDE-3 inhibitor that elevates cAMP to<strong> increase contractility</strong> while dilating arterioles and veins.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308880cebf9-37f0-4627-a41a-26c190bb002a.jpg\">\n<p><strong>Other drugs for heart failure, with their mechanism</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403086cfea968-36e0-4db3-b396-f6fc5e9d11f2.jpg\">", "options": ["1-A 2-C 3-D 4-B", "1-C 2-A 3-D 4-B", "1-C 2-D 3-A 4-B", "1-D 2-A 3-C 4-B"], "html_options": ["1-A 2-C 3-D 4-B", "1-C 2-A 3-D 4-B", "1-C 2-D 3-A 4-B", "1-D 2-A 3-C 4-B"], "corr_idx": 1}, {"id": "1179766", "html_qtxt": "A 72-year-old woman admitted to the ICU for a cardiac condition started on amrinone. Which of the following is NOT true about the drug?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Amrinone is a phosphodiesterase-3 inhibitor that increases intracellular cAMP in cardiac and vascular smooth muscle cells, enhancing contractility and causing vasodilation-so statement A is false.</li>\r\n<li>By preventing cAMP breakdown, it augments protein kinase A activity, raising calcium availability in myocytes for a positive inotropic and chronotropic effect and relaxing vascular smooth muscle to reduce afterload and preload.</li>\r\n<li>Amrinone's combined inotropic and vasodilatory properties make it useful in acute heart failure complicated by cardiogenic shock to improve cardiac output and perfusion. <strong>(Option B)</strong></li>\r\n<li>Chronic use is limited by an increased risk of ventricular arrhythmias and thrombocytopenia; therefore, it is reserved for short-term support. <strong>(Option C)</strong></li>\r\n<li>The rise in cAMP enhances calcium influx in cardiomyocytes (&uarr; inotropy, &uarr; chronotropy) and induces arterial and venous dilation, lowering filling pressures. <strong>(Option D)</strong></li>\r\n</ul>\r\n<p>Salient feature of PDE-3 inhibitor</p>\r\n<img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d1mobye7msb5bl.cloudfront.net/2NewQBImages/bd277f75-a4c1-40da-bf81-71531d57891a.png\">", "options": ["It is a PDE-3 inhibitor and acts by decreasing cAMP in myocardium and peripheral vessels.", "It can be used in cardiac failure with cardiogenic shock", "It should not be used long-term as it may cause ventricular arrhythmia.", "It can &uarr; inotropy and &uarr; chronotropy effects in the myocardium as well as vasodilation."], "html_options": ["It is a PDE-3 inhibitor and acts by decreasing cAMP in myocardium and peripheral vessels.", "It can be used in cardiac failure with cardiogenic shock", "It should not be used long-term as it may cause ventricular arrhythmia.", "It can &uarr; inotropy and &uarr; chronotropy effects in the myocardium as well as vasodilation."], "corr_idx": 0}, {"id": "1179770", "html_qtxt": "A 56-year-old man presents with a complaint of syncope. He had a sudden onset of palpitations followed by loss of consciousness while working in the office. Medications include lisinopril, metformin, and amiodarone. He has been taking itraconazole for 3 days. He's stable now. ECG shown below. What is the next line of treatment for his condition?<br><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d1mobye7msb5bl.cloudfront.net/2NewQBImages/69094ce6-5d56-4e17-ab22-91cbae1a7964.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Polymorphic ventricular tachycardia with cyclic alteration of the QRS axis</strong> (sinusoidal waveform) is referred to as <strong>torsades de pointes and can progress to life-threatening ventricular fibrillation. </strong></p>\r\n<p>Treatment consists of administering <strong>magnesium sulphate 2g IV</strong>, repeated as needed.</p>\r\n<p>Acquired prolongation of the QT interval can be caused by certain medications (e.g., amiodarone, methadone, and ondansetron) or electrolyte imbalances (e.g., hypokalemia, hypomagnesemia, and hypocalcemia). This patient's history of amiodarone and itraconazole therapy makes drug-induced QT prolongation that progressed to torsades de pointes the most likely cause of his syncope.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030871dfe581-7d68-4149-b69b-de0d806fda1d.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>IV lidocaine (Option B): </strong>A Class IB agent effective for ischemic ventricular tachycardia but ineffective against torsades, which stems from repolarisation abnormalities rather than reentry.</p>\r\n<p><strong>IV esmolol (Option C): </strong>A &beta;-blocker that may help congenital long QT syndromes but is not first-line in drug-induced torsades de pointes.</p>\r\n<p><strong>Increase dose of amiodarone (Option D):</strong> Would worsen QT prolongation and exacerbate torsades, making it contraindicated.</p>", "options": ["IV MgSO4", "IV lidocaine", "IV Esmolol", "Increase the dose of amiodarone"], "html_options": ["IV MgSO4", "IV lidocaine", "IV Esmolol", "Increase the dose of amiodarone"], "corr_idx": 0}, {"id": "1179772", "html_qtxt": "A 56-year-old woman comes to you for a follow-up. She feels well and wants to stop her only current medication, flecainide. Which of the following ECG changes is most likely to be seen on cardiac stress testing in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Flecainide is a class IC antiarrhythmic used in patients with paroxysmal supraventricular arrhythmias and no other structural heart disease.</strong> It blocks fast sodium channels responsible for phase 0 of the myocardial action potential (rapid upstroke and depolarisation).</p>\r\n<p>The effect is an action potential with decreased slope and amplitude, which prolongs the spread of depolarisation to neighbouring cells, slowing conduction through the myocardium. Since phase 0 for ventricular myocytes corresponds to the QRS complex on ECG, <strong>flecainide prolongs the QRS complex. </strong></p>\r\n<p>This particular effect of class I antiarrhythmic drugs, especially of class IC antiarrhythmic drugs, is use/state-dependent, i.e., it increases with the heart rate (e.g., during cardiac stress testing), as more sodium channels are recruited for cardiac contraction.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Prolongation of the QTc interval (Option A) </strong>is a possible ECG change seen on cardiac stress testing in patients taking class IA and class III antiarrhythmic drugs, which block potassium channels, resulting in a prolonged repolarisation phase of the cardiac action potential.</p>\r\n<p><strong>Shortened PR interval (Option B): </strong>Class I antiarrhythmic drugs act by blocking the sodium channels in cardiomyocytes, which results in <strong>prolongation of the PR interval, not shortening.</strong> In patients taking flecainide, first- and second-degree AV block may be seen on cardiac stress testing.</p>\r\n<p><strong>Decreased maximal heart rate (Option D)</strong> is an ECG change typically seen on cardiac stress testing in patients taking beta blockers.</p>", "options": ["Prolonged QT interval", "Shortened PR interval", "Prolonged QRS complex", "Decreased maximal heart rate"], "html_options": ["Prolonged QT interval", "Shortened PR interval", "Prolonged QRS complex", "Decreased maximal heart rate"], "corr_idx": 2}, {"id": "1179773", "html_qtxt": "Which of the following drugs prolongs the QRS and QT intervals?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Quinidine is a Class IA antiarrhythmic </strong>that blocks fast Na channels (phase 0) and also inhibits K<sup>+</sup> channels (phase 3), slowing depolarisation and delaying repolarisation, <strong>thereby widening the QRS and prolonging the QT interval.</strong></p>\n<p>The \"use-dependence\"of quinidine means its effects intensify at higher heart rates, increasing both QRS duration and QT prolongation, which can predispose to torsades de pointes.</p>\n<p>Clinically, monitoring both intervals is essential when initiating quinidine to balance antiarrhythmic efficacy against proarrhythmic risk.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403088d963a72-b513-48b6-ab4d-329f8ae47e2b.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Lidocaine (Option A):</strong> A Class IB agent that shortens action-potential duration and has minimal effect on QRS or QT intervals.</p>\n<p><strong>Verapamil (Option B): </strong>A Class IV calcium-channel blocker that prolongs the PR interval but does not significantly affect QRS or QT.</p>\n<p><strong>Carvedilol (Option C):</strong> A nonselective &beta;-blocker with &alpha;<sub>1</sub>-blockade that can slow heart rate and AV conduction but does not prolong QRS or QT intervals.</p>", "options": ["Lidocaine", "Verapamil", "Carvedilol", "Quinidine"], "html_options": ["Lidocaine", "Verapamil", "Carvedilol", "Quinidine"], "corr_idx": 3}, {"id": "1179775", "html_qtxt": "A 78-year-old man is presented with diarrhoea, palpitations, blurry vision, and headache for 3 days. Current medications include warfarin, metoprolol, digoxin, ramipril, insulin, and spironolactone. The abdomen is soft with diffuse, mild tenderness to palpation. An ECG shows a second-degree AV block. Next line of management?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>The combination of gastrointestinal symptoms, visual disturbances, headache, and new AV block in a patient on digoxin with potential renal impairment strongly suggests digoxin toxicity.</strong></p>\r\n<p>Digoxin-specific antibody fragments (Digibind) rapidly bind circulating digoxin, reversing Na<sup>+</sup>/K<sup>+</sup>-ATPase inhibition and resolving life-threatening arrhythmias and hyperkalemia.</p>\r\n<p>In severe or life-threatening digitalis overdose, manifested by high-grade AV block or hyperkalemia. Fab fragments are the definitive therapy and should be administered without delay.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Potassium supplementation (Option A):</strong> While correcting hypokalemia can mitigate chronic toxicity, acute severe overdose often presents with hyperkalemia and requires antidotal therapy rather than further K<sup>+</sup>.</p>\r\n<p><strong>Propranolol (Option B):</strong> A nonselective &beta;-blocker that may worsen bradyarrhythmias and does not address the underlying digitalis excess.</p>\r\n<p><strong>Atropine (Option C):</strong> Temporarily increases AV nodal conduction in bradycardia but does not remove digoxin or correct its direct myocardial effects, and is insufficient in severe toxicity.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308c329a111-2b85-422f-bfe9-6c722649ba56.jpg\">\r\n", "options": ["Potassium supplementation", "Propranolol", "Atropine", "Digibind"], "html_options": ["Potassium supplementation", "Propranolol", "Atropine", "Digibind"], "corr_idx": 3}, {"id": "1179777", "html_qtxt": "Mr. Agrawal underwent tPA administration for STEMI 2 hours previously. He had an excellent response with the resolution of his ST-elevation. However, you note a wide complex ventricular rhythm with a rate of 75 bpm. Mr. Agrawal feels well. The next most appropriate step?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This rhythm is an <strong>accelerated idioventricular rhythm</strong>, a benign reperfusion arrhythmia commonly seen after successful thrombolysis or PCI.</p>\r\n<p>It arises from enhanced automaticity of ventricular Purkinje fibres with a rate between the intrinsic ventricular escape rhythm and sinus rate, reflecting restored coronary perfusion.</p>\r\n<p>No antiarrhythmic therapy is indicated, as accelerated idioventricular rhythm resolves spontaneously and treatment can provoke more dangerous arrhythmias.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Amiodarone (Option A):</strong> Indicated for sustained ventricular tachycardia or fibrillation, not for benign reperfusion arrhythmias, and risks unnecessary toxicity.</p>\r\n<p><strong>Flecainide (Option B):</strong> A Class I agent contraindicated post-MI due to increased mortality risk and proarrhythmic potential.</p>\r\n<p><strong>Metoprolol (Option C):</strong> A &beta;-blocker useful for SVT or VT rate control, but unnecessary here and may depress sinus node function.</p>", "options": ["Amiodarone ", "Flecainide ", "Metoprolol ", "Continue observation"], "html_options": ["Amiodarone ", "Flecainide ", "Metoprolol ", "Continue observation"], "corr_idx": 3}, {"id": "1179780", "html_qtxt": "Mr. Kohli is a 26-year-old cricketer who comes to you for a regular check-up. On your assessment, you note a resting heart rate of 45 bpm with an occasional pause of up to 2 seconds. His blood pressure is 110/70 mmHg. He feels well and reports no syncopal or presyncopal episodes at rest or during exercise. ECG is normal. Which of the following would be the next step?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>In highly trained athletes, increased vagal tone commonly produces resting sinus bradycardia and brief sinus pauses (&le;3 seconds) that are physiologic and asymptomatic.</p>\r\n<p>Normal ECG and absence of symptoms or exercise intolerance confirm this benign adaptation-no evidence of intrinsic conduction disease.</p>\r\n<p>Reassurance without intervention avoids unnecessary tests and maintains athletic activity.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Atropine (Option A):</strong> Unnecessary in physiologic bradycardia and may provoke inappropriate tachycardia.</p>\r\n<p><strong>Follow-up and activity restriction (Option B):</strong> No indication to limit sports or repeat ECG in an asymptomatic athlete with normal findings.</p>\r\n<p><strong>Treadmill stress ECG (Option D): </strong>Indicated only if symptoms or ECG abnormalities suggest chronotropic incompetence, not in this asymptomatic context.</p>\r\n", "options": ["Atropine", "Follow-up after 1 week. Avoid cricket for a week", "No further follow-up", "He should undergo a treadmill stress ECG to determine the presence of chronotropic competence."], "html_options": ["Atropine", "Follow-up after 1 week. Avoid cricket for a week", "No further follow-up", "He should undergo a treadmill stress ECG to determine the presence of chronotropic competence."], "corr_idx": 2}, {"id": "1179791", "html_qtxt": "A 72-year-old man with a history of COPD and osteoporosis presents after a fall. On examination, there is tenderness to palpation over the left hip, and his leg is shortened and externally rotated. His mucous membranes are dry. Blood pressure is 160/80 mmHg and heart rate is 130 bpm. ECG is shown. What is the most appropriate first step for her tachycardia ?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308bcf5bbbd-c12b-4006-9204-209bab8c5719.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The ECG and clinical context (COPD, acute dehydration, and fall) are diagnostic of <strong>multifocal atrial tachycardia (MAT)</strong>, arising from multiple ectopic atrial foci, not a reentrant circuit.</p>\r\n<p>Because MAT is <strong>not</strong> due to a reentry phenomenon, interventions like electrical cardioversion, which are effective for reentrant arrhythmias, do <strong>not</strong> terminate MAT. MAT in acute illness responds poorly to antiarrhythmic drugs; the cornerstone of therapy is <strong>treating underlying triggers</strong> such as pain, hypoxia, and dehydration to restore normal atrial automaticity.</p>\r\n<p><strong>IV fluids</strong> to correct volume depletion and <strong>adequate analgesia</strong> to relieve pain, reduce sympathetic drive and atrial irritability, leading to resolution of MAT without drug toxicity.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Adenosine (Option A):</strong> Blocks AV nodal conduction briefly but does not affect multiple atrial foci and thus fails to terminate MAT.</p>\r\n<p><strong>Digoxin (Option B):</strong> Slows AV conduction but does not address the ectopic atrial activity driving MAT and risks toxicity in hypovolemic states.</p>\r\n<p><strong>Metoprolol (Option C):</strong> May reduce ventricular response but risks bronchospasm in COPD and again does not treat the precipitating factors of MAT.</p>", "options": ["Adenosine", "Digoxin ", "Metoprolol ", "Pain control and IV hydration"], "html_options": ["Adenosine", "Digoxin ", "Metoprolol ", "Pain control and IV hydration"], "corr_idx": 3}, {"id": "1179792", "html_qtxt": "A 68-year-old woman referred to you for an ECG showing 2:1 second-degree AV block. If you administer atropine intravenously to the patient, you would expect which of the following to occur?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>A 2:1 block may be either nodal (Mobitz I) or infranodal (Mobitz II). In the <strong>infranodal</strong> block-below the AV node-anticholinergic agents like atropine have <strong>little to no effect</strong> on conduction or sinus rate.</p>\r\n<p>Atropine acts by reducing vagal tone at the AV node and increasing SA nodal phase-4 slope; when the block is distal, these effects do not alter ventricular conduction or heart rate.</p>\r\n<p>Lack of response to atropine in a 2:1 block helps distinguish <strong>Mobitz II</strong> (infranodal) from Mobitz I (nodal), guiding prognosis and management.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Option A:</strong> &uarr; sinus rate with persistent 2:1 block suggests nodal block without conduction improvement; atropine would speed sinus but still improve AV nodal conduction in Mobitz I.</p>\r\n<p><strong>Option B:</strong> &uarr; sinus rate with conversion to 1:1 conduction indicates a nodal (Mobitz I) mechanism responsive to vagolysis-does not occur in infranodal block.</p>\r\n<p><strong>Option C:</strong> No change in rate with worsened block implies atrial rate constant and more dropped beats; atropine should raise sinus rate if SA node is responsive, so block would not worsen without rate change.</p>", "options": ["Increase sinus rate and maintain 2:1 AV block", "Increase sinus rate and improve heart block to 1:1 conduction", "No change in sinus rate and worsening heart block to >2:1", "No change"], "html_options": ["Increase sinus rate and maintain 2:1 AV block", "Increase sinus rate and improve heart block to 1:1 conduction", "No change in sinus rate and worsening heart block to >2:1", "No change"], "corr_idx": 3}, {"id": "1179793", "html_qtxt": "A 76-year-old man presents with 5 days of not feeling well. He has a history of nonischemic cardiomyopathy and hypertension. Blood pressure is 110/78 mmHg, and his heart rate is 150 bpm. His jugular veins are not distended, and his lungs are clear. His ECG is shown. What would be the appropriate next step?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308ee6c03e6-d9c9-46ad-aaa5-b6c9c6285818.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This ECG shows atrial flutter, with 2:1 conduction and the typical atrial rate of 300 bpm and ventricular rate of 150 bpm. The saw-tooth baseline pattern, best appreciated in the inferior leads, is a clue that this is <strong>atrial flutter</strong>. The appropriate next step should be to administer 5 mg of <strong>IV metoprolol, which brings his heart rate down.</strong></p>\r\n<p>However, given that the patient's symptoms have been ongoing for >48 hours, he is at risk for development of an atrial thrombus (similar to that in atrial fibrillation) and thus requires systemic anticoagulation before achievement of sinus rhythm. He will also likely require a transesophageal echocardiogram to ensure that no clot exists prior to ablation or cardioversion.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Digoxin (Option A):</strong> Provides modest rate control but is too slow in onset for acute rate reduction and ineffective at controlling high-rate atrial flutter alone.</p>\r\n<p><strong>DC cardioversion (Option C):</strong> Reserved for unstable patients or after anticoagulation in flutter >48 hours; immediate cardioversion without anticoagulation poses thromboembolic risk.</p>\r\n<p><strong>Amiodarone (Option D):</strong> A rhythm-control agent with slow onset and limited efficacy for acute rate reduction in atrial flutter; not first-line for rate control.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308d44faf48-8f76-4230-809e-b4a6f25babc3.jpg\">\r\n", "options": ["Digoxin", "Metoprolol", "DC cardioversion", "Amiodarone"], "html_options": ["Digoxin", "Metoprolol", "DC cardioversion", "Amiodarone"], "corr_idx": 1}, {"id": "1179794", "html_qtxt": "Which of the following has convincingly demonstrated mortality reduction for patients with HFpEF?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Multiple large randomised trials of <strong>ACE inhibitors</strong> (e.g., PEP-CHF with perindopril) and <strong>ARBs</strong> (I-PRESERVE with irbesartan; CHARM-Preserved with candesartan; TOPCAT with spironolactone, an aldosterone antagonist) in HFpEF <strong>failed to show a significant reduction in all-cause mortality</strong>. While some showed modest reductions in hospitalisations, none convincingly improved survival.</li>\r\n<li>The <strong>RELAX</strong> trial of <strong>sildenafil</strong> in HFpEF improved exercise capacity in a subset of patients but did <strong>not</strong> demonstrate a mortality benefit in longer-term follow-up.</li>\r\n<li>Pathophysiologic heterogeneity in HFpEF (diastolic dysfunction, comorbidities like hypertension, obesity, diabetes, fibrosis) likely underlies the lack of a \"one-size-fits-all\" therapeutic impact on survival.</li>\r\n<li>Current guidelines for HFpEF emphasise <strong>symptom management</strong> (diuretics for congestion), <strong>strict blood pressure control</strong>, and treatment of comorbid conditions (e.g., atrial fibrillation, ischemia) rather than reliance on agents proven to reduce mortality in HFrEF.</li>\r\n</ul>", "options": ["ACEIs", "ARBs", "Sildenafil", "None of the above"], "html_options": ["ACEIs", "ARBs", "Sildenafil", "None of the above"], "corr_idx": 3}, {"id": "1179795", "html_qtxt": "A 68-year-old man with a history of myocardial infarction and congestive heart failure is comfortable at rest. However, when walking to his car, he develops dyspnea, fatigue, and sometimes palpitations. He must rest for several minutes before these symptoms resolve. What are the current treatment guidelines for the patient?<br>1. Beta blocker<br>2.ACEIs<br>3. ARB <br>4. ARNI<br> 5. Furosemide <br>6. Spironolactone <br>7. Dobutamine <br>8. Milrinone", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>ARNI (sacubitril/valsartan)</strong> is now preferred over ACE inhibitors or ARBs in symptomatic HFrEF (Stage C) to reduce morbidity and mortality by augmenting natriuretic peptides and blocking angiotensin II.</p>\r\n<p><strong>Loop diuretics (furosemide)</strong> are indicated for symptomatic relief of congestion (dyspnea, fatigue) by reducing preload.</p>\r\n<p><strong>Mineralocorticoid receptor antagonists (spironolactone)</strong> further improve survival and reduce hospitalisations in NYHA class II-IV HFrEF by antagonising aldosterone's fibrotic and sodium-retaining effects.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308741f5619-f0ba-4557-94ed-51df5d679b8f.jpg\">\r\n<p>The AHA classification system categorizes patients according to the stage of disease based on an objective assessment of clinical features and diagnostic findings.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308b0b24a5f-03a2-4499-a57b-be51f630d492.jpg\">", "options": ["1+2 +5 +6", "5+7", "4+ 5+ 6", "1+ 4+ 5+ 6 + 7"], "html_options": ["1+2 +5 +6", "5+7", "4+ 5+ 6", "1+ 4+ 5+ 6 + 7"], "corr_idx": 2}, {"id": "1179796", "html_qtxt": "A 72-year-old woman with chemotherapy-related cardiomyopathy now has an ejection fraction of 15%. She has been hospitalised two times in the last 6 months with acute decompensated heart failure. She is currently NYHA class IV regarding symptoms. What drugs can be used continuously to support quality of life as a bridge therapy while waiting for a transplant?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>In <strong>Stage D heart failure </strong>(refractory to standard therapies and awaiting transplant), inotropic support with a PDE-3 inhibitor like <strong>milrinone provides symptomatic relief by increasing cardiac contractility and reducing afterload.</strong></li>\r\n<li>Milrinone raises intracellular cAMP in myocardium and vascular smooth muscle, improving stroke volume and producing vasodilation to lower filling pressures.</li>\r\n<li>Although continuous inotrope infusion can improve hemodynamics and quality of life as a bridge or palliative measure, it has not been shown to improve long-term survival and is reserved for end-stage patients awaiting advanced therapies.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308af771cee-e1b8-4171-8027-62ac9086a3e1.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Beta-blockers (Option A):</strong> Cornerstone of chronic HFrEF management but contraindicated in acute decompensation and Stage D where rapid inotropic support is needed.</p>\r\n<p><strong>Spironolactone (Option B):</strong> Provides mortality benefit in Stage C but lacks direct positive inotropic action and is insufficient for acute low-output support.</p>\r\n<p><strong>ACE inhibitors (Option D):</strong> Improve remodeling and survival in earlier stages but do not provide the immediate increase in contractility required in refractory Stage D HF.</p>", "options": ["Beta-blockers", "Spironolactone", "Milrinone", "ACEIs"], "html_options": ["Beta-blockers", "Spironolactone", "Milrinone", "ACEIs"], "corr_idx": 2}, {"id": "1179797", "html_qtxt": "A 56-year-old woman presents with complaints of feeling tired. She also has diarrhoea and weight loss. She also feels very anxious and nervous. She is being treated for ventricular arrhythmia. Which of the following is the next step in the management?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Amiodarone contains a high iodine load and disrupts thyroid function; clinical syndromes include <strong>Type I</strong> (iodine induced hyperthyroidism from increased hormone synthesis) and <strong>Type II</strong> (destructive thyroiditis eventually leading to hypothyroidism).</li>\n<li>Her symptoms (weight loss, diarrhea, and anxiety) are characteristic of amiodarone-induced hyperthyroidism (Type I), but laboratory confirmation with TSH and free T4 is essential to differentiate and guide therapy.</li>\n<li>Early thyroid testing prevents misdiagnosis and directs management, whether thionamides for hyperthyroidism or thyroid hormone replacement for hypothyroidism, without delay.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240319bf43b1bc-0215-4934-9df2-fba3fe3e02f2.jpg\"><br>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403082365f9b9-50d7-4866-989f-fc880c1e4c04.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Serum electrolyte measurement (Option A):</strong> Appropriate for suspected digitalis or diuretic toxicity but not for systemic thyroid effects.</p>\n<p><strong>ECG (Option B):</strong> May show conduction changes from amiodarone, but cannot diagnose thyroid dysfunction driving her systemic symptoms.</p>\n<p><strong>Anti-histone antibody assay (Option D):</strong> Used for drug-induced lupus (e.g., procainamide), irrelevant to amiodarone's thyroid effects.</p>", "options": ["Serum electrolyte", "ECG", "Thyroid function test", "Anti-histone antibody"], "html_options": ["Serum electrolyte", "ECG", "Thyroid function test", "Anti-histone antibody"], "corr_idx": 2}, {"id": "1179798", "html_qtxt": "A 28-year-old woman complains of fever, fatigue, weight loss, arthralgia, and transient patchy alopecia during the last 3 months. She is on treatment for a cardiovascular disease. Antinuclear antibody testing is positive. Presently, her hematocrit is 33% and creatinine is 1.2 mg/dL. The most likely cause?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Several drugs can cause a syndrome resembling systemic lupus erythematosus (SLE). The syndrome is most common with procainamide, which induces the presence of antinuclear antibodies in up to 75% of individuals within a few months. There is a genetic predisposition to drug-induced lupus determined by drug acetylation rates.</p>\n<ul>\n<li>Genetic susceptibility\n<ul>\n<li>Decreased acetyltransferase activity resulting in slow acetylation of drugs</li>\n<li>Presence of HLA-DR2, HLA-DR3, HLA-DR4, or an unexpressed C4 complement allele</li>\n</ul>\n</li>\n<li>Common drug triggers (<strong><em><u>SHyPS</u></em></strong>)\n<ul>\n<li>Sulfa drugs</li>\n<li>Certain nonsulfa drugs, e.g., procainamide, hydralazine, isoniazid, methyldopa, minocycline, phenytoin, TNF-&alpha; inhibitors</li>\n</ul>\n</li>\n</ul>\n<p>Typical symptoms include systemic complaints and arthralgias. The initial therapeutic approach is the withdrawal of the offending drug.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Ethosuximide (Option A):</strong> Rare, anecdotal reports exist, but it is not a well-established cause of drug-induced lupus.</p>\n<p><strong>Oral contraceptives (Option B):</strong> Do not reliably induce lupus and are rarely implicated in ANA positivity or clinical lupus syndromes.</p>\n<p><strong>Phenytoin (Option C):</strong> Can cause hypersensitivity and drug reactions, but has no strong association with lupus-like syndromes.</p>", "options": ["Ethosuximide", "Oral contraceptives", "Phenytoin", "Procainamide"], "html_options": ["Ethosuximide", "Oral contraceptives", "Phenytoin", "Procainamide"], "corr_idx": 3}, {"id": "1179799", "html_qtxt": "A 68-year-old man is on metoprolol, ACEIs and Chlorthalidone for his cardiac condition. Which of the following drugs should be avoided to prevent AV block?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Verapamil is a non-dihydropyridine calcium-channel blocker that slows AV nodal conduction.</p>\r\n<p>When combined with a &beta;-blocker like metoprolol, the additive AV block and sinus-node depression can lead to significant bradycardia or high-degree AV block.</p>\r\n<p>Verapamil also has negative inotropic effects, potentially worsening heart failure in this patient.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Amiodarone (Option B):</strong> Although it affects conduction, it is not typically combined with &beta;-blockers to produce AV block and is used cautiously for arrhythmias rather than for hypertension or fluid management.</p>\r\n<p><strong>Furosemide (Option C):</strong> A loop diuretic with no direct effects on AV nodal conduction.</p>\r\n<p><strong>Hydralazine (Option D):</strong> A direct arteriolar vasodilator that does not impact AV nodal conduction.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<p>To avoid drug-induced AV block, remember the \"ABCD\" agents that slow AV nodal conduction:</p>\r\n<ul>\r\n<li><strong>A</strong>denosine</li>\r\n<li><strong>B</strong>eta-blockers</li>\r\n<li><strong>C</strong>alcium-channel blockers (non-DHP: verapamil, diltiazem)</li>\r\n<li><strong>D</strong>igoxin</li>\r\n</ul>", "options": ["Verapamil", "Amiodarone", "Furosemide", "Hydralazine"], "html_options": ["Verapamil", "Amiodarone", "Furosemide", "Hydralazine"], "corr_idx": 0}, {"id": "1179800", "html_qtxt": "Match the following drugs with their side effects.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030821ff3a94-201f-43a6-9fa9-eb175600081b.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Disopyramide &rarr; B:</strong> As a Class IA antiarrhythmic with strong anticholinergic properties, disopyramide commonly causes dry mouth, hyperthermia, and mydriasis.</p>\r\n<p><strong>Lidocaine &rarr; D:</strong> Lidocaine toxicity manifests predominantly as central nervous system effects (nystagmus, confusion, and seizures), especially with high doses or reduced clearance.</p>\r\n<p><strong>Amiodarone &rarr; A:</strong> Chronic amiodarone therapy can induce peripheral neuropathy, along with pulmonary fibrosis and thyroid dysfunction, due to tissue accumulation of iodine-rich drugs.</p>\r\n<p><strong>MgSO<sup>4</sup> &rarr; C: </strong>In overdose or rapid infusion, magnesium sulfate causes neuromuscular blockade leading to respiratory depression and hyporeflexia.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403089dadd17e-7960-47d8-b652-a301f5763434.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030894702cc8-5218-4f14-bf5d-9aad98230b67.jpg\">", "options": ["1-B 2-C 3-A 4-D", "1-B 2-D 3-A 4-C", "1-C 2-D 3-A 4-B", "1-D 2-A 3-B 4-C"], "html_options": ["1-B 2-C 3-A 4-D", "1-B 2-D 3-A 4-C", "1-C 2-D 3-A 4-B", "1-D 2-A 3-B 4-C"], "corr_idx": 1}, {"id": "1179801", "html_qtxt": "Identify the incorrect choice regarding the choice of an anti-arrhythmic.", "html_expl": "<p><strong>Explanation for answer:</strong></p>\r\n<p>In congenital long QT syndrome, the cornerstone of therapy is chronic nonselective &beta;-blockade (e.g., propranolol or nadolol) to blunt sympathetic triggers and prevent torsades; magnesium sulfate is reserved for <strong>acute</strong> termination of torsades de pointes, not for long-term management of the channelopathy.</p>\r\n<p>Magnesium stabilises cardiomyocyte membranes and suppresses early afterdepolarizations in drug- or electrolyte-induced torsades, but it does not correct the underlying repolarisation defect in congenital LQTS.</p>\r\n<p>Thus, prescribing magnesium sulfate as the initial antiarrhythmic in congenital LQTS is inappropriate.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Verapamil (Option B):</strong> A nondihydropyridine CCB effective for rate control in reentrant SVTs by slowing AV nodal conduction.</p>\r\n<p><strong>Propranolol (Option C):</strong> A &beta;-blocker ideal for slowing ventricular rate in digoxin-induced supraventricular arrhythmias and protective against digoxin's proarrhythmic effects.</p>\r\n<p><strong>Lidocaine (Option D):</strong> A Class IB agent first-line for acute ventricular tachycardia post-myocardial infarction, reducing ectopic automaticity in ischemic tissue.</p>", "options": ["A 12-year-old with congenital LQTS = Magnesium sulphate", "A 45-year-old with supraventricular arrhythmia = Verapamil", "A 67-year-old on digoxin with supraventricular arrhythmia = Propranolol", "A 56-year-old with ventricular arrhythmia due after MI = lidocaine"], "html_options": ["A 12-year-old with congenital LQTS = Magnesium sulphate", "A 45-year-old with supraventricular arrhythmia = Verapamil", "A 67-year-old on digoxin with supraventricular arrhythmia = Propranolol", "A 56-year-old with ventricular arrhythmia due after MI = lidocaine"], "corr_idx": 0}, {"id": "1179802", "html_qtxt": "A 40-year-old woman presents with a sudden onset of palpitations. Her heart rate is 170 bpm and blood pressure is 100/60 mmHg with normal oxygen saturation. On examination, she has a 'frog sign' in her neck. ECG shows a narrow complex tachycardia without identifiable P waves. Which of the following is the most appropriate first step?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient has classical findings of AVNRT. The so-called frog sign (prominent venous pulsations in the neck due to cannon A waves seen in AV dissociation) on examination is frequently present and suggests simultaneous atrial and ventricular contraction.</p>\r\n<p>First-line therapy for these reentrant narrow complex tachyarrhythmias is carotid sinus massage to increase vagal tone. Often, this is all that is required to return the patient to sinus rhythm. If that is not successful, intravenous (IV) adenosine 6&ndash;12 mg may be attempted. If adenosine fails, IV &beta;-blockers or calcium channel blockers may be used (diltiazem or verapamil). Finally, in hemodynamically compromised patients or those who have failed to respond to previous measures, direct current (DC) cardioversion with 100-200 J is indicated.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403089f4b3a83-ebaf-44c5-93b6-3f7f63dfd003.jpg\">", "options": ["Metoprolol ", "Quinidine", "Carotid sinus massage", "DC cardioversion using 100 J"], "html_options": ["Metoprolol ", "Quinidine", "Carotid sinus massage", "DC cardioversion using 100 J"], "corr_idx": 2}]}, {"moduleId": 1008537, "name": "Diuretics", "questions": [{"id": "1167301", "html_qtxt": "A 45-year-old man is brought in for a syncopal episode. He started on lisinopril for his HTN today. On arrival, he is fully oriented. His pulse is 100/min and blood pressure is 90/60 mm Hg. Concurrent treatment with which of the following agents most likely predisposed the patient to this episode?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Patients on thiazide diuretics like hydrochlorothiazide have reduced intravascular volume from enhanced renal sodium and water excretion, making them particularly susceptible to first-dose hypotension when an ACE inhibitor is added.</p>\n<p>Lisinopril causes vasodilation and decreases angiotensin II-mediated sodium retention; in a volume-depleted patient, this synergism can precipitate a pronounced blood pressure drop.</p>\n<p>First-dose hypotension is a well-recognised adverse effect of ACE inhibitors, especially when initiated in patients taking diuretics or who are hypovolemic.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Lithium (Option B):</strong> ACE inhibitors can reduce lithium clearance, risking toxicity, but lithium does not directly potentiate hypotension.</p>\n<p><strong>TMP-SMX (Option C):</strong> Trimethoprim-sulfamethoxazole can elevate potassium but has no synergistic hypotensive effect with ACE inhibitors.</p>\n<p><strong>Metformin (Option D):</strong> Metformin does not affect blood pressure regulation and would not predispose to ACE inhibitor-induced hypotension.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403089bfd1639-750e-46bc-afe8-23ad58f5d295.jpg\">", "options": ["Hydrochlorothiazide", "Lithium", "TMP-SMX", "Metformin"], "html_options": ["Hydrochlorothiazide", "Lithium", "TMP-SMX", "Metformin"], "corr_idx": 0}, {"id": "1167303", "html_qtxt": "A 47-year-old woman develops a loss of hearing after getting admitted for acute decompensated heart failure. The responsible offending agent most likely acts on which part of the nephron?<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308de375576-1cdd-40d3-ab0b-4cb413483195.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Given the acute onset of symptoms (here, hearing loss) shortly after initiating treatment, an adverse medication effect should be suspected. This patient was most likely previously treated with intravenous furosemide, a loop diuretic used to treat acute decompensated heart failure that (like all loop diuretics) acts by inhibiting the Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup>-cotransporters on the thick ascending limb of the loop of Henle.</p>\n<p>Other important adverse effects of loop diuretics include metabolic abnormalities (hypokalemia, hypomagnesemia, hypocalcemia, metabolic alkalosis), dehydration, and sulfonamide hypersensitivity.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030839b21f36-f896-4945-b3ef-216622061747.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Proximal convoluted tubule (Option A): </strong>Carbonic anhydrase inhibitors act here and are not associated with ototoxicity.</p>\n<p><strong>Distal convoluted tubule (Option B): </strong>Thiazide diuretics target this segment, causing hypokalemia but not hearing loss.</p>\n<p><strong>Collecting duct (Option D): </strong>Potassium-sparing diuretics (e.g., spironolactone) work here and do not produce ototoxicity.</p>", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 2}, {"id": "1167306", "html_qtxt": "A 27-year-old woman presents with a severe headache and vomiting that started after she was hiking in the mountains at high altitude. Therapy is initiated with a drug that alkalinizes the urine. Which of the following is the most likely site of action of this drug in the kidney?<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403086322e751-a399-4f5d-83cb-355a465ed57d.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Acetazolamide</strong>, the treatment of choice for acute mountain sickness, is a carbonic anhydrase inhibitor that acts in the <strong>proximal convoluted tubule</strong> to block bicarbonate reabsorption.</p>\n<p>Inhibition of carbonic anhydrase decreases H<sup>+</sup> secretion and HCO<sub>3</sub><sup>-</sup> reabsorption, resulting in <strong>bicarbonate diuresis and</strong> <strong>urine alkalinization</strong>.</p>\n<p>The resultant <strong>normal anion-gap metabolic acidosis</strong> stimulates respiratory drive (hyperventilation), thereby increasing blood O<sub>2</sub> and decreasing CO<sub>2</sub> to aid acclimatisation at high altitude.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Thick ascending limb (Option B):</strong> Loop diuretics act here on the Na-K-2Cl<sup>-</sup> cotransporter but do not alkalinise urine or produce metabolic acidosis.</p>\n<p><strong>Distal convoluted tubule (Option C):</strong> Thiazide diuretics inhibit the Na<sup>+</sup>-Cl<sup>-</sup> cotransporter in this segment; they reduce Ca<sup>2+</sup> excretion but have minimal effect on bicarbonate.</p>\n<p><strong>Collecting duct (Option D):</strong> Potassium-sparing diuretics (e.g., spironolactone, amiloride) act here on aldosterone receptors or ENaC channels, neither of which significantly alters urine pH.</p>", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 0}, {"id": "1167310", "html_qtxt": "A 70-year-old man with congestive heart failure comes to you for a follow-up examination. Physical examination shows bilateral, mildly tender enlargement of breast tissue. This patient's physical examination finding is most likely caused by a drug that acts at which of the following sites in the kidney?<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403084e0514b6-ec64-497f-9285-26035232f7dd.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Gynecomastia is a classic side effect of spironolactone, which is used in the management of congestive heart failure.</li>\n<li>Spironolactone, which is a competitive aldosterone receptor antagonist, acts on the principal cells in the cortical collecting ducts. It is used to reduce morbidity and mortality in patients with heart failure.</li>\n<li>Spironolactone inhibits the binding of androgens to their receptors as well as the activity of enzymes involved in androgen synthesis (e.g., 17, 20-desmolase, 17&alpha;-hydroxylase). It also increases the peripheral conversion of testosterone to estradiol and displaces estradiol from SHBG. This combination of antiandrogenic and pro-estrogenic effects can cause painful gynecomastia and impotence in men.</li>\n<li>Eplerenone is an aldosterone receptor antagonist with a greater specificity for the mineralocorticoid receptor than spironolactone; it has a lower incidence of endocrine side effects.</li>\n</ul>", "options": ["B", "C", "D", "E"], "html_options": ["B", "C", "D", "E"], "corr_idx": 3}, {"id": "1167314", "html_qtxt": "A 48-year-old woman is brought to the emergency department, where her temperature is 99.1&deg;F, pulse is 182/min, respirations are 18/min, and blood pressure is 82/50 mm Hg. An ECG shows ventricular tachycardia. She was diagnosed with alcoholic liver cirrhosis 2 years ago. Examination shows a protruding, distended abdomen that is dull to percussion with a positive fluid wave. Which of the following treatments is most likely responsible for this patient's presentation?<br>Initial laboratory studies show:<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308b0e93db0-0635-40b3-8a82-a719fbb0bb6e.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient received medical therapy for ascites (indicated by her clinical findings and history of cirrhosis). Furosemide was likely prescribed to this patient to treat her ascites. If administered in excess, furosemide can lead to a profound diuresis with water and electrolyte depletion, resulting in <strong>hypokalemia, hypomagnesemia, hypocalcemia, hyponatremia,</strong>and ultimately the <strong>acute kidney injury and metabolic alkalosis</strong> as seen in this patient.</li>\n<li>Hypokalemia and hypomagnesemia can cause life-threatening arrhythmias, such as the ventricular tachycardia suffered by this patient. In addition to correcting this patient's electrolyte levels, management would also include prompt rehydration with intravenous fluids.The drug responsible for her laboratory findings can also cause hyperglycemia and ototoxicity.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acetazolamide (Option A):</strong> A proximal tubule carbonic anhydrase inhibitor used for glaucoma and altitude sickness; causes bicarbonate diuresis and <strong>metabolic acidosis</strong>, not alkalosis, and is not indicated for ascites.</p>\n<p><strong>Spironolactone (Option B):</strong> A potassium-sparing diuretic first-line for cirrhotic ascites; excess use produces <strong>hyperkalemia</strong> and <strong>metabolic acidosis</strong>, the opposite of this patient's hypokalemic, alkalotic state.</p>\n<p><strong>Mannitol (Option D):</strong> An osmotic diuretic for cerebral edema or acute glaucoma; not used for ascites and causes water diuresis with <strong>no metabolic alkalosis</strong>, instead it can worsen volume status and perhaps cause metabolic acidosis.</p>", "options": ["Acetazolamide", "Spironolactone", "Furosemide", "Mannitol"], "html_options": ["Acetazolamide", "Spironolactone", "Furosemide", "Mannitol"], "corr_idx": 2}, {"id": "1167316", "html_qtxt": "A 66-year-old woman is presented with a severe headache, nausea and vomiting. Her pulse is 50/min, respirations are 8/min and shallow, and blood pressure is 150/96 mm Hg. Treatment with an intravenous drug is initiated, and the patient's urine output subsequently increases. The patient is at greatest risk of which of the following adverse effects?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient presents with nausea, vomiting and headache. Examination shows the Cushing triad (bradycardia, respiratory depression, and hypertension).</p>\n<p>These are classic features of elevated intracranial pressure (ICP), which can be treated with mannitol, an osmotic diuretic.</p>\n<p>It causes an increase in plasma osmolality, resulting in osmotic shifts of water into the intravascular space. This effect decreases cerebral oedema but can lead to iatrogenic volume overload and pulmonary oedema.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Tinnitus (Option A)</strong>: A hallmark of loop diuretic-induced ototoxicity (e.g., furosemide), not seen with mannitol.</p>\n<p><strong>DRESS (Option C)</strong>: A severe drug reaction with eosinophilia and systemic symptoms linked to anticonvulsants or antibiotics, unrelated to osmotic diuretics.</p>\n<p><strong>Hypercalcemia (Option D)</strong>: Occurs with thiazide diuretics due to reduced renal calcium excretion, the opposite effect of mannitol.</p>", "options": ["Tinnitus", "Pulmonary edema", "DRESS", "Hypercalcemia"], "html_options": ["Tinnitus", "Pulmonary edema", "DRESS", "Hypercalcemia"], "corr_idx": 1}, {"id": "1167319", "html_qtxt": "A 49-year-old man with hypertension comes to the physician because of muscle cramps and weakness. His home medications also include amlodipine and hydrochlorothiazide. His blood pressure today is 160/90 mm Hg. The ECG are shown.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403083166944c-be31-4f65-bd78-44b1fece1de5.jpg\">The addition of which of the following drugs is most likely to have prevented this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient presents with clinical and ECG features suggestive of <strong>hypokalemia</strong>, a known adverse effect of thiazide diuretics like hydrochlorothiazide.</li>\n<li><strong>Eplerenone</strong>, a selective aldosterone receptor antagonist (SARA), acts on the <strong>collecting duct</strong> to reduce potassium excretion, counteracting the hypokalemic effects of thiazides.</li>\n<li>It is especially useful in <strong>resistant hypertension</strong> and in patients already on potassium-wasting diuretics, making it the most suitable adjunct in this scenario.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Furosemide (Option A):</strong> Loop diuretic; also causes hypokalemia and would <strong>exacerbate</strong> thiazide-induced potassium loss.</p>\n<p><strong>Hydralazine (Option B):</strong> Direct vasodilator; does <strong>not influence potassium</strong> levels and would not prevent thiazide-induced hypokalemia.</p>\n<p><strong>Mannitol (Option D):</strong> Osmotic diuretic; not used for hypertension and does <strong>not correct or cause</strong> significant hypokalemia.</p>", "options": ["Furosemide", "Hydralazine", "Eplerenone", "Mannitol"], "html_options": ["Furosemide", "Hydralazine", "Eplerenone", "Mannitol"], "corr_idx": 2}, {"id": "1167325", "html_qtxt": "An 80-year-old woman consumed a drug that inhibits Na+-Cl- cotransporters in the distal convoluted tubule in excess. Serum studies are most likely to show which of the following sets of findings?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Inhibition of Na<sup>+</sup>-Cl<sup>-</sup>cotransporters in the early distal convoluted tubule is the mechanism of action of thiazide diuretics, which are used to treat hypertension, a common comorbidity in elderly patients.</li>\n<li>Inhibition of Na<sup>+</sup>-Cl<sup>-</sup>cotransporters in the early DCT can cause hyponatremia due to increased Na<sup>+</sup> Inhibition of Na<sup>+</sup> reabsorption by the early DCT also increases Na<sup>+</sup> delivery to the late DCT and early collecting tubule, which can cause hypokalemia and metabolic alkalosis due to increased K<sup>+</sup> and H<sup>+</sup> secretion in exchange for luminal Na<sup>+</sup> reabsorption. It also causes hypercalcemia due in part to increased Ca2<sup>+</sup> reabsorption at the proximal tubule as a result of increased extracellular fluid reabsorption in this segment.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Option A:</strong> Loop diuretics can lead to hyponatremia, hypokalemia, and <strong>hypocalcemia</strong>, not hypercalcemia. They increase luminal Na<sup>+</sup> in the late DCT/collecting duct, promoting H<sup>+</sup> and K<sup>+</sup> secretion, raising pH.</p>\n<p><strong>Option C:</strong> Osmotic diuretics (e.g., mannitol) increase plasma osmolality, pulling water extracellularly. This causes <strong>dilutional hyponatremia, hypocalcemia</strong>, and <strong>metabolic acidosis</strong>. Cell shrinkage causes <strong>K<sup>+</sup> efflux</strong>, leading to <strong>hyperkalemia</strong>.</p>\n<p><strong>Option D:</strong> Carbonic anhydrase inhibitors (e.g., acetazolamide) cause <strong>bicarbonate loss</strong>, leading to <strong>metabolic acidosis</strong>, <strong>hyponatremia</strong>, and <strong>hypokalemia</strong> due to Na+-linked HCO<sub>3</sub><sup>-</sup> excretion and distal Na<sup>+</sup>-K<sup>+</sup> exchange.</p>", "options": ["pH-Increased, Potassium-decreased, Calcium-decreased, Sodium-decreased", "pH-Increased, Potassium-decreased, Calcium-Increased, Sodium-decreased", "pH-decreased, Potassium-Increased, Calcium-decreased, Sodium-decreased", "pH-decreased, Potassium-decreased, Calcium-Normal, Sodium-decreased"], "html_options": ["pH-Increased, Potassium-decreased, Calcium-decreased, Sodium-decreased", "pH-Increased, Potassium-decreased, Calcium-Increased, Sodium-decreased", "pH-decreased, Potassium-Increased, Calcium-decreased, Sodium-decreased", "pH-decreased, Potassium-decreased, Calcium-Normal, Sodium-decreased"], "corr_idx": 1}, {"id": "1167333", "html_qtxt": "A 62-year-old woman presents with shortness of breath, lower extremity oedema, and a 4-kg weight gain. She has ischemic cardiomyopathy and rheumatoid arthritis. Therapy is initiated with intravenous furosemide. After 2 hours, urine output is minimal. Concomitant treatment with which of the following drugs is most likely to have contributed to treatment failure?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Furosemide is a loop diuretic that inhibits the Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> co-transporter in the thick ascending limb and enhances diuresis partly by stimulating <strong>renal prostaglandin E<sub>2</sub> release</strong>, which dilates afferent arterioles and improves renal perfusion.</li>\r\n<li><strong>NSAIDs like diclofenac inhibit prostaglandin synthesis via COX inhibition</strong>, blunting this vasodilatory response and reducing glomerular filtration, leading to diuretic resistance.</li>\r\n<li>In patients with volume overload or reduced renal perfusion (e.g., CHF), this NSAID-induced antagonism of furosemide action can be clinically significant and impair response.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Digoxin (Option A): </strong>Furosemide and digoxin are frequently co-administered in ischemic cardiomyopathy. Loop diuretics like furosemide may cause hypokalemia, enhancing digoxin's binding to myocardial Na<sup>+</sup>/K<sup>+</sup>-ATPase and raising the risk of digoxin toxicity (e.g., arrhythmias). However, digoxin does not reduce urine output or interfere with diuretic efficacy, making it an unlikely cause for diuretic resistance.</p>\r\n<p><strong>Prednisolone (Option C): </strong>Prednisolone, due to its mineralocorticoid activity, increases sodium reabsorption and promotes potassium/hydrogen excretion in renal tubules, potentially worsening loop diuretic-induced hypokalemia. This increases the risk of metabolic disturbances, but not diuretic failure. It does not inhibit prostaglandins or reduce urine output.</p>\r\n<p><strong>Infliximab (Option D): </strong>Infliximab is a TNF-&alpha; inhibitor used in rheumatoid arthritis. It does not alter renal prostaglandin synthesis or interact with furosemide action. It may increase infection risk, including TB reactivation, but has no known impact on diuretic efficacy or urine output.</p>", "options": ["Digoxin", "Diclofenac", "Prednisolone", "Infliximab"], "html_options": ["Digoxin", "Diclofenac", "Prednisolone", "Infliximab"], "corr_idx": 1}, {"id": "1167335", "html_qtxt": "A 60-year-old patient complains of paresthesias and occasional nausea associated with one of the drugs she is taking. She is found to have hyperchloremic metabolic acidosis. She is probably taking", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Acetazolamide is a carbonic anhydrase inhibitor that reduces HCO<sub>3</sub><sup>-</sup> reabsorption in the proximal tubule, leading to urinary bicarbonate loss and a hyperchloremic (normal anion gap) metabolic acidosis.</strong></p>\r\n<p>Chronic use is associated with paresthesias and gastrointestinal upset (e.g., nausea), especially in long-term treatments such as glaucoma.</p>\r\n<p>This metabolic disturbance and neurologic symptoms are classic clues pointing toward acetazolamide toxicity or side effects.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Amiloride (Option B): </strong>A potassium-sparing diuretic that typically causes hyperkalemia and does not lead to metabolic acidosis or paresthesias.</p>\r\n<p><strong>Furosemide (Option C): </strong>A loop diuretic that causes metabolic alkalosis due to increased H<sup>+</sup> and K<sup>+</sup> loss, not acidosis; ototoxicity, not paresthesias, is a notable side effect.</p>\r\n<p><strong>Hydrochlorothiazide (Option D): </strong>Causes hypokalemia and metabolic alkalosis; paresthesias and metabolic acidosis are not seen.</p>", "options": ["Acetazolamide for glaucoma", "Amiloride for edema associated with aldosteronism", "Furosemide for severe hypertension and heart failure", "Hydrochlorothiazide for hypertension"], "html_options": ["Acetazolamide for glaucoma", "Amiloride for edema associated with aldosteronism", "Furosemide for severe hypertension and heart failure", "Hydrochlorothiazide for hypertension"], "corr_idx": 0}, {"id": "1167338", "html_qtxt": "Which of the following diuretics would be most useful in the acute treatment of a comatose patient with traumatic brain injury and cerebral oedema?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Mannitol is an osmotic diuretic that increases plasma osmolality, drawing fluid from the intracellular to the extracellular space, including brain tissue, thereby reducing cerebral oedema and intracranial pressure.</li>\n<li>It is the first-line agent in acute neurologic emergencies such as traumatic brain injury with cerebral oedema due to its rapid onset and ability to reduce intracranial pressure effectively.</li>\n<li>Common adverse effects include volume expansion &rarr; hyponatremia/pulmonary oedema initially, followed by excessive diuresis &rarr; hypernatremia and hypovolemia.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403084422a4f6-8b03-46c7-a56f-ac03acf1b213.jpg\">\n</ul>\n<p>Stepwise increased ICP management</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308dba02419-3fc2-4559-83dd-1eff0ce14004.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acetazolamide (Option A): </strong>Carbonic anhydrase inhibitor used in glaucoma or altitude sickness; does not reduce cerebral oedema effectively.</p>\n<p><strong>Chlorthalidone (Option C): </strong>A thiazide-like diuretic, useful in chronic hypertension but ineffective for acute reduction of intracranial pressure.</p>\n<p><strong>Furosemide (Option D): </strong>A loop diuretic with some role in cerebral edema adjunctively, but slower and less effective than mannitol in acute management.</p>", "options": ["Acetazolamide", "Mannitol", "Chlorthalidone", "Furosemide"], "html_options": ["Acetazolamide", "Mannitol", "Chlorthalidone", "Furosemide"], "corr_idx": 1}, {"id": "1167357", "html_qtxt": "A 32-year-old man has a history of frequent episodes of renal colic with calcium-containing renal stones. A careful workup indicates that he has a defect in proximal tubular calcium reabsorption, which results in high concentrations of calcium salts in the tubular urine. The most useful diuretic agent in the treatment of recurrent calcium stones is", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Chlorthalidone is a thiazide diuretic that decreases calcium excretion in the urine by increasing calcium reabsorption in the distal convoluted tubule.</li>\n<li>This calcium-sparing effect helps prevent calcium-containing kidney stones, especially in patients with idiopathic hypercalciuria.</li>\n<li>It is considered the drug of choice for patients with recurrent calcium oxalate nephrolithiasis due to its ability to correct hypercalciuria.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Furosemide (Option B):</strong> Loop diuretics increase urinary calcium excretion and can exacerbate renal colic due to calcium stone formation.</p>\n<p><strong>Diazoxide (Option C):</strong> A thiazide-like vasodilator used in hypertension and insulinoma, but it has no diuretic action and may cause sodium retention; it doesn't help in stone prevention.</p>\n<p><strong>Spironolactone (Option D):</strong> Although it has diuretic activity, it does not reduce calcium excretion. It may cause endocrine side effects like gynecomastia, and has no role in preventing renal stone formation.</p>", "options": ["Chlorthalidone", "Furosemide", "Diazoxide", "Spironolactone"], "html_options": ["Chlorthalidone", "Furosemide", "Diazoxide", "Spironolactone"], "corr_idx": 0}, {"id": "1167359", "html_qtxt": "A 57-year-old woman with \"fainting spell\", her blood pressure is 120/60 when lying down and 60/20 when she sits up. Which of the following drugs is the most likely cause of her fainting spell?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Furosemide is a potent loop diuretic that can cause significant volume depletion, leading to orthostatic hypotension, especially in elderly patients.</p>\n<p>In this case, the large drop in systolic and diastolic pressures upon sitting is characteristic of postural hypotension, often due to over-diuresis.</p>\n<p>Additionally, furosemide-induced hypokalemia can predispose to arrhythmias, which may also contribute to fainting spells in susceptible individuals.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acetazolamide (Option A):</strong> Causes mild diuresis and metabolic acidosis, but it is less likely to cause significant volume depletion and postural hypotension.</p>\n<p><strong>Amiloride (Option B):</strong> A potassium-sparing diuretic with mild natriuretic effect; unlikely to cause orthostatic hypotension or significant volume depletion.</p>\n<p><strong>Hydrochlorothiazide (Option D):</strong> Though it causes potassium loss, it rarely leads to volume depletion sufficient to cause orthostatic hypotension, especially at usual doses.</p>", "options": ["Acetazolamide", "Amiloride", "Furosemide", "Hydrochlorothiazide"], "html_options": ["Acetazolamide", "Amiloride", "Furosemide", "Hydrochlorothiazide"], "corr_idx": 2}, {"id": "1167360", "html_qtxt": "A 45-year-old woman with lung cancer has abnormally low serum osmolality and hyponatremia. A drug that increases the formation of dilute urine and is used to treat SIADH is", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</strong> causes water retention, leading to <strong>euvolemic hyponatremia with low serum osmolality and inability to excrete dilute urine.</strong></li>\n<li><strong>Tolvaptan is a selective oral vasopressin V2 receptor antagonist that increases free water clearance</strong> (aquaresis), corrects serum sodium levels, and is indicated for the treatment of clinically significant hyponatremia.</li>\n<li><strong>Vaptans block the action of antidiuretic hormone (ADH) at renal collecting ducts.</strong> They are classified based on their route and receptor specificity:\n<ul>\n<li><strong>IV</strong>: Conivaptan (blocks both V1 and V2 receptors)</li>\n<li><strong>Oral</strong>: Tolvaptan (selective V2 receptor blocker)</li>\n<li><strong>V1 antagonist</strong>: Relcovaptan</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Amiloride (Option A):</strong> Potassium-sparing diuretic; may be used in lithium-induced nephrogenic diabetes insipidus, but is not effective in SIADH.</p>\n<p><strong>Desmopressin (Option B):</strong> A synthetic ADH analogue; would worsen SIADH by enhancing water reabsorption.</p>\n<p><strong>Mannitol (Option C):</strong> Osmotic diuretic; increases urine output but does not counteract ADH effects or correct serum sodium.</p>", "options": ["Amiloride", "Desmopressin", "Mannitol", "Tolvaptan"], "html_options": ["Amiloride", "Desmopressin", "Mannitol", "Tolvaptan"], "corr_idx": 3}, {"id": "1167365", "html_qtxt": "A 27-year-old girl with a history of major depression and bulimia is brought to the emergency department after a suicide attempt. She claims to have ingested several pills. She has also been very thirsty. Her temperature is 98&deg;F, blood pressure is 100/60 mm Hg, pulse is 110/min, and respirations are 14/min. Physical examination shows dry oral mucosa and reduced skin turgor.<br> Laboratory results are as follows:<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240308d380a45b-d174-489f-9a55-bf12ab9df9e5.jpg\"><br> Which of the following medications did this patient most likely ingest?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>As per the given clinical scenario, the patient has consumed a diuretic, which can cause hyponatremia, hypokalemia and hypercalcemia. Thiazide diuretics match the given description.</li>\r\n<li>Loop diuretics function by inhibiting the absorption of solutes within the thick ascending limb of Henle's loop, a process that is critical for maintenance of the corticomedullary concentration gradient. As a result, patients on loop diuretics are unable to maximally concentrate their urine and thus lose substantial amounts of both salt and water in the urine. In contrast, patients taking thiazides have a normal corticomedullary concentration gradient and are better able to retain free water in response to increased vasopressin levels. Thus, patients taking thiazide diuretics are more likely to retain free water and develop hyponatremia.</li>\r\n<li>Thiazide diuretics can also lead to hypercalcemia secondary to increased proximal and distal tubule Ca++ reabsorption.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Acetazolamide (Option A):</strong> Causes metabolic acidosis and hypokalemia, but typically <strong>does not cause hypercalcemia or significant hyponatremia</strong>.</p>\r\n<p><strong>Furosemide (Option B):</strong> Loop diuretic; causes <strong>hypocalcemia</strong>, not hypercalcemia. Also leads to volume depletion, hyponatremia, and hypokalemia, but is not consistent with the full electrolyte profile in this case.</p>\r\n<p><strong>Spironolactone (Option D):</strong> Potassium-sparing diuretic; causes <strong>hyperkalemia</strong> and <strong>hyponatremia</strong>, but <strong>not hypokalemia or hypercalcemia</strong> as seen here.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Acetazolamide (Option A):</strong> Induces <strong>natriuresis</strong> by inhibiting bicarbonate reabsorption in the <strong>proximal tubule</strong>, leading to <strong>metabolic acidosis</strong>, not alkalosis or hypercalcemia. Also, it is not associated with significant electrolyte disturbances like those seen in this patient.</p>\r\n<p><strong>Furosemide (Option B):</strong> Inhibits Ca<sup>2+</sup> reabsorption in the thick ascending limb, leading to <strong>hypocalcemia</strong>, not hypercalcemia. It also causes natriuresis and kaliuresis, but does not match the observed lab profile.</p>\r\n<p><strong>Spironolactone (Option D):</strong> Produces <strong>mild natriuresis</strong> by inhibiting Na<sup>+</sup> reabsorption in the <strong>cortical collecting tubule</strong>, reducing the luminal electronegative gradient. This <strong>reduces K<sup>+</sup> and H<sup>+</sup> secretion</strong>, leading to <strong>hyperkalemia and metabolic acidosis</strong>, the opposite of this patient's findings.</p>", "options": ["Acetazolamide", "Furosemide", "Hydrochlorothiazide", "Spironolactone"], "html_options": ["Acetazolamide", "Furosemide", "Hydrochlorothiazide", "Spironolactone"], "corr_idx": 2}, {"id": "1167372", "html_qtxt": "Which of the following diuretics will most likely result in afferent arteriole vasoconstriction?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Acetazolamide inhibits <strong>carbonic anhydrase</strong> in the <strong>proximal tubule</strong>, reducing HCO<sub>3</sub><sup>-</sup> and Na<sup>+</sup> reabsorption and increasing delivery of NaCl to the macula densa.</p>\n<p>The macula densa senses this elevated NaCl via <strong>Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> cotransporters (NKCC)</strong>, triggering <strong>tubuloglomerular feedback (TGF)</strong>.</p>\n<p>TGF causes <strong>afferent arteriole vasoconstriction</strong> and <strong>efferent arteriole dilation</strong>, thereby reducing GFR to limit further salt loss-this mimics a physiologic feedback mechanism used to autoregulate GFR.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Amiloride (Option B):</strong> Potassium-sparing diuretic that acts on the <strong>collecting duct</strong>, inhibits ENaC, and does not significantly influence macula densa or afferent arteriolar tone.</p>\n<p><strong>Furosemide (Option C):</strong> Inhibits NKCC2 in the thick ascending limb, <strong>blunts macula densa sensing</strong>, and may cause <strong>afferent vasodilation</strong>, the opposite effect.</p>\n<p><strong>Hydrochlorothiazide (Option D):</strong> Thiazide diuretic acting on the <strong>distal convoluted tubule</strong>, increases Na<sup>+</sup> excretion but does not significantly trigger TGF-mediated afferent constriction.</p>", "options": ["Acetazolamide", "Amiloride", "Furosemide", "Hydrochlorothiazide"], "html_options": ["Acetazolamide", "Amiloride", "Furosemide", "Hydrochlorothiazide"], "corr_idx": 0}, {"id": "1167379", "html_qtxt": "An investigator has designed a drug that acts on the kidneys to increase the urine flow rate. It is increasing the free water clearance (CH20) without affecting sodium or potassium excretion. This drug most likely blocks which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The net effects of vasopressin are mediated by its interaction with the three types of receptors, V1a, V1b, and V2. V2 receptors are primarily located in the principal cells of the renal collecting duct system, as well as on epithelial cells in the thick ascending limb, and on vascular endothelial cells. The drug in this question is blocking vasopressin type 2 (V2) receptors in the collecting duct, because it is increasing the free water clearance (CH20) without affecting sodium or potassium excretion.</li>\n<li>Free water clearance compares the osmolarity of the urine with plasma osmolarity; increased free water clearance occurs when very dilute urine is formed. Since vasopressin has little effect on sodium excretion, vasopressin antagonists tend to increase urine flow without increasing sodium excretion.</li>\n<li>Remember that antidiuretic hormone (ADH) or arginine vasopressin regulates serum osmolarity and blood pressure via the V2 and V1 receptors, respectively. ADH decreases serum osmolarity and increases urine osmolarity via regulation of aquaporin channel transcription in the apical membrane of the principal cells of the distal tubule and collecting ducts, leading to increased water permeability.</li>\n<li>Tolvaptan, for example, acts by selectively antagonising vasopressin V2 receptors, increasing free water excretion. It is indicated for the treatment of both euvolemic and hypervolemic hyponatremia that is symptomatic and resistant to correction with fluid restriction, including patients with heart failure and SIADH.</li>\n<li>Vaptans block the action of antidiuretic hormone (ADH) at renal collecting ducts. They are classified based on their route and receptor specificity:\n<ul>\n<li><strong>IV</strong>: Conivaptan (blocks both V1 and V2 receptors)</li>\n<li><strong>Oral</strong>: Tolvaptan (selective V2 receptor blocker)</li>\n<li><strong>V1 antagonist</strong>: Relcovaptan</li>\n</ul>\n</li>\n</ul>", "options": ["Carbonic anhydrase", "Na+ Cl- cotransporter", "Na+ K+ 2CI- cotransporter", "Vasopressin receptors"], "html_options": ["Carbonic anhydrase", "Na+ Cl- cotransporter", "Na+ K+ 2CI- cotransporter", "Vasopressin receptors"], "corr_idx": 3}, {"id": "1167386", "html_qtxt": "A 45-year-old man goitre undergoes a thyroidectomy. One week later, he develops carpopedal spasms, muscle and abdominal cramps, and tingling of his lips and hands. Laboratory studies show a serum calcium of 6.2 mg/dL and serum phosphorus of 5.7 mg/dL. Which of the following drugs will most likely improve this patient's symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient is presenting with signs and symptoms highly suggestive of hypoparathyroidism, a condition that occurs most frequently after thyroidectomy or the removal of a parathyroid adenoma. Hypoparathyroidism is a condition of parathyroid hormone (PTH) deficiency leading to decreased calcium levels and other electrolyte abnormalities.</li>\n<li>Normally, a fall in extracellular fluid ionised calcium concentration leads to stimulation of PTH secretion. When released, PTH enhances active reabsorption of calcium and magnesium from distal tubules and the thick ascending limb in the kidney, enhances the release of calcium from bones and enhances the absorption of calcium in the intestine by increasing the production of activated vitamin D. However, in hypoparathyroidism, PTH levels are greatly reduced, resulting in severe hypocalcemia.</li>\n<li>There are three principal reasons for low Ca2<sup>+</sup>in such cases\n<ul>\n<li>Low PTH reduces renal reabsorption of Ca<sup>++</sup>but increases reabsorption of phosphate.</li>\n<li>The resulting high plasma phosphate binds plasma Ca<sup>++</sup>, so plasma Ca<sup>++</sup> decreases.</li>\n<li>Low PTH causes low production of the active form of vitamin D, so Ca<sup>++</sup>absorption in the small intestine is decreased.</li>\n</ul>\n</li>\n<li>Hypoparathyroidism is characterised by severe hypocalcemia and hyperphosphatemia, resulting in tetany, carpopedal spasms, muscle and abdominal cramps, and tingling of the lips and hands. A positive Chvostek sign (tapping the face in front of the ear elicits tetany) and Trousseau sign (abnormal muscular contractions elicited by applying a blood pressure cuff) will often be noted.</li>\n<li>Since the blood calcium levels are often very low, either calcium gluconate or vitamin D preparations should be administered to correct the condition. Vitamin D preparations, such as Cholecalciferol, elevate calcium levels and also increase phosphate levels. Another treatment option would be to use the vitamin D3 analogue calcitriol. Calcitriol has a mechanism of action similar to that of cholecalciferol. Ergocalciferol is also used, but has a shorter duration and lower potency than cholecalciferol. Although further elevation of serum phosphate would be undesirable, vitamin D analogues are front-line therapy for hypoparathyroidism; phosphate levels may be addressed with phosphate binders or other measures.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Bumetanide (Option A): </strong>A loop diuretic that promotes calcium and potassium excretion; worsens hypocalcemia.</p>\n<p><strong>Levothyroxine (Option C): </strong>Replaces thyroid hormone, useful in hypothyroidism, not in managing hypocalcemia due to hypoparathyroidism.</p>\n<p><strong>Metolazone (Option D): </strong>A thiazide-like diuretic that reduces calcium excretion but is not sufficient as a standalone therapy in severe hypocalcemia due to hypoparathyroidism.</p>", "options": ["Bumetanide", "Cholecalciferol", "Levothyroxine", "Metolazone"], "html_options": ["Bumetanide", "Cholecalciferol", "Levothyroxine", "Metolazone"], "corr_idx": 1}, {"id": "1167393", "html_qtxt": "A 54-year-old man is presented with an acute onset of severe ocular pain and blurred vision that is associated with halos around lights. The painful episode began when he walked into a dark room. Ophthalmologic examination shows erythema of the left eye. Which of the following drugs is most appropriate for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The patient is presenting with <strong>acute angle-closure glaucoma</strong>, a medical emergency characterised by sudden eye pain, halos around lights, decreased vision, and a mid-dilated nonreactive pupil. Common in the elderly, hyperopes, and Asian individuals, it can be <strong>triggered by pupillary dilation</strong> (e.g., in dark rooms or after anticholinergic drugs).</li>\n<li><strong>Acetazolamide</strong>, a <strong>carbonic anhydrase inhibitor</strong>, is a <strong>first-line systemic agent</strong> in such cases. It works by <strong>decreasing bicarbonate production</strong> in the ciliary epithelium, thereby <strong>reducing aqueous humour formation</strong> and rapidly lowering intraocular pressure (IOP).</li>\n<li>Additional management includes <strong>IV mannitol</strong> (osmotic diuretic) and <strong>topical agents</strong> such as <strong>timolol</strong>, <strong>apraclonidine</strong>, and <strong>pilocarpine</strong>. These drugs are used to stabilise IOP while preparing the patient for <strong>laser peripheral iridotomy</strong>, the definitive treatment.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Epinephrine (Option B):</strong> Sympathomimetic with <strong>mydriatic effect</strong>, which can <strong>worsen angle closure</strong> by further narrowing the anterior chamber angle.</p>\n<p><strong>Latanoprost (Option C):</strong> A <strong>prostaglandin F2&alpha; analogue</strong> used for <strong>chronic open-angle glaucoma</strong>; it acts by increasing uveoscleral outflow, but is <strong>ineffective in acute angle-closure episodes</strong>.</p>\n<p><strong>Scopolamine (Option D):</strong> A <strong>potent anticholinergic</strong> that <strong>dilates the pupil</strong> and can <strong>precipitate or exacerbate</strong> acute angle-closure glaucoma in predisposed individuals.</p>", "options": ["Acetazolamide", "Epinephrine", "Latanoprost", "Scopolamine"], "html_options": ["Acetazolamide", "Epinephrine", "Latanoprost", "Scopolamine"], "corr_idx": 0}, {"id": "1167404", "html_qtxt": "<p>A 72-year-old woman is presented with periorbital oedema, a maculopapular rash on her chest, and a fever of 101&deg;F. She has a history of hypertension, diabetes, and osteoarthritis. Laboratory studies of serum show:<br>1. Sodium = 139 mEq/L<br>2. Potassium = 4.8 mEq/L<br>3. Chloride = 100 mEg/L<br>4. Bicarbonate = 24 mEq/L<br>5. BUN =58 mg/dL<br>6. Creatinine = 3.1 mg/dL<br>Urinalysis shows mild proteinuria and eosinophils. Which of the following drugs is most likely responsible for the findings seen in this patient?</p>", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with the classic triad of <strong>fever, rash, and eosinophiluria</strong> along with acute kidney injury (elevated BUN and creatinine), which strongly suggests <strong>acute interstitial nephritis (AIN)</strong>.</p>\n<p><strong>AIN is most often caused by a hypersensitivity reaction to drugs</strong>, especially <strong>NSAIDs like ibuprofen</strong>, antibiotics (e.g., penicillins, cephalosporins, sulfonamides), diuretics (e.g., furosemide, thiazides), and others such as phenytoin, cimetidine, allopurinol, and PPIs.</p>\n<p>NSAIDs not only cause hypersensitivity-induced AIN but can also lead to <strong>hemodynamically-mediated renal failure</strong> by inhibiting <strong>prostaglandin synthesis</strong>. This impairs renal vasodilation, especially dangerous in <strong>volume-depleted states or comorbidities</strong> like <strong>diabetes, heart failure, cirrhosis</strong>, or <strong>elderly age</strong>, where prostaglandins are vital for maintaining renal perfusion.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acarbose (Option A):</strong> Alpha-glucosidase inhibitor used for postprandial hyperglycemia in diabetes; does <strong>not cause nephritis</strong> or renal impairment.</p>\n<p><strong>Clonidine (Option B):</strong> Centrally acting alpha-2 agonist for hypertension; adverse effects include sedation and rebound hypertension, <strong>not AIN or AKI</strong>.</p>\n<p><strong>Diltiazem (Option C):</strong> Non-dihydropyridine calcium channel blocker; may cause bradycardia or constipation, but <strong>AIN is not a known side effect</strong>.</p>", "options": ["Acarbose", "Clonidine", "Diltiazem", "Ibuprofen"], "html_options": ["Acarbose", "Clonidine", "Diltiazem", "Ibuprofen"], "corr_idx": 3}, {"id": "1167410", "html_qtxt": "A 78-year-old man with primary hyperparathyroidism and heart failure is brought in because of progressive difficulty breathing and a weight gain of 2 kg over the past week. Physical examination shows jugular venous distention, ales are heard bilaterally on auscultation of the chest, and there is 3+ bilateral pitting oedema of the ankles. Which of the following diuretics is contraindicated for use in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient has a history of <strong>primary hyperparathyroidism</strong>, characterised by unregulated overproduction of parathyroid hormone (PTH) and <strong>abnormally elevated serum calcium</strong>. The classical manifestations can be remembered as:</li>\n<li><strong>\"Bones\" (cortical bone loss), \"Stones\" (renal stones), \"Abdominal groans\" (constipation), and \"Psychic moans\" (depression).</strong></li>\n<li><strong>Thiazide diuretics</strong>, which inhibit the NaCl transporter in the distal convoluted tubule (DCT), are known to <strong>enhance calcium reabsorption</strong>. This occurs due to increased activity of the <strong>basolateral Na<sup>+</sup>/Ca<sup>2+</sup> exchanger</strong>, which is stimulated as a secondary effect of sodium loss in the DCT.</li>\n<li>Although thiazides rarely cause significant hypercalcemia in normal individuals, they can <strong>exacerbate hypercalcemia in patients with underlying causes such as primary hyperparathyroidism</strong>, and are therefore contraindicated in such patients.</li>\n<li>In contrast, <strong>loop diuretics</strong> such as furosemide promote <strong>calcium excretion</strong> and are the first-line agents for <strong>volume overload in heart failure</strong>.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aldosterone antagonists (Option A):</strong> Used in heart failure with reduced ejection fraction. They help reduce mortality and are potassium-sparing; they <strong>do not increase calcium</strong> levels.</p>\n<p><strong>Carbonic anhydrase inhibitors (Option B):</strong> Mild diuretics (e.g., acetazolamide) acting in the proximal tubule, often used in glaucoma or metabolic alkalosis. <strong>Do not significantly affect calcium</strong> balance.</p>\n<p><strong>Loop diuretics (Option C):</strong> First-line agents in acute decompensated heart failure. Inhibit Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> cotransporter in the thick ascending limb and promote <strong>calcium excretion</strong>, making them <strong>preferred in hypercalcemia</strong>.</p>", "options": ["Aldosterone antagonists", "Carbonic anhydrase inhibitors", "Loop diuretics", "Thiazides"], "html_options": ["Aldosterone antagonists", "Carbonic anhydrase inhibitors", "Loop diuretics", "Thiazides"], "corr_idx": 3}, {"id": "1167414", "html_qtxt": "A 65-year-old man comes in with shortness of breath on exertion. Physical examination shows bilateral 2+ pitting oedema of the lower limbs, and faint crackles are heard on auscultation of the chest. Treatment begins with a drug. A few days later, the man returns to the physician because of muscle weakness. Laboratory studies show:<br> Arterial PCO<sub>2</sub>  = 48 mm Hq:<br> Arterial pH = 7.49:<br> Plasma HCO<sub>3</sub> = 35 mEq/L:<br> Which of the following is most likely decreased in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>The data indicate that the man has developed metabolic alkalosis (increased PCO2, pH). This patient has developed <strong>metabolic alkalosis</strong>, evidenced by <strong>elevated pH</strong>, <strong>elevated bicarbonate (HCO<sub>3</sub><sup>-</sup>)</strong>, and <strong>compensatory elevation of PCO<sub>2</sub></strong> (hypoventilation). This is a <strong>classical complication of loop or thiazide diuretic overuse</strong>, which are commonly prescribed for <strong>congestive heart failure (CHF)</strong> with volume overload.</li>\r\n</ul>\r\n<p>Loop diuretics (e.g., furosemide) act by inhibiting the <strong>Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> cotransporter</strong> in the <strong>thick ascending limb</strong> of Henle&rsquo;s loop. This leads to:</p>\r\n<ul>\r\n<li><strong>&uarr; distal sodium delivery</strong></li>\r\n<li><strong>&uarr; Potassium and hydrogen ion loss</strong> in the <strong>collecting duct</strong> due to compensatory exchange mechanisms</li>\r\n<li><strong>Metabolic alkalosis</strong> (from hydrogen ion loss)</li>\r\n<li><strong>Hypokalemia</strong> (from excessive renal potassium loss)</li>\r\n</ul>\r\n<p>Therefore, the most likely <strong>decreased parameter is plasma potassium</strong>, which can also explain the patient's <strong>muscle weakness</strong> (classic symptom of hypokalemia).</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Plasma angiotensin (Option A):</strong> Would be increased due to volume depletion from diuretic-induced natriuresis, triggering RAAS activation.</p>\r\n<p><strong>Potassium excretion (Option C):</strong> Would be <strong>increased</strong>, not decreased, due to elevated distal Na<sup>+</sup> delivery and aldosterone activation.</p>\r\n<p><strong>Sodium excretion (Option D):</strong> Is <strong>increased</strong> as the primary effect of loop and thiazide diuretics is to block sodium reabsorption.</p>", "options": ["Plasma angiotensin", "Plasma potassium", "Potassium excretion", "Sodium excretion"], "html_options": ["Plasma angiotensin", "Plasma potassium", "Potassium excretion", "Sodium excretion"], "corr_idx": 1}, {"id": "1167417", "html_qtxt": "A 26-year-old woman is brought in because of a crush injury. Physical examination shows multiple bruises on the lower abdomen and thighs. Two days later, she developed generalised oedema. Laboratory studies show a rise in creatinine from 1.0 to 4.0 mg/dL. She is aggressively hydrated, but remains oliguric. Which of the following drugs is most likely contraindicated in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient has developed <strong>acute kidney injury (AKI)</strong>, as evidenced by the rise in creatinine and oliguria (<400 mL/day). The underlying cause appears to be <strong>rhabdomyolysis</strong> secondary to crush injury. In rhabdomyolysis, intracellular contents such as <strong>myoglobin, potassium, phosphate</strong>, and <strong>uric acid</strong> are released into circulation, leading to tubular obstruction and <strong>direct nephrotoxicity</strong>.</p>\n<p>A major complication of AKI is <strong>hyperkalemia</strong>, due to reduced excretion and massive potassium release from injured muscle cells.</p>\n<p><strong>Spironolactone</strong>, a potassium-sparing diuretic, blocks aldosterone receptors in the distal nephron, leading to <strong>sodium excretion and potassium retention</strong>. In the setting of AKI, where potassium levels are already high, spironolactone can <strong>exacerbate hyperkalemia</strong> and provoke life-threatening arrhythmias. Hence, it is <strong>contraindicated</strong> in this context.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acetazolamide (Option A):</strong> Carbonic anhydrase inhibitor; not commonly used in AKI but does not worsen hyperkalemia.</p>\n<p><strong>Furosemide (Option B):</strong> Loop diuretic that promotes potassium excretion; may be cautiously used to manage volume overload in oliguric AKI.</p>\n<p><strong>Hydrochlorothiazide (Option C):</strong> Thiazide diuretic; generally ineffective in advanced renal dysfunction but does not cause potassium retention.</p>", "options": ["Acetazolamide", "Furosemide", "Hydrochlorothiazide", "Spironolactone"], "html_options": ["Acetazolamide", "Furosemide", "Hydrochlorothiazide", "Spironolactone"], "corr_idx": 3}, {"id": "1167425", "html_qtxt": "A 47-year-old man comes in because of an increase in the size of his breasts over the past two months. He has a longstanding history of hypertension and congestive heart failure. Which of the following best describes the mechanism of action of the drug most likely responsible for the increase in the size of the breasts in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The patient is experiencing gynecomastia, which is relatively common in men as they age and may be related to the extra-glandular conversion of androgens to estrogen. A variety of pathological and drug-related causes can also promote the development of this condition. Causes of gynecomastia include:\n<ul>\n<li>Deficient production or action of testosterone</li>\n<li>Renal failure</li>\n<li>Increased estrogen production (as a result of various tumours)</li>\n<li>Liver disease</li>\n<li>Drug-induced</li>\n</ul>\n</li>\n<li>Medications Associated with Gynecomastia Development:&nbsp;<strong>(DISCKO)</strong>\n<ul>\n<li>Spironolactone</li>\n<li>Digoxin</li>\n<li>Cimetidine</li>\n<li>Alcohol</li>\n<li>Ketoconazole</li>\n<li>Estrogens</li>\n<li>Omeprazole</li>\n<li>Calcium-channel blockers</li>\n</ul>\n</li>\n<li>Each of the answer choices in this question represents the mechanism of action for five different classes of medications that can be used to treat hypertension and/or heart failure.</li>\n<li>Spironolactone is a \"potassium-sparing\" diuretic that acts primarily as a competitive inhibitor of aldosterone receptors in the distal segments [distal convoluted tubule, connecting tubule, and collecting tubule (also known as the collecting duct)]. It is used to treat oedema, hypertension, primary hyperaldosteronism, diuretic-induced hypokalemia and NYHA Class III/IV heart failure, as well as idiopathic hirsutism and acne vulgaris. (Remember, one of the primary functions of aldosterone is to increase sodium reabsorption in principal cells of the kidney, which plays a key role in regulating extracellular volume. Aldosterone helps to regulate plasma potassium. The two primary factors that stimulate aldosterone release are plasma angiotensin II and plasma potassium levels.)</li>\n<li>Spironolactone may cause gynecomastia by displacing androgen from the androgen receptor and sexual-hormone-binding globulin, and by causing increased metabolic clearance of testosterone and higher estradiol production. None of the other choices has gynecomastia as a side effect. Spironolactone also causes hyperkalemia and acidosis.</li>\n</ul>", "options": ["Antagonizes collecting tubule aldosterone receptors", "Inhibits distal convoluted tubule sodium and chloride resorption", "Inhibits loop of Henle and proximal and distal convoluted tubule sodium and chloride resorption", "Inhibits the conversion of angiotensin I to angiotensin Il"], "html_options": ["Antagonizes collecting tubule aldosterone receptors", "Inhibits distal convoluted tubule sodium and chloride resorption", "Inhibits loop of Henle and proximal and distal convoluted tubule sodium and chloride resorption", "Inhibits the conversion of angiotensin I to angiotensin Il"], "corr_idx": 2}, {"id": "1167429", "html_qtxt": "A 54-year-old man comes with severe pain with tenderness in his first metatarsophalangeal joint. He says that the pain was so bad that it woke him up from sleep. Which of the following drugs is the most likely cause of this patient's symptoms?<br> Laboratory studies show WBC count is 12 &times; 103/mL, creatinine is 1.0 mg/dL, calcium is 8.6 mg/dL, and uric acid is 9.5 mg/dL.", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient presents with acute gouty arthritis (AGA), classically involving the first metatarsophalangeal (MTP) joint with intense pain and swelling, especially at night. His elevated serum uric acid (9.5 mg/dL) and symptoms point to a gout flare.</p>\n<p>Hydrochlorothiazide, a thiazide diuretic, is a common cause of hyperuricemia. It reduces urate excretion by enhancing reabsorption in the proximal tubule, leading to increased serum uric acid levels and predisposing to gout.</p>\n<p><strong>Mnemonic: THe NIce PYRAmid drugs cause gout</strong></p>\n<ul>\n<li><strong>Thiazides (+ loop diuretics)</strong></li>\n<li><strong>Niacin</strong></li>\n<li><strong>Pyrazinamide</strong></li>\n<li><strong>Aspirin (low dose)</strong></li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aripiprazole (Option A):</strong> Atypical antipsychotic with no known association with hyperuricemia or gout.</p>\n<p><strong>Enalapril (Option B):</strong> ACE inhibitor; can cause hyperkalemia or dry cough, but does not raise uric acid.</p>\n<p><strong>Pravastatin (Option D): </strong>Statin used for hyperlipidemia; not associated with uric acid metabolism or gout.</p>", "options": ["Aripiprazole", "Enalapril", "Hydrochlorothiazide", "Pravastatin"], "html_options": ["Aripiprazole", "Enalapril", "Hydrochlorothiazide", "Pravastatin"], "corr_idx": 2}]}, {"moduleId": 1008538, "name": "Autacoids (Part 1)", "questions": [{"id": "1166544", "html_qtxt": "A 20-year-old woman is taking diphenhydramine for severe hay fever. Which of the following adverse effects is she most likely to report?", "html_expl": "<p><strong>Explanation:<br /></strong> Diphenhydramine is a <strong>first-generation H1 receptor antagonist</strong>, widely used for allergic conditions such as hay fever. It is <strong>lipophilic</strong>, allowing it to cross the blood-brain barrier easily, and thus exerts significant <strong>CNS effects</strong>, the most prominent of which is <strong>sedation</strong>.</p>\n<ul>\n<li>These older antihistamines <strong>block both H1 receptors</strong> and <strong>muscarinic (M3) receptors</strong>, contributing to their <strong>anticholinergic side effects</strong> (e.g., dry mouth, urinary retention, constipation), but sedation remains the <strong>most commonly reported adverse effect</strong>.</li>\n<li>Due to their sedative property, first-generation H1 blockers like diphenhydramine are <strong>not recommended before driving or operating heavy machinery</strong>.</li>\n<li>In contrast, <strong>second-generation antihistamines</strong> such as cetirizine, fexofenadine, and loratadine are <strong>less lipid-soluble</strong>, and hence, have <strong>minimal sedative effects</strong></li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Muscarinic increase in bladder tone (Option A): </strong>Diphenhydramine <strong>blocks muscarinic receptors</strong>, which actually leads to <strong>decreased bladder tone</strong> and can cause <strong>urinary retention</strong>, especially in elderly males with prostatic hypertrophy.</p>\n<p><strong>Nausea (Option B): </strong>While nausea can occur with many drugs, it is <strong>not a characteristic or prominent adverse effect</strong> of diphenhydramine. In fact, some first-generation antihistamines like meclizine are <strong>used to treat nausea and motion sickness</strong>.</p>\n<p><strong>Nervousness, anxiety (Option C): </strong>Diphenhydramine <strong>does not typically cause CNS stimulation</strong>; rather, it causes <strong>CNS depression</strong>, leading to sedation. Nervousness or anxiety is more likely with stimulants or decongestants like pseudoephedrine.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Comparison of Antihistaminic Agents:</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509054a37c1dc-f4e0-416f-991b-2422fd0cbeed.png\">", "options": ["Muscarinic increase in bladder tone", "Nausea", "Nervousness, anxiety", "Sedation"], "html_options": ["Muscarinic increase in bladder tone", "Nausea", "Nervousness, anxiety", "Sedation"], "corr_idx": 3}, {"id": "1166584", "html_qtxt": "A 67-year-old man presents with sneezing and clear nasal discharge. He reports similar episodes in the past. His medical history includes benign prostatic hyperplasia (BPH), for which he is on tamsulosin. Examination of the nasal cavity shows red, swollen turbinates. Which of the following is the most appropriate pharmacotherapy for this patient's condition?", "html_expl": "<p><strong>Explanation:<br /> </strong> The patient presents with <strong>allergic rhinitis</strong>, characterized by <strong>recurrent sneezing, clear nasal discharge, and swollen nasal turbinates</strong>. This is an IgE-mediated hypersensitivity reaction to environmental allergens.</p>\n<p>The treatment of choice is <strong>H1 receptor antagonists</strong>. However, due to the patient's history of benign prostatic hyperplasia (BPH), it is important to select agents that do not worsen urinary retention.</p>\n<ul>\n<li><strong>First-generation H1 blockers</strong> like diphenhydramine have <strong>significant anticholinergic effects</strong>, which can worsen BPH by causing urinary retention.</li>\n<li><strong>Second-generation H1 blockers</strong> such as <strong>desloratadine</strong>, <strong>loratadine</strong>, <strong>fexofenadine</strong>, and <strong>cetirizine</strong> are preferred because:\n<ul>\n<li>They are <strong>less sedating</strong> (they do not cross the blood-brain barrier due to their ionized nature at physiologic pH)</li>\n<li>They <strong>lack significant anticholinergic activity</strong>, making them safer in elderly patients or those with comorbidities like BPH.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Theophylline (Option B) </strong>is a methylxanthine bronchodilator used to treat <strong>acute exacerbations of asthma, </strong>particularly in patients with <strong>atopic conditions</strong> like allergic rhinitis. However, it is <strong>not indicated for isolated allergic rhinitis </strong>and does not relieve nasal symptoms such as sneezing or rhinorrhea.</p>\n<p><strong>Diphenhydramine (Option C)</strong> is a first-generation H1 antihistamine, effective in treating <strong>allergic rhinitis.</strong> However, it has <strong>strong anticholinergic effects,</strong> which can lead to urinary retention, a significant concern in patients with BPH. In such patients, it is contraindicated, and a second-generation antihistamine with minimal anticholinergic action is preferred.</p>\n<p><strong>Nizatidine (Option D) </strong>is an <strong>H2 receptor antagonist,</strong> primarily used to reduce gastric acid secretion in conditions like <strong>peptic ulcer disease, gastritis, or GERD.</strong> It has no role in the treatment of allergic rhinitis.</p>", "options": ["Desloratadine", "Theophylline", "Diphenhydramine", "Nizatidine"], "html_options": ["Desloratadine", "Theophylline", "Diphenhydramine", "Nizatidine"], "corr_idx": 0}, {"id": "1166588", "html_qtxt": "A 34-year-old man presents with generalized pruritus and raised, erythematous plaques on the skin, 30 minutes after eating at a seafood restaurant. Four months ago, he had an episode of narrow-angle glaucoma. Which of the following is the most appropriate pharmacotherapy?", "html_expl": "<p><strong>Explanation:<br /> </strong>This patient presents with <strong>acute urticaria</strong> and <strong>generalized pruritus</strong> shortly after ingestion of seafood, suggesting a <strong>type I hypersensitivity reaction</strong> (IgE-mediated food allergy). The standard treatment includes <strong>H1-antihistamines</strong>.</p>\n<p>However, in this case, the <strong>past history of narrow-angle glaucoma</strong> is a critical factor influencing drug selection. Many <strong>first-generation antihistamines</strong> (e.g., diphenhydramine, chlorpheniramine) have <strong>anticholinergic properties</strong> that can <strong>induce mydriasis</strong>, narrowing the iridocorneal angle and potentially precipitating <strong>acute angle-closure glaucoma</strong>.</p>\n<p><strong>Fexofenadine is a second-generation H1-antihistamine that is:</strong></p>\n<ul>\n<li>Effective in managing allergic reactions</li>\n<li>Free from significant anticholinergic activity</li>\n<li>Non-sedating</li>\n<li>Safe in patients with pre-existing glaucoma, BPH, or pyloric stenosis</li>\n</ul>\n<p>Thus, <strong>fexofenadine is the most appropriate pharmacotherapy</strong> in this scenario.</p>\n<p><strong>Common contraindications for first-generation antihistamines include:</strong></p>\n<ul>\n<li>Benign prostatic hyperplasia (BPH)</li>\n<li>Angle-closure glaucoma</li>\n<li>Pyloric stenosis<strong><br /> </strong></li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Chlorpheniramine (Option A): </strong>A <strong>first-generation H1-antihistamine</strong>. While it is commonly used for allergic conditions, it has <strong>significant anticholinergic side effects</strong>, including mydriasis, which can <strong>trigger acute angle-closure in glaucoma</strong>. Hence, contraindicated in this patient.</p>\n<p><strong>Calamine lotion (Option B):</strong> A <strong>topical antipruritic</strong> used for conditions such as chickenpox, xerosis, or sunburn. It may relieve surface itching, but is <strong>not effective in treating the underlying systemic allergic reaction</strong>, especially in cases like food allergy.</p>\n<p><strong>Vitamin K (Option C):</strong> Occasionally used for <strong>pruritus related to cholestasis or liver disease</strong>, but this patient has <strong>no evidence of hepatic dysfunction</strong> (e.g., jaundice, hepatomegaly, RUQ pain). It has no role in allergy management.</p>", "options": ["Chlorpheniramine", "Calamine lotion", "Vitamin K", "Fexofenadine"], "html_options": ["Chlorpheniramine", "Calamine lotion", "Vitamin K", "Fexofenadine"], "corr_idx": 3}, {"id": "1166592", "html_qtxt": "Match the following histamine receptors with their corresponding post-receptor signaling mechanisms:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509056568948d-678f-4473-9b23-03900d999080.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Histamine and Serotonin Receptor Subtypes:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905bfb548f3-3ce4-4570-9a48-7f962f82030c.png\">", "options": ["1-a; 2-b; 3-c", "1-a; 2,3-b; 4-c", "1,2-a; 3-b; 4-c", "1,4-a; 2-b; 3-c"], "html_options": ["1-a; 2-b; 3-c", "1-a; 2,3-b; 4-c", "1,2-a; 3-b; 4-c", "1,4-a; 2-b; 3-c"], "corr_idx": 0}, {"id": "1166595", "html_qtxt": "A laboratory study of new H<sub>2</sub> blockers is planned. Which of the following will result from the blockade of H<sub>2</sub> receptors?", "html_expl": "<p><strong>Explanation:<br /> H<sub>2</sub> receptors</strong> are <strong>Gs protein-coupled receptors</strong> predominantly found in the <strong>gastric parietal cells</strong>, where their activation by histamine stimulates <strong>adenylyl cyclase</strong>, leading to <strong>increased intracellular cAMP</strong> and subsequent <strong>acid secretion</strong>.</p>\n<ul>\n<li><strong>Blockade</strong> of H<sub>2</sub> receptors (e.g., by cimetidine or ranitidine) <strong>inhibits this Gs-mediated pathway</strong>, resulting in <strong>decreased cAMP levels</strong>, thereby <strong>reducing gastric acid secretion</strong>.</li>\n<li>This mechanism is the basis for the use of <strong>H<sub>2</sub> receptor antagonists</strong> in the treatment of <strong>peptic ulcers</strong> and <strong>GERD</strong>.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Increased cAMP in cardiac muscle (Option A):</strong> <strong>H<sub>2</sub> receptors</strong> in the heart <strong>increase cAMP</strong> via Gs when stimulated. <strong>Blockade</strong> would <strong>reduce</strong>, not increase, cAMP levels.</p>\n<p><strong>Decreased channel opening in enteric nerves (Option B): </strong>This refers more to <strong>5-HT<sub>2</sub> receptors</strong>, which are <strong>ligand-gated ion channels</strong> found in <strong>sensory and enteric nerves</strong>, not H<sub>2</sub> receptors.</p>\n<p><strong>Increased IP<sub>3</sub> in platelets (Option D): </strong>Platelet activation is mediated via <strong>5-HT<sub>2</sub> receptors</strong>, which are Gq-coupled and increase IP<sub>3</sub>. H<sub>2</sub> receptors are <strong>not</strong> involved in platelet activation.</p>\n<p><strong>Key Takeaway:</strong> </p>\n<p>Histamine and Serotonin Receptor Subtypes:</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509050dc45b4f-2a2e-469a-9be4-f80636ea11f8.png\">", "options": ["Increased cAMP in cardiac muscle", "Decreased channel opening in enteric nerves", "Decreased cAMP in the gastric mucosa", "Increased IP<sub>3</sub> in platelets"], "html_options": ["Increased cAMP in cardiac muscle", "Decreased channel opening in enteric nerves", "Decreased cAMP in the gastric mucosa", "Increased IP<sub>3</sub> in platelets"], "corr_idx": 2}, {"id": "1166601", "html_qtxt": "A 27-year-old woman, G1P0 at 8 weeks' gestation, presents with progressively worsening emesis and nausea, along with a 2-kg weight loss over the past 2 weeks. She reports vomiting 3-4 times daily. She is currently taking ginger and vitamin B6 with minimal relief. On examination, her abdomen is soft and non-tender. Urinalysis is normal, and hematocrit is 40%. In addition to oral fluid resuscitation, which of the following is the most appropriate next step in management?", "html_expl": "<p><strong>Explanation:<br /> </strong>This patient presents with <strong>nausea and vomiting of pregnancy (NVP)</strong>, commonly known as <strong>morning sickness</strong>, in the first trimester. Her symptoms are <strong>moderate</strong>, without signs of <strong>severe dehydration</strong> or <strong>electrolyte imbalance</strong>, and she has already started first-line therapy with <strong>vitamin B6 (pyridoxine)</strong>.</p>\n<ul>\n<li>When pyridoxine alone is <strong>not sufficient</strong>, the recommended next step is to <strong>add doxylamine</strong>, an H1 antihistamine, which in combination with B6 forms the <strong>first-line pharmacologic therapy</strong> for NVP, recommended by <strong>ACOG</strong>.</li>\n<li>This combination is both <strong>safe in pregnancy</strong> and effective in reducing mild to moderate nausea and vomiting.</li>\n</ul>\n<p>Other supportive measures include:</p>\n<ul>\n<li>Dietary adjustments (e.g., bland food, small frequent meals)</li>\n<li>Avoidance of triggers (e.g., odors, warm environments)</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Metoclopramide (Option A):</strong> This dopamine antagonist is typically used as a <strong>second-line agent</strong> for NVP <strong>after</strong> failure of pyridoxine and doxylamine. It is more appropriate in cases of <strong>moderate to severe</strong> NVP or <strong>hyperemesis gravidarum</strong>.</p>\n<p><strong>Bismuth subsalicylate (Option C):</strong> This is <strong>contraindicated in pregnancy</strong> due to the <strong>salicylate component</strong>, which may cross the placenta and cause fetal harm, including premature closure of the ductus arteriosus and bleeding complications.</p>\n<p><strong>IV fluid (Option D): </strong>This patient <strong>does not show signs of dehydration</strong> or electrolyte imbalance. IV fluid rehydration is reserved for <strong>hyperemesis gravidarum</strong>, or when oral hydration fails or is not tolerated.</p>", "options": ["Metoclopramide", "Doxylamine", "Bismuth subsalicylate", "IV fluid"], "html_options": ["Metoclopramide", "Doxylamine", "Bismuth subsalicylate", "IV fluid"], "corr_idx": 1}, {"id": "1166604", "html_qtxt": "A 10-year-old girl is brought to the physician because of occasional severe, throbbing headaches, usually after playing cricket. The headache is located in the right frontotemporal region. Which of the following is the most appropriate next step in management?", "html_expl": "<p><strong>Explanation:<br /> </strong></p>\n<p>The patient presents with <strong>recurrent, unilateral, throbbing headaches</strong>, often triggered by physical exertion, which is <strong>typical of migraine without aura</strong> in children. The absence of red flag features (e.g., fever, altered sensorium, focal neurological signs, or meningeal irritation) supports a primary headache diagnosis, most likely <strong>pediatric migraine</strong>.</p>\n<ul>\n<li>In <strong>children</strong>, the <strong>first-line </strong>abortive therapy for acute migraine includes <strong>paracetamol </strong>or <strong>NSAIDs</strong> (e.g., ibuprofen), which are both effective and have a <strong>favorable safety profile</strong>.</li>\n<li>Treatment should be <strong>initiated early</strong>, ideally <strong>at the onset of symptoms</strong>, for maximal efficacy.</li>\n</ul>\n<p><strong>Lifestyle advice</strong>, including adequate hydration, proper sleep hygiene, and avoidance of known triggers (e.g., exertion, dehydration), is also essential at this stage.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Sumatriptan (Option B): </strong>Triptans (e.g., sumatriptan) are reserved for <strong>moderate to severe migraines</strong> or <strong>failure of NSAIDs/acetaminophen</strong>. Their use in children is more restricted due to potential side effects and limited pediatric approval.</p>\n<p><strong>Dihydroergotamine (Option C)</strong> is a <strong>second-line abortive medication</strong>, used only when standard abortive therapies (acetaminophen, NSAIDs, or triptans) fail. It also carries a <strong>higher side-effect burden</strong>.</p>\n<p><strong>Amitriptyline (Option D) </strong>is used for migraine<strong> prophylaxis</strong>, particularly when attacks are <strong>frequent, prolonged,</strong> or disabling, and abortive therapy has<strong> failed</strong>. It is <strong>not indicated</strong> for initial management.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p>Triptans vs Ergotamine</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905f6803426-d84b-43dd-bbee-1f5e69199a9c.png\">", "options": ["Paracetamol", "Sumatriptan", "Dihydroergotamine", "Amitriptyline"], "html_options": ["Paracetamol", "Sumatriptan", "Dihydroergotamine", "Amitriptyline"], "corr_idx": 0}, {"id": "1166608", "html_qtxt": "The hospital pharmacy committee is preparing a formulary for staff use. Which of the following is a correct application of the drug mentioned?", "html_expl": "<p><strong>Explanation:<br /> Cetirizine</strong> is a <strong>second-generation H1 antihistamine</strong>, commonly used to treat <strong>allergic rhinitis (hay fever)</strong>, urticaria, and other allergic conditions.</p>\n<ul>\n<li>It has minimal sedative effects due to its <strong>poor penetration across the blood-brain barrier</strong>.</li>\n<li>Cetirizine selectively blocks <strong>peripheral H1 receptors</strong>, reducing symptoms like rhinorrhea, sneezing, and itchy eyes.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Option A: Alosetron</strong> is a <strong>selective 5-HT<sub>3</sub> receptor antagonist</strong>, indicated <strong>only for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D)</strong> unresponsive to conventional therapy. It is <strong>not used for obstetric bleeding</strong>, and serious adverse effects include <strong>constipation</strong> and rare <strong>ischemic colitis</strong>.</p>\n<p><strong>Option C: Ergonovine (ergometrine)</strong> is an <strong>ergot alkaloid</strong> used to control <strong>postpartum uterine bleeding</strong> by causing uterine contraction. It has <strong>no role in Alzheimer's disease</strong>.</p>\n<p><strong>Option D: Ondansetron</strong> is a <strong>5-HT<sub>3</sub> receptor antagonist</strong> used primarily for <strong>nausea and vomiting</strong> associated with <strong>chemotherapy, radiation, or postoperative recovery</strong>. While not typically used for acute migraine (triptans are preferred), it may be adjunctively used for <strong>migraine-associated nausea</strong>, but it is <strong>not the primary drug</strong> for migraine treatment.</p>\n<p><strong>Key Takeaway:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905a63febe9-73fe-4f32-922c-b8a2df837b3d.png\">", "options": ["Alosetron - for obstetric bleeding", "Cetirizine - for hay fever", "Ergonovine - for Alzheimer's disease", "Ondansetron - for acute migraine headache"], "html_options": ["Alosetron - for obstetric bleeding", "Cetirizine - for hay fever", "Ergonovine - for Alzheimer's disease", "Ondansetron - for acute migraine headache"], "corr_idx": 1}, {"id": "1166614", "html_qtxt": "A 26-year-old woman presents with amenorrhea and galactorrhea. Her serum prolactin level is markedly elevated (200 ng/mL). Which of the following is most useful in the treatment of hyperprolactinemia?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Hyperprolactinemia is most often caused by a <strong>prolactin-secreting pituitary adenoma (prolactinoma)</strong>. Elevated prolactin levels inhibit GnRH release, resulting in <strong>menstrual disturbances</strong>, <strong>amenorrhea</strong>, <strong>galactorrhea</strong>, and <strong>infertility</strong> in women.</p>\n<p>The <strong>drug of choice</strong> for treatment is <strong>Bromocriptine</strong>, a <strong>dopamine D2 receptor agonist</strong>, which acts at the <strong>pituitary level</strong> to <strong>inhibit prolactin secretion</strong>.</p>\n<ul>\n<li>Bromocriptine has the added advantage of being <strong>orally active</strong> and has been in long-term clinical use.</li>\n<li>It <strong>reduces tumor size</strong>, normalizes prolactin levels, and restores ovulation.</li>\n<li><strong>Bromocriptine is also the preferred agent during pregnancy</strong>, as it has a longer safety record.</li>\n<li>For non-pregnant patients, <strong>cabergoline</strong>, another dopamine agonist with longer half-life and fewer side effects, is often preferred due to <strong>better tolerability</strong> and <strong>less frequent dosing</strong>.</li>\n</ul>\n<p><strong> Explanation of Other Options:</strong></p>\n<p><strong>Cimetidine (Option B)</strong> is an <strong>H2 receptor antagonist</strong> used for peptic ulcer disease. It has <strong>no role in treating hyperprolactinemia</strong>.</p>\n<p><strong>Ergotamine (Option C): </strong>Although structurally related to ergot alkaloids like bromocriptine, ergotamine is used in <strong>migraine treatment</strong> and lacks significant <strong>dopamine agonist activity</strong> at the pituitary level.</p>\n<p><strong>Ketanserin (Option D)</strong> is a <strong>5-HT2A antagonist</strong> and has <strong>no significant dopaminergic activity</strong>. It is sometimes used as an antihypertensive.</p>", "options": ["Bromocriptine", "Cimetidine", "Ergotamine", "Ketanserin"], "html_options": ["Bromocriptine", "Cimetidine", "Ergotamine", "Ketanserin"], "corr_idx": 0}, {"id": "1166617", "html_qtxt": "A 28-year-old woman suffers from intense migraine headaches. She is on fluoxetine for her mental illness. Which of the following drugs should be avoided?<br />1. Naproxen<br />2. Paracetamol<br />3. Ondansetron<br />4. Tramadol<br />5. Linezolid<br />6. Domperidone", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient is currently on <strong>fluoxetine</strong>, an <strong>SSRI (Selective Serotonin Reuptake Inhibitor)</strong>. Coadministration of other serotonergic agents may lead to <strong>serotonin syndrome</strong>, a potentially life-threatening condition due to <strong>excess serotonin activity in the CNS</strong>.</p>\n<p>The drugs that should be avoided in combination with SSRIs include:</p>\n<ul>\n<li><strong>Ondansetron (Option 3):</strong> A 5-HT<sub>3</sub> receptor antagonist with serotonergic properties, can precipitate serotonin syndrome when combined with SSRIs.</li>\n<li><strong>Tramadol (Option 4):</strong> An analgesic that inhibits serotonin and norepinephrine reuptake, strong serotonergic potential.</li>\n<li><strong>Linezolid (Option 5):</strong> An antibiotic with <strong>MAOI-like properties</strong>; can significantly increase serotonin levels and precipitate serotonin syndrome when combined with SSRIs.</li>\n</ul>\n<p><strong>Safe drugs in this context:</strong></p>\n<ul>\n<li><strong>Naproxen (1):</strong> NSAID; no serotonergic action.</li>\n<li><strong>Paracetamol (2):</strong> Analgesic/antipyretic; not serotonergic.</li>\n<li><strong>Domperidone (6):</strong> Dopamine antagonist; does not affect serotonin significantly.</li>\n</ul>\n<p><strong>Serotonin syndrome:</strong></p>\n<ul>\n<li><strong>Clinical features:</strong>\n<ul>\n<li><strong>Neuromuscular:</strong> Clonus, hyperreflexia, tremor, rigidity, myoclonus (especially in lower limbs)</li>\n<li><strong>ANS:</strong> Hyperthermia, tachycardia, hypertension. diaphoresis, flushing, diarrhea</li>\n<li><strong>Mental status changes:</strong> Agitation, anxiety, delirium, confusion, seizures, coma (in severe cases)</li>\n</ul>\n</li>\n<li><strong>Treatment: Cyproheptadine</strong>, a <strong>5-HT<sub>2</sub> antagonist</strong>, along with <strong>supportive care</strong>, is the mainstay of treatment.</li>\n</ul>", "options": ["3, 4, 5, 6", "3, 4", "3, 4, 5", "1, 3, 4, 5"], "html_options": ["3, 4, 5, 6", "3, 4", "3, 4, 5", "1, 3, 4, 5"], "corr_idx": 2}, {"id": "1166621", "html_qtxt": "In which of the following cases is use of triptans not contraindicated for migraine management?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Triptans</strong> (e.g., sumatriptan, naratriptan, zolmitriptan) are <strong>5-HT<sub>1</sub>B/1D receptor agonists</strong> used for acute migraine attacks. They <strong>cause vasoconstriction</strong> of cranial and coronary vessels and are therefore <strong>contraindicated in several cardiovascular and vascular conditions</strong> due to the risk of vasospasm.</p>\n<p><strong>Absolute contraindications include:</strong></p>\n<ul>\n<li>Coronary artery disease (CAD)</li>\n<li>Vasospastic (Prinzmetal's) angina <strong>(Option A ruled out)</strong></li>\n<li>Peripheral vascular disease (PVD) including Thromboangiitis obliterans (TAO) <strong>(Option B ruled out)</strong></li>\n<li>Uncontrolled hypertension</li>\n<li>Pregnancy and lactation (due to uterine vasoconstriction) <strong>(Option D ruled out)</strong></li>\n<li>Certain arrhythmias (e.g., WPW syndrome with zolmitriptan)</li>\n</ul>", "options": ["65-year-old woman with vasospastic angina", "45-year-old smoker with thromboangiitis obliterans (TAO), ABPI = 0.5", "36-year-old man with uncontrolled diabetes", "27-year-old pregnant woman (G1P0) without any comorbidities"], "html_options": ["65-year-old woman with vasospastic angina", "45-year-old smoker with thromboangiitis obliterans (TAO), ABPI = 0.5", "36-year-old man with uncontrolled diabetes", "27-year-old pregnant woman (G1P0) without any comorbidities"], "corr_idx": 2}, {"id": "1166622", "html_qtxt": "A 33-year-old woman attempted to induce an abortion using ergotamine. She presents with severe pain in both legs. Which of the following is the most useful antidote for reversing severe ergot-induced vasospasm?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509055e3fa2a5-1ccc-43e1-8165-8e98ace49a74.png\">", "html_expl": "<p><strong>Explanation:<br /> </strong>Ergotamine is a potent <strong>vasoconstrictor</strong>, acting primarily through <strong>partial agonist activity at &alpha;-adrenergic and serotonergic (5-HT1) receptors</strong>. In overdose or misuse (e.g., attempted abortion), it can cause <strong>intense peripheral vasospasm</strong>, leading to <strong>limb ischemia and severe pain</strong>.</p>\n<ul>\n<li>The most effective treatment in such cases is the administration of a <strong>powerful vasodilator</strong> that can quickly reverse the intense vasoconstriction.</li>\n<li><strong>Sodium nitroprusside</strong>, a <strong>direct-acting arterial and venous vasodilator</strong>, works by releasing <strong>nitric oxide</strong>, which activates guanylate cyclase and increases <strong>cyclic GMP</strong>, resulting in <strong>smooth muscle relaxation</strong>.</li>\n<li>It is effective irrespective of receptor blockade, making it the most useful antidote for ergot-induced vasospasm.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Ketanserin (Option A): </strong>While ketanserin is a <strong>5-HT<sub>2</sub>A antagonist</strong> with some vasodilatory effect, it is <strong>less effective than nitroprusside</strong> in managing acute, severe vasospasm.</p>\n<p><strong>Sumatriptan (Option C)</strong> is a <strong>5-HT<sub>1</sub>B/<sub>1</sub>D receptor agonist</strong> and causes <strong>vasoconstriction</strong>, not vasodilation. It is contraindicated in this scenario and may worsen vasospasm.</p>\n<p><strong>Ondansetron (Option D)</strong> is a <strong>5-HT<sub>3</sub> antagonist</strong> used primarily for <strong>nausea and vomiting</strong>. It has <strong>no role</strong> in reversing ergot-induced vasospasm.</p>", "options": ["Ketanserin", "Nitroprusside", "Sumatriptan", "Ondansetron"], "html_options": ["Ketanserin", "Nitroprusside", "Sumatriptan", "Ondansetron"], "corr_idx": 1}, {"id": "1166625", "html_qtxt": "Match the following drugs with their clinical indications:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090598db5b66-c21f-4935-b9f7-bc15cf3d0dc2.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905ddf35337-dce9-4b2d-bb1e-fc55ce45f877.png\">", "options": ["1-d, 2-b, 3-c, 4-a", "1-d, 2-c, 3-a, 4-b", "1-d, 2-c, 3-b, 4-a", "1-c, 2-d, 3-a, 4-b"], "html_options": ["1-d, 2-b, 3-c, 4-a", "1-d, 2-c, 3-a, 4-b", "1-d, 2-c, 3-b, 4-a", "1-c, 2-d, 3-a, 4-b"], "corr_idx": 1}, {"id": "1166627", "html_qtxt": "A 43-year-old woman is admitted with acute difficulty in breathing. Examination reveals significant laryngeal edema. Which of the following drugs is the most effective physiologic antagonist of the mediator responsible for smooth muscle contraction in this scenario?", "html_expl": "<p><strong>Explanation:<br /> </strong>The patient's presentation of <strong>laryngeal edema and respiratory difficulty</strong> suggests <strong>acute histamine-mediated hypersensitivity</strong>, such as anaphylaxis or severe allergic reaction.</p>\n<ul>\n<li>Histamine exerts <strong>contractile effects on bronchial and gastrointestinal smooth muscle</strong>, and <strong>vasodilatory and permeability effects</strong> on blood vessels, primarily via <strong>H1 receptors</strong>.</li>\n<li><strong>Epinephrine</strong> acts as a <strong>physiologic antagonist</strong> by activating <strong>&alpha;1, &beta;1, and &beta;2 adrenergic receptors</strong>, which:\n<ul>\n<li><strong>Reverse vasodilation and edema</strong> via &alpha;1-mediated vasoconstriction</li>\n<li><strong>Relax bronchial smooth muscle</strong> via &beta;2 agonism</li>\n<li>Support cardiac output via &beta;1 activity</li>\n</ul>\n</li>\n</ul>\n<p>Thus, <strong>epinephrine is the most effective agent</strong> to rapidly counteract the effects of histamine during severe allergic reactions.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Loratadine (Option B): </strong>A<strong> selective H1 receptor antagonist, </strong>used in <strong>mild allergic reactions</strong>, but <strong>not effective in emergencies</strong> like anaphylaxis. Acts slowly and does not reverse bronchospasm acutely.</p>\n<p><strong>Ondansetron (Option C):</strong> A <strong>5-HT<sub>3</sub> receptor antagonist</strong>, used for <strong>nausea and vomiting</strong>, particularly in chemotherapy or postoperative settings. Not related to histamine pathways.</p>\n<p><strong>Ranitidine (Option D):</strong> An <strong>H2 receptor antagonist</strong> used for <strong>acid suppression</strong> in the GI tract. It has <strong>no role in smooth muscle relaxation</strong> or emergency treatment of histamine-induced bronchospasm.</p>", "options": ["Epinephrine", "Loratadine", "Ondansetron", "Ranitidine"], "html_options": ["Epinephrine", "Loratadine", "Ondansetron", "Ranitidine"], "corr_idx": 0}, {"id": "1166630", "html_qtxt": "A 54-year-old man presents with severe pain in a dermatomal distribution of his chest, persisting in the same area where he had a herpes zoster rash several weeks ago. Which of the following drugs might be beneficial in controlling this post-herpetic neuralgia?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Postherpetic neuralgia (PHN)</strong> is a chronic neuropathic pain syndrome that can persist for months after resolution of a <strong>herpes zoster (shingles)</strong> rash, especially in older adults. It is characterized by burning, sharp, or shooting pain in the affected dermatome.</p>\n<p>One of the key mediators of neuropathic pain is <strong>substance P</strong>, a neuropeptide released from sensory nerve terminals.</p>\n<p><strong>Capsaicin</strong>, derived from chili peppers, <strong>binds to TRPV1 (transient receptor potential vanilloid 1)</strong> receptors on nociceptive neurons. This leads to:</p>\n<ul>\n<li><strong>Depletion of substance P</strong> from peripheral sensory neurons</li>\n<li><strong>Desensitization</strong> of sensory fibers</li>\n<li><strong>Reduction in neuropathic pain perception</strong>, including postherpetic neuralgia</li>\n</ul>\n<p><strong>Topical capsaicin</strong> is FDA-approved for managing <strong>localized neuropathic pain</strong>, including <strong>PHN</strong>. Its benefit is local, with minimal systemic side effects when applied properly.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aliskiren (Option A)</strong> is a direct renin inhibitor, used for treating <strong>arterial hypertension</strong>. It has no role in pain modulation or neuropathic pain syndromes.</p>\n<p><strong>Aprepitant (Option B) </strong>is a <strong>neurokinin-1 (NK1) receptor antagonist</strong> used in <strong>chemotherapy-induced nausea and vomiting (CINV)</strong>. It has <strong>central antiemetic effects</strong>, but does not affect peripheral pain pathways or substance P activity relevant to post-herpetic neuralgia.</p>\n<p><strong>Bosentan (Option C) </strong>is an endothelin receptor antagonist used to manage <strong>pulmonary arterial hypertension</strong>. It does not influence sensory neurotransmission or pain pathways.</p>", "options": ["Aliskiren", "Aprepitant", "Bosentan", "Capsaicin"], "html_options": ["Aliskiren", "Aprepitant", "Bosentan", "Capsaicin"], "corr_idx": 3}, {"id": "1166634", "html_qtxt": "Which mechanism explains aspirin's inhibition of thromboxane synthesis?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Aspirin (acetylsalicylic acid) <strong>irreversibly inhibits the cyclooxygenase (COX) enzyme</strong>, which is crucial in the <strong>conversion of arachidonic acid to prostaglandin H<sub>2</sub></strong>, the precursor for both <strong>thromboxane A<sub>2</sub> (TXA<sub>2</sub>)</strong> and <strong>prostacyclin (PGI<sub>2</sub>)</strong>.</p>\r\n<ul>\r\n<li>In <strong>platelets</strong>, COX-1 inhibition by aspirin leads to <strong>decreased thromboxane A<sub>2</sub> synthesis</strong>, impairing platelet aggregation and promoting an antithrombotic effect.</li>\r\n<li>Since <strong>platelets lack nuclei</strong>, they cannot synthesize new COX enzymes, making aspirin's action <strong>long-lasting and irreversible</strong> in them.</li>\r\n<li>In contrast, <strong>endothelial cells</strong> (which produce PGI<sub>2</sub>, a vasodilator and inhibitor of platelet aggregation) can regenerate COX, thus <strong>preserving prostacyclin production</strong> with low-dose aspirin use.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905a3f0f8aa-8300-4d51-8736-ccf692b91235.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Blocks lipoxygenase (Option B): </strong>Lipoxygenase is involved in leukotriene synthesis. <strong>Zileuton</strong> is an inhibitor of 5-lipoxygenase, not aspirin.</p>\r\n<p><strong>Blocks phospholipase A<sub>2</sub> (Option C): Corticosteroids</strong> (e.g., hydrocortisone) inhibit phospholipase A<sub>2</sub>, thereby blocking the release of arachidonic acid from membrane phospholipids, not the mechanism of aspirin.</p>\r\n<p><strong>Blocks PGI<sub>2</sub> receptors (Option D): </strong>Aspirin does not block prostacyclin (PGI<sub>2</sub>) receptors. In fact, <strong>PGI<sub>2</sub> is vasodilatory and anti-aggregatory</strong>, and inhibition of PGI<sub>2</sub> is a side effect, not a therapeutic action.</p>", "options": ["Blocks cyclooxygenase", "Blocks lipoxygenase", "Blocks phospholipase A2", "Blocks PGI<sub>2</sub> receptors"], "html_options": ["Blocks cyclooxygenase", "Blocks lipoxygenase", "Blocks phospholipase A2", "Blocks PGI<sub>2</sub> receptors"], "corr_idx": 0}, {"id": "1166636", "html_qtxt": "A newborn infant is diagnosed with a congenital anomaly, which can be understood by the image illustrated below. Which of the following drugs is likely to be used in preparation for surgical correction of this anomaly?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509053d1a01f1-980a-4a6d-9186-ad95b1ee6138.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The image and clinical context describe <strong>Transposition of the Great Arteries (TGA)</strong>, a cyanotic congenital heart defect where the <strong>aorta arises from the right ventricle</strong> and the <strong>pulmonary artery arises from the left ventricle</strong>. This parallel circulation results in <strong>oxygenated</strong> blood recirculating<strong> to the lungs</strong> and <strong>deoxygenated </strong>blood being pumped<strong> to the systemic circulation</strong>, leading to profound <strong>hypoxemia</strong> shortly after birth.</p>\n<ul>\n<li><strong>Survival</strong> in these infants is dependent on <strong>mixing of oxygenated and deoxygenated blood</strong>, which can occur via a <strong>patent ductus arteriosus (PDA)</strong>, atrial septal defect (ASD), or ventricular septal defect (VSD).</li>\n<li>To <strong>maintain ductal patency</strong>, <strong>Prostaglandin E1 (PGE1)</strong> is administered. It acts as a <strong>vasodilator</strong> that <strong>keeps the ductus arteriosus open</strong>, and helps maintain systemic oxygenation until definitive surgical correction (arterial switch operation) is possible.</li>\n<li>Without PGE1, the <strong>ductus may close</strong>, worsening hypoxia and possibly leading to death.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aspirin (Option A)</strong> is an antiplatelet agent that <strong>can promote ductal closure</strong>, not useful in ductus-dependent lesions.</p>\n<p><strong>Leukotriene LTC4 (Option B)</strong> is involved in <strong>inflammatory responses</strong> and <strong>bronchoconstriction</strong> in asthma; they have no role in maintaining ductal patency or congenital heart disease management.</p>\n<p><strong>Prednisone (Option C)</strong> is a corticosteroid is used in inflammatory and autoimmune conditions but does <strong>not maintain PDA</strong> or aid in TGA stabilization.</p>", "options": ["Aspirin", "Leukotriene LTC4", "Prednisone", "Prostaglandin PGE1"], "html_options": ["Aspirin", "Leukotriene LTC4", "Prednisone", "Prostaglandin PGE1"], "corr_idx": 3}, {"id": "1166637", "html_qtxt": "A 17-year-old patient complains that he develops wheezing and severe shortness of breath whenever he takes aspirin for headache. Increased levels of which of the following may be responsible, in part, for some cases of aspirin hypersensitivity?", "html_expl": "<p><strong>Explanation:<br /> </strong></p>\n<p>Aspirin hypersensitivity, particularly in the context of respiratory symptoms (e.g., bronchospasm, wheezing), is often attributed to <strong>increased leukotriene production</strong>.</p>\n<ul>\n<li>Aspirin and other NSAIDs <strong>irreversibly inhibit cyclooxygenase (COX)</strong> enzymes, blocking the synthesis of prostaglandins.</li>\n<li>This leads to a <strong>shunting of arachidonic acid metabolism toward the lipoxygenase pathway</strong>, resulting in the overproduction of <strong>cysteinyl leukotrienes</strong> like <strong>LTC<sub>4</sub></strong>, LTD<sub>4</sub>, and LTE<sub>4</sub>.</li>\n<li>These leukotrienes are <strong>potent bronchoconstrictors</strong> and <strong>pro-inflammatory mediators</strong>. Elevated levels are associated with <strong>aspirin-exacerbated respiratory disease (AERD)</strong>, characterized by asthma, nasal polyps, and aspirin sensitivity.</li>\n<li>In such patients, even small doses of aspirin can trigger <strong>acute bronchospasm</strong>, rhinorrhea, and worsening asthma symptoms due to <strong>leukotriene overactivity</strong>.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905c7e24a4a-faa3-44d0-a475-1df67c34d8b6.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>PGE<sub>2</sub> (Option B): </strong>PGE<sub>2</sub> has <strong>bronchodilatory and anti-inflammatory</strong> effects. Its levels <strong>decrease</strong> when COX is inhibited, contributing to bronchoconstriction, but it is not the mediator causing bronchospasm.</p>\n<p><strong>Prostacyclin (Option C):</strong> Also known as PGI<sub>2</sub>, prostacyclin is a <strong>vasodilator and inhibitor of platelet aggregation</strong>. It plays no significant role in the pathogenesis of aspirin-induced bronchospasm.</p>\n<p><strong>Thromboxane (Option D): </strong>Thromboxane A<sub>2</sub> promotes <strong>vasoconstriction and platelet aggregation</strong>, but its role in <strong>bronchospasm</strong> is far less significant than leukotrienes. Also, COX inhibition reduces thromboxane synthesis.</p>", "options": ["Leukotriene LTC<sub>4</sub>", "PGE<sub>2</sub>", "Prostacyclin", "Thromboxane"], "html_options": ["Leukotriene LTC<sub>4</sub>", "PGE<sub>2</sub>", "Prostacyclin", "Thromboxane"], "corr_idx": 0}, {"id": "1166638", "html_qtxt": "A 35-year-old woman with arthritis has been treated with NSAIDs. She now complains of heartburn and indigestion, and a fecal occult blood test is positive. You prescribe a drug to be taken along with the anti-inflammatory agent. However, two days later, she reports severe diarrhea and uterine cramping that resemble her menstrual cramps. Which of the following drugs is most likely responsible for increased gastrointestinal motility and uterine cramping?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The clinical scenario is indicative of <strong>NSAID-induced gastric mucosal injury, </strong>a condition for which misoprostol is commonly prescribed as a gastroprotective agent in high-risk patients.</p>\n<p><strong>Misoprostol,</strong> a <strong>prostaglandin E1 (PGE1) analog,</strong> exerts a <strong>cytoprotective effect on the gastric mucosa</strong> by increasing mucus and bicarbonate secretion and reducing acid production.</p>\n<p>However, prostaglandins also have a <strong>smooth muscle-stimulating effect</strong> on the <strong>gastrointestinal</strong> and <strong>uterine musculature</strong>. As a result:</p>\n<ul>\n<li><strong>Diarrhea</strong> is a common adverse effect due to increased intestinal motility.</li>\n<li><strong>Uterine cramping</strong> and even <strong>uterine contractions</strong> can occur, which is why <strong>misoprostol is contraindicated in pregnancy</strong> unless used for medical termination of pregnancy.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aspirin (Option A) </strong>is a non-selective NSAID and may itself contribute to <strong>gastric mucosal injury</strong>, but does not increase GI motility or cause uterine cramping.</p>\n<p><strong>Famotidine (Option B)</strong> is an H2 receptor antagonist that <strong>reduces gastric acid secretion</strong>. It is <strong>not associated with increased motility or uterine contractions</strong> and typically has a favorable GI side effect profile.</p>\n<p><strong>Zileuton (Option D) </strong>is a 5-lipoxygenase inhibitor <strong>used in asthma</strong> to reduce leukotriene production. It does not affect GI or uterine motility and is not used for GI protection.</p>", "options": ["Aspirin", "Famotidine", "Misoprostol", "Zileuton"], "html_options": ["Aspirin", "Famotidine", "Misoprostol", "Zileuton"], "corr_idx": 2}]}, {"moduleId": 1013387, "name": "Autacoids (Part 2)", "questions": [{"id": "1166642", "html_qtxt": "Match the following drugs with their respective uses.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240309405ed74a-6732-40ac-9efd-d76eae9f32e2.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403099b44dd9b-2ee2-413f-a3d3-ea573845dbc7.jpg\">", "options": ["a-1, b-2, c-4, d-3", "a-1, b-3, c-2, d-4", "a-2, b-4, c-1, d-3", "a-1, b-4, c-2, d-3"], "html_options": ["a-1, b-2, c-4, d-3", "a-1, b-3, c-2, d-4", "a-2, b-4, c-1, d-3", "a-1, b-4, c-2, d-3"], "corr_idx": 3}, {"id": "1166644", "html_qtxt": "A 65-year-old woman is being treated with eye drops for primary open angle glaucoma (POAG). At a follow-up visit, you notice changes in the iris pigmentation as shown below. The prescribed drug most likely acts on which of the following targets?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403093f2ad58f-e710-486b-8624-1d94422afed1.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient is exhibiting <strong>hyperpigmentation of the iris</strong>, which is a <strong>known side effect of prostaglandin analogues</strong>, particularly <strong>latanoprost</strong>, a drug commonly used in <strong>first-line therapy for open-angle glaucoma (OAG)</strong>.</p>\n<ul>\n<li>Latanoprost and similar agents (<strong>bimatoprost, travoprost</strong>) are <strong>PGF2&alpha; analogues</strong>.</li>\n<li>These drugs <strong>increase uveoscleral outflow</strong> of aqueous humor, effectively lowering intraocular pressure.</li>\n<li>They are preferred in OAG due to <strong>once-daily dosing</strong>, <strong>high efficacy</strong>, and <strong>favorable systemic safety profile</strong>.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905fcf7de36-6018-4289-8821-2a372bdf03ba.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>PGI2 (Option A): </strong>PGI2 analogues (like epoprostenol) are not used in glaucoma treatment. They are mainly used in <strong>pulmonary arterial hypertension</strong>.</p>\n<p><strong>Alpha-1 (Option C):</strong> Alpha-1 agonists (e.g., phenylephrine) are <strong>mydriatics</strong>, not used for lowering IOP in OAG. However,<strong> alpha-2 agonists</strong> like <strong>brimonidine</strong> <strong>are used in glaucoma</strong>, as they decrease aqueous humor production and increase uveoscleral outflow.</p>\n<p><strong>Rho-kinase (Option D): </strong>While <strong>Rho-kinase inhibitors</strong> (e.g., netarsudil) are newer agents in glaucoma management, they are <strong>not first-line</strong>, and do <strong>not cause iris pigmentation</strong>.</p>", "options": ["PGI2", "PGF2&alpha;", "Alpha-1 receptor", "Rho-kinase"], "html_options": ["PGI2", "PGF2&alpha;", "Alpha-1 receptor", "Rho-kinase"], "corr_idx": 1}, {"id": "1166649", "html_qtxt": "Which one of the following is not a nitric oxide (NO) donor, but instead causes NO to be synthesized and released from endogenous precursors, resulting in vasodilation?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Acetylcholine</strong> is <strong>not a direct nitric oxide donor</strong>. Instead, it promotes <strong>endogenous nitric oxide synthesis</strong>. When acetylcholine binds to <strong>M3 muscarinic receptors</strong> on <strong>vascular endothelial cells</strong>, it activates endothelial nitric oxide synthase (<strong>eNOS</strong>), which converts <strong>L-arginine</strong> into <strong>nitric oxide (NO)</strong>. This NO diffuses into adjacent vascular smooth muscle cells, causing <strong>vasodilation</strong> through activation of <strong>guanylate cyclase</strong> and increased cyclic GMP.</p>\n<p>In contrast, the other given options are either <strong>exogenous NO donors</strong> or precursors:</p>\n<ul>\n<li><strong>Arginine </strong>is the <strong>endogenous substrate</strong> used by <strong>eNOS</strong> to synthesize NO. <strong>(Option B ruled out)</strong></li>\n<li><strong>Isosorbide mononitrate</strong> and <strong>Nitroglycerin</strong> are <strong>organic nitrates</strong>, which act as <strong>NO donors</strong> by releasing nitric oxide directly in the vasculature, thereby bypassing the endothelial synthesis pathway. <strong>(Options C & D ruled out)</strong></li>\n</ul>", "options": ["Acetylcholine", "Arginine", "Isosorbide mononitrate", "Nitroglycerin"], "html_options": ["Acetylcholine", "Arginine", "Isosorbide mononitrate", "Nitroglycerin"], "corr_idx": 0}, {"id": "1166653", "html_qtxt": "A 70-year-old woman presents with nausea and vomiting. She has been taking paracetamol (PCM) for knee pain. On examination, she has scleral icterus and tender hepatomegaly. She also appears confused.<br>Her liver function tests show:<br>ALT: 820 U/L <br>AST: 746 U/L<br> ALP: 140 U/L<br>Which of the following is the most likely underlying mechanism of this patient's liver failure?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with <strong>acute liver failure</strong>, characterized by <strong>elevated transaminases (ALT and AST > ALP)</strong>, hepatic encephalopathy (confusion), and signs of hepatocellular injury. Her history of <strong>paracetamol (acetaminophen) use</strong> is highly suggestive of <strong>acetaminophen-induced hepatotoxicity</strong>.</p>\n<p>Acetaminophen is primarily metabolized in the liver via <strong>glucuronidation and sulfation</strong>. However, a small proportion is oxidized by the <strong>cytochrome P450 enzyme CYP2E1</strong>, forming the highly reactive intermediate<strong> N-acetyl-p-benzoquinoneimine (NAPQI)</strong>.</p>\n<ul>\n<li>Under normal conditions, <strong>NAPQI</strong> is detoxified by <strong>glutathione</strong></li>\n<li>In <strong>overdose or chronic high-dose use</strong>, <strong>glutathione stores are depleted</strong>, allowing NAPQI to accumulate.</li>\n<li><strong>NAPQI causes oxidative damage</strong> to hepatocytes, leading to <strong>centrilobular necrosis</strong> and <strong>acute liver failure</strong>.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509059a42fb96-6979-415a-a29f-147a26fdad61.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Glucuronide-conjugate formation (Option A): </strong>This is a <strong>normal phase II detoxification pathway</strong> of acetaminophen metabolism. It does <strong>not cause toxicity</strong> and actually helps excrete the drug safely.</p>\n<p><strong>Salicylic acid formation (Option B):</strong>. This is part of <strong>aspirin (salicylate) metabolism</strong>, unrelated to acetaminophen toxicity.</p>\n<p><strong>N-acetylcysteine formation (Option D): N-acetylcysteine (NAC)</strong> is the <strong>antidote</strong> for acetaminophen poisoning. It acts by <strong>restoring glutathione levels</strong> and detoxifying NAPQI. While critical to treatment, it is <strong>not a mechanism of toxicity</strong>.</p>", "options": ["Glucuronide-conjugate formation", "Salicylic acid formation", "N-acetyl-p-benzoquinoneimine formation", "N-acetylcysteine formation"], "html_options": ["Glucuronide-conjugate formation", "Salicylic acid formation", "N-acetyl-p-benzoquinoneimine formation", "N-acetylcysteine formation"], "corr_idx": 2}, {"id": "1166657", "html_qtxt": "A 42-year-old woman presents with abdominal pain, nausea, and vomiting. She is currently on prednisone and naproxen. On examination, she has a rigid abdomen with rebound tenderness and hypoactive bowel sounds. Labs show a leukocyte count of 13,300/mm3 and an ESR of 70 mm/h. Chest X-ray is taken and is shown below. Treatment with which of the following could have prevented this complication?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030956a783e1-9c78-4cf7-8497-303f0313c8f1.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with <strong>perforated peptic ulcer</strong>, evidenced by:</p>\n<ul>\n<li><strong>Pneumoperitoneum</strong> (air under diaphragm on chest X-ray)</li>\n<li><strong>Peritoneal signs</strong> (rigid abdomen, rebound tenderness)</li>\n<li>Use of<strong> NSAIDs (naproxen) and corticosteroids (prednisone),</strong> both of which increase the risk of PUD and its complications\n<ul>\n<li>NSAIDs inhibit COX-1, reducing prostaglandin synthesis and impairing gastric mucosal protection and blood flow. Corticosteroids further impair ulcer healing and, when combined with NSAIDs, significantly increase the risk of complications such as bleeding and perforation.</li>\n<li>Chronic NSAID use increases the risk of PUD approximately fourfold; the addition of corticosteroids amplifies this risk.</li>\n</ul>\n</li>\n</ul>\n<p>Initial management of peptic perforation includes: <strong>NPO</strong>, <strong>IV fluids</strong>, <strong>antibiotics</strong>, and <strong>surgical intervention</strong> (typically laparotomy or laparoscopy)</p>\n<p><strong>Prophylactic treatment with proton pump inhibitors (PPIs)</strong> such as <strong>omeprazole</strong> significantly reduces the risk of NSAID-induced gastric injury and its complications (ulcer, perforation, bleeding). PPIs are <strong>recommended</strong> in all patients on <strong>long-term NSAID or corticosteroid therapy</strong>, especially when taken together.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Calcium with vitamin D (Option A): </strong>While useful for <strong>steroid-induced osteoporosis</strong>, this does <strong>not prevent NSAID- or steroid-induced gastric ulcers or perforation</strong>.</p>\n<p><strong>Pyridoxine (Option C): </strong>Pyridoxine (Vitamin B6) is used to prevent <strong>isoniazid-induced neuropathy</strong>, not GI complications.</p>\n<p><strong>Folic acid (Option D): </strong>Folic acid is used to manage <strong>folate deficiency</strong>, commonly caused by drugs like methotrexate or in pregnancy, not protective against NSAID-induced GI complications.</p>\n<p><strong>Key Takeaway:</strong></p>\n<p><strong>H. pylori prophylaxis in PUD:</strong></p>\n<ul>\n<li><strong>Triple regimen</strong> (clarithromycin-sensitive):</li>\n</ul>\n<p><strong>CAMP</strong> - Clarithromycin + (Amoxicillin << Metronidazole) + PPI - for 2 weeks BD</p>\n<ul>\n<li><strong>Quadruple regimen</strong> (clarithromycin-resistant or failed therapy):</li>\n</ul>\n<p><strong>TOMB</strong> - Tetracycline + Omeprazole + Metronidazole + Bismuth - for 10 days to 6 weeks</p>", "options": ["Calcium with vitamin D", "Omeprazole", "Pyridoxine", "Folic acid"], "html_options": ["Calcium with vitamin D", "Omeprazole", "Pyridoxine", "Folic acid"], "corr_idx": 1}, {"id": "1166660", "html_qtxt": "A 32-year-old woman presents with a 1-day history of severe pain and swelling of her left great toe. She has had similar episodes sporadically over the past year. Examination shows erythema, warmth, and tenderness of the left first metatarsophalangeal joint. What is the most appropriate next step in treatment?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with <strong>acute monoarthritis</strong> of the <strong>first metatarsophalangeal joint</strong>, a classic presentation of <strong>acute gout</strong>. The sudden onset, joint erythema, warmth, and tenderness suggest <strong>an acute inflammatory response</strong> to <strong>monosodium urate crystal deposition</strong>.</p>\n<ul>\n<li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs)</strong> are the <strong>first-line therapy</strong> for acute gout flares. <strong>Indomethacin</strong> is a potent NSAID that <strong>reversibly inhibits cyclooxygenase (COX-1 and COX-2)</strong>, blocking prostaglandin synthesis and inflammation.</li>\n<li>NSAIDs are most effective when started early during an acute gout attack. Other first-line treatments include <strong>colchicine</strong> (if started within 36 hours) and <strong>glucocorticoids</strong> (oral or intra-articular), particularly in NSAID-intolerant patients or those with renal contraindications.</li>\n</ul>\n<p>It is important to <strong>avoid initiating urate-lowering therapy (ULT)</strong> like allopurinol or probenecid during an <strong>acute attack</strong>, as these drugs can <strong>exacerbate</strong> or <strong>prolong</strong> the current flare.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aspirin (Option B): </strong>While aspirin is technically an NSAID, <strong>low-dose aspirin </strong>(1-2 g/day) <strong>inhibits uric acid excretion</strong>, thereby <strong>worsening hyperuricemia</strong>. It is contraindicated in acute gout attacks.</p>\n<p><strong>Probenecid (Option C): </strong>Probenecid is a <strong>uricosuric agent</strong> that promotes renal uric acid excretion. It is used in <strong>chronic gout</strong> management but is <strong>not suitable for acute flares</strong>, as it can paradoxically worsen the attack.</p>\n<p><strong>Allopurinol (Option D): </strong>Allopurinol is a <strong>xanthine oxidase inhibitor</strong> used to <strong>prevent gout attacks in chronic hyperuricemia.</strong> However, initiating allopurinol during an acute attack can exacerbate symptoms, and should be deferred until the flare subsides.</p>", "options": ["Indomethacin", "Aspirin", "Probenecid", "Allopurinol"], "html_options": ["Indomethacin", "Aspirin", "Probenecid", "Allopurinol"], "corr_idx": 0}, {"id": "1166662", "html_qtxt": "A 14-year-old boy is brought in with progressive shortness of breath, difficulty speaking, and diffuse, colicky abdominal pain for the past 3 hours. He had undergone a tooth extraction yesterday. His father has a history of repeated hospitalizations for orofacial swelling. Administration of a drug targeting which of the following is the most appropriate treatment for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This clinical presentation is classic for <strong>hereditary angioedema (HAE)</strong>:</p>\n<ul>\n<li>Colicky abdominal pain, dyspnea, orofacial/laryngeal swelling, and a positive family history of similar episodes</li>\n<li>Triggering event: dental procedures are well-known precipitating factors</li>\n<li>HAE is caused by <strong>C1 esterase inhibitor deficiency (Type I) or dysfunction (Type 2)</strong>, leading to uncontrolled activation of kallikrein and <strong>excess bradykinin production</strong>, which increases vascular permeability and results in angioedema.</li>\n</ul>\n<p><strong>Bradykinin is the key mediator</strong> of symptoms in HAE, unlike histamine-mediated angioedema (no urticaria or pruritus).</p>\n<ul>\n<li><strong>Icatibant</strong> is a <strong>bradykinin B2 receptor antagonist</strong>, making it a <strong>first-line treatment for acute HAE attacks</strong>.</li>\n<li>Other first-line options include <strong>C1-INH concentrate</strong> or <strong>kallikrein inhibitors</strong> (e.g., ecallantide).</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030998944d73-2e1e-4bdf-92ff-d62d901acf7e.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Danazol (Option B)</strong> is an <strong>attenuated androgen</strong> that increases hepatic synthesis of C1-INH and is used for <strong>long-term prophylaxis</strong>, not for acute attacks.</p>\n<p><strong>Epsilon aminocaproic acid - EACA (Option C)</strong> is an <strong>antifibrinolytic agent</strong> sometimes used <strong>prophylactically in surgical settings</strong>, but it is <strong>not effective for acute symptom control</strong> in HAE.</p>\n<p><strong>Lanadelumab (Option D) </strong>is a <strong>monoclonal antibody that inhibits plasma kallikrein</strong>, used for <strong>long-term prophylaxis</strong>. It is not a first-line agent for acute episodes.</p>\n<p><strong>Key Takeaway:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509053f83aa18-eeee-4097-9b84-0c2a1d1535d8.png\">", "options": ["Icatibant", "Danazol", "Epsilon aminocaproic acid (EACA)", "Lanadelumab"], "html_options": ["Icatibant", "Danazol", "Epsilon aminocaproic acid (EACA)", "Lanadelumab"], "corr_idx": 0}, {"id": "1166663", "html_qtxt": "A 32-year-old woman presents with facial swelling and difficulty swallowing. She was recently diagnosed with hypertension and started on an antihypertensive drug. Which of the following is the most likely cause of this patient's symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient's presentation is characteristic of <strong>ACE inhibitor-induced angioedema</strong>, a known adverse effect of drugs like <strong>lisinopril</strong>.</p>\n<ul>\n<li><strong>Angiotensin-converting enzyme (ACE)</strong> not only converts angiotensin I to angiotensin II but also degrades <strong>bradykinin</strong>.</li>\n<li>ACE inhibitors (like lisinopril) <strong>increase bradykinin levels</strong>, leading to <strong>vasodilation and increased vascular permeability</strong>, which causes <strong>angioedema</strong>, often presenting as <strong>facial swelling</strong>, <strong>tongue swelling</strong>, and <strong>airway compromise</strong>.</li>\n<li>This form of angioedema is <strong>non-allergic</strong> and <strong>not associated with urticaria or pruritus</strong>, distinguishing it from <strong>mast cell-mediated angioedema</strong>.</li>\n<li>Symptoms may occur <strong>shortly after initiation</strong> or <strong>even years after continuous use</strong>.</li>\n<li>It can present with <strong>dysphagia</strong>, <strong>dysphonia</strong>, or even <strong>stridor</strong> in severe cases.</li>\n<li><strong>ARBs</strong> (e.g., <strong>losartan</strong>) do <strong>not affect bradykinin metabolism</strong> and are often used as substitutes when ACE inhibitors cause angioedema.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Chlorthalidone (Option A): </strong>Thiazide diuretics like chlorthalidone are not associated with angioedema. Common side effects include <strong>hypokalemia</strong>, <strong>hyperuricemia</strong>, and <strong>hyperglycemia</strong>.</p>\n<p><strong>Losartan (Option C): </strong>Losartan is an <strong>ARB</strong> and does <strong>not inhibit bradykinin breakdown</strong>. It is generally considered <strong>safe</strong> in patients who have developed ACEI-induced angioedema.</p>\n<p><strong>Nifedipine (Option D):</strong> Nifedipine, a <strong>dihydropyridine calcium channel blocker</strong>, does not affect bradykinin. Side effects include <strong>peripheral edema</strong>, headache, and flushing-not angioedema.</p>", "options": ["Chlorthalidone", "Lisinopril", "Losartan", "Nifedipine"], "html_options": ["Chlorthalidone", "Lisinopril", "Losartan", "Nifedipine"], "corr_idx": 1}, {"id": "1166667", "html_qtxt": "A 15-year-old boy presents with headache, nausea, dizziness, fever, conjunctival hyperemia, and blurred vision 30 minutes after taking ibuprofen. He subsequently develops emesis and neck stiffness. Cerebrospinal fluid analysis is normal. What is the next step in management?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with symptoms suggestive of <strong>meningitis-like syndrome</strong>, but with a <strong>normal CSF analysis</strong> and <strong>rapid onset after ibuprofen intake</strong>, which strongly indicates <strong>Drug-Induced Aseptic Meningitis (DIAM)</strong>.</p>\n<ul>\n<li><strong>DIAM</strong> is a rare, non-infectious inflammatory condition of the meninges associated with various drugs, <strong>especially NSAIDs</strong> like <strong>ibuprofen</strong>, the most commonly implicated agent.</li>\n<li>Clinical features mimic infectious meningitis: <strong>fever, headache, neck stiffness, photophobia, nausea</strong>, and sometimes <strong>altered mental status</strong>.</li>\n<li>The hallmark clue is the <strong>temporal relationship</strong> between drug exposure and onset of symptoms, and <strong>normal or mildly abnormal CSF</strong>.</li>\n</ul>\n<p><strong>Management involves:</strong></p>\n<ul>\n<li><strong>Immediate withdrawal of the offending agent</strong> (in this case, <strong>ibuprofen</strong>), which typically results in <strong>complete resolution</strong> of symptoms within 24-48 hours.</li>\n<li><strong>Antibiotics or antivirals are not indicated</strong> once infectious etiologies are excluded through clinical and laboratory evaluation.</li>\n</ul>\n<p><strong>Potential Causes of Drug-induced Aseptic Meningitis:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240309b061fc9e-b02a-4b5e-8939-40515d1081c5.jpg\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Start ceftriaxone (Option B): </strong>Ceftriaxone is used for <strong>bacterial meningitis</strong>, which would present with <strong>abnormal CSF</strong> (e.g., high WBCs, elevated protein, low glucose). This patient's CSF is <strong>normal</strong>, and the rapid onset after drug intake further suggests a non-infectious cause.</p>\n<p><strong>Start acyclovir (Option C): </strong>Acyclovir is indicated in <strong>viral (especially HSV) encephalitis</strong>, which typically presents with <strong>altered mental status</strong>, <strong>seizures</strong>, or <strong>temporal lobe findings</strong>, not just meningitic signs. CSF in viral encephalitis usually shows <strong>lymphocytic pleocytosis</strong>, not normal findings.</p>\n<p><strong>Start prednisone (Option D): </strong>Corticosteroids are not the first-line management of DIAM. The condition is <strong>self-limiting</strong> and resolves with <strong>withdrawal of the offending drug</strong>. Steroids may be considered in some autoimmune-mediated aseptic meningitis but not in NSAID-induced DIAM.</p>", "options": ["Withdraw ibuprofen", "Start ceftriaxone", "Start acyclovir", "Start prednisone"], "html_options": ["Withdraw ibuprofen", "Start ceftriaxone", "Start acyclovir", "Start prednisone"], "corr_idx": 0}, {"id": "1166671", "html_qtxt": "Which of the following NSAIDs undergoes enterohepatic metabolism?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Piroxicam</strong> is a non-selective NSAID belonging to the oxicam class. One of its unique pharmacokinetic properties is that it undergoes <strong>extensive enterohepatic circulation</strong>, which significantly <strong>prolongs its half-life (~45-50 hours)</strong> and allows for <strong>once-daily dosing</strong>. This also contributes to its <strong>long duration of action</strong>, making it effective in the <strong>management of chronic inflammatory conditions</strong> like osteoarthritis and rheumatoid arthritis.</p>\n<ul>\n<li><strong>Enterohepatic metabolism</strong> refers to the process where a drug is excreted into bile after hepatic metabolism, enters the intestine, and is then <strong>reabsorbed</strong> into systemic circulation, extending the drug's activity.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905f84afadf-442e-40a9-9089-25cd408f1734.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Diclofenac (Option A):</strong> While diclofenac undergoes <strong>hepatic metabolism</strong>, it shows <strong>limited enterohepatic recirculation</strong> and is mostly excreted via urine. Its shorter half-life (~1-2 hours) makes it unsuitable for long-acting effects.</p>\n<p><strong>Nimesulide (Option B):</strong> Nimesulide is metabolized in the liver and excreted mainly in the urine. It does <strong>not exhibit significant enterohepatic circulation</strong>. It is also not recommended for long-term use due to <strong>hepatic toxicity</strong> concerns.</p>\n<p><strong>Ketorolac (Option D):</strong> Ketorolac is a short-acting NSAID, mainly used for <strong>acute pain</strong>, especially post-operative. It undergoes hepatic metabolism and <strong>does not undergo significant enterohepatic recycling</strong>. Its duration of action is short (half-life ~4-6 hours).</p>", "options": ["Diclofenac", "Nimesulide", "Piroxicam", "Ketorolac"], "html_options": ["Diclofenac", "Nimesulide", "Piroxicam", "Ketorolac"], "corr_idx": 2}, {"id": "1166674", "html_qtxt": "A 62-year-old woman presents with pain and swelling in her left knee. She has a history of peptic ulcer disease for which she is taking cimetidine. On examination, there is palpable crepitus and a limited range of motion in the affected joint. X-ray is shown below. Which of the following is the most appropriate pharmacotherapy for this patient's symptoms?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030993b4c046-f5d6-44d7-a7b4-fcccbe837cd2.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with classic features of <strong>knee osteoarthritis (OA)</strong>, both clinically and radiologically:</p>\n<ul>\n<li><strong>Joint space narrowing</strong>, <strong>subchondral sclerosis</strong>, and <strong>osteophyte formation</strong> on X-ray are hallmark features of OA.</li>\n<li>NSAIDs are the mainstay for symptomatic relief in OA. However, the patient's <strong>history of peptic ulcer disease (PUD)</strong> makes <strong>non-selective NSAIDs</strong> risky due to their <strong>COX-1 inhibition</strong>, which impairs gastric mucosal protection.</li>\n</ul>\n<p><strong>Celecoxib</strong> is a <strong>selective COX-2 inhibitor</strong>, offering <strong>anti-inflammatory and analgesic effects</strong> similar to traditional NSAIDs but with <strong>less risk of GI toxicity</strong> since it <strong>spares COX-1</strong>.</p>\n<p>This makes <strong>celecoxib the most appropriate agent</strong> in patients with GI comorbidities like PUD.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509057296fd37-5086-4b31-90d0-db361bcebdad.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Diclofenac (Option A):</strong> A <strong>non-selective NSAID</strong> that inhibits both COX-1 and COX-2. While effective for pain, it carries a <strong>high risk of gastric irritation and ulceration</strong>, which is undesirable in patients with <strong>peptic ulcer disease</strong>.</p>\n<p><strong>Nimesulide (Option B):</strong> Although it has some <strong>COX-2 preference</strong>, it is not a fully selective COX-2 inhibitor. It still poses <strong>GI and hepatic risks</strong>, and is not a safer alternative in a patient with <strong>PUD</strong>.</p>\n<p><strong>Piroxicam (Option C):</strong> A long-acting <strong>non-selective NSAID</strong> associated with <strong>high GI toxicity</strong>, especially in elderly patients and those with a prior history of ulcers. <strong>Not recommended</strong> in this patient population.</p>", "options": ["Diclofenac", "Nimesulide", "Piroxicam", "Celecoxib"], "html_options": ["Diclofenac", "Nimesulide", "Piroxicam", "Celecoxib"], "corr_idx": 3}, {"id": "1166681", "html_qtxt": "A 36-year-old woman with chronic tension headaches on aspirin presents with several episodes of bilateral flank pain and reddish urine over the past month. Her temperature is 99&deg;F, and blood pressure is 160/90 mm Hg. Physical examination reveals bilateral costovertebral angle tenderness. Laboratory findings show:<br>Hemoglobin: 10.2 g/dL<br>Serum creatinine: 2 mg/dL<br>Urinalysis:<br>1. Protein: +<br>2. RBCs: >12/hpf<br>3. WBCs: 2/hpf<br>Which of the following is the most likely underlying cause of this patient's hematuria?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient's chronic NSAID use, anemia, renal dysfunction, and painless hematuria with costovertebral angle (CVA) tenderness are characteristic of <strong>renal papillary necrosis,</strong> a hallmark of <strong>analgesic nephropathy.</strong></p>\n<ul>\n<li><strong>Pathophysiology</strong>: NSAIDs like aspirin inhibit cyclooxygenase, <strong>decreasing prostaglandin synthesis. </strong>Prostaglandins normally maintain renal papillary perfusion by<strong> dilating the vasa recta.</strong> The renal papillae are relatively hypovascular and thus prone to ischemic injury, resulting in <strong>necrosis and sloughing</strong> into the collecting system.</li>\n<li><strong>Clinical presentation</strong>: Often includes <strong>flank pain</strong>, <strong>hematuria</strong>, sometimes <strong>sterile pyuria</strong>, and <strong>renal insufficiency</strong>. Sloughed papillae can obstruct the ureters, mimicking renal colic.</li>\n<li>This condition is often <strong>bilateral</strong>, as in this case, and urinalysis typically shows <strong>hematuria</strong>, <strong>mild proteinuria</strong>, and <strong>minimal WBCs</strong>, with or without signs of AKI (elevated creatinine).</li>\n</ul>\n<p><strong>Common causes of renal papillary necrosis include:</strong></p>\n<ul>\n<li>NSAID abuse</li>\n<li>Sickle cell disease or trait</li>\n<li>Diabetes mellitus</li>\n<li>Acute pyelonephritis</li>\n<li>Obstructive uropathy</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acute pyelonephritis (Option A): </strong>Though it may present with <strong>CVA tenderness and hematuria</strong>, it typically causes <strong>fever</strong> and <strong>significant pyuria (WBCs in urine)</strong>. This patient is afebrile with low WBCs in urine, making this less likely.</p>\n<p><strong>Nephrolithiasis (Option B): </strong>Can cause hematuria, but typically causes <strong>colicky, unilateral flank pain</strong>, and may show <strong>microscopic or gross hematuria</strong>. This patient has <strong>bilateral pain</strong> and <strong>NSAID use</strong>, which favors papillary necrosis.</p>\n<p><strong>Interstitial nephritis (Option D): </strong>Though NSAIDs can cause <strong>acute interstitial nephritis</strong>, this is usually associated with <strong>fever</strong>, <strong>rash</strong>, <strong>eosinophilia</strong>, and <strong>pyuria</strong>, especially with <strong>WBC casts</strong> on urinalysis. The <strong>low WBC count</strong> here makes this less likely.</p>\n<p><strong>Key Takeaway:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905f0f6ec6b-9247-4ed9-8189-ae5c965e6d2d.png\">", "options": ["Acute pyelonephritis", "Nephrolithiasis", "Papillary necrosis", "Interstitial nephritis"], "html_options": ["Acute pyelonephritis", "Nephrolithiasis", "Papillary necrosis", "Interstitial nephritis"], "corr_idx": 2}, {"id": "1166683", "html_qtxt": "The main advantage of ketorolac over aspirin is that ketorolac:", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Ketorolac</strong> is a potent NSAID with analgesic, anti-inflammatory, and antipyretic properties. It is most widely used for <strong>short-term management </strong>(maximum 5 days) <strong>of moderate to severe pain</strong>, especially in <strong>postoperative settings</strong>, where parenteral administration is preferred.</p>\n<ul>\n<li>Unlike <strong>aspirin</strong>, ketorolac is available in <strong>injectable formulations (both IM and IV)</strong>, making it highly useful for <strong>patients unable to take oral medications</strong> or those requiring <strong>rapid pain relief</strong>.</li>\n<li>This <strong>parenteral availability</strong> is its main advantage over aspirin, which is primarily available in oral and topical forms.</li>\n</ul>\n<p>However, ketorolac <strong>still carries typical NSAID risks</strong>, including:</p>\n<ul>\n<li><strong>Prolonged bleeding time</strong> (due to COX-1 inhibition and reduced thromboxane A2 synthesis). <strong>(Option B ruled out)</strong></li>\n<li><strong>Nephrotoxicity</strong>, especially in patients with <strong>preexisting renal impairment. (Option D ruled out)</strong></li>\n<li>Hence, it should not be used beyond <strong>5 days</strong>, due to increased risk of GI bleeding and nephrotoxicity</li>\n</ul>\n<p>While ketorolac is sometimes used in combination with opioids for additive analgesic effect, it <strong>does not have a superior safety profile in such combinations</strong> compared to aspirin.<strong> (Option A ruled out)</strong></p>", "options": ["Can be combined more safely with an opioid such as codeine", "Does not prolong the bleeding time", "Available in a parenteral formulation that can be injected intramuscularly or intravenously", "Less likely to cause acute renal failure in patients with some preexisting degree of renal impairment"], "html_options": ["Can be combined more safely with an opioid such as codeine", "Does not prolong the bleeding time", "Available in a parenteral formulation that can be injected intramuscularly or intravenously", "Less likely to cause acute renal failure in patients with some preexisting degree of renal impairment"], "corr_idx": 2}, {"id": "1166687", "html_qtxt": "Which of the following drugs is most likely to increase serum concentrations of conventional doses of methotrexate, a weak acid that is primarily cleared in the urine?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Methotrexate is a <strong>weak acid</strong> that undergoes <strong>renal elimination</strong>, largely via <strong>active tubular secretion</strong> in the <strong>proximal tubule</strong>.</p>\n<p><strong>Probenecid</strong>, a uricosuric agent, <strong>inhibits organic anion transporters (OATs)</strong>, especially in the proximal renal tubule, thereby interfering with the <strong>tubular secretion</strong> of weak acids such as <strong>methotrexate</strong> and <strong>penicillin</strong>. By competitively inhibiting this transporter, <strong>probenecid reduces methotrexate clearance</strong>, causing <strong>increased serum concentrations</strong>, and hence may increase the risk of <strong>methotrexate toxicity</strong>.</p>\n<p><strong>Probenecid:</strong></p>\n<ul>\n<li><strong>Mechanism of action:</strong>\n<ul>\n<li>Inhibits <strong>URAT1</strong> transporter in the proximal tubule &rarr; &darr; uric acid reabsorption &rarr; &uarr; uric acid excretion (uricosuric effect)</li>\n<li><strong>Inhibits tubular secretion of weak acids</strong> (e.g., methotrexate, penicillin) &rarr; &uarr; serum concentrations of such drugs</li>\n</ul>\n</li>\n<li><strong>Uses:</strong>\n<ul>\n<li>Treatment of <strong>chronic gout</strong> (not used in acute attacks)</li>\n<li>Historically used to <strong>prolong the action of penicillin</strong> by decreasing its renal clearance</li>\n</ul>\n</li>\n<li><strong>Contraindications:</strong>\n<ul>\n<li><strong>Renal stones (urate nephrolithiasis)</strong></li>\n<li><strong>Renal insufficiency</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Allopurinol (Option A):</strong> Xanthine oxidase inhibitor, used to lower uric acid production. It <strong>does not affect renal tubular secretion of methotrexate</strong>. However, it may increase toxicity of drugs like 6-mercaptopurine.</p>\n<p><strong>Colchicine (Option B): </strong>Used for <strong>acute gout</strong>, acts via inhibition of microtubule polymerization. It <strong>does not interfere with methotrexate excretion</strong>.</p>\n<p><strong>Hydroxychloroquine (Option C): </strong>An antimalarial and immunomodulator used in <strong>SLE and RA</strong>; <strong>no effect on methotrexate excretion</strong>.</p>", "options": ["Allopurinol", "Colchicine", "Hydroxychloroquine", "Probenecid"], "html_options": ["Allopurinol", "Colchicine", "Hydroxychloroquine", "Probenecid"], "corr_idx": 3}, {"id": "1166689", "html_qtxt": "Which of the following patient characteristics is the most compelling reason for avoiding celecoxib in the treatment of rheumatoid arthritis?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Celecoxib</strong> is a <strong>COX-2 selective NSAID</strong> that was developed to reduce <strong>gastrointestinal toxicity</strong> compared to non-selective NSAIDs. While it indeed causes fewer GI adverse effects, it is associated with an <strong>increased risk of cardiovascular events</strong>, particularly <strong>arterial thrombotic events</strong> such as myocardial infarction (MI) and stroke.</p>\n<ul>\n<li>COX-2 inhibition leads to reduced prostacyclin (PGI2) production without affecting thromboxane A2 (produced via COX-1), thereby promoting <strong>pro-thrombotic</strong> and <strong>vasoconstrictive</strong> effects.</li>\n<li>Therefore, <strong>a prior history of myocardial infarction is a strong contraindication</strong> to COX-2 inhibitors like celecoxib.</li>\n<li>This cardiovascular risk outweighs its GI protective benefits in such patients.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Alcohol abuse (Option A):</strong> Although alcohol use can increase the risk of hepatotoxicity and GI bleeding with NSAIDs, <strong>celecoxib has less GI toxicity</strong> than non-selective NSAIDs and is not primarily hepatotoxic. Hence, alcohol abuse, while relevant, is <strong>not the most compelling reason</strong> to avoid celecoxib.</p>\n<p><strong>Gout (Option B):</strong> Gout is not a contraindication to celecoxib. In fact, <strong>NSAIDs including selective COX-2 inhibitors</strong> can be used for acute gout attacks, though indomethacin is more commonly used.</p>\n<p><strong>Peptic ulcer disease (Option D):</strong> COX-2 inhibitors like celecoxib are often <strong>preferred</strong> over traditional NSAIDs in patients with <strong>prior PUD</strong> due to their <strong>lower GI risk</strong>, particularly when used with PPIs. However, caution is still warranted in active ulcers.</p>", "options": ["Alcohol abuse", "Gout", "Myocardial infarction", "Peptic ulcer disease"], "html_options": ["Alcohol abuse", "Gout", "Myocardial infarction", "Peptic ulcer disease"], "corr_idx": 2}, {"id": "1166690", "html_qtxt": "Over the next 7 months, the patient had two more attacks of acute gout. Her serum uric acid levels were elevated. The decision was made to initiate chronic drug therapy to prevent further attacks. Which of the following drugs can be used to decrease the production of uric acid?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The goal of chronic therapy in gout is to reduce <strong>serum uric acid levels</strong> and prevent further acute attacks.</p>\n<p><strong>Allopurinol</strong> is a <strong>xanthine oxidase inhibitor</strong>, which blocks the conversion of hypoxanthine and xanthine into <strong>uric acid</strong>, thus directly <strong>reducing uric acid production</strong>. It is the drug of choice for <strong>chronic management</strong> in patients with recurrent gout or complications like tophi or uric acid nephropathy.</p>\n<ul>\n<li><strong>Mechanism of Action:</strong> Inhibits <strong>xanthine oxidase</strong> &rarr; &darr; uric acid synthesis</li>\n<li><strong>Key adverse effects:</strong>\n<ul>\n<li><strong>Rash</strong>, including rare but severe <strong>Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN)</strong></li>\n<li><strong>Allopurinol Hypersensitivity Syndrome (AHS)</strong>: life-threatening with rash, renal and hepatic dysfunction</li>\n</ul>\n</li>\n<li><strong>Drug interactions:</strong> &uarr; toxicity of <strong>azathioprine</strong> and <strong>6-mercaptopurine</strong> &rarr; dose reduction required</li>\n<li><strong>Allopurinol should never be initiated during an acute gout flare</strong>, as <strong>it may transiently worsen the attack</strong> by altering uric acid levels and triggering further crystal mobilization. Initiation should only occur once the acute episode has fully resolved, and typically with concurrent anti-inflammatory prophylaxis (e.g., colchicine or NSAIDs).</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aspirin (Option B):</strong> <strong>Low-dose aspirin</strong> inhibits renal uric acid excretion, thereby <strong>raising serum uric acid levels</strong>, <strong>contraindicated in gout</strong>.</p>\n<p><strong>Hydroxychloroquine (Option C):</strong> This is an <strong>immunomodulatory drug</strong> used in <strong>rheumatoid arthritis</strong> and <strong>SLE</strong>. It has <strong>no role in uric acid metabolism</strong>.</p>\n<p><strong>Probenecid (Option D):</strong> Probenecid is a <strong>uricosuric agent</strong>, which <strong>increases excretion</strong> of uric acid via renal tubular inhibition of reabsorption. It does <strong>not reduce production</strong>, and is contraindicated in renal dysfunction or uric acid nephrolithiasis.</p>", "options": ["Allopurinol", "Aspirin", "Hydroxychloroquine", "Probenecid"], "html_options": ["Allopurinol", "Aspirin", "Hydroxychloroquine", "Probenecid"], "corr_idx": 0}, {"id": "1166691", "html_qtxt": "A 6-year-old girl presents with symptoms following an aspirin overdose. Which of the following syndromes is this patient most likely to exhibit as a result of this drug overdose?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Salicylate (aspirin) toxicity</strong> typically presents with a <strong>triad of hyperventilation, metabolic acidosis, and hyperthermia</strong>, especially in <strong>acute overdose in children</strong>.</p>\n<ul>\n<li><strong>Pathophysiology:</strong> Salicylates uncouple oxidative phosphorylation in mitochondria, leading to <strong>increased heat production</strong>, <strong>lactic acidosis</strong>, and <strong>anion gap metabolic acidosis</strong>.</li>\n<li>CNS involvement includes <strong>tinnitus, vertigo</strong>, confusion, and with progression: <strong>seizures, coma</strong>, and potentially death.</li>\n<li>Additional findings may include <strong>tachypnea</strong> (due to direct stimulation of the respiratory center), <strong>dehydration</strong>, <strong>electrolyte disturbances</strong>, and <strong>hypoglycemia</strong>.</li>\n<li>Children are especially vulnerable due to lower detoxification capacity.</li>\n<li>Timely recognition and initiation of treatment with <strong>activated charcoal, correction of acid-base disturbances, </strong>and, if indicated, <strong>hemodialysis</strong> are essential for optimal management.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Bone marrow suppression and possibly aplastic anemia (Option A): </strong>This is typically seen with <strong>chloramphenicol toxicity</strong>, not aspirin.</p>\n<p><strong>Fever, hepatic dysfunction, and encephalopathy (Option B): </strong>These findings are more consistent with <strong>Reye's syndrome</strong>, which occurs when aspirin is given to children during or after <strong>viral infections</strong>. However, this is <strong>not the acute overdose presentation</strong> of salicylate toxicity.</p>\n<p><strong>Rapid, fulminant hepatic failure (Option D): </strong>This is characteristic of <strong>acetaminophen (paracetamol) overdose</strong>, which causes centrilobular hepatic necrosis, not salicylate toxicity.</p>", "options": ["Bone marrow suppression and possibly aplastic anemia", "Fever, hepatic dysfunction, and encephalopathy", "Hyperthermia, metabolic acidosis, and coma", "Rapid, fulminant hepatic failure"], "html_options": ["Bone marrow suppression and possibly aplastic anemia", "Fever, hepatic dysfunction, and encephalopathy", "Hyperthermia, metabolic acidosis, and coma", "Rapid, fulminant hepatic failure"], "corr_idx": 2}, {"id": "1166692", "html_qtxt": "Which of the following is a parenterally administered DMARD whose mechanism of anti-inflammatory action is antagonism of tumor necrosis factor?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Etanercept</strong> is a <strong>biologic DMARD</strong> that exerts its<strong> anti-inflammatory action</strong> <strong>by</strong> <strong>antagonizing TNF-&alpha;</strong>. It is a <strong>fusion protein</strong> composed of the <strong>soluble TNF recepto</strong>r linked to the <strong>Fc portion of IgG1, </strong>which binds circulating TNF-&alpha;, thereby <strong>p</strong>reventing its interaction with cell surface receptors and blocking downstream inflammatory effects.</p>\n<ul>\n<li><strong>Etanercept is administered parenterally (subcutaneously)</strong> and is indicated for:\n<ul>\n<li>Rheumatoid arthritis</li>\n<li>Ankylosing spondylitis</li>\n<li>Psoriatic arthritis</li>\n<li>Plaque psoriasis</li>\n<li>Inflammatory bowel disease (off-label)</li>\n</ul>\n</li>\n<li><strong>It is not a monoclonal antibody (mAb)</strong> like infliximab or adalimumab, but it still inhibits TNF-&alpha; effectively.</li>\n<li><strong>Common adverse effects</strong> include:\n<ul>\n<li>Increased risk of infections, particularly reactivation of latent tuberculosis (hence TB screening is required before initiation)</li>\n<li>Injection site reactions</li>\n<li>Hypersensitivity</li>\n<li>Worsening of heart failure</li>\n</ul>\n</li>\n</ul>\n<p><strong><strong>Explanation of Other Options:</strong></strong></p>\n<p><strong>Cyclosporine (Option A):</strong> It is a <strong>calcineurin inhibitor</strong> that suppresses T-cell activation by blocking IL-2 transcription, not TNF-&alpha; antagonism.</p>\n<p><strong>Phenylbutazone (Option C):</strong> It is a <strong>non-selective NSAID</strong>, now rarely used due to toxicity. It has no disease-modifying or TNF-&alpha; blocking action.</p>\n<p><strong>Sulfasalazine (Option D):</strong> Though used as a <strong>conventional synthetic DMARD</strong>, its mechanism involves suppression of pro-inflammatory cytokines (IL-1, TNF) <strong>indirectly</strong>, not direct TNF antagonism like etanercept.</p>", "options": ["Cyclosporine", "Etanercept", "Phenylbutazone", "Sulfasalazine"], "html_options": ["Cyclosporine", "Etanercept", "Phenylbutazone", "Sulfasalazine"], "corr_idx": 1}, {"id": "1166696", "html_qtxt": "Many clinical guidelines recommend treating acute gout with corticosteroids or indomethacin rather than high-dose colchicine because the latter is more likely to cause which of the following adverse effects?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Colchicine is an anti-inflammatory drug used for both <strong>acute gout flares</strong> and prophylaxis. However, in the <strong>acute setting</strong>, colchicine must be administered in higher doses, which are frequently associated with <strong>dose-limiting gastrointestinal toxicity</strong>.</p>\n<ul>\n<li>The most common adverse effect at therapeutic doses is <strong>severe diarrhea</strong>, often accompanied by nausea, vomiting, and abdominal cramping.</li>\n<li>These side effects occur due to <strong>colchicine's inhibition of microtubule polymerization</strong>, affecting rapidly dividing gastrointestinal epithelial cells.</li>\n<li>Because of this narrow therapeutic index, many guidelines now prefer <strong>NSAIDs (like indomethacin)</strong> or <strong>corticosteroids</strong> for acute gout, especially in older adults or those with renal dysfunction.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>High blood pressure (Option A): </strong>Colchicine is <strong>not associated with hypertension</strong>. This is more commonly a concern with NSAIDs.</p>\n<p><strong>Rash (Option B): </strong>Although <strong>hypersensitivity reactions</strong> can occur, rash is <strong>not a common or dose-limiting side effect</strong> of colchicine.</p>\n<p><strong>Sudden gastrointestinal bleeding (Option D):</strong> GI bleeding is <strong>not typical</strong> of colchicine. It is more likely with <strong>NSAIDs</strong>, particularly in elderly patients or those with peptic ulcer disease.</p>", "options": ["High blood pressure", "Rash", "Severe diarrhea", "Sudden gastrointestinal bleeding"], "html_options": ["High blood pressure", "Rash", "Severe diarrhea", "Sudden gastrointestinal bleeding"], "corr_idx": 2}]}, {"moduleId": 1008539, "name": "Drugs That Act In Respiratory System", "questions": [{"id": "1176850", "html_qtxt": "A 34-year-old female presents to the OPD with complaints of cough and mild nocturnal dyspnea for the past 2 months. She reports that the symptoms worsen in cold weather. On examination, bilateral wheezing is noted over lung fields. Chest X-ray reveals increased lung fields bilaterally and a tubular-shaped heart. A diagnosis of bronchial asthma is made, and she is started on a combination of inhaled beta-2 agonist and corticosteroids. Beta-2 agonists improve symptoms of bronchial asthma primarily by which of the following mechanisms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>&beta;2-adrenergic agonists, such as salbutamol or formoterol, are a mainstay in the treatment of bronchial asthma due to their bronchodilatory effect.</p>\n<ul>\n<li>These drugs act by stimulating &beta;2-adrenoceptors on bronchial smooth muscle.</li>\n<li>This activates adenylyl cyclase, leading to increased intracellular cyclic AMP (cAMP).</li>\n<li>Elevated cAMP levels activate protein kinase A (PKA), which inhibits myosin light-chain kinase, resulting in relaxation of bronchial smooth muscle.</li>\n<li>Additionally, &beta;2-agonists reduce the release of bronchoconstricting mediators from mast cells, reduce vascular permeability, and enhance mucociliary clearance by increasing ciliary activity.</li>\n</ul>\n<p>These actions make &beta;2-agonists effective for rapid symptom relief in asthma, particularly during nocturnal or exercise-induced bronchospasm.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030846c4d6c2-7fab-4c36-a86e-e14ba8159033.jpg\">\n<p>Side Effects of &beta;2-Agonists - \"3H, 3T\" Mnemonic:</p>\n<p>Due to increased cAMP levels (&beta;2-mediated):</p>\n<ul>\n<li>Hyperglycemia</li>\n<li>Hypotension</li>\n<li>Tremor (most common side effect)</li>\n<li>Tachycardia</li>\n</ul>\n<p>Other important adverse effects:</p>\n<ul>\n<li>Hypokalemia (due to intracellular shift of K<sup>+</sup> mediated by &beta;2 stimulation)</li>\n<li>Tachyphylaxis/Tolerance (with prolonged use due to receptor desensitization)</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<ul>\n<li><strong>Stimulates release of acetylcholine (Option A):</strong>\n<ul>\n<li>Acetylcholine causes <strong>bronchoconstriction</strong> via muscarinic receptors. Beta-2 agonists do <strong>not</strong> stimulate its release; rather, anticholinergics block its effects.</li>\n</ul>\n</li>\n<li><strong>Inhibits adenosine (Option B):</strong>\n<ul>\n<li><strong>Methylxanthines</strong> (e.g., theophylline), not beta agonists, inhibit adenosine. Adenosine causes bronchoconstriction.</li>\n</ul>\n</li>\n</ul>", "options": ["Stimulates release of acetylcholine", "Inhibits adenosine", "Stimulates adenylyl cyclase", "All of the above"], "html_options": ["Stimulates release of acetylcholine", "Inhibits adenosine", "Stimulates adenylyl cyclase", "All of the above"], "corr_idx": 2}, {"id": "1176851", "html_qtxt": "A 65-year-old male presents to the emergency department with severe dyspnea. He refuses to lie down. Vital signs reveal SpO2 of 75% on room air, respiratory rate of 24/min, pulse rate of 124/min, and blood pressure of 130/86 mm Hg. Bilateral crepitations are heard on chest auscultation, and a chest X-ray reveals emphysematous changes. His relatives mention a history of chronic smoking. He is diagnosed with COPD. Which beta-agonist should be administered for management of this acute attack of dyspnea?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>In an <strong>acute exacerbation of COPD</strong>, <strong>short-acting beta-2 agonists (SABAs)</strong> are the <strong>first-line agents</strong> for rapid bronchodilation.</p>\n<ul>\n<li><strong>Salbutamol (Albuterol)</strong> is a <strong>short-acting &beta;<sub>2</sub>-agonist (SABA)</strong> that acts within minutes and is used as the <strong>drug of choice</strong> for <strong>immediate relief</strong> of dyspnea in acute COPD exacerbations. It improves airflow by relaxing bronchial smooth muscles.</li>\n<li><strong>Salmeterol</strong> and <strong>Indacaterol</strong> are <strong>long-acting beta-2 agonists (LABAs)</strong>:\n<ul>\n<li>Salmeterol is a twice-daily LABAsc.</li>\n<li>Indacaterol is an ultra-long-acting beta agonist, given once daily.</li>\n<li>Both are not suitable for acute relief and are instead used for <strong>maintenance therapy</strong> to reduce symptoms and prevent exacerbations.</li>\n</ul>\n</li>\n<li>For relief of <strong>acute symptoms</strong>, inhalation of a <strong>SABA (e.g., salbutamol)</strong>, a <strong>short-acting anticholinergic drug (e.g., ipratropium bromide)</strong>, or a <strong>combination of both</strong>, is usually effective and often used in emergency settings.</li>\n<li>For patients with <strong>persistent symptoms </strong>of exertional dyspnea and limitation of activities, regular use of <strong>long-acting bronchodilators,</strong> such as a <strong>LABA (e.g., salmeterol)</strong> or a <strong>long-acting anticholinergic (e.g., tiotropium)</strong> is recommended.</li>\n</ul>\n<p>In patients with <strong>severe airflow obstruction</strong> or <strong>frequent exacerbations</strong>, <strong>inhaled corticosteroids</strong> may be added to the regimen to reduce future flare-ups.</p>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li><strong>Salbutamol</strong> is the drug of choice for <strong>acute relief</strong> of dyspnea in COPD.</li>\n<li><strong>Salmeterol</strong> and <strong>Indacaterol</strong> are for <strong>long-term control</strong>, not acute use.</li>\n<li>Combined <strong>SABA + anticholinergic</strong> therapy improves acute bronchodilation.</li>\n</ul>", "options": ["Indacaterol", "Salbutamol", "Salmeterol", "All the above"], "html_options": ["Indacaterol", "Salbutamol", "Salmeterol", "All the above"], "corr_idx": 1}, {"id": "1176853", "html_qtxt": "A 70-year-old male patient presents to the emergency department with severe dyspnea. He is a known case of COPD but has been non-compliant with medications. On room air, his SpO2 is 95%, pulse rate is 96/min, and BP is 126/80 mmHg. Clinical examination reveals clubbing in both hands, and coarse crepitations over lung fields. For symptom relief, he is administered intravenous aminophylline along with inhalational short-acting beta-agonist (SABA) and corticosteroids. What is the mechanism of action of aminophylline?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Aminophylline</strong>, a methylxanthine derivative, acts through <strong>multiple mechanisms</strong> to relieve bronchospasm and improve airflow in obstructive airway diseases like COPD and asthma:</p>\n<ul>\n<li><strong>Inhibition of phosphodiesterase (PDE) enzymes</strong>:</li>\n</ul>\n<p>Aminophylline inhibits PDE, particularly PDE3 and PDE4, which prevents breakdown of <strong>cyclic AMP (cAMP)</strong> and <strong>cyclic GMP (cGMP)</strong>. Elevated intracellular cAMP leads to <strong>bronchodilation</strong>, <strong>cardiac stimulation</strong>, and <strong>anti-inflammatory effects</strong>.</p>\n<ul>\n<li><strong>Antagonism of adenosine receptors</strong>:</li>\n</ul>\n<p>Aminophylline <strong>blocks adenosine receptors (A1 and A2A)</strong> on airway smooth muscle and mast cells. Adenosine normally causes <strong>bronchoconstriction</strong> and <strong>histamine release</strong>, especially in asthmatics, this antagonism contributes to bronchodilation.</p>\n<ul>\n<li><strong>Enhancement of histone deacetylation</strong>:</li>\n</ul>\n<p>Theophylline (active form of aminophylline) is thought to <strong>enhance histone deacetylase-2 (HDAC2)</strong> HDAC2 reverses histone acetylation, suppressing the expression of <strong>pro-inflammatory genes</strong>, thereby <strong>augmenting the anti-inflammatory effects</strong> of corticosteroids.</p>", "options": ["Inhibits the Phosphodiesterase enzyme", "Inhibition of cell surface receptors for adenosine", "Enhancement of histone deacetylation", "All of the above"], "html_options": ["Inhibits the Phosphodiesterase enzyme", "Inhibition of cell surface receptors for adenosine", "Enhancement of histone deacetylation", "All of the above"], "corr_idx": 3}, {"id": "1176856", "html_qtxt": "A 70-year-old male patient presents to the OPD with complaints of cough, exertional dyspnea, and chest pain. On auscultation, bilateral rhonchi are heard over the lung fields, but no abnormal heart sounds or murmurs are detected. His pulse is 88/min and blood pressure is 116/78 mmHg. A chest X-ray is suggestive of COPD, and the patient is started on oral theophylline. What is the effect of theophylline on the cardiovascular system?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Theophylline</strong>, a <strong>methylxanthine derivative</strong>, is used as a bronchodilator in COPD and asthma. In the cardiovascular system, it exerts <strong>positive chronotropic</strong> (increased heart rate) and <strong>positive inotropic</strong> (increased myocardial contractility) effects.</p>\n<p>These effects occur due to:</p>\n<ul>\n<li><strong>Adenosine receptor antagonism</strong> at low concentrations: This <strong>inhibits presynaptic adenosine receptors</strong>, leading to <strong>increased catecholamine (e.g., norepinephrine)</strong> release from sympathetic nerve endings, enhancing cardiac stimulation.</li>\n<li><strong>Phosphodiesterase (PDE) inhibition</strong> at therapeutic levels (>10 &micro;mol/L or ~2 mg/L): Increases intracellular cyclic AMP <strong>(cAMP)</strong> levels, which enhances <strong>calcium influx</strong>, promoting <strong>cardiac muscle contraction</strong>.</li>\n<li>At toxic levels (>100 &micro;mol/L), there may be impaired <strong>calcium sequestration by the sarcoplasmic reticulum</strong>, potentially leading to arrhythmias or toxicity.</li>\n</ul>", "options": ["Positive chronotropic, negative inotropic", "Negative chronotropic, positive inotropic", "Positive chronotropic and inotropic", "Negative chronotropic and inotropic"], "html_options": ["Positive chronotropic, negative inotropic", "Negative chronotropic, positive inotropic", "Positive chronotropic and inotropic", "Negative chronotropic and inotropic"], "corr_idx": 2}, {"id": "1176857", "html_qtxt": "Which of the following sentences are true for methylxanthines?<br>1. They have positive chronotropic and inotropic effects on heart.<br>2. They inhibit the secretion of gastric acid and digestive enzymes.<br>3. They are weak diuretics but have no therapeutic significance.<br>4. They reverse fatigue of diaphragm in patient with COPD.<br>5. They cause bronchoconstriction.", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Methylxanthines</strong> (notably <strong>theophylline</strong>) are bronchodilators with systemic effects, mediated by:</p>\n<ul>\n<li><strong>Phosphodiesterase (PDE) inhibition</strong> &rarr; &uarr; intracellular <strong>cAMP</strong></li>\n<li><strong>Adenosine receptor antagonism</strong></li>\n</ul>\n<p><strong>CVS effects:</strong></p>\n<ul>\n<li>Produce <strong>positive chronotropic and inotropic effects (Statement 1 is true)</strong></li>\n<li>At <strong>low concentrations</strong>, this results from <strong>adenosine receptor inhibition</strong>, increasing catecholamine release</li>\n<li>At <strong>higher concentrations</strong>, <strong>PDE inhibition</strong> leads to &uarr; cAMP and Ca2+ influx, enhancing myocardial contractility and heart rate</li>\n</ul>\n<p><strong>GIT effects:</strong></p>\n<ul>\n<li><strong>Stimulate</strong> gastric acid and <strong>digestive enzyme secretion</strong>, not inhibit <strong>(Statement 2 is false)</strong></li>\n<li>May lead to gastric irritation and risk of <strong>peptic ulceration</strong> in sensitive individuals</li>\n</ul>\n<p><strong>Renal effects:</strong></p>\n<ul>\n<li>Act as weak diuretics</li>\n<li>Mechanism: &uarr; <strong>glomerular filtration rate</strong> + &darr; <strong>tubular sodium reabsorption</strong></li>\n<li>However, the diuretic effect is <strong>minimal</strong> and has <strong>no therapeutic value (Statement 3 is true)</strong></li>\n</ul>\n<p><strong>Respiratory System:</strong></p>\n<ul>\n<li>Enhance <strong>skeletal muscle contractility</strong>, especially the <strong>diaphragm</strong></li>\n<li><strong>Reverse fatigue of respiratory muscles in COPD,</strong> improving ventilatory response to hypoxia and <strong>reducing dyspnea</strong> even in irreversible airway obstruction <strong>(Statement 4 is true)</strong></li>\n</ul>\n<p><strong>Airway Effect (Primary Therapeutic Action):</strong></p>\n<ul>\n<li><strong>Bronchodilation</strong>, not bronchoconstriction <strong>(Statement 5 is false)</strong></li>\n<li>Achieved by <strong>relaxation of airway smooth muscle</strong> and <strong>mast cell stabilization</strong></li>\n<li>No tolerance develops to this bronchodilatory action</li>\n</ul>", "options": ["1, 3, 5", "1, 2, 4", "1, 3, 4", "1, 4, 5"], "html_options": ["1, 3, 5", "1, 2, 4", "1, 3, 4", "1, 4, 5"], "corr_idx": 2}, {"id": "1176864", "html_qtxt": "Assertion (A): Tiotropium does not inhibit M2 receptor-mediated auto-downregulation of acetylcholine release.<br>Reason (R): Tiotropium dissociates most rapidly from M2 receptors.<br>Which of the following is correct?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Tiotropium is a long-acting antimuscarinic agent <strong>(LAMA)</strong> used in the management of <strong>COPD</strong>.</p>\n<ul>\n<li>It binds with high affinity to <strong>M1, M2, and M3 muscarinic receptors</strong>, but its dissociation kinetics provide a functional selectivity.</li>\n<li>Specifically, <strong>tiotropium dissociates most rapidly from the M2 receptors</strong>, which are <strong>located presynaptically on parasympathetic nerves</strong> and are responsible for <strong>inhibiting acetylcholine release</strong> via negative feedback (auto-downregulation).</li>\n<li>Because tiotropium does <strong>not inhibit M2 receptor function</strong>, <strong>acetylcholine release is preserved</strong>, and excessive cholinergic stimulation is avoided. This preserved M2 function explains why tiotropium has a <strong>better safety and side effect profile</strong> than agents like ipratropium.</li>\n</ul>", "options": ["Both A and R are true, and R is the correct explanation of A", "Both A and R are true, but R is not the correct explanation of A", "A is true, but R is false", "A is false, but R is true"], "html_options": ["Both A and R are true, and R is the correct explanation of A", "Both A and R are true, but R is not the correct explanation of A", "A is true, but R is false", "A is false, but R is true"], "corr_idx": 0}, {"id": "1176871", "html_qtxt": "A 75-year-old male patient is a known case of COPD and is on combination therapy with a long-acting &beta;2 agonist (LABA) and corticosteroids. What is the most important action of corticosteroids in this context?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Corticosteroids are widely used in the <strong>management of COPD and asthma</strong> due to their potent <strong>anti-inflammatory properties</strong>.</p>\n<ul>\n<li>Their <strong>primary mechanism</strong> is the <strong>inhibition of inflammatory cell infiltration</strong> into the airway wall. This includes suppression of <strong>eosinophils</strong>, <strong>mast cells</strong>, and <strong>lymphocytes</strong>, which play a major role in chronic airway inflammation.</li>\n<li><strong>They do not act as direct bronchodilators</strong>, i.e., they <strong>do not activate &beta;2 receptors</strong>, although they can <strong>enhance the sensitivity and response to &beta;2 agonists</strong>, thereby offering a <strong>synergistic effect</strong> when used with LABAs. <strong>(Option A ruled out)</strong></li>\n<li>Although corticosteroids may exert some <strong>anti-fibrotic</strong> and <strong>mucus-suppressing</strong> effects, these are <strong>not the primary reason</strong> for their clinical use in obstructive airway disease.<strong> (Options B & D ruled out)</strong></li>\n</ul>", "options": ["Beta receptor agonist", "Anti-fibrotic effect", "Inhibition of infiltration of airway", "Suppression of mucus secretion"], "html_options": ["Beta receptor agonist", "Anti-fibrotic effect", "Inhibition of infiltration of airway", "Suppression of mucus secretion"], "corr_idx": 2}, {"id": "1176874", "html_qtxt": "A 78-year-old male presents to the emergency department with severe dyspnea. He is a known case of COPD and is on inhalational LABA + corticosteroids. His SpO2 on room air is 96%, pulse rate is 120/min, and blood pressure is 140/90 mm Hg. On auscultation, bilateral fine crepitations are heard. He needs urgent treatment for dyspnea. What is the appropriate dose of intravenous methylprednisolone every 6-12 hours?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>In cases of <strong>acute exacerbation of COPD</strong>, especially when patients present with <strong>increased dyspnoea</strong>, <strong>tachycardia</strong>, or auscultatory abnormalities (e.g., fine crepitations), <strong>systemic corticosteroids</strong> are a key component of initial management.</p>\n<ul>\n<li>For patients with <strong>moderate to severe dyspnea</strong>, or those who require hospitalization, <strong>intravenous corticosteroids</strong> are preferred.</li>\n<li>The recommended <strong>initial dose</strong> of IV <strong>methylprednisolone</strong> is <strong>1 mg/kg every 6 to 12 hours</strong> during the acute phase. This helps reduce airway inflammation, improve airflow, and accelerate recovery.</li>\n<li>Alternatively, <strong>oral prednisone</strong> can be started at <strong>30-60 mg per day</strong>, particularly when IV access is delayed or the patient is stable enough for oral administration.</li>\n<li>Once clinical improvement is noted, the corticosteroid dose is gradually <strong>tapered</strong> over 7-10 days.</li>\n<li>Prompt corticosteroid administration in acute exacerbation leads to <strong>faster improvement in lung function, reduced hospitalization duration, and decreased relapse rates</strong>.</li>\n</ul>", "options": ["0.5 mg/kg", "1 mg/kg", "1.5 mg/kg", "2 mg/kg"], "html_options": ["0.5 mg/kg", "1 mg/kg", "1.5 mg/kg", "2 mg/kg"], "corr_idx": 1}, {"id": "1176876", "html_qtxt": "Inhalational corticosteroids are preferred over oral prednisolone due to fewer systemic side effects. Which dose of inhalational beclomethasone is approximately equivalent to oral prednisone 10-15 mg/day?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Inhalational corticosteroids (ICS) are the <strong>mainstay of controller therapy in asthma</strong>, primarily because they allow for <strong>local delivery</strong> to the airways with <strong>minimal systemic absorption</strong>, thereby avoiding many of the systemic side effects seen with oral steroids.</p>\n<p><strong>Beclomethasone dipropionate</strong>, delivered via metered-dose inhaler, is a commonly used ICS.</p>\n<ul>\n<li>A total daily dose of <strong>400 mcg of inhaled beclomethasone</strong> (typically administered as <strong>two puffs twice daily</strong>) is considered <strong>therapeutically equivalent</strong> to <strong>oral prednisone 10-15 mg/day</strong> in terms of anti-inflammatory activity for asthma control.</li>\n<li>This dose achieves adequate airway anti-inflammatory effect <strong>without significant systemic effects</strong>, especially compared to systemic corticosteroids like oral prednisone.</li>\n</ul>\n<p>Other inhaled corticosteroids such as budesonide and fluticasone have similar efficacy but different potency and dosage equivalence.</p>", "options": ["200 mcg/day", "400 mcg/day", "600 mcg/day", "800 mcg/day"], "html_options": ["200 mcg/day", "400 mcg/day", "600 mcg/day", "800 mcg/day"], "corr_idx": 1}, {"id": "1176877", "html_qtxt": "Which of the following agents has no effect on airway smooth muscle tone and is ineffective in reversing asthmatic bronchospasm?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Cromolyn sodium (disodium cromoglycate)</strong> is a mast cell stabilizer that was once used in asthma management, especially in children, before being largely replaced by more effective treatments like inhaled corticosteroids and long-acting &beta;2-agonists.</p>\n<ul>\n<li><strong>Mechanism of Action:</strong> Cromolyn acts by <strong>inhibiting degranulation of mast cells</strong>, thereby preventing the release of histamine and other mediators involved in early and late-phase allergic responses.</li>\n<li><strong>Key Limitation:</strong> It <strong>does not relax airway smooth muscle</strong> and thus has <strong>no role in reversing acute bronchospasm</strong>. Its utility lies <strong>only in prophylaxis</strong>, particularly for <strong>exercise-induced</strong> or <strong>antigen-induced asthma</strong>, and requires regular dosing (usually 4 times daily) to reduce overall bronchial reactivity.</li>\n<li>Due to <strong>poor gastrointestinal absorption</strong>, it must be <strong>inhaled as a fine powder or aerosol suspension</strong>.</li>\n<li>While it can reduce the frequency of asthma attacks with regular use, <strong>it is ineffective in acute settings</strong>, where bronchodilators like &beta;2 agonists are preferred.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Salmeterol (Option A):</strong> A <strong>long-acting beta-2 agonist (LABA)</strong> that causes <strong>bronchodilation</strong> by directly acting on airway smooth muscle. Used in maintenance therapy of asthma (not for acute attacks), but <strong>has direct effect on smooth muscle tone</strong>.</p>\n<p><strong>Beclomethasone (Option B):</strong> An <strong>inhaled corticosteroid (ICS)</strong> that reduces <strong>airway inflammation</strong>. Although it does not directly cause bronchodilation, it <strong>reduces airway hyperreactivity over time</strong> and is effective in <strong>preventing asthma symptoms</strong>. Its role is <strong>anti-inflammatory</strong>, not smooth muscle relaxation.</p>\n<p><strong>Montelukast (Option D): </strong>A <strong>leukotriene receptor antagonist (LTRA)</strong> that blocks leukotriene-mediated effects such as <strong>bronchoconstriction and inflammation</strong>. It does not act directly on airway smooth muscle but <strong>reduces bronchospasm indirectly</strong> and is effective as an <strong>oral controller drug</strong>.</p>", "options": ["Salmeterol", "Beclomethasone", "Cromolyn", "Montelukast"], "html_options": ["Salmeterol", "Beclomethasone", "Cromolyn", "Montelukast"], "corr_idx": 2}, {"id": "1176879", "html_qtxt": "Cromolyn and nedocromil are used as nasal sprays and eye drops to reduce symptoms of which of the following conditions?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Cromolyn sodium and nedocromil are <strong>mast cell stabilizers</strong> that inhibit the degranulation of sensitized mast cells, thereby preventing the release of inflammatory mediators like <strong>histamine and leukotrienes</strong>. These drugs are particularly useful in <strong>IgE-mediated hypersensitivity reactions</strong>, such as <strong>allergic rhinoconjunctivitis</strong>.</p>\n<ul>\n<li>When administered as a <strong>nasal spray or ophthalmic solution</strong>, they are effective in reducing symptoms like <strong>sneezing, nasal congestion, rhinorrhea, and conjunctival itching</strong> in allergic rhinoconjunctivitis, especially during pollen season.</li>\n<li>These agents are <strong>most effective when used prophylactically</strong> and require <strong>regular dosing (2-4 times daily)</strong>.</li>\n<li>Studies have shown efficacy in <strong>about 75% of patients</strong>, especially during high-allergen seasons like spring.</li>\n<li>They are <strong>not effective</strong> against infectious causes such as bacterial or viral conjunctivitis, since they act on allergic (immune-mediated) pathways, not infectious agents. <strong>(Options A, B & D ruled out)</strong></li>\n</ul>\n<p>Though less potent than <strong>inhaled corticosteroids</strong>, they have the advantage of <strong>minimal systemic side effects</strong> and are commonly used in pediatric and mild allergic cases.</p>", "options": ["Bacterial rhinoconjunctivitis", "Viral rhinoconjunctivitis", "Allergic rhinoconjunctivitis", "All of the above"], "html_options": ["Bacterial rhinoconjunctivitis", "Viral rhinoconjunctivitis", "Allergic rhinoconjunctivitis", "All of the above"], "corr_idx": 2}, {"id": "1176882", "html_qtxt": "Leukotrienes are derived from arachidonic acid by the action of which enzyme?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Leukotrienes are <strong>inflammatory lipid mediators</strong> synthesized from <strong>arachidonic acid</strong> via the <strong>lipoxygenase pathway</strong>. The enzyme <strong>5-lipoxygenase</strong> is responsible for this conversion and is a <strong>key rate-limiting enzyme</strong> in leukotriene biosynthesis.</p>\n<ul>\n<li>This enzyme acts in <strong>inflammatory cells</strong> such as <strong>eosinophils, mast cells, basophils, and macrophages</strong>, playing a critical role in conditions like <strong>asthma and anaphylaxis</strong>.</li>\n<li><strong>Leukotriene B4 (LTB4)</strong> functions as a <strong>potent chemoattractant</strong> for neutrophils.</li>\n<li><strong>LTC4 and LTD4</strong> contribute to <strong>bronchoconstriction</strong>, <strong>mucosal edema</strong>, <strong>mucus hypersecretion</strong>, and <strong>airway hyperreactivity</strong>, all of which are hallmark features of <strong>asthma</strong> and other allergic conditions.</li>\n<li>Blocking leukotriene synthesis or receptor binding has been a major target in drug development, leading to agents like <strong>zileuton (5-lipoxygenase inhibitor)</strong> and <strong>montelukast (leukotriene receptor antagonist).</strong></li>\n</ul>", "options": ["4-lipoxygenase", "5-lipoxygenase", "6-lipoxygenase", "7-lipoxygenase"], "html_options": ["4-lipoxygenase", "5-lipoxygenase", "6-lipoxygenase", "7-lipoxygenase"], "corr_idx": 1}, {"id": "1176884", "html_qtxt": "What is the mechanism of action of leukotriene pathway inhibitors?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Leukotriene pathway inhibitors work through <strong>two primary mechanisms</strong> to counteract leukotriene-mediated inflammation, particularly in asthma and allergic conditions:</p>\n<ol>\n<li><strong>Inhibition of 5-lipoxygenase enzyme </strong>\n<ul>\n<li><strong>Zileuton</strong> is the prototype drug in this category.</li>\n<li>It inhibits the <strong>5-lipoxygenase enzyme</strong>, which converts arachidonic acid into leukotriene A4 (LTA4), thereby blocking the synthesis of downstream leukotrienes (including LTB4, LTC4, LTD4, and LTE4).</li>\n</ul>\n</li>\n<li><strong>Antagonism of the cysteinyl leukotriene receptor (specifically LTD4 receptor)</strong>\n<ul>\n<li><strong>Montelukast</strong>, <strong>zafirlukast</strong>, and <strong>pranlukast</strong> are selective antagonists of the <strong>CysLT1 receptor</strong>, which binds LTD4.</li>\n<li>This prevents bronchoconstriction, mucus production, and vascular permeability mediated by LTD4.</li>\n</ul>\n</li>\n</ol>\n<p>By either <strong>inhibiting leukotriene synthesis</strong> or <strong>blocking receptor-mediated actions</strong>, both mechanisms attenuate bronchoconstriction, mucus secretion, and inflammation in airway diseases. <strong>(Options A & B ruled out)</strong></p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>LTB4 receptor agonist (Option D): </strong>LTB4 is a potent neutrophil chemoattractant. Agonism would <strong>exacerbate inflammation</strong>, not inhibit it. No therapeutic drugs use this pathway.</p>", "options": ["Inhibition of 5-lipoxygenase", "LTD4 receptor antagonist", "A and B both", "LTB4 receptor agonist"], "html_options": ["Inhibition of 5-lipoxygenase", "LTD4 receptor antagonist", "A and B both", "LTB4 receptor agonist"], "corr_idx": 2}, {"id": "1176890", "html_qtxt": "What is the pediatric dose of montelukast?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Montelukast</strong> is a <strong>leukotriene receptor antagonist (LTRA)</strong> used for the prophylaxis and chronic treatment of asthma and allergic rhinitis.</p>\n<ul>\n<li>The <strong>standard pediatric dose</strong> of montelukast is <strong>4 mg once daily</strong>, typically used for children <strong>aged 2 to 5 years</strong>.</li>\n<li>For older children (6-14 years), the dose is <strong>5 mg once daily</strong>, and for adolescents and adults (&ge;15 years), <strong>10 mg once daily</strong> is the standard dose.</li>\n</ul>\n<p>Other leukotriene modifiers:</p>\n<ul>\n<li><strong>Zileuton</strong> (a 5-lipoxygenase inhibitor): 1200 mg twice daily (sustained-release)</li>\n<li><strong>Zafirlukast</strong>: 20 mg twice daily</li>\n</ul>", "options": ["10 mg once daily", "10 mg twice daily", "4 mg once daily", "4 mg twice daily"], "html_options": ["10 mg once daily", "10 mg twice daily", "4 mg once daily", "4 mg twice daily"], "corr_idx": 2}, {"id": "1176892", "html_qtxt": "Which of the following is an anti-IgE monoclonal antibody?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Omalizumab</strong> is a <strong>recombinant humanized monoclonal antibody</strong> that specifically targets <strong>immunoglobulin E (IgE)</strong>, a key mediator in the allergic cascade of asthma and other atopic conditions.</p>\n<ul>\n<li>It binds to the <strong>Fc region of free IgE</strong>, specifically the site that interacts with high-affinity IgE receptors (<strong>Fc&epsilon;RI and Fc&epsilon;RII</strong>) on <strong>mast cells and basophils</strong>, thereby <strong>preventing allergen-triggered degranulation</strong> and inflammatory mediator release.</li>\n<li>Importantly, it <strong>does not bind to IgE already attached to mast cells</strong>, avoiding receptor cross-linking and minimizing the risk of anaphylaxis.</li>\n</ul>\n<p>This makes Omalizumab a pivotal drug in the treatment of <strong>moderate to severe persistent allergic asthma</strong>, especially in patients with elevated IgE levels who are inadequately controlled with inhaled corticosteroids.</p>\n<p>Monoclonal antibodies used in asthma target different interleukins or receptors:</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905da5a54ed-c848-4f42-9bd9-0d7f2c7936bd.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Tocilizumab (Option A):</strong> This is an <strong>anti-IL-6 receptor monoclonal antibody</strong>, used in <strong>rheumatoid arthritis</strong> and cytokine release syndromes, not in allergic asthma.</p>\n<p><strong>Itolizumab (Option B): </strong>This is a <strong>humanized anti-CD6 monoclonal antibody</strong>, used in <strong>psoriasis</strong> and <strong>COVID-19 cytokine storm</strong>, with no role in IgE-mediated conditions.</p>\n<p><strong>Bevacizumab (Option C): </strong>This monoclonal antibody targets <strong>VEGF (vascular endothelial growth factor)</strong> and is primarily used in <strong>cancers</strong> (e.g., colorectal, renal cell carcinoma) and <strong>ocular neovascular diseases</strong>.</p>", "options": ["Tocilizumab", "Itolizumab", "Bevacizumab", "Omalizumab"], "html_options": ["Tocilizumab", "Itolizumab", "Bevacizumab", "Omalizumab"], "corr_idx": 3}, {"id": "1176894", "html_qtxt": "Additional treatment with inhalational beta agonists is needed when FEV1 is less than ____ % of predicted.", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Bronchial asthma</strong> management depends on the severity and frequency of symptoms, as well as objective measures of lung function, such as <strong>forced expiratory volume in 1 second (FEV1)</strong>.</p>\n<ul>\n<li>Patients with <strong>intermittent asthma</strong>, who experience symptoms <strong>less than twice a week</strong> and have <strong>normal FEV1 (>80%)</strong>, usually require only <strong>as-needed inhaled &beta;2-agonists</strong> (e.g., albuterol).</li>\n<li>However, if:\n<ul>\n<li>Symptoms occur <strong>more than twice per week</strong>,</li>\n<li><strong>Nocturnal symptoms</strong> are present <strong>more than twice a month</strong>, or</li>\n<li><strong>FEV1 < 80% of predicted</strong>, then <strong>additional maintenance therapy</strong> is warranted.</li>\n</ul>\n</li>\n<li>The <strong>first-line controller medication</strong> is a <strong>low-dose inhaled corticosteroid (ICS)</strong>. Alternatives include <strong>leukotriene receptor antagonists (LTRAs)</strong> or <strong>mast cell stabilizers</strong> like <strong>cromolyn</strong>.</li>\n<li><strong>Theophylline</strong> is now rarely used due to its narrow therapeutic window and side effect profile and is typically reserved for cases unresponsive to standard therapies.</li>\n</ul>", "options": ["50", "60", "80", "90"], "html_options": ["50", "60", "80", "90"], "corr_idx": 2}, {"id": "1176898", "html_qtxt": "Which of the following is false regarding Deriphylline?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Deriphylline</strong> is a combination of <strong>theophylline and etofylline</strong>, both of which belong to the <strong>methylxanthine class</strong> of drugs. These agents exhibit both <strong>bronchodilator</strong> and <strong>cardiostimulant</strong> effects.</p>\n<ul>\n<li>Methylxanthines have <strong>positive inotropic</strong> (increased contractility) and <strong>chronotropic</strong> (increased heart rate) effects.</li>\n<li><strong>Mechanism:</strong> At <strong>low concentrations</strong>, they block <strong>adenosine receptors</strong> on presynaptic sympathetic nerves, leading to <strong>increased catecholamine release</strong>, thereby stimulating the heart.</li>\n<li>At <strong>moderate to high concentrations</strong>, they <strong>inhibit phosphodiesterase</strong>, increasing <strong>cAMP</strong> levels, which enhances <strong>calcium influx</strong>, contributing to arrhythmogenic potential.</li>\n<li>At <strong>very high concentrations (>100 &micro;mol/L)</strong>, <strong>calcium sequestration by the sarcoplasmic reticulum</strong> is impaired, further contributing to <strong>cardiac excitability and arrhythmias</strong>.</li>\n</ul>\n<p>Hence, <strong>tachycardia and cardiac arrhythmias</strong> are known adverse effects. <strong>Bradycardia</strong> is <strong>not</strong> typically associated with methylxanthine toxicity or therapeutic use</p>", "options": ["Causes tachycardia", "Causes bradycardia", "Causes cardiac arrhythmias", "None of the above"], "html_options": ["Causes tachycardia", "Causes bradycardia", "Causes cardiac arrhythmias", "None of the above"], "corr_idx": 1}, {"id": "1176899", "html_qtxt": "Initial treatment with oral and inhalational corticosteroids is recommended for patients with severe airway obstruction. Severe airway obstruction is defined as FEV1 less than what percentage of the predicted value?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>In the management of <strong>bronchial asthma</strong>, if symptoms are <strong>frequent or severe</strong>, or if there is <strong>significant airflow limitation despite bronchodilator therapy</strong>, <strong>inhaled corticosteroids (ICS)</strong> should be initiated.</p>\n<ul>\n<li>In cases. where <strong>FEV1 < 50% of predicted</strong>, this is classified as <strong>severe airway obstruction</strong>, and treatment should include <strong>both inhaled and oral corticosteroids</strong>.</li>\n<li>A common regimen is <strong>prednisone 30 mg/day</strong> orally for approximately <strong>3 weeks</strong>, combined with ICS.</li>\n<li>Clinical improvement is generally observed within <strong>7-10 days</strong>, after which oral corticosteroids can be <strong>tapered or discontinued</strong>.</li>\n</ul>\n<p>Additionally, the <strong>GOLD (Global Initiative for Chronic Obstructive Lung Disease)</strong> classification stages the severity of COPD based on the <strong>post-bronchodilator FEV1 percentage of predicted value</strong>, with the <strong>mandatory criterion</strong> of FEV1/FVC < 0.7.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906c8641b12-5d3c-40b6-a72c-cac032620d39.png\">", "options": ["80", "70", "60", "50"], "html_options": ["80", "70", "60", "50"], "corr_idx": 3}, {"id": "1176900", "html_qtxt": "Omalizumab is used to reduce the frequency and severity of exacerbations by targeting which type(s) of inflammation?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Omalizumab</strong> is a recombinant <strong>humanized monoclonal antibody</strong> that targets <strong>IgE</strong>. It is indicated in patients with <strong>chronic moderate-to-severe allergic asthma</strong> who remain <strong>symptomatic despite high-dose inhaled corticosteroids and long-acting &beta;2-agonists</strong>.</p>\n<ul>\n<li>The drug acts by binding to the <strong>Fc portion of free IgE</strong>, preventing it from attaching to mast cells and basophils.</li>\n<li>This reduces the <strong>release of proinflammatory mediators</strong>, ultimately leading to <strong>downregulation of allergic inflammation</strong>.</li>\n</ul>\n<p>Omalizumab has been shown to reduce:</p>\n<ul>\n<li><strong>Lymphocytic inflammation</strong>, particularly <strong>Th2 cells</strong>, which drive allergic responses.</li>\n<li><strong>Eosinophilic inflammation</strong>, which contributes significantly to airway hyperresponsiveness and late-phase allergic reactions. <strong>(Options A & B ruled out)</strong></li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Basophilic (Option D):</strong></p>\n<p>Omalizumab binds to <strong>circulating IgE</strong> and prevents mast cell and basophil activation but <strong>does not directly reduce basophilic inflammation</strong> in the bronchial mucosa.</p>", "options": ["Lymphocytic", "Eosinophilic", "A and B both", "Basophilic"], "html_options": ["Lymphocytic", "Eosinophilic", "A and B both", "Basophilic"], "corr_idx": 2}]}, {"moduleId": 1008540, "name": "GI Pharmacology", "questions": [{"id": "1167147", "html_qtxt": "A 74-year-old man with Type II Diabetes mellitus presents with new onset dystonia, resting tremor, rigidity, and bradykinesia. He was recently started on a medication for a gastrointestinal disorder. Which of the following drugs was most likely prescribed?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient likely has <strong>diabetic gastroparesis</strong> and was started on metoclopramide, which caused <strong>drug-induced Parkinsonism</strong>, presenting as tremor, rigidity, bradykinesia, and dystonia.</p>\n<p><strong>Metoclopramide:</strong></p>\n<ul>\n<li>Metoclopramide is a<strong> dopamine D2 receptor antagonist</strong> used as a prokinetic and antiemetic.</li>\n<li>It acts by blocking D2 receptors, stimulating 5-HT4 receptors, and antagonising 5-HT3 receptors centrally and peripherally.</li>\n<li>It <strong>enhances gastric motility </strong>by increasing lower oesophageal sphincter tone and promoting antral and small intestinal contractions.</li>\n</ul>\n<p><strong>Uses:</strong></p>\n<ul>\n<li>Metoclopramide is a first-line therapy in patients with gastroparesis.</li>\n<li>As an adjunctive agent for the prevention of cisplatin-induced delayed emesis and for emesis failing first-line treatments.</li>\n</ul>\n<p><strong>Side effects:</strong></p>\n<ul>\n<li><strong>Extrapyramidal symptoms:</strong>\n<ul>\n<li>Dystonias usually occur acutely after intravenous administration, and Parkinsonian-like symptoms may occur several weeks after initiation of therapy.</li>\n<li>Generally respond to treatment with anticholinergic or antihistaminic drugs and reverse on discontinuation of metoclopromide.</li>\n<li><strong>Tardive dyskinesia </strong>can also occur with chronic use.</li>\n</ul>\n</li>\n<li>Anxiety, depression</li>\n<li><strong>Prolonged QT intervals</strong></li>\n<li>Galactorrhea - By blocking the inhibitory effect of dopamine on prolactin release.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Cimetidine (Option A): </strong>Cimetidine is an H2 receptor antagonist used to treat gastric and duodenal ulcers, uncomplicated GERD, and prevent stress ulcers. Common side effects include diarrhoea, headache, fatigue, and constipation.  Less commonly, it may cause central nervous system effects such as confusion, delirium, hallucinations, and slurred speech.</p>\n<p><strong>Erythromycin (Option B): </strong>Erythromycin is a macrolide antibiotic that also treats gastroparesis by stimulating motilin receptors in the gastrointestinal tract. However, it does not cause CNS side effects or extrapyramidal symptoms.</p>\n<p><strong>Granisetron (Option D): </strong>Granisetron is a 5-HT3 receptor antagonist used as an antiemetic.  It may cause asymptomatic ECG changes like QT and PR interval prolongation and is not associated with CNS symptoms.</p>", "options": ["Cimetidine", "Erythromycin", "Granisetron", "Metoclopramide"], "html_options": ["Cimetidine", "Erythromycin", "Granisetron", "Metoclopramide"], "corr_idx": 3}, {"id": "1167148", "html_qtxt": "A 60-year-old man presents with altered mental status and ataxia. Physical examination revealed scleral icterus, flapping tremor and severe abdominal distension. Laboratory studies showed altered LFt and elevated serum ammonia levels. He was started on a drug that lowers serum ammonia levels. Which of the following best describes the mechanism of action of the drug?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The clinical symptoms and signs suggest <strong>hepatic encephalopathy</strong>, and <strong>lactulose </strong>is the first-line treatment, which reduces ammonia levels by acidification of the gut contents.</p>\n<ul>\n<li>Severe liver disease impairs the <strong>detoxification of ammonia </strong>(NH3) generated as a result of colonic bacterial metabolism of urea.</li>\n<li>The resultant effect is neuropsychiatric dysfunction, which can range from disorientation and asterixis (flapping tremor of the hand) to coma.</li>\n<li>The treatments of choice for hepatic encephalopathy are lactulose, low-protein diets, and rifaximin.</li>\n</ul>\n<p><strong>Mechanism of action of lactulose:</strong></p>\n<ul>\n<li>Normal bacterial flora degrade lactulose into the short-chain fatty acid lactic acid, resulting in acidification of the gut lumen.</li>\n<li>This acidic environment favours the conversion of colonic ammonia (NH3) to ammonium (NH4).</li>\n<li>This therapy significantly lowers blood ammonia levels.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Bile acid sequestrant  (Option A): A </strong>Bile acid sequestrant, such as cholestyramine, is used to lower LDL cholesterol and also to treat bile-salt-induced diarrhoea.</p>\n<p><strong>Binds to 50S ribosomal subunit (Option C):</strong> Drugs like neomycin have been used in the management of hepatic encephalopathy in patients unresponsive to lactulose therapy.Neomycin acts by binding to the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis and suppressing the growth of urease-producing bacteria. Other antibiotics like rifaximin, metronidazole, oral vancomycin, paromomycin, and quinolones also lower ammoniagenic bacteria in the colon.</p>\n<p><strong>Chelators (Option D):</strong> Chelators are used to treat heavy metal toxicity. One example of a chelator is penicillamine, which is used to lower copper levels in patients with Wilson's disease.</p>", "options": ["Acidification of intestinal contents", "Bile acid sequestrant", "Binds to 50S ribosomal subunit", "Chelator"], "html_options": ["Acidification of intestinal contents", "Bile acid sequestrant", "Binds to 50S ribosomal subunit", "Chelator"], "corr_idx": 0}, {"id": "1167149", "html_qtxt": "A 44-year-old man presents with abdominal cramps associated with blood in his stools and fever. A colonoscopy performed revealed ulceration of the mucosa and submucosa. Which of the following drugs is the most appropriate initial pharmacotherapy for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient's symptoms and colonoscopy findings are suggestive of <strong>ulcerative colitis</strong>. First-line treatment for <strong>mild to moderate disease</strong> typically includes 5-aminosalicylates, such as <strong>mesalamine</strong> or <strong>sulfasalazine</strong>.</p>\n<ul>\n<li>Ulcerative colitis is a form of inflammatory bowel disease that affects the rectum and extends proximally.</li>\n<li>It presents as bloody diarrhoea, lower abdominal cramps, faecal urgency, anaemia, leucocytosis, and low serum albumin in the presence of negative stool cultures.</li>\n<li>Ulcerative colitis is characterised by inflammation of the colonic mucosa and has a relapsing and remitting appearance of symptoms.</li>\n<li>Treatment of choice depends on the severity of the disease:\n<ul>\n<li><strong>5&shy;-ASA drugs</strong> induce and maintain remission in ulcerative colitis and are considered to be the first&shy;line agents for treatment of mild to moderate active ulcerative colitis.</li>\n<li><strong>Glucocorticoids</strong> are commonly used in the treatment of patients with moderate to severe active IBD.</li>\n</ul>\n</li>\n<li>Among 5-ASA drugs, mesalamine is the first choice in treatment. Sulfasalazine is a secondary treatment option because other 5-ASA compounds (mesalamine, olsalazine, balsalazide) are generally better tolerated</li>\n</ul>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090664858a30-145a-4347-9e34-93903783c283.png\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Docusate sodium (Option A): </strong>Docusate sodium is a stool softener used in the treatment of constipation.</p>\n<p><strong>Lansoprazole (Option B): </strong>Lansoprazole is a <strong>proton pump inhibitor </strong>that acts by suppressing gastric acid secretion. It is primarily used in the treatment of GERD, gastric and duodenal ulcers, H. pylori eradication, and Zollinger-Ellison syndrome. They are ineffective in the treatment of IBDs.</p>\n<p><strong>Metoclopramide (Option D): </strong>Metoclopramide is a<strong> dopamine D2 receptor antagonist</strong> used as a prokinetic and antiemetic. They are used in the treatment of gastroparesis and chemotherapy-induced vomiting.</p>", "options": ["Docusate sodium", "Lansoprazole", "Mesalamine", "Metoclopramide"], "html_options": ["Docusate sodium", "Lansoprazole", "Mesalamine", "Metoclopramide"], "corr_idx": 2}, {"id": "1167150", "html_qtxt": "A 57-year-old man presented with an acute onset of severe intermittent abdominal pain, associated with nausea and vomiting. He reports the symptoms have started shortly after starting on a new medication, and he is unable to tolerate oral fluids. On examination, high-pitched, tinkling bowel sounds are heard on auscultation. Which of the following drugs most likely triggered his symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The presence of high-pitched tinkling bowel sounds and intermittent abdominal pain with vomiting indicates possible <strong>intestinal obstruction. </strong>Prokinetic agents like <strong>metoclopramide</strong>, which increase gastrointestinal motility, may aggravate the obstruction.</p>\n<ul>\n<li>Intestinal obstruction typically presents with intermittent abdominal pain, abdominal distension, obstipation, nausea, and vomiting.</li>\n<li>Early symptoms may include episodic pain and constipation.</li>\n<li>Medications should be carefully considered for those with any degree of bowel obstruction because of the risk of worsening the obstruction or causing perforation of the intestinal tract.</li>\n<li>Generally, the administration of any product that stimulates the intestinal tract is contraindicated in patients with mechanical bowel obstruction.</li>\n<li>These products can promote an intestinal tract perforation secondary to the build-up of pressure behind the obstruction.</li>\n<li>Prokinetic agents like metoclopramide act by sensitising tissues to acetylcholine via D2 receptor antagonism to <strong>enhance peristalsis and gastric emptying</strong>.</li>\n<li>Medications contraindicated in bowel obstruction:\n<ul>\n<li>Prokinetic agents</li>\n<li>Bowel stimulants like Senna</li>\n<li>Medications prone to constipation: Calcium channel blockers and anticholinergics.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Antacids (Option A): </strong>The use of antacids may be a suitable option for these patients. However, certain antacids can cause constipation and may worsen the degree of obstruction. As a general rule, aluminium and calcium antacids cause constipation and magnesium antacids cause diarrhoea. This is why aluminium and magnesium-containing antacids are often combined in a single product.</p>\n<p><strong>Famotidine (Option B):</strong> Famotidine is an H2 receptor antagonist which helps suppress acid secretion, and its use is not associated with intestinal obstruction.</p>\n<p><strong>Lansoprazole (Option D): </strong>The proton pump inhibitor lansoprazole is considered safe in patients with bowel obstruction. They have no role in GI motility.</p>", "options": ["Antacids", "Famotidine", "Lansoprazole", "Metoclopramide"], "html_options": ["Antacids", "Famotidine", "Lansoprazole", "Metoclopramide"], "corr_idx": 3}, {"id": "1167151", "html_qtxt": "A 48-year-old man presents with non-bloody diarrhoea and right lower quadrant abdominal pain. On physical examination, there is tenderness and a palpable mass in the right lower quadrant. Which of the following drugs is the most appropriate treatment for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient is presenting with signs and symptoms of <strong>Crohn's disease</strong>. Acute flare-ups are usually treated with corticosteroids like<strong> prednisone.</strong></p>\n<ul>\n<li>Crohn's disease is an idiopathic inflammatory process which can affect any portion of the alimentary tract.</li>\n<li>This condition is often characterised by intermittent bouts of low-grade fever, diarrhoea, malaise, and weight loss, as well as focal tenderness and a palpable, tender mass in the lower abdomen.</li>\n<li>Nonpharmacologic therapy can be efficacious in some cases, but more severe cases may require corticosteroids such as prednisone. </li>\n<li><strong>Glucocorticoids</strong> induce a reduction in the inflammatory response and symptomatic remission in most patients with Crohn's disease.</li>\n<li><strong>Prednisone </strong>is the most commonly administered glucocorticoid and is used for the induction of remission of<strong> moderate-to-severe Crohn's disease.</strong></li>\n<li>It is sometimes given as a first-line therapeutic to <strong>induce remission.</strong></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Dicyclomine (Option A): </strong>Dicyclomine is an oral antispasmodic with weak muscarinic receptor antagonism. It relaxes smooth muscles in the intestinal tract and inhibits bradykinin-induced and histamine-induced spasms of the intestinal tract. Dicyclomine is occasionally used in the treatment of diarrhoea-predominant irritable bowel syndrome.</p>\n<p><strong>Hydrocortisone (Option B): </strong>Hydrocortisone suppositories are indicated for the treatment of distal ulcerative colitis, not Crohn's disease.</p>\n<p><strong>Mesalamine (Option C):</strong> Mesalamine is a 5-aminosalicylic acid derivative indicated for the maintenance of remission of ulcerative colitis.</p>", "options": ["Dicyclomine", "Hydrocortisone suppositories", "Mesalamine", "Prednisone"], "html_options": ["Dicyclomine", "Hydrocortisone suppositories", "Mesalamine", "Prednisone"], "corr_idx": 3}, {"id": "1167152", "html_qtxt": "A 52-year-old man with a history of alcoholic cirrhosis is brought to the ER with complaints of vomiting blood. On examination, he was diaphoretic, hypotensive. An upper GI endoscopy revealed active oesophageal bleeding. Which of the following is the most appropriate pharmacotherapy for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>In patients with cirrhosis and portal hypertension, somatostatin analogue <strong>octreotide </strong>is used for the acute management of variceal bleeding.</p>\n<ul>\n<li><strong>Octreotide</strong> is a synthetic somatostatin analogue that inhibits multiple hormones, including vasoactive intestinal polypeptide (VIP), luteinizing hormone, growth hormone, glucagon, and insulin.</li>\n<li>Octreotide inhibits the release of vasodilator hormones, thus causing <strong>splanchnic vasoconstriction</strong>, which decreases portal inflow and therefore helps to decrease variceal bleeding.</li>\n<li>It is also used to treat acromegaly and diarrhoea in various endocrine disorders, such as carcinoid syndrome, gastrinoma, and glucagonoma.</li>\n<li>Management of the acute variceal bleeding:\n<ul>\n<li>Drug of choice: Terlipressin > Octreotide</li>\n<li>Endoscopic ligation</li>\n<li>Prophylaxis: Beta-blockers like propranolol</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Misoprostol (Option A): </strong>Misoprostol is a synthetic analogue of PGE1 that is FDA-approved to prevent NSAID-induced mucosal Injury. They act by inhibiting intracellular cyclic AMP and gastric acid secretion.</p>\n<p><strong>Omeprazole (Option C): </strong>Omeprazole, being a proton pump inhibitor, is mainly used in the treatment of GERD and gastric ulcers. They are not useful in the acute management of variceal bleeding.</p>\n<p><strong>Tranexamic acid (Option D):</strong> Tranexamic acid can be used as an adjuvant in controlling variceal bleeding, but it is not a definitive management.</p>\n<p><strong>Key Takeaways:</strong></p>\n<p>DOC for acute variceal bleeding:<strong> Terlipressin </strong>> Octreotide</p>", "options": ["Misoprostol", "Octreotide", "Omeprazole", "Tranexamic acid"], "html_options": ["Misoprostol", "Octreotide", "Omeprazole", "Tranexamic acid"], "corr_idx": 1}, {"id": "1167153", "html_qtxt": "A 28-year-old woman presents with nausea, vomiting, headache, blurred vision, and dizziness shortly after drinking a glass of wine. On examination, she is diaphoretic and tachycardic. She was diagnosed with a duodenal ulcer 3 days ago and is currently on treatment. Which of the following drugs is most likely responsible for her symptoms?", "html_expl": "<p><strong>Explanation for answer:</strong></p>\n<p>The patient was likely started on metronidazole as part of H. pylori eradication therapy for a duodenal ulcer. <strong>Metronidazole </strong>can cause a disulfiram-like reaction when taken with alcohol, explaining her symptoms.</p>\n<ul>\n<li>Metronidazole inhibits acetaldehyde dehydrogenase, leading to an accumulation of acetaldehyde, producing a <strong>disulfiram-like reaction. </strong></li>\n<li>Patients experience abdominal distress, vomiting, flushing, or headache if they drink alcoholic beverages during or within 3 days of therapy.</li>\n</ul>\n<p><strong>Drugs that produce a disulfiram like reaction:</strong></p>\n<ul>\n<li>Cephalosporins like cefoperazone, cefotetan</li>\n<li>Metronidazole</li>\n<li>Sulfonylureas: Chloropropamide</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906824be02b-5f67-4d49-ad03-faa5802eeb9d.png\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250913be89282d-a04f-4c6f-b39c-b40da20fb466.png\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Amoxicillin (Option A): </strong>Though a component of triple therapy in H. pylori eradication, it doesn't cause a disulfiram like reaction. <strong>Hypersensitivity reactions</strong> are the most clinically important adverse effects noted with the penicillins. Manifestations of hypersensitivity to penicillins include maculopapular rash, urticarial rash, fever, bronchospasm, vasculitis, serum sickness, and exfoliative dermatitis.</p>\n<p><strong>Bismuth subsalicylate (Option B): </strong>Bismuth compounds have antisecretory, anti-inflammatory, and antimicrobial effects, and are used in H. pylori treatment. They may cause harmless black stool and tongue discolouration. Use should be short-term and avoided in renal impairment, as prolonged use can rarely cause bismuth-induced encephalopathy.</p>\n<p><strong>Omeprazole (Option D): </strong>Omeprazole is an integral component of the H.pylori eradication regimen. PPIs are generally safe and reported to have the least side effects like headache, abdominal pain. Chronic use can result in Vit B12 deficiency. Hypomagnesemia and hypocalcemia.</p>", "options": ["Amoxicillin", "Bismuth subsalicylate", "Metronidazole", "Omeprazole"], "html_options": ["Amoxicillin", "Bismuth subsalicylate", "Metronidazole", "Omeprazole"], "corr_idx": 2}, {"id": "1167155", "html_qtxt": "A 47-year-old woman presents with right upper abdominal pain, especially after eating fatty foods. On examination, she is febrile and has right upper quadrant tenderness as well as inspiratory arrest on deep palpation. The patient deferred surgery and opted for medical management. Which of the following best describes the mechanism of action of the agent that can be used to treat the patient's underlying condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This presentation is typical of <strong>cholecystitis</strong>, most likely due to gallstones <strong>(cholelithiasis)</strong>. In patients opting for non-surgical management, <strong>ursodeoxycholic acid</strong> can be used for oral litholysis, which acts by reducing cholesterol synthesis, secretion, and absorption.</p>\n<ul>\n<li>Ursodeoxycholic acid is a secondary bile acid, which is a metabolic byproduct of intestinal bacteria.</li>\n<li>The drug gets concentrated in bile and decreases biliary cholesterol by suppressing hepatic synthesis and secretion of cholesterol as well as inhibiting its intestinal absorption.</li>\n<li>Thus, the <strong>decreased cholesterol saturation</strong> causes the gradual solubilisation of cholesterol from gallstones, resulting in their eventual dissolution.</li>\n<li>Ursodiol is also the first&shy;line agent used for the treatment of early primary biliary cirrhosis.</li>\n<li>When used alone, it may take months to years to be fully effective, and it may not produce a full therapeutic response in all patients.</li>\n<li>It can be combined with ultrasonic lithotripsy to dissolve gallstone fragments.</li>\n<li>Laparoscopic cholecystectomy may also be used in patients who are surgical candidates.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Agonist of &mu;-opiate receptors of the gastrointestinal tract (Option A):</strong> Drugs like loperamide are agonists of &mu;-opiate receptors in the enteric nervous system. They decrease gut motility and are used as an anti-diarrhoeal agent.</p>\n<p><strong>Catalyses the hydrolysis of fats to monoacylglycerols, glycerol, and fatty acids (Option B): </strong>This is basically the function of pancreatic lipase, and pancreatic lipase preparations are available in the market to be used for pancreatic enzyme replacement. Two major preparations are pancrelipase and pancreatin, used for the treatment of exocrine pancreatic insufficiency.</p>\n<p><strong>Somatostatin analogue (Option D): </strong>Octreotide and lanreotide are commonly used somatostatin analogues. They are used in the treatment of acromegaly, acute management of variceal bleeding and refractory diarrhoea.</p>", "options": ["Agonist of &mu;-opiate receptors of the gastrointestinal tract", "Catalyses the hydrolysis of fats to monoacylglycerols, glycerol, and fatty acids", "Decreases cholesterol synthesis, secretion, and absorption", "Somatostatin analogue"], "html_options": ["Agonist of &mu;-opiate receptors of the gastrointestinal tract", "Catalyses the hydrolysis of fats to monoacylglycerols, glycerol, and fatty acids", "Decreases cholesterol synthesis, secretion, and absorption", "Somatostatin analogue"], "corr_idx": 2}, {"id": "1167158", "html_qtxt": "A 63-year-old woman is started on an opioid analgesic along with docusate sodium. Which of the following best describes the action of docusate sodium?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Constipation and miosis are the only opioid effects that do not develop tolerance.<strong> Laxatives </strong>are the first-line treatment for opioid-induced constipation, and <strong>docusate</strong> is a commonly used <strong>stool softener.</strong></p>\n<ul>\n<li>For the treatment of constipation, <strong>stool softeners and bulk-forming laxatives </strong>are the preferred initial treatment choices.</li>\n<li>In patients with hard stool and/or straining on defecation, stool softeners may be preferred.</li>\n<li><strong>Docusate</strong> is a <strong>stool softener</strong>that is available over the counter.</li>\n<li>It acts as a detergent to allow water and fatty substances in stool to mix, increasing luminal mass. It is particularly useful to prevent constipation.</li>\n<li>In patients with loose stools between episodes of constipation, a bulk-forming laxative may be preferred.</li>\n</ul>\n<p>Another alternative to a laxative is the use of <strong>&mu;-opioid receptor antagonists like </strong>methylnaltrexone and naloxegol.</p>\n<p><strong>Drugs causing constipation:</strong></p>\n<ul>\n<li>Opioid analgesics (e.g., codeine, hydrocodone, oxycodone, and morphine)</li>\n<li>Calcium channel blockers</li>\n<li>Anticholinergics</li>\n<li>Tricyclic antidepressants</li>\n<li>Antipsychotics.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Bulk-forming laxative (Option A): </strong>Bulk&shy;forming laxatives are indigestible, hydrophilic colloids that absorb water, forming a bulky, emollient gel that distends the colon and promotes peristalsis. Common preparations include natural plant products (bran, psyllium, methylcellulose) and synthetic fibres (polycarbophil).</p>\n<p><strong>Stimulant laxative (Option B): </strong>Bisacodyl, senna, and aloe are used as stimulant laxatives. They act by inducing limited low-grade inflammation in the small and large bowel to promote the accumulation of water and electrolytes and stimulate intestinal motility.</p>\n<p><strong>Osmotic agents (Option D): </strong>Osmotic laxatives are soluble but nonabsorbable compounds that result in increased stool liquidity due to an obligate increase in faecal fluid. Commonly used agents include milk of magnesia, polyethylene glycol.</p>\n<p><strong>Key Takeaways:</strong></p>\n<p><strong>Treatment of opioid induced constipation:</strong></p>\n<ul>\n<li>Laxative</li>\n<li>&mu;-opioid receptor antagonists like methylnaltrexone and naloxegol.</li>\n</ul>", "options": ["Bulk-forming laxative", "Stimulant laxative", "Osmotic agent", "Stool softener"], "html_options": ["Bulk-forming laxative", "Stimulant laxative", "Osmotic agent", "Stool softener"], "corr_idx": 3}, {"id": "1167160", "html_qtxt": "A patient being treated with verapamil for hypertension and angina develops constipation. Which of the following is an osmotic laxative that can be used to relieve this patient's constipation?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Constipation is a known side effect of <strong>calcium channel blockers</strong> like verapamil and can be treated with osmotic laxatives like<strong> magnesium hydroxide.</strong></p>\n<p>Laxatives may be classified by their major mechanism of action and include:</p>\n<ul>\n<li><strong>Bulk-forming laxatives: </strong>Bulk&shy;forming laxatives are indigestible, hydrophilic colloids that absorb water, forming a bulky, emollient gel that distends the colon and promotes peristalsis. Common preparations include natural plant products (bran, psyllium, methylcellulose) and synthetic fibres (polycarbophil)</li>\n<li><strong>Stool surfactant agents (softeners): </strong>These agents soften stool material, permitting water and lipids to penetrate. Common agents include <strong>docusate</strong> and glycerin suppositories.</li>\n<li><strong>Osmotic laxatives:</strong> Osmotic laxatives are soluble but nonabsorbable compounds that result in increased stool liquidity due to an obligate increase in faecal fluid.<strong> Magnesium hydroxide and PEG</strong> are commonly used osmotic laxatives.</li>\n<li><strong>Stimulant laxatives:</strong> They act by inducing limited low-grade inflammation in the small and large bowel to promote the accumulation of water and electrolytes and stimulate intestinal motility.<strong> Bisacodyl</strong>, senna, and aloe are used as stimulant laxatives.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Aluminium hydroxide (Option A): </strong>Aluminium hydroxide causes constipation and is thus used in combination with magnesium salts to preserve normal bowel function.</p>\n<p><strong>Diphenoxylate (Option B): </strong>Diphenoxylate is an opioid agonist used in the treatment of diarrhoea in combination with atropine. In normal doses, it has no analgesic effects, while high doses can cause CNS toxicity.</p>\n<p><strong>Metoclopramide (Option D): </strong>Metoclopramide is a D2 receptor antagonist used as first&shy;line therapy in the treatment of patients with delayed gastric emptying due to postsurgical disorders (vagotomy, antrectomy) and diabetic gastroparesis. It is also used in the treatment of GERD and has antiemetic action.</p>", "options": ["Aluminium hydroxide", "Diphenoxylate", "Magnesium hydroxide", "Metoclopramide"], "html_options": ["Aluminium hydroxide", "Diphenoxylate", "Magnesium hydroxide", "Metoclopramide"], "corr_idx": 2}, {"id": "1167164", "html_qtxt": "A 40-year-old male presents with burning chest pain radiating into his neck. On evaluation, ECG and troponin levels were normal. He was diagnosed with gastroesophageal reflux disease and initiated on a drug that irreversibly inhibits the H<sup>+</sup>/K<sup>+</sup> ATPase enzyme in gastric parietal cells. Which of the following is not a side-effect of the drug prescribed?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Proton pump inhibitors </strong>are drugs that act by <strong>inhibiting H<sup>+</sup>/K<sup>+</sup> ATPase enzyme</strong> in gastric parietal cells, and hypogastrinemia is not a side effect of PPI.</p>\n<ul>\n<li>Proton pump inhibitors are prodrugs that require activation in an acidic environment.</li>\n<li>The activated form of the drug binds covalently with the sulfhydryl groups of cysteines in the H+, K+-ATPase, irreversibly inactivating the pump molecule.</li>\n<li>Because they block the final step in acid production, the PPIs effectively suppress stimulated acid production.</li>\n</ul>\n<p><strong>Side effects of PPIs:</strong></p>\n<ul>\n<li><strong>Gastrointestinal</strong>\n<ul>\n<li>Nausea, diarrhoea, abdominal pain, flatulence <em>(Option C ruled out)</em></li>\n<li>&uarr; Risk of <strong> Difficile</strong> infection <em>(Option A ruled out)</em></li>\n</ul>\n</li>\n<li><strong>Reactive hypergastrinemia</strong>\n<ul>\n<li>&darr; Absorption of <strong>iron</strong> and vitamin B12</li>\n<li>&darr; Absorption of calcium and magnesium &rarr; &uarr; risk of <strong>osteoporosis</strong> in long-term use&rarr; &uarr; risk of fractures in elderly individuals. <em>(Option B ruled out)</em></li>\n</ul>\n</li>\n<li><strong>Neurological</strong>\n<ul>\n<li>Light-headedness, headaches</li>\n<li>Possibly increased risk of developing cognitive impairment/dementia</li>\n</ul>\n</li>\n<li><strong>Others</strong>\n<ul>\n<li>Exanthema</li>\n<li>Visual disturbances (rare)</li>\n<li>&uarr; Risk of pneumonia</li>\n<li>In rare cases, acute interstitial nephritis</li>\n</ul>\n</li>\n</ul>", "options": ["&uarr; Risk of C. difficile infection", "Osteoporosis", "Flatulence", "Hypogastrinemia"], "html_options": ["&uarr; Risk of C. difficile infection", "Osteoporosis", "Flatulence", "Hypogastrinemia"], "corr_idx": 3}, {"id": "1167165", "html_qtxt": "A 2-year-old child presents with a history of watery diarrhoea with 4-6 episodes daily. There is no blood or mucus in the stool. While awaiting medical evaluation. Which of the following is the most appropriate oral fluid to prevent dehydration in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Sodium-glucose solution refers to <strong>ORS</strong> and is the most effective and evidence-based method to prevent and treat dehydration due to diarrhoea in children.</p>\n<ul>\n<li>Oral rehydration therapy is the cornerstone for patients with acute illnesses resulting in significant diarrhoea.</li>\n<li>This therapy exploits the fact that<strong> nutrient-linked cotransport</strong> of water and electrolytes remains intact in the small bowel in most cases of acute diarrhoea.</li>\n<li>Na+ absorption links to glucose uptake by the enterocyte, which is followed by movement of water in the same direction.</li>\n<li>A balanced mixture of glucose and electrolytes in volumes matched to losses, therefore, can prevent dehydration.</li>\n<li>This can be provided by many commercial premixed formulas using glucose-electrolyte or rice-based physiological solutions.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Chicken broth with added salt (Option A), Diluted cow's milk (Option B):</strong> Neither of these is recommended in diarrhoea and can even worsen the condition.</p>\n<p><strong>Filtered water with no added solutes (Option D):</strong> Filtered water can help in fluid replacement, but does not provide optimal nutrients and electrolyte requirements needed in diarrhoea.</p>", "options": ["Chicken broth with added salt", "Diluted cow's milk", "Filtered water with no added solutes", "Sodium-glucose solution"], "html_options": ["Chicken broth with added salt", "Diluted cow's milk", "Filtered water with no added solutes", "Sodium-glucose solution"], "corr_idx": 3}, {"id": "1167167", "html_qtxt": "A 32-year-old woman with irritable bowel syndrome with diarrhoea has not responded to conventional treatments. After discussing potential side effects, she opts to begin therapy with alosetron. Which of the following best describes the mechanism of action of this drug?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Alosetron</strong> is a potent<strong> 5-HT3 receptor antagonist</strong> that is approved for the treatment of irritable bowel syndrome in women whose main symptom is diarrhoea.</p>\n<ul>\n<li>The clinical effect of 5-HT3 antagonism is a general reduction in GI contractility with decreased colonic transit, along with an increase in fluid absorption.</li>\n<li><strong>Alosetron </strong>is a highly potent and selective antagonist of the 5&shy;HT3 receptor.</li>\n<li>The most serious adverse reactions are <strong>constipation </strong>and<strong> ischemic colitis.</strong></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>5-HT4 receptor agonist (Option B): </strong> 5-HT4 agonists enhance the release of acetylcholine, which stimulates motility throughout the GI tract. Prucalopride is a high&shy;affinity 5&shy;HT4 agonist that is approved for the treatment of chronic constipation. Other 5-HT4 agonists are tegaserod, cisapride and mosapride.</p>\n<p><strong>D2 receptor antagonist (Option C):</strong> Metoclopramide and domperidone are D2 receptor antagonists used a prokinetic and antiemetic agents.  Metoclopamide is also used in the treatment of GERD and gastroparesis.</p>\n<p><strong>NK1 Receptor antagonist (Option D): </strong>Neurokinin 1 (NK1)&shy;receptor antagonists have antiemetic properties that are mediated through central blockade in the area postrema. These are mainly used for treating chemotherapy-induced emesis. Aprepitant, netupitant and fosaprepitant are examples of the NK1 receptor antagonist.</p>", "options": ["5-HT3 receptor antagonist", "5-HT4 receptor agonist", "D2 receptor antagonist", "NK1 receptor antagonist"], "html_options": ["5-HT3 receptor antagonist", "5-HT4 receptor agonist", "D2 receptor antagonist", "NK1 receptor antagonist"], "corr_idx": 0}, {"id": "1167169", "html_qtxt": "A 45-year-old man with dyslipidaemia is started on simvastatin and cholestyramine. Which of the following best describes the respective independent effects of simvastatin and cholestyramine on hepatic cholesterol synthesis?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Statins decrease hepatic cholesterol synthesis, while bile acid resins like cholestyramine increase hepatic cholesterol synthesis.</p>\n<ul>\n<li><strong>Statins</strong> are the<strong> first-line therap</strong>y for most patients with hypercholesterolemia. </li>\n<li>These drugs competitively<strong> inhibit HMG CoA reductase</strong>, the enzyme responsible for the conversion of HMG CoA to mevalonate.</li>\n<li>This inhibition decreases hepatic cholesterol synthesis, and the resulting upregulation of LDL receptors causes increased uptake of LDL from the circulation.</li>\n<li>Statins are very effective in reducing LDL cholesterol.</li>\n<li><strong>Bile acid-binding resins</strong> (ie, bile acid sequestrants) work by binding bile acids in the gastrointestinal tract, thereby interfering with the enterohepatic circulation of bile acids and causing increased bile acid excretion.</li>\n<li>This results in hepatic synthesis of new bile acids, a process that consumes liver cholesterol stores. </li>\n<li>Hepatic uptake of LDL from the circulation is increased for continued bile acid synthesis. Bile acid production and secretion are increased by 10-fold due to this interruption of the enterohepatic circulation of bile acids. </li>\n<li>Hepatic cholesterol reduction is an activating factor for HMG CoA reductase and subsequently results in increased hepatic cholesterol synthesis. </li>\n<li>This effect can be blocked with the addition of a statin drug to the treatment regimen, leading to a greater reduction in LDL levels than with use of either drug alone (synergistic action).</li>\n</ul>", "options": ["Increase and increase", "Decrease and increase", "Decrease and decrease", "Increase and no change"], "html_options": ["Increase and increase", "Decrease and increase", "Decrease and decrease", "Increase and no change"], "corr_idx": 1}, {"id": "1167171", "html_qtxt": "A 23-year-old woman presents with an acute onset of nausea and vomiting after returning from a trip to Varanasi and Mathura. There is no history of blood or mucus in the stools. Which of the following receptor targets would be most effective in improving her symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The patient's symptoms are typical of classic<strong> traveller's diarrhoea. </strong></li>\n<li>Traveller's diarrhoea can be caused by a variety of organisms, including bacteria (eg, Escherichia coli), viruses (eg, rotaviruses), or occasionally, parasites (eg, Cryptosporidium parvum).</li>\n<li>The choice of antiemetic therapy depends on the source of the emetogenic stimulus. </li>\n<li>Conditions that cause gastrointestinal irritation (eg, infections, chemotherapy, distention) result in increased mucosal serotonin release and activation of 5-HT3 receptors on vagal and spinal afferent nerves.</li>\n<li>These then relay their impulses to the medullary vomiting centre, inducing emesis.</li>\n<li><strong>5-HT3 receptor antagonists</strong> (eg, ondansetron) are well-tolerated medications that are very effective at reducing nausea and vomiting caused by gastrointestinal upset.</li>\n<li>5HT3 receptor antagonists:\n<ul>\n<li>Ondansetron</li>\n<li>Granisetron</li>\n<li>Alosetron</li>\n<li>Dolasetron</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>&mu;- Opioid Receptors (Option A): </strong>Mu-opioid receptors are primarily responsible for the analgesic effects of opioids. Activation of these receptors can worsen nausea and vomiting and can cause constipation. &mu;- Opioid Receptor antagonist, like methylnaltrexone and naloxegol, are used to treat opioid induced constipation.</p>\n<p><strong>Dopamine receptor (Option C):</strong> D2 receptor antagonists like metaclopramide are used in the treatment of gastroparesis and GERD due to their prokinetic action. Though inhibition of D2 receptor in chemoreceptor zone of the medulla explains their antiemetic action, but are not first-line for gastroenteritis.</p>\n<p><strong>Histamine receptor (Option D): </strong>H1 receptor blockers like diphenhydramine and promethazine are highly effective in the treatment of nausea associated with motion sickness and vestibular disturbances.</p>", "options": ["5-HT3 receptor", "&mu;-Opioid Receptors", "Dopamine receptor", "Histamine receptor"], "html_options": ["5-HT3 receptor", "&mu;-Opioid Receptors", "Dopamine receptor", "Histamine receptor"], "corr_idx": 0}, {"id": "1167173", "html_qtxt": "Which of the following drugs stimulates chloride secretion into the gut lumen and is used for irritable bowel syndrome?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Linaclotide </strong>stimulates chloride and fluid secretion into the intestinal lumen via<strong> guanylate cyclase-C activation,</strong> relieving constipation in irritable bowel syndrome.</p>\n<ul>\n<li>Linaclotide is approved for the treatment of chronic constipation and IBS with predominant constipation.</li>\n<li>Linaclotide activates guanylyl cyclase-C on the luminal intestinal epithelial surface, which leads to activation of the cystic fibrosis transmembrane conductance regulator, leading to<strong> increased chloride-rich secretion </strong>and<strong> acceleration of intestinal transit.</strong></li>\n</ul>\n<p><strong>Drugs used in irritable bowel syndrome:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906e8fd003f-cd7e-42e7-933a-3a7e7211a42b.png\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Balsalazide (Option A):</strong> Balasalazide is, 5-ASA drug used in the treatment of inflammatory bowel disease, especially ulcerative colitis. 5-ASA drugs are not used in the treatment of IBS.</p>\n<p><strong>Omeprazole (Option B): </strong>Omeprazole is a proton pump inhibitor which acts by inhibiting H+/K+ ATPase in gastric parietal cells to suppress acid secretion. They are used in the treatment of GERD, gastric and duodenal ulcers and Zollinger-Ellison syndrome; they have no role in chloride secretion.<strong> </strong></p>\n<p><strong>Pancrelipase (Option D):</strong> Pancrelipase is a pancreatic enzyme replacement therapy commonly used as the mainstay treatment for pancreatic insufficiency.</p>", "options": ["Balsalazide", "Omeprazole", "Linaclotide", "Pancrelipase"], "html_options": ["Balsalazide", "Omeprazole", "Linaclotide", "Pancrelipase"], "corr_idx": 2}, {"id": "1167174", "html_qtxt": "A 78-year-old male with advanced dementia presents with abdominal pain and constipation. He was treated with polyethylene glycol is administered which produces a bowel movement within 24 hours. The mechanism of action of polyethylene glycol is most similar to the pathophysiology of which of the following disorders?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Polyethylene glycol is an <strong>osmotic laxative</strong> that draws water into the intestinal lumen, softening stool and promoting bowel movements. Its mechanism closely resembles the pathophysiology of osmotic diarrhoea, such as in <strong>lactase deficiency, </strong>where unabsorbed lactose retains water in the gut, causing diarrhoea.</p>\n<ul>\n<li>Osmotic laxatives are<strong> nonabsorbable or poorly absorbable </strong>substances that attract water into the intestinal lumen, thus distending the intestinal wall and increasing peristalsis. </li>\n<li>Polyethylene glycol and Magnesium hydroxide are examples of osmotic laxatives that are often used.</li>\n<li>Lactase deficiency is a disease state characterised by osmotic diarrhoea. Inherited or acquired deficiency of the intestinal brush border enzyme lactase causes an inability to break down lactose into glucose and galactose. </li>\n<li>Undigested lactose is a nonabsorbable osmotic substance, and its accumulation in the small intestine leads to an increase in the secretion of water and electrolytes into the intestinal lumen.</li>\n<li>Lactase deficiency (i.e., lactose intolerance) presents with abdominal pain and distension and watery diarrhoea.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Irritable bowel syndrome (Option A): </strong>IBS is an idiopathic chronic, relapsing disorder characterised by abdominal discomfort in association with alterations in bowel habits (diarrhoea, constipation, or both). Diarrhoea predominant IBS is usually treated with stool softeners and 5-HT3 antagonist alosetron, while constipation predominant IBS is treated with anti-diarrheal agents like loperamide and chloride channel activators like lubiprostone.</p>\n<p><strong>Crohn's disease (Option B)</strong>: Crohn's disease is a type of inflammatory bowel disease that typically presents with non-bloody diarrhoea and right lower quadrant abdominal pain. It is primarily managed with corticosteroids such as prednisone during acute flares.</p>\n<p><strong>Rectal prolapse (Option D): </strong>Rectal prolapse usually follows chronic constipation and straining, with patients presenting with a mass protruding from the anus, painful defecation and sometimes bleeding. It can be managed with stool softeners and pelvic floor exercises; surgery is indicated in full-thickness prolapse.</p>", "options": ["Irritable bowel syndrome", "Crohn's disease", "Lactase deficiency", "Rectal prolapse"], "html_options": ["Irritable bowel syndrome", "Crohn's disease", "Lactase deficiency", "Rectal prolapse"], "corr_idx": 2}, {"id": "1167175", "html_qtxt": "38-year-old woman with a history of motion sickness is planning a vacation cruise and visits her family doctor before the trip. She was recommended an appropriate drug therapy. If so, she should be advised about which of the following most common side effects of this medication?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Antimuscarinic agents </strong>and<strong> first-generation antihistamines </strong>are most effective for the management of motion sickness. Anticholinergic side effects are common with these medications and may include&nbsp;<strong>blurry vision, dry mouth, urinary retention, and constipation.</strong></p>\n<ul>\n<li><strong>Scopolamine</strong>, the muscarinic antagonist, given orally, parenterally, or transdermally, is the most effective drug for the prophylaxis and treatment of motion sickness.</li>\n<li>Scopolamine is available in a <strong>transdermal patch</strong> placed behind the ear that delivers</li>\n<li>scopolamine for approximately 3 days.</li>\n<li>When administered in this fashion, scopolamine is effective against motion sickness without causing substantial anticholinergic side effects.</li>\n<li>Among H1 receptor antagonists, <strong>Cyclizine</strong> and meclizine have been used primarily to counter motion sickness, although <strong>promethazine </strong>and diphenhydramine are more effective.</li>\n</ul>\n<p><strong>Key Takeaways:</strong></p>\n<p><strong>Drugs used for motion sickness:</strong></p>\n<ul>\n<li>Scopolamine (First-line treatment)</li>\n<li>H1 receptor antagonist: cyclizine, promethazine, diphenhydramine</li>\n</ul>", "options": ["Cough", "Diarrhoea", "Dry mouth", "Nasal congestion"], "html_options": ["Cough", "Diarrhoea", "Dry mouth", "Nasal congestion"], "corr_idx": 2}, {"id": "1167176", "html_qtxt": "Which of the following is a small molecule that polymerises in stomach acid and coats the ulcer bed, resulting in accelerated healing and reduction of symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>In an acid environment (pH <4), <strong>sucralfate</strong> undergoes extensive cross-linking to produce a viscous, sticky polymer that <strong>adheres to epithelial cells and ulcer craters </strong>for up to 6 h after a single dose.</li>\n<li>In addition to inhibiting the hydrolysis of mucosal proteins by pepsin, sucralfate may have other<strong> cytoprotective effects</strong>, including stimulation of local production of PGs and epidermal growth factor.</li>\n<li>Sucralfate is no longer used to treat peptic ulcer disease because PPIs are more effective.</li>\n<li>However, it is used for the initial treatment of GERD in pregnancy because it is poorly absorbed and for the treatment of mucositis secondary to cancer therapy.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Omeprazole (Option A): </strong>Omeprazole belongs to the class of proton pump inhibitors and is mainly used to treat GERD, peptic ulcers, and erosive esophagitis, especially when H2 blockers fail. They are also combined with antibiotics for <em>H. pylori</em> eradication and are first-line for conditions like Zollinger-Ellison syndrome. PPIs act by inhibiting H+ K+-ATPase, irreversibly to block the final pathway of acid production.</p>\n<p><strong>Cimetidine (Option C): </strong>The H2 receptor antagonists, like cimetidine, inhibit acid production by reversibly competing with histamine for binding to H2 receptors on the basolateral membrane of parietal cells. The major therapeutic indications for H2 receptor antagonists are to promote healing of gastric and duodenal ulcers, to treat uncomplicated GERD, and to prevent the occurrence of stress ulcers.</p>\n<p><strong>Aluminum hydroxide (Option D): </strong>Aluminum salts act as antacids, which are weak bases that react with gastric hydrochloric acid to form a salt and water. Their principal mechanism of action is the reduction of intragastric acidity. They provide temporary relief of upset stomach with heartburn, acid indigestion, and sour stomach.</p>\n<p><strong>Key Takeaways:</strong></p>\n<p><strong>Drugs used in acid peptic diseases:</strong></p>\n<ul>\n<li>Proton pump inhibitors: Omeprazole, lansoprazole (first-line)</li>\n<li>H2 receptor blockers: Cimetidine, Ranitidine</li>\n<li>Sucralfate</li>\n<li>Antacids</li>\n</ul>", "options": ["Omeprazole", "Sucralfate", "Cimetidine", "Aluminum hydroxide"], "html_options": ["Omeprazole", "Sucralfate", "Cimetidine", "Aluminum hydroxide"], "corr_idx": 1}, {"id": "1167177", "html_qtxt": "A 57-year-old man with a history of alcoholic cirrhosis is brought to the ER with complaints of altered mental status. On examination, he is confused and has flapping tremors and is initiated on rifaximin as part of his management. Which of the following best describes the mechanism of action of rifaximin in this setting?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient likely has <strong>hepatic encephalopathy, </strong>a neurologic complication of cirrhosis due in part to the liver's inability to convert ammonia to urea. Rifaximin helps alter the GI flora to <strong>decrease intraluminal ammonia</strong> production and absorption.</p>\n<ul>\n<li>Excess ammonia in hepatic encephalopathy leads to altered mental status and asterixis (flapping tremor).</li>\n<li>In patients with HE,<strong> rifaximin </strong>is generally used in addition to <strong>lactulose</strong>, which is catabolized by intestinal bacterial flora to short-chain fatty acids, lowering the colonic pH and i<strong>ncreasing conversion of ammonia to ammonium. </strong></li>\n<li>Rifaximin is a <strong>nonabsorbable antibiotic </strong>that alters the Gl flora to decrease intestinal production and absorption of ammonia.</li>\n<li>Rifaximin is also sometimes used for traveller's diarrhoea, as it inhibits bacterial RNA synthesis through binding with DNA-dependent RNA polymerase.</li>\n<li>Rifaximin was originally approved by the FDA for the<strong> treatment of travellers' diarrhoea, </strong>and it is now used in the management of hepatic encephalopathy, irritable bowel syndrome with diarrhoea.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Binding of dietary phosphate (Option A): </strong>This is essentially the function of phosphate binders, which are used for treating hyperphosphatemia in renal failure.  Control of hyperphosphatemia can be achieved with  phosphate&shy;binding gels such as sevelamer or lanthanum carbonate.</p>\n<p><strong>Exchange of intraluminal sodium ions for potassium ions (Option C): </strong>This mechanism is utilised in the treatment of hyperkalemia by drugs like sodium polystyrene sulfonate, which work by exchanging sodium for potassium in the intestinal lumen. It has no role in altering ammonia levels.</p>\n<p><strong>Formation of a nonabsorbable complex with bile acids (Option D): </strong>Bile acid resins like cholestyramine, colestipol act by forming a nonabsorbable complex with bile acids to lower the cholesterol levels.</p>\n<p><strong>Key Takeaways:</strong></p>\n<p><strong>Uses of rifaximin:</strong></p>\n<ul>\n<li>Travellers diarrhea</li>\n<li>Hepatic encephalopathy</li>\n<li>Diarrhoea predominant IBS</li>\n<li>recurrent or refractory C difficile infection in adults</li>\n</ul>", "options": ["Binding of dietary phosphate", "Decreased intraluminal ammonia production", "Exchange of intraluminal sodium ions for potassium ions", "Formation of a nonabsorbable complex with bile acids"], "html_options": ["Binding of dietary phosphate", "Decreased intraluminal ammonia production", "Exchange of intraluminal sodium ions for potassium ions", "Formation of a nonabsorbable complex with bile acids"], "corr_idx": 1}, {"id": "1167178", "html_qtxt": "A 32-year-old man with Type 1 diabetes and diabetic neuropathy is evaluated for multiple episodes of vomiting undigested food. He gives no history of fever or diarrhoea. A macrolide antibiotic was prescribed, which improved his symptoms. Which of the following mechanisms is most likely responsible for the improvement in his symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>A diabetic patient with neuropathy presenting with vomiting strongly raises suspicion for <strong>diabetic gastroparesis</strong>, characterised by delayed gastric emptying. Macrolides like erythromycin <strong>stimulate motilin receptors </strong>to promote gastric emptying, which explains the mechanism responsible for improvement of his symptoms.</p>\n<ul>\n<li><strong>Diabetic gastroparesis</strong>, an autonomic neuropathy of the gastrointestinal tract marked by delayed gastric emptying in the absence of mechanical obstruction.</li>\n<li><strong>Metoclopramide, </strong>a dopamine 2 receptor antagonist, is primarily used to treat diabetic gastroparesis, but is occasionally associated with extrapyramidal side effects (eg, dystonia) and tardive dyskinesia.</li>\n<li>For patients who cannot tolerate metoclopramide, <strong>erythromycin</strong>, a macrolide antibiotic, can be used as an <strong>alternate prokinetic agent.&nbsp;</strong></li>\n<li>The prokinetic effects of erythromycin stem from the <strong>activation of the motilin receptor</strong> in the smooth muscle of the upper digestive tract, which results in coordinated peristaltic contractions that begin in the stomach and move through the entire upper digestive system.</li>\n<li>When used as an antibiotic, erythromycin can cause significant abdominal cramping, but in the setting of gastroparesis, the prokinetic effects can be leveraged to improve gastric emptying and ameliorate gastroparesis symptoms.</li>\n<li>However, the agonist effects of erythromycin diminish over time, so it is generally used for short periods (<4 weeks).</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Blockade of gastrointestinal muscarinic receptors (Option B):</strong> In the GIT, blockade of muscarinic receptors reduces GI motility and gastric secretion. Thus, using muscarinic receptor antagonists (anti-cholinergics) will worsen gastroparesis.</p>\n<p><strong>Increase in intestinal fluid secretion  (Option C): </strong>Drugs which stimulate intestinal fluid and electrolyte secretion are effectively used in the treatment of constipation. These include stool wetting agents like docusate and chloride channel activators like lubiprostone.</p>\n<p><strong>Protective effect on gastric mucosa  (Option D): </strong>Drugs which offer a protective effect on the gastric mucosa used in the treatment of peptic ulcer disease, which include sucralfate, bismuth compounds, and antacids. These agents act by enhancing mucosal defence, binding to the ulcer base or neutralising acid, but do not affect gastric motility.</p>\n<p><strong>Key Takeaways:</strong></p>\n<p>Drugs used in the treatment of gastroparesis:</p>\n<ul>\n<li>D2 receptor antagonist:\n<ul>\n<li>Metoclopramide - Drug of choice</li>\n<li>Domperidone</li>\n</ul>\n</li>\n<li>Erythromycin (Macrolide)</li>\n<li>Cisapride (5HT4 receptor agonist)</li>\n</ul>", "options": ["Agonistic activity on motilin receptors", "Blockade of gastrointestinal muscarinic receptors", "Increase in intestinal fluid secretion", "Protective effect on gastric mucosa"], "html_options": ["Agonistic activity on motilin receptors", "Blockade of gastrointestinal muscarinic receptors", "Increase in intestinal fluid secretion", "Protective effect on gastric mucosa"], "corr_idx": 0}, {"id": "1167179", "html_qtxt": "A 62-year-old man presents with severe abdominal pain and diarrhoea following treatment for a recent urinary tract infection. Investigations confirm Clostridium difficile colitis. The patient is started on an antibiotic that inhibits the sigma subunit of RNA polymerase. Which of the following agents was most likely administered?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Fidaxomicin</strong>, a macrocyclic antibiotic which acts by inhibiting the sigma subunit of RNA polymerase, can be used in the treatment of Clostridium difficile infection.</p>\n<ul>\n<li>Fidaxomicin is a narrow&shy;-spectrum, <strong>macrocyclic antibiotic </strong>that is active against gram&shy;positive aerobes and anaerobes but lacks activity against gram-negative bacteria.</li>\n<li>Fidaxomicin inhibits bacterial protein synthesis by binding to the sigma subunit of RNA polymerase.</li>\n<li>When administered orally, systemic absorption is negligible, but faecal concentrations are high, so it is not associated with many systemic toxicities and should only be used to treat infections confined to the gastrointestinal tract.</li>\n<li>Fidaxomicin has been approved for the <strong>treatment of C.difficile infection </strong>in adults.</li>\n<li>It is as effective as <strong>oral vancomycin</strong> and is recommended as the preferred first&shy;line agent for treatment of C difficile given its lower rates of relapsing disease compared to oral vancomycin.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Doxycycline (Option A): </strong>Doxycycline is a tetracycline antibiotic that can predispose to C. difficile colitis by disrupting normal gut flora. It suppresses susceptible coliforms, allowing overgrowth of organisms such as Clostridia, Pseudomonas, Proteus, Staphylococci, resistant coliforms, and Candida. Tetracycline acts by binding to the 30S ribosomal subunit.</p>\n<p><strong>Metronidazole (Option C): </strong><strong> </strong>Metronidazole is reserved for mild cases of C difficile infection in patients who are unable to tolerate the fidaxomicin and vancomycin or as an additional agent in fulminant C difficile infection.</p>\n<p><strong>Neomycin (Option D): </strong>Neomycin is an aminoglycoside, and it inhibits protein synthesis by binding to the 30S ribosomal subunit. They are mainly used as topical antibiotics for treating infected surfaces or joints and in preparation for elective bowel surgeries.</p>\n<p><strong>Key Takeaways:</strong></p>\n<p><strong>Drugs used in the treatment of C. difficile infections:</strong></p>\n<ul>\n<li>Fidaxomycin - Drug of choice</li>\n<li>Vancomycin</li>\n<li>Metronidazole</li>\n</ul>", "options": ["Doxycycline", "Fidaxomicin", "Metronidazole", "Neomycin"], "html_options": ["Doxycycline", "Fidaxomicin", "Metronidazole", "Neomycin"], "corr_idx": 1}, {"id": "1167180", "html_qtxt": "A 65-year-old woman with breast cancer presents with intractable nausea and vomiting after her first cycle of chemotherapy. Which of the following agents would be most helpful in managing her symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>5-HT3 receptor antagonists are highly effective in preventing chemotherapy-induced vomiting.</p>\n<ul>\n<li>5-HT3 receptor antagonists include drugs like ondansetron, granisetron, palnosetron and dolasetron.</li>\n<li>These agents act by 2 primary mechanisms:\n<ul>\n<li>Blocking vagus-mediated nausea and vomiting (from the Gl tract stimuli)</li>\n<li>Blocking central serotonin receptors in the area postrema and the Nucleus tractus solitarius.</li>\n</ul>\n</li>\n<li>5&shy;HT3 &shy;receptor antagonists are the <strong>primary agents</strong> for the prevention of acute <strong>chemotherapy-&shy;induced nausea and emesis. </strong></li>\n<li>When used alone, first-generation agents have little efficacy for the prevention of delayed nausea and emesis (ie, occurring >24 hours after chemotherapy).</li>\n<li>The second-generation agent <strong>palonosetron</strong> is more effective than the first&shy; generation agents in the prevention of acute nausea and emesis, and it is also effective in the prevention of delayed nausea and emesis.</li>\n<li>The drugs are most effective when given as a single dose by intravenous injection 30 minutes before administration of chemotherapy.</li>\n<li>Although 5&shy;HT3&shy;receptor antagonists are effective as single agents for the prevention of chemotherapy-induced nausea and vomiting, their efficacy is enhanced by combination therapy with a corticosteroid (dexamethasone), an NK1&shy;receptor antagonist, and a dopamine D2 antagonist.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Histamine H1 blocker (Option A): </strong>As single agents, these drugs have weak antiemetic activity, although they are particularly useful for the prevention or treatment of motion sickness. Their use may be limited by anticholinergic side effects. Diphenhydramine, a first-generation histamine H1 antagonist because of its sedating properties, commonly used in conjunction with other antiemetics for the treatment of emesis due to chemotherapy.</p>\n<p><strong>Motilin receptor agonist (Option B): </strong>Motilin receptor stimulation enhances gastric motility, as seen with drugs like erythromycin, a motilin receptor agonist used in the treatment of gastroparesis. However, it has no significant role in treating chemotherapy-induced nausea, which is centrally mediated. Moreover, at high doses, erythromycin causes impairment in bowel transit and vomiting.</p>\n<p><strong>Mu opioid receptor agonist (Option C): </strong>Nausea and vomiting are important side-effects of Mu opioid receptor agonists due to stimulation of the chemoreceptor trigger zone for emesis in the area postrema. Hence, Mu receptor agonists like morphine will only worsen emesis.</p>\n<p><strong>Key Takeaways:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906be54f0b3-2b7f-4ffe-9a13-32ddc86e2888.png\">", "options": ["Histamine H1 blocker", "Motilin receptor agonist", "Mu opioid receptor agonist", "Serotonin 5-HT3 receptor antagonist"], "html_options": ["Histamine H1 blocker", "Motilin receptor agonist", "Mu opioid receptor agonist", "Serotonin 5-HT3 receptor antagonist"], "corr_idx": 3}, {"id": "1167181", "html_qtxt": "A 40-year-old woman sustains a right knee injury and is administered an opioid analgesic for pain relief. While her knee pain improves, she soon develops new-onset upper abdominal discomfort that worsens when lying down. Which of the following tissue types is most likely involved in this adverse drug reaction?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Administration of &mu; opioid analgesics, such as morphine, can cause contraction of smooth muscle cells in the sphincter of Oddi, leading to spasm and an increase in common bile duct pressures.</li>\n<li>Although uncommon, pressures in the gallbladder can also increase, potentially leading to biliary colic. </li>\n<li>Patients who develop biliary colic will have severe pain and cramping in the right upper abdomen.</li>\n<li>Management involves discontinuation of &mu; opioid analgesics and pain control with alternative agents such as nonsteroidal anti-inflammatory drugs (eg, ketorolac, diclofenac).</li>\n</ul>", "options": ["Blood vessels", "Enterocytes", "Skeletal muscles", "Smooth muscle cells"], "html_options": ["Blood vessels", "Enterocytes", "Skeletal muscles", "Smooth muscle cells"], "corr_idx": 3}, {"id": "1167182", "html_qtxt": "A 65-year-old man presents with watery diarrhoea and episodes of dyspnea with wheezing and facial flushing. Abdominal CT scan revealed mass lesions in the right liver lobe and the ileum. Which of the following medications can be used to relieve this patient's symptoms before surgery?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The clinical presentation is suggestive of a neuroendocrine tumour, likely a <strong>carcinoid tumour </strong>with hepatic metastasis. Somatostatin analogues - octreotide are used to control symptoms associated with carcinoid tumours.</p>\n<ul>\n<li>Carcinoid tumours (the most common ileal tumours) secrete many biologically active substances, including serotonin, and can cause symptoms when they metastasise.</li>\n<li>Common manifestations of carcinoid syndrome include flushing, asthma-like symptoms (wheezing, dyspnea), diarrhoea, and syncope (due to low blood pressure).</li>\n<li>The most definitive treatment for carcinoid syndrome is<strong> surgical excision.</strong></li>\n<li>Medical therapy with <strong>octreotide</strong> can be used to control symptoms.</li>\n</ul>\n<p><strong>Octreotide:</strong></p>\n<ul>\n<li>Octreotide is a synthetic analogue of somatostatin with a longer half-life.</li>\n<li>It acts on somatostatin receptors and inhibits the secretion of many hormones and hormone-like substances.</li>\n<li>Octreotide is used in the treatment of <strong>secretory diarrhoea </strong>associated with neuroendocrine tumours like carcinoid tumours and pancreatic endocrine tumours.</li>\n<li>Octreotide is effective in higher doses for the treatment of <strong>diarrhoea due to vagotomy</strong> or <strong>dumping syndrome</strong>, as well as for diarrhoea caused by short&shy;bowel syndrome or AIDS.</li>\n<li>While at low doses it stimulates small bowel motility in patients with small bowel bacterial overgrowth or intestinal pseudo&shy;obstruction secondary to scleroderma.</li>\n<li>Octreotide is also used in the treatment of GH-secreting pituitary tumours causing acromegaly.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Cabergoline (Option A):</strong> A dopamine agonist used primarily to treat hyperprolactinemia by inhibiting prolactin secretion.</p>\n<p><strong>Leuprolide (Option B): </strong>Leuprolide is an agonist at the GnRH receptor used for controlled ovarian stimulation and treatment of central precocious puberty.</p>\n<p><strong>Rituximab (Option D):</strong> Rituximab is a monoclonal antibody against CD-20. It is approved for the treatment of CD20-positive non-Hodgkin lymphoma and chronic lymphocytic leukaemia. It is also indicated for rheumatoid arthritis in patients unresponsive to anti-TNF&alpha; therapy.</p>", "options": ["Cabergoline", "Leuprolide", "Octreotide", "Rituximab"], "html_options": ["Cabergoline", "Leuprolide", "Octreotide", "Rituximab"], "corr_idx": 2}, {"id": "1167183", "html_qtxt": "A 40-year-old woman presents with 4 4-week history of non-bloody, mucus-containing diarrhoea, bloating, and occasional heartburn. There is no history of fever. She avoids dairy due to an unpleasant taste and has a history of chronic allergic rhinitis. Vitals and examination are normal. She was started on a trial of diphenoxylate therapy. What is the primary target of this drug?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient has been started on diphenoxylate empirically for chronic functional diarrhoea, likely <strong>irritable bowel syndrome</strong> with associated <strong>lactose intolerance </strong>(suggested by dairy avoidance). Diphenoxylate acts on gut motility by slowing intestinal transit.</p>\n<p><strong>Opioid agonists used as antidiarrheal agents:</strong></p>\n<p><strong>Diphneoxylate:</strong></p>\n<ul>\n<li>Diphenoxylate is an opioid anti-diarrheal agent structurally related to meperidine.</li>\n<li>It binds to mu opioid receptors in the gastrointestinal tract and slows motility.</li>\n<li>Low doses relieve diarrhoea without other significant opiate effects.</li>\n<li>However, higher doses can produce morphine-like euphoria and physical dependence.</li>\n<li>To discourage abuse, diphenoxylate is combined with atropine, which produces adverse symptoms (dry mouth, blurry vision, nausea) if taken in high doses.</li>\n</ul>\n<p><strong>Loperamide:</strong></p>\n<ul>\n<li>Loperamide is another low-potency opioid agonist used in the symptomatic treatment of diarrhoea.</li>\n</ul>\n<p><strong>Eluxadoline:</strong></p>\n<ul>\n<li>When taken orally, eluxadoline binds to gut opioid receptors, resulting in slower colonic transit and increased faecal fluid absorption. Eluxadoline is approved for the treatment of patients with diarrhea&shy;-predominant IBS.</li>\n</ul>\n<p><strong>Common side effects of these drugs:</strong></p>\n<p>Rebound constipation and mild sedation.</p>\n<p>They should not be used in diarrhoea due to toxin-producing or invasive organisms (eg, Shigella, Salmonella) or Clostridium difficile infections.</p>", "options": ["Absorption", "Digestion", "Motility", "Secretion"], "html_options": ["Absorption", "Digestion", "Motility", "Secretion"], "corr_idx": 2}, {"id": "1167184", "html_qtxt": "A new drug (Drug A) is being developed for the treatment of peptic ulcer disease. In experimental animals, acid secretion was stimulated using vagal stimulation, histamine, or gastrin. Before the stimulus was administered, the animals were divided into 2 groups: one group received pretreatment with drug A, and the second one served as the control and received an injection of an equivalent volume of normal saline. Which of the following drugs is Drug A most likely similar to in its mechanism of action?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906c455efe3-f2b9-40cb-9198-ff9730e6b431.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>It is inferred from the graphs that Drug A inhibits gastric acid secretion regardless of whether it is stimulated by vagal stimulation, histamine, or gastrin. Therefore, drug A is most similar to a <strong>proton pump inhibitor</strong> like lanzoprazole.</p>\r\n<ul>\r\n<li>Gastric parietal cells secrete hydrochloric acid in response to three major stimuli: histamine, acetylcholine, and gastrin.</li>\r\n<li>Histamine is released from enterochromaffin-like cells and binds to H<sub>2</sub> receptors on parietal cells, directly stimulating acid secretion.</li>\r\n<li>Vagal stimulation causes acetylcholine release, which binds to M<sub>3</sub> receptors on parietal cells, promoting HCl secretion.</li>\r\n<li>Additionally, vagal stimulation triggers gastrin-releasing peptide (GRP), leading to gastrin release from G cells.</li>\r\n<li>Gastrin primarily acts on CCK-B receptors on ECL cells, inducing histamine release.</li>\r\n<li>Proton pump inhibitors<strong> irreversibly inhibit the H<sup>+</sup>/K<sup>+</sup> ATPase </strong>(proton pump) in gastric parietal cells, which is the <strong>final common pathway for acid secretion</strong>, regardless of the stimulus (vagal, histamine, or gastrin).</li>\r\n<li>Because it blocks the terminal step, it reduces acid secretion from all sources, just like Drug A in the experiment.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Atropine (Option A): </strong>Atropine is a muscarinic receptor antagonist that blocks acetylcholine at muscarinic receptors on parietal cells, reducing vagally mediated acid secretion. However, it does not block histamine- or gastrin-induced acid secretion.</p>\r\n<p><strong>Bethanechol (Option B): </strong>Bethanechol acts by stimulating muscarinic receptors in gastric parietal cells, resulting in increased gastric acid secretion and hence has no role in acid suppression therapy.</p>\r\n<p><strong>Cimetidine (Option C):</strong> Cimetidine inhibits gastric acid secretion by blocking H2 receptors on parietal cells, but it does not inhibit acid secretion stimulated by vagal or gastrin pathways.<br /> </p>", "options": ["Atropine", "Bethanechol", "Cimetidine", "Lansoprazole"], "html_options": ["Atropine", "Bethanechol", "Cimetidine", "Lansoprazole"], "corr_idx": 3}, {"id": "1167185", "html_qtxt": "A 34-year-old woman presents with intermittent abdominal pain and nausea, especially after a fatty meal. Abdominal ultrasound showed a small, non-obstructing gallstone. If the patient is not keen on surgical management, which of the following is the most appropriate medical therapy for her condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The woman probably has cholesterol gallstones, and the best non-surgical (medical) therapy is <strong>oral bile acid supplementation</strong>, like <strong>ursodeoxycholic acid</strong>, which can <strong>gradually dissolve cholesterol stones</strong>.</p>\n<ul>\n<li>Cholesterol gallstones are the most common type of gallstone.</li>\n<li>Administration of hydrophilic bile acids reduces cholesterol secretion and increases biliary bile acid concentration. This improves cholesterol solubility and<strong> promotes gallstone dissolution.</strong></li>\n<li><strong>Ursodiol</strong> (Ursodeoxycholic acid) is a bile acid agent used for the dissolution of small cholesterol gallstones in patients with symptomatic gallbladder disease who refuse cholecystectomy or who are poor surgical candidates.</li>\n<li>At a dosage of 10 mg/kg/d orally for 12-24 months, dissolution occurs in up to 50% of patients with small (<5-10 mm) noncalcified gallstones.</li>\n<li>It is also effective for the prevention of gallstones in obese patients undergoing rapid weight loss therapy.</li>\n<li>Ursodiol is also the<strong> first-&shy;line agent </strong>used for the treatment of <strong>early primary biliary cirrhosis.</strong></li>\n<li>Ursodiol is practically free of serious adverse effects. Bile salt &shy;induced diarrhoea is uncommon.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Cholestyramine therapy (Option B): </strong>Cholestyramine is a bile acid resin which can help in the reduction of LDL cholesterol and is also useful in the treatment of bile-salt-induced diarrhoea. The y are not effective in dissolving gallstones.</p>\n<p><strong>Phosphate-binding agent (Option C): </strong>Phosphate-binding agents are primarily used in the treatment of hyperphosphatemia in CKD patients.</p>\n<p><strong>Rapid weight loss (Option D): </strong>Rapid weight loss increases the risk of gallstone formation due to increased cholesterol secretion into bile and is frequently seen in bariatric surgery patients.</p>", "options": ["Bile acid supplement", "Cholestyramine therapy", "Phosphate-binding agent", "Rapid weight loss"], "html_options": ["Bile acid supplement", "Cholestyramine therapy", "Phosphate-binding agent", "Rapid weight loss"], "corr_idx": 0}, {"id": "1167186", "html_qtxt": "A 34-year-old man presents with epigastric pain that is worse at night and is relieved by eating since 3 months. Upper gastrointestinal endoscopy revealed a 1 cm ulcer in the first portion of the duodenum. In addition to proton pump inhibitor therapy, which of the following would most likely prevent ulcer recurrence in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient's symptoms and endoscopic findings are consistent with a <strong>duodenal peptic ulcer</strong>, most commonly caused by <strong>Helicobacter pylori infection. </strong>H.pylori eradication therapy includes a combination of antibiotics and a proton pump inhibitor.</p>\n<ul>\n<li>Up to 90% of duodenal ulcers are caused by Helicobacter pylori infection.The remaining cases are typically associated with nonsteroidal anti-inflammatory drug (NSAID) use, which is unlikely in this patient who takes no medications.</li>\n<li>Over 50% of the world population is colonised with H pylori, with a particularly high prevalence in resource-limited countries.</li>\n<li>To reduce the likelihood of PUD recurrence after ulcer healing, H pylori infection must be eradicated. </li>\n<li>Effective regimens typically involve a <strong>combination of antibiotics and proton pump inhibitors,</strong> often with bismuth subsalicylate ( in quadruple therapy).  </li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509067e3d4172-d8c0-419d-95dc-63cc3fd204bf.png\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Gastric cytoprotectants (Option B): </strong>Gastric cytoprotectants like bismuth or salicylate coat the ulcer base to promote healing, but do not address the underlying H. pylori infection or prevent recurrence.</p>\n<p><strong>Histamine 2 receptor blockers (Option C):</strong> H2 receptor blockers like cimetidine and ranitidine also suppress gastric acid secretion by blocking H2 receptors in gastric parietal cells, but are not as effective as PPIs.</p>\n<p><strong>Prostaglandin analogues (Option D)</strong>: Prostaglandin analogues such as misoprostol are primarily used in the treatment of NSAID-induced ulcers and have no role H.pyolri pylori-related ulcers.<br /> </p>", "options": ["Antibiotics", "Gastric cytoprotectants", "Histamine 2 receptor blockers", "Prostaglandin analogues"], "html_options": ["Antibiotics", "Gastric cytoprotectants", "Histamine 2 receptor blockers", "Prostaglandin analogues"], "corr_idx": 0}, {"id": "1167188", "html_qtxt": "A 34-year-old woman presents with heartburn and sour taste in her mouth shortly after meals. She was started on a medication that significantly improved her symptoms within 2 weeks. The drug most likely acts on which of the following targets?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The woman has symptoms of dyspepsia likely due to <strong>gastroesophageal reflux</strong> and <strong>proton pump inhibitors</strong>, which work by inhibiting the H<sup>+</sup>/K<sup>+</sup>-ATPase enzyme in gastric parietal cells, and are the most effective treatment option.</p>\r\n<ul>\r\n<li>GERD is a common disorder that occurs due to the reflux of gastric acid into the oesophagus.</li>\r\n<li>Management of patients with frequent symptoms includes:\r\n<ul>\r\n<li>Lifestyle and dietary modifications like weight loss, avoidance of tobacco.</li>\r\n<li>Medications to suppress gastric acid secretion: Antacids, H2 receptor antagonists, Proton pump inhibitors and prokinetic agents</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Proton pump inhibitors:</strong></p>\r\n<ul>\r\n<li>PPl are the most effective inhibitors of gastric acid secretion; they bind to and irreversibly <strong>inhibit</strong> <strong>H<sup>+</sup>/K<sup>+</sup> ATPase</strong> on parietal cells.</li>\r\n<li>PPIs inhibit both fasting and meal&shy;stimulated secretion because they block the final common pathway of acid secretion,</li>\r\n<li>Six PPIs are available for clinical use: omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, and pantoprazole.</li>\r\n<li>They are used in the treatment of GERD, <strong>peptic ulcer disease </strong>and are the mainstay treatment for <strong>Zollinger-Ellison syndrome.</strong></li>\r\n</ul>\r\n<p><strong>Side effects:</strong></p>\r\n<ul>\r\n<li>Nutritional deficiencies: &darr; absorption of Fe, Mg, Ca,<strong> Vitamin B12</strong></li>\r\n<li>Anaemia (due to iron or B12 deficiency)</li>\r\n<li><strong>Osteoporosis </strong>(due to calcium malabsorption)</li>\r\n<li>Predisposes to <strong>Clostridium difficile</strong> (pseudomembranous colitis)</li>\r\n<li>interstitial nephritis</li>\r\n</ul>\r\n<p><strong>Drug interactions:</strong></p>\r\n<ul>\r\n<li>Decreased gastric acidity may alter the absorption of drugs for which intragastric acidity affects drug bioavailability, eg, ketoconazole, itraconazole, digoxin, and atazanavir.</li>\r\n<li>All PPIs are metabolised by hepatic <strong>P450 cytochromes</strong>, including CYP2C19 and CYP3A4.</li>\r\n<li>Omeprazole may inhibit the metabolism of clopidogrel, warfarin, diazepam, and phenytoin.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>CCK-B (gastrin-binding) receptor (Option B): </strong>These receptors bind gastrin to stimulate acid production via histamine release from enterochromaffin-like cells. Thus, H2 receptor antagonists like cimetidine and ranitidine can be used in the management of GERD, but are not effective as PPIs.</p>\r\n<p><strong>Chloride ion channel (option C): </strong>Drugs acting on chloride ion channels are used in the treatment of cystic fibrosis, which include CFTR protein modulators lumicaftor and ivacaftor.</p>\r\n<p><strong>Dopamine receptor (Option D):</strong> D2 receptor antagonists like metoclopramide and domperidone are used as prokinetic agents. These agents are first-line therapy in the treatment of gastroparesis and are rarely used in the treatment of GERD.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<p><strong>Drugs used in the treatment of GERD:</strong></p>\r\n<ul>\r\n<li>Proton pump inhibitors- Drug of choice</li>\r\n<li>H2 receptor antagonists - Cimetidine, ranitidine</li>\r\n<li>Antacids</li>\r\n<li>D2 receptor antagonist - Metoclopramide, Domperidone</li>\r\n</ul>", "options": ["CCK-B (gastrin-binding) receptor", "Chloride ion channel", "Dopamine receptor", "H+/K+-ATPase"], "html_options": ["CCK-B (gastrin-binding) receptor", "Chloride ion channel", "Dopamine receptor", "H+/K+-ATPase"], "corr_idx": 3}, {"id": "1167189", "html_qtxt": "A 12-year-old boy presents with chronic diarrhoea, failure to thrive, and recurrent respiratory infections. Sputum cultures have repeatedly grown Pseudomonas aeruginosa. His younger sibling died of a severe respiratory illness. Which of the following treatments is most likely to provide long-term improvement in his condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This clinical presentation, along with a family history of death of a sibling from pulmonary infection, suggests a diagnosis of cystic fibrosis.</li>\n<li>Cystic fibrosis is a genetic disorder that affects exocrine secretion. Exocrine pancreatic insufficiency occurs in most patients with more severe forms of cystic fibrosis.</li>\n<li>Fat malabsorption (steatorrhea) and protein maldigestion occur when the pancreas loses more than 90% of its ability to produce digestive enzymes occurs in cystic fibrosis.</li>\n<li>The resultant diarrhoea and malabsorption can be managed with <strong>pancreatic lipase </strong>delivered to the duodenum during a 4-h period before and after meals.</li>\n<li>Pancreatic lipase supplementation is likely to improve this patient's condition by enhancing macronutrient and vitamin absorption.</li>\n<li><strong>Lumacaftor </strong>and<strong> ivacaftor</strong> act as <strong>allosteric modulators of the CFTR</strong> and are the drug of choice in the treatment of cystic fibrosis.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Antimotility agents (Option A): </strong>Antimotility agents reduce bowel movement frequency by slowing intestinal transit and are indicated in conditions like diarrhoea predominant irritable bowel syndrome. In cystic fibrosis, diarrhoea is typically due to malabsorption.</p>\n<p><strong>Metronidazole (Option B): </strong>Metronidazole is a nitroimidazole with strong activity against anaerobic bacteria and certain protozoa. However, Pseudomonas aeruginosa is a gram-negative aerobic bacterium and is not susceptible to metronidazole. Instead, infections caused by Pseudomonas are treated with agents like beta-lactams and cephalosporins.</p>\n<p><strong>Octreotide (Option C):</strong> Octreotide is effective in managing <strong>secretory diarrhoea</strong> caused by neuroendocrine tumours such as carcinoid tumours and VIPomas. However, it is not effective in diarrhoea due to malabsorption.</p>", "options": ["Antimotility agents", "Metronidazole", "Octreotide", "Pancreatic lipase"], "html_options": ["Antimotility agents", "Metronidazole", "Octreotide", "Pancreatic lipase"], "corr_idx": 3}, {"id": "1167190", "html_qtxt": "A 28-year-old woman with inflammatory bowel disease presents with worsening abdominal pain, bloating, and non-bloody diarrhoea. Colonoscopy done 2 months back revealed a cobblestone mucosa and deep ulcers in the sigmoid and ascending colon, and was started on prednisone. Now on evaluation, she has a perianal fistula and tender red nodules on both shins. She also has painful, limited movement in the knees and spine. Which of the following is the most appropriate next step in management?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient's presentation is consistent with <strong>moderate to severe Crohn's disease </strong>unresponsive to prednisone. In such cases,<strong> infliximab-azathioprine combination therapy </strong>is the most appropriate treatment, especially for fistulizing disease and those with extra manifestations.</p>\n<p><strong>Drugs used in the treatment of Moderate to severe Crohn's disease:</strong></p>\n<p><strong>Glucocorticoids:</strong></p>\n<ul>\n<li>Glucocorticoids are commonly used in the treatment of patients with moderate to severe active IBD.</li>\n<li>Prednisone and prednisolone are the most commonly used oral glucocorticoids.</li>\n</ul>\n<p><strong>Anti-tumour necrosis factor therapy:</strong></p>\n<ul>\n<li><strong>Infliximab, </strong>adalimumab, and certolizumab are approved for the acute and chronic treatment of patients with moderate to severe Crohn's disease who have had an inadequate response to conventional therapies.</li>\n</ul>\n<p><strong>Purine analogues:</strong></p>\n<ul>\n<li>Azathioprine and 6&shy;MP are important agents in the<strong> induction and maintenance of remission</strong> of ulcerative colitis and Crohn's disease.</li>\n<li>They are most commonly used in combination with anti&shy;TNF therapy during acute induction and maintenance therapy of patients with moderate to severe disease.</li>\n</ul>\n<p><strong>Anti-integrin therapy:</strong></p>\n<ul>\n<li><strong>Vedolizumab </strong>is used as a <strong>second&shy;-line treatment </strong>for patients with moderate to severe ulcerative colitis or Crohn disease who cannot take anti&shy;TNF agents due to side effects, lack of efficacy, or loss of response.</li>\n<li>It is used as first-&shy;line therapy in elderly patients in whom the risks of anti&shy;TNF therapy may be increased.</li>\n</ul>\n<p><strong>Anti-IL 23 therapy:</strong></p>\n<ul>\n<li><strong>Ustekinumab </strong>is a human IgG1 monoclonal antibody which can be used in adults with moderate to severe Crohn's disease who are naive to biologics or have failed standard therapy with corticosteroids, immunomodulators (eg, thiopurine analogues), or anti&shy;TNF agents.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Cyclosporine A therapy (Option A): </strong>Cyclosporine is an <strong>inhibitor of calcineurin</strong> and a potent immunomodulator. Cyclosporine is used to treat specific cases of severe Crohn's, including <strong>fistulous complications.</strong> But its use is limited due to significant adverse effects like increased susceptibility to infections, renal insufficiency, hypertension, seizures, and peripheral neuropathy.</p>\n<p><strong>Controlled ileal release- budesonide therapy (Option C): </strong>Budesonide is used for the induction of remission in mild-to-moderate Crohn's disease and ulcerative colitis, particularly in distal disease. It is available as retention enemas.</p>\n<p><strong>Proctocolectomy (Option D):</strong> Proctocolectomy is the surgical removal of the colon and rectum and is primarily the surgical management of ulcerative colitis. In contrast, Crohn's disease is a chronic, incurable inflammatory condition that may involve any part of the gastrointestinal tract. Surgery in Crohn's disease is reserved for medical treatment failure or life-threatening complications, and is typically limited to segmental resections or stricturoplasty.</p>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906d20016f2-9fb4-4835-b0ec-13a5ad5cd632.png\">", "options": ["Cyclosporine A therapy", "Infliximab-azathioprine combination therapy", "Controlled ileal release  budenoside therapy", "Proctocolectomy"], "html_options": ["Cyclosporine A therapy", "Infliximab-azathioprine combination therapy", "Controlled ileal release  budenoside therapy", "Proctocolectomy"], "corr_idx": 1}, {"id": "1167192", "html_qtxt": "Administration of atropine will most likely cause which of the following effects on gastric acid secretion stimulated by gastrin, acetylcholine, and histamine?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509069bd65c94-071c-4509-b835-70022beea4d6.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Parietal cells have five receptors regulating acid secretion: three excitatory (for acetylcholine, gastrin, and histamine) and two inhibitory. All signals via G-protein-coupled pathways.</li>\n<li><strong>Histamine</strong> is the primary direct stimulant of acid secretion. The effects of acetylcholine and gastrin are largely indirect, mediated through histamine release.</li>\n<li>During a meal, all three secretagogues act together, producing a potentiated effect greater than their individual effects combined due to synergistic G-protein signalling.</li>\n</ul>\n<p><strong>Effect of atropine on gastric acid secretion:</strong></p>\n<ul>\n<li>Atropine is a <strong>muscarinic receptor antagonist</strong>, competitively inhibits the action of acetylcholine (ACh) at parasympathetic sites.</li>\n<li>Atropine only partially inhibits the gastric acid secretory responses to vagal activity because vagal stimulation of gastrin secretion is mediated not by ACh but by peptidergic neurons in the vagal trunk that release gastrin-releasing peptide (GRP).</li>\n<li>GRP stimulates gastrin release from G cells; gastrin can act directly to promote acid secretion by parietal cells and to stimulate histamine release from enterochromaffin-like (ECL) cells.</li>\n<li>Parietal cells (acid secretors) respond to at least three agonists: gastrin, histamine, and ACh.</li>\n<li>Atropine will inhibit only the components of acid secretion that result from muscarinic stimulation of parietal cells and muscarinic stimulation of ECL cells that secrete histamine.</li>\n</ul>\n<p><strong>Key Takeaways:</strong></p>\n<p>Effects of atropine in the GIT:</p>\n<ul>\n<li>Reduces gastric acid secretion</li>\n<li>Inhibitory effect on GI motility</li>\n</ul>", "options": ["i", "ii", "iii", "iv"], "html_options": ["i", "ii", "iii", "iv"], "corr_idx": 2}]}, {"moduleId": 1008541, "name": "Benzodiazepines, Barbiturates & Anti-Epileptics", "questions": [{"id": "1180552", "html_qtxt": "A 27-year-old man is brought to the ED after being found violently shaking on the floor. The patient bit his tongue during the episode. He has a history of post-traumatic epilepsy. In the hospital, he has several back-to-back generalised tonic-clonic seizures without regaining consciousness in between. Initial management is started, and the seizure stops. Identify the mechanism of action for a drug which used?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Given the clinical scenario of a seizure with several back-to-back generalised tonic-clonic seizures without regaining consciousness in between, with past history of post-traumatic epilepsy, suggests STATUS EPILEPTICUS.</li>\r\n<li>Initial Drug of Choice for treatment is IV LORAZEPAM, which acts by potentiating the inhibitory effects of GABA in the CNS by increasing the frequency of GABA-mediated chloride ion channel opening.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240320b6a778f9-f77a-4097-a2aa-a737db016be0.jpg\">\r\n<p><strong>Irreversible inhibition of GABA catabolism in CNS (Option B)</strong>: Vigabatrin is an irreversible inhibitor of GABA transaminase, which is the enzyme responsible for catabolism in CNS, used in treatment-resistant partial seizures and infantile spasm with tuberous sclerosis.</p>\r\n<p><strong>Decreases sodium current in cortical neurons (Option C)</strong>: Phenytoin and Carbamazepine act on voltage-gated sodium channels of cortical neurons and decrease firing from cortical neurons. Uses of Phenytoin include the prevention of another episode of status epilepticus after administration of benzodiazepines and neuropathic pain. Both drugs can be used in partial seizures.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030720fa593f-922d-4d18-82da-1998e9adee45.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307f1e98fb7-5792-4cca-8835-375f71db630b.jpg\"><p><strong>Decreases calcium current in thalamic neurons (Option D)</strong>: Valproate and Ethosuximide decrease calcium current in thalamic neurons, used as primary treatment of GTCS as well as absence seizures. Other uses of Valproate are Acute Mania, Rapid cyclers in BPD and Prophylaxis of Migraine.</p>", "options": ["Increases post-synaptic chloride influx", "Irreversible inhibition of GABA catabolism in the CNS", "Decreases sodium current in cortical neurons", "Decreases calcium current in thalamic neurons"], "html_options": ["Increases post-synaptic chloride influx", "Irreversible inhibition of GABA catabolism in the CNS", "Decreases sodium current in cortical neurons", "Decreases calcium current in thalamic neurons"], "corr_idx": 0}, {"id": "1180555", "html_qtxt": "An 11-year-old child is having learning difficulties at primary school. He has brief lapses of awareness with eyelid fluttering that occur every 10-20 minutes. Electroencephalogram (EEG) studies reveal brief 3-Hz spike and wave discharges appearing in all leads. Which drug would not be effective in this child?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Given the clinical scenario of a child with learning difficulties and brief lapses of awareness with eyelid fluttering suggestive of Absence Seizure, which can be confirmed by EEG showing a typical 3-Hz spike and wave. Phenytoin would not be effective in this case.</li>\r\n<li>The first-line drug for the treatment is Ethosuximide > Valproate. <strong>(Option A & B)</strong></li>\r\n<li>However, Clonazepam can be used but exerts troublesome CNS-depressant effects, and tolerance develops with chronic use. <strong>(Option C) </strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307a2ec5266-ef7a-4699-b2ea-ce91fe42b844.jpg\">\r\n", "options": ["Ethosuximide", "Valproate", "Clonazepam", "Phenytoin"], "html_options": ["Ethosuximide", "Valproate", "Clonazepam", "Phenytoin"], "corr_idx": 3}, {"id": "1180570", "html_qtxt": "A 32-year-old female presents to OPD with sudden episodes of severe, right-sided facial pain, described as 'stabbing' pain that lasts for several seconds, which initiated while brushing teeth. Negative history for nausea-vomiting and visual changes. Vital signs are within normal limits, and no rash on physical examination. Treatment has been started, which causes pain reduction. You'll ask to follow up with the patient regularly with what?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Serum Electrolytes</strong> involve monitoring the levels of various electrolytes in the blood, including sodium, potassium, chloride, and others.</p>\n<ul>\n<li>It is essential in cases of trigeminal neuralgia because electrolyte imbalances, particularly sodium imbalances, can trigger or exacerbate these painful episodes.</li>\n<li>Ensuring that electrolyte levels are within the normal range is crucial for the patient's well-being and symptom management.</li>\n</ul>\n<p><strong>Serum Ammonia and Liver Function Test</strong>: <strong>(Option A)</strong></p>\n<ul>\n<li>This option involves monitoring serum ammonia levels and liver function.</li>\n<li>It is typically used to evaluate liver health and detect liver diseases such as cirrhosis or hepatitis.</li>\n<li>In the context of trigeminal neuralgia (severe facial pain), this option is less relevant because the patient's symptoms are more indicative of a neurological issue rather than a liver problem. Trigeminal neuralgia is often related to the trigeminal nerve dysfunction and is not primarily associated with liver issues.</li>\n</ul>\n<p><strong>Serum Electrolytes</strong>: <strong>(Option </strong><strong>B)</strong></p>\n<ul>\n<li>This option involves monitoring the levels of various electrolytes in the blood, including sodium, potassium, chloride, and others.</li>\n<li>It is essential in cases of trigeminal neuralgia because electrolyte imbalances, particularly sodium imbalances, can trigger or exacerbate these painful episodes. Ensuring that electrolyte levels are within the normal range is crucial for the patient's well-being and symptom management.</li>\n</ul>\n<p><strong>Complete Blood Count (CBC)</strong>: <strong>(Option C)</strong></p>\n<ul>\n<li>A CBC is a blood test that measures various components of the blood, including red blood cells, white blood cells, and platelets.</li>\n<li>While a CBC is a useful general screening test, it may not provide specific information related to trigeminal neuralgia. This test is more commonly used to assess conditions like anaemia, infections, or other haematological disorders.</li>\n</ul>\n<p><strong>Renal Function Test</strong>: <strong>(Option D)</strong></p>\n<ul>\n<li>Renal function tests assess the functioning of the kidneys and include tests like serum creatinine and blood urea nitrogen (BUN) levels.</li>\n<li>These tests are typically used to evaluate kidney health and function.</li>\n<li>In the context of trigeminal neuralgia, renal function tests are not directly relevant to the patient's symptoms unless there are specific reasons to suspect kidney-related issues as a cause of facial pain, which would be unusual.</li>\n</ul>", "options": ["Serum Ammonia and Liver Function Test", "Serum Electrolytes", "Complete Blood Count", "Renal function test"], "html_options": ["Serum Ammonia and Liver Function Test", "Serum Electrolytes", "Complete Blood Count", "Renal function test"], "corr_idx": 1}, {"id": "1180575", "html_qtxt": "A 50-year-old male comes to your OPD for follow-up for seizure disorder, for which he has been on treatment for 15 years, and now presents with the following findings. Which of the following drugs does NOT cause this side effect?.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307d448a812-fdd0-4111-8ca6-a6a4e29b27c7.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The given image is suggestive of Gingival Hyperplasia in a patient with Seizure disorders is caused by antiepileptic drugs (Phenytoin > Carbamazepine), not cyclophosphamide.</li>\n<li>Cyclophosphamide is an alkylating agent indicated for the treatment of Malignant Diseases and treatment-resistant minimal change nephrotic syndrome in Pediatric Patients, which can cause Myelosuppression, Hemorrhagic cystitis, and Cardiotoxicity.</li>\n</ul>\n<p><strong>Drugs which can cause Gingival Hyperplasia are: (Option A, C & D) </strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307234a8e9d-c73f-49c3-9109-d4c9e5098352.jpg\">\n<p>Common side effects of AEDs</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030742853d9e-819b-458e-93a2-cee8798c10be.jpg\">", "options": ["Phenytoin", "Cyclophosphamide", "Cyclosporine", "Nifedipine"], "html_options": ["Phenytoin", "Cyclophosphamide", "Cyclosporine", "Nifedipine"], "corr_idx": 1}, {"id": "1180576", "html_qtxt": "A 25-year-old patient is on a stable dose of Carbamazepine. Which of the following drugs, if prescribed, does the physician need to decrease the dose of carbamazepine? ", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Carbamazepine is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active carbamazepine 10,11-epoxide, which is further metabolized to the trans-diol by epoxide hydrolase.</li>\r\n<li>Therefore, the potential exists for interaction between carbamazepine and any agent that inhibits CYP3A4 and/or epoxide hydrolase.</li>\r\n<li>Agents that are CYP3A4 inhibitors that have been expected to increase plasma levels of Carbamazepine.</li>\r\n<li>Thus, if a patient has been titrated to a stable dosage of Carbamazepine and then begins a course of treatment with one of these CYP3A4, it is reasonable to expect that a dose reduction for Carbamazepine may be necessary.</li>\r\n<li>Agents that are CYP inducers that have been expected to decrease plasma levels of Carbamazepine.</li>\r\n<li>Thus, if a patient has been titrated to a stable dosage on Carbamazepine, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for Carbamazepine may be necessary. <strong>(Options A, B, and C)</strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030771b1a78b-a13d-4089-b45c-3f460b865f97.jpg\">\r\n", "options": ["Griseofulvin ", "Phenobarbital", "Erythromycin", "Rifampin"], "html_options": ["Griseofulvin ", "Phenobarbital", "Erythromycin", "Rifampin"], "corr_idx": 2}, {"id": "1180578", "html_qtxt": "A 13-year-old boy is presented with a pruritic generalised rash for 2 days. The patient was diagnosed with a seizure disorder. He is on treatment. Examination shows facial oedema and a diffuse rash over the face, trunk, and extremities, as shown below. Which of the following is the most appropriate next step in management?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030780d776fd-6122-4598-9ea7-1c639340b3d8.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Carbamazepine is a common antiepileptic drug used for the treatment of both generalised seizures and focal seizures. In rare cases, it can also cause an acute drug-induced hypersensitivity syndrome (HSS), which may present with fever and a diffuse morbilliform rash that progresses to a confluent erythema with accentuation of the hair follicles, as well as facial oedema and lymphadenopathy.</li>\r\n<li>HSS usually develops 2-8 weeks after initiating treatment and is also referred to as drug reaction with eosinophilia and systemic symptoms (DRESS), as further symptoms include hematologic abnormalities (e.g., leukocytosis with eosinophilia), and internal organ involvement (e.g., hepatitis, pneumonitis, nephritis).</li>\r\n<li>Carbamazepine should be discontinued immediately, and this patient should now transition to a different antiepileptic medication (e.g., valproic acid) to avoid life-threatening complications.</li>\r\n<li>Other important side effects of carbamazepine include diplopia, vertigo, agranulocytosis, hyponatremia (due to SIADH), and dermatologic reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis).</li>\r\n</ul>\r\n<p><strong>Monospot test (Option A)</strong> is the diagnostic test of choice for infectious mononucleosis. It can manifest with fever, lymphadenopathy and a rash (typically prompted by administration of aminopenicillin). However, the absence of other hallmark features of the disease, such as fatigue, splenomegaly, and pharyngotonsillitis, makes this diagnosis unlikely in this patient.</p>\r\n<p>Administration of topical clotrimazole <strong>(Option B)</strong> is indicated in fungal infections, such as tinea. Tinea is a superficial dermatophyte infection characterised by scaly patches. This patient presents with a diffuse rash that does not show scaly patches.</p>\r\n<p>Although <strong>Rickettsial serolo</strong><strong>gy (RMSF) (Option C)</strong> presents with a diffuse rash, it usually starts at the extremities and progresses towards the trunk before progressing to pruritic papules and petechiae. Unlike in this patient, the face is only rarely involved. This patient does not have typical signs of the disease, such as a history of tick bite, severe headache, malaise, abdominal pain, conjunctivitis, nausea, and/or vomiting, making RMSF an unlikely diagnosis.</p>", "options": ["Monospot test", "Topical clotrimazole", "Rickettsial serology", "Discontinue anti-seizure drug"], "html_options": ["Monospot test", "Topical clotrimazole", "Rickettsial serology", "Discontinue anti-seizure drug"], "corr_idx": 3}, {"id": "1180580", "html_qtxt": "A 24-year-old girl presented with a painful, blistering rash. She has a history of bipolar disorder and has been on treatment for one month. Physical examination shows numerous coalescing bullae with epidermal detachment covering the face, trunk, and extremities. There are haemorrhagic erosions on the hard palate and buccal mucosa. Which of the following drugs is most likely responsible for this patient's current condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This girl's fever, blistering rash, positive Nikolsky sign, and recent medication change are consistent with a diagnosis of Stevens-Johnson syndrome (SJS). Toxic epidermal necrolysis is a severe form of this condition that involves > 30% of the skin.</li>\r\n<li>Lamotrigine is an anti-epileptic drug with mood-stabilising properties that is used to treat bipolar disorder. It is one of the most commonly implicated triggers of SJS. Most cases of SJS develop within 2-8 weeks of initiating the offending medication.</li>\r\n<li>The risk of developing SJS induced by lamotrigine therapy is greatest when high doses are used, so the initial dose should be low and increased slowly.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030742b3145b-985e-4ad6-9840-d28f4a5d8e98.jpg\">\r\n<p><strong>Lithium (Option A)</strong> is a mood stabiliser used to treat bipolar disorder. However, cases of SJS attributed to lithium therapy have not been reported.</p>\r\n<p><strong>Valproic acid (Option B)</strong> is an antiepileptic drug with mood-stabilizing properties that is used to treat bipolar disorder. However, valproic acid is an extremely rare cause of SJS.</p>\r\n<p><strong>Topiramate (Option C)</strong> is an antiepileptic drug with mood-stabilizing properties that is sometimes used in conjunction with other agents to treat refractory bipolar disorder. However, cases of SJS attributed to topiramate therapy have not been reported.</p>", "options": ["Lithium", "Valproate", "Topiramate", "Lamotrigine"], "html_options": ["Lithium", "Valproate", "Topiramate", "Lamotrigine"], "corr_idx": 3}, {"id": "1180583", "html_qtxt": "A 2100-g female newborn is delivered vaginally. Examination of the newborn shows a short, mildly webbed neck and low-set ears. Ocular hypertelorism, along with slanted palpebral fissures, is noted. A cleft palate and hypoplasia of the nails and distal phalanges are present. There is increased coarse hair on the body and face. Which of the following best explains the clinical findings found in this newborn?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Fetal hydantoin syndrome is a collection of defects associated with maternal use of anticonvulsants, such as phenytoin.</li>\r\n<li>Use of these medications interferes with folate metabolism, which often induces a deficiency.</li>\r\n<li>Common features of fetal hydantoin syndrome include\r\n<ul>\r\n<li>Intrauterine growth restriction</li>\r\n<li>Craniofacial abnormalities (e.g., cleft palate, hypertelorism, slanted palpebral fissures, and low-set ears)</li>\r\n<li>A short neck</li>\r\n<li>Phalanx/fingernail hypoplasia</li>\r\n<li>Excessive hair on the body and face.</li>\r\n</ul>\r\n</li>\r\n<li>Treatment is largely supportive and includes surgery to fix the cleft palate in addition to special education.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240429c58d371a-9af3-4d99-926c-ec80ac4457e1.jpg\">\r\n<p><strong>Fetal alcohol syndrome (Option A): </strong>Maternal alcohol intake can lead to fetal alcohol spectrum disorders, which can also cause intrauterine growth restriction, hypoplastic nails, and facial dysmorphisms (ocular hypertelorism in this case). However, fetal alcohol spectrum disorders typically do not cause cleft palate or excessive hair growth, making it an unlikely cause of this infant's symptoms.</p>\r\n<p><strong>Maternal diabetes mellitus (Option B): </strong>Infants born to diabetic mothers are at risk for caudal regression syndrome, a condition that causes abnormalities in the caudal portion of the body. In addition, infants born to diabetic mothers tend to have macrosomia, not growth restriction as seen here.</p>\r\n<p><strong>Aplasia cutis (Option D):</strong> A congenital dermatological condition characterised by the absence of a portion of skin in a localised or widespread area at birth. It's caused by the use of methimazole for hyperthyroidism in the first trimester.</p>", "options": ["Fetal alcohol disorder", "Maternal diabetes mellitus", "Fetal hydantoin syndrome", "Aplasia cutis"], "html_options": ["Fetal alcohol disorder", "Maternal diabetes mellitus", "Fetal hydantoin syndrome", "Aplasia cutis"], "corr_idx": 2}, {"id": "1180584", "html_qtxt": "Which statement concerning the proposed mechanisms of action of anticonvulsant drugs is most accurate?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Phenytoin selectively blocks the Na+ channel and prolongs the inactivated state.</p>\r\n<ul>\r\n<li>Benzodiazepines facilitate GABA-mediated inhibitory actions. <strong>(Option</strong><strong> A)</strong></li>\r\n<li>Ethosuximide selectively blocks calcium channels in thalamic neurons. <strong>(Option</strong><strong> B)</strong></li>\r\n<li>Phenobarbital produces multiple effects, mainly enhancement of GABA-chloride inhibitory activity. <strong>(Option C)</strong></li>\r\n</ul>", "options": ["Benzodiazepines facilitate glutamate-mediated inhibitory actions", "Ethosuximide selectively blocks potassium ion (K+) channels in thalamic neurons", "Phenobarbital produces a selective blockade of Calcium ion (Ca2+) channels", "Phenytoin prolongs the inactivated state of the Na+ channel"], "html_options": ["Benzodiazepines facilitate glutamate-mediated inhibitory actions", "Ethosuximide selectively blocks potassium ion (K+) channels in thalamic neurons", "Phenobarbital produces a selective blockade of Calcium ion (Ca2+) channels", "Phenytoin prolongs the inactivated state of the Na+ channel"], "corr_idx": 3}, {"id": "1180585", "html_qtxt": "A 1-year-old boy is presented with an episode of loss of consciousness followed by jerky movements of his arms and legs for 30 seconds. After this episode, he immediately regained consciousness. The child began crying after his 4-year-old brother snatched a toy from him. The brief, shrill cry was followed by a period of expiration; he then turned blue. He had a similar episode 1 week ago when his mother refused to give him ice cream. Which of the following is the most appropriate next step in management?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient's episode of cyanosis with loss of consciousness following emotional upset (i.e., frustration) and vigorous crying is indicative of a <strong>breath-holding spell</strong>. It typically manifests between the ages of 6-18 months.</li>\r\n<li>Types of breath-holding spells:\r\n<ul>\r\n<li>Cyanotic: Most common</li>\r\n<li>Pallid</li>\r\n</ul>\r\n</li>\r\n<li>They are typically triggered by emotional distress, as is the case in this patient.</li>\r\n<li>The typical sequence includes crying, exhaling, and holding the breath, followed by cyanosis and loss of consciousness.</li>\r\n<li>Patients usually resume breathing and regain consciousness in less than 1 minute.</li>\r\n<li>Most importantly, parents should be reassured that the condition is benign and their child will outgrow it by the age of 4-8 years.</li>\r\n<li>The diagnosis is usually based on the clinical features and a detailed description of the episode; no treatment is required.</li>\r\n<li>Parents should be aware of the triggers of breath-holding spells, such as tantrums, minor injuries, and distress. However, they should not avoid reprimands for fear of triggering an episode.</li>\r\n<li>Since several studies suggest an association between breath-holding spells and iron-deficiency anaemia, confirmatory tests (e.g., CBC, serum ferritin) may be considered.</li>\r\n<li>Iron supplements may decrease the frequency of breath-holding spells in these children.</li>\r\n</ul>", "options": ["IV Lorazepam", "IM Midazolam", "Clonazepam", "No treatment required"], "html_options": ["IV Lorazepam", "IM Midazolam", "Clonazepam", "No treatment required"], "corr_idx": 3}, {"id": "1180633", "html_qtxt": "A 32-year-old man presented with violent jerky movements of his arms and legs for 10 minutes. He has a history of epilepsy. He is not responsive. IV lorazepam is initiated. The second agent administered was most likely which of the following drugs?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient's history of epilepsy and ongoing seizure for > 5 minutes is diagnostic of status epilepticus. Lorazepam was given to abort the seizure, and the second agent, like Phenytoin/ Fosphenytoin, was given to prevent recurrence of the seizure in the acute period.</li>\r\n<li>Fosphenytoin is an intravenous prodrug of phenytoin with a more favourable safety profile than phenytoin preparations delivered via other routes.</li>\r\n<li>It is converted to phenytoin, the active moiety of this drug, by hydrolysis.</li>\r\n<li>Once activated, it reduces the influx and increases the efflux of sodium ions across neuronal membranes in the motor cortex.</li>\r\n<li>It is indicated for the prevention of seizure recurrence in status epilepticus and short-term (< 5 days) treatment of epilepsy.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240320b6a778f9-f77a-4097-a2aa-a737db016be0.jpg\">", "options": ["Propofol", "Phenobarbital", "Fosphenytoin", "Lamotrigine"], "html_options": ["Propofol", "Phenobarbital", "Fosphenytoin", "Lamotrigine"], "corr_idx": 2}, {"id": "1180636", "html_qtxt": "A 7-year-old girl has presented with multiple episodes of staring and facial grimacing for 4 weeks. She recalls having a vague, muddy taste in her mouth prior to the onset of symptoms. After the episode, she feels lethargic and is confused. There are no precipitating factors for these episodes. Which of the following is the most appropriate treatment for seizures?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The symptoms described in the case, including staring, facial grimacing, a vague, muddy taste in the mouth, post-ictal lethargy, and confusion, are indicative of <strong>complex partial seizures</strong>, which often originate from the temporal lobe of the brain. This type of seizure can be associated with a condition called \"temporal lobe epilepsy.\"</p>\r\n<p>The most appropriate treatment for this type of seizure in a 7-year-old girl is:</p>\r\n<p><strong>Lamotrigine</strong>: Lamotrigine is an antiepileptic medication, more commonly used for treating various types of seizures, including focal (partial) seizures and generalised seizures, but not typically absence seizures.</p>\r\n<p><strong>Ethosuximide (Option D)</strong>: Ethosuximide is a medication commonly used to treat absence seizures, which are a type of generalised seizure characterised by brief staring spells and altered awareness. Ethosuximide is particularly effective for this type of seizure and is considered a first-line treatment.</p>\r\n<p><strong>Felbamate (Option B)</strong>: Felbamate is another antiepileptic medication, but it is not typically used as a first-line treatment for absence seizures in children due to its potential for serious side effects.</p>\r\n<p><strong>Zonisamide (Option C)</strong>: Zonisamide is used to treat various types of seizures, but it is not considered the first-line treatment for absence seizures in children.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307667a8046-1986-4656-9829-11e357759d06.jpg\">", "options": ["Lamotrigine", "Felbamate", "Zonisamide", "Ethosuximide"], "html_options": ["Lamotrigine", "Felbamate", "Zonisamide", "Ethosuximide"], "corr_idx": 0}, {"id": "1180641", "html_qtxt": "A 32-year-old man is on valproate therapy for GTCS. Which of the following is NOT true about this therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Valproate does not cause cytochrome P450 induction.</p>\r\n<ul>\r\n<li>Sodium valproate is a CYP3A4 inhibitor and not an inducer.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905386d9ec0-6a2c-4c5a-b2d7-b0eb3ede87e5.png\"><p><strong>Side effects of Valproate:</strong></p>\r\n<ul>\r\n<li>Gastrointestinal upset</li>\r\n<li>Tremor</li>\r\n<li>Alopecia</li>\r\n<li>Pancreatitis</li>\r\n<li>Weight gain</li>\r\n<li>Teratogenicity: Especially neural tube defects (contraindicated in women of childbearing age/pregnancy)</li>\r\n<li>Hepatotoxicity (rare): LFT should be regularly performed in people taking valproate (child)</li>\r\n<li>Cytochrome P450 inhibition (valproic acid inhibits the metabolism of carbamazepine, ethosuximide, phenytoin, phenobarbital, and lamotrigine).</li>\r\n<li>Rash</li>\r\n<li>Sedation</li>\r\n<li>Ataxia</li>\r\n<li>Thrombocytopenia</li>\r\n<li>Agranulocytosis</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307fa67bc37-e7cf-4e46-96ee-6c44bb48feb5.jpg\">\r\n<br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030749f05cfc-0c87-4323-84d7-0c4d8905e5df.jpg\">\r\n<br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307da26bdea-7e32-487d-a43e-b40af7966333.jpg\">\r\n", "options": ["It is contraindicated in women of childbearing age", "It causes cytochrome P450 induction", "LFT should be regularly performed in people taking valproate.", "It may lead to weight gain and PCOS like feature in young women."], "html_options": ["It is contraindicated in women of childbearing age", "It causes cytochrome P450 induction", "LFT should be regularly performed in people taking valproate.", "It may lead to weight gain and PCOS like feature in young women."], "corr_idx": 1}, {"id": "1180642", "html_qtxt": "Which of the following drugs may cause irreversible vision loss?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Vigabatrine acts by inhibition of GABA transaminase irreversibly &rarr; &uarr; GABA, used in Refractory focal seizures (adjunctive therapy) and Monotherapy for infantile spasms (West syndrome).</li>\r\n<li>It can cause irreversible vision loss in up to 50% of patients; therefore, it is used only in patients if other anticonvulsants are ineffective.</li>\r\n</ul>\r\n<p><strong>Gabapentin, levetiracetam, and tiagabine (Options A, B, & C) </strong>are not known for causing blindness.</p>", "options": ["Gabapentin", "Levetiracetam", "Tiagabine", "Vigabatrine"], "html_options": ["Gabapentin", "Levetiracetam", "Tiagabine", "Vigabatrine"], "corr_idx": 3}, {"id": "1180643", "html_qtxt": "A 62-year-old woman presents with a sudden onset of severe left eye pain, blurred vision, nausea, and vomiting. She is on an anti-seizure drug. Gonioscopy shows that the iris meets the cornea at an angle of 10&deg; (N = 20-45&deg;). Which of the following drugs may precipitate this condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Topiramate blocks voltage-gated Na<sup>+</sup>&nbsp;channels and increases GABA. Dose-related adverse effects that often occur in the first 4 weeks of topiramate therapy include somnolence, fatigue, dizziness, nervousness, and confusion.</li>\r\n<li>Acute myopia and angle-closure glaucoma may require prompt drug withdrawal.</li>\r\n<li>Urolithiasis occurs in 0.5-1.5% of patients on long-term therapy and is more common in men. In some patients, carbonic anhydrase inhibition is associated with reduced serum bicarbonate that is usually asymptomatic but may result in nonspecific symptoms such as fatigue, anorexia, or nausea and vomiting.</li>\r\n</ul>", "options": ["Lamotrigine", "Levetiracetam", "Topiramate", "Pregabalin"], "html_options": ["Lamotrigine", "Levetiracetam", "Topiramate", "Pregabalin"], "corr_idx": 2}, {"id": "1180644", "html_qtxt": "A 45-year-old man undergoes brain surgery for oligodendroglioma, after which he is initiated on an anti-epileptic drug. After 3 months of follow-up, he complained of more irritability and aggression over tiny issues. Which of the following drugs may explain the rare side effect?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Levetiracetam is a broad-spectrum anti-seizure agent and one of the most commonly prescribed drugs for epilepsy, primarily because of its perceived favourable adverse effect profile, broad therapeutic window, favourable pharmacokinetic properties, and lack of drug-drug interactions.</li>\r\n<li>Less common but more serious are behavioural and mood changes, such as irritability, aggression, agitation, anger, anxiety, apathy, depression, and emotional lability.</li>\r\n<li>Long-term topiramate therapy is often associated with significant weight loss, primarily due to a reduction in body fat mass.</li>\r\n<li>In clinical trials, 85% of adults receiving topiramate lost weight, which on average amounted to 5% of mean baseline body weight.</li>\r\n<li>Greater weight loss occurs in those with higher pretreatment weight.</li>\r\n<li>Weight loss is gradual and typically peaks at 12-18 months after initiation of therapy.</li>\r\n<li>Beneficial changes in lipid profile, glycemic control, and blood pressure may accompany the weight loss.</li>\r\n</ul>", "options": ["Lamotrigine", "Levetiracetam", "Topiramate", "Pregabalin"], "html_options": ["Lamotrigine", "Levetiracetam", "Topiramate", "Pregabalin"], "corr_idx": 1}, {"id": "1180645", "html_qtxt": "A 45-year-old is started on a drug for recurrent major depression. After a week, she presents with influenza-like symptoms, including fevers and neck stiffness. After a thorough investigation diagnosis of HLH (Hemophagocytic lymphohistiocytosis) has been made. Which of the drugs may cause secondary HLH?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>While secondary HLH is usually triggered by infection or malignancy, a thorough medication history is essential for prompt recognition and cessation of potentially offending agents such as lamotrigine.</li>\r\n<li>Outcomes for such patients include withholding of the offending drug and prompt initiation of dexamethasone treatment.</li>\r\n<li>Although most controlled studies have evaluated lamotrigine as add-on therapy, the drug is effective as mono-therapy for focal seizures, and lamotrigine is now widely prescribed for this indication because of its excellent tolerability. It can also improve depression in patients with epilepsy and reduce the risk of relapse in bipolar disorder.</li>\r\n</ul>\r\n<p><strong>Reference:</strong>&nbsp;</p>\r\n<p><a href=\"https://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-019-2295-1\" target=\"_blank\">https://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-019-2295-1</a></p>", "options": ["Lamotrigine", "Levetiracetam", "Topiramate", "Pregabalin"], "html_options": ["Lamotrigine", "Levetiracetam", "Topiramate", "Pregabalin"], "corr_idx": 0}, {"id": "1180646", "html_qtxt": "A 38-year-old man presents with severe, right-sided, colicky flank pain that radiates to the groin for 2 hours. Patient has a history of brain surgery for which he's on anti-seizure therapy. An x-ray of the abdomen shows a 4-mm radiopaque mass in the right ureter. Microscopic examination of the urine shows biconcave, dumbbell-shaped crystals. Which of the following is responsible for the current symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Topiramate blocks voltage-gated Na+ channels and increases GABA activity. It can trigger acute myopia and angle-closure glaucoma, which may necessitate prompt drug withdrawal.</li>\r\n<li>Dose-related adverse effects that occur frequently in the first 4 weeks of topiramate therapy are somnolence, fatigue, dizziness, nervousness, and confusion.</li>\r\n<li>Acute myopia and angle-closure glaucoma may require prompt drug withdrawal.</li>\r\n<li>Urolithiasis occurs in 0.5-1.5% of patients on long-term therapy and is more common in men.</li>\r\n<li>In some patients, carbonic anhydrase inhibition is associated with reduced serum bicarbonate that is usually asymptomatic but may result in nonspecific symptoms such as fatigue, anorexia, or nausea and vomiting.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030720fa593f-922d-4d18-82da-1998e9adee45.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307cde12e32-8fec-475c-a6c0-45865a75ec0a.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307c47fd55f-721d-4898-a5d2-0002049f62f4.jpg\">\r\n", "options": ["Lamotrigine", "Levetiracetam", "Topiramate", "Pregabalin"], "html_options": ["Lamotrigine", "Levetiracetam", "Topiramate", "Pregabalin"], "corr_idx": 2}, {"id": "1180647", "html_qtxt": "Match the following drugs with it's molecular targets..<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307be3abde3-4bf6-4ef5-8908-10ee0e338da4.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Antiseizure drugs inhibit the spread of epileptic activity to nearby and distant sites, either by strengthening the inhibitory surround mediated by GABAergic interneurons (A) or by reducing glutamate-mediated excitatory neurotransmission.</p>\r\n<p>The specific actions of antiseizure drugs on their targets are broadly described as:</p>\r\n<ul>\r\n<li>Modulation of voltage-gated sodium, calcium, or potassium channels</li>\r\n<li>Enhancement of fast GABA-mediated synaptic inhibition</li>\r\n<li>Modification of synaptic release processes</li>\r\n<li>Diminution of fast glutamate-mediated excitation</li>\r\n</ul>", "options": ["1-C 2-B 3-D 4-A", "1-B 2-C 3-D 4-A", "1-C 2-D 3-B 4-A", "1-B 2-D 3-C 4-A"], "html_options": ["1-C 2-B 3-D 4-A", "1-B 2-C 3-D 4-A", "1-C 2-D 3-B 4-A", "1-B 2-D 3-C 4-A"], "corr_idx": 1}, {"id": "1180648", "html_qtxt": "You're being asked about the difference between carbamazepine and oxcarbazepine. Which of the following sentences is NOT true about the difference between these two drugs?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Oxcarbazepine is the 10-keto analogue of carbamazepine. Unlike carbamazepine, it cannot form an epoxide metabolite. Oxcarbazepine is less potent than carbamazepine, both in animal tests and in patients; clinical doses of oxcarbazepine may need to be 50% higher than those of carbamazepine to obtain equivalent seizure control. Some studies report fewer hypersensitivity reactions to oxcarbazepine, and cross-reactivity with carbamazepine does not always occur.</li>\r\n<li>Furthermore, the drug appears to induce hepatic enzymes to a lesser extent than carbamazepine, minimising drug interactions. Although hyponatremia may occur more commonly with oxcarbazepine than with carbamazepine, most adverse effects of oxcarbazepine are similar to those of carbamazepine.</li>\r\n</ul>", "options": ["Oxcarbazepine is less potent than carbamazepine", "Oxcarbazepine appears to induce hepatic enzymes to a lesser extent than carbamazepine", "Hyponatremia may occur more commonly with carbamazepine than with oxcarbazepine", "Unlike carbamazepine, oxcarbazepine cannot form an epoxide metabolite"], "html_options": ["Oxcarbazepine is less potent than carbamazepine", "Oxcarbazepine appears to induce hepatic enzymes to a lesser extent than carbamazepine", "Hyponatremia may occur more commonly with carbamazepine than with oxcarbazepine", "Unlike carbamazepine, oxcarbazepine cannot form an epoxide metabolite"], "corr_idx": 2}, {"id": "1180649", "html_qtxt": "A 27-year-old woman comes to you for advice regarding discontinuation of valproate as she is planning to conceive. She has seizure-free interval for 12 months. What would be appropriate advice?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>In the majority of cases, pregnancy does not affect seizure frequency; however, 20&ndash;35% of individuals experience an increased seizure frequency. Seizure activity 1 year before pregnancy was identified as the best predictor of seizure activity during pregnancy. It is recommended to measure AED levels before conception (if possible) and monthly during pregnancy.</li>\r\n</ul>\r\n<p><strong>Risk factors associated with epileptic seizures during pregnancy include:</strong></p>\r\n<ul>\r\n<li>Reduced plasma concentration of antiepileptic drugs (AEDs, e.g., due to steroid-hormone induced hepatic enzyme induction, increased renal clearance)</li>\r\n<li>Psychosocial stress, sleep deprivation</li>\r\n<li>Hormonal changes (e.g., increased estrogen: progesterone ratio)</li>\r\n<li><strong>Fetal complications:</strong>\r\n<ul>\r\n<li>Maternal seizures are associated with an increased risk of low birth weight and small size for gestational age</li>\r\n<li>Compared to AEDs such as lamotrigine and levetiracetam, exposure to AEDs such as valproate, phenobarbital, and topiramate is associated with a significantly increased risk of congenital malformations (e.g., neural tube defects, hypospadias, cardiac defects)</li>\r\n</ul>\r\n</li>\r\n<li><strong>Maternal complications</strong>:\r\n<ul>\r\n<li>Increased risk of preterm delivery</li>\r\n<li>Need for cesarean section</li>\r\n<li>Preeclampsia</li>\r\n<li>Severe postpartum haemorrhage</li>\r\n<li>Death during delivery</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Key points to remember for AEDs in pregnancy: </strong></p>\r\n<ul>\r\n<li>Classic anticonvulsants (especially carbamazepine and sodium valproate!) should be avoided if possible &rarr; teratogenic effects.</li>\r\n<li>Newer anticonvulsants: Lack of medical data and trials during pregnancy, Levetiracetam and lamotrigine are among the most widely used due to lower risk for malformations.</li>\r\n<li>The choice of treatment depends on the type of seizure and which substance enables optimal control of seizures.</li>\r\n<li>Approach\r\n<ul>\r\n<li>Optimise seizure control before conception</li>\r\n<li>Avoid multiple therapies</li>\r\n<li>Administer the drug at the lowest dose that controls seizures</li>\r\n<li>Monitor plasma drug levels regularly</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>She can conceive as the seizure is controlled, the same drug to continue (Option A):</strong> Valproate has the highest side effects in pregnancy; it's preferred to shift to safer AEDs like lamotrigine before conception and optimise seizure control.</p>\r\n<p><strong>Valproate to be continued, add lamotrigine with it (Option C)</strong>: Multiple therapies should be avoided. As it may increase the risk of side effects.</p>\r\n<p><strong>Measure AED level every 6 months (Option D)</strong>: It is recommended to measure AED levels before conception (if possible) and monthly during pregnancy.</p>", "options": ["She can conceive as the seizure is controlled, the same drug to continue", "Valproate should be discontinued, patient should be started on lamotrigine", "Valproate to be continued, add lamotrigine with it", "Measure AED level every 6 months"], "html_options": ["She can conceive as the seizure is controlled, the same drug to continue", "Valproate should be discontinued, patient should be started on lamotrigine", "Valproate to be continued, add lamotrigine with it", "Measure AED level every 6 months"], "corr_idx": 1}, {"id": "1180650", "html_qtxt": "A 44-year-old woman comes to you for a routine examination. She has been on phenytoin for her brain surgery for 10 years. She has no other complaint other than weakness. Her CBC report is shown below. What would be your next step? <br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307646488e4-e24c-4ee9-a3ab-8121319e8530.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient is having megaloblastic anaemia, probably due to long-term phenytoin therapy. She should be given <strong>vitamin B12 + folic acid</strong> for the same.</p>\r\n<ul>\r\n<li>Long-term use is associated in some patients with coarsening of facial features and with mild peripheral neuropathy, usually manifested by diminished deep tendon reflexes in the lower extremities.</li>\r\n<li>Long-term use may also result in abnormalities of vitamin D metabolism, leading to osteomalacia.</li>\r\n<li>If <strong>folic acid</strong> <strong>(Option A) </strong>alone is given, it will utilise B12 in its pathways, leaving a deficiency of B12, causing neurological symptoms.</li>\r\n<li>So B12 should always be supplemented, even if it's just for folate deficiency.</li>\r\n</ul>", "options": ["Folic acid", "Vitamin B12 + Folic acid", "Iron + Folic acid", "Serum phenytoin level"], "html_options": ["Folic acid", "Vitamin B12 + Folic acid", "Iron + Folic acid", "Serum phenytoin level"], "corr_idx": 1}, {"id": "1180651", "html_qtxt": "A 42-year-old woman with a history of refractory seizure disorder has been treated with numerous anti- epileptic agents, which have failed to control her seizures. She has begun therapy with Rufinamide. This agent is contraindicated in which of the following situations?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Rufinamide in vitro acts at the sodium channels. It is approved for the adjunctive treatment of seizures associated with Lennox&ndash;Gastaut syndrome in children older than the age of 4 years and adults.</li>\r\n<li>Rufinamide is a weak inhibitor of CYP2E1 and a weak inducer of CYP3A4 enzymes.</li>\r\n<li>Food increases absorption and peak serum concentrations.</li>\r\n<li>Serum concentrations of rufinamide are affected by other antiseizure medications. It is induced by carbamazepine and phenytoin and inhibited when given with valproate.</li>\r\n<li>Women taking birth control tablets should be counselled that they may not be effective when used concurrently with rufinamide. Adverse effects include the potential for shortened QT intervals.</li>\r\n<li>Patients with familial short QT syndrome should not be treated with rufinamide.</li>\r\n</ul>", "options": ["Glaucoma", "Familial short QT syndrome ", "Nephrolithiasis", "Irreversible vision loss "], "html_options": ["Glaucoma", "Familial short QT syndrome ", "Nephrolithiasis", "Irreversible vision loss "], "corr_idx": 1}, {"id": "1180652", "html_qtxt": "A 23-year-old woman with a history of seizure disorder is planning to become pregnant. She realises that being on this medication during pregnancy can have fetal effects of intellectual disability. Which of the following agents would likely produce a newborn with the lowest intelligence quotient (IQ)?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>In utero exposure to valproate, when compared with other commonly used anti-epileptic drugs, is associated with an increased risk of impaired cognitive function at 3 years of age. Valproate should not be used in women of childbearing potential.</p>", "options": ["Carbamezapine ", "Lamotrigine", "Valproic acid", "Phenytoin"], "html_options": ["Carbamezapine ", "Lamotrigine", "Valproic acid", "Phenytoin"], "corr_idx": 2}, {"id": "1180653", "html_qtxt": "A 58-year-old woman with epilepsy refractory to medical therapy is hospitalised for deep-brain stimulation. This new modality uses a pacemaker-like device to stimulate which of the following structures? ", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Deep brain stimulation (DBS) therapy uses a pacemaker-like device to deliver targeted electrical stimulation to the anterior nucleus of the thalamus.</li>\r\n<li>The therapy is FDA-approved with conditions for adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy.</li>\r\n<li>DBS is also FDA-approved for the treatment of advanced Parkinson's disease and essential tremor.</li>\r\n</ul>", "options": ["Cerebrum", "Thalamus", "Hypothalamus", "Basal ganglia"], "html_options": ["Cerebrum", "Thalamus", "Hypothalamus", "Basal ganglia"], "corr_idx": 1}, {"id": "1180654", "html_qtxt": "A 26-year-old woman with lifelong epilepsy controlled with medication has just found out that she is pregnant. She has seizures once a month but seems to be controlled at present. Which of the following statements about epilepsy in pregnancy is true?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Women with epilepsy are often very concerned about pregnancy and what effect the medications might have on fetal development. Planning is the most important component. All women considering pregnancy should be on high doses of folic acid before conception.</li>\n<li>Valproate and barbiturates should be avoided. Those women already on valproate and barbiturates should be switched to other drugs before pregnancy when possible.</li>\n<li>When seizures are controlled, maintenance medication may be reduced, if possible, to the lowest dose that provides control. If seizures are not controlled, medications and dosages will need to be adjusted before pregnancy, if possible. The frequency and severity of seizures may change during pregnancy.</li>\n</ul>", "options": ["Barbiturates should be considered", "Valproate is considered a drug of choice", "She should be taking high doses of folic acid", "She will likely have no change in seizure activity during pregnancy"], "html_options": ["Barbiturates should be considered", "Valproate is considered a drug of choice", "She should be taking high doses of folic acid", "She will likely have no change in seizure activity during pregnancy"], "corr_idx": 2}, {"id": "1180655", "html_qtxt": "Drug \"X\" is used in the management of insomnia and facilitates the inhibitory actions of GABA, but it lacks anticonvulsant or muscle-relaxing properties and has minimal effect on REM sleep. Its actions are antagonised by flumazenil. Find \"X\".", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Only two of the drugs listed are used for insomnia, eszopiclone and ramelteon. Eszopiclone, zaleplon, and zolpidem are related hypnotics that, though structurally different from benzodiazepines, appear to have a similar mechanism of action.</li>\r\n<li>However, unlike benzodiazepines, these drugs are not used in seizures or in muscle spasticity states. Compared with benzodiazepines, the newer hypnotics are less likely to alter sleep patterns.</li>\r\n</ul>\r\n<p><strong>Buspirone (Option A)</strong>: Buspirone is not a hypnotic. But it is an ANXIOLYTIC used for generalised anxiety disorder.</p>\r\n<p><strong>Ramelteon</strong> <strong>(Option C)</strong> activates melatonin receptors in the suprachiasmatic nuclei; flumazenil does not reverse its effects.</p>", "options": ["Buspirone", "Eszopiclone", "Ramelteon", "Phenobarbital"], "html_options": ["Buspirone", "Eszopiclone", "Ramelteon", "Phenobarbital"], "corr_idx": 1}, {"id": "1180656", "html_qtxt": "A 34-year-old woman has complained of poor sleep for the past 3 months. She has difficulty initiating sleep at night. She does not have trouble maintaining sleep. Short-term treatment with which of the following drugs is the most appropriate pharmacotherapy for this patient's symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient has difficulty initiating sleep at night but does not have difficulty maintaining sleep, which is characteristic of sleep onset insomnia.</li>\r\n<li>This type of insomnia is treated with a short-acting.</li>\r\n<li>Triazolam is a short-acting benzodiazepine (half-life approx. 2&ndash;5 hours) used for the short-term treatment of sleep onset insomnia and as a second-line therapy for social anxiety disorder.</li>\r\n<li>It facilitates the GABA-mediated inhibition of neuronal depolarisation (through increased frequency of Cl- channel opening) and improves sleep quality by reducing the time to sleep onset (latency) and reducing phase one of non-REM sleep (light sleep).</li>\r\n<li>Adverse effects include headache, amnesia, and, most importantly, the addictive potential.</li>\r\n<li>Alternative therapeutic options for sleep-onset insomnia with equal effectiveness but less addictive potential than benzodiazepines include nonbenzodiazepine hypnotics such as zolpidem and zaleplon.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307e953a809-f2da-4cf8-8b4d-f0d93c3d7862.jpg\">\r\n", "options": ["Diazepam", "Triazolam", "Flurazepam", "Phenobarbital"], "html_options": ["Diazepam", "Triazolam", "Flurazepam", "Phenobarbital"], "corr_idx": 1}, {"id": "1180657", "html_qtxt": "A 72-year-old man has complained of poor sleep and taking longer to fall asleep for the past several years. He would like to start a short-term pharmacological therapy trial, but does not want a drug that makes him drowsy during the day. Which of the following is the most appropriate pharmacotherapy for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This elderly patient presents with sleep-onset insomnia. The most appropriate pharmacotherapy for this patient is a short-acting agent that acts as a selective agonist on the BZ subtype of the GABA receptor.</li>\r\n<li>Zaleplon is a non-benzodiazepine hypnotic with a very short half-life (&sim; 1 hour).</li>\r\n<li>Therefore, it is effective for the treatment of sleep-onset insomnia, as seen in this patient.</li>\r\n<li>Zolpidem is another non-benzodiazepine hypnotic, with a longer half-life than Zaleplon (up to 4.5 hours). It is used for patients who have difficulty with sleep onset and/or sleep maintenance.</li>\r\n<li>Non-benzodiazepines have marked sedative effects and are not associated with drug dependence.</li>\r\n<li>Because of their more favourable side effect profile, they are preferred over benzodiazepines for the treatment of sleep disorders, particularly among elderly persons (except zolpidem increases the risk for falls in the elderly).</li>\r\n<li>However, like benzodiazepines, they are not approved for long-term use.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403071da3a0be-820e-42b1-86ae-0d50db8d8e07.jpg\">\r\n", "options": ["Temazepam", "Phenobarbital", "Lorazepam", "Zaleplon"], "html_options": ["Temazepam", "Phenobarbital", "Lorazepam", "Zaleplon"], "corr_idx": 3}, {"id": "1180658", "html_qtxt": "A 23-year-old man presents to you with recurrent episodes of chest pain, shortness of breath and impending doom. Treatment with lorazepam is initiated. The concurrent intake of which of the following drugs should be avoided in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient's symptoms are consistent with panic disorder, for which he was prescribed lorazepam, an oral benzodiazepine that has CNS depressant effects.</li>\r\n<li>Simultaneous administration of other drugs that possess CNS depressant properties, such as first-generation antihistamines (e.g., diphenhydramine, promethazine, hydroxyzine), opioids, and barbiturates (primidone), should be avoided because of the synergistic effects and risk of respiratory depression.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307ef34ad90-c69c-4d1c-9be4-d52c9d2f97c3.jpg\">\r\n", "options": ["Primidone", "Levocetrizine", "Venlafaxine", "Phenelzine"], "html_options": ["Primidone", "Levocetrizine", "Venlafaxine", "Phenelzine"], "corr_idx": 0}, {"id": "1180659", "html_qtxt": "Which statement concerning the barbiturates is most accurate?<br>1. Abstinence syndromes are more severe during withdrawal from phenobarbital than from secobarbital.<br>2. Barbiturates depress neuronal activity in the midbrain reticular formation.<br>3. Alkalinization of the urine accelerates the elimination of phenobarbital.<br>4. Barbiturates may increase the half-lives of drugs metabolised by the liver.<br>5. Barbiturates increase the duration of GABA-mediated chloride ion channel opening.<br>6. Compared with barbiturates, the benzodiazepines exhibit a steeper dose-response relationship.<br>7. Respiratory depression caused by barbiturate overdosage can be reversed by flumazenil.", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Barbiturates depress neuronal activity in the midbrain reticular formation, facilitating and prolonging the inhibitory effects of GABA and glycine. Barbiturates also bind to multiple isoforms of the GABAA receptor, but at different sites from those with which benzodiazepines interact</li>\r\n<li>Withdrawal symptoms from the use of the shorter-acting barbiturate secobarbital are more severe than with phenobarbital. The dose-response curve for benzodiazepines is flatter than that for barbiturates. Induction of liver drug-metabolising enzymes occurs with barbiturates and may lead to decreases in the half-life of other drugs.</li>\r\n<li>Flumazenil is an antagonist at BZ receptors and is used to reverse the CNS depressant effects of benzodiazepines. As a weak acid (pKa 7), phenobarbital will be more ionised (nonprotonated) in the urine at alkaline pH and less reabsorbed in the renal tubule.</li>\r\n</ul>", "options": ["1,2,3,4", "2,3,4,6", "2,3,5", "3,5,6"], "html_options": ["1,2,3,4", "2,3,4,6", "2,3,5", "3,5,6"], "corr_idx": 2}, {"id": "1180662", "html_qtxt": "A 34-year-old woman complains about being easily startled, worries about inconsequential matters. Diagnosed as suffering from generalised anxiety disorder, he is prescribed buspirone. The patient should be informed to anticipate<br>1. A need to continually increase drug dosage because of tolerance.<br>2. A significant effect of the drug on memory.<br>3. Additive CNS depression with alcoholic beverages.<br>4. It can cause tachycardia, paresthesia, pupillary constriction, and gastrointestinal distress.<br>5. That the drug is likely to take a week or more to begin working.<br>6. If he stops taking the drug abruptly, he will experience withdrawal symptoms.<br>7. It is safe in pregnancy", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Buspirone is a selective anxiolytic with pharmacologic characteristics different from those of sedative-hypnotics.</li>\r\n<li>Buspirone has minimal effects on cognition or memory; it is not additive with ethanol in terms of CNS depression (alcohol enhances psychomotor depression and the amnestic effects of the benzodiazepine group of drugs); tolerance is minimal; and it has no dependence liability. Buspirone is not effective in acute anxiety because it has a slow onset of action (&sim;1 week).</li>\r\n<li>Buspirone is metabolised by CYP3A4, and its plasma levels are markedly increased by drugs such as erythromycin and ketoconazole. Side effects of buspirone include tachycardia, paresthesia, pupillary constriction, and gastrointestinal distress. Buspirone has minimal abuse liability and is not a schedule-controlled drug. The drug appears to be safe in pregnancy.</li>\r\n</ul>", "options": ["2,3,4,5,6", "1,2,4,5", "4,5,7", "1,4,6"], "html_options": ["2,3,4,5,6", "1,2,4,5", "4,5,7", "1,4,6"], "corr_idx": 2}, {"id": "1180664", "html_qtxt": "A 78-year-old man has difficulty sleeping. Triazolam is prescribed for her at one-half of the conventional adult dose. Which statement about the use of triazolam in this elderly patient is most accurate?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>In elderly patients taking benzodiazepines, hypotension is far more likely than an increase in blood pressure. Elderly patients are more prone to the CNS depressant effects of hypnotics; a dose reduction of 50% may still cause excessive sedation with possible ambulatory impairment.</li>\r\n<li>Additive CNS depression occurs commonly with drugs used in over-the-counter cold medications, especially antihistamines, and rebound insomnia can occur with abrupt discontinuance of benzodiazepines used as sleeping pills. Alcohol enhances psychomotor depression and the amnestic effects of the benzodiazepines.</li>\r\n</ul>", "options": ["Hypertension is a common adverse effect of benzodiazepines in elderly patients", "Over-the-counter cold medications may antagonize the hypnotic effects of the drug", "The patient may experience amnesia, especially if he also consumes alcoholic beverages", "Triazolam does not cause rebound insomnia on abrupt discontinuance"], "html_options": ["Hypertension is a common adverse effect of benzodiazepines in elderly patients", "Over-the-counter cold medications may antagonize the hypnotic effects of the drug", "The patient may experience amnesia, especially if he also consumes alcoholic beverages", "Triazolam does not cause rebound insomnia on abrupt discontinuance"], "corr_idx": 2}]}, {"moduleId": 1008542, "name": "Anaesthetic Pharmacology", "questions": [{"id": "1176852", "html_qtxt": "A 35-year-old male patient came to the emergency department with complaints of severe abdominal pain, vomiting for 4-5 hours. On PA examination abdomen was tender. His Chest radiogram and X-Ray abdominal standing were done. The chest radiogram was suggestive of pneumoperitoneum. The surgeon elects for emergency laparotomy, which is to be done under general anaesthesia. What are the neurophysiological states produced by general anaesthetic agents?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The neurophysiologic state produced by general anaesthetics is characterised by five primary effects: <strong>Unconsciousness, amnesia, analgesia, inhibition of autonomic reflexes</strong>, and <strong>skeletal muscle relaxation</strong>.</li>\n<li>None of the currently available anaesthetic agents, when used alone, can achieve all five of these desired effects.</li>\n<li>In addition, an ideal anaesthetic drug should induce rapid, smooth loss of consciousness, be rapidly reversible upon discontinuation and possess a wide margin of safety.</li>\n<li>The modern practice of anaesthesiology relies on the use of combinations of intravenous and inhaled drugs (<strong>balanced anaesthesia </strong>techniques) to take advantage of the favourable properties of each agent while minimising their adverse effects.</li>\n<li>The choice of anaesthetic technique is determined by the type of diagnostic, therapeutic, or surgical intervention to be performed.</li>\n</ul>", "options": ["Analgesia, Amnesia, Unconsciousness", "Inhibition of autonomic reflexes", "Skeletal muscle relaxation  ", "All of the above"], "html_options": ["Analgesia, Amnesia, Unconsciousness", "Inhibition of autonomic reflexes", "Skeletal muscle relaxation  ", "All of the above"], "corr_idx": 3}, {"id": "1176854", "html_qtxt": "Which of the following sentences are TRUE for inhalational anaesthetic agents?<br> 1. More solubility of gases causes rapid induction of anaesthesia<br> 2. Less solubility of gases causes rapid induction of anaesthesia<br> 3. More solubility of gases causes slow induction of anaesthesia<br> 4. Less solubility of gases causes slow induction of anaesthesia", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>One of the most important factors influencing the transfer of an anaesthetic from the lungs to the arterial blood is its solubility characteristics.</li>\n<li>The blood-gas partition coefficient is a useful index of solubility and defines the relative affinity of an anaesthetic for blood compared with that of the inspired gas.</li>\n<li>The partition coefficients for desflurane and nitrous oxide, which are relatively insoluble in blood, are extremely low.</li>\n<li><strong>Low blood solubility anaesthetics:</strong>\n<ul>\n<li>Few molecules are needed to raise the blood partial pressure.</li>\n<li>Arterial tension rises <strong>rapidly</strong>.</li>\n<li>Leads to <strong>faster induction</strong> of anaesthesia.</li>\n</ul>\n</li>\n<li><strong>Moderate to high blood solubility anaesthetics:</strong>\n<ul>\n<li>More molecules dissolve in the blood before the partial pressure rises.</li>\n<li>Arterial tension increases <strong>more slowly</strong>.</li>\n<li>Results in <strong>slower induction</strong>.</li>\n</ul>\n</li>\n<li><strong>Blood: Gas Partition Coefficient:</strong>\n<ul>\n<li>Indicates how much anaesthetic dissolves in blood relative to alveolar gas.</li>\n<li><strong>Nitrous oxide</strong> has a coefficient of <strong>47</strong>, meaning:\n<ul>\n<li>At equilibrium, its <strong>blood concentration is 0.47x</strong> the alveolar concentration.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><strong>Effect of higher blood: gas partition coefficient:</strong>\n<ul>\n<li>Greater uptake into the blood.</li>\n<li>Slows the rate at which <strong>FA/FI (alveolar to inspired ratio)</strong> approaches 1.</li>\n<li>Therefore, there is a <strong>slower onset</strong> of anaesthesia.</li>\n</ul>\n</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307110ba8ed-5a32-447e-8faa-4a8c86aa6a1a.jpg\">", "options": ["1,3", "2,4", "1,4", "2,3"], "html_options": ["1,3", "2,4", "1,4", "2,3"], "corr_idx": 3}, {"id": "1176855", "html_qtxt": "Traditionally, anaesthetic effect on the brain produces four stages. Match the following four stages of anaesthesia with their effects.<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403072bcc8722-9047-4045-8585-a7d1c568d08b.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Traditionally, anaesthetic effects on the brain produce four stages or levels of increasing depth of CNS depression (Guedel's signs, derived from observations of the effects of inhaled diethyl ether):\n<ul>\n<li><strong>Stage I-analgesia:</strong>The patient initially experiences analgesia without amnesia. Later in stage I, both analgesia and amnesia are produced.</li>\n<li><strong>Stage II-excitement:</strong>During this stage, the patient appears delirious, may vocalise, but is completely amnesic. Respiration is rapid, and heart rate and blood pressure increase. Duration and severity of this light stage of anaesthesia rapidly increase with the concentration of the agent.</li>\n<li><strong>Stage III-surgical anaesthesia:</strong>This stage begins with slowing of respiration and heart rate, and extends to complete cessation of spontaneous respiration (apnea). Four planes of stage III are described based on changes in ocular movements, eye reflexes, and pupil size, indicating increasing depth of anaesthesia.</li>\n<li><strong>Stage IV-medullary depression:</strong>This deep stage of anaesthesia represents severe depression of the CNS, including the vasomotor centre in the medulla and the respiratory centre in the brainstem. Without circulatory and respiratory support, death would rapidly ensue.</li>\n</ul>\n</li>\n</ul>", "options": ["1-d, 2-c, 3-b, 4-a", "1-d, 2-b, 3-c, 4-a", "1-d, 2-a, 3-b, 4-c", "1-d, 2-a, 3-c, 4-b"], "html_options": ["1-d, 2-c, 3-b, 4-a", "1-d, 2-b, 3-c, 4-a", "1-d, 2-a, 3-b, 4-c", "1-d, 2-a, 3-c, 4-b"], "corr_idx": 2}, {"id": "1176858", "html_qtxt": "Which of the following sentences are true for their action of halogenated inhaled anaesthetic agents?<br> 1. They cause CNS depression<br> 2. They depress cardiac activity<br> 3. They cause bronchoconstriction<br> 4. They increase GFR<br> 5. They decrease portal vein flow<br> 6. They relax the Uterine muscles", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Halothane, enflurane, isoflurane, desflurane, and sevoflurane all depress normal cardiac contractility (halothane and enflurane more so than isoflurane, desflurane, and sevoflurane). As a result, all volatile agents tend to decrease mean arterial pressure in direct proportion to their alveolar concentration.</li>\n<li>All volatile anaesthetics possess varying degrees of bronchodilating properties, an effect of value in patients with active wheezing and in status asthmatics. However, airway irritation, which may provoke coughing or breath-holding, is induced by the pungency of some volatile anaesthetics. The pungency of isoflurane and desflurane makes these agents less suitable for the induction of anaesthesia in patients with active bronchospasm. These reactions rarely occur with halothane and sevoflurane, which are considered non-pungent.\n<ul>\n<li>Therefore, the bronchodilating action of halothane and sevoflurane makes them the agents of choice in patients with underlying airway problems. Nitrous oxide is also nonpungent and can facilitate inhalational induction of anaesthesia in a patient with bronchospasm.</li>\n</ul>\n</li>\n<li>Inhaled anaesthetics tend to decrease glomerular filtration rate (GFR) and urine flow. Renal blood flow may also be decreased by some agents, but filtration fraction is increased, implying that autoregulatory control of efferent arteriole tone helps compensate and limits the reduction in GFR.</li>\n<li>Volatile anaesthetics cause a concentration-dependent decrease in portal vein blood flow that parallels the decline in cardiac output produced by these agents. However, total hepatic blood flow may be relatively preserved as hepatic artery blood flow to the liver may increase or stay the same. Although transient changes in liver function tests may occur following exposure to volatile anaesthetics, persistent elevation in liver enzymes is rare except following repeated exposures to halothane (see Toxicity of Anaesthetic Agents).\n<ul>\n<li>Nitrous oxide appears to have little effect on uterine musculature. However, the halogenated anaesthetics are potent uterine muscle relaxants and produce this effect in a concentration-dependent fashion. This pharmacologic effect can be helpful when profound uterine relaxation is required for intrauterine fetal manipulation or manual extraction of a retained placenta during delivery. However, it can also lead to increased uterine bleeding.</li>\n</ul>\n</li>\n</ul>", "options": ["1,2,5,6", "1,2,3,4", "1,2,4,6", "1,3,5,6"], "html_options": ["1,2,5,6", "1,2,3,4", "1,2,4,6", "1,3,5,6"], "corr_idx": 0}, {"id": "1176859", "html_qtxt": "A 45-year-old female patient underwent abdominal hysterectomy under general anaesthesia with skeletal muscle relaxant Succinylcholine. Suddenly she develops Muscle rigidity, hyperthermia, rapid onset of tachycardia, hypercapnia, hyperkalemia and metabolic acidosis. Which of the following drugs should be given to reduce calcium release from the Sarcoplasmic reticulum?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Malignant hyperthermia is a heritable genetic disorder of skeletal muscle that occurs in susceptible individuals exposed to volatile anaesthetics while undergoing general anaesthesia.</li>\n<li>The depolarising muscle relaxant succinylcholine may also trigger malignant hyperthermia.\n<ul>\n<li>The malignant hyperthermia syndrome consists of muscle rigidity, hyperthermia, rapid onset of tachycardia and hypercapnia, hyperkalemia, and metabolic acidosis following exposure to one or more triggering agents.</li>\n<li>Malignant hyperthermia is a rare but important cause of anaesthetic morbidity and mortality. The specific biochemical abnormality is an increase in free cytosolic calcium concentration in skeletal muscle cells.</li>\n<li>Treatment includes administration of <strong>dantrolene </strong>(to reduce calcium release from the sarcoplasmic reticulum) and appropriate measures to reduce body temperature and restore electrolyte and acid-base balance</li>\n</ul>\n</li>\n</ul>", "options": ["Atracurium", "Propofol", "Dantrolene", "All of the above"], "html_options": ["Atracurium", "Propofol", "Dantrolene", "All of the above"], "corr_idx": 2}, {"id": "1176861", "html_qtxt": "Propofol is a widely used general anaesthetic agent. What is the presumed mechanism of action of Propofol?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Propofol (2,6-diisopropylphenol) is an alkyl phenol with hypnotic properties that is chemically distinct from other groups of intravenous anaesthetics.</li>\n<li>Because of its poor solubility in water, it is formulated as an emulsion containing 10% soybean oil, 2.25% glycerol, and 1.2% lecithin, the major component of the egg yolk phosphatide fraction.</li>\n<li>Hence, susceptible patients may experience allergic reactions.</li>\n<li>The presence of soybean oil makes the injection painful.</li>\n<li>The solution appears milky white and slightly viscous, has a pH of approximately 7, and a Propofol concentration of 1% (10 mg/mL).</li>\n<li>In some countries, a 2% formulation is available.</li>\n<li>Although retardants of bacterial growth are added to the formulations, solutions should be used as soon as possible (no more than 8 hours after opening the vial), and proper sterile technique is essential.</li>\n<li>The addition of metabisulfite in one of the formulations has raised concern regarding its use in patients with reactive airway disease (eg, asthma) or sulfite allergies.</li>\n<li>The presumed mechanism of action of Propofol is through potentiation of the chloride current mediated through the GABA A receptor complex.</li>\n</ul>", "options": ["Potentiation of chloride current mediated through the GABAa receptor complex", "Potentiation of chloride current mediated through the GABAb receptor complex", "Potentiation of Sodium current mediated through the GABAa receptor complex", "Potentiation of sodium current mediated through the GABAb receptor complex"], "html_options": ["Potentiation of chloride current mediated through the GABAa receptor complex", "Potentiation of chloride current mediated through the GABAb receptor complex", "Potentiation of Sodium current mediated through the GABAa receptor complex", "Potentiation of sodium current mediated through the GABAb receptor complex"], "corr_idx": 0}, {"id": "1176863", "html_qtxt": "Which of the following is TRUE for Propofol? <br> 1. Propofol produces the most pronounced decrease in systemic blood pressure<br> 2. Propofol decreases both preload and afterload", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Compared with other induction drugs, Propofol produces the most pronounced decrease in systemic blood pressure; this is a result of profound vasodilation in both arterial and venous circulations, leading to reductions in preload and afterload.</li>\n<li>This effect on systemic blood pressure is more pronounced with increased age, in patients with reduced intravascular fluid volume, and with rapid injection.</li>\n<li>Because the hypotensive effects are further augmented by the inhibition of the normal baroreflex response, the vasodilation only leads to a small increase in heart rate.</li>\n<li>Profound bradycardia and asystole after the administration of Propofol have been described in healthy adults despite prophylactic anticholinergic drugs.</li>\n</ul>", "options": ["Sentence 1 and 2 both are True, and 2 is the correct reason for 1", "Sentence 1 and 2 both are True, but 2 is not the correct reason for 1", "Sentence 1 is True, but Sentence 2 is False", "Sentences 1 and 2 are both False."], "html_options": ["Sentence 1 and 2 both are True, and 2 is the correct reason for 1", "Sentence 1 and 2 both are True, but 2 is not the correct reason for 1", "Sentence 1 is True, but Sentence 2 is False", "Sentences 1 and 2 are both False."], "corr_idx": 0}, {"id": "1176865", "html_qtxt": "Which of the following is False regarding propofol and fospropofol?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Injection pain during the administration of Propofol is often perceived as severe, and the lipid emulsion has several disadvantages.</li>\n<li>Intense research has focused on finding alternative formulations or related drugs that would address some of these problems.</li>\n<li>Fospropofol is a water-soluble prodrug of Propofol, chemically described as 2,6-diisopropylphenoxymethyl phosphate disodium salt, that was licensed by the Food and Drug Administration in 2008 as a sedating agent for use in adult patients during monitored anaesthesia care.</li>\n<li>The prodrug is rapidly metabolised by alkaline phosphatase, producing Propofol, phosphate, and formaldehyde.</li>\n<li>The formaldehyde is metabolised by aldehyde dehydrogenase in the liver and in erythrocytes.</li>\n<li>The available fospropofol formulation is a sterile, aqueous, colourless, and clear solution that is supplied in a single-dose vial at a concentration of 35 mg/mL under the trade name Lusedra.</li>\n</ul>", "options": ["Propofol is a lipid-soluble agent", "Fospropofol is a water-soluble agent", "Fospropofol is a prodrug of Propofol", "Propofol is a prodrug of Fospropofol"], "html_options": ["Propofol is a lipid-soluble agent", "Fospropofol is a water-soluble agent", "Fospropofol is a prodrug of Propofol", "Propofol is a prodrug of Fospropofol"], "corr_idx": 3}, {"id": "1176866", "html_qtxt": "Which of the following general anaesthetic agents should not be used in a patient with Acute Intermittent Porphyria?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Thiopental and methohexital undergo hepatic metabolism, mostly by oxidation but also by <em>N </em>-N-dealkylation, desulfuration, and destruction of the barbituric acid ring structure.</li>\n<li>Barbiturates should not be administered to patients with acute intermittent porphyria because they increase the production of porphyrins through stimulation of aminolevulinic acid synthetase.</li>\n<li>Methohexital has a shorter elimination half-time than thiopental due to its larger plasma clearance, leading to a faster and more complete recovery after bolus injection.</li>\n<li>Although thiopental is metabolised more slowly and has a long elimination half-time, recovery after a single bolus injection is comparable to that of methohexital and propofol because it depends on redistribution to inactive tissue sites rather than on metabolism.</li>\n<li>However, if administered through repeated bolus injections or continuous infusion, recovery will be markedly prolonged because elimination will depend on metabolism under these circumstances.</li>\n</ul>", "options": ["Propofol", "Pentothal", "Etomidate", "Ketamine"], "html_options": ["Propofol", "Pentothal", "Etomidate", "Ketamine"], "corr_idx": 1}, {"id": "1176867", "html_qtxt": "What is the correct dose of thiopental?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The principal clinical uses of thiopental (3-5 mg/kg IV) or methohexital (1-5 mg/kg IV) is for induction of anaesthesia (unconsciousness), which usually occurs in less than 30 seconds. Patients may experience a garlic or onion taste after administration.</li>\n<li>Barbiturates such as methohexital (20-30 mg/kg) may be administered per rectum to facilitate induction of anaesthesia in mentally challenged and uncooperative paediatric patients. When a barbiturate is administered with the goal of neuroprotection, an isoelectric EEG indicating maximal reduction of CMR O 2 has traditionally been used as the end point.</li>\n</ul>", "options": ["1-2 mg/kg", "3-5 mg/kg", "5-10 mg/kg", "10-12 mg/kg"], "html_options": ["1-2 mg/kg", "3-5 mg/kg", "5-10 mg/kg", "10-12 mg/kg"], "corr_idx": 1}, {"id": "1176868", "html_qtxt": "Benzodiazepines are usually used as premedication before general anaesthesia. Which are the desired effect of benzodiazepines useful in premedication?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Benzodiazepines commonly used in the perioperative period include midazolam, lorazepam, and less frequently, diazepam.</li>\n<li>Benzodiazepines are unique among the group of intravenous anaesthetics in that their action can readily be terminated by administration of their selective antagonist, flumazenil. Their most desired effects are anxiolysis and anterograde amnesia, which are extremely useful for premedication.</li>\n</ul>", "options": ["Anxiolysis", "Unconscious", "Anterograde Amnesia", "A&C both"], "html_options": ["Anxiolysis", "Unconscious", "Anterograde Amnesia", "A&C both"], "corr_idx": 3}, {"id": "1176869", "html_qtxt": "Which of the following intravenous general anaesthetic agents has cardiovascular stability?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>A characteristic and desired feature of induction of anaesthesia with etomidate is <strong>cardiovascular stability</strong> after bolus injection.</li>\n<li><strong>Systemic effects of etomidate:</strong>\n<ul>\n<li><strong>Cardiovascular Effects:</strong>\n<ul>\n<li>Minimal effect on the cardiovascular system</li>\n<li>Mild decrease in peripheral vascular resistance &rarr; slight drop in blood pressure</li>\n<li>Myocardial contractility and cardiac output remain stable</li>\n<li>Does not cause histamine release</li>\n<li>May lead to increased heart rate and blood pressure during laryngoscopy if used alone</li>\n</ul>\n</li>\n<li><strong>Respiratory Effects:</strong>\n<ul>\n<li>Ventilation generally preserved</li>\n<li>Apnea is unlikely unless combined with opioids</li>\n<li>Slight increase in arterial carbon dioxide tension (PaCO&#8322;)</li>\n</ul>\n</li>\n<li><strong>Central Nervous System Effects:</strong>\n<ul>\n<li>Decreases cerebral metabolic rate, cerebral blood flow, and intracranial pressure</li>\n<li>Cerebral perfusion pressure remains well-maintained</li>\n<li>Increases somatosensory evoked potentials (beneficial for ECT)</li>\n<li>No analgesic effect</li>\n<li>Postoperative nausea and vomiting (PONV) is more frequent than with propofol or barbiturates, but similar to general anaesthesia rates</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Side effects of etomidate:\n<ul>\n<li>Adrenocortical suppression</li>\n<li>Pain on injection</li>\n<li>Myoclonus (muscle jerks)</li>\n<li>Postoperative nausea and vomiting (PONV)</li>\n</ul>\n</li>\n</ul>", "options": ["Benzodiazepines", "Etomidate", "Propofol", "None of the above"], "html_options": ["Benzodiazepines", "Etomidate", "Propofol", "None of the above"], "corr_idx": 1}, {"id": "1176870", "html_qtxt": "Which of the following is TRUE for ketamine?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Ketamine is a partially water-soluble and highly lipid-soluble phencyclidine derivative differing from most other intravenous anaesthetics in that it produces significant analgesia.</li>\n<li>The characteristic state observed after an induction dose of ketamine is known as \"dissociative anaesthesia,\" wherein the patient's eyes remain open with a slow nystagmic gaze (cataleptic state).</li>\n<li>Of the two stereoisomers, the (+) form is more potent than the <em>R </em>(-) isomer, but only the racemic mixture of ketamine is available in the USA.</li>\n<li>Ketamine's mechanism of action is complex, but the major effect is probably produced through inhibition of the NMDA receptor complex.</li>\n</ul>", "options": ["It is known as dissociative anaesthesia", "It differs from other agents in that it produces significant analgesia", "Major effect is produced through the inhibition of the NMDA receptor complex", "All of the above"], "html_options": ["It is known as dissociative anaesthesia", "It differs from other agents in that it produces significant analgesia", "Major effect is produced through the inhibition of the NMDA receptor complex", "All of the above"], "corr_idx": 3}, {"id": "1176872", "html_qtxt": "Which is the drug that increases systemic blood pressure, but is a myocardial depressant?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Ketamine can produce transient but significant <em>increases </em>in systemic blood pressure, heart rate, and cardiac output, presumably by centrally mediated sympathetic stimulation.</li>\n<li>These effects, which are associated with increased cardiac workload and myocardial oxygen consumption, are not always desirable and can be blunted by co-administration of benzodiazepines, opioids, or inhaled anaesthetics.</li>\n<li>Though the effect is more controversial, ketamine is considered to be a direct myocardial depressant.</li>\n<li>This property is usually masked by its stimulation of the sympathetic nervous system, but may become apparent in critically ill patients with limited ability to increase their sympathetic nervous system activity.</li>\n<li>Ketamine can be used in shock as it <strong>stimulates the sympathetic nervous system </strong>and uncontrolled asthmatics whereas propofol is used in controlled asthmatics.</li>\n</ul>", "options": ["Etomidate", "Ketamine", "Benzodiazepines", "Propofol"], "html_options": ["Etomidate", "Ketamine", "Benzodiazepines", "Propofol"], "corr_idx": 1}, {"id": "1176873", "html_qtxt": "Which drug can provide analgesia without respiratory depression", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Dexmedetomidine is principally used for the short-term sedation of intubated and ventilated patients in an ICU setting. In the operating room, dexmedetomidine may be used as an adjunct to general anaesthesia or to provide sedation, eg, during awake fibre optic tracheal intubation or regional anaesthesia.</li>\n<li>When administered during general anaesthesia, dexmedetomidine decreases the dose requirements for inhaled and injected anaesthetics.</li>\n<li>Awakening and the transition to the postoperative setting may benefit from dexmedetomidine-produced sedative and analgesic effects without respiratory depression.</li>\n</ul>", "options": ["Propofol", "Dexmedetomidine", "BZDs", "Thiopental"], "html_options": ["Propofol", "Dexmedetomidine", "BZDs", "Thiopental"], "corr_idx": 1}, {"id": "1176875", "html_qtxt": "A 35-year-old male alcoholic patient came to the emergency department with complaints of severe abdominal pain, vomiting, and weakness. His laboratory investigation and USG were performed. Laboratory investigations are<br> Hb- 14gm%<br> Platelets- 1,25,000/cu mm<br> SGPT- 100U/L<br> SGOT- 600 U/L<br> His USG report was suggestive of multiple hepatic liquefied abscesses. So, the surgeon is planning for pigtail catheterisation under local anaesthesia. What is the primary mechanism of action of local anaesthetics?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The primary mechanism of action of local anaesthetics is blockade of voltage-gated sodium channels.</li>\n<li>The excitable membranes of nerve axons, cardiac muscle, and neuronal cell bodies maintain a <strong>resting membrane potential</strong> between <strong>-90 to -60 mV</strong>.</li>\n<li>During excitation, <strong>voltage-gated sodium channels open</strong>, allowing a <strong>fast inward sodium current</strong>, which <strong>depolarizes the membrane</strong> toward <strong>+40 mV</strong> (sodium equilibrium potential).</li>\n<li>This depolarization leads to <strong>inactivation of sodium channels</strong> and the <strong>opening of potassium channels</strong>.</li>\n<li>The <strong>outward flow of potassium</strong> repolarizes the membrane toward the <strong>potassium equilibrium potential</strong> (approximately <strong>-95 mV</strong>).</li>\n<li><strong>Repolarization</strong> resets the sodium channels to their <strong>resting state</strong>, with a <strong>recovery time</strong> that determines the <strong>refractory period</strong>.</li>\n<li><strong>Transmembrane ionic gradients</strong> are maintained by the <strong>sodium-potassium pump (Na&#8314;/K&#8314;-ATPase)</strong>.</li>\n<li>These <strong>ionic fluxes</strong> are similar to those in <strong>cardiac muscle</strong>, though simpler, and <strong>local anaesthetics affect both tissues</strong> in a similar manner.</li>\n</ul>", "options": ["Blockade of voltage-gated chloride channels", "Blockade of voltage gated sodium channels ", "Blockade of voltage gated Calcium channels ", "Blockade of voltage gated potassium channels "], "html_options": ["Blockade of voltage-gated chloride channels", "Blockade of voltage gated sodium channels ", "Blockade of voltage gated Calcium channels ", "Blockade of voltage gated potassium channels "], "corr_idx": 1}, {"id": "1176878", "html_qtxt": "Which of the following sentences are TRUE regarding the added effects of vasoconstrictors?<br> 1. Localised neuronal uptake is enhanced?<br> 2. Gives short-duration blocks?<br> 3. Peak blood level is increased?<br> 4. Peak blood level is lowered?<br> 5. Epinephrine exerts an analgesic effect during spinal anaesthesia", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Adding a <strong>vasoconstrictor</strong> to a local anaesthetic increases <strong>local tissue concentration</strong>, enhancing <strong>neuronal uptake</strong> and resulting in a <strong>longer duration of block</strong>.</li>\n<li>This prolonged effect can provide <strong>adequate anaesthesia for longer procedures</strong>, extend <strong>postoperative pain control</strong>, and <strong>reduce the total dose</strong> of anaesthetic required.</li>\n<li>Vasoconstrictors help <strong>lower peak blood levels</strong> of the anaesthetic by slowing absorption, allowing better alignment with <strong>metabolism and elimination</strong>, which <strong>reduces systemic toxicity risk</strong>.</li>\n<li>In <strong>spinal anaesthesia</strong>, epinephrine not only <strong>prolongs anaesthetic effect</strong> through vasoconstriction but may also produce a <strong>direct analgesic effect</strong> via activation of <strong>postsynaptic &alpha;<sub>2</sub>-adrenoceptors</strong> in the spinal cord.</li>\n<li>This property of &alpha;<sub>2</sub>-mediated analgesia has led to the <strong>clinical use of clonidine</strong>, an <strong>&alpha;<sub>2</sub>-agonist</strong>, as an <strong>adjuvant in spinal anaesthesia</strong>.</li>\n<li>However, epinephrine may <strong>increase the neurotoxicity</strong> of local anaesthetics when used in <strong>peripheral nerve blocks</strong> or <strong>spinal anaesthesia</strong>.</li>\n<li>The use of vasoconstrictors in areas with <strong>limited collateral circulation</strong> (e.g., fingers, toes) is generally <strong>avoided</strong> to prevent <strong>ischemic complications</strong>, although this caution is sometimes <strong>debated</strong> in current practice.</li>\n</ul>", "options": ["1,4,5", "1,3,5", "1,2,4", "1,2,3"], "html_options": ["1,4,5", "1,3,5", "1,2,4", "1,2,3"], "corr_idx": 0}, {"id": "1176880", "html_qtxt": "Which of the following sentences is TRUE for CNS toxicity of local anaesthetic agents?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>All local anaesthetics can cause <strong>sedation</strong>, <strong>light-headedness</strong>, <strong>visual and auditory disturbances</strong>, and <strong>restlessness</strong> when <strong>high plasma concentrations</strong> occur due to <strong>rapid absorption</strong> or <strong>accidental intravascular injection</strong>.</li>\n<li><strong>Early symptoms</strong> of local anaesthetic toxicity include <strong>numbness of the tongue and around the mouth</strong>, as well as a <strong>metallic taste</strong>.</li>\n<li>At <strong>higher plasma levels</strong>, patients may develop <strong>nystagmus</strong> and <strong>muscular twitching</strong>, which can progress to <strong>tonic-clonic seizures</strong>.</li>\n<li>These effects are believed to result from <strong>depression of cortical inhibitory pathways</strong>, leading to <strong>unopposed excitatory activity</strong> in the brain.</li>\n<li>This <strong>excitatory phase</strong> (often seen as seizure activity) is typically followed by <strong>generalised CNS depression</strong>.</li>\n<li>The classic pattern of toxicity has been mostly observed in <strong>controlled human studies</strong> (with low doses) and <strong>animal models using graded dosing</strong>.</li>\n<li>In actual clinical settings, <strong>deviations from the classic toxicity pattern</strong> are common and depend on factors like:\n<ul>\n<li><strong>Patient susceptibility</strong></li>\n<li><strong>Type of local anaesthetic</strong></li>\n<li><strong>Concurrent medications</strong></li>\n<li><strong>Speed of serum drug level increase</strong></li>\n</ul>\n</li>\n<li>A review of clinical cases of <strong>local anaesthetic-induced cardiac toxicity</strong> found that <strong>only 18%</strong> of patients showed <strong>early CNS warning signs</strong> before cardiovascular collapse.</li>\n</ul>", "options": ["Early symptoms are circumoral and tongue numbness and metallic taste", "At higher concentration,s nystagmus and muscular twitching occur", "Causes tonic-clonic convulsions", "All of the above"], "html_options": ["Early symptoms are circumoral and tongue numbness and metallic taste", "At higher concentration,s nystagmus and muscular twitching occur", "Causes tonic-clonic convulsions", "All of the above"], "corr_idx": 3}, {"id": "1176881", "html_qtxt": "Local anaesthetic agents cause neural toxicity. Which of the following is TRUE?<br>1.\tNeural injury occurs from voltage gated sodium channels<br>2.\tClinical effect and toxicity is tightly linked.", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>It is not clear what role these factors or others play in clinical injury.</li>\n<li>It is clear, however, that injury does not result from blockade of the voltage-gated sodium channel per se, and thus clinical effect and toxicity are not tightly linked.</li>\n</ul>", "options": ["Sentence 1 and 2 both are True and 2 is correct reason for 1", "Sentence 1 and 2 both are True but 2 is not the correct reason for 1", "Sentence 1 is True but Sentence 2 is False", "Sentence 1 and 2 both are False."], "html_options": ["Sentence 1 and 2 both are True and 2 is correct reason for 1", "Sentence 1 and 2 both are True but 2 is not the correct reason for 1", "Sentence 1 is True but Sentence 2 is False", "Sentence 1 and 2 both are False."], "corr_idx": 3}, {"id": "1176883", "html_qtxt": "Which is the FALSE sentence regarding Articaine?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Articaine has a shorter plasma half-life of approximately 20 minutes.</p>\n<ul>\n<li><strong>Articaine</strong> was approved for use as a <strong>dental anaesthetic</strong> in the <strong>USA in April 2000</strong>.</li>\n<li>It is unique among <strong>amino-amide anaesthetics</strong> because it contains a <strong>thiophene ring</strong> instead of a benzene ring.</li>\n<li>Articaine also includes an <strong>ester group</strong>, which allows for <strong>metabolism by plasma esterases</strong>.</li>\n<li>The <strong>thiophene ring increases lipophilicity</strong>, enhancing <strong>tissue penetration</strong>. <strong>(Option A & B)</strong></li>\n<li>The <strong>ester group shortens the plasma half-life</strong> to approximately <strong>20 minutes</strong>, potentially improving the <strong>therapeutic index</strong> and <strong>reducing systemic toxicity</strong>. <strong>(Option D)</strong></li>\n<li>Due to these properties, articaine has become <strong>widely used in dental anaesthesia</strong>, often considered <strong>more effective and possibly safer</strong> than <strong>lidocaine</strong>, the previous standard.</li>\n<li>However, there are concerns about a <strong>higher risk of persistent paraesthesia</strong> with articaine, though this complication remains <strong>rare</strong>.</li>\n<li><strong>Prilocaine</strong> has been reported to have an <strong>even higher relative risk</strong> of causing paraesthesia, <strong>twice that of articaine</strong>.</li>\n</ul>", "options": ["It has enhanced lipophilicity", "Has improved tissue penetration", "Longer plasma half-life", "Better therapeutic index"], "html_options": ["It has enhanced lipophilicity", "Has improved tissue penetration", "Longer plasma half-life", "Better therapeutic index"], "corr_idx": 2}, {"id": "1176885", "html_qtxt": "1. Bupivacaine is avoided when high volumes or concentrations are needed<br> 2. It is a cardiotoxic drug and can cause cardiac arrest", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Due to <strong>cardiotoxicity concerns</strong>, <strong>bupivacaine</strong> is often <strong>avoided</strong> in procedures requiring <strong>large volumes of concentrated anaesthetic</strong>, such as <strong>epidural</strong> or <strong>peripheral nerve blocks</strong> for surgical anaesthesia.</li>\n<li><strong>Low concentrations</strong> (&le; 0.25%) of bupivacaine are commonly used to provide <strong>prolonged peripheral anaesthesia</strong> and <strong>postoperative analgesia</strong>.</li>\n<li>Bupivacaine is widely used for <strong>anaesthetic infiltration</strong> to manage <strong>incisional pain</strong> after surgery.</li>\n<li>It is a <strong>preferred agent</strong> for <strong>epidural infusions</strong> in <strong>postoperative pain management</strong> and <strong>labour analgesia</strong>.</li>\n<li>Bupivacaine has a <strong>favourable safety profile</strong> as a <strong>spinal anaesthetic</strong>, with a <strong>low risk of neurotoxicity</strong> and minimal risk of <strong>transient neurologic symptoms (TNS)</strong>.</li>\n<li>However, its <strong>long duration of action</strong> makes it <strong>less suitable for outpatient or ambulatory surgery</strong>, as it may <strong>delay recovery and discharge</strong>.</li>\n</ul>", "options": ["Sentences 1 and 2 both are True, and 2 is the correct reason for 1", "Sentences 1 and 2 both are True, but 2 is not the correct reason for 1", "Sentence 1 is True, but Sentence 2 is False", "Sentences 1 and 2 are both False"], "html_options": ["Sentences 1 and 2 both are True, and 2 is the correct reason for 1", "Sentences 1 and 2 both are True, but 2 is not the correct reason for 1", "Sentence 1 is True, but Sentence 2 is False", "Sentences 1 and 2 are both False"], "corr_idx": 0}, {"id": "1176886", "html_qtxt": "Levobupivacaine is ___________ compared to bupivacaine.", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Levobupivacaine</strong> is the <strong>S(-) enantiomer</strong> of bupivacaine and is considered <strong>less cardiotoxic</strong> than the racemic mixture.</li>\n<li>It is <strong>slightly less potent</strong> and may have a <strong>longer duration of action</strong>, though these differences are <strong>not clinically significant</strong>.</li>\n<li><strong>Recent studies on lipid resuscitation</strong> indicate a potential <strong>advantage of levobupivacaine over ropivacaine</strong>.</li>\n<li>Levobupivacaine is <strong>more effectively sequestered</strong> into a <strong>lipid sink</strong>, suggesting a <strong>greater potential for reversing toxicity</strong> if it occurs.</li>\n</ul>", "options": ["Less cardiotoxic", "Less potent", "Has a longer duration of action", "All of the above"], "html_options": ["Less cardiotoxic", "Less potent", "Has a longer duration of action", "All of the above"], "corr_idx": 3}, {"id": "1176888", "html_qtxt": "Which is the reference local anaesthetic agent against which all agents are compared?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Aside from the issue of a high incidence of TNS with spinal administration, lidocaine has had an excellent record as an intermediate-duration anaesthetic, and remains the reference standard against which most anaesthetics are compared.</li>\n</ul>", "options": ["Lidocaine", "Bupivacaine", "Levobupivacaine", "All of the above"], "html_options": ["Lidocaine", "Bupivacaine", "Levobupivacaine", "All of the above"], "corr_idx": 0}, {"id": "1176891", "html_qtxt": "Which is TRUE for Ropivacaine?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Due to its <strong>lower cardiotoxicity</strong>, ropivacaine is <strong>widely used</strong> for <strong>high-volume peripheral nerve blocks</strong>.</p>\n<ul>\n<li><strong>Ropivacaine</strong> is the <strong>S(-) enantiomer</strong> in a homologous series that includes <strong>bupivacaine</strong> and <strong>mepivacaine</strong>.</li>\n<li>It is characterised by its <strong>chirality</strong> and the presence of a <strong>propyl group</strong> on the <strong>piperidine ring</strong>.</li>\n<li>It is also a <strong>common choice</strong> for <strong>epidural infusions</strong> in <strong>labour analgesia</strong> and <strong>postoperative pain control</strong>. <strong>(Option C)</strong></li>\n<li>Some studies suggest that ropivacaine may offer a <strong>more favourable differential block</strong> compared to bupivacaine.</li>\n<li>However, its <strong>lower clinical potency</strong> complicates direct comparisons with bupivacaine.</li>\n</ul>", "options": ["Its low cardiac toxicity has led to use for high-volume peripheral blocks", "Its high cardiac toxicity has led to decreased use for high-volume peripheral blocks", "It is not used for epidural infusions for the control of labour", "All of the above"], "html_options": ["Its low cardiac toxicity has led to use for high-volume peripheral blocks", "Its high cardiac toxicity has led to decreased use for high-volume peripheral blocks", "It is not used for epidural infusions for the control of labour", "All of the above"], "corr_idx": 0}, {"id": "1176893", "html_qtxt": "Which skeletal muscle relaxant follows Hoffman elimination?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Atracurium</strong> is an <strong>intermediate-acting</strong>, <strong>nondepolarizing muscle relaxant</strong> of the <strong>isoquinoline</strong> class.</li>\n<li>It is metabolised by both the <strong>liver</strong> and <strong>Hofmann elimination</strong>, a form of <strong>spontaneous nonenzymatic breakdown</strong>.</li>\n<li>The primary breakdown products are <strong>laudanosine</strong> and a <strong>quaternary acid</strong>, neither of which has <strong>neuromuscular blocking activity</strong>.</li>\n<li><strong>Laudanosine</strong> is <strong>slowly metabolised by the liver</strong> and has a relatively <strong>long elimination half-life</strong> of about <strong>150 minutes</strong>.</li>\n<li>It can <strong>cross the blood-brain barrier</strong>, and <strong>high concentrations</strong> may cause <strong>seizures</strong> and <strong>increase the requirement for volatile anaesthetics</strong>.</li>\n<li>During routine <strong>surgical anaesthesia</strong>, laudanosine blood levels typically range from <strong>2 to 1 mcg/mL</strong>.</li>\n<li>With <strong>prolonged atracurium infusions</strong> in the <strong>ICU</strong>, laudanosine levels may exceed <strong>5 mcg/mL</strong>, raising the risk of <strong>CNS toxicity</strong>.</li>\n</ul>", "options": ["Thiocolchicoside", "Succinylcholine", "Atracurium", "All of the above"], "html_options": ["Thiocolchicoside", "Succinylcholine", "Atracurium", "All of the above"], "corr_idx": 2}, {"id": "1176895", "html_qtxt": "Which of the following is not a nondepolarizing relaxant agent?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Succinylcholine</strong> is a <strong>depolarising </strong>muscle relaxant.</p>\n<p><strong>Depolarising Relaxant Drugs:</strong></p>\n<ul>\n<li>Succinylcholine is a depolarising muscle relaxant with a very short duration of action (5-10 minutes).</li>\n<li>Its rapid breakdown is due to hydrolysis by butyrylcholinesterase in the liver and pseudocholinesterase in the plasma.</li>\n<li>Plasma cholinesterase metabolism is the main elimination pathway for succinylcholine.</li>\n<li>Succinylcholine is metabolised faster than mivacurium, resulting in a shorter duration of action.</li>\n<li>Its primary metabolite, succinylmonocholine, is further broken down into succinic acid and choline.</li>\n<li>Only a small fraction of the administered dose reaches the neuromuscular junction, due to the high hydrolytic capacity of plasma cholinesterase.</li>\n<li>Since there is minimal or no plasma cholinesterase at the motor end plate, the blockade ends as the drug diffuses away into the extracellular fluid.</li>\n<li>The circulating levels of plasma cholinesterase influence the duration of succinylcholine action by regulating how much drug reaches the motor end plate.</li>\n</ul>", "options": ["Atracurium", "Mivacurium", "Succinylcholine", "Gantacurium"], "html_options": ["Atracurium", "Mivacurium", "Succinylcholine", "Gantacurium"], "corr_idx": 2}, {"id": "1176896", "html_qtxt": "Which of the following is FALSE for depolarising agents?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Depolarising Relaxant Drugs</strong></p>\n<ul>\n<li>The very short duration of action of succinylcholine (5-10 minutes) is due to its rapid hydrolysis by butyrylcholinesterase in the liver and pseudocholinesterase in the plasma.</li>\n<li>Plasma cholinesterase metabolism is the primary route of succinylcholine elimination.</li>\n<li>Because succinylcholine is metabolised faster than mivacurium, it has a shorter duration of action.</li>\n<li>The main metabolite, succinylmonocholine, is quickly broken down into succinic acid and choline.</li>\n<li>Due to the high hydrolytic capacity of plasma cholinesterase, only a small fraction of the intravenous dose reaches the neuromuscular junction.</li>\n<li>There is little or no plasma cholinesterase at the motor end plate, so blockade ends by diffusion of succinylcholine away from the end plate into the extracellular fluid.</li>\n<li>The duration of action of succinylcholine is influenced by circulating plasma cholinesterase levels, which determine how much drug reaches the motor end plate.</li>\n</ul>", "options": ["Succinylcholine is a depolarising agent", "Mechanism of action is through depolarising and desensitising", "It is extremely long-acting", "None of the above"], "html_options": ["Succinylcholine is a depolarising agent", "Mechanism of action is through depolarising and desensitising", "It is extremely long-acting", "None of the above"], "corr_idx": 2}, {"id": "1176901", "html_qtxt": "The adverse effects of depolarising agents are <br> 1. Hyperkalemia<br> 2. Hypokalemia<br> 3. Increased intraocular pressure<br> 4. Decreased intraocular pressure<br> 5. Increased intragastric pressure<br> 6. Muscle pain", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The adverse effects of depolarising agents are hyperkalemia, raised intraocular pressure, increased intragastric pressure, and myalgias.</p>\n<ul>\n<li><strong>Hyperkalemia:</strong>\n<ul>\n<li>Patients with burns, nerve damage, neuromuscular diseases, closed head injury, or other trauma may experience potassium release into the bloodstream after succinylcholine administration.</li>\n<li>This potassium surge can, in rare cases, lead to cardiac arrest.</li>\n</ul>\n</li>\n</ul>\n<ul>\n<li><strong>Increased Intraocular Pressure:</strong>\n<ul>\n<li>Succinylcholine administration can cause a rapid rise in intraocular pressure within 60 seconds, peaking at 2-4 minutes, and subsiding after 5 minutes.</li>\n<li>The mechanism may involve tonic myofibril contraction or transient dilation of choroidal vessels.</li>\n<li>Although intraocular pressure increases, succinylcholine is not contraindicated for eye surgery unless the anterior chamber is open (e.g., open globe injury).</li>\n</ul>\n</li>\n</ul>\n<ul>\n<li><strong>Increased Intragastric Pressure:</strong>\n<ul>\n<li>In heavily muscled patients, succinylcholine-induced fasciculations can raise intragastric pressure by 5 to 40 cm H&#8322;O.</li>\n<li>This raises the risk of regurgitation and aspiration, especially in patients with delayed gastric emptying (e.g., diabetes), emergency trauma cases, oesophageal dysfunction, or morbid obesity.</li>\n</ul>\n</li>\n</ul>\n<ul>\n<li><strong>Muscle Pain (Myalgias):</strong>\n<ul>\n<li>Postoperative myalgias are common in heavily muscled individuals and those receiving higher doses of succinylcholine (> 1.5 mg/kg).</li>\n</ul>\n</li>\n</ul>", "options": ["2,3,5,6", "1,2,4,6", "2,4,5,6", "1,3,5,6"], "html_options": ["2,3,5,6", "1,2,4,6", "2,4,5,6", "1,3,5,6"], "corr_idx": 3}, {"id": "1176902", "html_qtxt": "Baclofen acts by...", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Baclofen ( <em>p </em>-p-chlorophenyl-GABA) was designed to be an orally active GABA-mimetic agent and is an agonist at GABA B receptors.</li>\n<li>Activation of these receptors by baclofen results in hyperpolarisation, probably by increased K+ + conductance</li>\n</ul>", "options": ["Activation of GABAb receptors resulting in depolarisation", "Activation of GABAb receptors resulting in repolarisation", "Activation of GABAb receptors resulting in hyperpolarisation", "None of the above"], "html_options": ["Activation of GABAb receptors resulting in depolarisation", "Activation of GABAb receptors resulting in repolarisation", "Activation of GABAb receptors resulting in hyperpolarisation", "None of the above"], "corr_idx": 2}]}, {"moduleId": 1008543, "name": "Parkinsonism & Other Movement Disorders Management, Alzheimer Drugs", "questions": [{"id": "1186224", "html_qtxt": "A 60-year-old man presents with gradually worsening tremor of the right hand with a frequency of approximately 5 Hz when the limbs are relaxed. When the patient is asked to move his arm the tremor decreases. He has reduced arm swing while walking. Which of the following is the most appropriate pharmacotherapy?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>A unilateral resting tremor with a frequency of 4-6 Hz that worsens with stress and improves with voluntary movements, as well as signs of mild bradykinesia (decreased arm swing), are features consistent with Parkinson disease (PD).</li>\n<li>Trihexyphenidyl is a muscarinic antagonist, an anticholinergic, that reduces cholinergic activity in the CNS.</li>\n<li>Initial monotherapy with an anticholinergic (e.g., trihexyphenidyl) can be considered in younger patients with PD (&le; 65 years of age) if they have resting tremor as the main complaint and no evidence of cognitive impairment, significant bradykinesia, or gait disturbance.</li>\n<li>Benztropine is a commonly used alternative to trihexyphenidyl. If monotherapy with anticholinergics is not effective in reducing tremor, they may be given in combination with a dopamine agonist and/or levodopa, as well as MAO-B inhibitors, or replaced altogether.</li>\n<li>Dopamine agonists are a reasonable initial therapy in patients &le; 65 years of age whose symptoms have begun to impact daily function and quality of life (e.g., those with significant bradykinesia or gait disturbance).</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Clonazepam(</strong><strong>Option B):</strong> Can be used to treat patients with orthostatic tremor, a condition with an average onset of 60 years of age. Typical clinical features of orthostatic tremor are triggered by longer periods of standing and include leg tremors as well as a sensation of instability. However, the condition only affects the legs and would not be the cause of this patient's hand tremor or reduced arm swing.</p>\n<p><strong>Methimazole(</strong><strong>Option C):</strong> Is used to treat hyperthyroidism with a tremor, that increases with stress, as in this patient, the tremor is usually symmetric and occurs while holding a position against gravity (e.g., extending arms in front of the body). It would also not explain this patient's bradykinesia.</p>\n<p><strong>Propranolol(</strong><strong>Option D):</strong> Is a first-line treatment of benign essential tremor. However, unlike the asymmetric resting tremor seen in this patient, essential tremor is symmetrical, worsen with voluntary movements, and resolves completely at rest.</p>\n<p><strong>The below table gives A list of different drugs used in Parkinson disease and their indications:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307987b1c9c-ad75-4cb5-be6e-e5f7eefc7fa6.jpg\">", "options": ["Trihexyphenidyl", "Clonazepam", "Methimazole", "Propranolol"], "html_options": ["Trihexyphenidyl", "Clonazepam", "Methimazole", "Propranolol"], "corr_idx": 0}, {"id": "1186229", "html_qtxt": "<p>Consultant prescribes a drug that increases the bioavailability of levodopa by preferentially preventing its peripheral methylation. Identify the drug from the given option</p>", "html_expl": "<p><strong>Explanation:</strong></p><ul><li>Motor fluctuations increase during long-term therapy with levodopa because the neurons gradually lose their capacity to store and release dopamine. The severity of symptoms is directly related to the drug dose.</li><li>Entacapone is a peripherally acting COMT inhibitor that reduces the methylation of levodopa and dopamine, thus allowing a more stable and long-lasting plasma concentration of the drug.</li><li>This results in fewer periods of end-of-dose akinesia and less variability of symptoms during the day. Tolcapone is a centrally acting COMT inhibitor that is used for refractory parkinsonian disease.</li></ul><figure class=\"image\"><img src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307cc84500c-99f0-4e55-9de5-a637ee3db9ca.jpg\"></figure><p><strong>Decarboxylase inhibitors:</strong></p><figure class=\"image\"><img src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307a6bbf84c-d47c-4df4-a19f-a5f7b42b10b1.jpg\"></figure>", "options": ["<p>Ropinirole</p>", "<p>Selegiline</p>", "<p>Entacapone</p>", "<p>Carbidopa</p>"], "html_options": ["<p>Ropinirole</p>", "<p>Selegiline</p>", "<p>Entacapone</p>", "<p>Carbidopa</p>"], "corr_idx": 2}, {"id": "1186231", "html_qtxt": "The addition of carbidopa in a patient on levodopa is most likely to decrease the risk of which of the following potential adverse drug effects?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Following administration, L-DOPA is absorbed into the systemic circulation, where it is partially converted to dopamine by the enzyme DOPA decarboxylase.</li>\n<li>The remaining L-DOPA is then transported across the blood-brain barrier and enters the central nervous system to produce the desired effects.</li>\n<li>Carbidopa reduces the peripheral (systemic) conversion of L-DOPA to dopamine, thereby mitigating the peripheral side effects, including <strong>orthostatic hypotension</strong>, nausea, and vomiting.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403077f887ec9-4853-42ec-b1c6-3f955dd2d4be.jpg\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Resting tremor(</strong><strong>Option A):</strong></p>\n<ul>\n<li>Is reduced by L-DOPA therapy. The addition of carbidopa is likely to further reduce the incidence of resting tremor because a combination of these drugs would increase the amount of centrally available dopamine.</li>\n<li>However, resting tremor is a feature of Parkinson's disease and not an adverse effect of L-DOPA therapy.</li>\n</ul>\n<p><strong>Dyskinesia(</strong><strong>Option B):</strong></p>\n<ul>\n<li>It is a central nervous system side effect of L-DOPA that typically occurs with long-term therapy.</li>\n<li>By decreasing the peripheral conversion of L-DOPA to dopamine, carbidopa increases the fraction of the administered drug that crosses the blood-brain barrier.</li>\n<li>Therefore, symptoms of dyskinesia would be expected to increase rather than decrease.</li>\n</ul>\n<p><strong>Hallucinations(</strong><strong>Option D): </strong></p>\n<ul>\n<li>It is a central side effect of L-DOPA therapy, and they correlate to the concentration of dopamine in the central nervous system.</li>\n<li>By decreasing the peripheral conversion of L-DOPA to dopamine, carbidopa increases the fraction of the administered drug that crosses the blood-brain barrier.</li>\n<li>Therefore, visual hallucinations would be expected to increase rather than decrease.</li>\n</ul>", "options": ["Resting tremor", "Dyskinesia", "Hypotension", "Hallucination"], "html_options": ["Resting tremor", "Dyskinesia", "Hypotension", "Hallucination"], "corr_idx": 2}, {"id": "1186232", "html_qtxt": "A 53-year-old man is brought to the office by his wife because of unusual behaviour for the past 2 weeks. His wife reports that the patient spent a large sum of money at the local casino. He is on a drug for restless leg syndrome. Which of the following is the most appropriate next step in management?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Dopamine agonists (DAs) such as ropinirole, used in restless leg syndrome, may lead to impulse control disorders (ICDs).</li>\n<li>Patients taking DAs should be aware of this adverse effect and regularly monitored, because ICDs may have debilitating effects on their work and social functioning.</li>\n<li>If the patient shows signs of ICDs, the dose should be slowly tapered or discontinued until symptoms resolve.</li>\n<li>Abrupt discontinuation of DAs can lead to dopamine agonist withdrawal syndrome. Although most patients with ICDs due to DA therapy respond well to discontinuation of the medication, ICDs may persist in some patients.</li>\n<li>Other adverse effects of DAs include restlessness, nausea, orthostatic hypotension, drowsiness, hallucinations, and psychosis.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>CBT(Option A):</strong> It is used in the treatment of some ICDs, such as kleptomania and conduct disorder. This patient's history suggests a specific cause of his ICD for which CBT is not primarily indicated.</p>\n<p><strong>Fluoxetine(</strong><strong>Option B):</strong> It is used in the treatment of a gambling disorder, which is a type of ICD. Although this patient has recently spent a lot of money on gambling, he does not meet the criteria for a gambling disorder, and other symptoms, such as hypersexuality, suggest another diagnosis. Furthermore, SSRIs such as fluoxetine can aggravate the symptoms of restless legs syndrome.</p>\n<p><strong>Risperidone(Option C):</strong> It is used to treat bipolar disorder, which can manifest with increased goal-directed activity (e.g., increased libido, sudden purchase of a new car), loss of social inhibitions, and decreased sleep. This patient's history, however, suggests a specific cause of his symptoms for which risperidone is not useful.</p>", "options": ["CBT", "Fluoxetine", "Risperidone", "Discontinue the drug"], "html_options": ["CBT", "Fluoxetine", "Risperidone", "Discontinue the drug"], "corr_idx": 3}, {"id": "1186234", "html_qtxt": "A 51-year-old patient with Parkinsonism is being maintained on levodopa-carbidopa with adjunctive use of low doses of tolcapone but continues to have off-periods of akinesia. A drug used to \"rescue\" the patient that provides temporary relief is", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Apomorphine, via subcutaneous injection, is used for temporary relief of off-periods of akinesia (rescue) in Parkinsonian patients on dopaminergic drug therapy.</li>\n<li>A non-ergoline dopamine agonist, with high affinity for D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub> receptors and moderate activity at D<sub>1</sub>/D<sub>5</sub>. Also acts as an antagonist at certain serotonergic (5-HT<sub>2</sub>) and &alpha;-adrenergic receptors.</li>\n<li>Pretreatment with the antiemetic trimethobenzamide for 3 days is essential to prevent severe nausea.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Benztropine(Option B): </strong>An anticholinergic, used primarily for tremor or dystonia in early Parkinsonism, not helpful for off-period akinesia.</p>\n<p><strong>Pramipexole(Option C):</strong> An oral dopamine agonist better suited as maintenance therapy rather than rapid-onset rescue during off-periods; its peak effect comes hours after dosing, not minutes.</p>\n<p><strong>Selegiline(Option D): </strong>A MAO-B inhibitor that mildly extends the levodopa effect but is not used as an on-demand rescue.</p>", "options": ["Apomorphine", "Benztropine", "Pramipexole", "Selegiline"], "html_options": ["Apomorphine", "Benztropine", "Pramipexole", "Selegiline"], "corr_idx": 0}, {"id": "1186235", "html_qtxt": "A patient with Parkinsonism is being treated with levodopa. He suffers from irregular, involuntary muscle jerks that affect the proximal muscles of the limbs. Which of the following statements about these symptoms is most accurate?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The form and severity of dyskinesias resulting from levodopa may vary widely in individual patients.</li>\n<li>Dyskinesias occur in up to 80% of patients receiving levodopa for long periods.</li>\n<li>Dyskinesias in Parkinson's disease are commonly peak-dose choreic or ballistic movements that occur when levodopa-derived dopamine levels are high in the brain.</li>\n<li>With continued treatment, dyskinesias may develop at a dose of levodopa that was previously well tolerated.</li>\n<li>Muscarinic receptor blockers do not prevent their occurrence. <strong>(Option A ruled out)</strong></li>\n<li>Increasing levodopa dose typically worsens peak-dose dyskinesias, because higher dopamine levels exacerbate involuntary movements.</li>\n<li>Management often involves reducing or fractionating the dose to mitigate dyskinesia at the expense of potential off-time worsening. <strong>(Option B rulked out)</strong></li>\n<li>They occur more commonly in patients treated with levodopa in combination with carbidopa or with other dopamine receptor agonists. <strong>(Option C ruled out)</strong></li>\n</ul>", "options": ["Coadministration of muscarinic blockers prevents the occurrence of dyskinesias during treatment with levodopa", "Drugs that activate dopamine receptors can exacerbate dyskinesias in a patient taking levodopa", "Dyskinesias are less likely to occur if levodopa is administered with carbidopa", "The symptoms are usually reduced if the dose of levodopa is increased"], "html_options": ["Coadministration of muscarinic blockers prevents the occurrence of dyskinesias during treatment with levodopa", "Drugs that activate dopamine receptors can exacerbate dyskinesias in a patient taking levodopa", "Dyskinesias are less likely to occur if levodopa is administered with carbidopa", "The symptoms are usually reduced if the dose of levodopa is increased"], "corr_idx": 1}, {"id": "1186236", "html_qtxt": "A 38-year-old woman presents with slowed mentation, lack of coordination, and brief writhing movements of her hands that are not rhythmic with delusions. Her mother has had similar symptoms. Genetic testing shows a mutation on chromosome 4. The most appropriate drug for treatment will likely be", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Although further diagnosis is desirable, choreo-athetosis with decreased mental abilities and psychosis (paranoia) suggests that this patient has the symptoms of Huntington's disease.</li>\n<li>Huntington's disease-associated chorea is best managed with dopamine antagonists or dopamine-depleting agents, which reduce dopaminergic transmission in the striatum and thereby diminish involuntary movements.</li>\n  <li>Haloperidol, a first-generation antipsychotic with strong D<sub>2</sub> receptor antagonism, has been widely used and shown to significantly reduce choreiform movements in clinical series (e.g. mean involuntary movement scores dropped substantially in treated patients)</li>\n<li>Drugs that are partly ameliorative include agents that deplete dopamine (eg, tetrabenazine) or that block dopamine receptors (eg, haloperidol).</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Amantadine(Option A): </strong>Though an NMDA-receptor antagonist, evidence for its effectiveness in HD chorea is inconclusive. Some small trials show modest benefit, but other studies show no significant effect, and experts consider its efficacy small or transient.</p>\n<p><strong>Bromocriptine(Option B): </strong>A dopamine agonist that would likely worsen chorea, not reduce the opposite of the needed dopamine antagonist action.</p>\n<p><strong>Levodopa(Option C): </strong>Would increase dopamine levels and almost certainly exacerbate chorea; used in Parkinsonism but contraindicated here.</p>", "options": ["Amantadine", "Bromocriptine", "Levodopa", "Haloperidol"], "html_options": ["Amantadine", "Bromocriptine", "Levodopa", "Haloperidol"], "corr_idx": 3}, {"id": "1186237", "html_qtxt": "A 28-year-old man presents with symmetrical tremor, worsens with voluntary movements, and resolves completely at rest. He has a history of asthma. Which of the following drugs is most suitable for management?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient has essential tremor, which is symmetrical, worsens with voluntary movements, and resolves completely at rest.</li>\n<li>Increased activation of &beta;-adrenoceptors has been implicated in essential tremor, and management commonly involves the administration of propranolol.</li>\n<li>However, the more selective &beta;1 blocker metoprolol may be equally effective and is more suitable for a patient with pulmonary disease like asthma.</li>\n</ul>", "options": ["Diazepam", "Levodopa", "Metoprolol", "Propranolol"], "html_options": ["Diazepam", "Levodopa", "Metoprolol", "Propranolol"], "corr_idx": 2}, {"id": "1186238", "html_qtxt": "A 72-year-old woman complains that sometimes she sees a dog in her kitchen and at other times she sees a snake in her garden, both of which no one else can see. She has Parkinson's disease and is on treatment. Which of the following is the most likely underlying cause of this patient's symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Since this patient has been taking levodopa for 3 years and is elderly, her symptoms are most likely the result of levodopa therapy.</li>\n<li>The risk for developing psychiatric symptoms increases with age, other psychiatric conditions, long duration of levodopa treatment, and high doses.</li>\n<li>Levodopa (L-DOPA), a dopamine precursor, is the most effective medication for controlling the motor symptoms of Parkinson's disease</li>\n<li>Primary effects of L-DOPA are achieved by stimulating D2-receptors in the substantia nigra and striatum. However, overstimulation of D2-receptors by levodopa may also induce psychosis and hallucinations (usually visual).</li>\n<li>Other adverse effects of L-DOPA therapy include dizziness, somnolence or insomnia, anxiety, and aggressive behaviour.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Carbidopa(Option B):</strong> It is present only as part of the combination with levodopa to reduce peripheral conversion; it does not directly induce central hallucinations.</p>\n<p><strong>Tolcapone(Option C): </strong>It is a COMT inhibitor that enhances central levodopa levels but is rarely used (due to liver toxicity), and isn't classically associated with hallucinations independent of levodopa.</p>\n<p><strong>Safinamide(Option D): </strong>Is an MAO-B inhibitor that can cause hallucinations, but it's normally added as adjunct therapy-not primary therapy-and any psychosis would typically be milder or later in the illness; levodopa remains the dominant culprit in typical Parkinson's psychosis scenarios</p>", "options": ["Levodopa", "Carbidopa", "Tolcapone", "Safinamide"], "html_options": ["Levodopa", "Carbidopa", "Tolcapone", "Safinamide"], "corr_idx": 0}, {"id": "1186239", "html_qtxt": "A 66-year-old man presents with the complaint that he sees dark shadows that keep following him. He has a 6-year history of Parkinson's disease treated with levodopa, carbidopa, and entacapone. The patient is admitted to the hospital and the dose of her antiparkinson medications is reduced. Four days later, the patient still feels threatened by the dark shadows that follow him. Which of the following is the most appropriate next step in management?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Patients with PD are at an increased risk of developing psychosis (most commonly in the form of visual hallucinations) as a side effect of dopamine replacement therapy.</li>\n<li>If other causes of psychotic symptoms have been excluded (e.g., infections) and adjusting the dose of antiparkinson medication does not provide symptomatic relief, as seen here, antipsychotic medication is indicated.</li>\n<li>Quetiapine, or other second-generation antipsychotics like clozapine or pimavanserin, is the first-line option for patients with PD with persistent psychotic symptoms.</li>\n<li>Patients taking quetiapine, especially elderly individuals, should be monitored for common side effects of the drug, including anticholinergic stimulation, metabolic symptoms, and QT prolongation.</li>\n<li>Haloperidol & Risperidone should not be used in patients with PD because it is a dopamine antagonists and have anticholinergic activity; it can exacerbate both motor and psychotic symptoms.<strong> (Option A and B ruled out)</strong></li>\n<li>Benztropine is used in individuals with PD to manage tremor and rigidity. This patient, however, presents with signs of psychosis, which can worsen with the use of an anticholinergic drug. <strong>(Option D ruled out)</strong></li>\n</ul>", "options": ["Haloperidol", "Risperidone", "Quetiapine", "Benztropine"], "html_options": ["Haloperidol", "Risperidone", "Quetiapine", "Benztropine"], "corr_idx": 2}, {"id": "1186242", "html_qtxt": "A 23-year-old man comes presents with low frequency tremor that affects the patient's right hand to a greater extent than his left. When the patient holds his arms fully abducted with his elbows flexed, he has a bilateral low frequency arm tremor that increases in amplitude the longer he holds his arms up. When he wakes up in the morning, his pillow is soaked in saliva. Deep tendon reflexes are 4+ bilaterally. Dysmetria is present. A photograph of the patient's eye is shown. Which of the following is the most appropriate pharmacotherapy?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307f75b7e01-fb8e-454f-841d-3a018b116b71.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Clinical presentation suggests Wilson's disease, a rare genetic disorder.</li>\n<li>Characterized by impaired copper metabolism, leading to copper accumulation in various body tissues, including the brain and liver.</li>\n<li>Neurological manifestations are evident, including a low-frequency tremor, dysmetria, sialorrhea (excessive drooling), and elevated deep tendon reflexes.</li>\n<li>To manage Wilson's disease, the most appropriate pharmacotherapy is needed.</li>\n<li>Penicillamine is a chelating agent used to remove excess copper from the body.</li>\n<li>Forms a complex with copper, facilitating its excretion in urine, reducing tissue copper levels.</li>\n<li>Considered the mainstay of treatment for Wilson's disease, addressing both neurological and systemic symptoms.</li>\n</ul>\n<p><strong>Explanation for Incorrect Options:</strong></p>\n<p><strong>Propranolol(Option A):</strong> Propranolol is a beta-blocker used for essential tremor and cardiac conditions, not for Wilson's disease.</p>\n<p><strong>Deferoxamine(Option B):</strong> Deferoxamine is used to chelate excess iron in iron overload disorders, not for copper chelation in Wilson's disease.</p>\n<p><strong>Levodopa(Option C):</strong> Levodopa is used in Parkinson's disease and related movement disorders but is not the primary treatment for Wilson's disease.</p>", "options": ["Propranolol", "Deferoxamine", "Levodopa", "Penicillamine"], "html_options": ["Propranolol", "Deferoxamine", "Levodopa", "Penicillamine"], "corr_idx": 3}, {"id": "1186243", "html_qtxt": "When ingested in large doses, monosodium glutamate can precipitate severe headaches, weakness, flushing, and tingling in healthy volunteers. Which of the following best characterises the glutamate receptors most likely responsible for these effects?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Glutamate is an important excitatory neurotransmitter in the central nervous system. There are two types of glutamate receptors: ionotropic (ion channel receptors: AMPA, Kainate, NMDA) and metabotropic (G-protein coupled: mGluR) glutamate receptors.</li>\n<li>The type that is most likely responsible for the excitotoxic effect is the N-methyl-D-aspartate (NMDA) receptor.</li>\n</ul>\n<p><strong>NMDA Receptor:</strong></p>\n<ul>\n<li>NMDA receptors are permeable to Ca2+ and Na+. The NMDA receptor is unique because it requires a ligand to activate it (ligand-gated), and it requires depolarisation (voltage-gated) to expel the Mg2+ ion that plugs the channel under resting membrane conditions.</li>\n<li>So, depolarisation may initially occur with stimulation of the AMPA receptor, which allows Na+ ions to enter the cell.</li>\n<li>If there is a sufficient level of depolarisation, then the Mg2+ plug is released from the NMDA receptor, allowing the passage of both Ca2+ and Na+ ions.</li>\n<li>High Ca2+ levels can activate a cascade of cellular degeneration processes, leading to cell death (excitotoxicity) and are thought to play a role in many neurodegenerative diseases.</li>\n<li>On the other hand, activation of the NMDA receptor is also thought to play an important role in the cellular mechanisms involved in synaptic plasticity, such as learning and memory.</li>\n</ul>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li>Ketamine, an NMDA receptor antagonist, is a dissociative anaesthetic used as a sole anaesthetic for procedures that do not require skeletal relaxation, as an inducing agent, and as an anaesthetic supplement.</li>\n<li>It is also being investigated as a treatment in resistant major depression and as an agent to decrease suicidal thoughts.</li>\n<li>Ketamine is also abused, and street names for it include Special K and Vitamin K. mGluR (which has many subtypes) is an example of a G protein-coupled glutamate receptor.</li>\n<li>Other G protein-coupled receptors include adrenergic and muscarinic receptors. Glutamate is an amino acid and would not bind intracellular receptors such as steroid receptors, which usually act directly in the nucleus as transcription factors.</li>\n</ul>", "options": ["G protein-coupled receptor", "Intracellular receptor", "Ligand-gated anion channel", "Ligand-gated and voltage-gated cation channel"], "html_options": ["G protein-coupled receptor", "Intracellular receptor", "Ligand-gated anion channel", "Ligand-gated and voltage-gated cation channel"], "corr_idx": 3}, {"id": "1186244", "html_qtxt": "A 27-year-old man is brought to the emergency department by paramedics because of fever, altered mental status, tachycardia, rigidity, dysphagia, and diaphoresis. The patient's wife says that he began taking a new medication three days ago. His temperature is 103.1 F, pulse is 112/min, blood pressure is 138/86 mmHg, and respirations are 23/min. The patient is alert but not oriented to time, place, or person. Laboratory studies show:<br>1. Creatine kinase = 1200 IU/L<br>2. Aspartate aminotransferase = 35 IU/L<br>3. Alanine aminotransferase = 38 IU/L<br>4. Lactate dehydrogenase = 128 IU/L<br>Which of the following best describes the mechanism of the drug that is most likely causing this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient is presenting with signs and symptoms of neuroleptic malignant syndrome (NMS).</li>\n<li>NMS is a potentially fatal condition most commonly associated with typical antipsychotic medications as well as abrupt withdrawal of dopamine agonists.</li>\n<li>Clinical characteristics of NMS include hyperpyrexia, muscle rigidity, altered mental status, myoglobinuria, and evidence of autonomic instability (tachycardia, diaphoresis, irregular pulse or blood pressure, and cardiac arrhythmias).</li>\n<li>Laboratory studies often show a creatine kinase (CK) > 1000 1U/L (and can be as high as 100,000 1U/L). The AST, ALT, and LDH are all generally mildly elevated (as seen in this patient). Haloperidol, chlorpromazine, and fluphenazine are typical antipsychotics that act by blocking dopamine D2 receptors.</li>\n<li>They are associated with the development of MS as well as acute extrapyramidal symptoms (parkinsonism, dystonia, akathisia) and tardive dyskinesia. None of the other answer choices is associated with the development of NMS.</li>\n<li>MS can be treated with immediate withdrawal of the offending drug, and other treatment measures are primarily supportive and directed toward controlling the rigidity and hyperthermia and preventing complications.</li>\n<li>Antipyretics and cooling methods can be used to reduce hyperthermia. Fluid resuscitation and alkalization of urine can help prevent acute renal failure and increase the excretion of muscle breakdown products.</li>\n<li>Dantrolene, amantadine, and bromocriptine have all been used for the treatment of NMS.</li>\n</ul>", "options": ["Blocks angiotensin II receptors", "Blocks beta-1 receptors", "Blocks dopamine D2 receptors", "Potentates GABA"], "html_options": ["Blocks angiotensin II receptors", "Blocks beta-1 receptors", "Blocks dopamine D2 receptors", "Potentates GABA"], "corr_idx": 2}, {"id": "1186245", "html_qtxt": "A 74-year-old man developed ataxia, then exhibited incontinence, frequent confusion, and difficulty with memory. Neurologic examination shows a bradykinetic, broad-based, magnetic gait, prominent memory loss, and decreased executive functioning. Which of the following is the most appropriate treatment?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient has normal pressure hydrocephalus (PH), which is a clinical syndrome produced by the build-up of cerebrospinal fluid (CSF). Patients have enlarged ventricles often with normal opening pressures on lumbar puncture. It is characterized by the classic triad (with the accompanying mnemonic):</li>\n<li>\"Wet\": urinary incontinence</li>\n<li>\"Wacky\": dementia (memory loss, slowed thought)</li>\n<li>\"Wobbly\" gait abnormality (apraxic \"magnetic\" gait)</li>\n<li>PH is thought to be caused by impaired CSF absorption by arachnoid granulations. It is idiopathic in half of the cases.</li>\n<li>Secondary causes include meningitis, brain trauma, subarachnoid hemorrhage, or prior brain surgery. The treatment for NPH is ventricular shunting.</li>\n<li>A ventriculoperitoneal shunt drains excess CSF to the abdomen, where it is absorbed.</li>\n</ul>", "options": ["Donepezil", "L-DOPA", "Ventricular shunt", "Vitamin B1 (thiamine)"], "html_options": ["Donepezil", "L-DOPA", "Ventricular shunt", "Vitamin B1 (thiamine)"], "corr_idx": 2}, {"id": "1186246", "html_qtxt": "A 50-year-old man is brought with progressive weakness of his hands and arms and difficulty walking. He has also had progressive difficulty swallowing and talking over the past year. Neurologic examination shows moderate immobility of the soft palate bilaterally in response to phonation or the gag reflex. The tongue also appears mildly atrophic with bilateral fasciculations. There is spasticity with flexion and extension at the elbows, and moderate spasticity with flexion and extension at the knees. Deep tendon reflexes are moderately increased and Babinski responses are present bilaterally. Which of the following drugs will most likely prolong this patient's life?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient has amyotrophic lateral sclerosis (ALS), a disorder of the lower motor neurons (located in the ventral horn, producing muscular atrophy and fasciculations), and upper motor neurons (corticospinal neurons, producing hyperreflexia, hypertonia, clasp knife spasticity, and the Babinksi sign). Bulbar involvement may lead to dysarthria and dysphagia.</li>\n<li>Currently there is no cure for ALS and the primary goal of medical care is to provide support and palliative intervention.</li>\n<li>Riluzole is the only agent that has been shown to extend the survival of patients and/or the time until tracheotomy. ALS may involve excitatory toxicity to neurons caused by glutamate. Riluzole is a glutamate release inhibitor and glutamate receptor blocker, as well as a sodium channel blocker.</li>\n<li>The most useful agent for the symptomatic treatment of spasticity of ALS is baclofen <strong>(Option A)</strong>, a GABA-B agonist. However, baclofen does not prolong survival in ALS.</li>\n<li>Clonazepam <strong>(Option B)</strong>, a benzodiazepine, is an effective antispasmodic but may contribute to respiratory depression in patients with advanced ALS. Benzodiazepines increase the frequency of GABA chloride channel opening. It does not prolong survival in ALS.</li>\n<li>Tizanidine <strong>(Option D) </strong>is an agonist of alpha-2 adrenergic receptors in the central nervous system and increases presynaptic inhibition of motor neurons. Therefore, it can be used to treat spasticity in ALS patients. However, tizanidine does not prolong survival in ALS.</li>\n</ul>", "options": ["Baclofen", "Clonazepam", "Riluzole", "Tizanidine"], "html_options": ["Baclofen", "Clonazepam", "Riluzole", "Tizanidine"], "corr_idx": 2}]}, {"moduleId": 1008544, "name": "Psychiatric Pharmacology", "questions": [{"id": "1185676", "html_qtxt": "A 36-year-old man is brought to the AIIMS-ED for a throbbing headache and photophobia for 5 hours. He has severe occipital pain. On asking further, he was at bar with friends, where he had red wine. The patient is on medication for psychiatry disorder, for which he's on daily medication. He is conscious and well oriented to time, place and person.<br>Temp: 98.6<br>Pulse: 94/min,<br>Respiratory rate: 18/min<br>Blood pressure: 190/130 mm-Hg<br>Deep tendon reflex: 2+<br>This patient's symptoms are most likely caused by a side effect of which of the following medications", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Given clinical scenario with throbbing occipital headache, history of consumption of red wine (which contains Tyramine) along with psychiatric drug history (anti-depressants) with high blood pressure, well oriented and normal DTR suggestive of Hypertensive crisis (cheese reaction)</li>\n<li>Hypertensive crisis precipitates when MAO inhibitors (eg. Selegeline and Phenelzine) with ingestion of foods containing tyramine (aged cheeses aka Cheese reaction), smoked meats, alcoholic beverages (red wine), dried fruits, chocolate) are taken.</li>\n<li>Tyramine stimulates the sympathetic nervous system by releasing other neurotransmitters, such as noradrenaline, from vesicles into the synaptic cleft.</li>\n<li>Sertraline & Fluoxetine<strong>(Option A & C)</strong> are SSRI, used as first-line treatment for major depressive disorder.\n<ul>\n<li>Patients taking SSRIs may develop serotonin syndrome, which can also present with hypertension.</li>\n<li>However, serotonin syndrome is usually characterized by altered mental state, hyperthermia, hyperreflexia (>2+), none of which are seen in this patient</li>\n</ul>\n</li>\n<li>Amitriptyline<strong>(Option B)</strong>, a tricyclic antidepressant, can be used for the treatment of depression and migraine prophylaxis.</li>\n<li>Its side effects include anticholinergic effects (tachycardia, flushed skin), sedation, and delirium.</li>\n<li>Furthermore, it is also associated with increased risk of developing serotonin syndrome.</li>\n</ul>", "options": ["Sertraline", "Amitriptyline", "Fluoxetine", "Phenelzine"], "html_options": ["Sertraline", "Amitriptyline", "Fluoxetine", "Phenelzine"], "corr_idx": 3}, {"id": "1185702", "html_qtxt": "A 26-year-old man comes to the psychiatrist because he feels depressed, has difficulty sleeping, lost interest in playing the badminton and low concentration for the past 4 months. He's known alcoholic for which he was referred to therapy. He has tried to cut down or stop more than once, but could not. There is no evidence of suicidal ideation. The physician offers to prescribe a medication for his current symptoms. Treatment with which of the following drugs should most be avoided in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Given clinical scenario of patient with major depressive disorder (with depressed mood, sleep disturbance, anhedonia and loss of concentration for more than 2 weeks) with risk factor for seizure disorder (alcoholic/ alcoholic withdrawal) requires avoidance of Bupropion, as it increases risk of seizures.</li>\n<li>Bupropion is an atypical antidepressant used as a 2nd line treatment for major depressive disorder & smoking cessation therapy.</li>\n<li>It selectively inhibits the reuptake of norepinephrine and dopamine (Dopamine > NE)</li>\n<li>The most severe side effect is a reduce seizure threshold; therefore, bupropion is contraindicated in patients with other seizure risk factors (e.g., anorexia/bulimia, epilepsy, alcoholic/ alcohol withdrawal).</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403076e2b1c5c-2636-4206-ae5b-e9da18c27476.jpg\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Duloxetine(Option A)</strong>: It is a serotonin-norepinephrine reuptake inhibitor (SNRI) used as a second-line treatment for major depressive disorder.</p>\n<ul>\n<li>Duloxetine is contraindicated with concomitant serotonergic drug use (including up to 1 weeks after discontinuation) because this combination increases the risk of serotonin syndrome.</li>\n<li>However, duloxetine is not known to increase the risk of seizures in alcoholics.</li>\n</ul>\n<p><strong>Fluoxetine(Option B):</strong></p>\n<ul>\n<li>It is a selective serotonin reuptake inhibitor (SSRI) used as a first-line treatment for major depressive disorder.</li>\n<li>SSRIs are frequently associated with sexual dysfunction (e.g., decreased libido, difficulty achieving erection, anorgasmia) and are thus not preferred in patients with pre-existing sexual impairment.</li>\n<li>It can also cause serotonin syndrome if used with serotonergic drugs (including up to 5 weeks for fluoxetine, 2 weeks for other SSRIs after discontinuation).</li>\n<li>However, it is not associated with seizure in alcoholics and could be an appropriate treatment option.</li>\n</ul>\n<p><strong>Mirtazapine(Option C):</strong></p>\n<ul>\n<li>It is an atypical antidepressant used as a second-line treatment for major depressive disorder.</li>\n<li>It increases appetite and weight gain, which may not always be desirable in bulimia patients as it can decrease drug compliance (a history of bulimia nervosa is not a contraindication to its use).</li>\n<li>It can also cause serotonin syndrome as other serotonergic drugs.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307ccaae33c-bdc3-46f1-8c1b-85fb88bd3174.jpg\">", "options": ["Duloxetine", "Fluoxetine", "Mirtazapine", "Bupropion"], "html_options": ["Duloxetine", "Fluoxetine", "Mirtazapine", "Bupropion"], "corr_idx": 3}, {"id": "1185721", "html_qtxt": "A 28-year-old woman comes to the ED for the evaluation of a headache and palpitations associated with increased sweating for the last 6 hours. Patient has history of psychiatric disorder, was on citalopram for four weeks, but stopped three days ago and is now on venlafaxine. She does not smoke or drink alcohol.<br>Temperature : 102.2&deg;F<br>Pulse : 120/min<br>Blood pressure : 150/90 mm Hg.<br>On mental status examination, the patient is only oriented to person, but not to place or time. Deep tendon reflexes are 3+ bilaterally. Which of the following is the most likely cause of this patient's symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient presents with <strong><u>H</u></strong>yperthermia, <strong><u>A</u></strong>utonomic hyperactivity (diaphoresis, tachycardia, hypertension), neuromuscular hyperactivity (hyper <strong><u>R</u></strong>eflexia) and <strong><u>M</u></strong>ental status changes (disorientation to place and time). <strong><u>(MNEMONIC: HARM)</u></strong></li>\n<li>These features in a patient who is taking serotonergic drugs (citalopram and venlafaxine) are diagnostic of serotonin syndrome, which is caused by increased serotonergic neurotransmission.</li>\n<li>It can be triggered by taking two serotonergic agents simultaneously or rapidly switching from one serotonergic agent to another without tapering the dose, as was the case with this patient.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403078ed0565b-06ea-405b-a7c2-1a1d78206958.jpg\">\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030730821da5-d1cd-4554-a734-baa36680e97e.jpg\">", "options": ["Discontinuation of Venlafaxine and Administer Cyproheptadine", "Discontinuation of Venlafaxine and administer Dantrolene", "Discontinuation of Venlafaxine and Obtain ECG", "Discontinuation of Venlafaxine, antihypertensive, fluid replacement and provide sedatives"], "html_options": ["Discontinuation of Venlafaxine and Administer Cyproheptadine", "Discontinuation of Venlafaxine and administer Dantrolene", "Discontinuation of Venlafaxine and Obtain ECG", "Discontinuation of Venlafaxine, antihypertensive, fluid replacement and provide sedatives"], "corr_idx": 3}, {"id": "1185743", "html_qtxt": "You've been asked to identify mechanism of action of one of the anti-depressants, illustrated below. Which of the following is incorrect about the drug \"X\"<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030781b3086c-c5e7-4131-8013-1663a72553b4.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Mirtazapine:</strong></p>\n<p>As given picture illustration, given drug \"X\" is Mirtazapine which acts by Noradrenergic and specific serotonergic antidepressants (NaSSAs).</p>\n<ul>\n<li>It has a dual mechanism of action that increases the concentration of 5-HT and noradrenaline in the synaptic cleft to within the normal range.</li>\n<li>Selective &alpha;2-adrenergic antagonist &rarr; &uarr; serotonin and norepinephrine release</li>\n<li>5-HT2 and 5-HT3 receptor antagonists &rarr; &uarr; effect of serotonin on free 5-HT1 receptor is the likely cause of antidepressant action</li>\n<li>Mirtazapine is atypical anti-depressant which acts as 2nd line therapy for major depressive disorder, especially in patients who are underweight and/or who have insomnia.</li>\n<li>In contrast to SSRI, Mirtazapine has Minimal sexual side effects.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Option A</strong> :&uarr; Appetite and weight gain: can also be a desired effect in underweight patient.</p>\n<p><strong>Option B </strong>: Sedation (due to H1 antagonism): can also be a desired effect for those with insomnia with MDD</p>\n<p><strong>Option D </strong>: It causes&uarr; Serum cholesterol and triglyceride levels in blood. Monitoring required in patient with dyslipidemia along with comorbidities. (E.g. Diabetes Mellitus).</p>", "options": ["It can cause &uarr; Appetite and weight gain.", "Sedation is known side effect of this drug", "Sexual side effects like loss of libido and erectile dysfunction, even after dose reduction is indication of discontinuation of drug.", "It can increase cholesterol and triglyceride level in blood"], "html_options": ["It can cause &uarr; Appetite and weight gain.", "Sedation is known side effect of this drug", "Sexual side effects like loss of libido and erectile dysfunction, even after dose reduction is indication of discontinuation of drug.", "It can increase cholesterol and triglyceride level in blood"], "corr_idx": 2}, {"id": "1185749", "html_qtxt": "A 21-year-old man comes to the psychiatrist for a follow-up. He has been on Paroxetine for 8 months for a major depressive episode. He now feels much better. He gets around 7 hours of sleep nightly, and his appetite has increased. Over the past two years, he has also had two episodes of depressed mood, insomnia, low energy, and loss of appetite that lasted 6 weeks, for which he received treatment. On mental status examination, he describes his mood as \"good\" In addition to regular follow-up, which of the following is the most appropriate recommendation for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>In the given clinical scenario, the patient presents with remission of symptoms after paroxetine therapy.</li>\n<li>But Paroxetine therapy should be continued for at least 1-3 years in this patient with major depressive disorder because he has already had three major depressive episodes.</li>\n</ul>\n<p><strong>Antidepressant therapy is divided into three phases:</strong></p>\n<ul>\n<li>The acute phase refers to the initial therapy following diagnosis.</li>\n<li>In the continuation phase of treatment, patients remain on their therapeutic regimen for 4-9 months after achieving remission.</li>\n<li>Patients who have a sustained response to continuation pharmacotherapy for at least 6 months are recommended to transition to maintenance therapy if at least one of the following indications is present.\n<ul>\n<li>Three or more major depressive episodes (SIGECAPS)</li>\n<li>Severe episodes (e.g., suicidal ideation)</li>\n<li>Risk factors for recurrence (e.g., onset &le; 18-21 years)</li>\n</ul>\n</li>\n<li>The total duration of maintenance phase treatment is patient-dependent and must be reevaluated regularly; it can be lifelong. Ideally, pharmacotherapy is combined with cognitive-behavioural therapy.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Discontinue Paroxetine(Option A)</strong>:</p>\n<ul>\n<li>Antidepressants such as paroxetine should never be discontinued abruptly in patients with major depressive disorder, but rather tapered off over weeks or months to avoid antidepressant discontinuation syndrome or a relapse of depression.</li>\n<li>Moreover, this patient responded well to paroxetine therapy and has not reported side effects. Discontinuation is not recommended at this point</li>\n</ul>\n<p><strong>Switch from Paroxetine to valproate(Option B)</strong>:</p>\n<ul>\n<li>Patients with depressive symptoms should be thoroughly screened for bipolar disorder before beginning treatment and monitored for new-onset insomnia and irritability after initiating an SSRI.</li>\n<li>Paroxetine can precipitate a shift to hypomania or mania in patients with bipolar disorder. While this patient has become more active and his mood is elevated, he does not have a history of hypomania or mania and lacks characteristic symptoms (i.e., decreased need for sleep, flight of ideas, distractibility, and/or excessive involvement in risky activities).</li>\n<li>Therefore, a switch to valproic acid is unnecessary.</li>\n</ul>\n<p><strong>Taper Paroxetine over 3 months(Option C)</strong>:</p>\n<ul>\n<li>SSRIs should always be tapered off at some point.</li>\n<li>However, only three additional months is too short of a time frame for this patient with recurrent depressive episodes, and premature cessation could lead to a recurrence of depressive symptoms</li>\n</ul>", "options": ["Discontinue Paroxetine", "Switch from Paroxetine to valproate", "Taper Paroxetine over 3 months", "Maintain Paroxetine for at least 1 year"], "html_options": ["Discontinue Paroxetine", "Switch from Paroxetine to valproate", "Taper Paroxetine over 3 months", "Maintain Paroxetine for at least 1 year"], "corr_idx": 3}, {"id": "1185775", "html_qtxt": "A 33-year-old male complains that he feels \"flat\" and that he gets confused at times. He has been gaining weight and has lost his sex drive. As he moves his hands, you notice a slight tremor. He tells you that since he has been on medication, he is always thirsty and frequently has to urinate. Which of the following patients is on?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Confusion, mood changes, decreased sexual interest, and weight gain are symptoms that may be unrelated to drug administration. On the other hand, psychiatric drugs are often responsible for such symptoms.</li>\n<li>Tremor and symptoms of nephrogenic diabetes insipidus are characteristic adverse effects of lithium that may occur at blood levels within the therapeutic range.</li>\n<li>Lithium is a psychiatric medication used primarily as a first-line therapy for bipolar disorder. It is also used in treatment-resistant depression to augment antidepressants</li>\n<li>It is thought to be due to inhibition of the phosphoinositol cascade.</li>\n<li>Lithium therapy has a very narrow therapeutic index; frequent monitoring is therefore required to prevent toxicity. therapeutic levels (0.4-1.2 mEq/L)</li>\n</ul>\n<p><strong>Common adverse events of lithium:</strong></p>\n<ul>\n<li>Tremor (fine hand tremor)</li>\n<li>Nausea, vomiting, diarrhoea</li>\n<li>Polyuria and polydipsia (due to nephrogenic diabetes insipidus)</li>\n<li>Weight gain</li>\n<li>Hypothyroidism</li>\n<li>Cognitive dulling / mental slowing</li>\n<li>Acne and skin issues (e.g., worsening of psoriasis)</li>\n<li>Hair thinning (alopecia)</li>\n<li>ECG changes (e.g., T-wave flattening)</li>\n<li>Chronic kidney disease (with long-term use)</li>\n<li>Teratogenicity - risk of Ebstein's anomaly (if used in 1st trimester)</li>\n</ul>", "options": ["Carbamazepine", "Clozapine", "Lithium", "Risperidone"], "html_options": ["Carbamazepine", "Clozapine", "Lithium", "Risperidone"], "corr_idx": 2}, {"id": "1185791", "html_qtxt": "A young woman recently diagnosed as schizophrenic has started on atypical anti-psychotic therapy. She occasionally has palpitations and dizziness. ECG is shown below. Which of the following drugs should be avoided?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307ee5df615-459d-41fd-9338-eb4a00d011b8.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Given an ECG with palpitation and a history of psychiatric drug, suggest a diagnosis of long QT syndrome. The primary finding in LQTS is a long QT interval corrected for heart rate (QTc) interval &rArr; 440 ms.</li>\n<li>Flucanazole also causes QT prolongation, so it should be avoided in this patient.</li>\n<li>Long QT syndrome (LQTS) is a congenital or acquired heart condition in which the QT interval (i.e., ventricular depolarisation and repolarisation) is prolonged.</li>\n<li>Most patients with LQTS are asymptomatic, but some present with seizures, syncope, or even life-threatening arrhythmias and sudden death.</li>\n<li>Treatment depends on the underlying cause: Beta blockers and implantable cardioverter defibrillator (ICD) insertion are commonly used for congenital LQTS, whereas treatment of the underlying cause (drug, electrolyte abnormality, etc.) is the first-line therapy for acquired LQTS.</li>\n<li>Of the currently available atypical antipsychotic drugs, ziprasidone carries the greatest risk of QT prolongation.</li>\n<li>Warfarin, cefixime and aspirin do not cause QT prolongation. <strong>(Other options ruled out).</strong></li>\n</ul>\n<p><strong>Other drugs causing LQTS are:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403074ed764e2-0ec3-40de-9d87-5562df500b39.jpg\">", "options": ["Fluconazole", "Warfarin", "Cefexime", "Aspirin"], "html_options": ["Fluconazole", "Warfarin", "Cefexime", "Aspirin"], "corr_idx": 0}, {"id": "1185794", "html_qtxt": "A 60-year-old woman presents with involuntary movements of the tongue and face that started 4 days ago. She has schizophrenia that has been controlled with haloperidol for the past 3 years. Treatment with benztropine is begun. One week later, her symptoms have worsened. Next step in the treatment?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Involuntary movements of the tongue and mouth, as seen in this patient, that manifest within months to years following the administration of dopamine-blocking agents like haloperidol, suggest the diagnosis of Tardive dyskinesia.</li>\n<li>Treatment options include benzodiazepines and botulinum toxin injection. VMAT inhibitors for moderate or severe symptoms include Valbenazine.</li>\n<li>Anticholinergic drugs (e.g., benztropine) can exacerbate symptoms, as seen in this patient.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Increase the dose of benztropine(Option A):</strong> It can exacerbate symptoms of TD and should be avoided.</p>\n<p><strong>Propranolol(Option B): </strong></p>\n<ul>\n<li>Propranolol can be used in akathasia but not for TD. Akathasia is a movement disorder that can manifest following the administration of antipsychotic medications (most often first-generation antipsychotics, such as haloperidol).</li>\n<li>However, it usually develops within the first 1-8 weeks after initiation of therapy. In addition, this condition is characterised by motor restlessness (i.e., a compelling urge to move), which can manifest with an inability to sit or stand still; it does not cause involuntary movements of the tongue and face.</li>\n<li>Moreover, this condition typically improves with benztropine therapy.</li>\n</ul>\n<p><strong>Diphenhydramine(Option D):</strong> Diphenhydramine is 1st generation antihistamine having anti-muscarinic action that can be used in place of benztropine.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509058c80ae44-277a-432c-9f7e-0845f350d56e.png\">", "options": ["Increase the dose of benztropine", "Propranolol", "Valbenazine", "Diphenhydramine"], "html_options": ["Increase the dose of benztropine", "Propranolol", "Valbenazine", "Diphenhydramine"], "corr_idx": 2}, {"id": "1185796", "html_qtxt": "A 30-year-old man is brought to the physician by his husband because of difficulty walking over the past 7 days. He reports feeling stiffness in the legs and has difficulty standing from a seated position. During his last hospitalisation, 10 days ago, fluphenazine therapy was initiated. The patient takes short, quick steps during ambulation and has difficulty maintaining his balance while standing. What could be the diagnosis?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Here patient presents with a drug-induced movement disorder that develops days to weeks after the initiation of dopamine-blocking agents (e.g., first-generation antipsychotics).</li>\n<li>This condition manifests with symptoms of Parkinsonism, such as limb rigidity, shuffling gait, bradykinesia, postural instability, and an unhabituated glabellar reflex, all of which are seen in this patient.</li>\n<li>Other medications associated with pseudoparkinsonism include metoclopramide and valproate.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307edc9f516-9135-4c08-8247-0effec4e43db.jpg\">", "options": ["Parkinsonism", "Pseudoparkinsonism", "Restless leg syndrome", "Neuroleptic malignant syndrome"], "html_options": ["Parkinsonism", "Pseudoparkinsonism", "Restless leg syndrome", "Neuroleptic malignant syndrome"], "corr_idx": 1}, {"id": "1185808", "html_qtxt": "A 76-year-old man with a history of Parkinson's disease is diagnosed with clinical depression. Treatment with an antidepressant is begun. Which of the following drugs will be most effective in treating both Parkinson's disease and depression?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Parkinson's disease is a condition caused by dopamine depletion secondary to the degeneration of the dopaminergic nigrostriatal tract, leading to an imbalance of dopamine (DA) and acetylcholine (ACh) (DA levels are too low and ACh levels are too high).</li>\n<li>Treatment is directed at restoring the balance between these two neurotransmitters by either increasing dopamine levels or blocking the effect of acetylcholine with anticholinergic agents.</li>\n<li>Therefore, an agent with strong anticholinergic side effects would help to alleviate some of the signs and symptoms of Parkinson's disease.</li>\n<li>Amitriptyline is a tricyclic antidepressant (CA) that has very strong anticholinergic properties and could help treat both conditions.</li>\n<li>In general, most of the tricyclic antidepressants (e.g., nortriptyline) have strong anticholinergic properties.</li>\n</ul>", "options": ["Amitriptyline", "Citalopram", "Duloxetine", "Sertraline"], "html_options": ["Amitriptyline", "Citalopram", "Duloxetine", "Sertraline"], "corr_idx": 0}, {"id": "1185811", "html_qtxt": "A 34-year-old man with GAD is particularly concerned about how medication might affect his sexual performance. His past medical history is significant for alcohol dependence. If long-term pharmacotherapy is indicated, which of the following is the most appropriate drug for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient with generalised anxiety disorder (GAD) has been characterised by excessive, virtually daily, anxiety for more than 6 months.</li>\n<li>The anxiety and worry must cause functional impairment, must last at least 6 months, and must be associated with at least three of the following: restlessness, fatiguability, irritability, muscle tension, sleep disorders, and difficulty concentrating.</li>\n<li>Buspirone is a nonbenzodiazepine anxiolytic agent that is generally nonsedating, is not associated with tolerance or dependence, does not interact with benzodiazepine receptors or alcohol, has no abuse potential, and does not cause sexual dysfunction.</li>\n<li>Many physicians who treat patients with GAD start them on benzodiazepines (which act quickly) and then switch them to buspirone (which takes about 2 weeks to work) or, more commonly, the selective serotonin reuptake inhibitors, such as fluoxetine.</li>\n<li>In this case, benzodiazepines would be inadvisable because of his history of alcohol dependence. The most common side effects of buspirone are dizziness, some drowsiness (much less than with TCAs and benzodiazepines), fatigue, and impaired concentration.</li>\n<li>Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that is commonly used for the management of GAD and other anxiety disorders. Like buspirone, it can take several weeks before the therapeutic effect is seen in the patient.</li>\n<li>However, unlike buspirone, fluoxetine is associated with increased suicidal risk, anxiety, CNS stimulation, sexual dysfunction, and serotonin syndrome.</li>\n<li>Furthermore, because this patient is particularly concerned about sexual performance, prescribing a drug known to cause sexual dysfunction would not be advisable</li>\n</ul>", "options": ["Buspirone", "Fluoxetine", "Imipramine", "Lorazepam"], "html_options": ["Buspirone", "Fluoxetine", "Imipramine", "Lorazepam"], "corr_idx": 0}, {"id": "1185818", "html_qtxt": "A 52-year-old woman generalized anxiety disorder comes to the emergency department because of persistent nausea, malaise, muscle cramps, drowsiness, and confusion. Laboratory studies show a serum sodium of 120 mEq/L, serum osmolality of 260 mOsmol/kg H2O, urine osmolality of 270 mOsmol/kg H2O, and urine sodium of 48 mEq/L. Which of the following drugs is the most likely cause of this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>The patient is presenting with signs and symptoms of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).</li>\r\n<li><strong>Fluoxetine</strong>, a selective serotonin reuptake inhibitor (SSRI), is a well-documented cause of SIADH and resultant hyponatremia, especially in older adults.</li>\r\n<li>SIADH is characterized by hyponatremia, decreased serum osmolality (<280 mOsmol/kg H20) with inappropriately increased urine osmolality (>150 mOsmol/kg H20), urine sodium usually greater than 40 mEq/L, euvolemia, and normal thyroid and adrenal function.</li>\r\n<li>In SIADH, urine osmolarity is generally greater than serum osmolarity. The body will respond to increased water retention by decreasing aldosterone in an attempt to maintain euvolemia.</li>\r\n<li>SIADH can be caused by agents that increase ADH production and stimulate ADH release in the posterior pituitary.</li>\r\n<li>The most definitive treatment is to remove the offending agent and this may be sufficient.</li>\r\n<li>If removal of the drug is not sufficient or possible, treatment options include fluid restriction, salt administration, loop diuretics, conivaptan, tolvaptan, and demeclocycline.</li>\r\n<li>Hyponatremia should be treated slowly to prevent central pontine myelinolysis.</li>\r\n<li><strong>Buspirone</strong>: Though its serotonergic (5-HT2A agonist) activity raises theoretical concerns, there are no robust reports or evidence supporting it as a cause of SIADH when used alone. <strong>(Option B)</strong></li>\r\n<li><strong>Atenolol</strong> (a &beta;-blocker) and <strong>conjugated estrogens</strong> are not known to cause SIADH or hyponatremia.<strong> (Options A and C)</strong></li>\r\n</ul>", "options": ["Atenolol", "Buspirone", "Conjugated estrogens", "Fluoxetine"], "html_options": ["Atenolol", "Buspirone", "Conjugated estrogens", "Fluoxetine"], "corr_idx": 3}, {"id": "1185824", "html_qtxt": "A 25-year-old woman with a history of resistant depression is found unconscious after ingesting an unknown quantity of amitriptyline. Two hours after arrival, she dies, despite appropriate lifesaving measures. Which of the following is the most likely cause of death?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Patients who overdose on tricyclic antidepressants (TADs) experience dangerous and often lethal effects. These arrhythmias may produce hypotension, shock, and death.</li>\n<li>Thus, monitoring for the cardiac consequences of these drugs is paramount in treating tricyclic overdoses.</li>\n</ul>\n<p><strong>Tricyclic Antidepressants toxicity:</strong></p>\n<ul>\n<li>Tricyclics can lead to the development of QT prolongation, cardiac arrhythmias, AV block, and bundle branch block. Tricyclics act by directly blocking the fast Na channels in cardiac myocytes.</li>\n<li>The side effects of TADs can result in cardiotoxicity, convulsions, and coma. Less serious but common side effects of the tricyclics include dry mouth, urinary retention, blurred vision, drowsiness and constipation.</li>\n</ul>\n<p><strong>Management:</strong></p>\n<ul>\n<li>Supportive management of toxicity may include endotracheal intubation, hyperventilation (use is controversial but helps produce respiratory alkalosis), and treatment with IV sodium bicarbonate, which can treat ventricular arrhythmias that are associated with tricyclic antidepressants.</li>\n<li>Sodium bicarbonate acts by alkalinising the serum to oppose the arrhythmia induced by the tricyclics and by directly providing Na+ for the fast channels. Lidocaine has also been used for the treatment of cardiac arrhythmias. The treatment of choice for prolonged or recurrent seizures in TA toxicity is a benzodiazepine.</li>\n<li>Due to their overall toxicity, the TCAs have largely been supplanted by the selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depressive disorder.</li>\n<li>However, TCAs are still used for treatment-resistant major depressive disorder as well as fibromyalgia, other pain syndromes, enuresis and obsessive compulsive disorder.</li>\n<li>When tricyclics are prescribed, they are often prescribed in smaller amounts than the typical prescription.</li>\n</ul>", "options": ["Hepatotoxicity", "Intracranial haemorrhage", "Lethal arrhythmia", "Respiratory depression"], "html_options": ["Hepatotoxicity", "Intracranial haemorrhage", "Lethal arrhythmia", "Respiratory depression"], "corr_idx": 2}]}, {"moduleId": 1008545, "name": "Opioids And Drugs Of Abuse, Alcohol", "questions": [{"id": "1179694", "html_qtxt": "A 70-year-old male patient came to the Emergency Dept. with severe chest pain, cough, difficulty in breathing while walking less than 100 yards. Patient has been a chronic smoker for 40-45 years, smoking around 30-35 bidis/day. On auscultation, bilateral ronchi were present, and there was decreased air entry on the right side. His laboratory investigation, ECG and chest X Ray were done. ECG was within normal limits. Chest X Ray was suggestive of a round mass on the right side with emphysematous changes in the lung fields. So, CECT thorax was done, which was suggestive of lung carcinoma. Which analgesic drug is best suited to give to this pt. for long-term pain relief via Transdermal Patch?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Codeine and hydroxycodone have reduced first-pass metabolism. So they can be given orally as they have a medium to high Oral: Parenteral potency Ratio, whereas fentanyl has high first-pass metabolism, it has a very low Oral: Parenteral Potency Ratio. So it is better not to give fentanyl orally. <strong>(Options A and B ruled out)</strong></li>\r\n<li>The <strong>transdermal patch </strong>provides stable blood levels of the drug and better pain control while avoiding the need for repeated parenteral injections.</li>\r\n<li>Fentanyl has been the most successful opioid in transdermal application and is indicated for the management of persistent, unremitting pain.</li>\r\n<li>Because of the complication of fentanyl-induced respiratory depression, the Food and Drug Administration (FDA) recommends that the introduction of a transdermal fentanyl patch (25 mcg/h) be reserved for patients with an established oral morphine requirement of at least 60 mg/d for 1 week or more.</li>\r\n<li>Extreme caution must be exercised in any patient initiating therapy or undergoing a dose increase because the peak effects may not be realised until 24-48 hours after patch application.</li>\r\n</ul>\r\n<p><strong>Metabolism of Fentanyl:</strong></p>\r\n<ul>\r\n<li>Hepatic oxidative metabolism is the primary route of degradation of the phenylpiperidine opioids (meperidine, fentanyl, alfentanil, sufentanil) and eventually leaves only small quantities of the parent compound unchanged for excretion.</li>\r\n<li>However, accumulation of a demethylated metabolite of meperidine, normeperidine, may occur in patients with decreased renal function and those receiving multiple high doses of the drug.</li>\r\n<li>In high concentrations, normeperidine may cause seizures. In contrast, no active metabolites of fentanyl have been reported. The P450 isozyme CYP3A4 metabolises fentanyl by N-dealkylation in the liver.</li>\r\n<li>CYP3A4 is also present in the mucosa of the small intestine and contributes to the first-pass metabolism of fentanyl when it is taken orally.</li>\r\n<li>Codeine, oxycodone, and hydrocodone undergo metabolism in the liver by P450 isozyme CYP2D6, resulting in the production of metabolites of greater potency.</li>\r\n</ul>", "options": ["Codeine", "Hydroxycodone", "Fentanyl", "All of the above"], "html_options": ["Codeine", "Hydroxycodone", "Fentanyl", "All of the above"], "corr_idx": 2}, {"id": "1179696", "html_qtxt": "A male 34 years old female patient came to OPD with the complaints of dry cough, mild difficulty in breathing on exertion, evening rise of temperature, loss of appetite, loosening of clothes, which is s/o weight loss since 4 months. She had consulted for the same complaints before, but was not willing to investigate. This time, laboratory investigations and a chest X Ray were done. Laboratory investigations were Hb-13.4 gm %, ESR 42, SGPT 32U/L, SGOT 26 U/L. Chest X Ray was s/o active pulmonary TB, which was confirmed by Positive AFB in Sputum examination. So, she was prescribed anti-TB medication. After 1-month follow-up visit, she complained of a dry cough, so she was prescribed an antitussive syrup. Antitussive agent which is synthesized from Morphine has _____ Efficacy.", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Commonly used antitussive opioid agents are Dextromethorphan and Codeine.</li>\n<li>DMR is a stereoisomer of Levorphanol, and codeine is synthesised from Morphine.</li>\n</ul>\n<p><strong>Common Opioids and their efficacies:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509052cac6031-c5cc-4565-b537-717fe2ccd1c4.png\">\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li>The opioids contract the biliary smooth muscle, which can result in biliary colic. The sphincter of Oddi may constrict, resulting in reflux of biliary and pancreatic secretions and elevated plasma amylase and lipase levels.</li>\n<li>Most opioids have no significant direct effects on the heart and, other than bradycardia, no major effects on cardiac rhythm. Meperidine is an exception to this generalisation because its antimuscarinic action can result in tachycardia.</li>\n<li>Anterolateral wall MI leads to Tachycardia and Hypertension. Meperidine causes tachycardia, so it cannot be used.</li>\n</ul>", "options": ["High", "Low", "Moderate", "Moderate - high "], "html_options": ["High", "Low", "Moderate", "Moderate - high "], "corr_idx": 0}, {"id": "1179701", "html_qtxt": "A 35-year-old male patient came to the Emergency Department with complaints of severe pain in abdomen right side radiating to the back and vomiting. He was given intravenous tramadol for pain relief. Opioids have their analgesic action by acting on mu, kappa and delta receptors. Which receptor has the maximum affinity towards endorphins?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Mu receptor has the maximum affinity towards endorphins.</li>\n</ul>\n<p><strong>The below given table below shows receptors and their endogenous peptides affinities:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905d00ad9b0-b581-4a4c-8bf7-2e0eee3ec87b.png\">", "options": ["Mu", "Kappa", "Delta", "All of the above"], "html_options": ["Mu", "Kappa", "Delta", "All of the above"], "corr_idx": 0}, {"id": "1179708", "html_qtxt": "A 50-year-old male patient came to the emergency department with complaints of difficulty in breathing, bilateral lower limb oedema, and chest pain. Sweating. The patient was on treatment for asthma, but he did not take medications for 3,4 months. His SpO2 was 97% on air. On Auscultation, the Third heart sound was heard, and bilateral coarse crepitus was heard over the lung fields. ECG was s/o CCF, and Chest X Ray was suggestive of pulmonary oedema. Intravenous morphine is started for pain. Mechanism of action of morphine in pulmonary oedema is ________________.", "html_expl": "<p>Explanation:</p>\r\n<p>The relief produced by intravenous morphine in dyspnea from pulmonary oedema associated with left ventricular heart failure is remarkable. Proposed mechanisms include reduced anxiety ( perception of shortness of breath) and reduced cardiac preload (reduced venous tone) and afterload (decreased peripheral resistance). However, if respiratory depression is a problem, furosemide may be preferred for the treatment of pulmonary oedema. On the other hand, morphine can be particularly useful when treating painful myocardial ischemia with pulmonary edema.</p>", "options": ["Reduced Anxiety", "Reduced cardiac preload", "Reduced cardiac afterload", "All of the above"], "html_options": ["Reduced Anxiety", "Reduced cardiac preload", "Reduced cardiac afterload", "All of the above"], "corr_idx": 3}, {"id": "1179709", "html_qtxt": "Match the following.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905b450d692-fc50-4c11-81b1-5fdf5027adf2.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905971fe495-87ad-4dc1-80e9-3f5ea5ec2222.png\">", "options": ["1 - a,b, 2 - c,d, 3 - e", "1 - b,d, 2 - a, 3 - c,e", "1 - b,c, 2 - a,d, 3 - e", "1 - b,c, 2 - a, 3 - d,e"], "html_options": ["1 - a,b, 2 - c,d, 3 - e", "1 - b,d, 2 - a, 3 - c,e", "1 - b,c, 2 - a,d, 3 - e", "1 - b,c, 2 - a, 3 - d,e"], "corr_idx": 3}, {"id": "1179710", "html_qtxt": "Which of the following are the adverse effects of opioids?<br />1. Respiratory depression<br />2. Urinary retention<br />3. Oedema<br />4 . Nausea and vomiting<br />5. Diarrhoea<br />6. Constipation", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905403732bf-2375-4396-9856-1c124e549095.png\">", "options": ["1,2,3,4,5", "1,2,3,5,6", "2,4,5,6", "1,2,4,6"], "html_options": ["1,2,3,4,5", "1,2,3,5,6", "2,4,5,6", "1,2,4,6"], "corr_idx": 3}, {"id": "1179712", "html_qtxt": "Which drug is used for opioid abuse?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Methadone is widely used in the treatment of opioid abuse.</li>\n<li>Tolerance and physical dependence develop more slowly with methadone than with morphine. The withdrawal signs and symptoms occurring after abrupt discontinuance of methadone are milder, although more prolonged, than those of morphine.</li>\n<li>These properties make methadone a useful drug for detoxification and for maintenance of the chronic relapsing heroin addict.</li>\n<li>For detoxification of a heroin-dependent addict, low doses of methadone (5&ndash;10 mg orally) are given two or three times daily for 2 or 3 days. Upon discontinuing methadone, the addict experiences a mild but endurable withdrawal syndrome.</li>\n</ul>", "options": ["MAO Inhibitors", "Methadone", "Corticosteroids", "Loperamide"], "html_options": ["MAO Inhibitors", "Methadone", "Corticosteroids", "Loperamide"], "corr_idx": 1}, {"id": "1179713", "html_qtxt": "Methadone acts by _________", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Methadone is not only a potent &mu;-receptor agonist but its racemic mixture of D- and L-methadone isomers can also block both NMDA receptors and monoaminergic reuptake transporters.</li>\n<li>These nonopioid receptor properties may help explain its ability to relieve difficult-to-treat pain (neuropathic, cancer pain), especially when a previous trial of morphine has failed. In this regard, when analgesic tolerance or intolerable side effects have developed with the use of increasing doses of morphine or hydromorphone, \"opioid rotation\" to methadone has provided superior analgesia at 10-20% of the morphine-equivalent daily dose.</li>\n<li>In contrast to its use in suppressing symptoms of opioid withdrawal, use of methadone as an analgesic typically requires administration at intervals of no more than 8 hours. However, given methadone's highly variable pharmacokinetics and long half-life (25-52 hours), initial administration should be closely monitored to avoid potentially harmful adverse effects, especially respiratory depression. Because methadone is metabolized by CYP3A4 and CYP2B6 isoforms in the liver, inhibition of its metabolic pathway or hepatic dysfunction has also been associated with overdose effects, including respiratory depression or, more rarely, prolonged QT-based cardiac arrhythmias.</li>\n</ul>", "options": ["Mu receptor agonist", "Block NMDA receptors", "Block monoaminergic reuptake transporters", "All of the above"], "html_options": ["Mu receptor agonist", "Block NMDA receptors", "Block monoaminergic reuptake transporters", "All of the above"], "corr_idx": 3}, {"id": "1179714", "html_qtxt": "Which properties of Remifentanil makes it useful in anesthesia practice ?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>These opioids differ mainly in their potency and biodisposition.</li>\n<li>Sufentanil is five to seven times more potent than fentanyl.</li>\n<li>Alfentanil is considerably less potent than fentanyl, but acts more rapidly and has a markedly shorter duration of action. Remifentanil is metabolized very rapidly by blood and nonspecific tissue esterases, making its pharmacokinetic and pharmacodynamic half-lives extremely short. Such properties are useful when these compounds are used in anesthesia practice.</li>\n</ul>", "options": ["Long half life", "Short half life", "More potency", "More efficacy"], "html_options": ["Long half life", "Short half life", "More potency", "More efficacy"], "corr_idx": 1}, {"id": "1179715", "html_qtxt": "Meperidine is contraindicated in heart failure because of its which action ?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Although fentanyl is now the predominant analgesic in the phenylpiperidine class, <strong>meperidine </strong>continues to be used. This older opioid has significant antimuscarinic effects, which may be a contraindication if tachycardia would be a problem.</li>\n<li>Meperidine is also reported to have a negative inotropic action on the heart. In addition, it has the potential for producing seizures secondary to accumulation of its metabolite, normeperidine, in patients receiving high doses or with concurrent renal failure. Given this undesirable profile, use of meperidine as a first-line analgesic is becoming increasingly rare.</li>\n</ul>", "options": ["Causes cardiac modification", "Causes bradycardia", "Causes negative inotropic effect on heart", "All of the above"], "html_options": ["Causes cardiac modification", "Causes bradycardia", "Causes negative inotropic effect on heart", "All of the above"], "corr_idx": 2}, {"id": "1179717", "html_qtxt": "Which opioids can be used in the treatment of diarrhoea ?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Loperamide </strong>is a phenylpiperidine derivative used to control diarrhea. However, due to action on peripheral &mu;-opioid receptors and lack of effect on CNS receptors, there is renewed interest in its potential for the treatment of neuropathic pain. Its potential for abuse is considered very low because of its limited access to the brain. It is therefore available without a prescription.</li>\n<li><strong>Diphenoxylate </strong>and its metabolite, <strong>difenoxin, </strong>are not used for analgesia but for the treatment of diarrhoea. They are scheduled for minimal control (difenoxin is Schedule IV, diphenoxylate Schedule V; see inside front cover) because the likelihood of their abuse is remote. The poor solubility of the compounds limits their use for parenteral injection. As antidiarrheal drugs, they are used in combination with atropine.</li>\n</ul>", "options": ["Loperamide", "Diphenoxylate", "Fentanyl", "All of the above"], "html_options": ["Loperamide", "Diphenoxylate", "Fentanyl", "All of the above"], "corr_idx": 3}, {"id": "1179718", "html_qtxt": "Which of the following is true for Nalbuphine ?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Nalbuphine </strong>is a strong &kappa;-receptor <em>agonist </em>and a &mu;-receptor <em>antagonist; </em>it is given parenterally. At higher doses there seems to be a definite ceiling-not noted with morphine-to the respiratory depressant effect. Unfortunately, when respiratory depression does occur, it may be relatively resistant to naloxone reversal.</li>\n</ul>\n<p>Nalbuphine is a mixed opioid agonist-antagonist, but it has a higher affinity for kappa receptors than for mu receptors. This means that it acts as an agonist at kappa receptors and an antagonist at mu receptors.</p>\n<p>As a kappa receptor agonist, nalbuphine can produce a variety of effects, including:</p>\n<ul>\n<li>Analgesia</li>\n<li>Sedation</li>\n<li>Miosis</li>\n<li>Diuresis</li>\n<li>Increased heart rate</li>\n</ul>\n<p>As a mu receptor antagonist, nalbuphine can block the effects of other mu receptor agonists, such as morphine.</p>\n<p>Nalbuphine is used to treat a variety of pain conditions, including:</p>\n<ul>\n<li>Postoperative pain</li>\n<li>Labor and delivery pain</li>\n<li>Cancer pain</li>\n<li>Acute pain</li>\n</ul>\n<p>Nalbuphine is also being investigated for use in the treatment of other conditions, such as chronic itch and opioid dependence.</p>", "options": ["Mu receptor agonist and kappa receptor antagonist", "Mu receptor antagonist and kappa receptor agonist", "Mu and kappa receptor agonist", "Mu and kappa receptor antagonist"], "html_options": ["Mu receptor agonist and kappa receptor antagonist", "Mu receptor antagonist and kappa receptor agonist", "Mu and kappa receptor agonist", "Mu and kappa receptor antagonist"], "corr_idx": 1}, {"id": "1179720", "html_qtxt": "Which drug can be used to treat overdose of opioids with Methadone ?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>In addition, studies continue to suggest that buprenorphine is as effective as methadone in the detoxification and maintenance of heroin abusers.</p>\n<ul>\n<li>Buprenorphine was approved by the FDA in 2002 for the management of opioid dependence. In contrast to methadone, high-dose administration of buprenorphine results in a &mu;-opioid <em>antagonist </em>action, limiting its properties of analgesia and respiratory depression.</li>\n</ul>\n<p>Moreover, buprenorphine is also available combined with a pure &mu;-opioid antagonist (Suboxone) to help prevent its diversion for illicit intravenous abuse. A slow-release transdermal patch preparation that releases drug over a 1-week period is also available.</p>", "options": ["Nalbuphine", "Buprenorphine", "Fentanyl", "Meperidone"], "html_options": ["Nalbuphine", "Buprenorphine", "Fentanyl", "Meperidone"], "corr_idx": 1}, {"id": "1179721", "html_qtxt": "Which drug can cause serotonin syndrome if taken with SSRI antidepressants ?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Tramadol </strong>is a centrally acting analgesic whose mechanism of action is predominantly based on blockade of serotonin reuptake.</li>\n<li>Tramadol has also been found to inhibit norepinephrine transporter function.</li>\n<li>Because it is only partially antagonized by naloxone, it is believed to be only a weak &mu;-receptor agonist. The recommended dosage is 50-100 mg orally four times daily.</li>\n<li>Toxicity includes association with seizures; the drug is relatively contraindicated in patients with a history of epilepsy and for use with other drugs that lower the seizure threshold. Another serious risk is the development of serotonin syndrome, especially if selective serotonin reuptake inhibitor (SSRI) antidepressants are being administered. Other side effects include nausea and dizziness, but these symptoms typically abate after several days of therapy. It is surprising that no clinically significant effects on respiration or the cardiovascular system have thus far been reported. Given the fact that the analgesic action of tramadol is largely independent of &mu;-receptor action, tramadol may serve as an adjunct with pure opioid agonists in the treatment of chronic neuropathic pain.</li>\n</ul>", "options": ["Butorphanol", "Pentazocine", "Tramadol", "Tapentadol"], "html_options": ["Butorphanol", "Pentazocine", "Tramadol", "Tapentadol"], "corr_idx": 2}, {"id": "1179722", "html_qtxt": "Which are the pure opioid antagonist agents ?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The pure opioid antagonist drugs <strong>naloxone, naltrexone, </strong>and <strong>nalmefene </strong>are morphine derivatives with bulkier substituents at the N 17 position. These agents have a relatively high affinity for &mu;-opioid binding sites. They have lower affinity for the other receptors but can also reverse agonists at &delta; and &kappa; sites.</p>", "options": ["Naloxone", "Naltrexone", "Nalmefene", "All of the above"], "html_options": ["Naloxone", "Naltrexone", "Nalmefene", "All of the above"], "corr_idx": 3}, {"id": "1179723", "html_qtxt": "A person has addiction of alcohol, smoking and opioids but wants to quit all three. Which drug is preferred ?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Naltrexone, 0.4-4 mg, is sequestered in the center of the formulation pellets and is present to prevent the abuse of the morphine (by grinding and extraction of the morphine from the capsules). There is evidence that naltrexone decreases the craving for alcohol in chronic alcoholics by increasing baseline &beta;-<strong>endorphin </strong>release, and it has been approved by the FDA for this purpose (see Chapter 23 ).</li>\n<li>Naltrexone also facilitates abstinence from nicotine (cigarette smoking) with reduced weight gain. In fact, a combination of naltrexone plus bupropion ( Chapter 30 ) may also offer an effective and synergistic strategy for weight loss. If current trials demonstrate cardiovascular safety during prolonged use, this and other weight-loss medications compounded with naltrexone may eventually win FDA approval.</li>\n</ul>", "options": ["Methadone", "Nalexone", "Naltrexone", "Nalbuphine"], "html_options": ["Methadone", "Nalexone", "Naltrexone", "Nalbuphine"], "corr_idx": 2}, {"id": "1179724", "html_qtxt": "Opioid antitussive agents are _________.<br />1.Codeine<br />2.Levopropoxyphen<br />3.Dextromethorphan<br />4.Pentazocine<br />5.Noscapine<br />6.Tramadol", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>The opioid derivatives most commonly used as antitussives are <strong>dextromethorphan, codeine, levopropoxyphene, </strong>and <strong>noscapine </strong>(levopropoxyphene and noscapine are not available in the USA). They should be used with caution in patients taking monoamine oxidase inhibitors (see Table 31-5 ).</li>\r\n<li>Antitussive preparations usually also contain expectorants to thin and liquefy respiratory secretions.</li>\r\n</ul>", "options": ["1,2,3,4", "1,2,3,6", "1,2,3,5", "2,3,5,6"], "html_options": ["1,2,3,4", "1,2,3,6", "1,2,3,5", "2,3,5,6"], "corr_idx": 2}, {"id": "1179725", "html_qtxt": "Opioid antitussive agents are banned by FDA for children of age under __.", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Importantly, due to increasing reports of death in young children taking dextromethorphan in formulations of over-the-counter \"cold/cough\" medications, its use in children less than 6 years of age has been banned by the FDA. Moreover, because of variations in the metabolism of codeine, its use for any purpose in young children is being reconsidered.</p>", "options": ["6 months", "5 years", "6 years", "12 years"], "html_options": ["6 months", "5 years", "6 years", "12 years"], "corr_idx": 2}]}, {"moduleId": 1008546, "name": "Hematology", "questions": [{"id": "1191474", "html_qtxt": "A 30-year-old man undergoes surgery for a mitral valve replacement. Five days later, he develops non-blanching, darkened and purpuric lesions on his trunk and arms. Laboratory studies show a WBC count of 11,000/mL, an Hb level of 14 mg/dL, and a platelet count of 70,000/mL. Administration of which of the following drugs is most appropriate for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient's presentation of thrombocytopenia and skin lesions (purpura, a sign of potential thrombosis) 5 days after a major surgery (where heparin is commonly used for anticoagulation) is highly suggestive of heparin-induced thrombocytopenia (HIT). </p>\n<p>HIT is an immune-mediated adverse drug reaction. It is caused by the formation of IgG autoantibodies against the heparin-platelet factor 4 (PF4) complex. This leads to widespread platelet activation and consumption, causing a paradoxical state of thrombocytopenia and a high risk of thrombosis (venous and/or arterial). </p>\n<p>The immediate management of HIT involves discontinuing all forms of heparin and initiating a non-heparin anticoagulant. Direct thrombin inhibitors, such as <strong>argatroban</strong> or bivalirudin, are the drugs of choice in this situation. </p>\n<p>There are two types of HIT: </p>\n<ul>\n<li><strong>Type 1 HIT:</strong> A non-immune, mild, and transient drop in platelets that occurs 1-2 days after starting heparin. It is not associated with thrombosis. </li>\n<li><strong>Type 2 HIT:</strong> An immune-mediated, serious condition occurring 4-14 days after heparin initiation. It is characterized by significant thrombocytopenia and a high risk of life-threatening thromboembolic complications, such as skin necrosis or gangrene. </li>\n</ul>\n<p><strong>Explanation of Other Options:</strong> </p>\n<ul>\n<li><strong>Aspirin (Option A):</strong> Aspirin is an antiplatelet agent, but it is not the appropriate treatment for HIT and would not address the underlying prothrombotic state. </li>\n<li><strong>Protamine (Option C):</strong> Protamine sulfate is a heparin antagonist used to reverse the anticoagulant effects of unfractionated heparin, typically in cases of overdose or bleeding. It is not used to treat HIT. </li>\n<li><strong>Warfarin (Option D):</strong> Warfarin should not be initiated alone in a patient with acute HIT. It can paradoxically increase the risk of thrombosis (e.g., venous limb gangrene) by rapidly depleting protein C levels before an adequate anticoagulant effect is achieved. If long-term anticoagulation with warfarin is needed, it should only be started after the platelet count has recovered and overlapped with a direct thrombin inhibitor. </li>\n</ul>", "options": ["Aspirin", "Argatroban", "Protamine", "Warfarin"], "html_options": ["Aspirin", "Argatroban", "Protamine", "Warfarin"], "corr_idx": 1}, {"id": "1191479", "html_qtxt": "A 75-year-old woman with a history of ischemic stroke presents with chest pain and diaphoresis. ECG shows atrial fibrillation. After treatment is instituted, the patient no longer has chest pain, and troponin is normal. Which of the following drugs is most appropriate for this patient after stabilisation?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The patient has <strong>atrial fibrillation (AF)</strong> and requires rate control, rhythm management, and anticoagulation after stabilisation.</li>\n<li>Given her age (>75 years) and history of ischemic stroke, she has a <strong>high stroke risk</strong> per the <strong>CHA2DS2-VASc score</strong>.</li>\n<li><strong>Anticoagulation</strong> is essential to prevent clot formation in the fibrillating atrium, reducing the risk of stroke or systemic embolism.</li>\n<li><strong>Warfarin</strong>, which inhibits vitamin K-dependent coagulation factors (II, VII, IX, X, and proteins C and S), is appropriate for long-term anticoagulation in AF.</li>\n<li><strong>Heparin </strong>is typically used initially alongside warfarin until a therapeutic INR (2.0-3.0) is achieved, usually after 4-5 days, at which point heparin is discontinued.</li>\n<li>In modern practice, <strong>direct oral anticoagulants (DOACs) </strong>like apixaban or rivaroxaban may be preferred for non-valvular AF due to predictable dosing and no need for INR monitoring, but warfarin remains a valid option, especially if DOACs are contraindicated.</li>\n</ul>\n<p><strong>Explanation of other options</strong>:</p>\n<ul>\n<li><strong>Aspirin (Option A)</strong>: Insufficient for high-risk AF patients like this one with advanced age and prior stroke; warfarin or DOACs are preferred for stroke prevention.</li>\n<li><strong>Morphine (Option B)</strong>: Used for acute pain relief, not indicated here as chest pain has resolved and troponin is normal.</li>\n<li><strong>Propylthiouracil (Option C)</strong>: Treats hyperthyroidism, irrelevant as no hyperthyroidism is indicated.</li>\n</ul>", "options": ["Aspirin", "Morphine", "Propylthiouracil", "Warfarin"], "html_options": ["Aspirin", "Morphine", "Propylthiouracil", "Warfarin"], "corr_idx": 3}, {"id": "1191482", "html_qtxt": "A 55-year-old man is brought 2 h after the onset of severe chest pain. He has a history of poorly controlled mild hypertension and elevated blood cholesterol, but does not smoke. ECG changes of ST elevation and cardiac enzymes confirm the diagnosis of myocardial infarction. The decision is made to attempt to open his occluded artery. Which of the following drugs accelerates the conversion of plasminogen to plasmin?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Reteplase</strong><strong>,</strong> a thrombolytic, accelerates the conversion of plasminogen to plasmin, promoting clot lysis in acute myocardial infarction (MI).</li>\n<li><strong>Heparin</strong> (anticoagulant), <strong>argatroban</strong> (direct thrombin inhibitor), and <strong>aminocaproic acid</strong> (plasminogen activation inhibitor) do not have this mechanism.</li>\n</ul>", "options": ["Aminocaproic acid", "Heparin", "Argatroban", "Reteplase"], "html_options": ["Aminocaproic acid", "Heparin", "Argatroban", "Reteplase"], "corr_idx": 3}, {"id": "1191494", "html_qtxt": "If a fibrinolytic drug is used for the treatment of acute myocardial infarction, which of the following is not an absolute contraindication?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Current SBP >180 mm Hg or DBP >110 mm Hg </strong>is a <strong>relative contraindication</strong>, as it can often be managed with antihypertensive therapy to allow fibrinolysis.</p>\n<p>Common contraindications for fibrinolysis in STEMI and STEMI-equivalents</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307898c0900-6f49-4088-8d29-aca92625d190.jpg\">", "options": ["Ischemic stroke within the past 3 months", "Intracranial malignancy", "Current SBP > 180 mm Hg or DBP > 110 mm Hg", "Suspected aortic dissection"], "html_options": ["Ischemic stroke within the past 3 months", "Intracranial malignancy", "Current SBP > 180 mm Hg or DBP > 110 mm Hg", "Suspected aortic dissection"], "corr_idx": 2}, {"id": "1191497", "html_qtxt": "A 68-year-old man presents with a sudden onset of shortness of breath and tachycardia. A spiral CT scan of the chest shows a pulmonary embolism. Treatment with a medication that causes an almost immediate inactivation of factor lla is begun. Which of the following laboratory studies will most likely be used to monitor the effect of the drug administered to this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Heparin</strong>, an anticoagulant, accelerates the activity of antithrombin III (ATIII), thereby inactivating thrombin (factor IIa) and factor Xa almost instantaneously.</li>\n<li>The <strong>heparin-ATIII complex</strong> can also inactivate factors IX, XI, XII, and plasmin.</li>\n<li>Heparin prevents the progression of existing clots by inhibiting further clotting, but does not directly cause lysis of existing clots, which relies on endogenous thrombolytic mechanisms.</li>\n<li>Heparin is often administered for <strong>acute pulmonary embolism or thrombosis</strong> by continuous IV infusion to achieve a therapeutic activated partial thromboplastin time (aPTT) range of approximately 1.5-2.5 times the control value.</li>\n<li>The <strong>aPTT</strong> measures the intrinsic system and common pathway, affected by factors I (fibrinogen), II (prothrombin), V, VIII, IX, X, XI, and XII.</li>\n<li>The anticoagulant effect of heparin should be monitored to ensure the aPTT remains within the therapeutic range of <strong>5-2.5</strong> times the control value.</li>\n<li>If the aPTT exceeds this range, the risk of internal bleeding increases.</li>\n</ul>", "options": ["Activated partial thromboplastin time", "Bleeding time", "Factor 2a levels", "Prothrombin time"], "html_options": ["Activated partial thromboplastin time", "Bleeding time", "Factor 2a levels", "Prothrombin time"], "corr_idx": 0}, {"id": "1191501", "html_qtxt": "A 26-year-old pregnant woman is referred by her obstetrician for evaluation of anaemia. This woman has macrocytic anaemia, an increased serum concentration of transferrin, and a normal serum concentration of vitamin B12. The most likely cause of her anaemia is deficiency of which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Deficiencies of folic acid or vitamin B12 are the most common causes of megaloblastic anaemia. If a patient with this type of anaemia has a normal serum vitamin B12 concentration, folate deficiency is the most likely cause of the anaemia.</li>\n</ul>", "options": ["Cobalamin", "Erythropoietin", "Folic acid", "Iron"], "html_options": ["Cobalamin", "Erythropoietin", "Folic acid", "Iron"], "corr_idx": 2}, {"id": "1191507", "html_qtxt": "A 64-year-old man presents with shortness of breath and chest pain. Coronary angiography shows a thrombotic occlusion of the left circumflex coronary artery. Treatment with a thrombolytic drug is begun. Which of the following measurements is most likely to be affected by this drug?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Thrombosis </strong>can lead to acute myocardial injury, and thrombolytic agents like <strong>alteplase</strong> (a recombinant tissue plasminogen activator) are used to treat ST-elevation myocardial infarction (STEMI).</li>\n<li><strong>Alteplase</strong> binds to fibrin in a thrombus, converting entrapped plasminogen to plasmin, which degrades fibrin clots, resulting in <strong>fibrinolysis</strong>.</li>\n<li>This process increases fibrin degradation products (e.g., D-dimer) and may deplete fibrinogen, leading to <strong>prolonged prothrombin time (PT)</strong> and <strong>partial thromboplastin time (PTT).</strong></li>\n<li>Both PT and PTT can be affected due to<strong> reduced fibrinogen levels</strong> and interference with the coagulation cascade, though D-dimer is a more specific marker of thrombolytic activity.</li>\n</ul>", "options": ["Platelet count only", "Prothrombin time (PT) only", "Partial thromboplastin time (PTT) only", "PT and PTT"], "html_options": ["Platelet count only", "Prothrombin time (PT) only", "Partial thromboplastin time (PTT) only", "PT and PTT"], "corr_idx": 3}, {"id": "1191510", "html_qtxt": "Which of the following is most likely to be required by a 5-year-old boy with chronic renal insufficiency?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The kidney produces erythropoietin; patients with chronic renal insufficiency often require exogenous erythropoietin to avoid chronic anaemia.</li>\n</ul>", "options": ["Cyanocobalamin", "Erythropoietin", "Filgrastim (G-CSF)", "Oprelvekin (IL-11)"], "html_options": ["Cyanocobalamin", "Erythropoietin", "Filgrastim (G-CSF)", "Oprelvekin (IL-11)"], "corr_idx": 1}, {"id": "1191514", "html_qtxt": "A 68-year-old woman had a relapse of breast cancer. The cancer was now unresponsive to the standard doses of chemotherapy. A decision was made to treat the patient with high-dose chemotherapy followed by autologous stem cell transplantation. Which of the following drugs is needed for the patient's autologous stem cell transplantation?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The success of transplantation with peripheral blood stem cells depends on the infusion of adequate numbers of hematopoietic stem cells.</li>\n<li>Administration of <strong>G-CSF </strong>to the donor (in the case of autologous transplantation, the patient who also will be the recipient of the transplantation) greatly increases the number of hematopoietic stem cells harvested from the donor's blood.</li>\n</ul>", "options": ["Filgrastim (G-CSF)", "Folic acid", "Intrinsic factor", "Oprelvekin (interleukin-11)"], "html_options": ["Filgrastim (G-CSF)", "Folic acid", "Intrinsic factor", "Oprelvekin (interleukin-11)"], "corr_idx": 0}, {"id": "1191517", "html_qtxt": "A 69-year-old man with a history of well-controlled hypertension, atrial fibrillation, and type 2 diabetes is brought in because of decreased responsiveness. He appeared normal 2 hours before. Neurologic examination shows rightward deviation of his gaze and head posture and severe dysarthria with prominent left facial droop. Strength is 2/5 in the left upper and lower extremities. Reflexes are preserved throughout, as are flexor plantar responses. CT scan of the head shows no haemorrhage, but MRI of the brain shows ischemic injury to the right cerebral cortex. Which of the following is the most appropriate pharmacotherapy?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Ischemic stroke is one of the leading causes of morbidity and mortality. It is considered a clinical emergency, and timely diagnosis and treatment can improve the patient's outcome.</li>\n<li>When a stroke is suspected, emergent brain imaging is essential to confirm the diagnosis of ischemic stroke before thrombolytics can be administered.</li>\n<li>Noncontrast computed tomography (CT) scanning is the most commonly used form of neuroimaging to evaluate a patient suspected of having an acute stroke.</li>\n<li>This patient presents with <strong>acute ischemic stroke</strong> (right MCA territory) within 2 hours, confirmed by CT (no haemorrhage) and MRI (ischemic injury).</li>\n<li><strong>Alteplase</strong>, a tissue plasminogen activator, is indicated within 3-4.5 hours of symptom onset in eligible patients to lyse clots and restore cerebral blood flow. It binds fibrin in thrombi, converting plasminogen to plasmin for fibrinolysis.</li>\n</ul>", "options": ["Alteplase", "Aspirin", "Corticosteroids", "Warfarin"], "html_options": ["Alteplase", "Aspirin", "Corticosteroids", "Warfarin"], "corr_idx": 0}, {"id": "1191519", "html_qtxt": "The lab for your pregnant patient indicates microcytic anaemia. Optimal treatment of normocytic or mild microcytic anaemia associated with pregnancy uses which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Iron deficiency microcytic anaemia is the anaemia that is most commonly associated with In this condition, oral iron supplementation is indicated.</li>\n</ul>", "options": ["A high-fibre diet", "Ferrous sulfate tablets", "Folic acid supplements", "Hydroxocobalamin injections"], "html_options": ["A high-fibre diet", "Ferrous sulfate tablets", "Folic acid supplements", "Hydroxocobalamin injections"], "corr_idx": 1}, {"id": "1191521", "html_qtxt": "A 34-year-old pregnant woman who has a young child at home and is taking iron-containing prenatal supplements should be warned that they are a common source of accidental poisoning in young children. Toxicity associated with acute iron poisoning usually includes which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Acute iron poisoning often causes severe gastrointestinal damage resulting from direct corrosive effects, <strong>shock from fluid loss in the gastrointestinal tract, and metabolic acidosis from cellular dysfunction.</strong></li>\n</ul>", "options": ["Dizziness, hypertension, and cerebral haemorrhage", "Hyperthermia, delirium, and coma", "Necrotising gastroenteritis, shock, and metabolic acidosis", "Severe hepatic injury, encephalitis, and coma"], "html_options": ["Dizziness, hypertension, and cerebral haemorrhage", "Hyperthermia, delirium, and coma", "Necrotising gastroenteritis, shock, and metabolic acidosis", "Severe hepatic injury, encephalitis, and coma"], "corr_idx": 2}, {"id": "1191524", "html_qtxt": "Which of the following most accurately describes the mechanism of action of clopidogrel?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Clopidogrel</strong> is a prodrug activated by the <strong>CYP2C19 enzyme</strong> in the liver.</li>\n<li>Its <strong>active metabolite irreversibly</strong> binds to the P2Y12 component of ADP receptors on the platelet surface, <strong>inhibiting platelet aggregation </strong>and reducing the risk of thrombus formation.</li>\n</ul>", "options": ["Clopidogrel directly binds to the platelet ADP receptors", "Clopidogrel facilitates the action of antithrombin III", "The active metabolite of clopidogrel binds to and inhibits the platelet ADP receptors", "The active metabolite of clopidogrel binds to and inhibits the platelet glycoprotein IIb/IIIa receptors"], "html_options": ["Clopidogrel directly binds to the platelet ADP receptors", "Clopidogrel facilitates the action of antithrombin III", "The active metabolite of clopidogrel binds to and inhibits the platelet ADP receptors", "The active metabolite of clopidogrel binds to and inhibits the platelet glycoprotein IIb/IIIa receptors"], "corr_idx": 2}, {"id": "1191526", "html_qtxt": "A 6-year-old child ingests the iron-containing supplements. What immediate treatment is necessary?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Activated charcoal does not bind iron and thus is ineffective.</li>\n<li>Oral deferasirox is effective for <strong>chronic iron toxicity.</strong></li>\n<li>Dantrolene inhibits Ca2+ release from the sarcoplasmic reticulum and is an antidote for malignant hyperthermia induced by inhaled anaesthetics.</li>\n</ul>", "options": ["Activated charcoal", "Oral deferasirox", "Parenteral deferoxamine", "Parenteral dantrolene"], "html_options": ["Activated charcoal", "Oral deferasirox", "Parenteral deferoxamine", "Parenteral dantrolene"], "corr_idx": 2}, {"id": "1191528", "html_qtxt": "A 67-year-old woman has been put on filgrastim after being treated with anticancer drugs. The therapeutic objective is to prevent which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Filgrastim (G-CSF) stimulates the production and function of neutrophils, important cellular mediators of the innate immune system that serve as the first line of defence against infection.</li>\n</ul>", "options": ["Cancer recurrence", "Excessive bleeding", "Hypoxia", "Systemic infection"], "html_options": ["Cancer recurrence", "Excessive bleeding", "Hypoxia", "Systemic infection"], "corr_idx": 3}, {"id": "1191529", "html_qtxt": "The megaloblastic anaemia that results from vitamin B12 deficiency is due to inadequate supplies of which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Deficiency of vitamin B12 (cobalamin) leads to a deficiency in <strong>tetrahydrofolate </strong>and, subsequently, a deficiency of the <strong>dTMP </strong>required for DNA synthesis. Homocysteine and N5-methyltetrahydrofolate accumulate.</li>\n</ul>", "options": ["Cobalamin", "dTMP", "Homocysteine", "N5-methyltetrahydrofolate"], "html_options": ["Cobalamin", "dTMP", "Homocysteine", "N5-methyltetrahydrofolate"], "corr_idx": 1}, {"id": "1191530", "html_qtxt": "A 58-year-old woman with breast cancer is scheduled to receive 4 cycles of cancer chemotherapy. Her first cycle was complicated by severe chemotherapy-induced thrombocytopenia. During the second cycle of chemotherapy, it would be appropriate to consider treating this patient with which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Oprelvekin (IL-11) </strong>stimulates<strong> platelet production </strong>and decreases the number of platelet transfusions required by patients undergoing bone marrow suppression therapy for cancer.</li>\n</ul>", "options": ["Darbepoetin alpha", "Filgrastim", "Iron dextran", "Oprelvekin"], "html_options": ["Darbepoetin alpha", "Filgrastim", "Iron dextran", "Oprelvekin"], "corr_idx": 3}, {"id": "1191532", "html_qtxt": "A 56-year-old man undergoes a percutaneous coronary angiography procedure and placement of a stent in a coronary blood vessel. Appropriate pharmacological management will be?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Dual antiplatelet therapy (DAPT)</strong> with <strong>aspirin</strong> and <strong>clopidogrel</strong> is the standard of care post-coronary stent placement to prevent stent thrombosis.</li>\n<li>DAPT is typically continued for <strong>6-12 months</strong> for drug-eluting stents, per current guidelines.</li>\n<li><strong>Clopidogrel</strong>, a prodrug, is activated by CYP2C19 in the liver, and its active metabolite irreversibly binds to the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation.</li>\n<li><strong>Aspirin </strong>inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and further preventing platelet activation.</li>\n</ul>", "options": ["Aspirin", "Clopidogrel", "Aspirin + Clopidogrel", "Abciximab"], "html_options": ["Aspirin", "Clopidogrel", "Aspirin + Clopidogrel", "Abciximab"], "corr_idx": 2}, {"id": "1191536", "html_qtxt": "A 58-year-old woman with chronic hypertension and diabetes mellitus was recently admitted to the hospital for congestive heart failure and new-onset atrial fibrillation. An echocardiogram shows an ejection fraction of 40%; there are no valvular abnormalities. An ECG reveals only atrial fibrillation. What would be your next step in the pharmacological management?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>The patient's <strong>high stroke risk</strong>, calculated using the<strong> CHA2DS2-VASc score</strong> due to her age, hypertension, diabetes, and heart failure, indicates the need for <strong>anticoagulation </strong>rather than antiplatelet therapy. <strong>Warfarin </strong>is appropriate for long-term anticoagulation in atrial fibrillation to prevent stroke, with heparin used initially until a therapeutic INR (2.0-3.0) is achieved.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307225c9e88-6b3c-4c23-ab1d-7d8e18155924.jpg\">", "options": ["Warfarin", "Aspirin + clopidogrel", "Aspirin", "Heparin"], "html_options": ["Warfarin", "Aspirin + clopidogrel", "Aspirin", "Heparin"], "corr_idx": 0}, {"id": "1191537", "html_qtxt": "Your consultants ask you to discuss the risks and benefits of anticoagulation therapy with the patient, including the option of using direct thrombin inhibitors. Which of the following anticoagulants is a direct inhibitor of thrombin?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Dabigatran </strong>is a direct inhibitor of thrombin</li>\n<li><strong>Abciximab</strong> is an antiplatelet agent that binds to and inhibits GPIIb/IIIa.</li>\n<li><strong>Rivaroxaban</strong> is an oral factor X inhibitor.</li>\n<li><strong>Warfarin</strong> inhibits vitamin K epoxide reductase (VKOR).</li>\n</ul>", "options": ["Abciximab", "Dabigatran", "Rivaroxaban", "Warfarin"], "html_options": ["Abciximab", "Dabigatran", "Rivaroxaban", "Warfarin"], "corr_idx": 1}, {"id": "1191540", "html_qtxt": "A 56-year-old male stomach cancer patient underwent surgery. After surgery, lab reports show Hb 7.8, MCH 28, MCV 120. His anaemia is caused by a deficiency of X and can be treated with Y.", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Resection of the stomach does lead to loss of<strong> intrinsic factor</strong><strong>,</strong> and the patient will be deficient in <strong>vitamin B12</strong>. Prevention or treatment of iron deficiency anaemia (microcytic cell size) is the only indication for iron administration. Sargramostim is a GM-CSF and is used to stimulate the production of neutrophils and other myeloid and megakaryocyte progenitors.</li>\n</ul>", "options": ["X = intrinsic factor; Y = folic acid", "X = intrinsic factor; Y = vitamin B12", "X = extrinsic factor; Y = parenteral iron", "X = extrinsic factor; Y = sargramostim"], "html_options": ["X = intrinsic factor; Y = folic acid", "X = intrinsic factor; Y = vitamin B12", "X = extrinsic factor; Y = parenteral iron", "X = extrinsic factor; Y = sargramostim"], "corr_idx": 1}, {"id": "1191543", "html_qtxt": "A 78-year-old woman presents with pain in her left thigh muscle. Doppler indicates the presence of DVT in the affected limb. The decision was made to treat this woman with enoxaparin. Relative to unfractionated heparin, enoxaparin:", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Enoxaparin's </strong>predictable pharmacokinetics and longer half-life allow for fixed subcutaneous dosing without routine aPTT monitoring, unlike <strong>unfractionated heparin</strong>, which requires aPTT monitoring to adjust dosing.</p>\n<ul>\n<li><strong>Enoxaparin</strong> is an LMW heparin. LMW heparins have a longer half-life than standard heparin and a more consistent relationship between dose and therapeutic effect.</li>\n<li>Enoxaparin is given subcutaneously, not intravenously. It is less, not more, likely to cause thrombosis and thrombocytopenia.</li>\n</ul>", "options": ["Can be used without monitoring the patient's aPTT", "Has a shorter duration of action", "Is more likely to be given intravenously", "Is more likely to cause thrombosis and thrombocytopenia"], "html_options": ["Can be used without monitoring the patient's aPTT", "Has a shorter duration of action", "Is more likely to be given intravenously", "Is more likely to cause thrombosis and thrombocytopenia"], "corr_idx": 0}, {"id": "1191546", "html_qtxt": "An 82-year-old woman with DVT is started on warfarin. One month later, she returned after a severe nosebleed. Laboratory analysis revealed an INR of 7.0. To prevent severe haemorrhage, the warfarin should be discontinued, and this patient should be treated immediately with which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The elevated INR indicates excessive anticoagulation with a high risk of haemorrhage.</li>\n<li>INR value in such a warfarin-treated patient should be 2.0-3.0.</li>\n<li>Warfarin should be discontinued and <strong>vitamin K1 </strong>administered to accelerate the formation of vitamin K-dependent factors.</li>\n</ul>", "options": ["Aminocaproic acid", "Factor VIII", "Protamine", "Vitamin K1"], "html_options": ["Aminocaproic acid", "Factor VIII", "Protamine", "Vitamin K1"], "corr_idx": 3}, {"id": "1191548", "html_qtxt": "A 45-year-old man presents with severe chest pain, sweating, and nausea. Examination shows normal heart sounds and breath sounds. ECG shows sinus tachycardia with ST segment elevation in leads II, III, and aVF. After initial treatment, the chest pain decreases in intensity, and a reperfusion complex ventricular arrhythmia emerges. The arrhythmia is asymptomatic and resolves spontaneously. Which of the following drugs is most likely responsible for rapid reperfusion in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient had an ST-elevation myocardial infarction (STEMI) and, following medical treatment, experienced symptomatic improvement and reperfusion-related arrhythmia; this is most likely the result of <strong>fibrinolytic (thrombolytic) therapy.</strong></li>\n<li>Fibrinolytic agents (e.g., <strong>alteplase</strong>) are indicated in patients with acute STEMI who cannot receive percutaneous coronary intervention promptly.</li>\n<li>Administration of these agents leads to breakdown of fibrin clot and often restoration of myocardial perfusion; some patients develop a self-limiting reperfusion-related arrhythmia (most commonly an accelerated idioventricular rhythm).</li>\n<li>In the fibrinolytic pathway, tissue plasminogen activator (PA) is released by the endothelium and cleaves plasminogen to form plasmin. Plasmin then acts to both degrade individual fibrinogen molecules and break down the fibrin clot that has already The breakdown of the fibrin clot leads to elevated levels of fibrin split products (eg, d-dimer) in the blood.</li>\n<li>Pharmacologic fibrinolytic agents that are used clinically include streptokinase and recombinant forms of tPA (e.g., <strong>alteplase</strong>, <strong>Tenecteplase</strong>).</li>\n<li>All of these agents inherently increase bleeding risk and are contraindicated in patients with increased risk of bleeding complications (e.g., recent hemorrhagic stroke).</li>\n</ul>", "options": ["Alteplase", "Apixaban", "Aspirin", "Heparin"], "html_options": ["Alteplase", "Apixaban", "Aspirin", "Heparin"], "corr_idx": 0}, {"id": "1191554", "html_qtxt": "A 64-year-old man comes due to exertional chest pain over the last 6 months. He is a lifelong cigarette smoker and has a history of type 2 diabetes mellitus and peripheral artery disease. The patient undergoes treadmill exercise stress testing and develops substernal chest pain on moderate exertion accompanied by ECG changes that resolve immediately upon rest. The patient is started on low-dose aspirin therapy for secondary prevention of cardiovascular disease but experiences shortness of breath and wheezing with the medication. Which of the following is the best alternate therapy for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient's clinical history is consistent with <strong>stable angina </strong>(angina pectoris) due to underlying coronary heart disease (CHD).</li>\n<li>Patients with stable angina should be started on <strong>aspirin </strong>to decrease the risk of adverse cardiovascular events.</li>\n<li>Aspirin impairs prostaglandin synthesis by irreversibly inhibiting cyclooxygenase (COX). Inhibition of COX-1 in platelets prevents synthesis of thromboxane A2, a potent stimulator of platelet aggregation and This helps reduce the risk of occlusive thrombus formation and subsequent myocardial infarction.</li>\n<li>Some patients are unable to tolerate aspirin due to exacerbation of pre-existing respiratory symptoms (e.g., rhinitis, asthma) or development of allergic reactions (e.g., urticaria, angioedema, anaphylaxis). In these patients, alternate antiplatelet agents should be used for the prevention of cardiovascular events.</li>\n<li><strong>Clopidogrel </strong>irreversibly blocks the <strong>P2Y 12 </strong>component of ADP receptors on the platelet surface and prevents platelet aggregation. Clopidogrel is as effective as aspirin for the prevention of cardiovascular events and should be used in patients with aspirin allergy.</li>\n</ul>", "options": ["Apixaban", "Clopidogrel", "Eptifibatide", "Warfarin"], "html_options": ["Apixaban", "Clopidogrel", "Eptifibatide", "Warfarin"], "corr_idx": 1}, {"id": "1191556", "html_qtxt": "A 78-year-old woman does not want oral anticoagulation because she does not want to come to the clinic for frequent blood tests. You suggest an oral alternative and start her on apixaban and counsel her on the importance of taking the medication each day, as suddenly stopping can lead to:", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Due to the shorter half-life of the oral factor X and thrombin inhibitors, the anticoagulant status of the patient changes rapidly.</li>\n<li>Sudden cessation of apixaban, a direct factor Xa inhibitor with a short half-life, can lead to a rebound hypercoagulable state, increasing the risk of stroke, especially in patients with atrial fibrillation.</li>\n<li>Excess bleeding is associated with taking any of the anticoagulants, not with stopping them.</li>\n<li>An increase in INR reflects increased anticoagulation by warfarin. Thrombocytopenia is a risk associated with heparin.</li>\n</ul>", "options": ["Anaphylaxis", "Excess bleeding", "Stroke", "Thrombocytopenia"], "html_options": ["Anaphylaxis", "Excess bleeding", "Stroke", "Thrombocytopenia"], "corr_idx": 2}, {"id": "1191557", "html_qtxt": "A 65-year-old man is started on rivaroxaban for his atrial fibrillation. Which of the following tests would provide accurate information about the coagulation status of a patient taking apixaban?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>INR</strong> (measured as PT test) reflects changes due to warfarin and, to some extent, the thrombin inhibitors.</li>\n<li>Factor X inhibition is not reliably measured by the aPTT (used for unfractionated heparin) or PT test.</li>\n</ul>", "options": ["aPTT", "Factor X assay", "INR-PT test", "Factor-II test"], "html_options": ["aPTT", "Factor X assay", "INR-PT test", "Factor-II test"], "corr_idx": 1}, {"id": "1191560", "html_qtxt": "A 76-year-old man with a history of hypertension, type 2 diabetes, and asymptomatic carotid stenosis presents with severe mid-sternal chest pain and diaphoresis. His blood pressure is 120/70 mmHg, and pulse is 75/min. ECG shows ST elevation in leads II, III, and aVF. He is treated with aspirin, alteplase, a low-dose beta blocker, and a single dose of IV morphine. Several hours later, he becomes comatose with asymmetric pupils and irregular breathing. What is the most likely cause of his current condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient's presentation of chest pain, diaphoresis, and ECG findings of ST elevation in leads II, III, and aVF indicates an <strong>inferior ST-elevation myocardial infarction (STEMI). </strong></li>\n<li>Fibrinolytic therapy with <strong>alteplase </strong>was administered, as percutaneous coronary intervention (PCI) was likely unavailable.</li>\n<li><strong>Alteplase</strong>, a tissue plasminogen activator, binds fibrin in the thrombus, converting plasminogen to plasmin, which degrades the fibrin clot to restore coronary blood flow.</li>\n<li>However, fibrinolytics carry a significant risk of haemorrhage, particularly <strong>intracerebral haemorrhage (ICH)</strong>, especially in elderly patients (age >75) or those with hypertension or other risk factors.</li>\n<li>The patient's subsequent coma, asymmetric pupils, and irregular breathing strongly suggest<strong> ICH </strong>as a complication of alteplase therapy.</li>\n</ul>", "options": ["Dissection of the ascending aorta", "Intracerebral haemorrhage", "Myocardial reperfusion injury", "Pulmonary embolism"], "html_options": ["Dissection of the ascending aorta", "Intracerebral haemorrhage", "Myocardial reperfusion injury", "Pulmonary embolism"], "corr_idx": 1}, {"id": "1191564", "html_qtxt": "If a fibrinolytic drug is used for the treatment of acute myocardial infarction, which of the following is NOT an absolute contraindication?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Prolonged or traumatic CPR</strong> is a relative contraindication, not an absolute.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307eb16b591-dcb2-4be8-b62c-788f22494394.jpg\">", "options": ["Prolonged or traumatic CPR", "Ischemic stroke within the past 3 months", "Any prior intracranial bleeding", "Intracranial malignancy"], "html_options": ["Prolonged or traumatic CPR", "Ischemic stroke within the past 3 months", "Any prior intracranial bleeding", "Intracranial malignancy"], "corr_idx": 0}, {"id": "1191570", "html_qtxt": "A 65-year-old woman with atrial fibrillation was prescribed medication to prevent stroke. She develops a lesion as shown in the photograph taken fourth and sixth days after the drug was begun, respectively. Which of the following drugs is most likely responsible for the findings seen in this patient?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307c38d9b8d-af51-41ad-b099-ba7a514ea8e3.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Warfarin, a coumarin anticoagulant, inhibits epoxide reductase, which blocks the ability to activate vitamin K.</li>\n<li>This prevents the vitamin K-dependent gamma-carboxylation of coagulation factors II, VII, IX, and X, thus inhibiting their synthesis.</li>\n<li>Warfarin similarly inhibits the vitamin-dependent synthesis of protein C and S, which have anticoagulant properties resulting from their inhibition of activated factors VIII and V.</li>\n<li>Because warfarin acts by inhibiting the synthesis of vitamin K-dependent factors, the factors affected first will be those with the shortest half-lives, which are protein C and factor VIIa.</li>\n<li>Thus, warfarin has an initial paradoxical procoagulant effect because of a rapid reduction in protein C, while activity of most of the endogenous clotting factors (vitamin-dependent factors within the common and intrinsic coagulation pathways, I, IX, and X) persists.</li>\n<li>This can lead to a state of hyper-coagulability and thrombosis. Warfarin may cause <strong>necrosis of the skin </strong>(typically on the breasts, buttocks, thighs, and abdomen), generally during the first several days of therapy.</li>\n<li>The lesions are initially sharply demarcated, erythematous, and purpuric. They may resolve or progress to large, irregular, hemorrhagic bullae that can eventually become necrotic.</li>\n<li>Patients receiving a large loading dose of warfarin or who have an existing protein C deficiency are most susceptible. Warfarin should be discontinued immediately, and heparin, vitamin K, and protein C should be used in therapy. Despite treatment, approximately 50% of patients will require skin grafting.</li>\n</ul>", "options": ["Clopidogrel", "Enoxaparin", "Heparin", "Warfarin"], "html_options": ["Clopidogrel", "Enoxaparin", "Heparin", "Warfarin"], "corr_idx": 3}]}, {"moduleId": 1008547, "name": "Steroids and Calcium metabolism", "questions": [{"id": "1166351", "html_qtxt": "A 34-year-old woman comes for a follow-up visit 2 months after RAIA. She reports improved symptoms but new-onset double vision. Examination shows conjunctival injection, proptosis, and lid lag. Slit-lamp examination reveals mild corneal ulcerations. The patient is given an additional medication that improves her diplopia and proptosis. What drug is that?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Glucocorticoids are the treatment of choice for moderate-to-severe Graves ophthalmopathy</strong>, particularly when it is triggered or worsened by radioactive iodine ablation (RAIA).</p>\r\n<ul>\r\n<li><strong>RAIA is associated with the development or exacerbation of Graves ophthalmopathy</strong> due to increased levels of anti-TSH receptor antibodies post-treatment.</li>\r\n<li>These antibodies stimulate:\r\n<ul>\r\n<li>Orbital fibroblasts &rarr; &uarr; Glycosaminoglycan (GAG) synthesis</li>\r\n<li>Orbital adipocytes &rarr; &uarr; Proliferation</li>\r\n</ul>\r\n</li>\r\n<li>GAGs are <strong>hyperosmolar</strong>, drawing fluid into the interstitial space and causing <strong>oedema</strong>.</li>\r\n<li><strong>Increased GAGs + oedema + adipocyte proliferation</strong> &rarr; &uarr; Orbital pressure &rarr; <strong>Exophthalmos, ophthalmoplegia, diplopia, corneal ulceration</strong>.</li>\r\n<li><strong>Glucocorticoids (e.g., prednisolone)</strong> reduce orbital inflammation and symptoms through:\r\n<ul>\r\n<li>Anti-inflammatory and immunosuppressive action</li>\r\n<li>Inhibition of GAG production</li>\r\n<li>&darr; Orbital oedema and pressure</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001344d4e08-3f9f-40c2-a4c8-69886288e1db.png\">\r\n<p><strong>(Other options ruled out)</strong></p>", "options": ["Propranolol", "PTU", "Steroids", "Diuretics"], "html_options": ["Propranolol", "PTU", "Steroids", "Diuretics"], "corr_idx": 2}, {"id": "1166373", "html_qtxt": "A 45-year-old woman has been on L-thyroxine therapy for 2 years with adequate therapeutic response. However, with all of the following drugs, the dose of L-thyroxine is to be increased except:", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Certain drugs and conditions can either increase or decrease the requirement for L-thyroxine therapy by affecting its <strong>absorption, metabolism, or protein binding</strong>. Glucocorticoids like prednisone <strong>decrease serum TBG</strong> levels and may <strong>reduce</strong> the need for thyroxine supplementation, making them the <strong>exception</strong> in this list.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510016476cd30-1dfe-4f11-bc98-5dbaf506a492.png\">\r\n<p><strong>(Other options ruled out)</strong></p>\r\n<ul>\r\n<li>Estrogens and SERMs <strong>increase</strong> TBG levels &rarr; more T4 is protein-bound &rarr; less free T4 &rarr; dose needs to be <strong>increased</strong>.</li>\r\n<li>Omeprazole <strong>decreases absorption</strong> by reducing gastric acidity.</li>\r\n<li>Enzyme inducers like <strong>phenytoin, carbamazepine</strong> accelerate <strong>hepatic metabolism</strong> of thyroid hormones.</li>\r\n<li>Propranolol <strong>blocks peripheral conversion</strong> of T4 to T3, possibly reducing effectiveness.</li>\r\n<li><strong>Glucocorticoids</strong> like prednisone reduce TBG levels, thus <strong>increasing free T4</strong> availability &rarr; dose of L-thyroxine may be <strong>lowered</strong>.</li>\r\n</ul>", "options": ["Propranolol", "Prednisone", "OCP", "Omeprazole"], "html_options": ["Propranolol", "Prednisone", "OCP", "Omeprazole"], "corr_idx": 1}, {"id": "1166379", "html_qtxt": "A 63-year-old man presents with headaches and back pain since 6 months. Examination shows mild sensorineural hearing loss. Serum concentration of alkaline phosphatase is increased. An X-ray of the skull is shown. The most appropriate pharmacotherapy for this patient is a drug that has which of the following mechanisms of action?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510016e0d52d4-a447-4244-9c9a-ece4dc299b9d.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The combination of <strong>hearing loss, headaches, and an elevated alkaline phosphatase concentration</strong> is concerning for a diagnosis of <strong>Paget's disease</strong> of bone.</p>\r\n<ul>\r\n<li>The x-ray showing characteristic deformities of bone, including <strong>thickening of the calvaria, sclerotic and osteolytic lesions, and osteoblastic lesions</strong>, confirms the diagnosis.</li>\r\n<li>The mainstay of<strong> treatment</strong> for Paget's disease of bone is <strong>bisphosphonate therapy</strong>, which functions by inducing apoptosis of osteoclasts. These drugs bind directly to the bone surface and are eventually taken up by osteoclasts during bone resorption. Once within a cell, they interfere with osteoclast survival, leading to apoptosis and reduced bone resorption.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510011e334d4b-2c08-4446-ae63-cdc01f2212f1.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Inhibition of nuclear factor-KB (Option A):</strong> This is the mechanism of <strong>denosumab</strong>, a monoclonal antibody against RANKL. It is used for osteoporosis and malignancy-related bone loss, <strong>not first-line</strong> for Paget's disease.</p>\r\n<p><strong>Formation of DNA strand breaks (Option B):</strong> This is characteristic of <strong>alkylating agents or chemotherapeutic drugs</strong> like bleomycin or cyclophosphamide. These are <strong>not used</strong> in Paget's disease.</p>\r\n<p><strong>Stimulation of osteoblast activity (Option C):</strong> Drugs like <strong>teriparatide</strong> stimulate osteoblasts but are <strong>contraindicated in Paget's disease</strong> due to the risk of osteosarcoma and high bone turnover states.</p>", "options": ["Inhibition of nuclear factor-KB", "Formation of DNA strand breaks", "Stimulation of osteoblast activity", "Apoptosis of osteoclasts"], "html_options": ["Inhibition of nuclear factor-KB", "Formation of DNA strand breaks", "Stimulation of osteoblast activity", "Apoptosis of osteoclasts"], "corr_idx": 3}, {"id": "1166384", "html_qtxt": "Which of the following inhibits the enzyme farnesyl pyrophosphate synthase, disrupting osteoclast metabolism and promoting osteoclast apoptosis?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Risedronate is a third-generation nitrogen-containing bisphosphonate that acts by inhibiting <strong>farnesyl pyrophosphate synthase</strong>, a key enzyme in the mevalonate pathway. This inhibition impairs osteoclast function and promotes apoptosis, thereby reducing bone resorption.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251003a81c0f04-36cf-4331-9bcb-461e164790d3.png\">\r\n<p><strong>(Other options ruled out)</strong></p>\r\n", "options": ["Etidronate", "Risedronate", "Raloxifene", "Teriparatide"], "html_options": ["Etidronate", "Risedronate", "Raloxifene", "Teriparatide"], "corr_idx": 1}, {"id": "1166388", "html_qtxt": "A 75-year-old woman presented with progressive pain and swelling of her right jaw over the past 8 weeks. She was diagnosed with osteoporosis 12 months ago, on oral alendronate to be taken weekly. Intraoral examination shows gingival erythema and swelling around the right lower molars without purulent discharge. A part of the alveolar bone of the mandible in the same area is exposed. Which of the following is most likely to have prevented this patient's orofacial disease?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The patient presents with signs suggestive of <strong>medication-related osteonecrosis of the jaw (MRONJ)</strong>, a complication seen with long-term <strong>bisphosphonate</strong> use, such as <strong>alendronate</strong>.</p>\r\n<ul>\r\n<li><strong>Key risk factor:</strong> Invasive dental procedures in patients on antiresorptive therapy (e.g., bisphosphonates or RANKL inhibitors).</li>\r\n<li><strong>Prevention strategies include:</strong>\r\n<ul>\r\n<li><strong>A comprehensive dental evaluation</strong> prior to starting therapy to address dental infections or unrestorable teeth.</li>\r\n<li><strong>Daily oral care</strong>: Proper oral hygiene measures such as <strong>oral rinsing</strong>, brushing, flossing, and routine dental visits are strongly advised after therapy initiation.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Management is conservative</strong>: Antibiotics, improved oral hygiene, and minimal debridement; <strong>surgery is avoided</strong> unless necessary.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Antibiotic prophylaxis (Option A):</strong> May be used before dental procedures, but does <strong>not prevent</strong> chronic MRONJ if hygiene is neglected. It plays a supportive role, not a preventive one.</p>\r\n<p><strong>Calcium supplementation (Option B):</strong> Used to enhance bone mineral density in osteoporosis, but has <strong>no role</strong> in preventing osteonecrosis of the jaw.</p>\r\n<p><strong>Smoking/tobacco cessation (Option C):</strong> While smoking is a general risk factor for poor wound healing, it is <strong>not the primary preventive measure</strong> for bisphosphonate-associated jaw necrosis.</p>", "options": ["Antibiotic prophylaxis", "Calcium supplementation", "Smoking/tobacco cessation", "Oral rinsing"], "html_options": ["Antibiotic prophylaxis", "Calcium supplementation", "Smoking/tobacco cessation", "Oral rinsing"], "corr_idx": 3}, {"id": "1166390", "html_qtxt": "Which of the following drugs acts by mimicking osteoprotegerin?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Denosumab</strong> acts by binding to <strong>RANK ligand (RANKL)</strong>, mimicking the natural action of <strong>osteoprotegerin</strong>. This inhibits osteoclast differentiation, activation, and survival, thereby reducing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.</p>\r\n<ul>\r\n<li>It is a fully human monoclonal antibody with high affinity for RANKL.</li>\r\n<li>It effectively inhibits the interaction of RANKL with its receptor RANK on osteoclasts and osteoclast precursors.</li>\r\n<li>Particularly indicated in patients at high risk of fracture and in those intolerant or unresponsive to bisphosphonates.</li>\r\n<li>Denosumab is administered subcutaneously every 6 months.</li>\r\n</ul>\r\n<p><strong>Note:</strong> Because it mimics osteoprotegerin - a decoy receptor for RANKL - it prevents RANKL from activating RANK, which would otherwise promote osteoclast formation and bone resorption.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Raloxifene (Option A):</strong> A selective estrogen receptor modulator (SERM); it reduces bone resorption by estrogenic agonism on bone, not by inhibiting RANKL.</p>\r\n<p><strong>Teriparatide (Option B):</strong> Recombinant PTH (1-34); increases bone formation by stimulating osteoblast activity; does not interact with RANKL or mimic osteoprotegerin.</p>\r\n<p><strong>Calcitonin (Option D):</strong> A Hormone that directly inhibits osteoclast activity and decreases bone resorption but does not mimic osteoprotegerin or inhibit RANKL.</p>", "options": ["Raloxifene", "Teriparatide", "Denosumab", "Calcitonin"], "html_options": ["Raloxifene", "Teriparatide", "Denosumab", "Calcitonin"], "corr_idx": 2}, {"id": "1166392", "html_qtxt": "The active metabolites of vitamin D act through a nuclear receptor to produce which of the following effects?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The active metabolites of vitamin D - particularly 1,25-dihydroxyvitamin D (calcitriol) - bind to nuclear vitamin D receptors and regulate transcription of genes involved in calcium and phosphate homeostasis.</p>\r\n<p>They <strong>increase serum calcium and phosphate</strong> by:</p>\r\n<ul>\r\n<li>Promoting <strong>intestinal absorption</strong> of calcium and phosphate</li>\r\n<li>Enhancing <strong>bone resorption</strong></li>\r\n<li>Reducing <strong>renal excretion</strong> of calcium and phosphate</li>\r\n<li>Inhibiting <strong>parathyroid hormone (PTH)</strong> formation through feedback suppression</li>\r\n</ul>\r\n<p>These effects collectively help in maintaining mineral ion homeostasis and bone turnover.</p>\r\n<p>Thus, they help increase serum calcium and phosphate levels and maintain mineral ion homeostasis.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251003cb089dbe-41bf-4085-8463-8677799b7646.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Decrease the absorption of calcium from bone (Option A):</strong> Incorrect; active vitamin D enhances bone resorption along with PTH to raise calcium levels.</p>\r\n<p><strong>Increase PTH formation (Option B):</strong> Incorrect; active vitamin D inhibits PTH production via negative feedback.</p>\r\n<p><strong>Increase renal production of erythropoietin (Option C):</strong> Incorrect; erythropoietin synthesis is primarily regulated by hypoxia, not vitamin D.</p>", "options": ["Decrease the absorption of calcium from bone", "Increase PTH formation", "Increase renal production of erythropoietin", "Increase the absorption of calcium from the gastrointestinal tract"], "html_options": ["Decrease the absorption of calcium from bone", "Increase PTH formation", "Increase renal production of erythropoietin", "Increase the absorption of calcium from the gastrointestinal tract"], "corr_idx": 3}, {"id": "1166393", "html_qtxt": "A 60-year-old postmenopausal woman with osteoporosis began oral therapy with alendronate. What would you not advise?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Alendronate is an oral bisphosphonate that can cause significant <strong>oesophageal irritation</strong>, ulcers, and even strictures if not taken properly. It should <strong>never be taken with food</strong>, especially <strong>fatty food</strong>, because it <strong>markedly reduces absorption</strong>. Instead:</p>\r\n<ul>\r\n<li>It should be taken <strong>on an empty stomach with a full glass of water</strong>, and the patient should <strong>remain upright for at least 30 minutes</strong> to minimise oesophageal adverse effects.</li>\r\n<li>Patients should <strong>avoid any food, calcium supplements, or other medications</strong> for at least 30-60 minutes after ingestion to ensure proper absorption.</li>\r\n<li><strong>Supplemental calcium and vitamin D</strong> are necessary to correct or prevent deficiencies and improve therapeutic outcomes.</li>\r\n<li>Alendronate <strong>should be given prior to starting teriparatide</strong> if using sequential therapy, since bisphosphonates reduce bone resorption and preserve bone mass, and teriparatide stimulates bone formation.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001358184dd-efe0-4a68-bfd4-ce2f9af6c0ed.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Advise to drink large quantities of water with the tablets and remain in an upright position for at least 30 min (Option A)</strong>: Prevents oesophagal irritation, ensures the tablet passes rapidly into the stomach.</p>\r\n<p><strong>Start calcium and vitamin D (Option C): </strong>Necessary to prevent hypocalcemia and optimise therapeutic response to bisphosphonates.</p>\r\n<p><strong>It should be started before treatment with teriparatide (Option D):</strong> Sequential use starting with bisphosphonates and followed by teriparatide is standard in patients with high fracture risk</p>", "options": ["Advise to drink large quantities of water with the tablets and remain in an upright position for at least 30 minutes.", "Advise to eat fatty food with tablets and remain in an upright position for at least 30 minutes.", "Start calcium and vitamin D", "It should be started before treatment with teriparatide."], "html_options": ["Advise to drink large quantities of water with the tablets and remain in an upright position for at least 30 minutes.", "Advise to eat fatty food with tablets and remain in an upright position for at least 30 minutes.", "Start calcium and vitamin D", "It should be started before treatment with teriparatide."], "corr_idx": 1}, {"id": "1166394", "html_qtxt": "Which of the following is not true about Teriparatide ?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Teriparatide is administered in a pulsatile (intermittent) manner</strong> to selectively stimulate osteoblasts and promote bone formation. Continuous administration would instead favour bone resorption due to increased osteoclast activity.</p>\r\n<ul>\r\n<li><strong>Mechanism of Action:</strong>\r\n<ul>\r\n<li>Teriparatide is a recombinant human PTH(1-34).</li>\r\n<li>Stimulates osteoblastic bone formation when given intermittently.</li>\r\n<li>Enhances bone mineral density (BMD), especially at vertebral and femoral sites.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Therapeutic Uses:</strong>\r\n<ul>\r\n<li>Indicated in osteoporosis with high fracture risk.</li>\r\n<li>Also used in men and postmenopausal women at high risk of vertebral or nonvertebral fractures.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Adverse Effects and Contraindications:</strong>\r\n<ul>\r\n<li><strong>Increased risk of osteosarcoma</strong> observed in animal studies.</li>\r\n<li>Contraindicated in patients with:\r\n<ul>\r\n<li><strong>Prior skeletal radiation therapy</strong></li>\r\n<li><strong>Paget disease</strong></li>\r\n<li><strong>Unexplained elevated alkaline phosphatase</strong></li>\r\n<li><strong>Bone metastasis or skeletal malignancies</strong></li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Acts by increased bone growth (Option A):</strong> Teriparatide stimulates new bone formation via osteoblast activation.</p>\r\n<p><strong>Increased risk of osteosarcoma (Option C):</strong> Seen in preclinical (rat) studies with long-term use.</p>\r\n<p><strong>Contraindicated in patients with prior radiation therapy (Option D):</strong> Due to increased osteosarcoma risk in previously irradiated bone.</p>", "options": ["Acts by increased bone growth", "Administered in continuous fashion", "Increased risk of osteosarcoma", "Contraindicated in patient with prior radiation therapy"], "html_options": ["Acts by increased bone growth", "Administered in continuous fashion", "Increased risk of osteosarcoma", "Contraindicated in patient with prior radiation therapy"], "corr_idx": 1}, {"id": "1166396", "html_qtxt": "Which of the following drugs is most useful for the treatment of hypercalcemia in Paget's disease?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Pamidronate</strong> is a bisphosphonate that <strong>inhibits osteoclast-mediated bone resorption</strong>. It is used parenterally to<strong> manage hypercalcemia in Paget's disease</strong>, as well as in <strong>malignancy-associated hypercalcemia</strong>. It is 100-1000 times more potent than etidronate and is one of the preferred agents for treating increased skeletal remodelling and calcium release.</p>\r\n<ul>\r\n<li>Paget's disease involves increased bone resorption and disorganised bone formation, often accompanied by hypercalcemia.</li>\r\n<li>Pamidronate acts by binding to hydroxyapatite in bone and inhibiting osteoclast activity, thereby reducing calcium release.</li>\r\n<li>It is preferred in patients requiring rapid reduction of serum calcium, especially when oral bisphosphonates are less feasible.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001930b3719-dbef-4ea6-80f0-2cb797e9843b.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Hydrochlorothiazide (Option A):</strong> A thiazide diuretic; it reduces urinary calcium excretion and is contraindicated in hypercalcemia. It is not used in Paget's disease.</p>\r\n<p><strong>Raloxifene (Option C):</strong> A selective estrogen receptor modulator (SERM); used for osteoporosis prevention and treatment. It has no role in the acute management of hypercalcemia or Paget's disease.</p>\r\n<p><strong>Teriparatide (Option D):</strong> Recombinant human PTH analogue that stimulates bone formation. It may worsen hypercalcemia and is contraindicated in Paget's disease.</p>", "options": ["Hydrochlorothiazide ", "Pamidronate", "Raloxifene", "Teriparatide"], "html_options": ["Hydrochlorothiazide ", "Pamidronate", "Raloxifene", "Teriparatide"], "corr_idx": 1}, {"id": "1166397", "html_qtxt": "A 56-year-old woman with a history of osteoporosis comes for a Colles' fracture after a recent fall. Which of the following drugs is most appropriate for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Risedronate is a third-generation bisphosphonate and the drug of choice for the treatment and prevention of postmenopausal osteoporosis, including in patients with a fragility fracture (like a Colles' fracture). It inhibits osteoclast-mediated bone resorption, thereby improving bone mineral density and reducing the risk of future fractures.</p>\r\n<ul>\r\n<li>Bisphosphonates like <strong>risedronate, alendronate, and ibandronate</strong> are considered first-line therapies for osteoporosis.</li>\r\n<li>Risedronate is well-absorbed, localises to bone, and is retained in the matrix where it inhibits osteoclastic activity.</li>\r\n<li>It is effective in reducing vertebral and nonvertebral fractures.</li>\r\n<li>Use is contraindicated in patients with oesophageal abnormalities or difficulty swallowing.</li>\r\n</ul>\r\n<p>For optimal efficacy, risedronate must be taken with a full glass of water at least 30 minutes before the first food or drink of the day.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510014c85c798-b072-4120-a6d9-3697c1bd0b22.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Calcitonin nasal spray (Option A):</strong> A less effective alternative for osteoporosis; mostly used for short-term pain relief in vertebral compression fractures and Paget's disease. Not preferred for long-term osteoporosis management.</p>\r\n<p><strong>Tamoxifene (Option B):</strong> A selective estrogen receptor modulator (SERM) used in estrogen receptor-positive breast cancer prevention and treatment. Though it has partial agonist effects on bone, raloxifene is the preferred SERM for osteoporosis, not tamoxifene.</p>\r\n<p><strong>Transdermal estradiol (Option D):</strong> Estrogen replacement can improve BMD but is not a first-line treatment due to risks of thromboembolism, breast cancer, and cardiovascular disease. Used only when other agents are contraindicated and the patient is symptomatic.</p>", "options": ["Calcitonin nasal spray", "Tamoxifene", "Risedronate", "Transdermal estradiol"], "html_options": ["Calcitonin nasal spray", "Tamoxifene", "Risedronate", "Transdermal estradiol"], "corr_idx": 2}, {"id": "1166399", "html_qtxt": "A 43-year-old woman with ESRD comes in because of pain in her extremities. Serum calcium is 7.8 mg/dL, and parathyroid hormone levels (iPTH) are 370 pg/mL (normal by this assay = 10-60 pg/mL). Calcium-containing phosphate binders and vitamin D are administered until the patient's serum calcium reaches 8.4 mg/dL. At this point, the physician prescribes a drug to treat the patient's osteolysis. Which of the following best describes the mechanism of action of this drug?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Cinacalcet</strong> is a calcimimetic agent that acts by increasing the sensitivity of the calcium-sensing receptor (CaSR) on the parathyroid gland's chief cells to extracellular calcium. This enhanced sensitivity leads to suppression of parathyroid hormone (PTH) secretion.</p>\r\n<ul>\r\n<li><strong>In ESRD</strong>, reduced phosphate excretion leads to hyperphosphatemia &rarr; phosphate binds calcium &rarr;</li>\r\n<li>Hypocalcemia stimulates <strong>parathyroid gland hyperplasia</strong> &rarr; <strong>secondary hyperparathyroidism.</strong></li>\r\n<li>Elevated PTH causes <strong>bone resorption</strong> and <strong>osteolysis</strong>, worsening bone disease</li>\r\n<li><strong>Cinacalcet</strong> is used once serum calcium &ge;8.4 mg/dL, to suppress PTH secretion by mimicking calcium's action on CaSR</li>\r\n<li>Target iPTH level in dialysis patients is <strong>150-300 pg/mL</strong></li>\r\n<li>Other therapies: dietary phosphate restriction, phosphate binders, vitamin D and analogues</li>\r\n<li><strong>Surgery</strong> is indicated when iPTH >800 pg/mL or when pharmacotherapy fails</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Competitive antagonist of the aldosterone receptor (Option A):</strong> Refers to spironolactone or eplerenone; used in hyperaldosteronism or heart failure, not effective in managing hyperparathyroidism.</p>\r\n<p><strong>Inhibits NaCl reabsorption in the early distal convoluted tubule (Option C):</strong> Refers to thiazide diuretics, which increase calcium reabsorption, not used for PTH suppression.</p>\r\n<p><strong>Inhibits the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle (Option D):</strong> Mechanism of loop diuretics like furosemide; leads to calcium loss, may worsen hypocalcemia in ESRD patients.</p>", "options": ["Competitive antagonist of the aldosterone receptor", "Increases sensitivity of the calcium-sensing receptor", "Inhibits NaCI reabsorption in the early distal convoluted tubule", "The Na<sup>+</sup>/K<sup>+</sup>/CIT cotransporter in the thick ascending limb of the loop of Henle"], "html_options": ["Competitive antagonist of the aldosterone receptor", "Increases sensitivity of the calcium-sensing receptor", "Inhibits NaCI reabsorption in the early distal convoluted tubule", "The Na<sup>+</sup>/K<sup>+</sup>/CIT cotransporter in the thick ascending limb of the loop of Henle"], "corr_idx": 1}, {"id": "1166401", "html_qtxt": "A 45-year-old man with goitre undergoes a thyroidectomy. One week later, he develops carpopedal spasms, muscle and abdominal cramps, and tingling of his lips and hands. Laboratory studies show a serum calcium of 6.2 mg/dL and serum phosphate of 5.7 mg/dL. Which of the following drugs will most likely improve this patient's symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient is presenting with signs and symptoms highly suggestive of <strong>hypoparathyroidism</strong>, a condition that occurs most frequently after thyroidectomy or the removal of a parathyroid adenoma. Hypoparathyroidism is a condition of parathyroid hormone (PTH) deficiency leading to decreased calcium levels and other electrolyte abnormalities.</p>\r\n<ul>\r\n<li>Normally, a fall in extracellular fluid ionised calcium concentration leads to stimulation of PTH secretion. When released, PTH enhances active reabsorption of calcium and magnesium from distal tubules and the thick ascending limb in the kidney, enhances the release of calcium from bones and enhances the absorption of calcium in the intestine by increasing the production of activated vitamin D. However, in hypoparathyroidism, PTH levels are greatly reduced, resulting in severe hypocalcemia.</li>\r\n<li>There are three principal reasons for low Ca2<sup>+</sup>in such cases\r\n<ul>\r\n<li>Low PTH reduces renal reabsorption of Ca<sup>++</sup>but increases reabsorption of phosphate.</li>\r\n<li>The resulting high plasma phosphate binds plasma Ca++, so plasma Ca<sup>++</sup></li>\r\n<li>Low PTH causes low production of the active form of vitamin D, so Ca<sup>++</sup>absorption in the small intestine is decreased.</li>\r\n</ul>\r\n</li>\r\n<li>Hypoparathyroidism is characterised by severe hypocalcemia and hyperphosphatemia, resulting in tetany, carpopedal spasms, muscle and abdominal cramps, and tingling of the lips and hands. A positive Chvostek sign (tapping the face in front of the ear elicits tetany) and Trousseau sign (abnormal muscular contractions elicited by applying a blood pressure cuff) will often be noted.\r\n<ul>\r\n<li>Since the blood calcium levels are often very low, either calcium gluconate or vitamin D preparations should be administered to correct the condition. Vitamin D preparations, such as Cholecalciferol, elevate calcium levels and also increase phosphate levels. Another treatment option would be to use the vitamin D3 analogue calcitriol. Calcitrol has a mechanism of action similar to that of cholecalciferol. Ergocalciferol is also used, but has a shorter duration and lower potency than cholecalciferol. Although further elevation of serum phosphate would be undesirable, vitamin D analogues are front-line therapy for hypoparathyroidism; phosphate levels may be addressed with phosphate binders or other measures.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Bumetanide (Option A):</strong> Loop diuretic; promotes calcium excretion, worsening hypocalcemia.</p>\r\n<p><strong>Levothyroxine (Option C):</strong> Replaces thyroid hormone; doesn't address calcium/phosphate imbalance from hypoparathyroidism.</p>\r\n<p><strong>Metolazone (Option D):</strong> Thiazide-like diuretic; mildly retains calcium but not adequate to treat severe hypocalcemia.</p>", "options": ["Bumetanide", "Cholecalciferol", "Levothyroxine", "Metolazone"], "html_options": ["Bumetanide", "Cholecalciferol", "Levothyroxine", "Metolazone"], "corr_idx": 1}]}, {"moduleId": 1008548, "name": "Thyroid and Antithyroid drugs", "questions": [{"id": "1166315", "html_qtxt": "A 38-year-old woman presents with tachycardia, heat intolerance, tremor, and unintentional weight loss. A thyroid scan shows multiple regions of the thyroid taking up excess iodine. She is prescribed a drug that will decrease the synthesis of thyroid hormones and decrease the peripheral conversion of T4 to T3. Which drug is this?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Propylthiouracil (PTU) is the preferred antithyroid agent in certain clinical situations due to its dual mechanism:</p>\r\n<ul>\r\n<li><strong>Inhibits thyroid peroxidase</strong>, thereby blocking organification and coupling steps in thyroid hormone synthesis.</li>\r\n<li><strong>Inhibits peripheral conversion of T4 to T3</strong>, which is especially useful in severe thyrotoxicosis and thyroid storm.</li>\r\n<li>Methimazole and propylthiouracil both decrease the synthesis of thyroid hormone, but only propylthiouracil decreases the peripheral conversion of T4 to T3.\r\n<ul>\r\n<li>These drugs both inhibit thyroid peroxidase, which is the enzyme responsible for oxidation and organification of iodide for its incorporation into T3 and T4. Because it also inhibits peripheral conversion to T3, propylthiouracil may be preferred in severe hyperthyroidism.</li>\r\n</ul>\r\n</li>\r\n<li>Lanreotide is a somatostatin analogue used in secondary hyperthyroidism because somatostatin normally inhibits TSH secretion.</li>\r\n<li>Levothyroxine is a synthetic T4. It is used to treat hypothyroidism and would worsen this patient&rsquo;s condition.</li>\r\n<li>Methimazole decreases the synthesis of thyroid hormone but does not decrease the peripheral conversion of T4 to T3. Octreotide is a somatostatin analogue used in secondary hyperthyroidism because somatostatin normally inhibits TSH secretion.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Lanreotide (Option A):</strong>  Somatostatin analogue; inhibits TSH secretion, but is not used for primary hyperthyroidism.</p>\r\n<p><strong>Levothyroxine (Option B):</strong>  Synthetic T4; used in hypothyroidism, would worsen this patient's condition.</p>\r\n<p><strong>Methimazole (Option C):</strong> Inhibits thyroid peroxidase but does <strong>not</strong>  inhibit peripheral T4 to T3 conversion.</p>", "options": ["Lanreotide", "Levothyroxine ", "Methimazole ", "Propylthiouracil"], "html_options": ["Lanreotide", "Levothyroxine ", "Methimazole ", "Propylthiouracil"], "corr_idx": 3}, {"id": "1166318", "html_qtxt": "A 58-year-old woman with longstanding hypothyroidism was diagnosed with uterine fibroids and started on iron recently. Her other medications include levothyroxine, atorvastatin, and hydrochlorothiazide. A TSH is checked, and it is elevated to 15 mU/L. Which of the following is the most likely reason for her elevated TSH?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>TSH elevation in a patient stable on levothyroxine suggests an issue with absorption or drug interaction. Ferrous sulfate is a known interfering agent that impairs the gastrointestinal absorption of levothyroxine.</p>\r\n<ul>\r\n<li><strong>Levothyroxine</strong>absorption occurs in the duodenum and jejunum and is impaired by iron salts such as <strong>ferrous sulfate</strong>.</li>\r\n<li>TSH elevation may occur despite compliance if <strong>concomitant administration of interfering drugs</strong></li>\r\n<li><strong>Iron salts</strong>are among the factors that <strong>increase levothyroxine dosage requirements</strong>  by reducing absorption.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510015ef65a62-8ab5-4295-b6ad-3233e5b2dbe7.png\">\r\n </li>\r\n<li>An increase in TSH in a patient with hypothyroidism that was previously stable with medication for many years suggests either a failure to take the medication, difficulty with absorption from bowel disease, medication interaction or drug-drug interaction affecting clearance.</li>\r\n<li>In patients with normal body weight taking >200 &mu;g of levothyroxine per day, an elevated TSH strongly suggests noncompliance. Such patients should be encouraged to take two tablets at one time on the day they remember to attempt to reach the weekly target dose; the long drug half-life makes this practice safe.</li>\r\n<li>Other causes of increased thyroxine requirements include malabsorption, such as with celiac disease or small bowel surgery, estrogen therapy, and drugs that interfere with T4 absorption (e.g., ferrous sulfate, cholestyramine) or clearance (e.g., lovastatin, amiodarone, carbamazepine, phenytoin).</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Celiac disease (Option A):</strong>  Can impair absorption, but would also present with other systemic signs and takes time to develop. Less likely than a recent drug interaction.</p>\r\n<p><strong>Medication noncompliance (Option B):</strong> Would typically be suspected if TSH elevation is seen despite no recent change in therapy or addition of new medications.</p>\r\n<p><strong>TSH-secreting pituitary adenoma (Option D):</strong> Rare and typically presents with <strong>high T3/T4 with inappropriately normal or elevated TSH</strong>, not isolated elevated TSH.</p>", "options": ["Celiac disease", "Medication noncompliance", "Poor absorption of levothyroxine due to ferrous sulfate", "TSH-secreting pituitary adenoma"], "html_options": ["Celiac disease", "Medication noncompliance", "Poor absorption of levothyroxine due to ferrous sulfate", "TSH-secreting pituitary adenoma"], "corr_idx": 2}, {"id": "1166320", "html_qtxt": "A 92-year-old woman is admitted to the ICU with depressed consciousness, hypothermia, sinus bradycardia, hypotension, and hypoglycemia. She has a history of hypothyroidism and hypertension. Lab reports show serum sodium of 129 mmol/L, glucose 48 mg/dL, and TSH >100 mIU/L. Which of the following statements regarding this condition is false?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Myxedema coma </strong>is a life-threatening expression of long-standing hypothyroidism most commonly seen in the<strong> elderly</strong>, typically precipitated by<strong>  infections, myocardial infarction, or other systemic illnesses. External warming should be used with caution</strong>, as it may precipitate cardiovascular collapse. <strong>Passive rewarming is preferred over aggressive external warming.</strong></p>\r\n<ul>\r\n<li><strong>Typical features:</strong>Hypothermia, altered consciousness, bradycardia, hypotension, and hypoglycemia.</li>\r\n<li><strong>Precipitating factors:</strong>Infection, congestive heart failure, narcotic use, and cold exposure.</li>\r\n<li><strong>Therapy includes:</strong>\r\n<ul>\r\n<li><strong>IV levothyroxine</strong>for thyroid hormone repletion</li>\r\n<li><strong>IV glucocorticoids</strong>to address possible adrenal insufficiency</li>\r\n<li><strong>Avoiding hypotonic solutions,</strong>which can worsen hyponatremia</li>\r\n<li><strong>Supportive care</strong>, careful fluid management, and cautious warming (external warming may worsen hypotension)</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Hypotonic intravenous solutions should be avoided (Option B):</strong>  May worsen hyponatremia or lead to fluid overload.</p>\r\n<p><strong>IV levothyroxine with IV glucocorticoids (Option C):</strong> Recommended due to the risk of adrenal insufficiency.</p>\r\n<p><strong>Occurs in the elderly and is often precipitated by illness (Option D):</strong> Frequently triggered by systemic insults in the elderly.</p>", "options": ["External warming is a critical feature of therapy in patients with a temperature &lt; 34C.", "Hypotonic intravenous solutions should be avoided.", "Intravenous (IV) levothyroxine should be administered with IV glucocorticoids.", "This condition occurs almost exclusively in the elderly and often is precipitated by an unrelated medical illness."], "html_options": ["External warming is a critical feature of therapy in patients with a temperature < 34C.", "Hypotonic intravenous solutions should be avoided.", "Intravenous (IV) levothyroxine should be administered with IV glucocorticoids.", "This condition occurs almost exclusively in the elderly and often is precipitated by an unrelated medical illness."], "corr_idx": 0}, {"id": "1166322", "html_qtxt": "A 24-year-old woman was found to have mild hyperthyroidism due to Graves disease. She appears to be in good health otherwise. The decision is made to begin treatment with methimazole. It reduces serum concentration of T3 primarily by which of the following mechanisms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Methimazole and propylthiouracil are antithyroid drugs classified as thioamides.</p>\r\n<p>They inhibit thyroid hormone synthesis by blocking thyroid peroxidase&ndash;mediated reactions.</p>\r\n<ul>\r\n<li>This action prevents <strong>oxidation of iodide</strong>and <strong>organification</strong>, thereby stopping the incorporation of iodine into tyrosine residues of thyroglobulin.</li>\r\n<li>As a result, production of monoiodotyrosine (MIT) and diiodotyrosine (DIT) is impaired, which are essential precursors of thyroid hormones T3 and T4.</li>\r\n<li>This mechanism decreases the formation and eventual secretion of T3 and T4, helping in the management of hyperthyroidism.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510019e13fbad-977c-4414-8159-1b9fa4143e9f.png\">\r\n \r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403257909598b-6610-436e-abe0-b84663b256d7.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Accelerating the peripheral metabolism of T3 (Option A):</strong>  Not a mechanism of thioamides. PTU blocks the conversion of T4 to T3, but not via enhanced T3 metabolism.</p>\r\n<p><strong>Inhibiting the proteolysis of thyroid-binding globulin (Option B):</strong>   Thioamides act on thyroid hormone synthesis, not on binding globulins.</p>\r\n<p><strong>Inhibiting the uptake of iodide by cells in the thyroid (Option C):</strong> Iodide uptake is blocked by ionic inhibitors (e.g., perchlorate, thiocyanate), not by methimazole.</p>", "options": ["Accelerating the peripheral metabolism of T3", "Inhibiting the proteolysis of thyroid-binding globulin", "Inhibiting the uptake of iodide by cells in the thyroid ", "Preventing the addition of iodine to tyrosine residues on thyroglobulin"], "html_options": ["Accelerating the peripheral metabolism of T3", "Inhibiting the proteolysis of thyroid-binding globulin", "Inhibiting the uptake of iodide by cells in the thyroid ", "Preventing the addition of iodine to tyrosine residues on thyroglobulin"], "corr_idx": 3}, {"id": "1166323", "html_qtxt": "A 65-year-old woman with multinodular goitre (MNG) is scheduled for a total thyroidectomy. Which of the following drugs is administered for 10-14 days preoperatively to reduce the vascularity of the thyroid gland?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Lugol&rsquo;s solution</strong>, which contains <strong>elemental iodine and potassium iodide</strong>, is used preoperatively for thyroidectomy to reduce thyroid gland vascularity and hormone synthesis.</p>\r\n<ul>\r\n<li><strong>Mechanism of action:</strong>\r\n<ul>\r\n<li>It decreases the size, vascularity, and friability of the hyperplastic thyroid gland.</li>\r\n<li>It acutely inhibits the organification and release of thyroid hormone from the thyroid gland.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Use:</strong>\r\n<ul>\r\n<li>Commonly administered for 10-14 days before surgery to facilitate a safer thyroidectomy.</li>\r\n<li>Its effects begin within 1-2 days and peak around 10-14 days.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Caution:</strong>\r\n<ul>\r\n<li>Should not be used long-term as it may lead to an 'escape phenomenon' where hormone synthesis resumes.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001bfa7be30-ed2a-432c-aea9-59185c1ea09a.png\">\r\n ", "options": ["Levothyroxine ", "Lugol's solution ", "Prednisone", "Radioactive iodine"], "html_options": ["Levothyroxine ", "Lugol's solution ", "Prednisone", "Radioactive iodine"], "corr_idx": 1}, {"id": "1166324", "html_qtxt": "A 36-year-old woman recently diagnosed with Graves' disease presents with fever, malaise, chills, and sore throat. She was started on methimazole 2 weeks ago. Her laboratory investigations reveal the following:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322e39b7ebe-782b-42e6-b47d-e87c3f37e529.jpg\"><br>Which of the following actions by the physician is most appropriate?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient presents with signs of infection and neutropenia, a known early adverse effect of methimazole. The absolute neutrophil count (ANC) here is <strong>8% of 3000 = 240/mm&sup3;</strong>, indicating <strong>agranulocytosis</strong> (<500/mm&sup3;), a medical emergency.</p>\r\n<ul>\r\n<li>Methimazole-induced agranulocytosis typically occurs <strong>within 2-12 weeks</strong>of therapy.</li>\r\n<li>Symptoms include <strong>fever, malaise, and sore throat</strong>, which precede or coincide with neutropenia.</li>\r\n<li>Once agranulocytosis is confirmed or strongly suspected, the drug must be <strong>immediately discontinued</strong>.</li>\r\n<li><strong>Switching to PTU is not recommended</strong>, as it has a similar risk of agranulocytosis.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001750e73d8-2e5f-400b-b2e3-135b995a9bd8.png\">\r\n \r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Decrease the dose of methimazole (Option A):</strong>    Not sufficient or safe; agranulocytosis is idiosyncratic and unrelated to dose.</p>\r\n<p><strong>Switch to PTU (Option C):</strong>  Contraindicated due to shared risk profile.</p>\r\n<p><strong>Conservative management (Option D):</strong>   Delaying drug cessation risks septic complications</p>", "options": ["Decrease the dose of methimazole", "Discontinue methimazole", "Switch to PTU", " Conservative management"], "html_options": ["Decrease the dose of methimazole", "Discontinue methimazole", "Switch to PTU", " Conservative management"], "corr_idx": 1}, {"id": "1166326", "html_qtxt": "A 54-year-old woman is brought to the emergency department after an accidental ingestion of a large dose of radioactive iodine. Which of the following pharmacologic agents should be administered immediately to prevent complications from this exposure?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Potassium iodide (KI)</strong> should be administered immediately to reduce the risk of radiation-induced thyroid damage.</p>\r\n<ul>\r\n<li>KI blocks the uptake of radioactive iodine (&sup1;&sup3;&sup1;I) by saturating the thyroid gland with stable iodine, thus preventing the accumulation of radioactive isotopes.</li>\r\n<li>It acts by acutely inhibiting the synthesis and release of thyroid hormones, known as the <strong>Wolff-Chaikoff effect</strong>.</li>\r\n<li>This protective effect is effective if administered within hours of exposure.</li>\r\n<li>KI is also used in hyperthyroidism and thyroid storm management due to its inhibitory action on thyroid hormone release.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100150452db5-7b14-4aef-bceb-28897d61b6e9.png\">\r\n \r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>PTU (Option B):</strong> Antithyroid drug that inhibits thyroid peroxidase and peripheral T4&rarr;T3 conversion; not effective in immediate blocking of &sup1;&sup3;&sup1;I uptake.</p>\r\n<p><strong>Methimazole (Option C):</strong> Inhibits thyroid peroxidase; not effective in emergency radioactive iodine exposure.</p>\r\n<p><strong>Dexrazoxane (Option D):</strong> Iron-chelating agent used to prevent anthracycline-induced cardiotoxicity; not relevant here.</p>", "options": ["KI", "PTU", "Methimazole", "Dexrazoxane"], "html_options": ["KI", "PTU", "Methimazole", "Dexrazoxane"], "corr_idx": 0}, {"id": "1166327", "html_qtxt": "A 24-year-old woman at 8 weeks of gestation presents with progressive fatigue for 1 month. She has had a 3.2-kg weight loss despite increased appetite, insomnia, and heightened anxiety. Her eyes are prominent, and the thyroid is diffusely enlarged. Serum TSH is 0.1 &mu;U/mL. What is the most appropriate next step in management?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>PTU (propylthiouracil) is the preferred treatment during the first trimester of pregnancy in Graves' disease. Methimazole is avoided in early pregnancy due to teratogenicity, whereas PTU has a lower placental transfer rate and reduced risk of embryopathy.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001c749e92e-c8b2-45c7-9b0f-2a38bd008b3b.png\">\r\n \r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Lugol's iodine (Option A):</strong> Used preoperatively for thyroidectomy; contraindicated in the first trimester due to transient suppression followed by rebound thyrotoxicosis.</p>\r\n<p><strong>Atenolol (Option C):</strong> Avoided in pregnancy due to risk of fetal growth restriction; beta-blockers like propranolol are preferred if needed.</p>\r\n<p><strong>Methimazole (Option D):</strong> Teratogenic in the first trimester; not used due to risk of congenital malformations.</p>", "options": ["Lugol's iodine", "PTU", "Atenolol", "Methimazole"], "html_options": ["Lugol's iodine", "PTU", "Atenolol", "Methimazole"], "corr_idx": 1}, {"id": "1166332", "html_qtxt": "Initiating T4 therapy for an elderly patient with long-standing hypothyroidism, it is important to begin with small doses to avoid which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>T4 therapy should be initiated cautiously in elderly hypothyroid patients to avoid cardiac overstimulation.</strong></p>\r\n<ul>\r\n<li>Elderly individuals and patients with long-standing hypothyroidism are highly sensitive to the cardiovascular effects of levothyroxine.</li>\r\n<li>These patients may have decreased cardiac reserve and underlying ischemic heart disease, making them vulnerable to arrhythmias and cardiac failure.</li>\r\n<li>Therapy should be initiated with a low dose (e.g., 12.5-25 &mu;g/day) and titrated gradually based on TSH and clinical response.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001d31a978c-9c1f-4040-be2b-07579e721386.png\">\r\n \r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Flare-up of exophthalmos (Option A):</strong> Seen in hyperthyroidism (especially Graves'disease), not relevant to T4 therapy in hypothyroid patients.</p>\r\n<p><strong>Seizures (Option B):</strong> Not a typical complication of T4 initiation in hypothyroidism.</p>\r\n<p><strong>Hemolysis (Option C):</strong> Not associated with thyroid hormone replacement therapy.</p>", "options": ["Flare-up of exophthalmos", "Seizures", "Hemolysis", "Overstimulation of the heart"], "html_options": ["Flare-up of exophthalmos", "Seizures", "Hemolysis", "Overstimulation of the heart"], "corr_idx": 3}, {"id": "1166333", "html_qtxt": "A 55-year-old woman presents with the complaint of 'something wrong with her heart, heart jumping out of her chest.' Lab tests confirm hyperthyroidism. Which of the following is a drug that produces a permanent reduction in thyroid activity?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Radioactive iodine (I131)</strong> is the <strong>only medical therapy that produces a permanent reduction in thyroid activity</strong>.</p>\r\n<ul>\r\n<li>I131 destroys thyroid tissue via &beta;-particle emission, taken up into follicular cells via <strong>sodium/iodine symporter (NIS)</strong>.</li>\r\n<li><strong>Gamma rays</strong>: diagnostic utility</li>\r\n<li><strong>Beta rays</strong>: therapeutic utility</li>\r\n</ul>\r\n<h4><strong>Indications:</strong></h4>\r\n<ul>\r\n<li>Toxic multinodular goitre (MNG) and toxic adenoma with high radioactive iodine uptake</li>\r\n<li>Graves' disease not controlled with antithyroid drugs (ATDs) due to:\r\n<ul>\r\n<li>Refractory hyperthyroidism</li>\r\n<li>Contraindications to ATDs (e.g., liver disease)</li>\r\n<li>Severe adverse effects from ATDs</li>\r\n<li>High surgical risk (due to comorbidities, previous neck surgery/radiation)</li>\r\n<li>Limited life expectancy</li>\r\n</ul>\r\n</li>\r\n<li>Thyrotoxic periodic paralysis</li>\r\n<li>Large or compressive nontoxic goitre</li>\r\n<li>Postoperative treatment of certain thyroid malignancies</li>\r\n</ul>\r\n<h4><strong>Contraindications:</strong></h4>\r\n<ul>\r\n<li>Pregnancy or breastfeeding</li>\r\n<li>Children < 5 years of age</li>\r\n<li>Initial treatment for suspected/confirmed thyroid malignancy</li>\r\n<li>Moderate to severe Graves ophthalmopathy</li>\r\n<li>Inability to follow radiation safety precautions</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Propylthiouracil (Option B):</strong> Reversible antithyroid drug; inhibits TPO and peripheral T4&rarr;T3 conversion. Does not destroy thyroid tissue.</p>\r\n<p><strong>Thiocyanate (Option C):</strong> An Anion inhibitor that blocks iodide uptake via NIS; rarely used due to <strong>unpredictable efficacy</strong>.</p>\r\n<p><strong>Propranolol (Option D):</strong> Used for <strong>symptom control</strong> (palpitations, tremor); blocks peripheral conversion of T4 to T3 but has no impact on hormone synthesis or gland structure.</p>", "options": ["I131", "Propylthiouracil", "Thiocyanate (SCN ) ", "Propranolol"], "html_options": ["I131", "Propylthiouracil", "Thiocyanate (SCN ) ", "Propranolol"], "corr_idx": 0}, {"id": "1166335", "html_qtxt": "A 56-year-old woman presents with complaints of fatigue, sluggishness, and weight gain. She has been taking T4 for the past 5 years without significant problems regarding her energy level. Her recent history is significant for a diagnosis of arrhythmia, and she is currently taking an anti-arrhythmic drug. What is the most likely cause of her current condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Amiodarone is an iodine-containing anti-arrhythmic agent that causes thyroid dysfunction due to its high iodine content and complex interactions with thyroid hormone synthesis and metabolism.</p>\r\n<ul>\r\n<li>Each 200 mg tablet of amiodarone contains about <strong>75 mg of iodine</strong>, of which <strong>6-8 mg is released daily</strong>, far exceeding daily iodine requirements.</li>\r\n<li>Amiodarone can cause <strong>hypothyroidism (Type 2)</strong>due to destructive thyroiditis or <strong>hyperthyroidism (Type 1)</strong> in patients with pre-existing thyroid disease.</li>\r\n<li>It also <strong>inhibits peripheral conversion</strong>of T4 to T3, further contributing to hypothyroid symptoms like fatigue and weight gain.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001c156aca7-58d0-471d-b739-6d3271289cef.png\">\r\n \r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Lidocaine (Option B):</strong> Class IB antiarrhythmic; no known effect on thyroid function.</p>\r\n<p><strong>Procainamide (Option C):</strong> Class IA antiarrhythmic; may cause SLE-like syndrome but does not affect thyroid hormones.</p>\r\n<p><strong>Verapamil (Option D):</strong> Calcium channel blocker; used for rate control in arrhythmias; does not affect thyroid function.</p>", "options": ["Amiodarone", "Lidocaine ", "Procainamide", "Verapamil"], "html_options": ["Amiodarone", "Lidocaine ", "Procainamide", "Verapamil"], "corr_idx": 0}, {"id": "1166337", "html_qtxt": "A 34-year-old woman underwent near-total thyroidectomy. She was started on levothyroxine. What hormone is produced in the peripheral tissues when levothyroxine is administered?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Levothyroxine (L-thyroxine)</strong> is a <strong>synthetic form of T4</strong> and is the<strong> drug of choice</strong> for replacement therapy in <strong>hypothyroidism and myxedema</strong>. After absorption, it is <strong>peripherally converted</strong>  into the <strong>biologically active hormone T3 and the inactive form rT3</strong>.</p>\r\n<ul>\r\n<li>T3 is the active thyroid hormone responsible for the majority of thyroid hormone effects.</li>\r\n<li>Levothyroxine therapy maintains consistent serum T4 levels and relies on peripheral conversion to achieve euthyroidism.</li>\r\n<li>Side effects of levothyroxine (especially in overdose or hyperthyroid states) include:\r\n<ul>\r\n<li>Sweating, heat intolerance</li>\r\n<li>Tachycardia, palpitations, arrhythmias, chest pain</li>\r\n<li>Tremors</li>\r\n<li>Weight loss (can be misused for weight reduction)</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100181c86187-81c6-4052-a714-b83e09f73961.png\">\r\n \r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>T4 (Option B):</strong> The administered form, but not the biologically active hormone; it requires conversion to T3.</p>\r\n<p><strong>TSH (Option C):</strong> Suppressed via negative feedback from adequate/excess T4/T3 levels.</p>\r\n<p><strong>FSH (Option D):</strong> Follicle-stimulating hormone; unrelated to thyroid physiology.</p>", "options": ["T3", "T4", "TSH", "FSH"], "html_options": ["T3", "T4", "TSH", "FSH"], "corr_idx": 0}, {"id": "1166338", "html_qtxt": "A 7-day-old newborn is becoming increasingly irritable and has had 10 bowel movements over the past 2 days. He was born at 38 weeks'gestation and weighed 1800 g; he currently weighs 1700 g. His mother has Graves' disease and received propylthiouracil during the last trimester of pregnancy. Examination shows mild diaphoresis and a firm 2-cm midline neck swelling. Which of the following is the most appropriate next step in management?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Neonatal thyrotoxicosis</strong> occurs due to transplacental passage of maternal TSH receptor-stimulating antibodies (TRAb), especially in mothers with active or treated Graves' disease.</p>\r\n<ul>\r\n<li><strong>Onset is often delayed</strong>until 7-10 days postpartum due to the suppressive effects of maternal antithyroid drugs like propylthiouracil.</li>\r\n<li><strong>Symptoms</strong>: Irritability, diaphoresis, goitre, tachycardia, increased bowel movements, and poor weight gain despite adequate feeding.</li>\r\n<li><strong>Complications</strong>: If untreated, it may lead to cardiac failure, craniosynostosis, and neurodevelopmental delay.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001f89584d3-aee7-4c4e-a042-77d8a362bdf7.png\">\r\n </li>\r\n<li>Methimazole and propranolol together form the cornerstone of treatment.</li>\r\n<li>Therapy is continued until the maternal antibodies clear from circulation, usually by <strong>12 weeks</strong></li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Potassium iodide therapy (Option B):</strong> Not used as first-line in neonates; typically adjunctive in thyroid storm or pre-op.</p>\r\n<p><strong>Dextrose therapy (Option C):</strong> May be supportive, but does not address underlying thyrotoxicosis.</p>\r\n<p><strong>Ampicillin and gentamicin therapy (Option D):</strong> Indicated for neonatal sepsis; not applicable in thyrotoxicosis.</p>", "options": ["Methimazole and propranolol therapy", "Potassium iodide therapy", "Dextrose therapy", "Ampicillin and gentamycin therapy"], "html_options": ["Methimazole and propranolol therapy", "Potassium iodide therapy", "Dextrose therapy", "Ampicillin and gentamycin therapy"], "corr_idx": 0}, {"id": "1166340", "html_qtxt": "A 56-year-old woman presents with tachycardia, shortness of breath, and chest pain. She had had shortness of breath and diarrhoea for the last 2 days and was sweating and anxious. TSH <0.01 mIU/L (normal 0.4-4.0 mIU/L). The diagnosis of thyroid storm was made. Which of the following is a drug that is a useful adjuvant in the treatment of thyroid storm?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Propranolol</strong> is a first-line adjuvant in thyroid storm due to its <strong>dual benefit</strong>:</p>\r\n<ul>\r\n<li><strong>Beta-adrenergic blockade</strong>to control tachycardia, palpitations, anxiety, and tremors</li>\r\n<li><strong>Inhibits peripheral conversion of T4 to T3</strong>, thus decreasing circulating active hormone levels</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001f14fe32b-9014-4abc-997f-d8f544307008.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Amiodarone (Option A):</strong> Can induce both hypothyroidism and thyrotoxicosis due to high iodine content; not used in thyroid storm treatment.</p>\r\n<p><strong>Betamethasone (Option B):</strong> A glucocorticoid, but hydrocortisone is preferred due to its mineralocorticoid activity.</p>\r\n<p><strong>Epinephrine (Option C):</strong> Contraindicated as it worsens adrenergic symptoms; may precipitate arrhythmias.</p>", "options": ["Amiodarone", "Betamethasone ", "Epinephrine", "Propranolol"], "html_options": ["Amiodarone", "Betamethasone ", "Epinephrine", "Propranolol"], "corr_idx": 3}, {"id": "1166343", "html_qtxt": "A 52-year-old woman presents with a gradually enlarging anterior neck swelling. On examination, a diffuse, soft goitre is palpated. Laboratory investigations reveal suppressed TSH and elevated T3 and T4 levels. Anti-TSH receptor antibodies are positive. Thyroid scintigraphy is shown below. She is administered a single oral dose of radioactive iodine. Which of the following is the most likely long-term treatment required in this patient?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322a1bec585-2c39-4ee2-8895-386e101e95ec.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient has <strong>Graves' disease</strong>, indicated by suppressed TSH, elevated thyroid hormones, positive TSH receptor antibodies, and a scintigraphy scan showing <strong>diffuse, homogeneous uptake</strong> of radioactive iodine.</p>\r\n<ul>\r\n<li><strong>Radioactive Iodine Ablation (RAIA)</strong>is selectively taken up by the hyperfunctioning thyroid tissue and gradually destroys it.</li>\r\n<li>As the entire thyroid gland is overactive in Graves' disease, the destruction is often <strong>complete</strong>, resulting in <strong>permanent hypothyroidism</strong>.</li>\r\n<li>Hence, most patients require <strong>lifelong L-thyroxine replacement</strong>following RAI therapy.</li>\r\n</ul>\r\n<p>RAIA is a definitive treatment for Graves' disease. However, because the entire gland is irradiated, the majority of patients develop hypothyroidism requiring lifelong levothyroxine therapy.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100138e92d2b-1ec1-47e7-ac59-a05d1a4dae76.png\">", "options": ["Near-total thyroidectomy", "Potassium iodide therapy", "Methimazole therapy", "L-thyroxine therapy"], "html_options": ["Near-total thyroidectomy", "Potassium iodide therapy", "Methimazole therapy", "L-thyroxine therapy"], "corr_idx": 3}, {"id": "1166345", "html_qtxt": "A 50-year-old woman presents with a diffusely enlarged thyroid gland with no palpable nodules. Serum studies show a TSH concentration of 0.2 &mu;U/mL, thyroxine (T4) concentration of 24 &mu;g/dL, and positive antibodies against the TSH receptor. Which of the following treatment modalities is associated with the lowest rate of recurrence for this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Radioactive iodine ablation (RAIA) achieves the lowest recurrence rates in Graves' disease by selectively destroying hyperfunctioning thyroid tissue.</p>\r\n<ul>\r\n<li><strong>Graves' disease</strong>involves diffuse hyperactivity of the thyroid gland due to TSH-receptor stimulating antibodies.</li>\r\n<li><strong>RAIA with I&sup1;&sup3;&sup1;</strong>concentrates in the overactive thyroid follicles, emits &beta;-radiation, and destroys thyroid tissue.</li>\r\n<li>It is administered orally and leads to a <strong>permanent cure</strong>in most cases by destroying all functioning thyroid tissue.</li>\r\n<li><strong>Hypothyroidism</strong>is a common consequence and usually requires <strong>lifelong L-thyroxine replacement</strong>.</li>\r\n<li>Compared to antithyroid drugs (e.g., methimazole) or surgery (e.g., subtotal thyroidectomy), RAIA has <strong>lower recurrence</strong>and is preferred when rapid, definitive therapy is desired.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001ac79d5d1-d9fa-4144-ac4d-1fa36d77b927.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Subtotal thyroidectomy (Option A):</strong> Though more definitive than medical therapy, it is associated with surgical risks and possible recurrence from remnant thyroid tissue.</p>\r\n<p><strong>Methimazole (Option C):</strong> Effective short-term, but recurrence is common after discontinuation.</p>\r\n<p><strong>Potassium iodide (Option D):</strong> Used acutely in thyroid storm or before surgery; not a long-term therapy and not curative.</p>", "options": ["Subtotal thyroidectomy", "Radioactive iodine ablation", "Methimazole", "Potassium iodide"], "html_options": ["Subtotal thyroidectomy", "Radioactive iodine ablation", "Methimazole", "Potassium iodide"], "corr_idx": 1}, {"id": "1166348", "html_qtxt": "A 32-year-old woman comes with retraction of the upper eyelids, anterior protrusion of both eyeballs, and restricted convergence during accommodation reflex testing. Serum studies show a thyroid-stimulating hormone concentration of 0.03&mu;U/mL, thyroxine concentration of 19 &mu;g/dL, and antibodies against the TSH receptor. Thyroid scintigraphy shows diffusely increased iodine uptake. Treatment with propranolol is initiated. Which of the following is the most appropriate next step in treatment?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The patient presents with classic features of <strong>Graves' disease (GD)</strong> and associated <strong>Graves orbitopathy (GO)</strong>. In the setting of moderate-to-severe GO, the next step after initial symptomatic control with propranolol is <strong>methimazole</strong>, an antithyroid drug.</p>\r\n<ul>\r\n<li><strong>Methimazole</strong>inhibits thyroid hormone synthesis and is used to establish euthyroidism before considering long-term treatments.</li>\r\n<li><strong>RAIA</strong>is <strong>not recommended</strong> in patients with moderate-to-severe GO, as it can exacerbate orbitopathy.</li>\r\n<li><strong>Tocilizumab</strong>is reserved for <strong>refractory GO</strong>, not first-line.</li>\r\n<li><strong>Thyroidectomy</strong>may be an option, but it is typically considered <strong>after</strong> failure or intolerance to antithyroid drugs or RAIA in patients without orbitopathy</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510016c27e9b7-20b8-4adc-83e6-aa3831796564.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>RAIA (Option A):</strong> Contraindicated in moderate-to-severe orbitopathy due to the risk of worsening symptoms.</p>\r\n<p><strong>Near-total thyroidectomy (Option C):</strong> More invasive; considered after failure of medical management or intolerance.</p>\r\n<p><strong>Tocilizumab (Option D):</strong> Reserved for steroid-refractory GO; not first-line after propranolol.</p>", "options": ["RAIA", "Methimazole", "Near total thyroidectomy", "Tocilizumab"], "html_options": ["RAIA", "Methimazole", "Near total thyroidectomy", "Tocilizumab"], "corr_idx": 1}, {"id": "1166357", "html_qtxt": "A 45-year-old woman with septic shock has persistent hypotension. Her blood cultures were initially positive for E. coli. She is currently on norepinephrine, ceftriaxone, and acetaminophen. Repeat blood cultures are now negative. Her temperature is 99.5&deg;F, heart rate is 96/min, and blood pressure is 90/60 mmHg. Laboratory studies are shown below:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403226809c5d5-0b71-4027-bc72-5685cd3e856d.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient has persistent hypotension from a resolving septic infection, but her lab parameters indicate steady improvement. She demonstrates a classic pattern of <strong>Sick Euthyroid Syndrome (SES)</strong> or <strong>Non-thyroidal Illness Syndrome (NTIS)</strong>:</p>\r\n<ul>\r\n<li>Low T3</li>\r\n<li>Normal to low-normal TSH</li>\r\n<li>Normal free T4</li>\r\n</ul>\r\n<p>This pattern is seen in critically ill patients with <strong>intact thyroid function</strong>, and the abnormalities are <strong>secondary to illness</strong>, not intrinsic thyroid pathology.</p>\r\n<h4><strong>Pathophysiology:</strong></h4>\r\n<ul>\r\n<li><strong>&darr; Type 1 deiodinase</strong>&rarr; &darr; peripheral T4 to T3 conversion</li>\r\n<li><strong>&uarr; Type 3 deiodinase</strong>&rarr; &uarr; degradation of T3 to inactive forms (rT3)</li>\r\n<li><strong>Type 2 deiodinase</strong>in the <strong>pituitary remains functional</strong>, maintaining pituitary T3 levels &rarr; <strong>TSH remains normal or slightly low</strong></li>\r\n<li>Therefore, there is <strong>no true hypothyroidism</strong>, and TSH stimulation does not increase</li>\r\n</ul>\r\n<p><strong>Management involves treating the underlying condition</strong> (sepsis in this case).</p>\r\n<p><strong>Thyroid hormone replacement is not recommended</strong>, as studies have not shown any consistent clinical benefit in NTIS/ESS.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Discontinue current medication (Option A):</strong> Not indicated. The patient is improving on the current treatment.</p>\r\n<p><strong>Check for visual field disturbance (Option B):</strong> Not relevant to NTIS. Applies to pituitary macroadenomas.</p>\r\n<p><strong>Add glucocorticoids (Option D):</strong> Not required unless adrenal insufficiency is suspected, which is not the case here.</p>", "options": ["Discontinue current medication", "Check for visual field disturbance", "Continue same treatment", "Add glucocorticoids in current treatment regimen"], "html_options": ["Discontinue current medication", "Check for visual field disturbance", "Continue same treatment", "Add glucocorticoids in current treatment regimen"], "corr_idx": 2}, {"id": "1166365", "html_qtxt": "A 68-year-old woman presents with lethargy and confusion. She is oriented only to person. Her temperature is 94.6&deg;F, pulse rate 49/min, respirations are 9/min, and blood pressure is 90/60 mm Hg. The pupils are 7 mm and reactive to light. Deep tendon reflexes are 1+ bilaterally. Physical examination shows periorbital oedema, non-pitting oedema in both lower extremities, and healed needle track marks in both antecubital fossae. Serum studies show a sodium concentration of 131 mEq/L, a potassium concentration of 4.9 mEq/L, and a glucose concentration of 54 mg/dL. Arterial blood gas analysis on room air is shown below. An ECG shows bradycardia, low voltage QRS complex, and widespread T-wave inversion. Which of the following is the most appropriate management?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403224cf3ea5a-bcb4-4ea5-849a-a42814c2a81f.jpg\"><br>1.\tNaloxone<br>2.\tSodium bicarbonate<br>3.\tHydrocortisone<br>4.\tLiothyronine<br>5.\tLevothyroxine<br>6.\tEpinephrine<br>7.\tIV fluids", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Altered mental status in combination with hypothermia, bradypnea (causing respiratory acidosis with hypoxemia due to hypoventilation), hypotension, bradycardia, and features of <strong>myxedema heart disease </strong>(low-voltage QRS complexes, flattened or inverted T waves) and non-printing oedema is suggestive of <strong>myxedema coma</strong>. Hyponatremia and hypoglycemia can be due to <strong>myxedema coma</strong>   itself or a <strong>concomitant adrenal insufficiency</strong>.</p>\r\n<ul>\r\n<li>Treatment with<strong>liothyronine and levothyroxine</strong>  should be started immediately upon clinical suspicion of myxedema coma because this condition can be life-threatening (up to 50% mortality); patients should also be treated with <strong>glucocorticoids</strong>  until a diagnosis of coexisting adrenal insufficiency is ruled out.</li>\r\n<li>This patient probably had a longstanding, undiagnosed or untreated hypothyroidism, which increases the risk of developing myxedema coma.</li>\r\n<li>Moreover, her presumed history of injection drug use (healed needle track marks) is an additional precipitating factor for this condition.</li>\r\n<li>Other triggers include infections, stroke, acute coronary syndrome, trauma, and surgical procedures.</li>\r\n<li>In patients with suspected myxedema coma, blood samples for evaluation of TSH, T4, and cortisol levels should be drawn before initiating treatment.</li>\r\n<li>The treatment must then be initiated without waiting for the results.</li>\r\n<li><strong>Naloxone (Option 1):</strong>Not appropriate unless opioid overdose is suspected.</li>\r\n<li><strong>Sodium bicarbonate (Option 2):</strong>Metabolic acidosis is not present; the primary problem is respiratory acidosis.</li>\r\n<li><strong>Hydrocortisone (Option 3):</strong>To cover possible adrenal insufficiency.</li>\r\n<li><strong>Liothyronine (Option 4):</strong>Rapid onset T3 therapy.</li>\r\n<li><strong>Levothyroxine (Option 5): </strong>Long-acting T4 support.</li>\r\n<li><strong>Epinephrine (Option 6):</strong>For bradycardia and hypotension.</li>\r\n<li><strong>IV fluids (Option 7):</strong>For hypotension and hypovolemia.</li>\r\n</ul>", "options": ["1,2,3,7", "2,3,5,6,7", "3,4,5,6,7", "1,3,4,6,7"], "html_options": ["1,2,3,7", "2,3,5,6,7", "3,4,5,6,7", "1,3,4,6,7"], "corr_idx": 2}, {"id": "1166369", "html_qtxt": "A 50-year-old woman presents with a pins-and-needles sensation in her hand that worsens at night and is relieved by shaking her hand. She also reports episodic left knee pain during the day. She is on medication for constipation. Her BMI is 35 kg/m2. Vitals reveal pulse 57/min and blood pressure 120/75 mmHg. On examination, sensation is decreased to light touch in the thumb and index finger. Deep tendon reflexes are 1+, and there is mild bilateral leg oedema. Which of the following treatments is most likely to benefit this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient has clinical features of hypothyroidism - constipation, bradycardia, hyporeflexia, oedema, and obesity - along with median nerve compression, suggesting <strong>carpal tunnel syndrome (CTS)</strong>&nbsp;due to <strong>hypothyroidism</strong>. Levothyroxine therapy treats the underlying cause.</p>\r\n<ul>\r\n<li>The patient presents with classic signs of hypothyroidism: constipation, fatigue, bradycardia, hyporeflexia, and lower limb oedema (which is usually myxedematous and non-pitting, but pitting oedema can also occur due to excessive albumin in extracellular spaces).</li>\r\n<li>While the precise etiopathology is uncertain, it is assumed that the excess deposition of glycosaminoglycans, hyaluronic acid, and mucopolysaccharides in hypothyroidism causes myxedema.</li>\r\n<li>These characteristic depositions can subsequently cause compression of the carpal tunnel. With thyroid hormone replacement and return to a euthyroid state, symptoms should improve within weeks to months.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510010a7564c1-a31a-4494-997e-4ed3c7075594.png\"></li>\r\n<li><strong>Hypothyroidism can lead to carpal tunnel syndrome</strong>due to the <strong>accumulation of mucopolysaccharides and glycosaminoglycans</strong>  in perineural tissues.</li>\r\n<li><strong>Levothyroxine</strong>, a synthetic T4 preparation, corrects the metabolic and neuromuscular manifestations of hypothyroidism, including CTS</li>\r\n<li>Symptom resolution may occur within <strong>weeks to months</strong>of therapy.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Prednisone (Option A):</strong> Used in inflammatory or autoimmune neuropathies; not first-line for CTS due to hypothyroidism.</p>\r\n<p><strong>Ibuprofen (Option B):</strong>  Temporary analgesia; does not address the underlying aetiology.</p>\r\n<p><strong>Surgery (Option C):</strong>Reserved for refractory CTS or severe nerve compression; not first-line in hypothyroid-induced CTS.</p>", "options": ["Prednisone", "Ibuprofen", "Surgery", "L-thyroxine"], "html_options": ["Prednisone", "Ibuprofen", "Surgery", "L-thyroxine"], "corr_idx": 3}, {"id": "1166371", "html_qtxt": "A 73-year-old woman is brought to you for progressive memory loss. She has gained 10 kg over the past year. Her father died due to complications of Alzheimer's disease. She is oriented but has short-term memory deficits. On examination, she has a normal gait and delayed relaxation of the Achilles reflex bilaterally. Her skin is dry, and her nails are brittle. Which of the following is the most appropriate treatment?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This elderly woman has clinical signs of hypothyroidism, including memory impairment, dry skin, brittle nails, delayed ankle reflexes, and weight gain. These features suggest <strong>Hashimoto thyroiditis</strong> progressing to <strong>primary hypothyroidism</strong>.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510011cdbd0b1-23d3-4212-ac6e-e76e748b2828.png\">\r\n<ul>\r\n<li><strong>Hashimoto thyroiditis</strong>is characterised by<strong> progressive destruction of thyroid tissue</strong> by <strong>antithyroid peroxidase antibodies</strong> and <strong>antithyroglobulin antibodies</strong>. Initially, it may manifest with transient hyperthyroidism before progressing to hypothyroidism.</li>\r\n<li>Hypothyroidism results in a generalised <strong>decrease of the basal metabolic rate</strong>, which can present with <strong>weight gain, fatigue, dry skin and brittle nails, along with concentration and memory impairment</strong>.</li>\r\n<li><strong>Treatment</strong>with<strong> Lifelong oral administration of L-thyroxine (T4)</strong>, commencing at a lower and more slow-acting dose, with increasing severity of hypothyroidism because of the risk of cardiac side effects.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Thiamine (Option A):</strong> Used in Wernicke encephalopathy and beriberi, not relevant here.</p>\r\n<p><strong>Vitamin B12 (Option B):</strong> Causes cognitive symptoms but usually includes anaemia, paresthesias, and gait abnormalities.</p>\r\n<p><strong>Rivastigmine (Option C):</strong> Cholinesterase inhibitor for Alzheimer's disease; not appropriate in this hypothyroid state.</p>", "options": ["Thiamine", "Vitamin B12", "Rivastigmine", "L-thyroxine"], "html_options": ["Thiamine", "Vitamin B12", "Rivastigmine", "L-thyroxine"], "corr_idx": 3}, {"id": "1166375", "html_qtxt": "A 38-year-old woman on L-thyroxine comes for follow-up with a TSH of 7 mU/L. Previous TSH level = 4.5 mU/L. No other complaints. What would you suggest?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>TSH elevation in a patient on L-thyroxine indicates under-replacement. The treatment goal is to titrate L-thyroxine dose to keep TSH within the normal range, especially in non-elderly patients without cardiovascular disease.</p>\r\n<ul>\r\n<li>A mild increase in TSH suggests <strong>subclinical hypothyroidism</strong>or insufficient hormone dose.</li>\r\n<li>L-thyroxine dose should be <strong>adjusted upward</strong>and TSH rechecked after 6&ndash;8 weeks.</li>\r\n<li>In the absence of symptoms, therapy is guided by <strong>biochemical values</strong>.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001d9a77370-cb2e-45ed-b896-cdf85b541be3.png\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322f6cbf980-2d27-44d4-a764-eb7484d93977.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Maintain the same dose (Option B):</strong> Not appropriate since the patient's TSH has increased above the normal reference range (0.4-4.5 mU/L), indicating <strong>suboptimal therapy</strong>.</p>\r\n<p><strong>Reduce the dose (Option C):</strong> Incorrect, as a dose reduction would worsen hypothyroidism by further increasing TSH levels.</p>\r\n<p><strong>Discontinue the drug (Option D):</strong> Absolutely contraindicated; discontinuing L-thyroxine would lead to <strong>full-blown hypothyroidism</strong> with potential metabolic and cardiovascular complications.</p>", "options": ["Increase the dose", "Maintain same dose", "Reduce the dose", "Discontinue the drug"], "html_options": ["Increase the dose", "Maintain same dose", "Reduce the dose", "Discontinue the drug"], "corr_idx": 0}]}, {"moduleId": 1008549, "name": "Drugs for Diabetes", "questions": [{"id": "1166545", "html_qtxt": "A 44-year-old man comes to you with fatigue and increased thirst for 3 months. His fasting serum glucose concentration is 220 mg/dL. Treatment with an oral hypoglycemic agent is begun. Which of the following is most likely affected by the drug that is most likely prescribed for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Metformin is the most commonly prescribed first-line oral agent for newly diagnosed type 2 diabetes mellitus. Its primary mechanism is the inhibition of hepatic gluconeogenesis via inhibition of mitochondrial glycerophosphate dehydrogenase (mGPD), leading to reduced glucose output by the liver.</p>\r\n<ul>\r\n<li>Metformin decreases hepatic glucose production and improves insulin sensitivity.</li>\r\n<li>It enhances peripheral glucose uptake and utilisation and slows intestinal glucose absorption.</li>\r\n<li>It does not increase insulin release, hence lower risk of hypoglycemia.</li>\r\n<li>Metformin is contraindicated in renal impairment due to the risk of lactic acidosis.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307209c063d-8763-4a5a-8b66-9863230ec101.jpg\">\r\n<p><strong>(Other options ruled out)</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030731e7ceee-6314-4928-a176-36feb736ad2f.jpg\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403072f591ed1-b78c-4389-96c2-e1ba988ecabd.jpg\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030785cc7d7d-00ed-43a9-8730-b89a5fc708a2.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Renal glucose elimination (Option A):</strong> Seen with SGLT2 inhibitors like canagliflozin, not metformin.</p>\r\n<p><strong>Insulin release (Option C):</strong> Stimulated by sulfonylureas like glipizide, not by metformin.</p>\r\n<p><strong>Carbohydrate hydrolysis (Option D):</strong> Inhibited by &alpha;-glucosidase inhibitors like acarbose, not metformin.</p>", "options": ["Renal glucose elimination", "Hepatic gluconeogenesis", "Insulin release", "Carbohydrate hydrolysis"], "html_options": ["Renal glucose elimination", "Hepatic gluconeogenesis", "Insulin release", "Carbohydrate hydrolysis"], "corr_idx": 1}, {"id": "1166549", "html_qtxt": "In response to drug X, pancreatic islet cells begin producing increasing amounts of secretory granules. Identify X.", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The secretory granules produced by pancreatic islet cells in response to drug X contain insulin and C-peptide, indicating stimulation of endogenous insulin secretion.</p>\r\n<ul>\r\n<li><strong>Glimepiride</strong>, a sulfonylurea, promotes insulin release from pancreatic &beta;-cells.</li>\r\n<li>It acts by <strong>inhibiting ATP-sensitive K<sup>+</sup> channels</strong> in the &beta;-cell plasma membrane.</li>\r\n<li>This leads to <strong>membrane depolarisation</strong> and <strong>Ca<sup><sub>2+</sub></sup>  influx</strong>, triggering <strong>exocytosis of insulin-containing secretory granules</strong>.</li>\r\n<li>Sulfonylureas are used in <strong>type 2 diabetes</strong> patients with functioning &beta;-cells to improve glycemic control.</li>\r\n<li>They are <strong>orally administered</strong>, bind to serum proteins, and have a <strong>daily dosing schedule</strong>.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100155ff6dc8-76db-41b1-87b3-5b39590398e8.PNG\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Metformin (Option A):</strong> A biguanide that decreases hepatic gluconeogenesis; does not stimulate insulin secretion.</p>\r\n<p><strong>Pioglitazone (Option B):</strong> A thiazolidinedione that increases insulin sensitivity in peripheral tissues; does not increase insulin granules.</p>\r\n<p><strong>Insulin (Option D):</strong> Exogenous hormone; bypasses endogenous &beta;-cell stimulation and C-peptide production.<br /> </p>", "options": ["Metformin", "Pioglitazone", "Glimepiride ", "Insulin "], "html_options": ["Metformin", "Pioglitazone", "Glimepiride ", "Insulin "], "corr_idx": 2}, {"id": "1166569", "html_qtxt": "A 52-year-old man with type 2 diabetes mellitus comes to the OPD for a follow-up. He is on metformin. He has a BMI of 36 kg/m<sub>2</sub> and has tried to lose weight for several years without success. His HbA1c is 8.2%. Which of the following is the most appropriate anti-diabetic drug to address both this patient's glucose control and weight?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Liraglutide</strong> is the most appropriate choice as it <strong>improves glycemic control and promotes significant weight loss</strong>, especially in obese individuals with type 2 diabetes.</p>\r\n<ul>\r\n<li>Liraglutide is a long-acting, DPP-4-resistant GLP-1 receptor agonist.</li>\r\n<li>It is administered subcutaneously once daily and induces glucose-dependent insulin secretion.</li>\r\n<li>It slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety.</li>\r\n<li>In clinical trials, liraglutide significantly reduced body weight compared to placebo and other agents.</li>\r\n<li>It is approved as monotherapy and as adjunctive therapy for type 2 diabetes, particularly useful in obese patients.<br /> </li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001d94b698a-8ba1-4fb6-be29-aeeb7767a8fb.png\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100141b0e1c0-75f4-4b9d-bf50-91db1c85cbdf.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Canagliflozin (Option A):</strong> Though it causes modest weight loss, GLP-1 agonists like liraglutide are superior in terms of both HbA1c reduction and weight control.</p>\r\n<p><strong>Linagliptin (Option B):</strong> DPP-4 inhibitor that is weight-neutral and has limited efficacy in obese patients.</p>\r\n<p><strong>Rosiglitazone (Option D):</strong> Associated with weight gain and adverse cardiac effects; not suitable for obese diabetic patients aiming for weight reduction.</p>", "options": ["Canaglifozin", "Linagliptin", "Liraglutide", "Rosiglitazone"], "html_options": ["Canaglifozin", "Linagliptin", "Liraglutide", "Rosiglitazone"], "corr_idx": 2}, {"id": "1166570", "html_qtxt": "A 50-year-old man with type 2 diabetes mellitus has an HbA1c of 8.5%. A consultant prescribes a drug that reversibly inhibits a membrane-bound enzyme that hydrolyses carbohydrate bonds. Which of the following drugs was most likely added to this patient's medication regimen?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Miglitol is an &alpha;-glucosidase inhibitor that acts by reversibly inhibiting membrane-bound &alpha;-glucosidases in the intestinal brush border.</p>\r\n<ul>\r\n<li>These enzymes hydrolyse complex carbohydrates into monosaccharides.</li>\r\n<li>Inhibition slows carbohydrate digestion and glucose absorption &rarr; blunts postprandial hyperglycemia.</li>\r\n<li>It reduces the postprandial rise in plasma glucose concentrations.</li>\r\n<li>Because polysaccharides are not absorbed as easily as monosaccharides, there is a slower glucose rise after meals.</li>\r\n<li>Adverse effects are primarily gastrointestinal (flatulence, diarrhoea, early satiety) due to impaired absorption and fermentation of undigested carbohydrates.</li>\r\n<li>Miglitol is cleared almost entirely by the kidneys.</li>\r\n<li>Recommended only for patients with creatinine clearance >30 mL/min.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Linagliptin (Option A):</strong> DPP-4 inhibitor; increases endogenous GLP-1 levels by preventing its degradation. Does not inhibit &alpha;-glucosidase.</p>\r\n<p><strong>Metformin (Option B):</strong> Biguanide; reduces hepatic glucose production and improves insulin sensitivity; does not act on carbohydrate digestion.</p>\r\n<p><strong>Rosiglitazone (Option C):</strong> Thiazolidinedione; activates PPAR-&gamma; to improve insulin sensitivity; no effect on intestinal carbohydrate digestion.</p>", "options": ["Linagliptin", "Metformin", "Rosiglitazone", "Miglitol"], "html_options": ["Linagliptin", "Metformin", "Rosiglitazone", "Miglitol"], "corr_idx": 3}, {"id": "1166574", "html_qtxt": "A 54-year-old man comes for a review of his home glucose monitoring, which shows postprandial blood glucose (PP2BS) = 320 mg/dL. He is currently on a regimen that includes a single daily injection of a long-acting subcutaneous insulin. Which of the following insulin preparations is most appropriate to administer before meals to reduce his postprandial glucose spikes?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Insulin aspart is a rapid-acting prandial insulin analogue designed to reduce postprandial blood glucose excursions by mimicking the physiological insulin spike after meals.</p>\r\n<ul>\r\n<li><strong>Onset of Action:</strong> <0.25 hours (very rapid), suitable for pre-meal use.</li>\r\n<li><strong>Peak Effect:</strong>5-1.5 hours - aligns well with postprandial glucose rise.</li>\r\n<li><strong>Duration:</strong> 3-5 hours - avoids prolonged hypoglycemia.</li>\r\n<li><strong>Structure:</strong> Formed by replacing proline at position B28 with aspartic acid, reducing self-association and enabling rapid absorption after subcutaneous injection.</li>\r\n<li><strong>Clinical Utility:</strong> Ideal for nutritional insulin coverage in patients already on basal insulin (e.g., glargine) but with persistently elevated post-meal glucose values.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403070fa18054-8141-4b81-a975-4fc7a5d97190.jpg\">\r\n<ul>\r\n<li>BBR= Basal-bolus insulin regimen = Basal insulin: administer as long-acting insulin (e.g., glargine) at bedtime. Nutritional insulin: administer as rapid-acting insulin (e.g., lispro) in equally divided doses before meals</li>\r\n<li>SSR = Sliding scale insulin regimen = Administer as short-acting insulin before each meal and at bedtime as per scale.</li>\r\n<li>BOT = Basal supported oral therapy = long-acting insulin injection (e.g., glargine) before bedtime combined with an oral antidiabetic drug regimen</li>\r\n</ul>", "options": ["Regular insulin ", "NPH insulin ", "Insulin aspart", "Insulin glargine "], "html_options": ["Regular insulin ", "NPH insulin ", "Insulin aspart", "Insulin glargine "], "corr_idx": 2}, {"id": "1166578", "html_qtxt": "A 28-year-old woman with type 1 diabetes mellitus visits the outpatient clinic seeking advice about initiating oral contraceptive pills (OCPs). She is currently on a regimen that includes a single daily dose of long-acting subcutaneous insulin. What is the most appropriate adjustment to her diabetes management?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Initiation of oral contraceptive pills (OCPs) in type 1 diabetic patients often requires insulin dose adjustment due to their metabolic effects.</strong></p>\r\n<ul>\r\n<li>Estrogen components in OCPs can lead to increased insulin resistance.</li>\r\n<li>This resistance results in reduced insulin sensitivity, especially to subcutaneous long-acting preparations.</li>\r\n<li>To maintain glycemic control, the insulin dose may need to be <strong>increased</strong>, particularly the basal component.</li>\r\n<li>This principle applies especially in regimens where long-acting insulins like <strong>glargine</strong>, <strong>detemir</strong>, or <strong>degludec</strong> are used.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403074af89336-a385-43e7-ab01-12e9c62a61fb.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Advise against starting OCPs (Option A):</strong> There is <strong>no contraindication</strong> to using OCPs in women with type 1 diabetes who do not have vascular complications. The focus is on adjusting insulin, not avoiding OCPs altogether.</p>\r\n<p><strong>Decrease insulin dose (Option C):</strong> OCPs reduce insulin sensitivity. Decreasing insulin would worsen glycemic control and is <strong>contraindicated</strong>.</p>\r\n<p><strong>Can start using OCPs without any modification (Option D):</strong> Starting OCPs without modifying the insulin regimen may lead to <strong>hyperglycemia</strong>, particularly if insulin resistance increases.</p>", "options": ["Advise against starting of OCPs", "Increase insulin dose", "Decrease insulin dose", "Can start using OCPs without any modification"], "html_options": ["Advise against starting of OCPs", "Increase insulin dose", "Decrease insulin dose", "Can start using OCPs without any modification"], "corr_idx": 1}, {"id": "1166586", "html_qtxt": "A 40-year-old woman comes to the office for follow-up of type 2 diabetes mellitus and hypertension, She is on the maximum tolerated dose of metformin and on amlodipine. After discussing various medication options, it is decided to add a new drug which acts by alterations in gene transcription and protein synthesis, This patient is most likely to experience which of the following side effects?<br>FBS= 180 mg/dL<br>HbA1c = 8.3%", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Thiazolidinediones</strong> act by binding to peroxisome proliferator-activated receptor-&gamma; (PPAR-&gamma;), leading to modulation of gene transcription and protein synthesis of insulin-responsive genes such as GLUT4 and adiponectin.</p>\r\n<ul>\r\n<li>This process results in enhanced insulin sensitivity, but the onset of action is <strong>delayed by days to weeks</strong>.</li>\r\n<li>A major adverse effect is <strong>fluid retention</strong>, leading to <strong>peripheral oedema</strong> and <strong>weight gain</strong>.</li>\r\n<li>Fluid retention may worsen <strong>congestive heart failure</strong>, especially when combined with <strong>insulin</strong>.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510019320c0be-4410-49f4-8f1f-ca046bc65bf2.PNG\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307c8f6e562-362c-4ee3-a475-7ed82b3f8af9.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307629f4ee4-0fde-4fd9-9d04-8e9eda5d3968.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307b7f2824a-9a05-4744-ad05-a29a04e7fd88.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Agranulocytosis (Option A):</strong> Not associated with thiazolidinediones. It is more classically seen with drugs like methimazole or clozapine.</p>\r\n<p><strong>Hypoglycemia (Option B):</strong> TZDs do not cause hypoglycemia when used as monotherapy since they don't stimulate insulin secretion.</p>\r\n<p><strong>Lactic acidosis (Option C):</strong> A rare but serious adverse effect of <strong>metformin</strong>, not of TZDs.</p>", "options": ["Agranulocytosis", "Hypoglycemia", "Lactic acidosis", "Weight gain and oedema"], "html_options": ["Agranulocytosis", "Hypoglycemia", "Lactic acidosis", "Weight gain and oedema"], "corr_idx": 3}, {"id": "1166590", "html_qtxt": "A 48-year-old man with type 2 diabetes mellitus is currently taking glipizide. He presents with persistently elevated blood glucose levels, with a recent fasting blood sugar of 190 mg/dL and HbA1c of 8.8%. The physician decides to add canagliflozin to his regimen. Which of the following investigations should be done before starting this drug?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Assessment of renal function is essential before starting SGLT2 inhibitors such as canagliflozin, as these drugs are contraindicated or not recommended in moderate to severe renal impairment.</p>\r\n<ul>\r\n<li><strong>Mechanism of SGLT2 inhibitors:</strong>\r\n<ul>\r\n<li>Inhibit sodium-glucose cotransporter 2 in the proximal renal tubules.</li>\r\n<li>Reduce glucose reabsorption &rarr; increase urinary glucose excretion &rarr; lower blood glucose levels.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Clinical consideration:</strong>\r\n<ul>\r\n<li>The efficacy of SGLT2 inhibitors is significantly reduced in patients with moderate to severe renal impairment.</li>\r\n<li>There is an increased risk of adverse effects such as volume depletion, hypotension, and urinary tract infections in renal dysfunction.</li>\r\n<li>Therefore, <strong>blood urea nitrogen (BUN) and serum creatinine</strong> should be measured before starting therapy and monitored periodically thereafter.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Complete blood count with differential (Option B):</strong> Not routinely required before initiating canagliflozin; unrelated to its mechanism or major side effects.</p>\r\n<p><strong>Liver function tests (Option C):</strong> Not mandatory before starting SGLT2 inhibitors; hepatotoxicity is not a notable concern.</p>\r\n<p><strong>Urinalysis (Option D):</strong> Not essential prior to starting therapy, though glycosuria is expected during treatment due to the drug mechanism.</p>", "options": ["Blood urea nitrogen and creatinine", "Complete blood count with differential", "Liver function tests", "Urinalysis"], "html_options": ["Blood urea nitrogen and creatinine", "Complete blood count with differential", "Liver function tests", "Urinalysis"], "corr_idx": 0}, {"id": "1166591", "html_qtxt": "A 56-year-old man complains of shortness of breath when walking. Echocardiography reveals an ejection fraction of 30% (normal >55%). Laboratory evaluation shows a fasting blood glucose level of 248 mg/dL and serum creatinine of 1.6 mg/dL. Which of the following best describes the mechanism of action of a drug that is contraindicated for use in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Thiazolidinediones</strong>, such as pioglitazone and rosiglitazone, <strong>increase insulin sensitivity</strong> by binding to<strong> PPAR-&gamma;</strong> in insulin-responsive tissues like adipose tissue, skeletal muscle, and liver. These agents are <strong>contraindicated</strong> in patients with<strong> NYHA Class III-IV heart failure.</strong></p>\r\n<ul>\r\n<li><strong>Mechanism of action:</strong>\r\n<ul>\r\n<li>Activate <strong>PPAR-&gamma;</strong> (peroxisome proliferator-activated receptor gamma)</li>\r\n<li>Regulate transcription of insulin-responsive genes</li>\r\n<li>Enhance <strong>insulin sensitivity</strong> in adipose tissue, skeletal muscle, and liver</li>\r\n<li>Reduce hepatic glucose production and increase peripheral glucose uptake</li>\r\n</ul>\r\n</li>\r\n<li><strong>Clinical significance in this patient:</strong>\r\n<ul>\r\n<li>The patient has <strong>NYHA Class III heart failure</strong> (EF 30%) - marked limitation of physical activity</li>\r\n<li>Thiazolidinediones can <strong>worsen heart failure</strong> by causing:\r\n<ul>\r\n<li><strong>Fluid retention</strong></li>\r\n<li><strong>Peripheral edema</strong></li>\r\n<li><strong>Weight gain</strong></li>\r\n</ul>\r\n</li>\r\n<li>Hence, <strong>contraindicated</strong> in this clinical setting</li>\r\n</ul>\r\n</li>\r\n<li><strong>Additional Adverse Effects:</strong></li>\r\n<li>Risk of <strong>bone fractures</strong>, <strong>macular oedema</strong></li>\r\n<li>May increase LDL cholesterol levels</li>\r\n<li>Associated with an <strong>increased risk of bladder cancer</strong> (rosiglitazone withdrawn in some countries due to cardiovascular risk)</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Alpha-glucosidase inhibitor (Option A):</strong> Delays intestinal carbohydrate absorption; not contraindicated in heart failure.</p>\r\n<p><strong>GLP-1 receptor agonist (Option B):</strong> Enhances insulin secretion and slows gastric emptying; no contraindication in heart failure.</p>\r\n<p><strong>Inhibits glucose absorption from the intestinal tract (Option C):</strong> Refers to drugs like acarbose; not contraindicated in this scenario.</p>", "options": ["Alpha-glucosidase inhibitor", "GLP-1 receptor agonist", "Inhibits glucose absorption from the intestinal tract", "Sensitizes peripheral tissues to insulin"], "html_options": ["Alpha-glucosidase inhibitor", "GLP-1 receptor agonist", "Inhibits glucose absorption from the intestinal tract", "Sensitizes peripheral tissues to insulin"], "corr_idx": 3}, {"id": "1166593", "html_qtxt": "A 53-year-old woman presents with marked hyperventilation. She has a known history of type 2 diabetes mellitus and hypertension. Laboratory investigations reveal the following:<br>1. Creatinine: 2.4 mg/dL <br>2. Arterial pH: 7.22 <br>3. Bicarbonate: 14 mEq/L <br>4. Sodium: 140 mEq/L <br>5. Potassium: 4.9 mEq/L <br>6. Chloride: 102 mEq/L<br>Which of the following drugs is most likely responsible for these findings?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The clinical and laboratory findings are indicative of lactic acidosis, a rare but life-threatening adverse effect of metformin therapy, especially in the context of renal dysfunction.</p>\r\n<ul>\r\n<li><strong>Mechanism:</strong>\r\n<ul>\r\n<li>Metformin inhibits mitochondrial glycerophosphate dehydrogenase &rarr; impairs gluconeogenesis &rarr; promotes anaerobic metabolism and lactic acid accumulation.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Characteristic features of lactic acidosis:</strong>\r\n<ul>\r\n<li>Low pH, decreased bicarbonate, elevated anion gap metabolic acidosis</li>\r\n<li>Symptoms include: malaise, myalgias, abdominal discomfort, somnolence, and respiratory distress</li>\r\n</ul>\r\n</li>\r\n<li><strong>Patient parameters:</strong>\r\n<ul>\r\n<li><strong>Serum creatinine = 2.4 mg/dL</strong> &rarr; indicates <strong>renal insufficiency</strong></li>\r\n<li><strong>Anion gap = [Na+] &minus; ([Cl&minus;] + [HCO3&minus;]) = 140 &minus; (102 + 14) = 24 mEq/L</strong> &rarr; elevated</li>\r\n<li>Thus, the patient has <strong>elevated anion gap metabolic acidosis</strong>, likely due to <strong>metformin-associated lactic acidosis</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>High-risk conditions for metformin-induced lactic acidosis:</strong>\r\n<ul>\r\n<li>Renal failure (Cr >1.4-1.5 mg/dL)</li>\r\n<li>Heart failure</li>\r\n<li>Hepatic dysfunction</li>\r\n<li>Sepsis or severe hypoxia</li>\r\n<li>Use of contrast media or nephrotoxic drugs</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Atenolol (Option A):</strong> May reduce cardiac output, but is not associated with lactic acidosis.</p>\r\n<p><strong>Enalapril (Option B):</strong> Can affect renal function, but does not directly cause metabolic acidosis of this severity.</p>\r\n<p><strong>Furosemide (Option C):</strong> Can cause hypokalemia and volume loss, but is not associated with lactic acidosis.</p>", "options": ["Atenolol", "Enalapril", "Furosemide", "Metformin"], "html_options": ["Atenolol", "Enalapril", "Furosemide", "Metformin"], "corr_idx": 3}, {"id": "1166594", "html_qtxt": "A 65-year-old man with type 2 diabetes mellitus presents for routine follow-up. He has NYHA class III heart failure with exertional dyspnea and fatigue. Laboratory studies show: <br>1. Fasting blood glucose: 200 mg/dL <br>2.Serum creatinine: 2.8 mg/dL<br>Which of the following drugs is most appropriate for initiating glycemic control in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Insulin lispro is the drug of choice in this patient with both renal dysfunction and NYHA class III heart failure, where most oral hypoglycemic agents are contraindicated.</p>\r\n<ul>\r\n<li><strong>Metformin (Option D):</strong>\r\n<ul>\r\n<li>Eliminated by the kidneys and contraindicated in <strong>serum creatinine >1.4-1.5 mg/dL</strong> due to risk of <strong>lactic acidosis</strong>.</li>\r\n<li>Goodman & Gilman: Metformin accumulation can precipitate lactic acidosis, especially in patients with <strong>renal insufficiency</strong> or those receiving <strong>nephrotoxic agents</strong> or contrast dyes.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Rosiglitazone (Option A):</strong>\r\n<ul>\r\n<li>A thiazolidinedione that increases insulin sensitivity via <strong>PPAR-&gamma; activation</strong>.</li>\r\n<li><strong>Contraindicated in NYHA Class III-IV heart failure</strong> due to fluid retention and risk of worsening cardiac status.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Insulin lispro (Option C):</strong>\r\n<ul>\r\n<li>A <strong>rapid-acting insulin analogue</strong> that mimics prandial insulin secretion.</li>\r\n<li><strong>Safe in renal and cardiac dysfunction</strong>, as it does not rely on renal clearance for metabolism.</li>\r\n<li>Goodman & Gilman states: Insulin lispro has <strong>faster absorption and shorter duration</strong>, with a <strong>lower risk of hypoglycemia</strong> when properly timed.</li>\r\n<li>It is especially useful when oral antidiabetic drugs are ineffective or contraindicated.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Glucagon (Option B):</strong>\r\n<ul>\r\n<li>Used for <strong>acute hypoglycemia</strong>, not for long-term glucose control in diabetes.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Insulin lispro is the best here, because:</strong>\r\n<ul>\r\n<li>Not nephrotoxic</li>\r\n<li>Not contraindicated in heart failure</li>\r\n<li>Can be titrated effectively</li>\r\n<li>Effective in achieving glycemic control when oral agents are inappropriate</li>\r\n</ul>\r\n</li>\r\n</ul>", "options": ["Rosiglitazone", "Glucagon", "Insulin lispro", "Metformin"], "html_options": ["Rosiglitazone", "Glucagon", "Insulin lispro", "Metformin"], "corr_idx": 2}, {"id": "1166596", "html_qtxt": "A 21-year-old woman is brought to the emergency room unconscious. She is breathing deeply and has visible bruises and facial lacerations. She has lost approximately 150 mL of blood. Arterial blood gas and serum chemistry findings are as follows:<br>1. pH =7.31<br>2. Bicarbonate =11.8 mEq/L<br>3. PCO2 = 24 mm Hg<br>4.Sodium = 130 mEg/L<br>5. Potassium = 6.0 mEg/L<br>6. Chloride =109 mEg/L<br>Which of the following best explains these laboratory abnormalities?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient presents with high anion gap metabolic acidosis, most consistent with diabetic ketoacidosis (DKA) caused by insulin deficiency.</p>\r\n<ul>\r\n<li><strong>Stepwise ABG interpretation:</strong>\r\n<ul>\r\n<li><strong>pH = 7.31</strong> &rarr; acidemia</li>\r\n<li><strong>HCO<sup>3-</sup> = 11.8 mEq/L</strong> (&darr;) &rarr; metabolic acidosis</li>\r\n<li><strong>PCO<sub>2</sub> = 24 mmHg</strong> (&darr;) &rarr; respiratory compensation (hyperventilation)</li>\r\n</ul>\r\n</li>\r\n<li><strong>DKA Mechanism:</strong>\r\n<ul>\r\n<li>Insulin deficiency &rarr; increased <strong>lipolysis</strong> &rarr; hepatic <strong>fatty acid oxidation</strong> &rarr; formation of ketone bodies (&beta;-hydroxybutyrate, acetoacetate)</li>\r\n<li>Accumulation of ketones &rarr; <strong>metabolic acidosis</strong> with high anion gap</li>\r\n<li><strong>Hyperventilation (Kussmaul breathing)</strong> compensates by blowing off CO<sub>2</sub></li>\r\n</ul>\r\n</li>\r\n<li><strong>Electrolyte changes:</strong>\r\n<ul>\r\n<li><strong>Serum potassium</strong> is high due to intracellular H<sup>+</sup>/K<sup>+</sup> exchange, but <strong>total body potassium is depleted</strong> due to urinary losses</li>\r\n<li><strong>Hyponatremia</strong> results from osmotic diuresis and water shift into the extracellular compartment due to hyperglycemia</li>\r\n</ul>\r\n</li>\r\n<li><strong>Anion gap calculation:</strong>\r\n<ul>\r\n<li>AG = Na<sup>+</sup> &minus; (Cl<sup>-</sup> + HCO<sup>3-</sup>) = 130 &minus; (109 + 11.8) = <strong>2 mEq/L</strong></li>\r\n<li>Although mild, the elevated gap alongside the clinical context supports DKA</li>\r\n</ul>\r\n</li>\r\n<li><strong>Mnemonic for high anion gap metabolic acidosis (MUDPILES):</strong>\r\n<ul>\r\n<li><strong>M</strong>ethanol</li>\r\n<li><strong>U</strong>remia</li>\r\n<li><strong>D</strong>iabetic ketoacidosis</li>\r\n<li><strong>P</strong>araldehyde</li>\r\n<li><strong>I</strong>ron/Isoniazid</li>\r\n<li><strong>L</strong>actic acidosis</li>\r\n<li><strong>E</strong>thylene glycol</li>\r\n<li><strong>S</strong>alicylates</li>\r\n</ul>\r\n</li>\r\n<li>Insulin deficiency leads to excessive fatty acid metabolism with <strong>ketone body production</strong>, resulting in <strong>ketoacidosis</strong> with accompanying <strong>acidosis, dehydration, hyperkalemia, and coma</strong>.</li>\r\n<li>Profound insulin deficiency results in <strong>hyperglycemia, metabolic acidosis, compensatory tachypnea</strong>, and fluid/electrolyte disturbances.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Antacid abuse (Option A):</strong> Typically causes <strong>metabolic alkalosis</strong>, not acidosis.</p>\r\n<p><strong>Furosemide abuse (Option B):</strong> Leads to <strong>hypokalemic metabolic alkalosis</strong>, not acidosis.</p>\r\n<p><strong>Oxycodone overdose (Option D):</strong> Causes <strong>respiratory depression and respiratory acidosis</strong>, not metabolic acidosis.</p>", "options": ["Antacid abuse", "Furosemide abuse", "Insulin deficiency.", "Oxycodone overdose"], "html_options": ["Antacid abuse", "Furosemide abuse", "Insulin deficiency.", "Oxycodone overdose"], "corr_idx": 2}, {"id": "1166597", "html_qtxt": "A 60-year-old woman with rheumatoid arthritis is started on methotrexate. As it may take several weeks for methotrexate to provide benefit, prednisone is added for short-term symptom relief. Which of the following is a likely adverse effect of glucocorticoid therapy in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Glucocorticoids cause hypocalcemia by reducing calcium absorption in the gut and increasing renal excretion, which may lead to bone resorption and osteoporosis.</p>\r\n<ul>\r\n<li>Glucocorticoids like prednisone are commonly used as bridging therapy in RA while waiting for DMARDs (e.g., methotrexate) to take effect.</li>\r\n<li>Although effective, prolonged glucocorticoid use is associated with multiple metabolic and electrolyte disturbances.</li>\r\n<li><strong>Mechanism of hypocalcemia:</strong>\r\n<ul>\r\n<li>&darr; Intestinal calcium absorption</li>\r\n<li>&uarr; Renal calcium excretion</li>\r\n<li>&darr; Osteoblast activity and &uarr; bone resorption</li>\r\n<li>Secondary hyperparathyroidism contributes to further bone loss</li>\r\n</ul>\r\n</li>\r\n<li>Long-term use may lead to osteoporosis, increased risk of fractures, and chronic hypocalcemia.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Dehydration (Option A):</strong> Glucocorticoids promote sodium and water retention via mineralocorticoid activity, leading to fluid retention, not dehydration.</p>\r\n<p><strong>Hyperkalemia (Option B):</strong> Glucocorticoids increase renal potassium excretion, often resulting in hypokalemia, not hyperkalemia.</p>\r\n<p><strong>Hyponatremia (Option D):</strong> Due to enhanced sodium reabsorption in renal tubules and intestines, glucocorticoids typically cause hypernatremia, not hyponatremia.</p>", "options": ["Dehydration", "Hyperkalemia", "Hypocalcemia", "Hyponatremia"], "html_options": ["Dehydration", "Hyperkalemia", "Hypocalcemia", "Hyponatremia"], "corr_idx": 2}, {"id": "1166598", "html_qtxt": "A 34-year-old woman presents with worsening breathlessness and cough. Chest auscultation reveals bilateral polyphonic inspiratory and expiratory wheeze. She has started on supplemental oxygen, nebulised albuterol and ipratropium, and intravenous methylprednisolone. Which of the following is a pharmacologic effect of exogenous glucocorticoids?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Glucocorticoids exert their potent anti-inflammatory effects by inhibiting the enzyme <strong>phospholipase A2</strong>, which suppresses the production of <strong>leukotrienes and prostaglandins</strong>, two key mediators of inflammation.</p>\r\n<ul>\r\n<li>This inhibition leads to:\r\n<ul>\r\n<li>Decreased recruitment and activation of inflammatory cells (e.g., eosinophils, macrophages)</li>\r\n<li>Reduced vascular permeability</li>\r\n<li>Suppression of the immune response</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p>They are essential in managing <strong>acute exacerbations of asthma and COPD</strong>, especially when inhaled &beta;2-agonists and anticholinergics are insufficient.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Increased muscle mass (Option A):</strong> Glucocorticoids promote protein catabolism, not anabolism, leading to <strong>muscle wasting</strong> rather than gain.</p>\r\n<p><strong>Improved wound healing (Option C):</strong> They <strong>delay wound healing</strong> by inhibiting fibroblast proliferation, angiogenesis, and collagen deposition.</p>\r\n<p><strong>Increased excretion of salt and water (Option D):</strong> Glucocorticoids typically have <strong>mineralocorticoid activity</strong>, promoting <strong>sodium retention and water retention</strong>, not increased excretion.</p>", "options": ["Increased muscle mass", "Inhibition of leukotriene synthesis ", "Improved wound healing", "Increased excretion of salt and water"], "html_options": ["Increased muscle mass", "Inhibition of leukotriene synthesis ", "Improved wound healing", "Increased excretion of salt and water"], "corr_idx": 1}, {"id": "1166599", "html_qtxt": "A 48-year-old man presents with signs of Cushing's syndrome. He is diagnosed with an adrenal tumour causing excess corticosteroid production. Which of the following drugs would most appropriately help reduce his symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Ketoconazole</strong> is an antifungal agent that inhibits multiple cytochrome P450 enzymes, including those involved in adrenal steroidogenesis. It is used off-label in the treatment of Cushing's syndrome due to its ability to reduce the synthesis of cortisol and other adrenal steroids.</p>\r\n<ul>\r\n<li>It blocks enzymes like CYP17 and CYP11A1, thereby suppressing adrenal androgen and corticosteroid production.</li>\r\n<li>It is especially useful in adrenal tumours where feedback regulation is lost, and corticosteroid overproduction is autonomous.</li>\r\n<li>Its clinical utility is limited by hepatotoxicity and other adverse effects, but it remains an important pharmacologic agent for cortisol excess.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Betamethasone (Option A):</strong> A potent glucocorticoid that would worsen symptoms of Cushing's syndrome if administered exogenously.</p>\r\n<p><strong>Cortisol (Option B):</strong> Endogenous glucocorticoid; giving additional cortisol would exacerbate rather than treat hypercortisolism.</p>\r\n<p><strong>Fludrocortisone (Option C):</strong> A synthetic mineralocorticoid with glucocorticoid activity, used in adrenal insufficiency; contraindicated in cortisol excess.</p>", "options": ["Betamethasone ", "Cortisol", "Fludrocortisone ", "Ketoconazole "], "html_options": ["Betamethasone ", "Cortisol", "Fludrocortisone ", "Ketoconazole "], "corr_idx": 3}, {"id": "1166600", "html_qtxt": "A newborn girl exhibits ambiguous genitalia, hyponatremia, hyperkalemia, and hypotension. She has started on intravenous fluids, salt replacement, and hydrocortisone. Which of the following describes the primary therapeutic effect of glucocorticoid administration in this case?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Glucocorticoid therapy suppresses ACTH secretion, which is the primary therapeutic goal in congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.</p>\r\n<ul>\r\n<li><strong>Pathophysiology:</strong>\r\n<ul>\r\n<li>Deficiency of 21-hydroxylase impairs cortisol and aldosterone synthesis.</li>\r\n<li>Low cortisol leads to loss of negative feedback &rarr; &uarr;ACTH &rarr; adrenal hyperplasia and &uarr;androgen production.</li>\r\n<li>Excess adrenal androgens result in virilisation in females.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Therapeutic Role of Glucocorticoids:</strong>\r\n<ul>\r\n<li>Replaces deficient cortisol.</li>\r\n<li>Suppresses ACTH &rarr; reduces adrenal androgen production.</li>\r\n<li>Helps prevent further virilisation and corrects electrolyte imbalance (via mineralocorticoid activity in some preparations).</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Increased adrenal estrogen synthesis (Option A):</strong> Glucocorticoids do not increase estrogen synthesis; androgens are diverted toward estrogens only in peripheral tissues, not in adrenal pathology.</p>\r\n<p><strong>Inhibition of adrenal aldosterone synthesis (Option B):</strong> This would worsen the mineralocorticoid deficiency seen in CAH.</p>\r\n<p><strong>Prevention of hypoglycemia (Option C):</strong> Although glucocorticoids have a role in gluconeogenesis, it is not the primary therapeutic mechanism in CAH.</p>", "options": ["Increased adrenal estrogen synthesis", "Inhibition of adrenal aldosterone synthesis ", "Prevention of hypoglycemia", "Suppression of ACTH secretion"], "html_options": ["Increased adrenal estrogen synthesis", "Inhibition of adrenal aldosterone synthesis ", "Prevention of hypoglycemia", "Suppression of ACTH secretion"], "corr_idx": 3}, {"id": "1166602", "html_qtxt": "A 56-year-old woman with systemic lupus erythematosus (SLE) had been receiving moderate-dose oral prednisone daily for 9 months. Now that the disease is in remission, her physician plans to taper the steroid dose. Gradual withdrawal of the glucocorticoid is primarily necessary for the recovery of which of the following physiological systems?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Gradual tapering of exogenous glucocorticoids is essential because they suppress the HPA axis via negative feedback on corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secretion.</p>\r\n<ul>\r\n<li>Sudden discontinuation after prolonged use may lead to adrenal insufficiency, as endogenous cortisol production remains impaired.</li>\r\n<li>Recovery of the HPA axis is slow and requires months of tapering to restore normal adrenal responsiveness.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001ea79977b-a08b-423c-941d-faa7f17f586e.PNG\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Depressed release of insulin from pancreatic &beta; cells (Option A):</strong> Glucocorticoids may cause insulin resistance, but tapering is not directed at restoring &beta;-cell function.</p>\r\n<p><strong>Hematopoiesis in the bone marrow (Option B):</strong> Glucocorticoids do not suppress hematopoiesis significantly; no tapering is needed for marrow recovery.</p>\r\n<p><strong>Normal osteoblast function (Option C):</strong> While chronic steroid use reduces bone formation, tapering is aimed at adrenal recovery, not bone cell activity.</p>", "options": ["Depressed release of insulin from pancreatic &beta; cells", "Hematopoiesis in the bone marrow", "Normal osteoblast function", "The hypothalamic-pituitary-adrenal (HPA) system"], "html_options": ["Depressed release of insulin from pancreatic &beta; cells", "Hematopoiesis in the bone marrow", "Normal osteoblast function", "The hypothalamic-pituitary-adrenal (HPA) system"], "corr_idx": 3}, {"id": "1166603", "html_qtxt": "Which of the following best describes a glucocorticoid response element?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Glucocorticoids exert their effects by binding to the glucocorticoid receptor (GR), which then translocates to the nucleus and binds to specific DNA sequences known as glucocorticoid response elements (GREs).</p>\n<p>These GREs are short DNA sequences located in the regulatory regions of target genes and mediate transcriptional activation or repression in response to glucocorticoid signalling.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251003895d393f-8bdf-428c-852d-13d3b92a4fd6.PNG\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Protein regulator that controls the interaction between an activated steroid receptor and DNA (Option A):</strong> Refers to co-regulators, not the GRE itself.</p>\n<p><strong>Short DNA sequence that binds tightly to RNA polymerase (Option B):</strong> Describes promoter elements, not GREs.</p>\n<p><strong>Small protein that binds to an unoccupied steroid receptor protein and prevents it from becoming denatured (Option C):</strong> Describes heat-shock proteins (e.g., Hsp90), not GREs.</p>", "options": ["A protein regulator that controls the interaction between an activated steroid receptor and DNA", "Short DNA sequence that binds tightly to RNA polymerase", "Small protein that binds to an unoccupied steroid receptor protein and prevents it from becoming denatured", "Specific nucleotide sequence that is recognised by a steroid hormone receptor-hormone complex"], "html_options": ["A protein regulator that controls the interaction between an activated steroid receptor and DNA", "Short DNA sequence that binds tightly to RNA polymerase", "Small protein that binds to an unoccupied steroid receptor protein and prevents it from becoming denatured", "Specific nucleotide sequence that is recognised by a steroid hormone receptor-hormone complex"], "corr_idx": 3}, {"id": "1166605", "html_qtxt": "Which one of the following is the most potent anti-inflammatory steroid?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Dexamethasone is the most potent anti-inflammatory steroid among the options listed.</p>\r\n<ul>\r\n<li>The glucocorticoid activity (anti-inflammatory effect) varies among corticosteroids.</li>\r\n<li>Dexamethasone has very high anti-inflammatory potency with negligible mineralocorticoid activity.</li>\r\n<li>In contrast, cortisol has both glucocorticoid and mineralocorticoid activity but low potency.</li>\r\n<li>This makes dexamethasone particularly effective in treating inflammatory and autoimmune conditions.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307b89cd32b-572a-425f-be52-623c79e7c892.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Cortisol (Option A):</strong> Natural glucocorticoid with both glucocorticoid and mineralocorticoid activity, but lowest anti-inflammatory potency.</p>\r\n<p><strong>Fludrocortisone (Option C):</strong> Has strong mineralocorticoid activity with modest anti-inflammatory action, used primarily for its salt-retaining effects.</p>\r\n<p><strong>Prednisone (Option D):</strong> Intermediate glucocorticoid potency; widely used but less potent than dexamethasone.</p>", "options": ["Cortisol", "Dexamethasone ", "Fludrocortisone ", "Prednisone"], "html_options": ["Cortisol", "Dexamethasone ", "Fludrocortisone ", "Prednisone"], "corr_idx": 1}, {"id": "1166606", "html_qtxt": "A 54-year-old man with advanced tuberculosis has developed signs of severe acute adrenal insufficiency. The patient should be treated immediately. Which of the following combinations is most rational?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The most rational therapy in acute adrenal insufficiency is the administration of both a glucocorticoid and a mineralocorticoid.</p>\r\n<ul>\r\n<li>Acute adrenal insufficiency is life-threatening and requires prompt glucocorticoid therapy, typically using cortisol (hydrocortisone), which has both glucocorticoid and mineralocorticoid activity.</li>\r\n<li>Fludrocortisone is added to ensure adequate mineralocorticoid replacement, especially after initial stabilisation.</li>\r\n<li>This combination corrects both volume depletion and impaired glucose homeostasis.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001c365b568-c072-4033-8c74-f45758cf4049.PNG\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Aldosterone and fludrocortisone (Option A):</strong> Aldosterone is not used pharmacologically; fludrocortisone already provides mineralocorticoid effects, but glucocorticoid is missing in this option.</p>\r\n<p><strong>Dexamethasone and metyrapone (Option C):</strong> Dexamethasone lacks mineralocorticoid activity; metyrapone inhibits steroid synthesis, contraindicated here.</p>\r\n<p><strong>Fludrocortisone and metyrapone (Option D):</strong> Lacks a glucocorticoid; metyrapone worsens adrenal insufficiency.</p>", "options": ["Aldosterone and fludrocortisone ", "Cortisol and fludrocortisone", "Dexamethasone and metyrapone ", "Fludrocortisone and metyrapone "], "html_options": ["Aldosterone and fludrocortisone ", "Cortisol and fludrocortisone", "Dexamethasone and metyrapone ", "Fludrocortisone and metyrapone "], "corr_idx": 1}, {"id": "1166607", "html_qtxt": "Which of the following is a drug that, in high doses, blocks the glucocorticoid receptor?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Mifepristone is a potent glucocorticoid receptor antagonist at high doses and is approved for use in hypercortisolism.</p>\r\n<ul>\r\n<li><strong>Mechanism of action:</strong>\r\n<ul>\r\n<li>Mifepristone competitively inhibits the glucocorticoid receptor (GR) and progesterone receptor (PR).</li>\r\n<li>At low doses, it acts as a progesterone antagonist; at high doses, it blocks GR.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Clinical use:</strong>\r\n<ul>\r\n<li>Approved for the control of hyperglycemia in patients with endogenous Cushing syndrome who are not candidates for surgery or have failed surgery.</li>\r\n<li>Especially useful in ACTH-independent Cushing syndrome.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Dose and response:</strong>\r\n<ul>\r\n<li>The usual dose is 300 mg orally once daily; it may be increased depending on response.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Key feature:</strong>\r\n<ul>\r\n<li>Unlike steroidogenesis inhibitors (e.g., ketoconazole), mifepristone does not decrease cortisol synthesis but blocks its peripheral action at the receptor level.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Aminoglutethimide (Option A):</strong> Inhibits conversion of cholesterol to pregnenolone; reduces synthesis of adrenal steroids but does not block glucocorticoid receptors.</p>\r\n<p><strong>Beclomethasone (Option B):</strong> A synthetic glucocorticoid agonist; it stimulates glucocorticoid receptors, not blocks them.</p>\r\n<p><strong>Ketoconazole (Option C):</strong> Inhibits steroidogenesis by blocking CYP450 enzymes like 17&alpha;-hydroxylase; it reduces cortisol production but does not block the receptor directly.</p>", "options": ["Aminoglutethimide", "Beclomethasone", "Ketoconazole", "Mifepristone"], "html_options": ["Aminoglutethimide", "Beclomethasone", "Ketoconazole", "Mifepristone"], "corr_idx": 3}, {"id": "1166609", "html_qtxt": "A 7-year-old boy is presented with progressive fatigue and weight loss. Physical examination shows tanned skin and hyperpigmentation of the gums. Serum studies show::<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403076110a7f8-949d-423a-bae1-312eef027c6d.jpg\"><br>Intravenous fluid resuscitation is begun. Which of the following is the most appropriate next step in management?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Hydrocortisone is the drug of choice for acute adrenal insufficiency to correct hypocortisolism and prevent adrenal crisis.</p>\r\n<ul>\r\n<li><strong>Symptoms of adrenal insufficiency</strong> include fatigue, anorexia, weight loss, hypotension, and hypoglycemia.</li>\r\n<li><strong>Hyperpigmentation of the gums and skin</strong> results from increased ACTH and MSH, characteristic of <strong>primary adrenal insufficiency</strong>.</li>\r\n<li><strong>Electrolyte abnormalities</strong> such as hyponatremia and hyperkalemia suggest <strong>aldosterone deficiency</strong>.</li>\r\n<li>In the <strong>acute setting</strong>, high-dose hydrocortisone provides both glucocorticoid and mineralocorticoid activity, which makes it suitable initially.</li>\r\n<li>In <strong>chronic treatment</strong>, a mineralocorticoid like fludrocortisone is added for more specific aldosterone replacement.</li>\r\n<li>Hydrocortisone is superior to dexamethasone or prednisone in this context as it has the right profile for both GC and MC effects and is preferred for rapid action in emergencies.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Gluten-free diet (Option A):</strong> Indicated in celiac disease, not in adrenal insufficiency.</p>\r\n<p><strong>Levothyroxine therapy (Option B):</strong> Used in hypothyroidism; this patient's symptoms and labs suggest adrenal insufficiency, not thyroid dysfunction.</p>\r\n<p><strong>Deferoxamine therapy (Option D):</strong> Used for iron overload, e.g., thalassemia with secondary hemochromatosis, not relevant in this case.</p>", "options": ["Gluten-free diet", "Levothyroxine therapy", "Hydrocortisone therapy", "Deferoxamine therapy"], "html_options": ["Gluten-free diet", "Levothyroxine therapy", "Hydrocortisone therapy", "Deferoxamine therapy"], "corr_idx": 2}, {"id": "1166610", "html_qtxt": "A 15-year-old girl is diagnosed with asthma, and treatment is begun with an albuterol + low-dose inhaled beclomethasone inhaler as needed. The patient is at greatest risk for which of the following adverse effects?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Oropharyngeal candidiasis</strong> is the<strong> most common </strong>adverse effect of<strong> inhaled corticosteroids, </strong>especially when used without proper technique.</p>\r\n<ul>\r\n<li>Inhaled corticosteroids (ICS), such as beclomethasone, deposit part of the drug in the oropharynx, creating a favourable environment for Candida overgrowth.</li>\r\n<li>Clinical trials and population studies show that up to <strong>30% of patients</strong> may develop thrush.</li>\r\n<li>Preventive measures include <strong>gargling and rinsing the mouth</strong> after inhalation and using a <strong>spacer device</strong> with metered dose inhalers.</li>\r\n<li>ICSs are recommended for persistent asthma, and low-dose beclomethasone is part of stepwise asthma therapy in adolescents.</li>\r\n<li>Therapeutic effects may take around <strong>1 week to manifest</strong>, so follow-up evaluation is necessary after initiating ICS.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Acneiform eruptions (Option A):</strong> Not a typical adverse effect of inhaled corticosteroids; more common with systemic corticosteroids.</p>\r\n<p><strong>Easy bruisability (Option C):</strong> Can occur with prolonged or high-dose ICS use but is less frequent than candidiasis.</p>\r\n<p><strong>Hypoglycemia (Option D):</strong> Not associated with corticosteroids; corticosteroids may cause <strong>hyperglycemia</strong>, not hypo.</p>", "options": ["Acneiform eruptions", "Oropharyngeal candidiasis", "Easy bruising", "Hypoglycemia"], "html_options": ["Acneiform eruptions", "Oropharyngeal candidiasis", "Easy bruising", "Hypoglycemia"], "corr_idx": 1}, {"id": "1166611", "html_qtxt": "A 74-year-old woman presents with a sudden loss of vision in her right eye, which subsided spontaneously. She has had multiple episodes of left-sided headaches and pain in her jaw while chewing. Her erythrocyte sedimentation rate is 70 mm/h. Treatment with the appropriate medication for this patient's condition is initiated. Which of the following sets of laboratory findings is most likely a consequence of treatment?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307aaa95399-6772-4c20-8a11-1f8d3a2aca46.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Glucocorticoids, used as first-line therapy for giant cell arteritis, produce characteristic changes in WBC counts: an <strong>increase in neutrophils</strong> (neutrophilic leukocytosis) and a <strong>decrease in lymphocytes and eosinophils</strong>.</p>\n<p><strong>Mechanism of WBC count changes due to glucocorticoids:</strong></p>\n<ul>\n<li><strong>Neutrophils: &uarr; </strong>\n<ul>\n<li>Glucocorticoids cause demargination of neutrophils, increasing their count in circulation.</li>\n<li>There is reduced neutrophil migration into tissues due to suppressed adhesion molecules.</li>\n</ul>\n</li>\n<li><strong>Lymphocytes: &darr; </strong>\n<ul>\n<li>Glucocorticoids promote lymphocyte apoptosis.</li>\n<li>There is a redistribution of lymphocytes out of the circulation.</li>\n</ul>\n</li>\n<li><strong>Eosinophils: &darr; </strong>\n<ul>\n<li>Glucocorticoids cause eosinophil apoptosis.</li>\n<li>They inhibit the release and function of eosinophil-promoting cytokines (e.g., IL-5).</li>\n</ul>\n</li>\n<li><strong>Monocytes: &darr; </strong> due to similar mechanisms</li>\n</ul>\n<p><strong>(Other options ruled out)</strong></p>", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 2}, {"id": "1166612", "html_qtxt": "A 10-year-old boy with asthma uses an albuterol inhaler and low-dose inhaled mometasone. Which of the following recommendations is most appropriate to prevent complications from this treatment?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Oral rinsing after use of inhaled corticosteroids like mometasone is essential to reduce local side effects, particularly oral candidiasis.</p>\r\n<ul>\r\n<li><strong>Inhaled corticosteroids (ICS)</strong> like mometasone are effective in asthma management with minimal systemic effects.</li>\r\n<li>However, <strong>ICS deposition in the oropharynx</strong> can lead to <strong>oral candidiasis</strong>.</li>\r\n<li><strong>Rinsing the mouth</strong> or <strong>gargling after inhalation</strong> helps reduce residual steroid deposition and the risk of fungal colonisation.</li>\r\n<li>This recommendation is standard practice to minimise local complications without reducing drug efficacy.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Trimethoprim-sulfamethoxazole (Option A):</strong> Not relevant to preventing ICS-related candidiasis; used for bacterial infections like Pneumocystis prophylaxis.</p>\r\n<p><strong>Pantoprazole use prior to meals (Option B):</strong> Useful in GERD or steroid-induced gastritis with systemic corticosteroids, but not indicated for inhaled steroid use.</p>\r\n<p><strong>Minimising use of a spacer (Option C):</strong> Incorrect. Spacers actually <strong>decrease oropharyngeal deposition</strong> and reduce local side effects; minimising spacer use increases risk.</p>", "options": ["Trimethoprim-sulfamethoxazole", "Pantoprazole use prior to meals", "Minimising the use of a spacer", "Oral rinsing after medication administration"], "html_options": ["Trimethoprim-sulfamethoxazole", "Pantoprazole use prior to meals", "Minimising the use of a spacer", "Oral rinsing after medication administration"], "corr_idx": 3}, {"id": "1166613", "html_qtxt": "A 35-year-old woman is diagnosed with systemic lupus erythematosus. Six months later, she complains of difficulty getting up from a chair and climbing stairs. On examination, she has proximal muscle weakness in the shoulders and hips. Deep tendon reflexes are 2+ bilaterally. Laboratory studies show normal erythrocyte sedimentation rate (ESR) and normal creatine kinase (CK). Which of the following is the most likely underlying cause of this patient's symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>This patient's presentation is consistent with <strong>glucocorticoid-induced myopathy</strong>, a known adverse effect of chronic corticosteroid therapy used in SLE.</p>\r\n<ul>\r\n<li><strong>Glucocorticoids</strong>, such as prednisone, are a mainstay in the management of autoimmune conditions like SLE.</li>\r\n<li><strong>Myopathy</strong> presents as <strong>painless, proximal muscle weakness</strong>, typically in the <strong>shoulders and hips</strong>, and is <strong>non-inflammatory</strong>.</li>\r\n<li><strong>Laboratory values</strong> such as ESR and CK are typically <strong>normal</strong>, helping distinguish it from inflammatory myopathies.</li>\r\n<li>The mechanism involves <strong>catabolic effects</strong> of corticosteroids on muscle protein metabolism.</li>\r\n<li>Muscle strength typically <strong>improves within weeks</strong> of reducing or stopping the steroid.</li>\r\n<li>Corticosteroid-induced myopathy is often <strong>underrecognized</strong> and <strong>not associated with muscle tenderness or elevated enzymes</strong>, distinguishing it from polymyositis or dermatomyositis.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Autoantibodies against postsynaptic acetylcholine receptors (Option A):</strong> Seen in myasthenia gravis, which presents with fatigable weakness and ptosis, not persistent proximal limb weakness with normal CK.</p>\r\n<p><strong>Autoantibodies against myelin (Option B):</strong> Associated with demyelinating diseases like multiple sclerosis, typically with sensory and CNS signs.</p>\r\n<p><strong>Autoantibodies against presynaptic voltage-gated calcium channels (Option C):</strong> Seen in Lambert-Eaton syndrome, which presents with autonomic symptoms and improvement in strength with use.</p>", "options": ["Autoantibodies against postsynaptic acetylcholine receptors", "Autoantibodies against myelin", "Autoantibodies against presynaptic voltage-gated calcium channels", "Adverse effect of medication"], "html_options": ["Autoantibodies against postsynaptic acetylcholine receptors", "Autoantibodies against myelin", "Autoantibodies against presynaptic voltage-gated calcium channels", "Adverse effect of medication"], "corr_idx": 3}, {"id": "1166615", "html_qtxt": "Therapy with a high-potency topical medication that inhibits NF-<sub>k</sub>B and phospholipase A<sub>2</sub> is begun. Long-term use of this agent is most likely to result in which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Chronic use of topical corticosteroids results in dermal collagen loss, leading to skin thinning and striae (stretch marks). This is one of the most common adverse effects of topical glucocorticoids. The risk increases with:</p>\r\n<ul>\r\n<li>High-potency corticosteroids (e.g., clobetasol)</li>\r\n<li>Prolonged duration of therapy</li>\r\n<li>Occlusion (e.g., plastic wrap)</li>\r\n</ul>\r\n<p><strong>Mechanism of action:</strong></p>\r\n<ul>\r\n<li>Corticosteroids bind to intracellular glucocorticoid receptors.</li>\r\n<li>This complex translocates to the nucleus and binds to GREs (glucocorticoid response elements).</li>\r\n<li>It inhibits transcription of pro-inflammatory cytokines via activation of <strong>I&kappa;B</strong>, which inhibits <strong>NF-&kappa;B</strong>.</li>\r\n</ul>\r\n<p>Also inhibits <strong>phospholipase A<sub>2,</sub></strong>, reducing arachidonic acid derivatives</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510014bdf37c2-70e0-4e93-b5e9-9db785bf07ef.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Dysplastic nevi (Option A):</strong> Not associated with corticosteroid use. Dysplastic nevi are atypical moles with irregular borders and pigmentation, not drug-induced lesions.</p>\r\n<p><strong>Nonblanchable pinpoint macules (Option B):</strong> These are characteristic of petechiae or purpura due to platelet disorders or vasculitis, not corticosteroid therapy.</p>\r\n<p><strong>Hair growth on upper lip (Option D):</strong> Hirsutism can occur with systemic corticosteroids due to androgenic effects, but it is uncommon with topical corticosteroids unless used extensively or in systemic absorption situations.</p>", "options": ["Dysplastic nevi", "Nonblanchable pinpoint macules", "Dermal collagen loss", "Hair growth on the upper lip"], "html_options": ["Dysplastic nevi", "Nonblanchable pinpoint macules", "Dermal collagen loss", "Hair growth on the upper lip"], "corr_idx": 2}, {"id": "1166616", "html_qtxt": "A 59-year-old woman with rheumatoid arthritis is undergoing evaluation for long-term complications. A recent DEXA scan reveals a T-score of 1.80. Which of the following drugs is most likely involved in the pathogenesis of this finding?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The most likely cause of this patient's osteopenia is long-term use of <strong>glucocorticoids</strong> like prednisone, commonly prescribed for refractory rheumatoid arthritis.</p>\r\n<ul>\r\n<li>Glucocorticoids such as prednisone increase <strong>osteoclastic bone resorption</strong> via the <strong>RANK ligand pathway</strong> and reduce osteoblast activity.</li>\r\n<li>They also impair <strong>intestinal calcium absorption</strong> and promote <strong>urinary calcium loss</strong>, leading to <strong>secondary hyperparathyroidism</strong>, which further worsens bone loss.</li>\r\n<li><strong>Postmenopausal status</strong> (common in this age group) adds to the risk due to reduced estrogen levels.</li>\r\n<li>Management includes <strong>calcium and vitamin D supplementation</strong>, and <strong>bisphosphonates or denosumab</strong> for prevention/treatment of glucocorticoid-induced osteoporosis.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Sulfasalazine (Option A):</strong> Disease-modifying antirheumatic drug (DMARD) with <strong>anti-inflammatory and immunosuppressive</strong> effects; not associated with osteoporosis or bone loss.</p>\r\n<p><strong>Medroxyprogesterone acetate (Option B):</strong> Synthetic progestin used in contraception and hormone therapy; long-term depot forms may reduce bone density, but it is not relevant in this patient with rheumatoid arthritis.</p>\r\n<p><strong>Adalimumab (Option D):</strong> TNF-&alpha; inhibitor used to treat RA; <strong>reduces inflammation</strong> and may help <strong>preserve bone</strong> by reducing cytokine-mediated bone resorption, not cause bone loss.</p>", "options": ["Sulfasalazine", "Medroxyprogesterone acetate", "Prednisone", "Adalimumab"], "html_options": ["Sulfasalazine", "Medroxyprogesterone acetate", "Prednisone", "Adalimumab"], "corr_idx": 2}, {"id": "1166618", "html_qtxt": "Which of the following patients is most likely to be treated with intravenous glucagon?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Glucagon is used as an antidote in beta-blocker overdose</strong>, as it bypasses the &beta;-adrenergic receptor and stimulates intracellular cAMP through a separate receptor mechanism.</p>\r\n<ul>\r\n<li><strong>Mechanism of action:</strong>\r\n<ul>\r\n<li>Acts on cardiac glucagon receptors.</li>\r\n<li>Increases intracellular cAMP &rarr; enhances heart rate and contractility.</li>\r\n<li>This is beneficial when &beta;-adrenergic receptors are blocked (e.g., &beta;-blocker overdose).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Clinical use in beta-blocker toxicity:</strong>\r\n<ul>\r\n<li>Improves bradycardia and hypotension.</li>\r\n<li>Given IV in emergencies.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other antidotal roles:</strong>\r\n<ul>\r\n<li>Also used in calcium channel blocker overdose.</li>\r\n<li>Included in standard antidote lists for these toxicities.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>An 18-year-old woman who took an overdose of cocaine and now has a blood pressure of 190/110 mm Hg (Option A):</strong> Cocaine overdose causes hypertension and tachycardia due to increased catecholamine activity, and glucagon is not indicated in this scenario.</p>\r\n<p><strong>A 57-year-old woman with type 2 diabetes who has not taken her glyburide for the last 3 days (Option B):</strong> Glucagon is used in hypoglycemia, but this patient is off glyburide and has no hypoglycemia; hence, glucagon is not needed.</p>\r\n<p><strong>A 74-year-old man with lactic acidosis as a complication of severe infection and shock (Option D):</strong> Lactic acidosis from septic shock is treated with supportive care; glucagon has no therapeutic role here.</p>", "options": [" An 18-year-old woman who took an overdose of cocaine and now has a blood pressure of 190/110 mm Hg", "A 57-year-old woman with type 2 diabetes who has not taken her glyburide for the last 3 days", "A 62-year-old man with severe bradycardia and hypotension resulting from ingestion of an overdose of Atenolol", "A 74-year-old man with lactic acidosis as a complication of severe infection and shock"], "html_options": [" An 18-year-old woman who took an overdose of cocaine and now has a blood pressure of 190/110 mm Hg", "A 57-year-old woman with type 2 diabetes who has not taken her glyburide for the last 3 days", "A 62-year-old man with severe bradycardia and hypotension resulting from ingestion of an overdose of Atenolol", "A 74-year-old man with lactic acidosis as a complication of severe infection and shock"], "corr_idx": 2}, {"id": "1166619", "html_qtxt": "A 12-year-old boy with known type 1 diabetes mellitus is brought to the emergency department with severe vomiting and drowsiness. On evaluation, he has marked hyperglycemia, ketonuria, and a blood pH of 7.20. Which of the following agents is the most appropriate for immediate management of his condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Regular insulin</strong> is the drug of choice in diabetic ketoacidosis (DKA) due to its rapid onset of action and ability to be administered intravenously. It helps to reverse hyperglycemia, suppress ketogenesis, and correct acidosis effectively.</p>\r\n<ul>\r\n<li><strong>Indication</strong>: First-line agent in DKA</li>\r\n<li><strong>Route</strong>: Intravenous infusion</li>\r\n<li><strong>Mechanism</strong>: &darr; glucose, &darr; lipolysis, &darr; ketone production</li>\r\n<li><strong>Monitoring</strong>: Blood glucose and potassium levels</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Glyburide (Option A):</strong> This sulfonylurea is used in type 2 diabetes and is not effective in type 1 diabetes or in the acute setting of DKA.</p>\r\n<p><strong>Insulin glargine (Option B):</strong> Long-acting insulin used for basal control and not suitable for rapid correction in emergencies like DKA.</p>\r\n<p><strong>NPH insulin (Option C):</strong> Intermediate-acting insulin, not used intravenously, and has a delayed onset; inappropriate for emergency management.</p>", "options": ["Glyburide", "Insulin glargine", "NPH insulin ", "Regular insulin"], "html_options": ["Glyburide", "Insulin glargine", "NPH insulin ", "Regular insulin"], "corr_idx": 3}, {"id": "1166620", "html_qtxt": "A 25-year-old woman with type 1 diabetes wishes to improve control of her diabetes to reduce long-term complications. Which of the following insulin regimens is most appropriate?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Tight glycemic control in type 1 diabetes is best achieved by mimicking physiologic insulin secretion using a <strong>basal-bolus regimen</strong>, combining a long-acting insulin such as <strong>insulin glargine</strong> for basal coverage and a rapid-acting insulin such as <strong>insulin lispro</strong> before meals to handle prandial glucose spikes.</p>\r\n<ul>\r\n<li>Insulin glargine provides sustained basal insulin with once-daily injection and a low risk of hypoglycemia.</li>\r\n<li>Insulin lispro has a rapid onset and short duration, mimicking mealtime insulin secretion.</li>\r\n<li>This regimen provides flexibility and better control over glucose fluctuations, reducing long-term microvascular and macrovascular complications.</li>\r\n<li>Morning administration of long-acting insulin is preferred to align with diurnal glucose intake patterns.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Morning injections of mixed insulin lispro and insulin aspart (Option A):</strong> Combining two rapid-acting insulins offers no basal coverage, leading to poor glycemic control between meals and overnight.</p>\r\n<p><strong>Evening injections of mixed regular insulin and insulin glargine (Option B):</strong> Evening glargine may increase nocturnal hypoglycemia risk; regular insulin is suboptimal due to delayed onset and less predictable action.</p>\r\n<p><strong>Morning and evening injections of regular insulin, supplemented by small amounts of NPH insulin at mealtimes (Option C):</strong> This is a reversed and outdated pattern; NPH is not ideal for prandial coverage due to delayed onset.</p>", "options": ["Morning injections of mixed insulin lispro and insulin aspart", "Evening injections of mixed regular insulin and insulin glargine", "Morning and evening injections of regular insulin, supplemented by small amounts of NPH insulin at mealtimes", "Morning injections of insulin glargine, supplemented by small amounts of insulin lispro at mealtimes"], "html_options": ["Morning injections of mixed insulin lispro and insulin aspart", "Evening injections of mixed regular insulin and insulin glargine", "Morning and evening injections of regular insulin, supplemented by small amounts of NPH insulin at mealtimes", "Morning injections of insulin glargine, supplemented by small amounts of insulin lispro at mealtimes"], "corr_idx": 3}, {"id": "1166623", "html_qtxt": "Which of the following is an important physiological effect of insulin?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>A key metabolic action of insulin is <strong>enhancing glucose uptake into cells</strong>, especially skeletal muscle and adipose tissue, by promoting translocation of GLUT-4 transporters to the cell membrane. This facilitates <strong>postprandial glucose clearance</strong> from the circulation and contributes significantly to its glucose-lowering effects.</p>\r\n<ul>\r\n<li>Insulin increases glucose utilisation in muscle and adipose tissue.</li>\r\n<li>It promotes glycogen synthesis and inhibits gluconeogenesis.</li>\r\n<li>It also inhibits lipolysis and proteolysis, supporting anabolic metabolism.</li>\r\n</ul>\r\n<p>These effects are mediated via activation of the insulin receptor tyrosine kinase and downstream signalling pathways.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307913f6712-c394-4f01-b223-41eef3484c2e.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Increased gluconeogenesis (Option A):</strong> Insulin suppresses hepatic gluconeogenesis; glucagon and cortisol stimulate it.</p>\r\n<p><strong>Inhibition of lipoprotein lipase (Option C):</strong> Insulin enhances the activity of lipoprotein lipase, promoting lipid storage.</p>\r\n<p><strong>Stimulation of glycogenolysis (Option D):</strong> Insulin inhibits glycogenolysis and promotes glycogen synthesis in the liver and muscle.</p>", "options": ["Increased gluconeogenesis", "Glucose transport into cells", "Inhibition of lipoprotein lipase ", "Stimulation of glycogenolysis"], "html_options": ["Increased gluconeogenesis", "Glucose transport into cells", "Inhibition of lipoprotein lipase ", "Stimulation of glycogenolysis"], "corr_idx": 1}, {"id": "1166624", "html_qtxt": "The PPAR-&gamma; receptor that is activated by thiazolidinediones increases tissue sensitivity to insulin by which of the following mechanisms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>PPAR-&gamma; (Peroxisome proliferator-activated receptor gamma)</strong> is a nuclear receptor activated by thiazolidinediones such as pioglitazone and rosiglitazone. Upon activation:</p>\r\n<ul>\r\n<li>It <strong>translocates to the nucleus</strong> and binds to DNA at <strong>PPAR response elements</strong>.</li>\r\n<li>This leads to <strong>modulation of transcription of insulin-sensitive genes</strong>, particularly those involved in <strong>glucose and lipid metabolism</strong>.</li>\r\n<li>It enhances <strong>insulin-mediated glucose uptake</strong>, especially in <strong>adipose tissue</strong>, and increases the expression of <strong>GLUT4</strong>, contributing to improved glycemic control.</li>\r\n<li>It also promotes <strong>adipocyte differentiation</strong>, redistribution of fat from visceral to subcutaneous stores, and <strong>decreased hepatic glucose output</strong>.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510010ce39434-b504-41d6-8b0a-db3776b0bde7.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Activating adenylyl cyclase and increasing cAMP (Option A):</strong> This is the mechanism of glucagon and &beta;-adrenergic agonists, not PPAR-&gamma; agonists.</p>\r\n<p><strong>Inactivating a cellular inhibitor of GLUT2 (Option B):</strong> GLUT2 is not the primary glucose transporter affected by thiazolidinediones; GLUT4 is.</p>\r\n<p><strong>Inhibiting acid glucosidase (Option C):</strong> This is the mechanism of alpha-glucosidase inhibitors like acarbose and miglitol, not thiazolidinediones.</p>", "options": ["Activating adenylyl cyclase and increasing the intracellular concentration of cAMP", "Inactivating a cellular inhibitor of the GLUT2 glucose transporter", "Inhibiting acid glucosidase, a key enzyme in glycogen breakdown pathways", "Regulating transcription of genes involved in glucose utilisation"], "html_options": ["Activating adenylyl cyclase and increasing the intracellular concentration of cAMP", "Inactivating a cellular inhibitor of the GLUT2 glucose transporter", "Inhibiting acid glucosidase, a key enzyme in glycogen breakdown pathways", "Regulating transcription of genes involved in glucose utilisation"], "corr_idx": 3}, {"id": "1166626", "html_qtxt": "Identify the incorrect pair of the drug with its adverse effect:", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Metformin is not known to cause agranulocytosis. Its major side effects include gastrointestinal disturbances and a rare but serious risk of lactic acidosis. Agranulocytosis is not mentioned among metformin-related adverse effects.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307f1f60ead-7100-48e4-804c-0b874a41934a.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20240307802eb5cc-31a2-4341-a293-08a58276e73d.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Acarbose (Option B):</strong> Causes flatulence due to delayed carbohydrate digestion in the gut.</p>\r\n<p><strong>Rosiglitazone (Option C):</strong> Known to cause peripheral oedema and weight gain due to PPAR-&gamma; activation effects.</p>\r\n<p><strong>Liraglutide (Option D):</strong> GLP-1 agonist, associated with gastrointestinal disturbances and has been linked to pancreatitis.</p>", "options": ["Metformin - Agranulocytosis", "Acarbose - Flatulence", "Rosiglitazone - Oedema", "Liraglutide - Pancreatitis"], "html_options": ["Metformin - Agranulocytosis", "Acarbose - Flatulence", "Rosiglitazone - Oedema", "Liraglutide - Pancreatitis"], "corr_idx": 0}, {"id": "1166628", "html_qtxt": "A 56-year-old man with type 2 diabetes mellitus presents with elevated serum creatinine and an estimated glomerular filtration rate (eGFR) of 28 mL/min/1.73 m<sup>2</sup>. Which of the following glucose-lowering drugs is contraindicated in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Metformin is contraindicated in patients with <strong>eGFR <30 mL/min/1.73 m<sup>2</sup></strong> due to the increased risk of <strong>lactic acidosis</strong>, particularly in those with renal impairment, liver disease, alcoholism, or conditions that predispose to tissue hypoxia.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Canagliflozin (Option B):</strong> Can be used in DKD with caution; may offer renal protection.</p>\r\n<p><strong>Sitagliptin (Option C):</strong> Dose needs adjustment in renal failure, but is not contraindicated.</p>\r\n<p><strong>Liraglutide (Option D):</strong> Not contraindicated in CKD; has CV and renal benefits.</p>", "options": ["Metformin", "Canagliflozin", "Sitagliptin", "Liraglutide"], "html_options": ["Metformin", "Canagliflozin", "Sitagliptin", "Liraglutide"], "corr_idx": 0}, {"id": "1166629", "html_qtxt": "A 67-year-old male with type 2 diabetes and a history of worsening heart failure is admitted for management of hyperglycemia. Which of the following oral hypoglycemic agents would be most appropriate to initiate, considering additional benefit in heart failure?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>SGLT2 inhibitors such as canagliflozin</strong> are beneficial in patients with type 2 diabetes and heart failure. They:</p>\r\n<ul>\r\n<li>Reduce hospitalisation for heart failure and cardiovascular mortality in patients with diabetes and established heart failure with reduced ejection fraction.</li>\r\n<li>Promote weight loss and blood pressure reduction.</li>\r\n<li>Can be used in combination with other antidiabetics.</li>\r\n</ul>\r\n<p>Other SGLT2 inhibitors like empagliflozin and dapagliflozin also show similar benefits in cardiovascular and renal outcomes.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Metformin (Option A):</strong> Should be used cautiously or avoided in patients with heart failure and impaired renal function due to the risk of lactic acidosis.</p>\r\n<p><strong>Sitagliptin (Option C):</strong> Does not offer cardiovascular mortality or heart failure benefit.</p>\r\n<p><strong>Liraglutide (Option D):</strong> Has cardiovascular benefits, but not primarily in heart failure reduction</p>", "options": ["Metformin", "Canaglifozin", "Sitagliptins", "Liraglutide"], "html_options": ["Metformin", "Canaglifozin", "Sitagliptins", "Liraglutide"], "corr_idx": 1}, {"id": "1166632", "html_qtxt": "A 45-year-old diabetic male presents with complaints of bloody diarrhoea with mucus and faecal urgency. He is poorly compliant with current therapy and requests a change in oral antidiabetic drug. Which one of the following drugs should be avoided in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Acarbose, an &alpha;-glucosidase inhibitor, is contraindicated in patients with inflammatory bowel disease such as ulcerative colitis due to its gastrointestinal side effects.</p>\r\n<ul>\r\n<li><strong>Acarbose</strong> delays carbohydrate absorption by inhibiting &alpha;-glucosidase enzymes in the small intestine.</li>\r\n<li>It frequently causes <strong>flatulence, diarrhoea, and abdominal discomfort</strong> due to fermentation of undigested carbohydrates in the colon.</li>\r\n<li><strong>Contraindications</strong> include <strong>inflammatory bowel disease</strong>, severe renal failure, and malabsorption syndromes.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510010f4913a9-4cb7-46db-9495-106c1b57f0d2.png\">", "options": ["Metformin", "Canagliflozin", "Acarbose", "Liraglutide"], "html_options": ["Metformin", "Canagliflozin", "Acarbose", "Liraglutide"], "corr_idx": 2}, {"id": "1166633", "html_qtxt": "A 67-year-old diabetic male presents with dizziness due to hypoglycemia. He is on treatment with metformin and acarbose. Which of the following is the appropriate management for his hypoglycemic episode?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Patients receiving &alpha;-glucosidase inhibitors (e.g., acarbose) who develop hypoglycemia should be treated specifically with <strong>oral glucose (dextrose)</strong>, not sucrose. This is because:</p>\r\n<ul>\r\n<li>&alpha;-glucosidase inhibitors <strong>delay sucrose digestion</strong> by inhibiting its breakdown in the intestinal brush border.</li>\r\n<li>Consequently, <strong>sucrose absorption is impaired</strong>, rendering it ineffective during a hypoglycemic episode.</li>\r\n<li><strong>Glucose</strong> absorption is not dependent on &alpha;-glucosidase activity and thus remains effective for prompt reversal of hypoglycemia.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Oral sucrose (Option B):</strong> Acarbose inhibits the breakdown of sucrose to glucose and fructose, delaying absorption and making it ineffective during hypoglycemia.</p>\r\n<p><strong>Glucagon (Option C):</strong> Glucagon stimulates hepatic glycogenolysis but is <strong>less effective</strong> when hepatic glycogen stores are low or in patients on &alpha;-glucosidase inhibitors, where the main issue is absorption.</p>\r\n<p><strong>No need to treat (Option D):</strong> Hypoglycemia in diabetic patients always requires prompt correction. <strong>Untreated hypoglycemia</strong> can lead to confusion, seizures, or coma.</p>", "options": ["Oral glucose", "Oral sucrose", "Glucagon", "No need to treat"], "html_options": ["Oral glucose", "Oral sucrose", "Glucagon", "No need to treat"], "corr_idx": 0}, {"id": "1166635", "html_qtxt": "A 67-year-old diabetic male is concerned about hypoglycemia as a complication of his oral hypoglycemic agent (OHA). Which of the following drugs is associated with the maximum risk of hypoglycemia?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Among oral hypoglycemic agents, <strong>sulfonylureas like glipizide</strong> pose the highest risk of <strong>hypoglycemia</strong> due to their direct stimulation of <strong>insulin release</strong> from pancreatic &beta;-cells.</p>\r\n<ul>\r\n<li>Glipizide binds to the <strong>SUR1 subunit</strong> of the KATP channel, causing <strong>depolarisation</strong> of the &beta;-cell membrane, &rarr; triggers insulin release.</li>\r\n<li>This insulin release is <strong>glucose-independent</strong>, meaning it can occur even when blood sugar is low, increasing the <strong>risk of hypoglycemia</strong>.</li>\r\n<li>Glipizide has a <strong>long duration of action</strong> (effects can last 12-24 hours) despite a short plasma half-life.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Canagliflozin (Option B):</strong> This SGLT2 inhibitor causes glucose loss via the kidneys. It has a <strong>low risk of hypoglycemia</strong> because it does not stimulate insulin release.</p>\r\n<p><strong>Sitagliptin (Option C):</strong> A DPP-4 inhibitor that increases endogenous GLP-1 levels. It is <strong>glucose-dependent</strong>, so the risk of hypoglycemia is minimal.</p>\r\n<p><strong>Liraglutide (Option D):</strong> A GLP-1 receptor agonist that also works <strong>only in the presence of high blood glucose</strong>, hence associated with <strong>minimal hypoglycemia</strong>.</p>", "options": ["Glipizide", "Canaglifozin", "Sitagliptins", "Liraglutide"], "html_options": ["Glipizide", "Canaglifozin", "Sitagliptins", "Liraglutide"], "corr_idx": 0}, {"id": "1190926", "html_qtxt": "A 48-year-old man with type 2 diabetes mellitus, currently on glipizide, presents to a primary health centre (PHC) for follow-up. His recent lab reports show a fasting blood sugar (FBS) of 190 mg/dL and HbA1c of 8.8%. After counselling, the physician decides to add canagliflozin to his regimen. Which of the following investigations should be performed before initiating therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Before initiating therapy with <strong>SGLT2 inhibitors</strong> like canagliflozin, <strong>renal function</strong> should be assessed.</p>\r\n<ul>\r\n<li>These drugs act by inhibiting <strong>glucose reabsorption in the proximal renal tubule</strong>, causing urinary glucose loss.</li>\r\n<li>Their <strong>efficacy decreases significantly</strong> in <strong>stage 3 chronic kidney disease (GFR 60-30 mL/min)</strong> and beyond.</li>\r\n<li>Moreover, their metabolites are <strong>excreted via the kidneys</strong>, and adverse effects (e.g., volume depletion, hypotension) are <strong>amplified in renal dysfunction</strong>.</li>\r\n<li>Thus, <strong>blood urea nitrogen (BUN)</strong> and <strong>serum creatinine</strong> are essential baseline tests prior to therapy.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202403073abcedfd-07b7-4fe2-9fcb-e32ad4119fff.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Complete blood count (Option A):</strong> Not necessary unless there's suspicion of infection or anaemia; unrelated to SGLT2 therapy safety.</p>\r\n<p><strong>Liver function test (Option B):</strong> Canagliflozin does not undergo hepatic metabolism and does not require baseline LFTs.</p>\r\n<p><strong>Urinalysis (Option D):</strong> Though glucosuria is a known effect of SGLT2 inhibitors, urinalysis is not mandatory before initiation.</p>", "options": ["Complete blood count", "Liver function test", "Blood urea and nitrogen", "Urinalysis"], "html_options": ["Complete blood count", "Liver function test", "Blood urea and nitrogen", "Urinalysis"], "corr_idx": 2}]}, {"moduleId": 1013783, "name": "Hypothalamus and Pituitary drugs", "questions": [{"id": "1166405", "html_qtxt": "On binding of drug  \"X\" to a GPCR receptor, there is increased production of inositol triphosphate (IP3) in the basophilic cells of the anterior pituitary. Administration of this drug every 90 minutes is most likely to be beneficial in the treatment of which of the following conditions?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Pulsatile administration of GnRH stimulates the pituitary to secrete FSH and LH, which promotes ovulation in women with hypogonadotropic anovulatory infertility.</p>\r\n<ul>\r\n<li>GnRH acts via <strong>Gq protein-coupled receptors</strong> &rarr; activation of <strong>IP3/DAG pathway</strong> in basophilic cells of the anterior pituitary.</li>\r\n<li>Pulsatile GnRH administration stimulates <strong>FSH & LH release</strong>, correcting ovulation in hypogonadotropic hypogonadism.</li>\r\n<li>Continuous administration causes <strong>downregulation/desensitisation</strong> of GnRH receptors &rarr; suppresses FSH/LH &rarr; used for hormone-sensitive cancers.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100130c6037d-80bf-4128-ac2e-e9259e770aca.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Prostate carcinoma (Option A):</strong> Treated with continuous GnRH agonists (e.g., leuprolide), which downregulate pituitary GnRH receptors and suppress gonadotropins.</p>\r\n<p><strong>Central Diabetes Insipidus (Option C):</strong> Managed with desmopressin, an ADH analogue that increases cAMP via V2 receptors in the kidney, not via IP3.</p>\r\n<p><strong>Variceal bleeding (Option D):</strong> Treated with octreotide, which reduces splanchnic blood flow via inhibition of cAMP, not by stimulating IP3 in the pituitary.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403221924d656-780c-4f68-8f5a-c91e6a7e2bbb.jpg\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403220bdc22e3-2fc6-4c5e-bf5c-26b9dc3493b2.jpg\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240325740d02e5-5895-4711-90cd-58a91bed52e4.jpg\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322ff766f77-6050-4d28-89ed-26ce9c78357f.jpg\">\r\n<p>GPCR pathway examples</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322dcc30664-2505-45dc-864a-b7a0f8f350a4.jpg\">", "options": ["Prostate carcinoma", "Anovulatory infertility", "Central Diabetes insipidus", "Variceal bleeding"], "html_options": ["Prostate carcinoma", "Anovulatory infertility", "Central Diabetes insipidus", "Variceal bleeding"], "corr_idx": 1}, {"id": "1166408", "html_qtxt": "A 30-year-old man complains of increased thirst and frequent urination after sustaining a head trauma. Neurologic examination shows no abnormalities. Serum sodium concentration is 152 mEq/L. Which of the following drugs is most appropriate for this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The clinical picture of polyuria, polydipsia, and hypernatremia following head trauma is characteristic of <strong>central diabetes insipidus (CDI)</strong> due to <strong>ADH deficiency</strong> from hypothalamic or pituitary damage.</p>\r\n<ul>\r\n<li><strong>Desmopressin</strong> is a synthetic analogue of vasopressin that selectively acts on <strong>V2 receptors</strong> in the kidney, leading to increased water reabsorption via <strong>aquaporin-2</strong> channel insertion in the collecting ducts.</li>\r\n<li>It effectively corrects the <strong>water diuresis</strong> seen in CDI and is the treatment of choice.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001e333031c-32a3-40d9-b886-22df168eef9e.png\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322b5650cab-5751-446b-bf51-68b49b17cd30.jpg\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403225099856c-e5da-4d49-9235-e81d53ef9c91.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Bromocriptine (Option A):</strong> Dopamine D2 agonist used to treat <strong>hyperprolactinemia</strong> and <strong>Parkinsonism</strong>; has no role in ADH-related disorders.</p>\r\n<p><strong>Demeclocycline (Option C):</strong> Tetracycline derivative used in <strong>SIADH</strong> due to its ADH antagonist effect; <strong>worsens DI</strong> by further reducing ADH action.</p>\r\n<p><strong>Tesamorelin (Option D):</strong> <strong>GHRH analogue</strong> used in HIV-associated lipodystrophy; not used for any form of DI.</p>", "options": ["Bromocriptine", "Desmopressin", "Demeclocycline", "Tesamorelin"], "html_options": ["Bromocriptine", "Desmopressin", "Demeclocycline", "Tesamorelin"], "corr_idx": 1}, {"id": "1166413", "html_qtxt": "A 2-year-old boy with failure to thrive is found to have an inactivating mutation of the growth hormone receptor gene. Which of the following agents is most appropriate to improve his metabolic function and support growth?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Mecasermin </strong>is a<strong> recombinant human IGF-1 analogue </strong>approved for use in children with<strong> severe primary IGF-1 deficiency</strong>, particularly when caused by<strong> inactivating mutations of the GH receptor.</strong></p>\r\n<p>In such cases, somatropin is ineffective as it acts via GH receptors to stimulate IGF-1 synthesis. Mecasermin directly replaces IGF-1, thereby restoring its anabolic and growth-promoting actions.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510015b2b423a-67a2-49a6-95fc-0285965caa22.png\">\r\n<p><strong>(other options ruled out)</strong></p>", "options": ["Atosiban", "Bromocriptine ", "Mecasermin ", "Somatropin"], "html_options": ["Atosiban", "Bromocriptine ", "Mecasermin ", "Somatropin"], "corr_idx": 2}, {"id": "1166414", "html_qtxt": "A 32-year-old woman presents with amenorrhea, galactorrhea, and infertility. She has started on oral bromocriptine therapy. Before initiating the drug, which of the following histories should be specifically elicited due to their relevance in assessing contraindications?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Bromocriptine</strong> is a<strong> dopamine receptor agonist </strong>used for treating <strong>hyperprolactinemia-related disorders </strong>such as<strong> amenorrhea and galactorrhea. </strong></p>\r\n<ul>\r\n<li>Because of its <strong>central dopaminergic activity, bromocriptine </strong>is contraindicated in patients with a history of<strong> schizophrenia </strong>or other<strong> psychotic disorders.</strong></li>\r\n<li>It acts by inhibiting prolactin secretion through activation of D<sub>2</sub> receptors in the hypothalamus and pituitary. The drug can cross the blood-brain barrier and may exacerbate psychotic symptoms due to its dopamine agonist effect.</li>\r\n</ul>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001f4fcb732-e765-4ad8-8a65-d0ccf5abc0c7.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Tremor (Option B):</strong> Not a contraindication. Tremor may occur at higher doses, but it is not a major concern in routine use.</p>\r\n<p><strong>Recent COVID-19 infection (Option C):</strong> Not directly relevant unless associated with severe cardiovascular complications.</p>\r\n<p><strong>Recent neurosurgery (Option D):</strong> Not a contraindication unless affecting hypothalamic-pituitary axis integrity or healing.</p>", "options": ["Schizophrenia", "Tremor", "Recent Covid19 infection", "Recent neurosurgery"], "html_options": ["Schizophrenia", "Tremor", "Recent Covid19 infection", "Recent neurosurgery"], "corr_idx": 0}, {"id": "1166415", "html_qtxt": "A 4-year-old girl presented with hirsutism, breast enlargement, and a height and bone age consistent with that of a 9-year-old. Which of the following is the most appropriate drug for the treatment of this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The clinical scenario indicates <strong>central precocious puberty</strong>, characterised by early sexual development with advanced bone age and secondary sexual characteristics.</p>\r\n<ul>\r\n<li>The most appropriate treatment is with <strong>continuous administration of a long-acting GnRH agonist such as leuprolide</strong>, which downregulates GnRH receptors in the pituitary, leading to decreased LH and FSH secretion and, hence, suppression of gonadotropin-dependent puberty.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510017ddd5bc0-f41d-4d81-81a6-2198b9605e19.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Atosiban (Option A):</strong> Oxytocin receptor antagonist; used as a <strong>tocolytic agent</strong> for preterm labour, not used in precocious puberty.</p>\r\n<p><strong>Follitropin (Option B):</strong> Recombinant FSH used for <strong>infertility</strong> treatment by stimulating follicular development; it would <strong>worsen</strong> precocious puberty.</p>\r\n<p><strong>Pegvisomant (Option D):</strong> GH receptor antagonist; used in <strong>acromegaly</strong> to reduce IGF-1 levels; has <strong>no role</strong> in puberty regulation.</p>", "options": ["Atosiban ", "Follitropin ", "Leuprolide ", "Pegvisomant"], "html_options": ["Atosiban ", "Follitropin ", "Leuprolide ", "Pegvisomant"], "corr_idx": 2}, {"id": "1166416", "html_qtxt": "A 47-year-old man presented with coarsened facial features, large hands and feet, and elevated serum IGF-1 levels. MRI revealed a large pituitary adenoma, and he underwent transsphenoidal surgery. However, hormone levels remain high postoperatively. Which of the following is the most appropriate next pharmacological treatment?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Somatostatin analogues like <strong>octreotide</strong> are first-line pharmacologic agents used to treat acromegaly when surgery is not fully effective or not feasible.</p>\r\n<ul>\r\n<li>Octreotide acts by binding to somatostatin receptors, inhibiting growth hormone (GH) secretion and reducing IGF-1 levels.</li>\r\n<li>It also leads to <strong>tumour shrinkage</strong> in many patients with GH-secreting pituitary adenomas.</li>\r\n<li>It is given subcutaneously or in long-acting formulations (e.g., LAR 20&ndash;30 mg every 4 weeks).</li>\r\n<li>Octreotide is well-tolerated, with GI side effects (diarrhoea, abdominal pain, nausea) in up to 50% of cases.</li>\r\n<li>Approximately 25% of patients show <strong>tumour size reduction</strong>, and over 50% show <strong>symptom control</strong> and normalisation of IGF-1 levels.</li>\r\n<li>The medicines most often used to treat acromegaly are called somatostatin analogues (SSAs) like octreotide. These drugs curb the release of GH and may also reduce the size of the pituitary tumour. Several studies have shown that these drugs are safe and effective for long-term treatment.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Somatropin (Option A):</strong> Recombinant growth hormone; used for GH deficiency, not excess.</p>\r\n<p><strong>Desmopressin (Option B):</strong> Vasopressin analogue used in diabetes insipidus and haemophilia A; has no role in acromegaly.</p>\r\n<p><strong>Leuprolide (Option C):</strong> GnRH agonist; used in prostate cancer, endometriosis, and precocious puberty, not in GH excess.</p>", "options": ["Somatropin", "Desmopressin ", "Leuprolide ", "Octreotide"], "html_options": ["Somatropin", "Desmopressin ", "Leuprolide ", "Octreotide"], "corr_idx": 3}, {"id": "1166417", "html_qtxt": "A 42-year-old woman comes to the physician for evaluation of a palpable mass in the left breast that she noticed 3 weeks ago. During this period, she has also had some left-sided blood-tinged nipple discharge. Biopsy confirms the diagnosis of lobular carcinoma in situ (LCIS) that is estrogen-receptor (ER) positive. The patient undergoes lumpectomy of the left breast, and hormonal therapy is started. The patient's therapy increases her risk of which of the following conditions?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Tamoxifen increases the risk of endometrial cancer due to its partial agonist effect on estrogen receptors in uterine tissue.</p>\r\n<ul>\r\n<li>Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an <strong>estrogen receptor antagonist in breast tissue</strong> and as a <strong>partial agonist in endometrial tissue</strong>.</li>\r\n<li>In premenopausal women with ER+ breast cancer, <strong>tamoxifen is preferred</strong> due to its <strong>antagonist action on breast tissue</strong>, which reduces recurrence risk.</li>\r\n<li>However, in the <strong>endometrium</strong>, <strong>tamoxifen exhibits partial agonist effects</strong>, which lead to <strong>proliferative effects</strong> and <strong>increased risk of endometrial carcinoma</strong>, particularly with long-term use.</li>\r\n<li>This dual effect explains the paradox of tamoxifen: <strong>anti-estrogenic in the breast</strong>, <strong>estrogenic in the uterus</strong>.</li>\r\n<li>Raloxifene, in contrast, has <strong>no agonist activity on endometrial tissue</strong> and hence is <strong>not associated with this increased risk</strong>.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322e7f93082-da5b-48d9-888e-05329aa129b0.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Ovarian cancer (Option A):</strong> Tamoxifen may increase the incidence of ovarian cysts, but <strong>does not significantly increase</strong> the risk of ovarian cancer.</p>\r\n<p><strong>Cardiotoxicity (Option C):</strong> A known side effect of <strong>doxorubicin and trastuzumab</strong>, not tamoxifen. Tamoxifen <strong>does not cause cardiotoxicity</strong>.</p>\r\n<p><strong>Osteoporosis (Option D):</strong> Tamoxifen has <strong>agonist activity in bone</strong> and <strong>reduces the risk</strong> of osteoporosis in postmenopausal women.</p>", "options": ["Ovarian cancer", "Endometrial cancer", "Cardiotoxicity", "Osteoporosis"], "html_options": ["Ovarian cancer", "Endometrial cancer", "Cardiotoxicity", "Osteoporosis"], "corr_idx": 1}, {"id": "1166418", "html_qtxt": "A 58-year-old woman was diagnosed with metastatic breast cancer, for which she is currently receiving pharmacotherapy. A recent DEXA scan of the hip reveals a T-score of -2.8. Six months ago, her T-score was -1.7. Which of the following drugs is most likely responsible for this change in her bone mineral density?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Exemestane</strong>, a steroidal aromatase inhibitor, reduces estrogen levels in postmenopausal women, leading to accelerated bone loss and osteoporosis.</p>\r\n<ul>\r\n<li>As given in the question, decreased bone density can occur during menopause due to a decrease in estrogen. However, the rapid decline in this patient's T-score suggests a drug-induced estrogen deficiency.</li>\r\n<li>Exemestane inhibits aromatase (CYP19A1), preventing the peripheral conversion of androgens to estrogen.</li>\r\n<li>It is commonly used as first-line endocrine therapy in postmenopausal women with ER+/PR+ metastatic breast cancer.</li>\r\n<li>The resulting hypoestrogenic state may lead to:\r\n<ul>\r\n<li>Vaginal dryness and dyspareunia (atrophic vaginitis)</li>\r\n<li>Accelerated bone loss and increased fracture risk<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100104969fd1-eada-449a-a84d-150c5659b192.png\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403229e2b7e47-3cb5-4502-ada8-d67e3ff7774e.jpg\"></li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Paclitaxel (Option A):</strong> Microtubule stabilising agent used in breast cancer, but does not cause significant bone loss. Bone density changes are not characteristic of its side effect profile.</p>\r\n<p><strong>Raloxifene (Option B):</strong> A SERM that acts as an estrogen agonist on bone &rarr; protects bone mineral density &rarr; used to treat and prevent osteoporosis.</p>\r\n<p><strong>Palbociclib (Option C):</strong> A CDK4/6 inhibitor used in metastatic breast cancer; may cause cytopenias and fatigue, but does not directly reduce estrogen or affect bone density like aromatase inhibitors do.</p>", "options": ["Paclitaxel", "Raloxifene", "Palbociclib", "Exemestane"], "html_options": ["Paclitaxel", "Raloxifene", "Palbociclib", "Exemestane"], "corr_idx": 3}, {"id": "1166421", "html_qtxt": "A 24-year-old woman comes to the physician requesting advice regarding contraception. She was diagnosed with deep vein thrombosis 2 years ago. Her menses occur at regular 30-day intervals with normal flow. She is sexually active with one male partner and uses condoms inconsistently. A urine pregnancy test is negative. Which of the following is the most appropriate recommendation regarding contraception for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>A copper intrauterine device (IUD) is the most appropriate choice for this patient due to her history of deep vein thrombosis, which is a contraindication for estrogen-containing contraceptives.</p>\r\n<ul>\r\n<li><strong>Copper IUD (CuT380A)</strong> is a long-acting, hormone-free intrauterine contraceptive that can be used safely in women with thromboembolic conditions. It has no systemic hormonal effects and provides reversible contraception for up to 10 years.</li>\r\n<li>It exerts its action primarily by producing an inflammatory reaction within the endometrium that impairs sperm viability, motility, and fertilisation.</li>\r\n<li>It is not associated with an increased risk of thromboembolic events.</li>\r\n</ul>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322293fc355-4a53-451e-9fd8-98c3e5d022b4.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403255e792449-c287-4433-9086-9bf3d8748f97.jpg\">\r\n<br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322b8db9e42-6899-4946-9137-dd4441a00548.jpg\">\r\n<br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403229362aa27-3ac3-421d-9525-962d65de6944.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Combined oral contraceptive pills (COC) (Option B):</strong> Contain estrogen, which promotes clot formation and is contraindicated in patients with a history of venous thromboembolism.</p>\r\n<p><strong>Implanon (Option C):</strong> A progestin-only implant; while not containing estrogen, it should still be avoided or used with caution in thrombotic patients due to an unclear safety profile.</p>\r\n<p><strong>DMPA (Depot medroxyprogesterone acetate) (Option D):</strong> A long-acting injectable progestin. Although estrogen-free, caution is advised due to its association with adverse effects like irregular bleeding and reduced bone mineral density; data in thrombotic patients is limited.</p>", "options": ["CuT (IUD)", "COC", "Implanon", "Inj. DMPA"], "html_options": ["CuT (IUD)", "COC", "Implanon", "Inj. DMPA"], "corr_idx": 0}, {"id": "1166423", "html_qtxt": "A 21-year-old woman comes to you for advice for contraception. Her menses are painful and occur at regular 30-day intervals with heavy flow. Current medications include sumatriptan and iron supplements, which she has a hard time remembering to take. A urine pregnancy test is negative. The patient does not wish to become pregnant in the next 5 years. Which of the following is the most appropriate recommendation for contraception?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>DMPA is the most suitable contraceptive in this patient due to its efficacy in treating menorrhagia, dysmenorrhea, and its estrogen-sparing profile, ideal for patients with migraine.</p>\r\n<ul>\r\n<li><strong>Medroxyprogesterone acetate (DMPA)</strong> is a long-acting injectable progestin administered every 3 months.</li>\r\n<li>It induces endometrial atrophy and anovulation &rarr; decreases menstrual blood loss and pain.</li>\r\n<li>Useful in <strong>iron deficiency anaemia</strong>, <strong>dysmenorrhea</strong>, and patients with <strong>migraine</strong> (where estrogen-containing contraceptives are contraindicated).</li>\r\n<li>Reduces the need for daily adherence &rarr; ideal for those with poor medication compliance.</li>\r\n<li>Also associated with reversible bone mineral density loss and delayed fertility return post-discontinuation.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510010d478d68-dcd9-4ccb-86a2-3040220ed6d4.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>CuT (Option A):</strong> Not preferred in this case because it may <strong>worsen dysmenorrhea and menorrhagia</strong>, although safe in migraine.</p>\r\n<p><strong>COC (Option B):</strong> Estrogen-containing pills are <strong>contraindicated in migraine</strong> due to increased stroke risk.</p>\r\n<p><strong>POP (Option C):</strong> While safe in migraine, <strong>strict timing adherence</strong> is required, not suitable for patients with poor compliance.</p>", "options": ["CuT (IUD)", "COC", "POP", "Inj. DMPA"], "html_options": ["CuT (IUD)", "COC", "POP", "Inj. DMPA"], "corr_idx": 3}, {"id": "1166427", "html_qtxt": "A 22-year-old woman comes to the physician because of bothersome hair growth on her face. She does not take any medications. She weighs 85 kg; her BMI is 32 kg/m<sup>2</sup>. Her serum follicle-stimulating hormone, luteinizing hormone, and testosterone are within the reference range. A urine pregnancy test is negative. Which of the following is the most appropriate pharmacotherapy at this time?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Given a clinical scenario of excessive male pattern hair growth (hirsutism) with normal gonadotropins and testosterone levels without signs of further virilisation.</p>\r\n<ul>\r\n<li>This combination is highly suggestive of idiopathic hirsutism (IH).</li>\r\n<li>COCs are recommended as the first-line therapy for women with hirsutism due to their ability to reduce androgen levels.</li>\r\n<li>Estrogen-progestin contraceptives reduce androgen levels by suppression of circulating luteinizing hormone (LH) and stimulation of sex hormone-binding globulin (SHBG) levels.</li>\r\n</ul>\r\n<p>&nbsp;</p><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001a5974704-429e-4a9b-9250-c5cf1a5e4fa7.png\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240325e200d770-11cc-4d67-8dbd-9fe70d7043f9.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Flutamide (Option A):</strong> May be used in IH but is a third-line anti-androgen reserved for refractory cases after &ge;6 months of other monotherapy.</p>\r\n<p><strong>Spironolactone (Option B):</strong> First-line anti-androgen in refractory moderate to severe hirsutism, not initial therapy.</p>\r\n<p><strong>Metformin (Option D):</strong> Used in PCOS to reduce insulin levels; not effective in idiopathic hirsutism.</p>", "options": ["Flutamide", "Spironolactone", "COC", "Metformin"], "html_options": ["Flutamide", "Spironolactone", "COC", "Metformin"], "corr_idx": 2}, {"id": "1166429", "html_qtxt": "A 42-year-old man comes to the dermatologist for evaluation of progressive hair loss from his scalp. He first noticed the receding of the hairline over the bitemporal regions of his scalp 5 years ago. Since then, his hair has gradually become thinner over the crown of his head. Administration of which of the following drugs is most appropriate to treat this patient's hair loss?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The patient has androgenetic alopecia, the most common cause of hair loss in adult males. Finasteride is a first-line agent that inhibits 5&alpha;-reductase, thereby reducing conversion of testosterone to dihydrotestosterone (DHT), the androgen responsible for follicular miniaturisation.</p>\r\n<ul>\r\n<li><strong>Finasteride</strong> 1 mg daily increases hair growth in men over a 2-year period.</li>\r\n<li>It improves hair density and slows the progression of hair loss.</li>\r\n<li>The drug is generally well tolerated but may cause sexual side effects such as decreased libido and erectile dysfunction.</li>\r\n<li><strong>Minoxidil</strong> (topical) is another first-line option that stimulates the anagen phase of the hair cycle.</li>\r\n</ul>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024032295545522-fb08-4823-97d4-d639e2405db4.jpg\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Flutamide (Option B):</strong> Non-steroidal antiandrogen; rarely used for hair loss due to hepatotoxicity risk and lack of evidence in male androgenetic alopecia.</p>\r\n<p><strong>Cyproterone (Option C):</strong> Antiandrogen and progestin; primarily used in female hirsutism and not suitable for male pattern hair loss.</p>\r\n<p><strong>Spironolactone (Option D):</strong> Potassium-sparing diuretic with antiandrogenic effects; used for hirsutism or androgenic alopecia in women, not men, due to risk of feminisation.</p>", "options": ["Finasteride", "Flutamide", "Cyproterone", "Spironolactone"], "html_options": ["Finasteride", "Flutamide", "Cyproterone", "Spironolactone"], "corr_idx": 0}, {"id": "1166433", "html_qtxt": "Rohan, a male athlete, uses large doses of anabolic steroids. He is at increased risk of which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Athletes who administer high doses of anabolic steroids, such as 17&alpha;-alkylated androgens, are at increased risk of hepatotoxic effects, including <strong>cholestatic jaundice and elevated serum transaminases (SGPT)</strong>. These agents are known to cause hepatocellular damage and other hepatic dysfunction.</p>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322a78cec1e-a37a-4579-9c64-946bef96d8d1.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100115cc5c64-54d7-49a3-8110-89f776e35f89.png\"><br>\r\n<p><strong>(Other options ruled out)</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322542a21f1-6306-411e-899f-e1b5538f4cb7.jpg\">", "options": ["Kidney failure", "Cholestatic jaundice and elevation of SGPT", "Hirsutism", "Hyperprolactinemia"], "html_options": ["Kidney failure", "Cholestatic jaundice and elevation of SGPT", "Hirsutism", "Hyperprolactinemia"], "corr_idx": 1}, {"id": "1166438", "html_qtxt": "A 27-year-old woman complains of abdominal pain at the time of menstruation. Laparoscopy findings are shown below. Which of the following is the most appropriate medical therapy for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Medroxyprogesterone is preferred for the medical management of endometriosis-related pain due to its effective ovarian suppression via gonadotropin inhibition.</p>\r\n<ul>\r\n<li>The clinical scenario and laparoscopic image showing characteristic dark spots indicate <strong>endometriosis</strong>.</li>\r\n<li>For <strong>mild to moderate symptoms</strong>, first-line management includes <strong>NSAIDs</strong> and <strong>continuous hormonal contraceptives</strong>.</li>\r\n<li>When pregnancy is not desired, <strong>long-acting intramuscular medroxyprogesterone</strong> is effective for suppressing the hypothalamic-pituitary-ovarian axis by <strong>inhibiting gonadotropin release</strong>.</li>\r\n<li>This provides 3 months of ovarian suppression and is a commonly used therapeutic option.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510019d741437-63eb-4088-af5c-5e07521a0af0.png\">\r\n<p><strong>(Other options ruled out)</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403221a8b3cd9-4613-4e3f-8a4c-78f863f2d041.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024032287dcfbde-83d9-4bca-9861-4ef15dbcc32b.jpg\">", "options": ["Goserelin", "Medroxyprogesterone ", "Danazol", "Mifepristone"], "html_options": ["Goserelin", "Medroxyprogesterone ", "Danazol", "Mifepristone"], "corr_idx": 1}, {"id": "1166440", "html_qtxt": "A 54-year-old postmenopausal woman has low bone mineral density. You are considering therapy with raloxifene or HRT. Which of the following patient characteristics is most likely to lead you to select raloxifene?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Raloxifene</strong> improves bone mineral density and reduces the risk of vertebral fractures, making it effective in osteoporosis. Importantly, it has estrogen antagonist activity in breast tissue and does not stimulate the endometrium, making it a safer alternative to HRT in patients with a family history of breast cancer.</p>\r\n<ul>\r\n<li><strong>Breast tissue</strong>: Raloxifene acts as an estrogen antagonist &rarr; reduces breast cancer risk (ideal for those with a family history).</li>\r\n<li><strong>Bone</strong>: Acts as an estrogen agonist &rarr; prevents bone loss and vertebral fractures.</li>\r\n<li><strong>Endometrium</strong>: Does not stimulate endometrial proliferation &rarr; safer than HRT for women with an intact uterus.</li>\r\n<li><strong>Hot flushes</strong>: May exacerbate vasomotor symptoms (not used if hot flushes predominate).</li>\r\n<li><strong>Atrophic vaginitis</strong>: Treated with local estrogen therapy, not raloxifene.</li>\r\n</ul>\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251001bea632f1-d0f6-4bad-9b20-dd56115c652b.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Previous hysterectomy (Option A):</strong> HRT without progesterone can be used safely post-hysterectomy; raloxifene has no additional benefit in this context.</p>\r\n<p><strong>Atrophic vaginitis (Option B):</strong> Local estrogen is more effective than raloxifene; raloxifene has little to no vaginal estrogenic effect.</p>\r\n<p><strong>Hot flushes (Option D):</strong> Raloxifene may worsen vasomotor symptoms like hot flushes; HRT is preferred in symptomatic women.</p>", "options": ["Previous hysterectomy", "Atrophic vaginitis", "Family history of breast cancer ", "Hot flushes"], "html_options": ["Previous hysterectomy", "Atrophic vaginitis", "Family history of breast cancer ", "Hot flushes"], "corr_idx": 2}, {"id": "1166567", "html_qtxt": "A 50-year-old man comes to the AIIMS OPD with a glomerular filtration rate (GFR) of 100 mL/min/1.73 m<sup>2</sup> and a glucose clearance rate of 96 mL/min. The consultant asks you which antidiabetic agent the patient is most likely taking.", "html_expl": "<p><strong>Correct Answer:</strong> <strong>C) Canagliflozin</strong></p>\r\n<p><strong>Explanation:</strong></p>\r\n<p>Glucose clearance nearly equal to GFR indicates that glucose is filtered but not reabsorbed, characteristic of SGLT2 inhibitor use, such as <strong>canagliflozin</strong>, which inhibits proximal tubule glucose reabsorption.</p>\r\n<ul>\r\n<li><strong>Normal physiology:</strong> Glucose filtered in the glomerulus is reabsorbed in the PCT via SGLT2 &rarr; normal glucose clearance &asymp; 0 mL/min</li>\r\n<li><strong>SGLT2 inhibitors:</strong> Block this reabsorption &rarr; filtered glucose is excreted unchanged &rarr; glucose clearance approaches GFR</li>\r\n<li><strong>Canagliflozin</strong> reduces plasma glucose and promotes renal excretion of glucose by inhibiting SGLT2 in PCT.</li>\r\n<li>Leads to <strong>osmotic diuresis</strong>, <strong>mild weight loss</strong>, and <strong>CV/renal benefit</strong></li>\r\n<li>The drug is <strong>contraindicated in advanced renal disease,</strong> as filtration is required for efficacy</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322b5f8f326-7ad9-47c6-8a82-bd3c5e4205d9.jpg\">\r\n<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322d6870d3e-2317-4f62-bca0-5acf3fe5bfac.jpg\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100121cf7428-dd44-4a2e-a41f-4ddd185ea0ae.png\">\r\n<p><strong>(Other options are ruled out)</strong></p>", "options": ["Glipizide", "Linagliptin", "Canaglifozin", "Metformin"], "html_options": ["Glipizide", "Linagliptin", "Canaglifozin", "Metformin"], "corr_idx": 2}]}, {"moduleId": 1008553, "name": "Anti - Fungal Drugs", "questions": [{"id": "1185435", "html_qtxt": "A 21-year-old patient has experienced severe headaches and double vision for a week. His temperature is 101.5&deg;F. His CSF culture was positive for cryptococcal antigen. What is the site of action of the drug, would be appropriate to treat this patient systemically (not intrathecally)?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322176c648d-2bcb-49a2-a0e0-a4811228111c.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>The classes of antifungal drugs that have activity against Cryptococcus are the polyenes (amphotericin B formulations), the azoles, and flucytosine.</li>\r\n<li><strong>Fluconazole</strong>is the best-absorbed member of the azole group and the only one that readily penetrates cerebrospinal fluid. Amphotericin would work if it were delivered intrathecally.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240325b1e02f2a-9df8-4332-b4cb-e4515c7d3af8.jpg\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322f674948d-3fd1-478d-aa13-f537383f8f0a.jpg\">\r\n<p><strong>Fluconazole</strong>:</p>\r\n<p>Fluconazole is a <strong>triazole antifungal</strong>.</p>\r\n<p>It inhibits fungal <strong>cytochrome P450-dependent enzyme (14-&alpha;-demethylase)</strong>, disrupts ergosterol synthesis, and impairs fungal cell membrane integrity.</p>\r\n<h3>Pharmacokinetics</h3>\r\n<ul>\r\n<li><strong>High oral bioavailability</strong>, even with food.</li>\r\n<li><strong>Highly water-soluble</strong>, well absorbed orally, and can be given IV.</li>\r\n<li><strong>Excellent CSF penetration</strong>, useful in fungal meningitis.</li>\r\n<li><strong>Minimal hepatic CYP450 inhibition</strong>, fewer drug interactions than other azoles.</li>\r\n<li><strong>Widely distributed</strong> in body fluids and tissues.</li>\r\n<li>Excreted <strong>unchanged in urine</strong> (renal dose adjustment needed)</li>\r\n</ul>\r\n<h3>Clinical Uses</h3>\r\n<ul>\r\n<li><strong>Cryptococcal meningitis</strong>: <strong>Drug of choice</strong> for treatment and <strong>secondary prophylaxis</strong>.</li>\r\n<li><strong>Candidemia</strong>: IV fluconazole is as effective as amphotericin B in ICU patients <strong>with normal neutrophil counts</strong>. <strong>Echinocandins</strong> may be preferred in neutropenic or unstable patients.</li>\r\n<li><strong>Mucocutaneous candidiasis</strong>: First-line agent.</li>\r\n<li><strong>Coccidioidomycosis</strong>: Especially effective in <strong>meningitis form</strong> &rarr; high-dose fluconazole may avoid the need for intrathecal amphotericin B.</li>\r\n<li><strong>Prophylaxis</strong>: Used in <strong>AIDS</strong> patients and <strong>bone marrow transplant (BMT)</strong> recipients to prevent fungal infections.</li>\r\n</ul>", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 2}, {"id": "1185441", "html_qtxt": "Interactions between this drug and cell membrane components can result in the formation of pores lined by hydrophilic groups present in the drug molecule.", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>The <strong>polyene antifungal drugs</strong> are amphipathic molecules that can interact with ergosterol in fungal cell membranes to form artificial pores lined by hydrophilic groups. These include <strong>amphotericin B and nystatin.</strong></li>\r\n</ul>\r\n<p><strong>Nystatin:</strong></p>\r\n<p>Nystatin is an antifungal drug belonging to the Class <strong>Polyene antifungal, which is related to Amphotericin B</strong><strong> </strong></p>\r\n<p><strong>Mechanism of action: </strong></p>\r\n<ul>\r\n<li>Nystatin is an <strong>amphipathic molecule</strong> that can interact with ergosterol in fungal cell membranes to form artificial pores lined by hydrophilic groups.</li>\r\n<li>In these structures, the<strong> lipophilic groups</strong> on the drug molecule are arranged on the outside of the pore, and the hydrophilic regions are located on the inside.</li>\r\n<li>The fungicidal action of the polyenes derives from this interaction, which results in leakage of intracellular constituents.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509046ef6c359-9a0b-4f0e-9e82-7a722dccf1d1.png\">\r\n<h3>Route of Administration:</h3>\r\n<ul>\r\n<li><strong>Not suitable for parenteral use</strong> due to systemic toxicity.</li>\r\n<li>Used <strong>topically or orally (not systemically absorbed)</strong>.</li>\r\n<li>Nystatin is available as Creams, Ointments, Suppositories, Oral suspension, or tablets (for local GI action)</li>\r\n</ul>\r\n<h3>Pharmacokinetics:</h3>\r\n<ul>\r\n<li><strong>Poorly absorbed</strong> from skin, mucous membranes, and GI trac,t therefore leading to <strong>Minimal systemic toxicity</strong> due to poor absorption.</li>\r\n<li>Oral use may be limited by <strong>unpleasant taste</strong>.<strong><br /> <br /> </strong></li>\r\n</ul>\r\n<h3>Clinical Uses</h3>\r\n<p>Primarily used for <strong>local suppression of candidal infections</strong>, including:</p>\r\n<ul>\r\n<li><strong>Oropharyngeal candidiasis (thrush)</strong></li>\r\n<li><strong>Vaginal candidiasis</strong></li>\r\n<li><strong>Intertriginous candidal infections</strong> (skin folds)</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Caspofungin(Option A)</strong>: An echinocandin; inhibits <strong>&beta;-1,3-glucan synthase</strong> (affects cell <strong>wall</strong>, not membrane)</p>\r\n<p><strong>Flucytosine(Option B)</strong>: A pyrimidine analog; gets converted to <strong>5-FU</strong> inside fungal cells and inhibits <strong>DNA and RNA synthesis</strong></p>\r\n<p><strong>Griseofulvin(Option C)</strong>: Disrupts <strong>microtubule function</strong>; interferes with mitosis in dermatophytes</p>", "options": ["Caspofungin", "Flucytosine", "Griseofulvin", "Nystatin"], "html_options": ["Caspofungin", "Flucytosine", "Griseofulvin", "Nystatin"], "corr_idx": 3}, {"id": "1185442", "html_qtxt": "Regarding the clinical use of liposomal formulations of amphotericin B, which statement is accurate?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Liposomal formulations of amphotericin B result in <strong>decreased accumulation</strong> of the drug in tissues, including the kidney. As a result, <strong>nephrotoxicity is decreased</strong>.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090437fbb862-00a3-492d-a69d-199ba9eaeaac.PNG\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403220217785c-0682-42cb-ba55-3a59008b9327.jpg\">", "options": ["Amphotericin B's affinity for these lipids is greater than its affinity for ergosterol", "Less expensive to use than conventional amphotericin B", "More effective in fungal infections because they increase tissue uptake of amphotericin B", "They decrease the nephrotoxicity of amphotericin B"], "html_options": ["Amphotericin B's affinity for these lipids is greater than its affinity for ergosterol", "Less expensive to use than conventional amphotericin B", "More effective in fungal infections because they increase tissue uptake of amphotericin B", "They decrease the nephrotoxicity of amphotericin B"], "corr_idx": 3}, {"id": "1185443", "html_qtxt": "A 32-year-old man living in Gujarat was transferred to California for several months. On his return to India, he complains of having influenza-like symptoms with fever and a cough. He also has red, tender nodules on his shins. You suspect that these symptoms are due to coccidioidomycosis contracted during his stay in California. This patient should be treated immediately with", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient likely has <strong>primary pulmonary coccidioidomycosis</strong>, which is often <strong>self-limiting</strong> in <strong>immunocompetent individuals</strong>.</li>\r\n<li>A travel history can be important in the diagnosis of fungal disease. If this patient has a fungal infection of the lungs, it is probably due to <strong> immitis</strong>, which is endemic in dry regions of the western US.</li>\r\n<li>Pulmonary symptoms of coccidioidomycosis are usually self-limiting, and drug therapy is not commonly required in an otherwise healthy patient.</li>\r\n<li>Tender red nodules on extensor surfaces constitute a good prognostic sign.</li>\r\n<li><strong>Erythema nodosum</strong> is a delayed hypersensitivity response to fungal antigens.</li>\r\n<li>No organisms are present in the lesions, and it is not a sign of disseminated disease.</li>\r\n</ul>\r\n<h3>When no treatment is required:</h3>\r\n<ul>\r\n<li>Immunocompetent patient</li>\r\n<li>Mild-to-moderate symptoms</li>\r\n<li>No evidence of dissemination</li>\r\n</ul>\r\n<p><br /> <strong>When to treat coccidioidomycosis:</strong></p>\r\n<ul>\r\n<li>Severe or progressive pulmonary disease</li>\r\n<li>Disseminated disease (skin, bones, CNS)</li>\r\n<li>High-risk groups: immunocompromised, pregnant women (especially 3rd trimester), diabetics</li>\r\n</ul>\r\n<p><strong>First-line treatment in coccidioidomycosis: Fluconazole or Itraconazole</strong></p>", "options": ["Amphotericin B", "Caspofungin", "Itraconazole", "No treatment required"], "html_options": ["Amphotericin B", "Caspofungin", "Itraconazole", "No treatment required"], "corr_idx": 3}, {"id": "1185448", "html_qtxt": "While doing endoscopy in an HIV+ patient, the following findings can be seen in the esophagus. Which drug is least likely to be effective in the treatment if it is used by the oral route?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322daecc90d-c10b-40ce-bd1a-1b9b26d60a7d.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>White plaques in the esophagus on endoscopy strongly suggest Candida esophagitis IN HIV HIV-positive patient.</li>\r\n<li>Griseofulvin is least effective against Candida species. It is used for dermatophytoses (e.g., tinea infections), not for yeast infections like esophageal candidiasis.</li>\r\n</ul>\r\n<p><strong>Candida esophagitis </strong></p>\r\n<p>Candida esophagitis is a <strong>fungal infection of the esophagus</strong>, most commonly caused by <em>Candida albicans</em>. It is the <strong>most frequent cause of infectious esophagitis</strong>, especially in immunocompromised individuals.</p>\r\n<h3>Risk Factors:</h3>\r\n<ul>\r\n<li><strong>HIV/AIDS </strong>(CD4 count < 200 cells/&mu;L)</li>\r\n<li>Prolonged corticosteroid therapy</li>\r\n<li>Chemotherapy</li>\r\n<li>Hematologic malignancies</li>\r\n<li>Transplant recipients</li>\r\n<li>Uncontrolled diabetes mellitus</li>\r\n<li>Prolonged antibiotic use</li>\r\n<li>Use of inhaled corticosteroids (e.g., for asthma/COPD, if mouth rinsing is not done)</li>\r\n</ul>\r\n<h3>Clinical Features:</h3>\r\n<ul>\r\n<li><strong>Odynophagia</strong> (painful swallowing) - most common symptom</li>\r\n<li><strong>Dysphagia</strong> (difficulty swallowing)</li>\r\n<li>Retrosternal chest pain</li>\r\n<li>Oral thrush (in ~75% cases)</li>\r\n</ul>\r\n<h3>Treatment:</h3>\r\n<h4>First-line (if no resistance suspected):</h4>\r\n<ul>\r\n<li><strong>Fluconazole</strong> 200 mg loading dose, then 100-200 mg/day orally for 14-21 days</li>\r\n<li>Swish and swallow formulations of <strong>clotrimazole and nystatin</strong> have been commonly used. <strong>(Option A and D ruled out)</strong></li>\r\n<li>Most of the <strong>azoles</strong> are effective in esophageal candidiasis<strong>. (Option C ruled out)</strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240325e2ba9b1d-4d32-440d-a73a-53bc4a42cac1.jpg\">\r\n", "options": ["Clotrimazole", "Griseofulvin", "Ketoconazole", "Nystatin"], "html_options": ["Clotrimazole", "Griseofulvin", "Ketoconazole", "Nystatin"], "corr_idx": 1}, {"id": "1185449", "html_qtxt": "A 64-year-old man presents with a headache, facial pain, and a black spot over the nose. He has a history of type 1 diabetes mellitus, and he was admitted to the ICU for COVID-19 15 days before. His temperature is 101 F. Examination shows left periorbital swelling that is tender to palpation, mucopurulent rhinorrhea. A photomicrograph of a specimen obtained on biopsy of the left maxillary sinus is shown. What will be the next step for management?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510047188858d-5ad9-4244-8126-c69177791f29.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This man has a <strong>rhino-orbital-cerebral infection</strong> caused by Mucor, a pathogen that is most commonly seen in patients with diabetes.</li>\n<li>Mucor species have<strong> broad, nonseptate hyphae that branch at right angles</strong>, as seen in the photomicrograph, and can cause <strong>mucormycosis</strong>.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510047894cf7c-b1c1-417f-91ac-ea3e1ac5e94c.png\">\n<ul>\n<li>Diabetes, particularly with ketoacidosis, Immunosuppression, Chronic sinusitis (> 3 months), Iron overload, or treatment with deferoxamine, is a significant risk factor that predisposes to this condition, which typically manifests as a <strong>unilateral, invasive, maxillofacial infection with headache, facial pain, nasal discharge, and fever</strong>, as seen in this patient.</li>\n<li>Treatment involves <strong>surgical debridement</strong> and intravenous <strong>Amphotericin B</strong>.</li>\n</ul>\n<p><strong>Mucormycosis management:</strong></p>\n<p>1. <strong>Medical</strong></p>\n<ul>\n<li>Liposomal Amphotericin B (drug of choice)\n<ul>\n<li>Dose: 5-10 mg/kg/day IV</li>\n<li>Start immediately once suspected</li>\n</ul>\n</li>\n<li>Alternatives (only if intolerant):\n<ul>\n<li>Isavuconazole</li>\n<li><strong>Posaconazole: the </strong>only azole with activity against Rhizopus, one of the agents of mucormycosis. Liver metabolism is responsible for the elimination of posaconazole, and is used for prophylaxis of fungal infections during cancer chemotherapy and in salvage therapy in invasive aspergillosis<strong>.</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong>2. Surgical</strong></p>\n<ul>\n<li>Aggressive debridement of necrotic tissue is essential</li>\n<li>May need orbital exenteration or craniofacial resection in severe cases</li>\n</ul>\n<p><strong>3. Control Underlying Condition</strong></p>\n<ul>\n<li>Strict glycemic control</li>\n<li>Minimize immunosuppressive agents if possible</li>\n<li>Correct acidosis</li>\n</ul>\n<p><strong>Amphotericin B</strong></p>\n<p>This is a <strong>Polyene macrolide antifungal</strong> obtained from<strong> Streptomyces nodosus.</strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<ul>\n<li><strong>Target</strong>: Fungal <strong>ergosterol</strong> in cell membranes</li>\n<li><strong>Action</strong>: Binds to ergosterol and forms <strong>pores</strong> in the membrane, which leads to <strong>leakage</strong> of intracellular ions (K+, Mg&sup2;+) and macromolecules. It is a <strong>Fungicidal</strong></li>\n</ul>\n<p><strong>Indications</strong></p>\n<ul>\n<li><strong>Broad-spectrum</strong>: Effective against:\n<ul>\n<li>Yeasts: Candida albicans, Cryptococcus neoformans</li>\n<li>Dimorphic fungi: Histoplasma, Blastomyces, Coccidioides</li>\n<li>Molds: Aspergillus, <strong>Mucorales</strong></li>\n</ul>\n</li>\n<li><strong>DOC</strong> for severe systemic <strong>mycoses</strong></li>\n<li><strong>Cryptococcal meningitis</strong>(induction therapy, followed by azole maintenance)</li>\n<li><strong>Other uses</strong>:\n<ul>\n<li>Topical for fungal keratitis</li>\n<li>Subconjunctival injections</li>\n<li>Bladder irrigation in candiduria</li>\n<li>Joint injections in fungal arthritis</li>\n</ul>\n</li>\n</ul>\n<p><strong>Adverse Effects</strong></p>\n<ul>\n<li><strong>A. Infusion-related</strong>(common)\n<ul>\n<li>Fever, chills, vomiting, headache, hypotension, muscle spasms</li>\n<li>Prevention: slow infusion, premedicate (antipyretics, antihistamines, steroids, meperidine)</li>\n</ul>\n</li>\n<li><strong>B. Cumulative Toxicity</strong>\n<ul>\n<li><strong>Renal Toxicity</strong>(most serious):\n<ul>\n<li>Reversible: &darr; renal perfusion (pre-renal failure)</li>\n<li>Irreversible: tubular damage &rarr; RTA, <strong>K+/Mg&sup2;+ wasting</strong></li>\n<li>Risk &uarr; with <strong> >4 g cumulative dose</strong></li>\n<li>Prevention: saline loading</li>\n</ul>\n</li>\n<li><strong>Hematologic</strong>: Normocytic anemia (&darr; EPO)</li>\n<li><strong>Hepatic</strong>: Mild LFT elevations</li>\n<li><strong>Neurologic</strong>(intrathecal): seizures, chemical arachnoiditis</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Oral voriconazole(Option A)</strong>: Not effective against mucormycosis. Primarily used for <strong>Aspergillus</strong><em><br /></em></p>\n<p><strong>Oral nystatin(Option B)</strong>: Only effective for mucosal <strong>Candida</strong> infections, Not absorbed systemically</p>\n<p><strong>IV amphotericin B + flucytosine(Option D)</strong>: Used for <strong>Cryptococcal meningitis</strong>, not mucormycosis</p>", "options": ["Oral voriconazole", "Oral nystatin", "IV amphotericin B", "IV amphotericin B in combination with flucytosine"], "html_options": ["Oral voriconazole", "Oral nystatin", "IV amphotericin B", "IV amphotericin B in combination with flucytosine"], "corr_idx": 2}, {"id": "1185452", "html_qtxt": "A 9-year-old boy with a history of cystic fibrosis is brought to the physician for evaluation of recurrent episodes of productive cough, wheezing, and shortness of breath over the past month. Serum studies show elevated levels of IgE and eosinophilia. An HRCT of the lungs is shown below. Antibiotic therapy is initiated. One week later, the patient continues to show deterioration in lung function. What will be your next step in management?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322ba2ee4a1-974a-4416-bea7-d739c590b996.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Failure to respond to antibiotic treatment in a patient with a history of cystic fibrosis, recurrent pulmonary exacerbations, elevated IgE levels, and CT findings of central bronchiectasis should raise concern for <strong>Allergic bronchopulmonary aspergillosis (ABPA).</strong></li>\r\n<li>Treatment is done with <strong>Oral glucocorticoids</strong>. For acute or recurrent ABPA (as seen in this patient), <strong>oral Itraconazole</strong> should be initiated, unlike for <strong>invasive aspergillosis, voriconazole is the drug of choice(Option D ruled out)</strong></li>\r\n</ul>\r\n<p><strong>Allergic bronchopulmonary aspergillosis:</strong></p>\r\n<ul>\r\n<li>ABPA is a <strong>hypersensitivity reaction</strong> to <strong>Aspergillus fumigatus</strong> (a common environmental fungus), typically occurring in <strong>patients with asthma or cystic fibrosis</strong>.</li>\r\n<li><strong>Type I hypersensitivity</strong> (IgE-mediated) and <strong>Type III hypersensitivity</strong> (immune complex-mediated)</li>\r\n<li>Leads to <strong>bronchial inflammation</strong>, <strong>mucoid impaction</strong>, and <strong>bronchiectasis</strong></li>\r\n<li><strong>Fungus colonizes bronchial mucus</strong>, but does not invade tissue<br /> </li>\r\n</ul>\r\n<p><strong>Treatment:</strong></p>\r\n<ul>\r\n<li><strong>First line: Oral corticosteroids</strong> (e.g., prednisolone)- tapered over months</li>\r\n<li><strong>Adjunct: Itraconazole</strong>- reduces fungal burden and steroid dose</li>\r\n<li><strong>Refractory cases: </strong>Biologics (e.g., omalizumab, mepolizumab)</li>\r\n<li><strong>Asthma control: </strong>Inhaled bronchodilators, ICS if needed</li>\r\n</ul>\r\n<p><strong>Itraconazole:</strong></p>\r\n<p>Available in both <strong>oral</strong> and <strong>intravenous</strong> forms</p>\r\n<p><strong>Mechanisms of Action:</strong></p>\r\n<p>The antifungal activity of azole drugs results from the reduction of ergosterol synthesis by inhibition of fungal cytochrome P450 enzymes</p>\r\n<p><strong>Effective Against:</strong></p>\r\n<ul>\r\n<li><strong>Dimorphic fungi</strong>:\r\n<ul>\r\n<li>Histoplasma capsulatum</li>\r\n<li>Blastomyces dermatitidis</li>\r\n<li>Sporothrix schenckii &rarr; <strong>drug of choice</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>Dermatophytes</strong>: Commonly used in <strong>dermatophytosis</strong> and <strong>onychomycosis</strong></li>\r\n<li><strong>Aspergillus sp.</strong>: Has activity, but <strong>voriconazole</strong> is preferred</li>\r\n</ul>\r\n<h3>Explanation of Other Options:</h3>\r\n<p><strong>IV Amphotericin B(Option A):</strong> Used in invasive fungal infections (e.g., mucormycosis), <strong>not indicated in ABPA</strong>.</p>\r\n<p><strong>Itraconazole alone(Option B):</strong> Insufficient in moderate/severe or progressive ABPA.</p>\r\n<p><strong>Voriconazole(Option C):</strong> Reserved for invasive aspergillosis or voriconazole-sensitive Aspergillus infections, <strong>not first-line in ABPA</strong>.</p>", "options": ["Itraconazole & Glucocorticoids", "IV Amphotericin B", "Itraconazole", "Voriconazole"], "html_options": ["Itraconazole & Glucocorticoids", "IV Amphotericin B", "Itraconazole", "Voriconazole"], "corr_idx": 0}, {"id": "1185457", "html_qtxt": "Match the following conditions with their drug of choice<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322c1583ebe-f349-486b-b9db-4f3c3f535fe1.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904af570be3-4d27-4fd6-89d1-263dacc25463.PNG\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322a43ae15a-d48c-4fd3-95c2-4a1a8f425f80.jpg\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024032220d59ba1-2955-4be0-8c12-2f8ce2903413.jpg\">\r\n", "options": ["1-D 2-C 3-A 4-B", "1-B 2-C 3-A 4-D", "1-A 2-D 3-C 4-B", "1-D 2-C 3-B 4-A"], "html_options": ["1-D 2-C 3-A 4-B", "1-B 2-C 3-A 4-D", "1-A 2-D 3-C 4-B", "1-D 2-C 3-B 4-A"], "corr_idx": 0}, {"id": "1185460", "html_qtxt": "A 34-year-old woman was admitted to the hospital with shortness of breath and a fever to 101.5F. She has recently received AHSCT for AML and is now immunosuppressed with tacrolimus. Serum galactomannan level is elevated. She is initiated on therapy with voriconazole. Which of the following is correct regarding the therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Calcineurin inhibitors such as <strong>tacrolimus and cyclosporine </strong>are immunosuppressive agents that are used following solid organ transplantations as well as for the treatment of graft-versus-host disease in bone marrow transplant patients.</li>\r\n<li>These drugs are primarily metabolized via the <strong>cytochrome P450 pathway </strong>and excreted into bile.</li>\r\n<li>In this case, <strong>voriconazole inhibits </strong><strong>the metabolism </strong>of tacrolimus, leading to increased serum concentrations of the drug.</li>\r\n<li><strong>It is recommended that the tacrolimus dose be decreased to one-third of the original dose when it is necessary to co-administer tacrolimus and voriconazole.</strong></li>\r\n<li>The clinical signs and symptoms of<strong> tacrolimus toxicity</strong> include<strong> hypertension, edema, headaches, insomnia, and tremor</strong>.</li>\r\n<li>In addition, elevated levels of tacrolimus can lead to worsening renal function and <strong>electrolyte abnormalities</strong><strong>, including hyperkalemia, hypomagnesemia, hypophosphatemia, and hyperglycemia.</strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904299d2dfd-9cf4-42f7-930f-17f4ed84c417.PNG\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090428aa56d4-0cba-468c-a783-1b84e91c6be9.PNG\">", "options": ["Half the dose of tacrolimus", "Double the dose of tacrolimus", "One-third the dose of voriconazole", "No need to change the dose"], "html_options": ["Half the dose of tacrolimus", "Double the dose of tacrolimus", "One-third the dose of voriconazole", "No need to change the dose"], "corr_idx": 2}, {"id": "1185470", "html_qtxt": "A 4-month-old boy is brought in for a progressively worsening rash on his buttocks for the last week. He cries during diaper changes and is more fussy than usual. An image of the lesion is shown below. What treatment will you prescribe?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322a2363a0b-6a79-493d-b958-48c4010e0033.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient has typical signs of a <strong>diaper rash due to Candida albicans</strong>. It can be treated with a variety of topical antifungal agents such as <strong>clotrimazole</strong>.</li>\r\n<li><strong>Candida albicans</strong> is part of the normal skin flora, but infection can occur when there is an imbalance that allows local Candida albicans overgrowth.</li>\r\n</ul>\r\n<p><strong>Diaper candidiasis</strong> often follows antibiotic use or prolonged wetness and presents with:</p>\r\n<ul>\r\n<li>Beefy red rash in the diaper area</li>\r\n<li><strong>Satellite pustules</strong></li>\r\n<li>Involvement of skin folds</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322a2363a0b-6a79-493d-b958-48c4010e0033.jpg\">\r\n<h3>Explanation of Other Options:</h3>\r\n<p><strong>Oral fluconazole(Option A):</strong> Oral fluconazole is used for esophageal or oral candidiasis. Diaper rash is a local infection. Reserved for <strong>refractory/severe</strong> or <strong>systemic</strong> cases</p>\r\n<p><strong>Topical terbinafine(Option C):</strong> Topical terbinafine is used for Dermatophytosis (especially onychomycosis) and Tinea infections.</p>\r\n<p><strong>Topical Ciclopirox(Option D):</strong> Topical Ciclopirox  is used in Tinea versicolor, Dermatophytosis, and Seborrheic dermatitis of the scalp</p>", "options": ["Oral fluconazole", "Topical clotrimazole", "Topical terbinafine", "Topical Ciclopirox"], "html_options": ["Oral fluconazole", "Topical clotrimazole", "Topical terbinafine", "Topical Ciclopirox"], "corr_idx": 1}, {"id": "1185472", "html_qtxt": "A 3-year-old child with a ventriculoperitoneal shunt develops fever with chills. On examination, the right eye deviated towards the left side. Treatment with antibiotics did not improve the condition. Culture, followed by microscopy, identifies the C. Glabrata organism. What is the preferred antifungal for the patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient with Candidemia with identified organism <strong> Glabrata</strong> is resistant to <strong>fluconazole and amphotericin B</strong>. Echinocandins like <strong>Caspofungin</strong> are the Preferred drug for the patient</li>\r\n</ul>\r\n<p><strong>ECHINOCANDINS:</strong></p>\r\n<p><strong>Examples: </strong>Caspofungin, Micafungin, Anidulafungin</p>\r\n<p><strong>Pharmacokinetics:</strong></p>\r\n<ul>\r\n<li><strong>Echinocandins</strong> are large cyclic peptides attached to a long-chain fatty acid.</li>\r\n<li>They are available only in <strong>intravenous</strong> form and are <strong>highly protein-bound</strong>.</li>\r\n<li><strong>Caspofungin</strong> has a half-life of 9-11 hours and is eliminated via the <strong>kidneys and gastrointestinal tract</strong>. It requires dose adjustment in severe hepatic insufficiency.</li>\r\n</ul>\r\n<p><strong>Mechanism of Action:</strong></p>\r\n<ul>\r\n<li>Echinocandins act by inhibiting the <strong>synthesis of &beta;(1&rarr;3)-D-glucan</strong>, an essential component of the fungal cell wall.</li>\r\n<li>This leads to disruption of the cell wall, <strong>osmotic instability</strong>, and <strong>fungal cell death</strong>.</li>\r\n</ul>\r\n<p><strong>Spectrum of Activity:</strong></p>\r\n<ul>\r\n<li>Echinocandins are highly active against most <strong>Candida species</strong> (including drug-resistant <em> glabrata</em>) and are also active against <strong>Aspergillus</strong>.</li>\r\n<li>They have <strong>no activity against Cryptococcus neoformans or zygomycetes</strong> (e.g., mucormycosis).</li>\r\n</ul>\r\n<h4>Clinical Uses</h4>\r\n<ul>\r\n<li><strong>Mucocutaneous and invasive candidiasis</strong>, and as empiric antifungal therapy in febrile neutropenic patients.</li>\r\n<li><strong>Invasive aspergillosis</strong> patients who are refractory to amphotericin B.</li>\r\n<li>Mucocutaneous candidiasis, candidemia, and for the prophylaxis of fungal infections in bone marrow transplant patients.</li>\r\n</ul>\r\n<p><strong>Adverse Effects & Drug Interactions</strong></p>\r\n<ul>\r\n<li><strong>Mild gastrointestinal upset</strong> and <strong>flushing</strong> may occur infrequently.</li>\r\n<li>Caspofungin, when combined with cyclosporine, can lead to elevated liver enzymes, so this combination should be avoided.</li>\r\n<li>Micafungin can increase blood levels of nifedipine, sirolimus, and cyclosporine, requiring monitoring.</li>\r\n<li>Anidulafungin has minimal drug interactions, though histamine-mediated reactions can occur during IV infusion, especially if administered rapidly.<br /> </li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Fluconazole(Option A): </strong>Resistance to C.Glabrata, not preferred</p>\r\n<p><strong>Amphotericin B(Option B): </strong>Active but nephrotoxic and less effective in biofilm-associated infections</p>\r\n<p><strong>Flucytosine (Option D): </strong>Not used alone due to rapid resistance</p>", "options": ["Amphotericin B", "Fluconazole", "Caspofungin", "Flucytosine"], "html_options": ["Amphotericin B", "Fluconazole", "Caspofungin", "Flucytosine"], "corr_idx": 2}, {"id": "1185473", "html_qtxt": "Which of the antifungal drugs causes visual disturbances?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Voriconazole</strong> causes immediate but transient visual disturbances, including blurring of vision of unknown cause in more than 30% of patients. Based on animal studies, voriconazole is a class D drug in terms of pregnancy risk.</li>\n</ul>\n<h4>Adverse Effects:</h4>\n<ul>\n<li><strong>Visual disturbances</strong> (30%)\n<ul>\n<li>Blurred vision, altered color perception, and photophobia.</li>\n<li>It occurs early, reversible.</li>\n</ul>\n</li>\n<li><strong>Hepatotoxicity</strong></li>\n<li><strong>Photosensitivity & skin cancer risk</strong> (long-term use)</li>\n<li><strong>Neurotoxicity</strong></li>\n<li><strong>QT prolongation</strong></li>\n<li><strong>Rash, hallucinations</strong></li>\n</ul>\n<h3>Explanation of Other Options:</h3>\n<p><strong>Caspofungin(Option B): </strong>Infusion-related effects of Caspofungin include headache, gastrointestinal distress, fever, rash, and flushing (histamine release).</p>\n<p><strong>Posaconazole(Option C):</strong> Visual dysfunction has not been reported with Posaconazole, but the drug is an inhibitor of CYP3A4, increasing the levels of cyclosporine and tacrolimus.</p>\n<p><strong>Flucytosine(Option D): </strong>Prolonged high plasma levels of flucytosine cause reversible bone marrow depression, alopecia, and liver dysfunction.</p>", "options": ["Voriconazole", "Caspofungin", "Posaconazole", "Flucytosine"], "html_options": ["Voriconazole", "Caspofungin", "Posaconazole", "Flucytosine"], "corr_idx": 0}, {"id": "1185475", "html_qtxt": "A 56-year-old woman with leukemia was undergoing chemotherapy. During treatment, she developed a systemic infection. There was no erythema or edema at the catheter insertion site. Empiric antibiotic therapy was started with gentamicin, nafcillin, and ticarcillin intravenously. This regimen was maintained for 72 h, during which time the patient's condition did not improve significantly. Her throat was sore, as shown below. On day 4, none of the cultures had shown any bacterial growth, but both the blood and urine cultures grew out Candida albicans. At this point, the best course of action is to", "html_expl": "<p><strong><strong>Explanation:</strong></strong></p>\r\n<ul>\r\n<li>The <strong>antibiotic regimen should be stopped</strong> immediately, since the condition of the patient did not improve after 3 days of such treatment, the cultures were negative for bacteria, and the clinical picture suggested that the patient had a fungal infection.</li>\r\n<li>This patient is immunocompromised (leukemia + chemotherapy) and has developed <strong>systemic candidiasis</strong> (<strong>Candida albicans</strong> in both blood and urine cultures), along with <strong>oropharyngeal candidiasis</strong></li>\r\n<li>The preferred antifungal would be<strong> amphotericin B</strong></li>\r\n</ul>\r\n<p><strong>Candida Infections Drug of Choice by Site & Severity</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904811defd5-983a-4f55-a33d-fa294f303953.PNG\">\r\n<p><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509046fd581cb-8f4f-42e4-b014-3cd3dfaa60fa.PNG\"></p>\r\n<h3>Explanation of Other Options:</h3>\r\n<p><strong>Continue current antibiotics and start griseofulvin(Option A):</strong> <strong>Griseofulvin</strong> is used for <strong>dermatophyte infections</strong> (like tinea), not Candida<strong>. </strong>Keeping antibiotics unnecessarily increases the risk of resistance & toxicity.</p>\r\n<p><strong>Continue current antibiotics and start amphotericin B(Option B): </strong>Amphotericin B is the correct antifungal for systemic candidiasis. Patient is likely <strong>not septic due to bacteria</strong>, so <strong>antibiotics should be stopped</strong> unless there's clear evidence of a mixed infection.</p>\r\n<p><strong><strong>Stop current antibiotics and start itraconazole(Option C):</strong> Itraconazole is not the drug of choice for systemic candidiasis.</strong></p>", "options": ["Continue current antibiotics and start griseofulvin ", "Continue current antibiotics and start amphotericin B ", "Stop current antibiotics and start itraconazole", "Stop current antibiotics and start amphotericin B"], "html_options": ["Continue current antibiotics and start griseofulvin ", "Continue current antibiotics and start amphotericin B ", "Stop current antibiotics and start itraconazole", "Stop current antibiotics and start amphotericin B"], "corr_idx": 3}, {"id": "1185480", "html_qtxt": "A 76-year-old woman comes in with discoloration of her toenails. Physical examination shows crumbling, friable nails with hyperkeratotic debris under the affected part of the nail. Treatment with which of the following is the most appropriate oral medication for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient has a fungal nail infection (<strong>onychomycosis</strong>). Terbinafine is the drug of choice.</li>\r\n</ul>\r\n<p><strong>Onychomycosis:</strong></p>\r\n<ul>\r\n<li>These infections are seen most commonly in the elderly, and are usually caused by dermatophyte infection, typically <strong>Trichophyton rubrum, T. mentagrophytes, or Epidermophyton floccosum.</strong></li>\r\n<li>Some of the more superficial lesions can be removed by simply scraping the fungus off the nail.</li>\r\n<li><strong>Systemic fungal therapy</strong> of months' duration (because nails grow so slowly) may be required for deeper nail lesions.</li>\r\n<li>Although oral imidazole is used in general for nail infections, terbinafine is the drug of choice for toenail infections because toenails are difficult to penetrate and extremely slow to respond<strong> </strong></li>\r\n</ul>\r\n<p><strong>Terbinafine:</strong></p>\r\n<p><strong>Terbinafine </strong>belongs to the synthetic <strong>allylamine antifungal drugs</strong></p>\r\n<h3>Mechanism of Action:</h3>\r\n<ul>\r\n<li><strong>Fungicidal</strong></li>\r\n<li>Inhibits <strong>squalene epoxidase</strong>, an essential enzyme in ergosterol synthesis.</li>\r\n<li>This causes a decrease in <strong>Ergosterol</strong> (disrupts fungal cell membrane) and <strong>Squalene accumulation</strong>, which is toxic to fungal cells</li>\r\n</ul>\r\n<h3>Clinical Uses:</h3>\r\n<ul>\r\n<li>Highly effective against <strong>dermatophytes</strong>, especially:\r\n<ul>\r\n<li><strong>Tinea unguium (onychomycosis)</strong></li>\r\n<li><strong>Tinea corporis/cruris/pedis</strong></li>\r\n</ul>\r\n</li>\r\n<li>Terbinafine is available in both oral and topical formulations.</li>\r\n<li>The oral formulation is indicated for the treatment of onychomycosis of the fingernails and toenails. The topical formulation is indicated for the treatment of tinea pedis, corporis, and cruris.</li>\r\n</ul>\r\n<h3>Adverse Effects:</h3>\r\n<ul>\r\n<li>Usually <strong>well-tolerated</strong></li>\r\n<li>Mild: GI upset, headache</li>\r\n<li>Rare but serious: <strong>Hepatotoxicity</strong> (monitor liver function)</li>\r\n<li><strong>Minimal drug interactions</strong> (no P450 interference)</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509042dacc84b-b34f-454c-9805-e5a829e68c07.PNG\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Clotrimazole(Option A): </strong>Topical agent; ineffective in nail infections due to<strong> poor nail penetration.</strong></p>\r\n<p><strong>Flucytosine(Option B): </strong>Antimetabolite used in systemic<strong> Candida/Cryptococcus infections, </strong>not dermatophytes<strong> </strong></p>\r\n<p><strong>Nystatin(Option C): </strong>Effective against <strong>Candida (e.g., oral thrush), </strong>not active against dermatophytes.</p>", "options": ["Clotrimazole", "Flucytosine", "Nystatin", "Terbinafine"], "html_options": ["Clotrimazole", "Flucytosine", "Nystatin", "Terbinafine"], "corr_idx": 3}]}, {"moduleId": 1008554, "name": "Antiviral Agents (Herpes, HIV, Influenza, HBV And HCV)", "questions": [{"id": "1176805", "html_qtxt": "A 34-year-old male patient came to the OPD with the complaint of bilateral genital vesicles, fever, and itching. He is a known case of HIV and has been on ART for the last 4 years. So, he is diagnosed with genital HSV infection in HIV. There are three nucleoside analogues licensed for the treatment of HSV and VZV. Which of the following are three agents?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Three oral nucleoside analogues are licensed for the treatment of HSV and VZV infections: <strong>acyclovir, valacyclovir, and famciclovir.</strong></li>\n<li>They have similar mechanisms of action and comparable indications for clinical use; all are well tolerated. Acyclovir has been the most extensively studied</li>\n<li>It was licensed first and is the only one of the three that is available for intravenous use in the United States.</li>\n<li>Comparative trials have demonstrated similar efficacies of these three agents for the treatment of HSV, but modest superiority of <strong>famciclovir and valacyclovir </strong>for the treatment of herpes zoster infections.</li>\n<li><strong>Acyclovir</strong>\n<ul>\n<li>First-line drug for HSV and VZV</li>\n<li>Inhibits viral DNA polymerase after phosphorylation by viral thymidine kinase</li>\n</ul>\n</li>\n<li><strong>Valacyclovir</strong>\n<ul>\n<li>Prodrug of acyclovir (better oral bioavailability)</li>\n<li>Converted to acyclovir in the body</li>\n</ul>\n</li>\n<li><strong>Famciclovir</strong>\n<ul>\n<li>Prodrug of penciclovir</li>\n<li>Also used in HSV and VZV infections</li>\n</ul>\n</li>\n</ul>\n<p><strong>Genital Herpes</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509054a7f3a80-2e07-4d5f-b6a7-45337131b286.png\">\n<p><strong>In Pregnancy:</strong> Suppressive therapy should begin at 36 weeks.</p>\n<p>Acyclovir 400 mg TID <strong>or</strong> Valacyclovir 500 mg BID</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acyclovir, penciclovir, famciclovir(Option A):</strong> Penciclovir is <strong>only topical</strong> and not commonly used systemically for genital HSV.</p>\n<p><strong>Valacyclovir, penciclovir, famciclovir(Option C): </strong>Again, <strong>penciclovir</strong> is topical and not a systemic treatment.</p>\n<p><strong>Valacyclovir, famciclovir, lamivudine(Option D): Lamivudine</strong> is <strong>not used for HSV or VZV</strong>; it's a reverse transcriptase inhibitor used in <strong>HIV</strong> and <strong>HBV</strong> treatment.</p>", "options": ["Acyclovir, penciclovir, famciclovir", "Acyclovir, valacyclovir, famciclovir", "Valacyclovir, penciclovir, famciclovir", "Valacyclovir, famciclovir, lamivudine"], "html_options": ["Acyclovir, penciclovir, famciclovir", "Acyclovir, valacyclovir, famciclovir", "Valacyclovir, penciclovir, famciclovir", "Valacyclovir, famciclovir, lamivudine"], "corr_idx": 1}, {"id": "1176807", "html_qtxt": "A 35-year-old female patient with recurrent herpes labialis came to the OPD for the 5th episode of herpes labialis. She was prescribed acyclovir topical ointment 5 times daily for 4 days. How many phosphorylation steps are required for the activation of acyclovir?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Acyclovir requires <strong>three </strong>phosphorylation steps for activation.</p>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509052d241e76-03a8-47a3-b7ca-1223cde3f9bf.jpg\">\n<ul>\n<li>Acyclovir is an acyclic guanosine derivative with clinical activity against HSV-1, HSV-2, and VZV, but it is approximately 10 times more potent against HSV-1 and HSV-2 than against VZV. In vitro activity against Epstein-Barr virus (EBV), cytomegalovirus (CMV), and human herpesvirus-6 (HHV-6) is present but weaker.</li>\n</ul>\n<p><strong>Acyclovir:</strong></p>\n<p><strong>Acyclovir</strong> is an Acyclic guanosine nucleoside analog, which is an Antiviral drug active against <strong>Herpesviridae</strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<p>Acyclovir is selectively activated in infected cells.</p>\n<ul>\n<li><strong>Requires three phosphorylation steps to become active:</strong>\n<ul>\n<li>Step 1: Viral thymidine kinase &rarr; acyclovir monophosphate</li>\n<li>Step 2 & 3: Host cell kinases &rarr; acyclovir diphosphate &rarr; triphosphate</li>\n</ul>\n</li>\n<li><strong>Antiviral effects:</strong>\n<ul>\n<li>Inhibits <strong>viral DNA polymerase</strong> by competing with deoxyGTP</li>\n<li>Causes chain termination after incorporation into viral DNA</li>\n<li>Forms an irreversible complex with viral DNA polymerase and DNA template</li>\n</ul>\n</li>\n</ul>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509050e47b823-1a1c-4405-9063-73a700bd550e.jpg\">\n<p><strong>Pharmacokinetics</strong></p>\n<ul>\n<li>Oral bioavailability: Low (15-20%), unaffected by food</li>\n<li>Topical use: High local concentration, no systemic levels</li>\n<li>IV use: Available and preferred for severe infections</li>\n<li><strong>Excretion: Renal (glomerular filtration + tubular secretion)</strong></li>\n<li><strong>Half-life:</strong>\n<ul>\n<li>~2.5-3 hrs (<strong>normal renal function</strong>)</li>\n<li>~20 hrs (<strong>anuric patients</strong>)</li>\n</ul>\n</li>\n<li>CNS penetration: CSF levels &asymp;20-50% of serum levels</li>\n</ul>\n<p><strong>Clinical Uses:</strong></p>\n<ul>\n<li><strong>HSV infections:</strong>\n<ul>\n<li>Genital/orolabial herpes</li>\n<li>Neonatal HSV (IV)</li>\n<li>Herpes encephalitis (IV)</li>\n</ul>\n</li>\n<li><strong>VZV infections:</strong>\n<ul>\n<li>Chickenpox (if started <24 hrs of rash)</li>\n<li>Herpes zoster (if <72 hrs)</li>\n<li>Immunocompromised VZV &rarr; IV acyclovir</li>\n</ul>\n</li>\n<li><strong>Prophylaxis:</strong>\n<ul>\n<li>In transplant/immunocompromised patients</li>\n<li>In pregnant women with recurrent genital herpes (from 36 weeks of gestation)</li>\n</ul>\n</li>\n</ul>\n<p><strong>Resistance</strong></p>\n<ul>\n<li>Due to Mutations in <strong>viral thymidine kinase (UL23 gene) </strong>and Mutations in <strong>viral DNA polymerase</strong></li>\n<li><strong>Cross-resistance with</strong> Valacyclovir, famciclovir, ganciclovir</li>\n<li><strong>Alternative agents (do not require viral kinase):</strong>\n<ul>\n<li>Foscarnet</li>\n<li>Cidofovir</li>\n<li>Trifluridine</li>\n</ul>\n</li>\n</ul>\n<p><strong>Adverse Effects</strong></p>\n<ul>\n<li><strong>Common (oral):</strong> Nausea, diarrhea, headache</li>\n<li><strong>IV-specific (rare):</strong>\n<ul>\n<li><strong>Nephrotoxicity</strong>: Crystalline nephropathy, interstitial nephritis</li>\n<li><strong>Neurotoxicity</strong>: Tremors, delirium, seizures</li>\n<li><strong>Hematologic:</strong> Reversible neutropenia</li>\n</ul>\n</li>\n<li><strong>High-dose animal toxicity:</strong> Chromosomal damage, testicular atrophy (not seen in long-term human use)</li>\n</ul>", "options": ["One", "Two", "Three", "Four"], "html_options": ["One", "Two", "Three", "Four"], "corr_idx": 2}, {"id": "1176812", "html_qtxt": "A newborn child is admitted to the NICU for phototherapy for neonatal jaundice. He develops a fever on the 4th day. So, blood culture investigation is done. Blood culture is positive for HSV-1 viral infection. The paediatrician wants to start intravenous acyclovir for treatment. What is the correct dose of acyclovir every 8 hours for the treatment of neonatal HSV infection?", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240325dbf2fad0-0e53-4089-a3cb-e42c86f149cd.jpg\">", "options": ["2-5 mg/kg", "5-10 mg/kg", "10-20 mg/kg", "30-35 mg/kg"], "html_options": ["2-5 mg/kg", "5-10 mg/kg", "10-20 mg/kg", "30-35 mg/kg"], "corr_idx": 2}, {"id": "1176815", "html_qtxt": "A 50-year-old man is being treated with IV acyclovir for HSV-1 encephalitis, confirmed by CSF culture. He initially improves but develops a fever with chills on day 10. Repeat CSF analysis shows HSV-1 resistant to acyclovir. Which IV drug is preferred for treating acyclovir-resistant HSV infections?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Preferred IV drug for acyclovir-resistant HSV is Foscarnet</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403253feeab37-9d79-4e67-8212-04e4506a602b.jpg\">\n<p><strong>Resistance to acyclovir: </strong></p>\n<ul>\n<li>Due to Mutations in <strong>viral thymidine kinase (UL23 gene) </strong>and Mutations in <strong>viral DNA polymerase</strong></li>\n<li><strong>Cross-resistance with</strong> Valacyclovir, famciclovir, ganciclovir</li>\n<li><strong>Alternative agents (do not require viral kinase):</strong>\n<ul>\n<li>Foscarnet</li>\n<li>Cidofovir</li>\n<li>Trifluridine</li>\n</ul>\n</li>\n</ul>\n<p><strong>Foscarnet:</strong></p>\n<p>Foscarnet is an Inorganic <strong>pyrophosphate analog</strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<ul>\n<li>Directly inhibits<strong> Herpesvirus DNA polymerase, RNA polymerase, and HIV reverse transcriptase</strong></li>\n<li>Binds to the pyrophosphate-binding site of enzymes &rarr; prevents cleavage of pyrophosphate from deoxynucleotide triphosphates &rarr; inhibits DNA synthesis</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905018401a5-72b7-4d97-97c9-b18e5a693de6.jpg\">\n<p><strong>Antiviral Spectrum: </strong>Effective against <strong>HSV</strong>, <strong>VZV, CMV</strong> (including ganciclovir-resistant), <strong>EBV</strong>, <strong>HHV-6</strong>, <strong>HHV-8, HIV-1</strong>, <strong>HIV-2</strong></p>\n<p><strong>Formulation & Administration:</strong></p>\n<ul>\n<li>Only IV (oral use limited by poor bioavailability and GI intolerance)</li>\n<li>Use an infusion pump and saline preloading to reduce nephrotoxicity</li>\n<li>Intravitreally used for CMV retinitis</li>\n</ul>\n<p><strong>Pharmacokinetics</strong></p>\n<ul>\n<li>CSF levels: ~43-67% of plasma</li>\n<li>Plasma half-life: 3-7 hours</li>\n<li>Bone deposition: up to 30% (half-life of months)</li>\n<li>Renal clearance proportional to creatinine clearance &rarr; dose adjustment required</li>\n<li>50% removed via hemodialysis</li>\n</ul>\n<p><strong>Adverse Effects</strong></p>\n<ul>\n<li><strong>Nephrotoxicity</strong>:\n<ul>\n<li>Prevent with <strong>hydration</strong></li>\n<li>Avoid with other nephrotoxic drugs (e.g., amphotericin B, aminoglycosides)</li>\n</ul>\n</li>\n<li><strong>Electrolyte Imbalances</strong>:\n<ul>\n<li>Hypo-/hypercalcemia</li>\n<li>Hypo-/hyperphosphatemia</li>\n<li>Hypokalemia, hypomagnesemia</li>\n</ul>\n</li>\n<li><strong>Genital ulcerations</strong>:\n<ul>\n<li>Due to high urinary concentration of ionized drug</li>\n</ul>\n</li>\n<li><strong>CNS toxicity</strong>:\n<ul>\n<li>Headache, <strong>hallucinations</strong>, <strong>seizures</strong></li>\n<li>Seizure risk &uarr; with <strong>imipenem</strong></li>\n</ul>\n</li>\n<li><strong>Hematologic</strong>:\n<ul>\n<li>Anemia (worse with <strong>zidovudine</strong>)</li>\n<li>&uarr; Liver enzymes</li>\n<li>Fatigue</li>\n</ul>\n</li>\n<li><strong>Carcinogenicity</strong>:\n<ul>\n<li><strong>Chromosomal damage</strong> noted in preclinical studies</li>\n</ul>\n</li>\n</ul>\n<p>S/E of Foscarnet, Cedofovir - Similar to Tenofovir- <strong>Pneumonic Neck Of Femur (NOF)</strong></p>\n<ul>\n<li>Nephrotoxciity</li>\n<li>Osteoporosis</li>\n<li>Fanconi syndrome</li>\n</ul>\n<p>Unique s/e of Foscarnet - Genital ulceration</p>", "options": ["Docosanol", "Foscarnet", "Penciclovir", "Trifluridine"], "html_options": ["Docosanol", "Foscarnet", "Penciclovir", "Trifluridine"], "corr_idx": 1}, {"id": "1176819", "html_qtxt": "In patients with AIDS receiving high-dose chronic valacyclovir therapy (8 g/day), which of the following complications has been observed with increased incidence?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Valacyclovir</strong> is generally well tolerated, although nausea, headache, vomiting, or rash occasionally occur.</li>\n<li>At high doses, confusion, hallucinations, and seizures have been reported.</li>\n<li>AIDS patients who received high-dose valacyclovir chronically (ie, 8 g/d) had an increased incidence of gastrointestinal intolerance as well as <strong>thrombotic thrombocytopenic purpura</strong> and<strong> hemolytic-uremic syndrome</strong>; this dose has also been associated with confusion and hallucinations in transplant patients.</li>\n<li>In a recent study, there was no evidence of increased birth defects in 181 infants who were exposed to valacyclovir during the first trimester.</li>\n</ul>\n<p><strong>Valacyclovir:</strong></p>\n<ul>\n<li>Valacyclovir is the L-valyl ester prodrug of acyclovir.</li>\n<li>After oral administration, it undergoes <strong>first-pass hydrolysis</strong> in the <strong>liver and intestine</strong>, converting rapidly to acyclovir.</li>\n<li>This conversion results in <strong>serum levels 3-5 times higher</strong> than oral acyclovir, <strong>approximating IV acyclovir</strong> levels.</li>\n</ul>\n<p><strong>Clinical Uses:</strong></p>\n<ul>\n<li>Herpes simplex virus (HSV) infections</li>\n<li>Varicella-zoster virus (VZV) infections</li>\n<li>Cytomegalovirus (CMV) prophylaxis in certain settings</li>\n<li><strong>Suppressive therapy</strong> from 36 weeks of gestation in <strong>pregnant women</strong> with <strong>recurrent genital herpes</strong></li>\n</ul>\n<p><strong>Adverse Effects:</strong></p>\n<ul>\n<li>Common: Nausea, headache, vomiting, rash</li>\n<li>High doses (e.g., 8 g/day):\n<ul>\n<li><strong>Neurotoxicity</strong>: Confusion, hallucinations, seizures (especially in transplant patients)</li>\n<li><strong>AIDS patients</strong>: Increased risk of <strong>thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS)</strong> and <strong>GI intolerance</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong><strong>Explanation of Other Options:</strong></strong></p>\n<p><strong>Idiopathic Thrombocytopenic Purpura (Option A): ITP</strong> is an autoimmune condition where the body attacks its platelets, leading to thrombocytopenia. ITP is typically triggered by viral infections, autoimmune diseases, or certain drugs, but <strong>valacyclovir is not among them</strong>.</p>\n<p><strong>Colon carcinoma(Option C): </strong>Valacyclovir is <strong>not mutagenic or carcinogenic</strong>, and there is <strong>no evidence</strong> that it increases the risk of any malignancy.</p>", "options": ["Idiopathic thrombocytopenic purpura", "Thrombotic thrombocytopenic purpura", "Colon carcinoma", "All of the above"], "html_options": ["Idiopathic thrombocytopenic purpura", "Thrombotic thrombocytopenic purpura", "Colon carcinoma", "All of the above"], "corr_idx": 1}, {"id": "1176822", "html_qtxt": "A 25-year-old patient came to the OPD with complaints of decreased urine, difficulty in breathing, and bilateral pedal oedema. USG was s/o CRF grade -V. He underwent a series of investigations, and a renal transplant was done. Which anti-viral agent is useful in this pt. for CMV infection prevention?", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403255a9b4cad-5498-4283-9fc2-90feb4168161.jpg\">", "options": ["Acyclovir", "Valacyclovir", "Ganciclovir", "All of the above"], "html_options": ["Acyclovir", "Valacyclovir", "Ganciclovir", "All of the above"], "corr_idx": 3}, {"id": "1176824", "html_qtxt": "Which of the following is the most common adverse effect associated with systemic (especially intravenous) ganciclovir therapy?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ol>\n<li><strong>Common Adverse Effect:</strong> Systemic ganciclovir treatment, especially intravenous use, often leads to myelosuppression.</li>\n<li><strong>Myelosuppression:</strong> Myelosuppression entails reduced blood cell production by the bone marrow, causing low white blood cells, red blood cells, and platelets.</li>\n<li><strong>Consequences of Myelosuppression:</strong> This condition increases the risk of infections (due to low white blood cells), causes anemia-related symptoms (due to low red blood cells), and can lead to bleeding tendencies (due to low platelet count).</li>\n</ol>\n<p><strong>Adverse Effects of Ganciclovir:</strong></p>\n<ul>\n<li><strong>Most common</strong>: <strong>Myelosuppression</strong> (dose-limiting)</li>\n<li><strong>Others:</strong>\n<ul>\n<li>GI: Nausea, diarrhea<strong>(Option B ruled out)</strong></li>\n<li>CNS: Headache, insomnia, confusion, seizures, psychiatric symptoms <strong>(Option D ruled out)</strong></li>\n<li>Skin: Rash</li>\n<li>Liver: Rare <strong>hepatotoxicity(Option A ruled out)</strong></li>\n<li>Eye (intravitreal use): Vitreous hemorrhage, retinal detachment</li>\n</ul>\n</li>\n<li><strong>Long-term risks</strong> (in animals):\n<ul>\n<li><strong>Carcinogenic</strong>, <strong>embryotoxic</strong>, and <strong>aspermatogenesis</strong></li>\n<li><strong>Mutagenic</strong> in mammalian cells (clinical significance unknown)</li>\n</ul>\n</li>\n</ul>", "options": ["Hepatotoxicity", "GI intolerance", "Myelosuppression", "Central nervous system toxicity"], "html_options": ["Hepatotoxicity", "GI intolerance", "Myelosuppression", "Central nervous system toxicity"], "corr_idx": 2}, {"id": "1176835", "html_qtxt": "Which of the following is not an ART agent?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>The CCR4 receptor antagonist </strong>is not used in HIV therapy. <strong>Maraviroc, a CCR5 receptor antagonis</strong>t, is used in ART. CCR4 is not a recognized target in HIV treatment.</p>\n<p><strong>Antiretroviral Therapy (ART) agents:</strong></p>\n<ol>\n<li><strong>NRTIs (Nucleoside/Nucleotide Reverse Transcriptase Inhibitors)</strong>\n<ul>\n<li><strong>Mechanism: </strong>Act as faulty DNA building blocks, inhibiting reverse transcription.</li>\n<li><strong>Examples: </strong>Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF, TAF), Emtricitabine (FTC), Abacavir (ABC), Stavudine (d4T), Didanosine (ddI)</li>\n</ul>\n</li>\n<li><strong>NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)</strong>\n<ul>\n<li><strong>Mechanism: </strong>Bind to and inhibit reverse transcriptase at a different site than NRTIs.</li>\n<li><strong>Examples: </strong>Efavirenz, Nevirapine, Etravirine, Rilpivirine, Doravirine</li>\n</ul>\n</li>\n<li><strong>PIs (Protease Inhibitors)</strong>\n<ul>\n<li><strong>Mechanism: </strong>Inhibits the HIV protease enzyme, preventing viral maturation.</li>\n<li><strong>Examples: </strong>Lopinavir, Ritonavir (used mainly as a booster), Atazanavir, Darunavir, Indinavir, Saquinavir</li>\n</ul>\n</li>\n<li><strong>INSTIs (Integrase Strand Transfer Inhibitors)</strong>\n<ul>\n<li><strong>Mechanism: </strong>Inhibits the HIV integrase enzyme, blocking the integration of viral DNA into host DNA.</li>\n<li><strong>Examples: </strong>Dolutegravir, Raltegravir, Bictegravir, Elvitegravir</li>\n</ul>\n</li>\n<li><strong>Entry and Fusion Inhibitors</strong>\n<ul>\n<li>Fusion Inhibitors: Enfuvirtide (T-20) blocks the fusion of HIV with the host cell.</li>\n<li>CCR5 Receptor Antagonists (Entry Inhibitors): Maraviroc blocks the CCR5 co-receptor (not CCR4).</li>\n</ul>\n</li>\n<li><strong>Post-Attachment Inhibitor: </strong>Ibalizumab, a monoclonal antibody used for multidrug-resistant HIV.</li>\n<li><strong>CXCR4 inhibitor: </strong>Plerixafor</li>\n</ol>", "options": ["NRTIs", "NNRTIs", "CCR4 receptor antagonist", "Fusion inhibitors"], "html_options": ["NRTIs", "NNRTIs", "CCR4 receptor antagonist", "Fusion inhibitors"], "corr_idx": 2}, {"id": "1176836", "html_qtxt": "Which of the following is true for Abacavir?", "html_expl": "<p><strong>Explanation</strong>:</p>\n<p><strong>HLA-B5701 testing is mandatory</strong> before starting therapy. If a patient is positive for this allele, <strong>abacavir is contraindicated</strong>. This test is essential to reduce the risk of <strong>abacavir hypersensitivity reaction</strong>, which can be severe and life-threatening.</p>\n<p><strong>Abacavir: </strong></p>\n<p><strong>Drug Class:</strong></p>\n<ul>\n<li>Nucleoside Reverse Transcriptase Inhibitor (NRTI)<strong>(Option A ruled out)</strong></li>\n<li>Guanosine analog</li>\n</ul>\n<p><strong>Pharmacokinetics:</strong></p>\n<ul>\n<li><strong>Oral bioavailability:</strong> ~83% (not affected by food)</li>\n<li><strong>Half-life (serum):</strong> ~1.5 hours</li>\n<li><strong>Metabolism:</strong>\n<ul>\n<li>Hepatic: via <strong>glucuronidation</strong> and <strong>carboxylation</strong></li>\n<li>Also metabolized by <strong>alcohol dehydrogenase</strong> &rarr; alcohol increases abacavir serum levels</li>\n</ul>\n</li>\n<li><strong>CSF penetration:</strong> ~1/3 of plasma levels</li>\n</ul>\n<p><strong>Drug Interactions:</strong></p>\n<ul>\n<li><strong>Increased levels with alcohol</strong> (ethanol competes for metabolism)<strong>(Option B ruled out)</strong></li>\n<li>Decreased levels when co-administered with:\n<ul>\n<li>Atazanavir</li>\n<li>Lopinavir</li>\n</ul>\n</li>\n</ul>\n<p><strong>Adverse Effects:</strong></p>\n<h4><strong>Hypersensitivity Reaction (HSR):</strong></h4>\n<ul>\n<li>Seen in <strong>~8%</strong> of patients</li>\n<li>May be <strong>fatal</strong></li>\n<li>More severe with <strong>once-daily dosing</strong></li>\n<li><strong>Onset:</strong> Usually within the <strong>first 6 weeks</strong></li>\n<li><strong>Symptoms:</strong>\n<ul>\n<li>Fever, fatigue, nausea, vomiting, diarrhea</li>\n<li>Abdominal pain, rash (~50%), dyspnea, cough</li>\n<li>Elevated <strong>ALT, CK</strong> levels</li>\n</ul>\n</li>\n<li><strong>Management:</strong>\n<ul>\n<li><strong>Do not rechallenge</strong></li>\n<li><strong>HLA-B*5701 testing is mandatory</strong> before starting therapy\n<ul>\n<li>Positive predictive value: ~50%</li>\n<li><strong>Negative predictive value: ~100%</strong></li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<p><strong>Other Adverse Effects:</strong></p>\n<ul>\n<li>Rash (~5%)</li>\n<li>Headache, fatigue, dyspnea</li>\n<li><strong>Pancreatitis</strong> (less common)</li>\n<li><strong>Potential CV risk:</strong> Avoid in patients with <strong>coronary artery disease</strong></li>\n<li><strong>Mitochondrial toxicity & lipid disorders:</strong> Less common than with other NRTIs</li>\n</ul>\n<p><strong>Use in Pregnancy: Recommended</strong> for use in pregnant women as part of a combination ART</p>", "options": ["Abacavir is an NNRTI agent", "Patient taking abacavir advised to take alcohol along with it", "Testing to rule out the HLA-B5701 allele is recommended before initiating therapy", "None of the above"], "html_options": ["Abacavir is an NNRTI agent", "Patient taking abacavir advised to take alcohol along with it", "Testing to rule out the HLA-B5701 allele is recommended before initiating therapy", "None of the above"], "corr_idx": 2}, {"id": "1176838", "html_qtxt": "A 35-year-old male patient with HIV presents with chronic diarrhea and is started on ART. While collecting a blood sample, an intern sustains a needle-stick injury. He reports immediately to the ART center for post-exposure prophylaxis (PEP). Which of the following drug combinations is recommended for PEP?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>According to <strong>NACO 2023 guidelines</strong> for <strong>HIV PEP</strong>, the recommended regimen is:</p>\n<ul>\n<li><strong>Tenofovir Disoproxil Fumarate (TDF)</strong> 300 mg</li>\n<li><strong>Lamivudine (3TC)</strong> 300 mg</li>\n<li><strong>Dolutegravir (DTG)</strong> 50 mg once daily</li>\n<li><strong>Duration:</strong> 28 days</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905d55550e6-a358-41e8-9bfd-1f6a3911eb46.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Zidovudine + Lamivudine + Nevirapine</strong>:</p>\n<p>Outdated. Nevirapine is <strong>not recommended</strong> due to <strong>hepatotoxicity risk</strong> and poor safety in PEP.</p>\n<p><strong>Tenofovir + Emtricitabine + Efavirenz</strong>:</p>\n<p>Previously used, but <strong>Efavirenz</strong> has <strong>CNS side effects</strong>, and <strong>DTG is now preferred</strong> for its high potency and tolerability.</p>\n<p><strong>Abacavir + Lamivudine + Rilpivirine</strong>:</p>\n<p>Not recommended for PEP. <strong>Abacavir requires HLA-B*5701 testing</strong>, and <strong>Rilpivirine</strong> has restrictions like food requirements and can't be used with high viral loads.</p>", "options": ["Zidovudine + Lamivudine + Nevirapine", "Tenofovir + Emtricitabine + Efavirenz", "Tenofovir Disoproxil Fumarate + Lamivudine + Dolutegravir", "Abacavir + Lamivudine + Rilpivirine"], "html_options": ["Zidovudine + Lamivudine + Nevirapine", "Tenofovir + Emtricitabine + Efavirenz", "Tenofovir Disoproxil Fumarate + Lamivudine + Dolutegravir", "Abacavir + Lamivudine + Rilpivirine"], "corr_idx": 2}, {"id": "1176839", "html_qtxt": "Which of the following drugs can be used as pre-exposure prophylaxis of HIV?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Pre-Exposure Prophylaxis (PrEP) for HIV:</strong></p>\n<p>Pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs by HIV-negative individuals at high risk of HIV exposure to prevent infection.</p>\n<p><strong>Recommended PrEP Regimens (as per NACO & WHO 2024 guidelines)</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509054dd9ee37-c379-46bf-81eb-a7c694327194.png\">\n<p><strong>Indications for PrEP</strong></p>\n<ul>\n<li>Serodiscordant couples (one partner HIV-positive)</li>\n<li>MSM (men who have sex with men)</li>\n<li>Transgender individuals are at risk</li>\n<li>Sex workers</li>\n<li>IV drug users sharing needles</li>\n<li>Individuals with multiple sexual partners who do not use condoms</li>\n</ul>", "options": ["Tenofovir", "Emtricitabine", "Lamivudine", "All the above"], "html_options": ["Tenofovir", "Emtricitabine", "Lamivudine", "All the above"], "corr_idx": 3}, {"id": "1176841", "html_qtxt": "Which drug is used as a single dose for the prevention of HIV from mother to neonate at the onset of labour?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>A single dose of <strong>nevirapine</strong> (200 mg) is effective in the prevention of transmission of HIV from mother to newborn when administered to women <strong>at the onset of labor </strong>and followed by a <strong>2 mg/kg oral dose to the neonate within 3 days after delivery.</strong></li>\n<li>There is no evidence of human teratogenicity. However, resistance has been documented after this single dose.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090591de0329-150c-4c28-a726-fabd86f1c52b.jpg\">\n<p><strong>Infant Prophylaxis (Post-Delivery)</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905b38ac5e9-3219-44c5-a039-aecd05f749b3.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Zidovudine(Option B): </strong>Used in <strong>combination regimens</strong> for PMTCT but <strong>not as a single dose</strong> at labor onset.</p>\n<p><strong>Tenofovir(Option C): </strong>Part of <strong>combination ART regimens</strong> during pregnancy, not used as a single dose at labor onset.</p>\n<p><strong>Sofosbuvir(Option D): </strong>An <strong>antiviral for Hepatitis C</strong>, <strong>not used in HIV prophylaxis</strong>.</p>", "options": ["Nevirapine", "Zidovudine", "Tenofovir", "Sofosbuvir"], "html_options": ["Nevirapine", "Zidovudine", "Tenofovir", "Sofosbuvir"], "corr_idx": 0}, {"id": "1176842", "html_qtxt": "1. Lopinavir is currently formulated only in combination with ritonavir<br>2. It inhibits CYP2A-mediated metabolism of lopinavir", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Lopinavir and ritonavir are Protease Inhibitors.</li>\n<li>Lopinavir is currently formulated only in combination with ritonavir, which inhibits the <strong>CYP3A-mediated metabolism</strong> of lopinavir, thereby resulting in increased exposure to lopinavir.</li>\n<li>In addition to improved patient compliance due to reduced pill burden, lopinavir/ritonavir is generally well tolerated.</li>\n</ul>\n<p><strong>Protease Inhibitors:</strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<p>PIs inhibit the HIV protease enzyme, which is essential for cleaving the Gag-Pol polyprotein during the final stages of the HIV life cycle.</p>\n<p><strong>Pharmacokinetics & Boosting:</strong></p>\n<ul>\n<li><strong>PIs are often co-administered</strong> with:\n<ul>\n<li><strong>Ritonavir</strong> (low-dose: 100-200 mg) or</li>\n<li><strong>Cobicistat</strong> (has no antiviral activity)</li>\n</ul>\n</li>\n<li><strong>Purpose of Boosting</strong>:<br /> Inhibits <strong>CYP3A4</strong>, increasing the serum levels and half-life of the primary PI.<br /> Improves efficacy and raises the <strong>genetic barrier to resistance</strong>.</li>\n</ul>\n<p><strong>Adverse Effects of Protease Inhibitors (PIs)</strong></p>\n<ul>\n<li><strong>Gastrointestinal:</strong>\n<ul>\n<li>Nausea</li>\n<li>Vomiting</li>\n<li>Diarrhea (often dose-limiting)</li>\n</ul>\n</li>\n<li><strong>Metabolic:</strong>\n<ul>\n<li>Hyperglycemia</li>\n<li>Hyperlipidemia</li>\n<li>Insulin resistance</li>\n</ul>\n</li>\n<li><strong>Morphologic (Lipodystrophy Syndrome):</strong>\n<ul>\n<li>Central obesity</li>\n<li>Buffalo hump (dorsocervical fat pad)</li>\n<li>Facial and peripheral fat wasting (lipoatrophy)</li>\n<li>Breast enlargement</li>\n<li>Cushingoid appearance</li>\n</ul>\n</li>\n<li><strong>Cardiovascular:</strong>\n<ul>\n<li>PR interval prolongation</li>\n<li>QT interval prolongation</li>\n<li>&uarr; Cardiovascular disease risk (notably with abacavir and lopinavir/ritonavir)</li>\n</ul>\n</li>\n<li><strong>Hepatic:</strong>\n<ul>\n<li>Drug-induced hepatitis</li>\n<li>Severe hepatotoxicity (especially with tipranavir/ritonavir)</li>\n<li>Unconjugated hyperbilirubinemia (especially with atazanavir)</li>\n</ul>\n</li>\n<li><strong>Skeletal:</strong>\n<ul>\n<li>Potential bone loss and osteoporosis (long-term use; under investigation)</li>\n</ul>\n</li>\n<li><strong>Hematologic:</strong>\n<ul>\n<li>Increased spontaneous bleeding in patients with hemophilia A or B</li>\n<li>Risk of intracranial hemorrhage (noted with tipranavir/ritonavir)</li>\n</ul>\n</li>\n<li><strong>Allergic Reactions:</strong>\n<ul>\n<li><strong>Darunavir</strong> is a sulfonamide &rarr; Use with caution in patients with sulfa allergy</li>\n</ul>\n</li>\n</ul>", "options": ["Sentence 1 and 2 both are True, and 2 is the correct reason for 1", "Sentences 1 and 2 both are True, but 2 is not the correct reason for 1", "Sentence 1 is True, but Sentence 2 is False", "Sentences 1 and 2 are both False"], "html_options": ["Sentence 1 and 2 both are True, and 2 is the correct reason for 1", "Sentences 1 and 2 both are True, but 2 is not the correct reason for 1", "Sentence 1 is True, but Sentence 2 is False", "Sentences 1 and 2 are both False"], "corr_idx": 2}, {"id": "1176843", "html_qtxt": "Match the following for ART agents.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024032259b83918-43da-42cc-913c-491a288ea328.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509056ba93ad3-a979-4e80-95a9-6f61c640bfe3.png\"><br>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403225c2eaa7e-0b82-4c39-8eb1-18373730f4bd.jpg\">", "options": ["1-a, 2-c, 3-d, 4-b", "1-b, 2-a, 3-d, 4-c", "1-c, 2-a, 3-d, 4-d", "1-d, 2-b, 3-a, 4-c"], "html_options": ["1-a, 2-c, 3-d, 4-b", "1-b, 2-a, 3-d, 4-c", "1-c, 2-a, 3-d, 4-d", "1-d, 2-b, 3-a, 4-c"], "corr_idx": 3}, {"id": "1176845", "html_qtxt": "Which of the following is not approved for HBV treatment?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>HBV infection in the United States: five oral nucleoside/nucleotide analogues (<strong>lamivudine</strong>, adefovir dipivoxil, <strong>tenofovir</strong>, entecavir, telbivudine) and two injectable interferon drugs (<strong>interferon alfa-2b</strong>, pegylated interferon alfa-2a)</li>\n</ul>\n<p><strong>First-Line Antiviral Drugs for HBV</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090502bf14b9-4b45-41e9-b470-e619127b2e4c.png\">\n<p><strong>Other Drugs:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905a1399877-da9c-45ad-8d93-8c098df04057.png\">", "options": ["Interferon alfa-2b", "Lamivudine", "Tenofovir", "Zidovudine"], "html_options": ["Interferon alfa-2b", "Lamivudine", "Tenofovir", "Zidovudine"], "corr_idx": 3}, {"id": "1176848", "html_qtxt": "Which drug is useful against HCV?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Sofosbuvir( Nucleotide Analog for HCV):</strong></p>\n<p><strong>Mechanism of Action: </strong></p>\n<ul>\n<li><strong>Prodrug</strong> converted intracellularly to active <strong>uridine analog triphosphate</strong> (GS-461203).</li>\n<li>Incorporated into viral RNA by <strong>NS5B RNA-dependent RNA polymerase</strong>.</li>\n<li>Causes <strong>chain termination</strong>, halting HCV replication.</li>\n</ul>\n<p><strong>Indications & Combinations</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905a4e38394-d7dc-457c-9140-3aef5d9208d9.png\">\n<p><strong>Pharmacokinetics</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905295e8ff8-70f3-4c2b-8b16-0b8ba3958488.png\">\n<p><strong>Adverse Effects</strong></p>\n<ul>\n<li><strong>Common</strong> (in combination therapy): Fatigue, headache, asthenia</li>\n<li><strong>Rare but notable</strong>: <strong>Symptomatic bradycardia</strong> (especially with <strong>amiodarone</strong>, &beta;-blockers, or advanced liver disease), <strong>Severe cutaneous reactions</strong></li>\n</ul>\n<p><strong><strong>Treatment of Hepatitis C:</strong></strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090530520de8-6071-4c24-89a3-e78a199a787f.png\">\n<p><strong>DAAs target proteins essential for viral replication:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090589a42f81-7e9e-43bf-9d1a-fb8fa5de3b33.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Tenofovir(Option A): </strong>Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI) primarily used for HIV and HBV infections. It has no significant role in treating HCV. While some studies explored its use in coinfection settings, Tenofovir does not directly act on the HCV replication machinery.</p>\n<p><strong>Zidovudine(Option B):</strong> Zidovudine is also an NRTI used in the management of HIV. It has no antiviral activity against HCV and is not part of any HCV treatment regimen.</p>", "options": ["Tenofovir", "Zidovudine", "Sofosbuvir", "All of the above"], "html_options": ["Tenofovir", "Zidovudine", "Sofosbuvir", "All of the above"], "corr_idx": 2}, {"id": "1176849", "html_qtxt": "A 28-year-old woman presents with the sudden onset of high-grade fever, dry cough, sore throat, and myalgia during the peak flu season. She reports recent contact with a co-worker diagnosed with H1N1 (Swine flu). What is the most commonly used antiviral drug for the treatment of this condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The neuraminidase inhibitors<strong> oseltamivir and zanamivir</strong>, analogues of sialic acid, interfere with the release of progeny <strong>influenza virus</strong> from infected host cells, thus halting the spread of infection within the respiratory tract.</li>\n<li>These agents competitively and reversibly interact with the active enzyme site to inhibit viral neuraminidase activity at low nanomolar concentrations.</li>\n<li>Inhibition of viral neuraminidase results in clumping of newly released influenza virions with each other and the membrane of the infected cell.</li>\n</ul>\n<p><strong>Oseltamivir:</strong></p>\n<p>Class of<strong> Neuraminidase inhibitors </strong>(along with Zanamivir)<strong>. </strong>Analog of sialic acid</p>\n<h4><strong>Mechanism of Action:</strong></h4>\n<ul>\n<li>Inhibits viral neuraminidase of <strong>Influenza A & B</strong></li>\n<li>Prevents the release of progeny virions from infected cells</li>\n<li>Causes clumping of virions &rarr; reduces the spread of infection</li>\n</ul>\n<p><strong>Clinical Use:</strong></p>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509052ccf6fc8-ac46-4eee-9239-004ea9297e7e.png\">\n<p><strong>Pharmacokinetics:</strong></p>\n<ul>\n<li><strong>Prodrug</strong> (activated by hepatic esterases)</li>\n<li><strong>Oral bioavailability:</strong> ~80%</li>\n<li><strong>Distribution:</strong> Plasma, sinus, middle ear fluid</li>\n<li><strong>Half-life:</strong> 6-10 hours</li>\n<li><strong>Excretion:</strong> Renal (glomerular filtration + tubular secretion)</li>\n<li><strong>Drug interaction:</strong> Probenecid &darr; reduces renal clearance by ~50%</li>\n</ul>\n<p><strong>Adverse Effects:</strong></p>\n<ul>\n<li><strong>Common: </strong>Nausea, vomiting, Headache, fatigue, diarrhea (more common in prophylaxis)</li>\n<li><strong>Rare: </strong>Rash, <strong>Neuropsychiatric events</strong> (delirium, self-injury), especially in adolescents (notably in Japan)</li>\n<li><strong>Caution: Renal insufficiency:</strong> Dose adjustment required</li>\n</ul>\n<p><strong>Classification of Anti-Influenza Drugs</strong></p>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905a2cf2a6e-9d25-4a79-bce7-5ac8caadfe99.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Favipiravir(Option B)</strong>: Used for severe or refractory viral infections, <strong>not first-line</strong> for seasonal influenza.</p>\n<p><strong>Remdesivir(Option C)</strong>: Approved for <strong>COVID-19</strong>, <strong>not used for influenza</strong>.</p>", "options": ["Oseltamivir", "Fevipiravir", "Remdesivir", "All of the above"], "html_options": ["Oseltamivir", "Fevipiravir", "Remdesivir", "All of the above"], "corr_idx": 0}]}, {"moduleId": 1008555, "name": "Anti - Parasitic Drugs", "questions": [{"id": "1176773", "html_qtxt": "An international traveller is travelling to the Caribbean. Which of the following drugs is advisable for the prophylaxis of Malaria?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Current recommendations from the <strong>Centre for Disease Control and Prevention (CDC) </strong>include the use of <strong>chloroquine</strong> for chemoprophylaxis in the few areas infested by only chloroquine-sensitive malaria parasites (principally the <strong>Caribbean and Central America west of the Panama Canal)</strong></li>\n<li>When patients are counseled on the prevention of malaria, it is imperative to emphasize measures to <strong>prevent mosquito bites</strong> (e.g., using insect repellents, insecticides, and bed nets), because parasites are increasingly resistant to multiple drugs, and no chemoprophylactic regimen is fully protective.</li>\n</ul>\n<p><strong>Chemoprophylactic Drugs for Travelers</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509041b612ff7-2697-4230-8cc1-ac3761055def.png\">\n<ul>\n<li>Primaquine and Tafenoquine are <strong>not first-line</strong> for primary prevention unless specific risk (e.g., <em>P. vivax</em> exposure).</li>\n</ul>\n<p><strong>Note:</strong></p>\n<ul>\n<li><strong><6 weeks travel - Doxycycline</strong> can be given, but C/I in pregnant and child, where <strong>Proguanil</strong> can be used</li>\n<li><strong>>6 weeks travel - Mefloquine </strong>has <strong>Neuropsychiatric symptoms </strong>side effects; therefore contraindicated in critical workers like pilots. In that case, <strong>chloroquine</strong> can be used.</li>\n</ul>", "options": ["Chloroquine", "Primaquine", "Mefloquine", "HCQ"], "html_options": ["Chloroquine", "Primaquine", "Mefloquine", "HCQ"], "corr_idx": 0}, {"id": "1176785", "html_qtxt": "A 15-year-old boy diagnosed with Plasmodium vivax malaria was admitted for treatment. Due to the unavailability of other antimalarials, he was given IV chloroquine, which was infused rapidly. What is the likely adverse outcome?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Large intramuscular injections or rapid intravenous infusions of <strong>chloroquine</strong> hydrochloride can result in <strong>severe hypotension</strong> and <strong>cardiac arrest</strong>.</li>\n<li>Parenteral administration of chloroquine is best avoided, but if other drugs are not available for parenteral use, it should be infused slowly.</li>\n</ul>\n<p>Mechanism of <strong>Severe Hypotension</strong> due to <strong>Rapid IV Infusion of Chloroquine:</strong></p>\n<ul>\n<li><strong>Direct myocardial depression:</strong> Chloroquine in high concentrations depresses myocardial contractility, reducing cardiac output. It also inhibits Na<sup>+</sup> and K<sup>+</sup> ion channels, affecting cardiac conduction and contractility.</li>\n<li><strong>Vasodilation:</strong> Rapid infusion causes peripheral vasodilation, lowering systemic vascular resistance. This results in a sudden drop in blood pressure.</li>\n<li><strong>Negative chronotropic and dromotropic effects:</strong> Chloroquine reduces heart rate (bradycardia) and slows AV conduction, potentially leading to arrhythmias and reduced cardiac output.</li>\n<li><strong>QT prolongation and arrhythmias:</strong> High serum levels from rapid infusion prolong the QT interval, predisposing to torsades de pointes and sudden cardiovascular collapse.</li>\n</ul>\n<p><strong>General Tolerance of Chloroquine: </strong>Usually well tolerated, even with prolonged use.</p>\n<p><strong>Common Adverse Effects of Chloroquine:</strong></p>\n<ul>\n<li><strong>Pruritus (especially common in Africans)</strong></li>\n<li><strong>Gastrointestinal: </strong>Nausea, Vomiting, Abdominal pain, Anorexia</li>\n<li><strong>Neurological: </strong>Headache, Malaise, Blurring of vision</li>\n<li><strong>Dermatological: </strong>Urticaria</li>\n</ul>\n<p><strong>Rare but Serious Adverse Effects:</strong></p>\n<ul>\n<li><strong>Hematologic: </strong>Hemolysis in G6PD-deficient individuals, Agranulocytosis</li>\n<li><strong>Neuropsychiatric: </strong>Impaired hearing, Confusion, Psychosis, Seizures</li>\n<li><strong>Dermatological: </strong>Exfoliative dermatitis, Alopecia, Bleaching of hair</li>\n<li><strong>Cardiovascular: </strong>Hypotension, ECG changes</li>\n</ul>\n<p><strong>Long-Term High-Dose Toxicities (mainly in rheumatologic use):</strong></p>\n<ul>\n<li>Ototoxicity (hearing loss)</li>\n<li>Retinopathy (may be irreversible)</li>\n<li>Myopathy</li>\n<li>Peripheral neuropathy</li>\n</ul>\n<p><strong>Intramuscular or rapid intravenous chloroquine hydrochloride can cause:</strong></p>\n<ul>\n<li>Severe hypotension</li>\n<li>Respiratory arrest</li>\n<li>Cardiac arrest</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Severe hypertension(Option A): </strong>Chloroquine does <strong>not</strong> cause hypertension. It actually leads to <strong>vasodilation and hypotension</strong> when infused rapidly.</p>\n<p><strong>CNS depression(Option C): </strong>While CNS effects like confusion or seizures may occur <strong>with overdose</strong>, CNS depression is not the <strong>immediate</strong> effect of rapid IV administration.</p>", "options": ["Severe hypertension", "Severe hypotension", "CNS depression", "None of the above"], "html_options": ["Severe hypertension", "Severe hypotension", "CNS depression", "None of the above"], "corr_idx": 1}, {"id": "1176788", "html_qtxt": "A 19-year-old male patient is on treatment for psoriasis. He came to OPD with the complaints of malaise, easy fatiguability, and fever with chills. He was diagnosed with malaria fever upon laboratory investigation. Which of the following drugs is contraindicated?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Chloroquine</strong> is contraindicated in patients with <strong>psoriasis</strong> or porphyria, in whom it may precipitate <strong>acute attacks</strong> of these diseases.</li>\n<li>Possibly due to immune modulation and effects on epidermal proliferation.</li>\n<li>Safe in pregnancy and young children.</li>\n</ul>\n<p><strong>Contraindications of Chloroquine:</strong></p>\n<ul>\n<li><strong>Psoriasis: Chloroquine </strong>may worsen skin lesions.</li>\n<li><strong>Porphyria: </strong>It increases the risk of triggering acute attacks.</li>\n<li><strong>Retinal or visual field abnormalities: </strong>Increased risk of worsening vision damage<strong>.</strong></li>\n<li><strong>Myopathy: Chloroquine </strong>may aggravate muscle weakness<strong>.</strong></li>\n</ul>\n<p>Use with caution in patients with<strong> Liver disease</strong>, <strong>Neurologic disorders,</strong> and <strong>Hematologic disorders</strong></p>\n<p>Avoid coadministration with<strong> Kaolin (antidiarrheal) </strong>and<strong> Calcium- and magnesium-containing antacids, </strong>as they may interfere with chloroquine absorption.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Primaquine(Option A): </strong>Not specifically contraindicated in psoriasis. However, caution is required in <strong>G6PD deficiency</strong> due to the risk of hemolysis, not psoriasis.<em><br /> </em></p>\n<p><strong>Malarone(Option C): Atovaquone + Proguanil, </strong>Not contraindicated in psoriasis. Generally well tolerated and safe for most patients, including those with skin conditions.</p>", "options": ["Primaquine", "Chloroquine", "Melarone", "All of the above"], "html_options": ["Primaquine", "Chloroquine", "Melarone", "All of the above"], "corr_idx": 1}, {"id": "1176790", "html_qtxt": "A 22-year-old male presents to the clinic with complaints of fever, chills, and headache for 3 days. A peripheral blood smear confirms Plasmodium vivax infection. He has no comorbidities and is not on any medications. The physician initiates treatment with chloroquine. Which of the following best explains chloroquine's primary mechanism of action in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>When not limited by resistance, <strong>chloroquine</strong> is a highly effective <strong>blood schizonticide</strong>.</li>\n<li>It is also moderately effective against gametocytes of <em>P vivax, P ovale, </em>and <em>P malariae </em>but not against those of <em>P falciparum.</em></li>\n</ul>\n<p><strong>Chloroquine: </strong></p>\n<p>Chloroquine has been a mainstay in the <strong>treatment and prophylaxis of malaria</strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<ul>\n<li>Acts as a <strong>blood schizonticide</strong>.</li>\n<li>Concentrates in the <strong>parasite's food vacuole</strong> and inhibits <strong>biocrystallization</strong> of heme into <strong>hemozoin,</strong> which leads to <strong>toxic buildup of free heme</strong>, killing the parasite.</li>\n</ul>\n<p><strong>Pharmacokinetics:</strong></p>\n<ul>\n<li><strong>Type</strong>: Synthetic 4-aminoquinoline.</li>\n<li><strong>Formulation</strong>: Administered as the phosphate salt for <strong>oral use</strong>.</li>\n<li><strong>Absorption</strong>: Rapid and almost complete from the GI tract.</li>\n<li><strong>Time to Peak</strong>: Maximum plasma concentration reached in ~3 hours.</li>\n<li><strong>Distribution</strong>:\n<ul>\n<li>Very large <strong>volume of distribution</strong>: 100-1000 L/kg.</li>\n<li>Rapidly distributed to tissues.</li>\n</ul>\n</li>\n<li><strong>Metabolism & Excretion</strong>:\n<ul>\n<li>Slowly released from tissues and metabolized.</li>\n<li>Primarily excreted in <strong>urine</strong>.</li>\n</ul>\n</li>\n<li><strong>Half-life</strong>:\n<ul>\n<li>Initial: 3-5 days.</li>\n<li>Terminal: 1-2 months (due to tissue binding).</li>\n</ul>\n</li>\n</ul>\n<p><strong>Resistance:</strong></p>\n<ul>\n<li>Common in <em>P. falciparum</em>, emerging in <em>P. vivax</em>.</li>\n<li>Caused by mutations in <strong>PfCRT (Plasmodium falciparum Chloroquine Resistance Transporter)</strong>.</li>\n<li>Resistance can be <strong>partially reversed</strong> by:\n<ul>\n<li>Verapamil</li>\n<li>Desipramine</li>\n<li>Chlorpheniramine</li>\n</ul>\n</li>\n</ul>\n<p><strong>Clinical Uses</strong></p>\n<p><strong>1. Treatment:</strong></p>\n<ul>\n<li>Drug of choice for <strong>Uncomplicated non-falciparum malaria</strong> and <strong>Sensitive P. falciparum infections</strong>.</li>\n<li>Reduces fever in <strong>24-48 hours</strong> and clears parasitemia in <strong>48-72 hours</strong>.</li>\n<li>Not active against the <strong>Liver stages</strong> of <em> vivax</em> or <em>P. ovale</em> and <strong>Gametocytes</strong>.</li>\n<li>Must be combined with <strong>primaquine or tafenoquine</strong> for radical cure of <em> vivax</em> and <em>P. ovale</em>.</li>\n</ul>\n<p><strong>2. Chemoprophylaxis: Preferred agent</strong> in regions <strong>without chloroquine resistance</strong>. For full eradication of liver stages (<em>P. vivax</em>, <em>P. ovale</em>), <strong>add primaquine</strong> after chloroquine.</p>\n<p><strong>3. Amebic Liver Abscess</strong></p>\n<ul>\n<li>Achieves <strong>high liver concentrations</strong>.</li>\n<li>Useful as an <strong>alternative agent</strong> in patients not responding to <strong>metronidazole</strong>.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Tissue Schizonticides(Option A): Agents </strong>acting on liver-stage (exoerythrocytic) parasites. Example: Primaquine. Chloroquine does not eliminate hepatic forms.</p>\n<p><strong>Gametocides(Option C): Agents </strong>targeting the sexual forms (gametocytes) in the blood to prevent transmission. Chloroquine is only partially effective here, mainly in <em>P. vivax</em>, not <em>P. falciparum</em>.</p>\n<p><strong>Sporonticide(Option D):</strong> Sporonticides are antimalarial agents that act on the sexual forms of the malaria parasite within the mosquito (not the human host). Examples: Primaquine, Tafenoquine. Chloroquine does <strong>not prevent transmission</strong> via mosquitoes and has <strong>no significant activity</strong> against gametocytes or sporogonic stages.</p>", "options": ["Tissue Schizonticides", "Blood Schizonticides", "Gametocides", "Sporonticide"], "html_options": ["Tissue Schizonticides", "Blood Schizonticides", "Gametocides", "Sporonticide"], "corr_idx": 1}, {"id": "1176791", "html_qtxt": "Which of the following sentences is false for Artemisinin?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Artemisinin & Its Derivatives:</strong></p>\n<ul>\n<li><strong>Artemisinin (qinghaosu): </strong>A <strong>sesquiterpene lactone endoperoxide</strong> derived from <em>Artemisia annua</em>, used in Chinese medicine for over 2000 years.</li>\n<li><strong>Parent compound:</strong> Insoluble, used only orally.</li>\n<li><strong>Derivatives (Improved solubility & efficacy):</strong>\n<ul>\n<li><strong>Artesunate</strong>: Water-soluble; IV, IM, oral, rectal</li>\n<li><strong>Artemether</strong>: Lipid-soluble; IM, oral, rectal</li>\n<li><strong>Dihydroartemisinin</strong>: Water-soluble; oral only</li>\n</ul>\n</li>\n</ul>\n<p><strong>Pharmacokinetics: </strong></p>\n<ul>\n<li>Rapid absorption</li>\n<li><strong>Metabolism:</strong> All convert to <strong>dihydroartemisinin</strong> (active form)</li>\n<li><strong>Half-life:</strong>\n<ul>\n<li><strong>Artesunate/DHA</strong>: 30-60 mins</li>\n<li><strong>Artemether</strong>: 2-3 hours</li>\n</ul>\n</li>\n<li>Drug levels fall with continued therapy due to enzyme induction.</li>\n</ul>\n<p><strong>Mechanism of Action: </strong></p>\n<ul>\n<li><strong>Rapidly acting blood schizonticides</strong> (active against all human malaria species)<strong>(Option B ruled out)</strong></li>\n<li>Generates <strong>free radicals</strong> via iron-catalyzed cleavage of the endoperoxide bridge &rarr; damages parasite proteins.</li>\n<li><strong>No effect on hepatic stages(Option C ruled out)</strong></li>\n<li>Active against <strong>young gametocytes</strong>, not mature ones.</li>\n</ul>\n<p><strong>Clinical Uses: </strong></p>\n<h4><strong>Uncomplicated Falciparum Malaria</strong></h4>\n<ul>\n<li>Always used as <strong>Artemisinin-Based Combination Therapy (ACT)</strong> to improve efficacy and prevent resistance</li>\n<li><strong>Common ACTs:</strong>\n<ul>\n<li>Artemether + Lumefantrine (Coartem)</li>\n<li>Artesunate + Amodiaquine</li>\n<li>Artesunate + Mefloquine</li>\n<li>Dihydroartemisinin + Piperaquine</li>\n<li>Artesunate + Pyronaridine</li>\n</ul>\n</li>\n</ul>\n<h4><strong>Severe Malaria</strong></h4>\n<ul>\n<li><strong>First-line: IV Artesunate(Option A ruled out)</strong>\n<ul>\n<li>Superior to quinine in terms of survival and side-effect profile</li>\n<li>IM Artemether or rectal formulations are alternatives if IV is not available</li>\n</ul>\n</li>\n</ul>\n<p><strong>Adverse Effects: </strong></p>\n<ul>\n<li><strong>Commonly</strong> Nausea, vomiting, dizziness (may overlap with malaria symptoms)</li>\n<li><strong>Serious (rare):</strong>\n<ul>\n<li>Neutropenia, anemia, hemolysis (delayed hemolysis in ~13% cases post-severe malaria treatment)</li>\n<li>Elevated liver enzymes</li>\n<li>Allergic reactions</li>\n</ul>\n</li>\n<li><strong>Neurotoxicity</strong>: Seen in animals at high doses only</li>\n<li><strong>Embryotoxicity in animals</strong>, but <strong>safe in pregnancy</strong> (2nd & 3rd trimesters)</li>\n</ul>", "options": ["Artemisinin is available for intravenous use", "They are very rapidly acting blood schizonticides", "They do not affect the hepatic stage", "None of the above"], "html_options": ["Artemisinin is available for intravenous use", "They are very rapidly acting blood schizonticides", "They do not affect the hepatic stage", "None of the above"], "corr_idx": 3}, {"id": "1176793", "html_qtxt": "Which of the following sentences are TRUE for the use of artemisinin-based combination therapy in pregnancy?<br>1. Recommended for uncomplicated falciparum malaria in the 2nd & 3rd trimesters<br>2. Not recommended for uncomplicated falciparum malaria in the 2nd & 3rd trimesters<br>3. Intravenous artesunate can be used for severe malaria in 1st trimester<br>4. Intravenous artesunate cannot be used for severe malaria in 1st trimester", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>WHO recommends for use of artemisinin-based combination therapy in Pregnancy:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509041a7bcf5d-3150-42a8-9b56-b7232f933343.png\">\n<p><strong>Artemisinin is <em>relatively contraindicated</em> in the first trimester of pregnancy due to the following reasons:</strong></p>\n<p><strong>1. Animal Studies Showed Embryotoxicity:</strong></p>\n<ul>\n<li>In animal models (especially rodents), artemisinin and its derivatives have shown:\n<ul>\n<li>Embryotoxicity (damage to the embryo)</li>\n<li>Increased fetal resorption</li>\n<li>Developmental abnormalities</li>\n</ul>\n</li>\n<li>The critical window was during the early organogenesis period, the first trimester equivalent in humans.</li>\n</ul>\n<p><strong>2. Limited High-Quality Human Data:</strong></p>\n<ul>\n<li>Although human observational studies (especially from endemic areas) have not consistently shown increased risk of:\n<ul>\n<li>Congenital malformations</li>\n<li>Stillbirth</li>\n<li>Spontaneous abortions</li>\n</ul>\n</li>\n<li>The data is still limited, and due to ethical constraints, no large randomized trials have confirmed safety in 1st trimester.</li>\n</ul>", "options": ["1,3", "2,4", "2,3", "1,4"], "html_options": ["1,3", "2,4", "2,3", "1,4"], "corr_idx": 0}, {"id": "1176795", "html_qtxt": "Which of the following is not an adverse effect of mefloquine?<br>1. Nausea and vomiting<br>2. Constipation<br>3. Diarrhoea<br>4. Sleep and behavioural disturbances<br>5. Headache<br>6. Abdominal pain<br>7.Peripheral neuropathy", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Mefloquine Adverse Effects:</strong></p>\n<ul>\n<li><strong>Common (GI & Neuro): Nausea, vomiting</strong>, Epigastric pain, <strong>abdominal pain</strong>, <strong>diarrhea</strong>, <strong>Headache,</strong> dizziness, <strong>Sleep disturbances</strong>,<strong> behavioral disturbances,</strong> and Rash</li>\n<li><strong>Neuropsychiatric Toxicities:</strong>\n<ul>\n<li>Reported cases: <strong>seizures, psychosis, depression</strong></li>\n<li>2013 FDA: <strong>Black box warning</strong> for <strong>neurologic and psychiatric toxicity</strong></li>\n<li>Controlled studies: Serious AEs are <strong>rare but possible</strong></li>\n<li><strong>Long-term effects</strong> after short-term use are reported anecdotally</li>\n</ul>\n</li>\n<li><strong>Others: </strong>Leukocytosis, Thrombocytopenia, and Elevated liver enzymes (aminotransferases)</li>\n</ul>\n<h4><strong>Treatment Dosage (Higher Dose):</strong></h4>\n<ul>\n<li><strong>Increased adverse effects</strong>\n<ul>\n<li>10x higher rate of neuropsychiatric symptoms than the prophylactic dose</li>\n<li>Symptoms: <strong>depression, confusion, psychosis, seizures</strong></li>\n<li>Serious neuropsychiatric AEs: ~<strong><1 in 1000</strong>, though possibly underreported</li>\n</ul>\n</li>\n<li><strong>Cardiac Effects: Altered cardiac conduction</strong>, arrhythmias, bradycardia</li>\n</ul>\n<p><strong>Contraindications:</strong></p>\n<ul>\n<li>Epilepsy or seizure disorder</li>\n<li>Current or past psychiatric disorders</li>\n<li>Cardiac conduction abnormalities or arrhythmias</li>\n<li>Known hypersensitivity to mefloquine or related compounds</li>\n<li>Avoid combination with<strong> Quinine, Quinidine,</strong> and<strong> Halofantrine</strong></li>\n<li><strong>If quinine is needed after mefloquine prophylaxis</strong>, monitor closely (risk of QT prolongation)</li>\n<li><strong>Discontinue mefloquine</strong> if any <strong>neuropsychiatric symptoms</strong> develop during prophylaxis</li>\n</ul>", "options": ["1,7", "2,7", "3,7", "2,3"], "html_options": ["1,7", "2,7", "3,7", "2,3"], "corr_idx": 1}, {"id": "1176796", "html_qtxt": "Which is the only drug available acting against dormant hypnozoite stages of P vivax and P ovale", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Primaquine i</strong>s the drug of choice for the eradication of<strong> dormant liver forms of P vivax </strong>and<strong> P ovale </strong>and can also be used for<strong> chemoprophylaxis </strong>against <strong>all malarial species.</strong></p>\n<p><strong>Primaquine: </strong></p>\n<p><strong>Primaquine </strong>belongs to<strong> the 8-aminoquinolines</strong></p>\n<p><strong>Mechanism of Action: </strong></p>\n<ul>\n<li>Active against <strong>hepatic stages</strong> (including dormant hypnozoites) of <strong> vivax and P. ovale.</strong></li>\n<li>Also effective against <strong>gametocytes</strong> and has modest activity on <strong>asexual </strong>blood stages.</li>\n<li>The precise mechanism remains unknown<strong>.</strong></li>\n</ul>\n<p><strong>Adverse Effects: </strong></p>\n<p><strong>Commonly </strong>nausea, epigastric pain, cramps, headache (especially on an empty stomach), Dizziness, rash, diarrhea (more with tafenoquine)</p>\n<p><strong>Serious but rare:</strong></p>\n<ul>\n<li>Hemolysis (especially in G6PD deficiency)</li>\n<li>Methemoglobinemia (cyanosis)</li>\n<li>Leukopenia, agranulocytosis, arrhythmias</li>\n</ul>\n<p><strong>Clinical use: </strong></p>\n<ul>\n<li><strong>Radical cure </strong>of P. vivax and P. ovale malaria<strong> (</strong>eradicate hypnozoites in the liver)<strong>.</strong></li>\n<li>Terminal prophylaxis after travel to endemic areas<strong> (prevents relapse).</strong></li>\n<li><strong>Chemoprophylaxis </strong>against all malaria species (alternative regimens).</li>\n<li><strong>Gametocidal </strong>action against falciparum (reduces transmission).</li>\n<li>Treatment of <strong>Pneumocystis jirovecii </strong>(in combination with clindamycin, for mild-moderate disease).</li>\n</ul>\n<p><strong>Contraindications & Cautions: </strong></p>\n<ul>\n<li><strong>G6PD deficiency: </strong>mandatory testing before use.\n<ul>\n<li>Tafenoquine is especially contraindicated due to its long half-life.</li>\n<li>In G6PD-deficient patients:\n<ul>\n<li>Consider weekly primaquine (45 mg) x 8 weeks with close monitoring</li>\n<li>Or postpone liver-stage therapy until relapse occurs.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><strong>Pregnancy:</strong> The Fetus is relatively G6PD-deficient and at risk of hemolysis.</li>\n<li><strong>Hematologic risk - Avoid in:</strong>\n<ul>\n<li>Myelosuppressed patients</li>\n<li>History of granulocytopenia or methemoglobinemia</li>\n<li>Concurrent use of myelosuppressive drugs</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Mefloquine(Option A): </strong>It is a <strong>Blood schizonticide</strong> which acts only on asexual blood stages of Plasmodium species. It has <strong>no action on liver stages</strong>, including hypnozoites of P. vivax/P. Ovale. Mainly used in prophylaxis and treatment of falciparum and vivax malaria (with additional drugs for relapse prevention).</p>\n<p><strong>Artesunate(Option C): </strong>It is an <strong>Artemisinin derivative</strong> and a rapidly acting <strong>blood schizonticide</strong>, has no hepatic stage activity (does not eradicate hypnozoites). Used treatment of severe malaria, especially P. falciparum.</p>", "options": ["Mefloquine", "Primaquine", "Artesunate", "None of the above"], "html_options": ["Mefloquine", "Primaquine", "Artesunate", "None of the above"], "corr_idx": 1}, {"id": "1176802", "html_qtxt": "A 25-year-old male patient came to the OPD with complaints of high-grade fever, coughing, blood in sputum, and dyspnoea. His pulse rate is 120/min, BP is 110/76 mm Hg, SpO2 in room air is 98%. He has been on ART for 3 years and AKT for 2 months. Blood culture and BAL were sent to rule out secondary bacterial infection. The BAL report came positive for Pneumocystis jiroveci. Which regimen offers more tolerance in this patient in comparison to the commonly used trimethoprim-sulfamethoxazole regimen?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The combination of <strong>clindamycin and primaquine</strong> is an alternative regimen in the treatment of <strong>pneumocystis</strong>, particularly <strong>mild to moderate disease.</strong></li>\n<li>This regimen offers improved tolerance compared with high-dose trimethoprim-sulfamethoxazole or pentamidine, although its efficacy against severe pneumocystis pneumonia is not well studied.</li>\n<li><strong>Clindamycin</strong>: anti-protozoal and antibacterial activity.</li>\n<li><strong>Primaquine</strong>: active against the trophic forms of P. jirovecii.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Primaquine with pentamidine(Option A): Both can cause severe hematologic and renal toxicity. Pentamidine (IV) is used as an alternative in severe PCP</strong>, but is <strong>less well tolerated</strong>, with risks of <strong>hypoglycemia, nephrotoxicity, hypotension, and pancreatitis</strong>. Not the best in terms of <strong>tolerability</strong>.</p>\n<p><strong>Primaquine with doxycycline (Option B): </strong>This combination is <strong>not standard or recommended</strong> for PCP. Doxycycline has <strong>no role</strong> in treating Pneumocystis jirovecii.</p>\n<p><strong>Primaquine with azithromycin(Option D): Not a standard regimen</strong> for PCP. Azithromycin is used for <strong>toxoplasmosis prophylaxis</strong> and <strong>MAC infections</strong>, not PCP.</p>", "options": ["Primaquine with pentamidine", "Primaquine with doxycycline", "Primaquine with clindamycin", "Primaquine with azithromycin"], "html_options": ["Primaquine with pentamidine", "Primaquine with doxycycline", "Primaquine with clindamycin", "Primaquine with azithromycin"], "corr_idx": 2}, {"id": "1176803", "html_qtxt": "A 35-year-old male patient came to the OPD with complaints of diarrhoea, mild fever, and weakness. His pulse rate is 100/min and BP is 100/70 mm Hg. He has already been treated with antibacterial drugs, which did not work. The physician is suspecting amebiasis. Which is the drug of choice for the treatment of extraluminal amebiasis?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Metronidazole, a nitroimidazole, is the drug of choice in the treatment of extraluminal amebiasis.</li>\n<li><strong>Extraluminal amebiasis</strong> refers to invasive forms of infection caused by <em>Entamoeba histolytica</em>, such as <strong>Amebic liver abscess, </strong>Amebic peritonitis, Pulmonary, cerebral, or other systemic involvement</li>\n<li>It is usually <strong>followed by</strong> a <strong>luminal amebicide</strong> like <strong>paromomycin</strong> or <strong>diloxanide furoate</strong> to clear any intraluminal cysts/trophozoites and prevent relapse. <strong>(Option D ruled out)</strong></li>\n</ul>\n<p><strong>Metronidazole:</strong></p>\n<p>Nitroimidazole <strong>antiprotozoal</strong> and <strong>antibacterial</strong> agent.</p>\n<p><strong>Mechanism of Action:</strong></p>\n<ul>\n<li><strong>Selective uptake</strong> by <strong>anaerobic bacteria</strong> and certain protozoa.</li>\n<li>Inside anaerobes, <strong>non-enzymatic reduction</strong> occurs via <strong>reduced ferredoxin</strong>.</li>\n<li>Form <strong>toxic free radical metabolites</strong> that <strong>disrupt bacterial DNA</strong> &rarr; Unstable molecules &rarr; Cell death.</li>\n<li>This process occurs <strong>only in anaerobes</strong>, making the drug <strong>safe for human cells and aerobic bacteria</strong>.</li>\n</ul>\n<p><strong>Clinical Indications:</strong></p>\n<ul>\n<li>Anaerobic & mixed intra-abdominal infections</li>\n<li><strong>Pelvic inflammatory disease</strong> (PID) with agents covering aerobes</li>\n<li><strong>Vaginitis:</strong>\n<ul>\n<li><em>Trichomonas vaginalis</em></li>\n<li><em>Bacterial vaginosis</em></li>\n</ul>\n</li>\n<li><strong>Amebiasis, giardiasis</strong></li>\n<li><strong>Brain abscess</strong></li>\n<li><strong>Clostridioides difficile i</strong>nfection (no longer first-line alone). Used IV with oral vancomycin in fulminant cases</li>\n</ul>\n<p><strong>Adverse Effects:</strong></p>\n<ul>\n<li>Common side effects are <strong>Nausea</strong>, <strong>diarrhea, </strong>and<strong> Stomatitis</strong></li>\n<li><strong>Peripheral neuropathy</strong> (especially with prolonged use)</li>\n<li><strong>Disulfiram-like reaction with alcohol</strong>: Traditionally believed, but recent evidence suggests this may not be significant.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Ofloxacin(Option A): </strong>It is a fluoroquinolone antibacterial, not effective against Entamoeba</p>\n<p><strong>Meropenem(Option C):</strong> Broad-spectrum antibacterial, not active against protozoa</p>", "options": ["Ofloxacin", "Metronidazole", "Meropenem", "Paromomycin"], "html_options": ["Ofloxacin", "Metronidazole", "Meropenem", "Paromomycin"], "corr_idx": 1}, {"id": "1176808", "html_qtxt": "A 54-year-old male alcoholic patient is brought to the emergency department with the complaints of severe pain in the right hypochondriac region, Vomiting, high-grade fever, weakness, and difficulty in breathing. His laboratory investigation and USG were performed. USG was suggestive of multiple liver abscesses. The physician wants to start intravenous metronidazole therapy. What should be the dose of IV Metronidazole in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322010c6283-b3c5-4cbd-b63e-a8dabafb173a.jpg\">", "options": ["500 mg OD", "500 mg BD", "500 mg TDS", "500 mg QDS"], "html_options": ["500 mg OD", "500 mg BD", "500 mg TDS", "500 mg QDS"], "corr_idx": 3}, {"id": "1176811", "html_qtxt": "Which of the following is the adverse effect of metronidazole?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Nausea, <strong>headache</strong>, <strong>dry mouth</strong>, or a <strong>metallic taste</strong> in the mouth occur commonly. Infrequent adverse effects include vomiting, diarrhoea, insomnia, weakness, dizziness, thrush, rash, dysuria, dark urine, vertigo, paraesthesia, and neutropenia.</li>\n<li>Taking the drug with meals lessens gastrointestinal irritation.</li>\n<li>Pancreatitis and severe central nervous system toxicity (ataxia, encephalopathy, seizures) are rare.</li>\n<li>Metronidazole has a disulfiram-like effect, so that nausea and vomiting can occur if alcohol is ingested during therapy.</li>\n<li>The drug should be used with caution in patients with central nervous system disease.</li>\n<li>Intravenous infusions have rarely caused seizures or peripheral neuropathy.</li>\n<li>The dosage should be adjusted for patients with severe liver or renal disease.</li>\n<li>Tinidazole has a similar adverse-effect profile, although it appears to be somewhat better tolerated than metronidazole.</li>\n</ul>", "options": ["Dry mouth", "Headache", "Metallic taste in the mouth", "All of the above"], "html_options": ["Dry mouth", "Headache", "Metallic taste in the mouth", "All of the above"], "corr_idx": 3}, {"id": "1176813", "html_qtxt": "Albendazole is the drug of choice for__________.", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>Albendazole, a broad-spectrum oral antihelminthic, is the drug of choice and is approved in the USA for the treatment of <strong>hydatid disease and cysticercosis.</strong></p>\n<p><strong>Albendazole:</strong></p>\n<ul>\n<li><strong>Albendazole</strong> is a broad-spectrum antihelminthic agent from the benzimidazole class. It works by inhibiting microtubule polymerization and glucose uptake in parasites, leading to energy depletion and death of the helminth.</li>\n<li>Albendazole is best taken <strong>with a fatty meal</strong> to enhance systemic absorption, especially when treating <strong>tissue parasites</strong> like hydatid cysts and cysticercosis.</li>\n</ul>\n<p><strong>Clinical Uses</strong></p>\n<h4><strong>1. Intestinal Helminth Infections</strong></h4>\n<ul>\n<li><strong>Ascariasis, pinworm</strong>: 400 mg single dose orally<em>. </em>Repeat after 2-3 days (for heavy infections) or after 2 weeks (for pinworm).</li>\n<li><strong>Hookworm, trichuriasis</strong>: <em>400 mg daily &times; 3 days. </em>Combination with ivermectin or oxantel pamoate improves efficacy.</li>\n</ul>\n<h4><strong>2. Hydatid Disease (Echinococcus granulosus)</strong></h4>\n<ul>\n<li><strong>Drug of choice</strong></li>\n<li>400 mg twice daily with meals &times; 1 month or more (up to 6 months)</li>\n<li>Combined with <strong>praziquantel or surgery</strong> as needed.</li>\n</ul>\n<h4><strong>3. Neurocysticercosis</strong></h4>\n<ul>\n<li>Most effective for <strong>parenchymal or intraventricular cysts</strong>.</li>\n<li>400 mg twice daily &times; up to 21 days</li>\n<li><strong>Given corticosteroids</strong> to prevent an inflammatory response.</li>\n<li>Superior to praziquantel in:<br />\n<ul>\n<li>Subarachnoid penetration</li>\n<li>Cost-effectiveness</li>\n<li>Drug levels when co-administered with steroids.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Roundworms (Nematodes)</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904389f9600-f852-41a7-8db7-4cfca5673c9e.png\">\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904b588d3ff-9812-4ff7-b985-29e57b5d5eea.png\">\n<p><strong>Flukes (Trematodes)</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509042112cefd-f22c-460d-be4f-071222d06885.png\">\n<p><strong>Tapeworms (Cestodes)</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509047e18fbb9-79ac-4a50-99c5-fc13f6889f60.png\">", "options": ["Hydatid diseases", "Cysticercosis", "A&B both", "Pinworm infestation"], "html_options": ["Hydatid diseases", "Cysticercosis", "A&B both", "Pinworm infestation"], "corr_idx": 2}, {"id": "1176818", "html_qtxt": "Which of the following is the adverse effect of long-term use of albendazole?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>When used for 1-3 days, albendazole is nearly free of significant adverse effects.</li>\n<li><strong>Mild and transient</strong> epigastric distress, diarrhoea, headache, nausea, dizziness, lassitude, and insomnia can occur.<strong>(Option A and B ruled out)</strong></li>\n<li>In <strong>long-term use</strong> for hydatid disease, albendazole is well tolerated, but it can cause abdominal distress, headaches, fever, fatigue, alopecia, increases in liver enzymes, and pancytopenia.</li>\n<li>Blood counts and liver function studies should be monitored during <strong>long-term therapy</strong>.</li>\n<li>The drug should not be given to patients with known hypersensitivity to other benzimidazole drugs or to those with cirrhosis.</li>\n<li>The safety of albendazole in pregnancy and in children younger than 2 years of age has not been established.</li>\n</ul>", "options": ["Insomnia", "Nausea", "Pancytopenia", "All of the above"], "html_options": ["Insomnia", "Nausea", "Pancytopenia", "All of the above"], "corr_idx": 2}, {"id": "1176826", "html_qtxt": "Ivermectin is widely used as an antiparasitic agent and serves as an alternative in various helminthic infections. For which of the following conditions is Ivermectin considered the drug of choice?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Ivermectin</strong> is the drug of choice in <strong>strongyloidiasis</strong> and <strong>onchocerciasis</strong>.</li>\n<li>It is also an alternative drug for a number of other helminthic infections.</li>\n</ul>\n<p><strong>Ivermectin:</strong> </p>\n<p>Ivermectin is a <strong>Semisynthetic macrocyclic lactone </strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<ul>\n<li>Binds to <strong>glutamate-gated chloride channels</strong> in nerve and muscle cells of parasites &rarr; <strong>paralysis and death</strong></li>\n<li>Also enhances <strong>GABA-mediated neurotransmission</strong> in the peripheral nerves of parasites</li>\n<li><strong>Does not cross the human blood-brain barrier significantly</strong> (hence relatively safe in humans)</li>\n</ul>\n<p><strong>Clinical Uses:</strong></p>\n<h4><strong>1. Onchocerciasis (River Blindness)</strong></h4>\n<ul>\n<li><strong>Drug of choice</strong></li>\n<li>Dose: <strong>150 mcg/kg single oral dose</strong>, repeated every 12 months</li>\n<li><strong>Microfilaricidal</strong>: Reduces skin microfilariae within 2-3 days</li>\n<li><strong>Does not kill adult worms</strong>, but reduces microfilarial release</li>\n<li><strong>Adjuvant corticosteroids</strong> are used in patients with ocular involvement to reduce inflammation</li>\n<li><strong>Long-term treatment</strong> (up to 10 years) is needed to wait out the adult worm's lifespan</li>\n<li><strong>Mass drug administration programs</strong> use ivermectin for transmission control</li>\n<li><strong>Resistance concerns</strong>: Decreased response seen in high-transmission areas</li>\n</ul>\n<h4><strong>2. Strongyloidiasis</strong></h4>\n<ul>\n<li><strong>Drug of choice</strong></li>\n<li>Dose: <strong>200 mcg/kg once daily for 2 days</strong></li>\n<li>In <strong>immunosuppressed or disseminated cases</strong>, prolonged or monthly suppressive therapy may be needed</li>\n<li>More effective than albendazole in severe cases</li>\n</ul>\n<h4><strong>3. Other Uses</strong></h4>\n<ul>\n<li><strong>Bancroftian Filariasis (W. bancrofti):</strong> Used with albendazole + DEC in MDA programs; <strong>not adulticidal</strong></li>\n<li><strong>Brugia malayi, Mansonella ozzardi:</strong> &darr; microfilariae</li>\n<li><strong>Loa loa (Loiasis):</strong> Reduces microfilariae, but may cause severe adverse reactions; <strong>DEC preferred</strong></li>\n<li><strong>Scabies and Lice:</strong> Topical and oral ivermectin used effectively</li>\n<li><strong>Cutaneous larva migrans</strong> and <strong>Ascaris</strong>: Effective against larvae and adult worms</li>\n<li><strong>Malaria vector control (experimental):</strong> Reduces the mosquito lifespan when they feed on treated individuals</li>\n</ul>\n<p><strong>Adverse Effects:</strong></p>\n<p><strong>General (in Strongyloidiasis): </strong>Fatigue, dizziness, nausea, vomiting, Abdominal pain, rash</p>\n<h4><strong>In Onchocerciasis (due to microfilarial death):</strong></h4>\n<ul>\n<li><strong>Mild (5-30%):</strong> Fever, headache, dizziness, weakness, rash, pruritus, diarrhea, joint/muscle pain, hypotension, tachycardia, lymphadenitis, edema</li>\n<li><strong>Moderate to severe (1-3%):</strong> High fever, bronchospasm, hypotension</li>\n<li><strong>Rare (0.1%):</strong> Intense inflammatory reactions</li>\n<li><strong>Management:</strong> Corticosteroids for severe systemic or ocular reactions</li>\n<li><strong>Eye lesions:</strong> Corneal opacities, usually self-resolving</li>\n</ul>\n<p><strong>Contraindications & Cautions:</strong></p>\n<ul>\n<li>Avoid <strong>co-administration with GABAergic drugs</strong> (e.g., barbiturates, benzodiazepines, valproic acid)</li>\n<li><strong>Pregnancy:</strong> Contraindicated (Category C)</li>\n<li><strong>Children <5 years:</strong> Safety not established</li>\n</ul>", "options": ["Strongyloidiasis", "Onchocerciasis", "A&B both", "Pneumocystis pneumonia"], "html_options": ["Strongyloidiasis", "Onchocerciasis", "A&B both", "Pneumocystis pneumonia"], "corr_idx": 2}, {"id": "1176829", "html_qtxt": "A 35-year-old man with nocturnal fever and leg swelling is diagnosed with Wuchereria bancrofti. Which is the first-line drug for treatment and also useful for mass prophylaxis?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Diethylcarbamazine</strong> is a drug of choice in the treatment of <strong>filariasis, loiasis, and tropical eosinophilia.</strong></li>\n<li>It has been replaced by ivermectin for the treatment of onchocerciasis.</li>\n</ul>\n<p><strong>Diethylcarbamazine:</strong></p>\n<p>Antifilarial drug, which is a <strong>Synthetic piperazine derivative</strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<ul>\n<li>Immobilizes <strong>microfilariae</strong></li>\n<li>Alters <strong>surface structure</strong> and facilitates immune-mediated destruction</li>\n<li>The adulticidal mechanism is <strong>unknown<br /> </strong></li>\n</ul>\n<h4><strong>Drug of Choice For:</strong></h4>\n<ul>\n<li>Lymphatic Filariasis (<em>Wuchereria bancrofti, Brugia malayi, B. timori</em>)</li>\n<li>Loiasis (<em>Loa loa</em>)</li>\n<li>Tropical Pulmonary Eosinophilia</li>\n<li>Mansonella streptocerca infections (kills adults & microfilariae)<br /> <strong>Note: Not effective against Onchocerciasis, where ivermectin is preferred.</strong></li>\n</ul>\n<p><strong>Adverse Effects & Precautions:</strong></p>\n<ul>\n<li><strong>Allergic reactions (due to rapid killing of microfilariae)<br /> </strong>Can be managed with:<br />\n<ul>\n<li>Antihistamines</li>\n<li>Corticosteroids</li>\n</ul>\n</li>\n<li>In high <em>Loa loa</em> burden (>2500/mL), there is an increased risk of <strong>encephalopathy<br /> </strong>Use pre-treatment strategies:\n<ul>\n<li><strong>Apheresis (removal of microfilariae)</strong></li>\n<li><strong>Albendazole first (slow-acting, safer), then DEC/ivermectin</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Albendazole(Option A): </strong>Broad-spectrum anthelmintic used against <strong>Soil-transmitted helminths</strong>, <strong>neurocysticercosis</strong>, and <strong>hydatid disease. Used in filariasis</strong> <strong>only as a combination partner</strong> in MDA programs. <strong>Monotherapy with albendazole is not effective</strong> against microfilariae or adult filarial worms in <em>W. bancrofti</em>.</p>\n<p><strong>Ivermectin(Option B): </strong>DOC for <strong>Onchocerciasis </strong>and <strong>Strongyloidiasis. </strong>In <strong>W. bancrofti</strong>, it is <strong>Microfilaricidal </strong>only, does not kill adult worms</p>\n<p><strong>Mebendazole(Option D): </strong>Mainly used in Intestinal helminths like <strong>Ascariasis</strong>, <strong>Enterobiasis</strong>, <strong>Trichuriasis</strong>, and <strong>Hookworm</strong>. Not used in <strong>filarial infections</strong></p>", "options": ["Albendazole", "Ivermectin", "Diethylcarbamazine", "Mebendazole"], "html_options": ["Albendazole", "Ivermectin", "Diethylcarbamazine", "Mebendazole"], "corr_idx": 2}, {"id": "1176830", "html_qtxt": "Henderson - Hasselbach trapping effect is seen in__________.", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Diethylcarbamazine, a synthetic piperazine derivative, is marketed as a citrate salt.</li>\n<li>It is rapidly absorbed from the gastrointestinal tract; after a 0.5 mg/kg dose, peak plasma levels are reached within 1-2 hours.</li>\n<li>The plasma half-life is 2-3 hours in the presence of acidic urine but about 10 hours if the urine is alkaline, a <strong>Henderson-Hasselbalch trapping effect</strong>.</li>\n<li>The drug rapidly equilibrates with all tissues except fat.</li>\n<li>It is excreted, principally in the urine, as the unchanged drug and the N-oxide metabolite.</li>\n<li>Dosage may have to be reduced in patients with persistent urinary alkalosis or renal impairment.</li>\n<li>Diethylcarbamazine immobilizes microfilariae and alters their surface structure, displacing them from tissues and making them more susceptible to destruction by host defence mechanisms.</li>\n<li>The mode of action against adult worms is unknown.</li>\n</ul>\n<p><strong>Henderson-Hasselbalch Trapping:</strong><strong> </strong></p>\n<p>This concept explains how weakly acidic or basic drugs can get trapped in compartments (like urine or the stomach) based on the pH difference across membranes.</p>\n<ul>\n<li>Only unionized drugs can freely cross cell membranes.</li>\n<li>Ionized forms are water-soluble but cannot cross lipid membranes easily.</li>\n<li>So, if a drug crosses into a compartment and gets ionized, it gets trapped there.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Ivermectin(Option A): </strong>Ivermectin is <strong>not significantly affected by urinary pH. </strong>Its distribution and metabolism are not dependent on acid-base trapping mechanisms</p>\n<p><strong>Metronidazole(Option C): </strong>Metronidazole is a <strong>nitroimidazole antibiotic. </strong>It is metabolized primarily in the <strong>liver</strong>, not significantly affected by urinary pH. No known Henderson-Hasselbalch trapping effect.</p>", "options": ["Ivermectin", "DEC", "Metronidazole", "All of the above"], "html_options": ["Ivermectin", "DEC", "Metronidazole", "All of the above"], "corr_idx": 1}, {"id": "1176831", "html_qtxt": "Which of the following helminthic infections is Pyrantel pamoate not effective against?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Pyrantel pamoate</strong> is a broad-spectrum antihelminthic highly effective for the treatment of <strong>pinworm, ascaris</strong>, and <strong>Trichostrongylus orientalis</strong></li>\n<li>It is moderately effective against both species of hookworm.</li>\n<li>It is not effective in <strong>trichuriasis</strong> or <strong>strongyloidiasis</strong>.</li>\n</ul>\n<p><strong>Note: Oxantel pamoate</strong>, an analog of pyrantel not available in the USA, has been used successfully in the treatment of t<strong>richuriasis</strong>; the two drugs have been combined for their broad-spectrum antihelminthic activity</p>\n<p><strong>Pyrantel pamoate:</strong> </p>\n<ul>\n<li><strong>Class</strong>: Tetrahydropyrimidine derivative</li>\n<li><strong>Action</strong>: Neuromuscular blocker which causes <strong>ACh release</strong> & <strong>cholinesterase inhibition leading to</strong> <strong>spastic paralysis</strong> of worms and expulsion</li>\n<li><strong>Absorption</strong>: Poorly absorbed; acts <strong>mainly in the intestinal lumen</strong></li>\n<li><strong>Excretion</strong>: >50% eliminated unchanged in feces</li>\n<li><strong>Effective against</strong>: <strong>Mature & immature</strong> worms in the GIT</li>\n<li><strong>Not effective against</strong>: Migratory tissue stages or ova</li>\n</ul>\n<p><strong>Adverse Effects</strong></p>\n<ul>\n<li>Usual <strong>mild and transient</strong> side effects are:\n<ul>\n<li>GI: Nausea, vomiting, cramps, diarrhea</li>\n<li>CNS: Dizziness, drowsiness, headache, insomnia</li>\n<li>Others: Rash, fever, weakness</li>\n</ul>\n</li>\n<li><strong>Liver caution</strong>: May cause <strong>transient transaminase elevation</strong></li>\n<li>Use with caution in <strong>liver dysfunction</strong>, in <strong>children <2 years,</strong> and during <strong>pregnancy </strong>(limited data)</li>\n</ul>\n<p><strong>Clinical Use</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090452a8fd3e-5a29-463f-a3c1-5622e85748c8.png\">", "options": ["Pinworm", "Hookworm", "Trichuriasis", "Ascaris"], "html_options": ["Pinworm", "Hookworm", "Trichuriasis", "Ascaris"], "corr_idx": 2}, {"id": "1176832", "html_qtxt": "1. Pyrantal pamoate acts by paralysing the worm <br>2. It is a neuromuscular blocking agent", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Pyrantel pamoate is a <strong>tetrahydro pyrimidine derivative.</strong></li>\n<li>The drug is a neuromuscular blocking agent that causes r<strong>elease of acetylcholine</strong> and <strong>inhibition of cholinesterase</strong>; this results in paralysis of worms, which is followed by expulsion.</li>\n<li>It is poorly absorbed from the gastrointestinal tract and is active mainly against luminal organisms.</li>\n<li>Peak plasma levels are reached in 1-3 hours.</li>\n<li>Over half of the administered dose is recovered unchanged in the faeces.</li>\n<li>Pyrantel is effective against mature and immature forms of susceptible helminths within the intestinal tract but not against migratory stages in the tissues or ova.</li>\n</ul>", "options": ["Sentence 1 and 2 both are True, and 2 is the correct reason for 1", "Sentences 1 and 2 both are True, but 2 is not the correct reason for 1", "Sentence 1 is True, but Sentence 2 is False", "Sentences 1 and 2 are both False."], "html_options": ["Sentence 1 and 2 both are True, and 2 is the correct reason for 1", "Sentences 1 and 2 both are True, but 2 is not the correct reason for 1", "Sentence 1 is True, but Sentence 2 is False", "Sentences 1 and 2 are both False."], "corr_idx": 0}]}, {"moduleId": 1008556, "name": "Anti-Cancer Drugs, Immunosuppressants and Immunomodulators", "questions": [{"id": "1167191", "html_qtxt": "A 56-year-old presents with fluid retention and edema. With which of the following drugs is this patient most likely being treated?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Imatinib</strong> is a <strong>protein-tyrosine kinase inhibitor</strong> that inhibits the <strong>bcr-abl tyrosine kinase</strong>, which is the constitutive abnormal tyrosine kinase produced by the Philadelphia chromosome in patients with CML.</li>\n<li><strong>Imatinib is associated with the development of fluid retention, including pleural effusion, ascites, pulmonary edema, and rapid weight gain.</strong></li>\n</ul>\n<p><strong>Imatinib:</strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<p>Imatinib is a tyrosine kinase inhibitor (TKI) that:</p>\n<ul>\n<li>Inhibits the Bcr-Abl tyrosine kinase by blocking the ATP-binding site, preventing phosphorylation of downstream substrates.</li>\n<li>Also inhibits other receptor tyrosine kinases, including<strong> PDGFR (Platelet-Derived Growth Factor Receptor)</strong> and <strong>c-KIT (CD117)</strong></li>\n</ul>\n<p><strong>Indications:</strong></p>\n<ul>\n<li><strong>Chronic Myelogenous Leukemia (CML)</strong>\n<ul>\n<li>Caused by the <strong>t(9;22) Philadelphia chromosome</strong>, resulting in the <strong>Bcr-Abl fusion protein</strong>.</li>\n<li>Approved for <strong>First-line therapy</strong> in chronic phase CML, <strong>Blast crisis, and Second-line therapy</strong> for CML patients progressing after IFN-&alpha; therapy</li>\n</ul>\n</li>\n<li><strong>Gastrointestinal Stromal Tumors (GIST): </strong>Effective when GIST expresses <strong>c-KIT tyrosine kinase</strong></li>\n</ul>\n<p><strong>Adverse Effects:</strong></p>\n<p>Common side effects include:</p>\n<ul>\n<li><strong>Fluid retention and edema</strong> (notably <strong>periorbital edema</strong>)</li>\n<li>Nausea, diarrhea</li>\n<li>Muscle cramps</li>\n<li>Rash</li>\n<li>Hepatotoxicity (rare)</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Anastrozole(Option A):</strong> Anastrozole is an aromatase inhibitor used to treat breast cancer. It is associated with hot flashes, thromboembolism, osteoporosis, and bone fractures.</p>\n<p><strong>Bleomycin(Option B): </strong>Bleomycin is an intercalating agent that complexes iron-forming reactive oxygen species and induces DNA strand breaks. It is used to treat squamous cell carcinoma, both Hodgkin and non-Hodgkin lymphoma, as well as testicular carcinoma. This agent is commonly associated with the development of pulmonary fibrosis.</p>\n<p><strong>Carmustine(Option C): </strong>Nitrosourea used for brain tumors. Toxicities cause CNS effects, <strong>pulmonary fibrosis</strong>, and myelosuppression. Edema is <strong>not typical</strong></p>", "options": ["Anastrozole", "Bleomycin", "Carmustine", "Imatinib"], "html_options": ["Anastrozole", "Bleomycin", "Carmustine", "Imatinib"], "corr_idx": 3}, {"id": "1186247", "html_qtxt": "A 42-year-old woman presents with severe pain in both of her wrist joints and her fingers for the past 8 hours. She has a 3-month history of similar episodes, which are often associated with stiffness for about 90 minutes when she wakes up in the morning. Which of the following is the most appropriate acute treatment for this patient's symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient has classic signs of<strong> rheumatoid arthritis (RA)</strong>, including morning stiffness. Her current symptoms are likely due to an acute attack of the disease.</li>\n<li>Glucocorticoids like <strong>prednisolone</strong> act rapidly to reduce symptoms of severe, acute flares of rheumatoid arthritis. A short course of glucocorticoids is more effective than NSAID therapy in reducing joint tenderness and pain.</li>\n</ul>\n<p>RA is a <strong>progressive autoimmune disease</strong> affecting joints and multiple systems.</p>\n<p>Leads to <strong>reduced mobility</strong>, <strong>impaired quality of life</strong>, and <strong>shortened lifespan</strong>.</p>\n<p>The goal of therapy is to <strong>slow or arrest disease progression</strong> using <strong>DMARDs</strong> (Disease-Modifying An tirheumatic Drugs).</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904b9357a40-080d-4fca-87ee-6c05dddd3640.png\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509044c1ad40c-c118-486d-bcb5-417387b5e5dc.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Indomethacin(Option A):</strong> NSAIDs such as indomethacin are a first-line treatment for mild to moderate pain relief in patients with acute flares of rheumatoid arthritis. Moreover, Steroid treatment is more effective than NSAID therapy in reducing joint tenderness and pain. NSAIDs relieve symptoms, but do not improve the prognosis.</p>\n<p><strong>Methotrexate(Option B):</strong> Methotrexate is the first-line DMARD for patients with rheumatoid arthritis. It is effective at preventing damage to joints. However, due to its long onset of action (weeks to months), it would not provide the fast-acting symptomatic relief this patient needs.</p>\n<p><strong>Vitamin D and calcium supplements(Option D):</strong> Vitamin D and calcium supplements are used to prevent osteoporosis in the course of long-term treatment for rheumatoid arthritis, but they would not help treat an acute flare.</p>", "options": ["Indomethacin", "Methotrexate", "Prednisolone", "Vitamin D and calcium supplements"], "html_options": ["Indomethacin", "Methotrexate", "Prednisolone", "Vitamin D and calcium supplements"], "corr_idx": 2}, {"id": "1186248", "html_qtxt": "A 28-year-old woman presents with intermittent pain and stiffness in her hands and feet. She takes ibuprofen for the pain, which provides good relief. She had her last attack 7 days ago. An X-ray of her hands is shown. Which of the following is the most appropriate pharmacotherapy?<br><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d1mobye7msb5bl.cloudfront.net/2NewQBImages/5a2844f3-5d6f-4dca-bd7c-c4c9dc720257.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient presents with a history of joint pain in <strong>> 2 small</strong> and <strong>medium-sized joints.</strong> The x-ray shows joint surface destruction and narrowed joint spaces of the metacarpophalangeal, proximal interphalangeal, and wrist joints. In addition, the distal interphalangeal joints are spared, which is typical for rheumatoid arthritis.</li>\n<li><strong>Methotrexate</strong> is a disease-modifying antirheumatic drug (DMARD) and the <strong>first-line</strong>, long-term therapy for moderate-to-severe rheumatoid arthritis.</li>\n<li>Early administration of DMARDs is crucial because damage to the affected joints occurs early in the course of RA. <strong>Methotrexate</strong> is highly effective, well-tolerated, and inexpensive but has a slow onset of action (> 6 weeks).</li>\n</ul>\n<p>For this reason, bridging therapy with glucocorticoids or NSAIDs is normally indicated during acute attacks, but this patient's last acute attack has already ended 7 days ago, obviating the need for bridging therapy.</p>\n<p><strong>Methotrexate: </strong></p>\n<p><strong>Mechanism of Action (MOA):</strong></p>\n<ul>\n<li><strong>Inhibits AICAR transformylase,</strong> which increases extracellular AMP, which in turn converts to adenosine. Adenosine has anti-inflammatory effects</li>\n<li><strong>Inhibits thymidylate synthetase</strong></li>\n<li>Suppresses immune cells like neutrophils, macrophages, dendritic cells, and lymphocytes</li>\n<li>Reduces polymorphonuclear chemotaxis</li>\n<li>Inhibits cell proliferation, induces apoptosis</li>\n<li>Minimal effect on dihydrofolate reductase at these doses (unlike in cancer therapy)</li>\n</ul>\n<p><strong>Pharmacokinetics:</strong></p>\n<ul>\n<li>Routes: Oral, subcutaneous, intramuscular</li>\n<li>Absorption: ~70% after oral administration</li>\n<li>Metabolism: Forms polyglutamated metabolites, which are retained inside cells for long periods</li>\n<li>Half-life: 6-9 hours</li>\n<li>Excretionis primarily through urine and up to 30% through bile</li>\n<li>Interaction: Hydroxychloroquine reduces MTX clearance</li>\n</ul>\n<p><strong>Indications:</strong></p>\n<p>Used in many autoimmune and inflammatory diseases:</p>\n<ul>\n<li>Rheumatoid arthritis (RA)</li>\n<li>Systemic sclerosis (skin involvement)</li>\n<li>Juvenile idiopathic arthritis (JIA)</li>\n<li>Psoriasis and psoriatic arthritis</li>\n<li>Peripheral arthritis in ankylosing spondylitis (not axial disease)</li>\n<li>Granulomatosis with polyangiitis (Wegener's)</li>\n<li>Polymyositis</li>\n<li>Giant cell arteritis</li>\n<li>Systemic lupus erythematosus (SLE)</li>\n<li>Vasculitis</li>\n</ul>\n<p><strong>Dosage:</strong></p>\n<ul>\n<li>Start with <strong>5 mg once weekly (oral)</strong></li>\n<li>Increase to<strong> 15-25 mg/week</strong></li>\n<li>Max effect up to<strong> 30-35 mg/week (but toxicity also increases)</strong></li>\n<li>Delays or prevents joint erosions in RA</li>\n</ul>\n<p><strong>Adverse Effects:</strong></p>\n<ul>\n<li>Commonly <strong>Nausea, stomatitis (mouth ulcers)</strong></li>\n<li>Due to cytotoxicity, causes<strong> Leukopenia, anemia, GI ulcers, alopecia</strong></li>\n<li><strong>Liver toxicity: </strong>Dose-related transaminitis (elevated liver enzymes)</li>\n<li><strong>Genetic predisposition to toxicity:</strong> Mutations in CYP20A1, CYP39A1, SLC22A2, SLC7A7, ALDH2</li>\n</ul>\n<p><strong>Contraindications:</strong></p>\n<ul>\n<li>Pregnancy: teratogenic, must be avoided</li>\n<li>Use with caution in hepatic or renal impairment</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Prednisolone(Option B):</strong> Prednisolone gives Temporary symptom control only, so used as <strong>bridge therapy, </strong>not long-term, not disease-modifying</p>\n<p><strong>Diclofenac(Option C): </strong>NSAID provides symptomatic relief only, No effect on disease progression</p>\n<p><strong>Adalimumab(Option D): </strong>Anti-TNF biologic, used when MTX fails or in severe RA, not first-line monotherapy</p>", "options": ["MTX", "Prednisolone", "Diclofenac", "Adalimumab"], "html_options": ["MTX", "Prednisolone", "Diclofenac", "Adalimumab"], "corr_idx": 0}, {"id": "1186249", "html_qtxt": "A 39-year-old woman comes to you because of severe progressive pain and swelling of her wrists and hands for the past 2 months. She is on methotrexate for RA, but remission could not be achieved. An X-ray of the hand is shown below. You're considering starting biologicals. What test should be done before initiating the treatment?<br><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d1mobye7msb5bl.cloudfront.net/2NewQBImages/974a61a2-b97c-468d-9c9d-08cc74c77063.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient has severe pain and x-ray findings of joint space narrowing, marginal erosions of cartilage and bone, suggesting severe rheumatoid arthritis (RA), for which she needs biologicals for remission.</li>\n<li>All of the <strong>anti-TNF-&alpha; agents</strong> increase the risk of serious infection, reactivation of <strong>tuberculosis</strong>, and <strong>lymphoma</strong>. In an Indian setting, it's necessary to rule out latent tuberculosis before initiating the treatment.</li>\n<li>If latent TB is detected, <strong>prophylactic anti-TB treatment</strong> is started <strong>before</strong> the biologic.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904728581ed-6af3-46c7-824e-0014dbc4f257.png\">\n<p><strong>Indications of Anti-TNF-&alpha; agent:</strong></p>\n<p>Refractory therapy for chronic inflammatory systemic diseases</p>\n<ul>\n<li>Rheumatoid arthritis</li>\n<li>Ankylosing spondylitis</li>\n<li>Psoriasis</li>\n<li>Crohn disease</li>\n<li>Ulcerative colitis</li>\n</ul>\n<p><strong>Adverse effects of Anti-TNF-&alpha; agents:</strong></p>\n<ul>\n<li>Infections</li>\n<li>Reactivation of prior infections</li>\n<li>Drug-induced lupus</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Urine &beta;-hCG test(Option B): </strong>Important in <strong>women of reproductive age</strong> before <strong>teratogenic drugs</strong> like <strong>methotrexate</strong>, <strong>leflunomide</strong>, etc. But <strong>not mandatory</strong> before biologics unless pregnancy is suspected.</p>\n<p><strong>Fundoscopy(Option C): </strong>Required <strong>before starting hydroxychloroquine</strong> or <strong>chloroquine</strong> (risk of <strong>retinal toxicity</strong>).</p>\n<p><strong>Serum creatinine(Option D): </strong>Important before using <strong>NSAIDs</strong> or <strong>methotrexate</strong>. Not specifically required before biologic DMARDs unless there's existing renal disease.</p>", "options": ["Tuberculin skin test", "Urine &beta;-hCG test", "Fundoscopy", "Serum creatinine"], "html_options": ["Tuberculin skin test", "Urine &beta;-hCG test", "Fundoscopy", "Serum creatinine"], "corr_idx": 0}, {"id": "1186250", "html_qtxt": "A 42-year-old woman with RA comes with a 10-month history of joint pain and stiffness in her wrists and fingers. The symptoms are worse in the morning and improve with activity. She has started on first-line DMARDs. All of the following are true about treatment except?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p>This patient with RA is initiated on first-line DMARDs, which would be <strong>Methotrexate</strong></p>\n<p><strong>Bull's eye Retinopathy is </strong>the major side effect caused by<strong> Hydroxychloroquine, </strong>not methotrexate<strong>. </strong>So Fundoscopy is required to start and monitor Hydroxychloroquine</p>\n<p>Methotrexate <strong>inhibits thymidylate synthetase, l</strong>eading to function deficiency of folic acid, so to avoid the side effects caused by the deficiency, folinic acid should be administered 7-10 mg PO once weekly, 24-48 hours after MTX administration<strong>(Option A ruled out)</strong></p>\n<p><strong>Methotrexate is contraindicated in pregnancy as it is teratogenic. </strong>If the couple plans to conceive, Sulfasalazine should be considered in patients with low disease activity.<strong>(Option B ruled out)</strong></p>\n<p>NSAIDs can inhibit the renal excretion of <strong>MTX</strong>, which may increase the risk of adverse effects. So NSAIDs and MTX should not be given on the same day<strong>(Option C ruled out)</strong></p>", "options": ["To minimize adverse effects, administer folinic acid.", "Pregnancy is a contraindication for the treatment.", "Avoid administering NSAIDs on the same day as DMARDs.", "Need yearly fundoscopy to rule out bull's eye Retinopathy."], "html_options": ["To minimize adverse effects, administer folinic acid.", "Pregnancy is a contraindication for the treatment.", "Avoid administering NSAIDs on the same day as DMARDs.", "Need yearly fundoscopy to rule out bull's eye Retinopathy."], "corr_idx": 3}, {"id": "1186251", "html_qtxt": "Match the following<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322146ed841-d6a3-4573-892f-f9604a5b9285.jpg\">", "html_expl": "<p><strong>Explanation:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250904773e0f9d-c834-4180-9905-25a259b00dc7.png\"><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240322c77d572e-7bfe-418d-ae62-538797d878a2.jpg\">", "options": ["1-c 2-b 3-a 4-d", "1-c 2-b 3-d 4-a", "1-b 2-c 3-d 4-a", "1-c 2-d 3-b 4-a"], "html_options": ["1-c 2-b 3-a 4-d", "1-c 2-b 3-d 4-a", "1-b 2-c 3-d 4-a", "1-c 2-d 3-b 4-a"], "corr_idx": 1}, {"id": "1186252", "html_qtxt": "A 60-year-old woman with RA comes in with progressive pain. Over the next 7 weeks, prednisone is also given as a \"bridging therapy\" to prevent pain and inflammation while waiting for the pharmacologic benefits of methotrexate. Which of the following is a possible adverse effect of the glucocorticoid therapy in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>In rheumatoid arthritis, <strong>prednisone</strong> is sometimes used when persistent synovitis is seen in multiple joints despite a sufficient dosage of nonsteroidal anti-inflammatory drugs (NSAIDs). Because it can take several weeks to months for the therapeutic effect of DMARDs to become evident, agents such as prednisone are needed as \"bridge therapy\" until the DMARDs become effective.</li>\n<li>The major <strong>disadvantage</strong> of using <strong>glucocorticoids</strong> for an extended period is the severe side-effect profile.</li>\n<li><strong>Corticosteroids</strong> affect <strong>calcium and bone metabolism</strong> in a variety of ways.</li>\n<li>For example, these drugs decrease the amount of calcium absorbed by the intestine and also increase calcium excretion through the kidneys, both of which lead to a decreased circulating ionized calcium concentration.</li>\n<li>Furthermore, this process stimulates the parathyroid glands to increase the secretion of parathyroid hormone, which leads to increased bone breakdown, as the body attempts to rectify low circulating calcium levels by releasing calcium from the bones into the blood.</li>\n<li>The <strong>mineralocorticoid effects</strong> of the corticosteroids can result in sodium reabsorption, potassium excretion, and fluid retention. Thus, long-term use of prednisone is associated with <strong>fluid</strong> <strong>retention (not dehydration, Option A ruled out),</strong> <strong>hypokalemia (not hyperkalemia, Option B ruled out)</strong>, and <strong>hypernatremia (not hyponatremia, Option D ruled out)</strong>.</li>\n<li>It should also be noted that electrolyte changes also occur outside the kidney in response to corticosteroid therapy, in the gastrointestinal mucosa, salivary and sweat glands, and exocrine pancreas.</li>\n<li>In the intestine, for example, glucocorticoids can increase sodium and water absorption, as well as potassium secretion.</li>\n<li>Other systemic effects of high doses of glucocorticoids include adrenocortical insufficiency upon glucocorticoid removal, steroid-induced diabetes, resulting in <strong>hyperglycemia, hyperlipidemia, elevated glucagon, and hypocalcemia</strong></li>\n</ul>", "options": ["Dehydration", "Hyperkalemia", "Hypocalcemia", "Hyponatremia"], "html_options": ["Dehydration", "Hyperkalemia", "Hypocalcemia", "Hyponatremia"], "corr_idx": 2}, {"id": "1186253", "html_qtxt": "A 12-year-old boy with a history of cystic fibrosis is brought to the hospital for a lung transplant. Immunosuppressive therapy is begun with mycophenolate mofetil to prevent tissue rejection. Which of the following best describes the mechanism of action of this drug?", "html_expl": "<p><strong>Explanation:</strong></p>\n<p><strong>Immunosuppressive Agents </strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509040905ccea-3091-4963-b997-709bce17e496.png\">", "options": ["Inhibits calcineurin", "Inhibits interleukin (IL)-2 receptor activity", "Inhibits interferon synthesis", "Inhibits purine synthesis"], "html_options": ["Inhibits calcineurin", "Inhibits interleukin (IL)-2 receptor activity", "Inhibits interferon synthesis", "Inhibits purine synthesis"], "corr_idx": 3}, {"id": "1186254", "html_qtxt": "A 58-year-old woman with a history of severe recalcitrant plaque psoriasis comes to the physician because of a recurrence of erythematous plaques despite current treatment measures. Treatment is begun with a calcineurin inhibitor that binds cyclophilin and blocks T cell activation by preventing IL-2 transcription. This patient is at greatest risk of experiencing which of the following adverse effects as a result of this drug?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Cyclosporine</strong> is a <strong>calcineurin inhibitor</strong> that induces immunosuppression by binding cyclophilin and inhibiting interleukin (IL)-1 and IL-2 receptor production, and inhibits macrophage/T-cell interaction and T-cell responsiveness through the regulation of gene transcription.</li>\n<li>Cyclosporine is used in the treatment of <strong>transplant rejection prophylaxis</strong>, <strong>severe psoriasis,</strong> and <strong>rheumatoid arthritis</strong></li>\n<li><strong>Nephrotoxicity</strong>, characterized by an elevated BUN (>35-45 mg/dL) and creatinine (>2.0-2.5 mg/dL), is the most common adverse effect of systemic cyclosporine therapy and has been documented in all types of patients who are receiving cyclosporine.</li>\n<li>Factors that increase the risk of nephrotoxicity with cyclosporine include <strong>age older than 50 years, concomitant nephrotoxic medications, and the period 6 to 8 weeks posttransplant (if used in transplant rejection prophylaxis).</strong></li>\n<li>Cyclosporine-induced nephrotoxicity is most likely due to intense <strong>renal vasoconstriction</strong>, which leads to increases in serum creatinine, arterial blood pressure, and serum potassium. Cyclosporin causes nephrotoxicity, <strong>severe hypertension</strong>, <strong>gingival hyperplasia</strong>, <strong>hyperlipidemia</strong>, and <strong>hyperglycemia.</strong></li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Corneal deposits(Option A): </strong>Corneal deposits are not a side effect of cyclosporine; however, it is commonly seen with hydroxychloroquine usage.</p>\n<p><strong>Hypotension(Option B): </strong>Cyclosporine typically causes <strong>hypertension</strong>, not hypotension.</p>\n<p><strong>Seizures(Option D)</strong>: Possible with <strong>cyclosporine-induced neurotoxicity</strong>, but <strong>less common</strong> than nephrotoxicity.</p>", "options": ["Corneal deposits", "Hypotension", "Nephrotoxicity", "Seizures"], "html_options": ["Corneal deposits", "Hypotension", "Nephrotoxicity", "Seizures"], "corr_idx": 2}, {"id": "1186255", "html_qtxt": "A 6-year-old boy is brought in with a fever of 101 F, rash, and urticaria. His mother states that he has been complaining about pain in his hands, wrists, and knees. He has a recent history of an upper respiratory tract infection, for which he completed a 5-day course of Cefexime. Which of the following is the most appropriate therapy for this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Serum sickness is a type Ill hypersensitivity reaction</strong> that is commonly caused by a reaction to certain Key features of serum sickness are <strong>rash, fever, and polyarthralgias or polyarthritis</strong>, which begin one to two weeks after exposure to the responsible agent. Patients are often extremely ill during the febrile stage, but serum sickness is <strong>self-limited</strong>, and once the responsible drug is discontinued, the prognosis is excellent.</li>\n<li>Due to the severity of the signs and symptoms in this patient, oral prednisone and diphenhydramine should be administered. The<strong> glucocorticoid prednisone</strong> will treat the arthralgias and the skin rash, and the <strong>diphenhydramine</strong> will alleviate the urticaria.</li>\n<li>In serum sickness, it is suggested that the drug acts as a hapten, which binds to serum or cell-bound proteins. This drug-protein complex is recognized as being foreign to the body and induces serum sickness.</li>\n<li>Medications commonly associated with the development of this condition include cephalosporins (especially cefaclor), <strong>penicillins, trimethoprim-sulfamethoxazole, vaccines, antitoxins, hormones from other species, tetracyclines, captopril, and ciprofloxacin.</strong></li>\n<li>Common signs and symptoms of serum sickness include<strong> fever, cutaneous eruptions, lymphadenopathy, and arthralgias</strong>. The reaction is generally delayed for <strong>5 to 10 days</strong> after initial exposure, because it takes that long for the generation of specific <strong>IgG </strong>antibodies.</li>\n<li>Treatment measures include <strong>withdrawal of the causative agen</strong>t, symptomatic treatment (antihistamines for urticaria), and <strong>glucocorticoids</strong>.</li>\n<li>Due to the severity of the signs and symptoms in this patient, oral prednisone and diphenhydramine should be administered. The glucocorticoid prednisone will treat the arthralgias and the skin rash, and the diphenhydramine will alleviate the urticaria.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Aspirin and diphenhydramine(Option B): </strong>Aspirin is not indicated and may increase the risk of Reye's syndrome in children</p>\n<p><strong>Azithromycin and diphenhydramine(Option C):</strong> No indication for antibiotics (no ongoing infection)</p>\n<p><strong>Betamethasone and erythromycin(Option D): </strong>Again, unnecessary antibiotic; betamethasone could help, but oral <strong>prednisone</strong> is preferred in systemic cases</p>", "options": ["Aspirin and diphenhydramine", "Azithromycin and diphenhydramine", "Betamethasone and erythromycin", "Prednisone and diphenhydramine "], "html_options": ["Aspirin and diphenhydramine", "Azithromycin and diphenhydramine", "Betamethasone and erythromycin", "Prednisone and diphenhydramine "], "corr_idx": 3}, {"id": "1186256", "html_qtxt": "A 40-year-old woman with a renal allograft is currently taking an immunosuppressive drug. Laboratory examination shows a uric acid level of 10.5 mg/dL. Treatment with allopurinol is begun, necessitating a reduction in the dose of the immunosuppressive drug. Which of the following immunosuppressive drugs is this patient most likely taking?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>In this question, you must identify the immunosuppressive drug that interacts with <strong>allopurinol</strong>, subsequently requiring a dose reduction of the immunosuppressant agent.</li>\n<li><strong>Azathioprine</strong> is an immunosuppressant that ultimately inhibits T-lymphocyte proliferation. This agent is converted to<strong> 6-mercaptopurine</strong>, which <strong>inhibits DNA purine synthesis</strong> and subsequent T-cell proliferation.</li>\n<li><strong>Xanthine oxidase</strong> is instrumental in the metabolism of azathioprine metabolites, and coadministration with allopurinol (an inhibitor of xanthine oxidase) can result in azathioprine toxicity.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Abatacept(Option A): </strong>A <strong>T-cell co-stimulation blocker</strong> (inhibits CD80/86 interaction with CD28). Used mainly for <strong>rheumatoid arthritis</strong>, not transplant rejection. <strong>No known interaction with allopurinol</strong>.</p>\n<p><strong>Cyclosporine(Option C): </strong>A <strong>calcineurin inhibitor</strong> that suppresses <strong>IL-2 transcription</strong> to prevent T-cell activation. Its side effects include <strong>nephrotoxicity, hypertension</strong>, and <strong>neurotoxicity</strong>, but it does <strong>not interact with allopurinol</strong>.</p>\n<p><strong>Mycophenolate mofetil(Option D): </strong>Inhibits <strong>inosine monophosphate dehydrogenase</strong>, blocking <strong>guanine nucleotide synthesis</strong>. Selectively affects lymphocytes (T and B cells). <strong>No xanthine oxidase metabolism</strong>, hence <strong>no interaction with allopurinol</strong>.</p>", "options": ["Abatacept", "Azathioprine", "Cyclosporine", "Mycophenolate mofetil"], "html_options": ["Abatacept", "Azathioprine", "Cyclosporine", "Mycophenolate mofetil"], "corr_idx": 1}, {"id": "1186257", "html_qtxt": "A 45-year-old man with a recent liver transplant is on a drug that reduces the activation of cytotoxic T lymphocytes by inhibiting IL-2 transcription to prevent transplant rejection. This additional drug is most likely which of the following?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Tacrolimus</strong> inhibits <strong>calcineurin-mediated transcription of IL-2</strong>. Tacrolimus binds to an immunophilin called FK binding protein 12 (<strong>FKBP12</strong>), and produces immunosuppression by a mechanism that involves inhibition of the first phase of T-cell activation.</li>\n<li>It is indicated for<strong> heart, liver, and kidney transplant prophylaxis.</strong> It has also been used in the treatment of severe cases of <strong>ulcerative colitis and eczema</strong>. This drug is associated with the development of <strong>thrombocytopenia, leukopenia, nephrotoxicity, hypertension, hyperlipidemia, hyperglycemia, tremor, and CNS toxicity.</strong></li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Azathioprine(Option A): </strong>Azathioprine is converted to 6-mercaptopurine, which inhibits DNA synthesis and subsequent cell proliferation. It is indicated for kidney transplant rejection and severe rheumatoid arthritis. It has also been used in the treatment of Crohn's disease and ulcerative colitis. This drug is associated with the development of leukopenia and thrombocytopenia.</p>\n<p><strong>Cyclophosphamide(Option B):</strong> Cyclophosphamide inhibits cell proliferation by alkylating DNA. This agent has been used in the treatment of a variety of cancers, such as leukemia, lymphoma, multiple myeloma, breast cancer, and ovarian cancer, as well as mycosis fungoides. This drug has also been used in the treatment of severe rheumatoid arthritis unresponsive to other disease-modifying antirheumatic drugs (DMARD) therapies. Cyclophosphamide causes hemorrhagic cystitis, urinary bladder fibrosis, heart failure, immunosuppression, and anemia.</p>\n<p><strong>Sirolimus(Option C): </strong>Like tacrolimus, sirolimus binds FKBP12, but sirolimus does not inhibit calcineurin or block cytokine gene transcription in T cells; rather, sirolimus inhibits the mammalian targets of rapamycin (mTOR), leading to the blockage of IL-2 cytokine signaling. By blocking mTOR, sirolimus inhibits the cellular response to IL-2 and inhibits the progression of the cell cycle, thereby prohibiting T cell proliferation.</p>", "options": ["Azathioprine", "Cyclophosphamide", "Sirolimus", "Tacrolimus"], "html_options": ["Azathioprine", "Cyclophosphamide", "Sirolimus", "Tacrolimus"], "corr_idx": 3}, {"id": "1186259", "html_qtxt": "A 34-year-old woman with hepatitis B virus develops fulminant hepatitis. A liver transplant is successfully performed, and treatment is begun with an immunosuppressant. You recommend avoiding the consumption of grapefruit and grapefruit juice when taking this drug. Which of the following is the most likely immunosuppressant administered to this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Cyclosporine</strong> is indicated for the prevention of renal, cardiac, and liver transplant rejection, as well as the treatment of rheumatoid arthritis. It may also be effective in patients with <strong>systemic lupus erythematosus, polymyositis, dermatomyositis, and granulomatosis with polyangiitis (Wegener's).</strong></li>\n<li>Calcineurin normally stimulates transcription factors that lead to increased production of interleukin 2 and related cytokines. Thus, cyclosporine decreases the production of IL-2.</li>\n<li>Cyclosporine has many drug interactions because the <strong>CYP3A enzyme</strong> system largely metabolizes it; compounds that alter the activity of this enzyme also affect cyclosporine levels. <strong>Grapefruit juice inhibits CYP3A</strong>, resulting in increased blood concentrations of cyclosporine.</li>\n<li>Common<strong> adverse effects</strong> seen with cyclosporine include elevated <strong>BUN, hypertension, tremor, infection, and renal impairment. Serious reactions include severe hypertension, severe hyperkalemia, thrombocytopenia, leukopenia, neutropenia, immunosuppression, nephrotoxicity, neurotoxicity, seizures, and opportunistic infections.</strong></li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Azathioprine(Option A):</strong> It's a <strong>prodrug</strong> that converts to <strong>6-mercaptopurine</strong>. Inhibits <strong>purine synthesis</strong>, suppressing both <strong>B and T lymphocyte proliferation. Mainly via xanthine oxidase and thiopurine methyltransferase (TPMT). Not metabolized by CYP3A4.</strong></p>\n<p><strong>Muromonab-CD3(Options C): </strong>A monoclonal antibody against the CD3 receptor on T-cells. As a monoclonal antibody, it's degraded by proteolysis, not via liver enzymes like CYP450.</p>\n<p><strong>Mycophenolate mofetil(Option D): </strong>Prodrug of mycophenolic acid. Undergoes glucuronidation, not CYP450-mediated.</p>", "options": ["Azathioprine", "Cyclosporine", "Muromonab-CD3", "Mycophenolate mofetil"], "html_options": ["Azathioprine", "Cyclosporine", "Muromonab-CD3", "Mycophenolate mofetil"], "corr_idx": 1}]}, {"moduleId": 1013785, "name": "Cell wall synthesis, Folate and DNS gyrase inhibitors", "questions": [{"id": "1332334", "html_qtxt": "Identify correct match out of the following options.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100895eeb308-9ff0-4121-8af0-2bcb6e8c1f7f.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The correct match among the given options is <strong>Daptomycin. </strong>Daptomycin is a <strong>lipopeptide antibiotic</strong> that exerts its bactericidal action by binding to the bacterial cell membrane in a <strong>calcium-dependent manner, </strong>causing rapid depolarization of membrane potential. This depolarization inhibits essential processes like protein, DNA, and RNA synthesis, ultimately leading to cell death. It is especially effective against resistant gram-positive organisms such as methicillin-resistant <strong><em>Staphylococcus aureus</em> (MRSA) and vancomycin-resistant enterococci (VRE). </strong>However, it is not useful in treating pneumonia, as it becomes inactivated by pulmonary surfactant.</p>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Vancomycin (Option B):</strong> This drug is a <strong>glycopeptide antibiotic</strong> that inhibits <strong>bacterial cell wall synthesis</strong> by binding to the <strong>D-Ala-D-Ala terminal</strong> of <strong>peptidoglycan precursors</strong>, thereby blocking <strong>transglycosylation and transpeptidation</strong>. It does <strong>not affect membrane potential</strong> and has a different mechanism than daptomycin. It is used against <strong>gram-positive organisms</strong>, especially in <strong>MRSA infections</strong>, but its mode of action is <strong>distinct</strong> from that of daptomycin.</p>\r\n<p><strong>Bacitracin (Option C):</strong> <strong>Bacitracin</strong> interferes with the <strong>late stage of peptidoglycan synthesis</strong> by inhibiting the <strong>dephosphorylation of bactoprenol</strong>, a <strong>lipid carrier molecule</strong> that transports peptidoglycan precursors across the cell membrane. It is mainly used <strong>topically</strong> due to its <strong>nephrotoxicity</strong> when administered systemically. This mechanism is <strong>different</strong> from the <strong>membrane depolarization</strong> caused by daptomycin.</p>\r\n<p><strong>Fosfomycin (Option D):</strong> <strong>Fosfomycin</strong> inhibits <strong>bacterial cell wall synthesis</strong> at an <strong>earlier step</strong> by blocking the enzyme <strong>MurA (enolpyruvyl transferase)</strong>, which catalyzes the formation of <strong>N-acetylmuramic acid</strong>, an essential precursor in peptidoglycan synthesis. It is commonly used in the treatment of <strong>uncomplicated urinary tract infections</strong>. It does <strong>not disrupt membrane potential</strong> like daptomycin.</p>", "options": ["Daptomycin", "Vancomycin", "Bacitracin", "Fosfomycin"], "html_options": ["Daptomycin", "Vancomycin", "Bacitracin", "Fosfomycin"], "corr_idx": 0}, {"id": "1332335", "html_qtxt": "A 72-year old man comes to the physician for fever, malaise, and skin rash. He appears pale. His temperature is 102 F, pulse is 120/min, and blood pressure is 140/90 mm Hg. Physical examination shows non-tender, erythematous macules on the palms as shown below. On auscultation, early diastolic murmur, loudest at the left sternal border is heard. Blood cultures grow gram-positive, catalase-positive cocci that express mecA. Intravenous antibiotic therapy is begun with an agent that disrupts cell membranes by creating transmembrane channels. Which of the following adverse events is associated with the use of this agent?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100873929243-8b3d-4d69-99c1-f184f89be7c4.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The patient is presenting with <strong>infective endocarditis</strong>, as suggested by <strong>fever, malaise, non-tender erythematous macules on the palms (Janeway lesions), a diastolic murmur</strong>, and <strong>positive blood cultures</strong>.</p>\r\n<p>In this setting, <strong>Daptomycin</strong> is a preferred intravenous antibiotic used for MRSA <strong>endocarditis</strong>, especially when vancomycin is contraindicated or ineffective. Daptomycin acts by <strong>disrupting the bacterial cell membrane</strong>, causing <strong>membrane depolarization</strong> via the formation of <strong>transmembrane channels</strong> in a <strong>calcium-dependent manner</strong>.</p>\r\n<p>Daptomycin is associated with <strong>rhabdomyolysis</strong> as a significant adverse effect, particularly at higher doses or with prolonged use. It can cause <strong>elevated creatine phosphokinase (CPK)</strong> levels and <strong>muscle toxicity</strong>, necessitating regular CPK monitoring during therapy.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Ototoxicity (Option A):</strong></p>\r\n<p>This is commonly associated with <strong>aminoglycosides</strong> (e.g., gentamicin) and <strong>vancomycin</strong>, not daptomycin.</p>\r\n<p><strong>QT prolongation (Option B):</strong></p>\r\n<p>Seen with <strong>macrolides</strong> (e.g., azithromycin), <strong>fluoroquinolones</strong>, and some <strong>antifungals-</strong>not typically linked to daptomycin.</p>\r\n<p><strong>Red Man syndrome (Option D):</strong></p>\r\n<p>A <strong>rate-related infusion reaction</strong> caused by <strong>vancomycin</strong>, not daptomycin. It presents as flushing, rash, and hypotension.</p>", "options": ["Ototoxicity", "QT prolongation", "Rhabdomyolysis", "Red Man syndrome"], "html_options": ["Ototoxicity", "QT prolongation", "Rhabdomyolysis", "Red Man syndrome"], "corr_idx": 2}, {"id": "1332336", "html_qtxt": "A 60-year-old male presents with painful red swelling on his right thigh since 1 week. Examination shows a 3- x 4-cm, tender, fluctuant mass s/o abscess. Culture of the abscess fluid grows gram-positive, coagulase-positive cocci that are resistant to oxacillin. Which of the following best describes the mechanism of resistance of the causal organism to oxacillin?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>MRSA exhibits resistance to beta-lactam antibiotics, including oxacillin and methicillin, through a well-characterized mechanism involving the <strong><em>mecA</em> gene</strong>. This gene encodes an altered <strong>penicillin-binding protein (PBP2a)</strong> that has <strong>low affinity for beta-lactams</strong>, thereby allowing bacterial cell wall synthesis to continue despite the presence of the antibiotic.</p>\r\n<p>The patient is presenting with a <strong>painful, red, fluctuant swelling</strong> on the thigh, consistent with a <strong>skin abscess</strong>. Culture of the abscess fluid reveals <strong>gram-positive, coagulase-positive cocci</strong> that are <strong>resistant to oxacillin</strong>, which is diagnostic of <strong>methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)</strong>.</p>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<p><strong>Reduced uptake (Option A):</strong></p>\r\n<p>This mechanism is typically seen in <strong>gram-negative organisms</strong>, where alterations in porin channels reduce the drug's entry. It is not relevant to MRSA.</p>\r\n<p><strong>Degradation (Option B):</strong></p>\r\n<p>This refers to <strong>&beta;-lactamase production</strong>, which is a common resistance mechanism in <strong>non-MRSA strains</strong> of <em>Staphylococcus aureus</em>. However, MRSA remains resistant even to &beta;-lactamase-resistant drugs like oxacillin due to PBP2a.</p>\r\n<p><strong>Active efflux (Option D):</strong></p>\r\n<p>Active efflux pumps contribute to resistance in organisms like <strong>Pseudomonas</strong> and <strong>Mycobacteria</strong>, but not to oxacillin resistance in <em>Staphylococcus aureus</em>.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008cacbbed6-39a4-4eed-8711-a43846688389.png\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008de22a250-da5e-4bb7-b9e1-9d75de7996e6.png\">", "options": ["Reduced uptake", "Degradation", "Altered target", "Active efflux"], "html_options": ["Reduced uptake", "Degradation", "Altered target", "Active efflux"], "corr_idx": 2}, {"id": "1332337", "html_qtxt": "A 33-year-old man presents with complaint of dysuria and urethral discharge. Gram stain of the urethral exudate shown below. Most appropriate treatment of in this patient is.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100890f2fee2-f4de-48b8-ab4c-008ebfdd1fab.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Given clinical scenario of urethral discharge along with Gram stain of the showing Gram-negative diplococci within PMNs suggest diagnosis of <strong>Gonorrhoea.</strong></p>\r\n<ul>\r\n<li>Treatments of choice for gonorrhoea include a <strong>single dose of ceftriaxone (IM).</strong> Because of the high incidence of beta-lactamase-producing gonococci, the use of penicillin G <strong>(Option C)</strong> or amoxicillin <strong>(Option B)</strong> is no longer appropriate for gonorrhoea. Similarly, many strains of gonococci are resistant to tetracyclines. Alternative drugs for gonorrhoea include cefixime or azithromycin.</li>\r\n<li>Meropenem (<strong>Option D)</strong> is used as Last-resort drugs (used only in life-threatening infections or after other antibiotics have failed) because of the significant adverse effects. Used in Intraabdominal infections, infections caused by Enterobacter spp. and ESBL-producing gram-negative bacilli.</li>\r\n</ul>", "options": ["A single intramuscular dose of ceftriaxone", "Amoxicillin orally for 7 d", "Procaine penicillin G intramuscularly as a single dose plus oral probenecid", "Meropenem orally for 7 d"], "html_options": ["A single intramuscular dose of ceftriaxone", "Amoxicillin orally for 7 d", "Procaine penicillin G intramuscularly as a single dose plus oral probenecid", "Meropenem orally for 7 d"], "corr_idx": 0}, {"id": "1332341", "html_qtxt": "A 57-year-old man is brought with right upper quadrant abdominal pain. He states that the pain is worse after eating a fatty meal. His temperature is 102.5 F. Physical examination shows tenderness of the right upper quadrant of the abdomen with guarding. His white blood cell count is 14,500 cells/pL. Ultrasonography shows pericholecystic fluid, gallbladder wall thickening, abdominal pain when the ultrasound probe is over the gallbladder, and gallstones. Surgery is planned and treatment with an antibiotic regimen is begun. Which of the following pharmacotherapy is most appropriate for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Empiric antibiotic therapy is indicated to cover <strong>enteric gram-negative bacilli</strong>, <strong>anaerobes</strong>, and <strong>some gram-positive organisms</strong>. The most appropriate pharmacologic regimen in this scenario is <strong>Cefotaxime plus Metronidazole (Option A)</strong>. <strong>Cefotaxime</strong>, a third-generation cephalosporin, provides broad coverage against <strong>gram-negative rods</strong> such as <em>E. coli</em>and <em>Klebsiella</em>, while <strong>metronidazole</strong> offers effective coverage against <strong>anaerobes</strong> like <em>Bacteroides</em> species. This combination is standard in the empiric management of <strong>intra-abdominal infections</strong>, including acute cholecystitis.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100804cac431-3350-465a-87b5-eb61f2284b5c.png\"><br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008de2e6c45-448c-4474-a2d2-564f26714591.png\">\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Ciprofloxacin (Option B)</strong>, although active against many gram-negative bacteria, offers <strong>limited anaerobic coverage</strong>, making it less suitable as monotherapy in cholecystitis.</p>\r\n<p><strong>Clindamycin (Option C)</strong> has good anaerobic and gram-positive coverage but <strong>does not cover gram-negative enteric bacilli</strong> effectively and is not a first-line agent for biliary tract infections.</p>\r\n<p><strong>Vancomycin + Gentamicin (Option D)</strong> is typically reserved for severe hospital-acquired infections or infective endocarditis and lacks sufficient <strong>anaerobic coverage</strong>, making it inappropriate for this setting.</p>", "options": ["Cefotaxime + metronidazole", "Ciprofloxacin", "Clindamycin", "Vancomycin + gentamicin"], "html_options": ["Cefotaxime + metronidazole", "Ciprofloxacin", "Clindamycin", "Vancomycin + gentamicin"], "corr_idx": 0}, {"id": "1332344", "html_qtxt": "60-year-old man presents with colicky abdominal pain and foul-smelling watery diarrhea. Current medications include intravenous ceftriaxone and oral azithromycin for CAP since 6 days. A PCR test is positive for C. difficile toxins. Oral treatment with vancomycin is started. Which of the following sentences are correct regarding the newly initiated treatment ?<br>A. It can cause red man syndrome, which can be prevented by slowing the rate of infusion and pretreating with antihistamines.<br>B. In contrast to amino-glycosides, ototoxicity and vestibular toxicity are more for vancomycin.<br>C. It can cause systemic side effects such as nephrotoxicity, ototoxicity and DRESS syndrome.<br>D. Patient may affected predominantly by dysgeusia and gastrointestinal side effects.", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Dysgeusia </strong>(an altered sense of taste) and gastrointestinal side effects, including diarrhea, nausea, and abdominal discomfort, are common side effects of oral vancomycin when used to treat C. difficile infection.</p>\r\n<p>The patient is experiencing <strong>Clostridioides difficile infection (CDI)</strong>, evidenced by <strong>colicky abdominal pain</strong>, <strong>foul-smelling watery diarrhea</strong>, and a <strong>positive PCR for C. difficile toxins</strong>. This infection developed following <strong>broad-spectrum antibiotic use (ceftriaxone and azithromycin)</strong>, which disrupted normal gut flora. The treatment initiated-<strong>oral vancomycin-</strong>is appropriate for <strong>mild to moderate C. difficile infection</strong>.</p>\r\n<p>Importantly, <strong>oral vancomycin acts locally in the gut and is minimally absorbed systemically</strong>, which significantly limits its potential for systemic side effects when used for CDI.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008f58168b4-4fb6-4e96-9da2-a4435edc6240.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Red man syndrome (Option A):</strong></p>\r\n<p>Red man syndrome is a <strong>histamine-mediated infusion reaction</strong> seen with <strong>intravenous vancomycin</strong>, not oral. It presents with <strong>flushing, rash</strong>, and <strong>hypotension</strong>, and can be prevented by <strong>slowing the IV infusion</strong> and <strong>premedicating with antihistamines</strong>. However, this side effect is <strong>not relevant</strong> in oral vancomycin therapy, as used here.</p>\r\n<p><strong>Ototoxicity and vestibular toxicity (Option B):</strong></p>\r\n<p>Both <strong>aminoglycosides</strong> and <strong>vancomycin</strong> can cause <strong>ototoxicity</strong>, but these are <strong>systemic effects</strong> of <strong>IV vancomycin</strong>. Since <strong>oral vancomycin is minimally absorbed</strong>, such <strong>vestibular or auditory toxicity</strong> is <strong>not a concern</strong> in this patient.</p>\r\n<p><strong>Nephrotoxicity, ototoxicity, and DRESS syndrome (Option C):</strong></p>\r\n<p>These are <strong>systemic adverse effects</strong> of <strong>intravenous vancomycin</strong>, especially when used in high doses or in combination with other nephrotoxic drugs. <strong>DRESS syndrome</strong>, a severe hypersensitivity reaction, and <strong>nephrotoxicity</strong> do not occur with <strong>oral vancomycin</strong> due to <strong>poor systemic absorption</strong>. Hence, this option is also incorrect.</p>", "options": ["A, B and D", "A, C and D", "A and D", "D"], "html_options": ["A, B and D", "A, C and D", "A and D", "D"], "corr_idx": 3}, {"id": "1332345", "html_qtxt": "A 23-year-old with otitis media treated with amoxicillin. The mechanism of action involves inhibition of", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Amoxicillin</strong>, a penicillin derivative, belongs to the <strong>beta-lactam</strong> class of antibiotics. It acts by <strong>inhibiting bacterial cell wall synthesis</strong>, specifically at the stage of <strong>peptidoglycan cross-linking</strong>, which is essential for bacterial structural integrity.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Beta-lactamases (Option A):</strong></p>\r\n<p>Incorrect. <strong>Beta-lactamases</strong> are bacterial enzymes that degrade beta-lactam antibiotics like amoxicillin. Amoxicillin does <strong>not inhibit beta-lactamases</strong>; instead, it is <strong>susceptible</strong> to degradation by them unless combined with a beta-lactamase inhibitor like clavulanic acid.</p>\r\n<p><strong>Cell membrane synthesis (Option B):</strong></p>\r\n<p>Incorrect. Inhibition of <strong>cell membrane synthesis</strong> is not the mechanism of amoxicillin. This mechanism is associated with antibiotics like <strong>daptomycin</strong> and <strong>polymyxins</strong>, which directly disrupt the bacterial cell membrane integrity.</p>\r\n<p><strong>N-acetylmuramic acid synthesis (Option C):</strong></p>\r\n<p>Incorrect. This step occurs early in the <strong>peptidoglycan biosynthesis pathway</strong> and is inhibited by <strong>fosfomycin</strong>, not amoxicillin. Amoxicillin acts at a later stage by blocking <strong>cross-linking</strong> rather than precursor formation.</p>", "options": ["Beta-lactamases", "Cell membrane synthesis", "N-acetylmuramic acid synthesis", "Peptidoglycan cross-linking"], "html_options": ["Beta-lactamases", "Cell membrane synthesis", "N-acetylmuramic acid synthesis", "Peptidoglycan cross-linking"], "corr_idx": 3}, {"id": "1332347", "html_qtxt": "A 84- year-old man with gram stain of CSF shows gram-positive rods resembling diphtheroids, the antibiotic regimen for empiric treatment would include", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>In elderly or immunocompromised patients, the presence of such organisms strongly suggests <strong>Listeria monocytogenes</strong> as the causative agent. Though it may resemble diphtheroids (Corynebacterium species), <em>Listeria</em> is a known cause of <strong>bacterial meningitis</strong> in <strong>neonates, elderly, pregnant women, and immunocompromised individuals</strong>.</p>\r\n<p>The empiric treatment of bacterial meningitis in the elderly must include coverage for <em>Listeria monocytogenes</em>. <strong>Ampicillin</strong> is the drug of choice for <strong>Listeria</strong>, as it is <strong>one of the few beta-lactam antibiotics effective against this intracellular gram-positive rod</strong>. It is typically combined with other agents (such as ceftriaxone and vancomycin) for broad coverage until culture results are confirmed.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Cefoxitin (Option B):</strong></p>\r\n<p>Incorrect. <strong>Cefoxitin</strong> is a <strong>second-generation cephalosporin</strong> with activity against certain anaerobes and gram-negative bacteria. It does <strong>not provide reliable coverage against <em>Listeria</em></strong> and is <strong>not used in meningitis regimens</strong>.</p>\r\n<p><strong>Ceftriaxone (Option C):</strong></p>\r\n<p>Incorrect. While <strong>ceftriaxone</strong> is an excellent choice for <strong>many common causes of bacterial meningitis</strong> (such as <em>Streptococcus pneumoniae</em> and <em>Neisseria meningitidis</em>), it is <strong>ineffective against <em>Listeria monocytogenes</em></strong>. Therefore, ampicillin must be added when Listeria is suspected.</p>\r\n<p><strong>Fosfomycin (Option D):</strong></p>\r\n<p>Incorrect. <strong>Fosfomycin</strong> is used primarily for <strong>urinary tract infections</strong>. It has <strong>limited CNS penetration</strong> and <strong>no established role in the treatment of meningitis</strong>, especially not in <em>Listeria</em> coverage.</p>", "options": ["Ampicillin", "Cefoxitin", "Ceftriaxone", "Fosfomycin"], "html_options": ["Ampicillin", "Cefoxitin", "Ceftriaxone", "Fosfomycin"], "corr_idx": 0}, {"id": "1332350", "html_qtxt": "A 45-year-old woman with CML is admitted to the hospital with malaise, chills, and high fever. A blood culture reveals the presence of Gram-negative bacilli. The initial diagnosis is bacteremia, and parenteral antibiotics are indicated. The records of the patient reveal that she had a severe urticarial rash, hypotension, and respiratory difficulty after oral penicillin V about 6 months ago. The most appropriate drug regimen for empiric treatment is", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>In patients with a <strong>severe penicillin allergy</strong>, the safest alternative for treating <strong>Gram-negative bacteremia</strong> is <strong>aztreonam</strong>, a <strong>monobactam</strong> antibiotic. Aztreonam has <strong>no cross-reactivity with penicillins or cephalosporins</strong>, making it the preferred choice in such scenarios. It is effective against <strong>aerobic gram-negative organisms</strong>, including <em>Pseudomonas aeruginosa</em>.</p>\r\n<p>The patient presents with <strong>high fever</strong> and <strong>Gram-negative bacilli in blood cultures</strong>, consistent with a diagnosis of <strong>Gram-negative bacteremia</strong>. Immediate <strong>parenteral empiric antibiotic therapy</strong> is warranted to cover potential pathogens, particularly members of the <strong>Enterobacteriaceae</strong> family and <em>Pseudomonas</em> species.</p>\r\n<p>The patient has a <strong>history of a severe immediate hypersensitivity reaction to penicillin</strong> (urticarial rash, hypotension, and respiratory difficulty), which is suggestive of a <strong>type I IgE-mediated anaphylactic reaction</strong>. In such cases, <strong>beta-lactam antibiotics</strong>, including <strong>penicillins, cephalosporins, and carbapenems</strong>, are generally <strong>avoided due to the risk of cross-reactivity</strong>.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Ceftriaxone (Option B):</strong></p>\r\n<p>Incorrect. <strong>Ceftriaxone</strong> is a third-generation cephalosporin with excellent gram-negative coverage, but in a patient with a <strong>severe penicillin allergy</strong>, <strong>cephalosporins should be avoided</strong> due to the <strong>risk of cross-reactivity</strong>.</p>\r\n<p><strong>Meropenem (Option C):</strong></p>\r\n<p>Incorrect. <strong>Meropenem</strong> is a carbapenem with broad-spectrum coverage, including gram-negative bacteria. However, due to <strong>structural similarity to penicillins</strong>, it can still <strong>cross-react in patients with penicillin anaphylaxis</strong>, and thus it is not safe in this setting.</p>\r\n<p><strong>Oxacillin (Option D):</strong></p>\r\n<p>Incorrect. <strong>Oxacillin</strong> is a penicillinase-resistant penicillin used primarily for <strong>methicillin-sensitive <em>Staphylococcus aureus</em>(MSSA)</strong>. It is <strong>not effective</strong> against gram-negative bacilli and is <strong>contraindicated</strong> in a patient with a prior <strong>severe penicillin reaction</strong>.</p>", "options": ["Aztreonam", "Ceftriaxone", "Meropenem", "Oxacillin"], "html_options": ["Aztreonam", "Ceftriaxone", "Meropenem", "Oxacillin"], "corr_idx": 0}, {"id": "1332352", "html_qtxt": "A patient needs antibiotic treatment for native valve, culture- positive infective enterococcal endocarditis. His medical history includes a severe anaphylactic reaction to penicillin G during the last year. The best approach would be treatment with", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The patient has a <strong>history of a severe anaphylactic reaction to penicillin G</strong>, which rules out the use of <strong>penicillins or any beta-lactam antibiotics</strong> due to risk of <strong>IgE-mediated cross-reactivity</strong>. In such cases, the best alternative is <strong>vancomycin</strong>, which is effective against <em>Enterococcus</em> and does not cross-react with penicillins.</p>\r\n<p>Vancomycin is the <strong>preferred treatment</strong> for native valve enterococcal endocarditis in patients with <strong>severe beta-lactam allergies</strong>. It is bactericidal when used in combination with an aminoglycoside (e.g., gentamicin), providing synergistic killing of <em>Enterococcus</em> species.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Amoxicillin-clavulanate (Option A):</strong></p>\r\n<p>Incorrect. Although active against <em>Enterococcus</em>, <strong>amoxicillin is a penicillin derivative</strong>. Given the patient's <strong>severe anaphylactic reaction to penicillin G</strong>, this drug is <strong>contraindicated</strong> due to the high risk of recurrence of life-threatening hypersensitivity.</p>\r\n<p><strong>Aztreonam (Option B):</strong></p>\r\n<p>Incorrect. While <strong>aztreonam</strong> is a safe alternative in penicillin-allergic patients for <strong>gram-negative infections</strong>, it has <strong>no activity against <em>Enterococcus</em></strong>. Hence, it is not suitable for enterococcal endocarditis.</p>\r\n<p><strong>Ceftriaxone (Option C):</strong></p>\r\n<p>Incorrect. Although ceftriaxone can be used in synergy with ampicillin for certain enterococcal infections, in patients with <strong>severe penicillin allergy</strong>, <strong>third-generation cephalosporins like ceftriaxone may still pose a risk of cross-reactivity</strong>, and are generally <strong>avoided</strong>.</p>", "options": ["Amoxicillin-clavulanate", "Aztreonam", "Ceftriaxone", "Vancomycin"], "html_options": ["Amoxicillin-clavulanate", "Aztreonam", "Ceftriaxone", "Vancomycin"], "corr_idx": 3}, {"id": "1332353", "html_qtxt": " A patient is diagnosed with pneumococcal infection. Laboratory testing reveals resistance to penicillin G. Which of the following best describes the mechanism of resistance in this organism?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Pneumococcal resistance to penicillins arises from structural modifications in the target penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. These changes reduce the binding affinity of penicillin, allowing the bacteria to continue synthesizing its cell wall despite the presence of the antibiotic. This mechanism is similar to the altered PBP-mediated resistance seen in MRSA.</p>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<p><strong>Alterations in porin structure (Option A):</strong></p>\r\n<p>This mechanism is primarily seen in gram-negative bacteria, where changes in porin channels reduce antibiotic uptake. It is not the mechanism in pneumococci.</p>\r\n<p><strong>Beta-lactamase production (Option B):</strong></p>\r\n<p>Beta-lactamase enzymes hydrolyze beta-lactam antibiotics, but penicillin resistance in pneumococci is not due to beta-lactamase production.</p>\r\n<p><strong>Changes in the d-Ala-d-Ala building block of peptidoglycan precursor (Option D):</strong></p>\r\n<p>This alteration is the basis of vancomycin resistance, not penicillin resistance.</p>", "options": ["Alterations in porin structure", "Beta-lactamase production", "Changes in chemical structure of target penicillin-binding proteins", "Changes in the d-Ala-d-Ala building block of peptidoglycan precursor"], "html_options": ["Alterations in porin structure", "Beta-lactamase production", "Changes in chemical structure of target penicillin-binding proteins", "Changes in the d-Ala-d-Ala building block of peptidoglycan precursor"], "corr_idx": 2}, {"id": "1332354", "html_qtxt": "Which of the following statements about beta-lactam antibiotics is most correct?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Ceftriaxone and nafcillin are predominantly eliminated via biliary secretion, making them exceptions among beta-lactams, which are mostly renally excreted. This property affects dosing considerations, especially in patients with renal impairment.</p>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<p><strong>Cephalexin and other first-generation cephalosporins cross the blood-brain barrier (Option A):</strong></p>\r\n<p>First- and second-generation cephalosporins do <strong>not</strong> readily enter the cerebrospinal fluid and are therefore ineffective in treating meningitis.</p>\r\n<p><strong>Instability of penicillins in gastric acid does not limit their oral absorption (Option C):</strong></p>\r\n<p>Penicillins such as penicillin G are acid-labile, and this instability <strong>does</strong> limit oral absorption.</p>\r\n<p><strong>Renal tubular reabsorption of amoxicillin is inhibited by probenecid (Option D):</strong></p>\r\n<p>Probenecid actually inhibits <strong>renal tubular secretion</strong> of amoxicillin, not reabsorption, thereby increasing plasma levels of the drug.</p>", "options": ["Cephalexin and other first-generation cephalosporins cross the blood-brain barrier", "Ceftriaxone and nafcillin are both eliminated mainly via biliary secretion", "Instability of penicillins in gastric acid does not limit their oral absorption", "Renal tubular reabsorption of amoxicillin is inhibited by probenecid"], "html_options": ["Cephalexin and other first-generation cephalosporins cross the blood-brain barrier", "Ceftriaxone and nafcillin are both eliminated mainly via biliary secretion", "Instability of penicillins in gastric acid does not limit their oral absorption", "Renal tubular reabsorption of amoxicillin is inhibited by probenecid"], "corr_idx": 1}, {"id": "1332356", "html_qtxt": "A 27-year-old woman presents with fever, vomiting, and painful urination. Physical examination shows pronounced costovertebral angle tenderness. Laboratory studies show 12,000 neutrophils/mL. Blood cultures are positive. Urinalysis shows:", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Acute pyelonephritis is an infectious disease involving the kidney parenchyma and the renal pelvis.This patient is presenting with the classical triad of pyelonephritis symptoms: fever, costovertebral angle pain, and nausea and/or vomiting. Also, symptoms of cystitis, which may or may not be present to varying degrees, include urinary frequency, hesitancy, lower abdominal pain, and urgency.</li>\r\n<li>Gram-negative bacteria, such as Escherichia coli, Proteus, Klebsiella, and Enterobacter, are the most common causative organisms in acute pyelonephritis. Laboratory evaluation will often reveal leukocytosis with a left shift, and urinalysis typically shows pyuria, varying degrees of hematuria, and white cell casts.</li>\r\n<li>Since bacteremia is present, this patient should be hospitalized and empirically started on ciprofloxacin, levofloxacin, or ceftriaxone. Extended-spectrum penicillins or carbapenems may also be used. This regimen may need to be changed, however, once the sensitivity results are available.</li>\r\n<li>Azithromycin (A) and doxycycline (C) are both bacteriostatic antibiotics and would not be recommended in a patient with a severe infection, such as acute pyelonephritis with bacteremia. Both of these drugs are however commonly used in the treatment of STIs such as Chlamydia trachomatis and Neisseria gonorrhoeae.</li>\r\n<li>Vancomycin (D) is primarily used in the treatment of severe gram-positive infections, such as Clostridium difficile and Staphylococcal enterocolitis. Although gentamicin (choice D) is used for the treatment of gram negative-infections, it would not be combined with vancomycin to treat actue gram-negative pyelonephritis.</li>\r\n</ul>", "options": ["Leukocyte esterase positive", "Nitrite positive", "Dipstick for blood positive", "Culture positive for 10000 CFUs/mL"], "html_options": ["Leukocyte esterase positive", "Nitrite positive", "Dipstick for blood positive", "Culture positive for 10000 CFUs/mL"], "corr_idx": 1}, {"id": "1332358", "html_qtxt": "A 32-year-old woman complaints of burning upon urination. Urinalysis shows 1+ WBC/hpf, 1+ RBC/hpf, and abundant bacteria, with mostly gram-negative rods. Treatment is begun with a drug that is associated with the development of tendon rupture. This drug most likely interferes with which of the following processes?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Urinary tract infections in adults are primarily associated with dysuria with accompanying urinary urgency and frequency. There may be a sensation of bladder fullness or lower abdominal discomfort. Treatment includes the use of fluoroquinolones, trimethoprim-sulfamethoxazole (TMP-SMX), nitrofurantoin, or cephalosporins. Some patients may also require a urinary analgesic such as oral phenazopyridine, which is useful to relieve discomfort due to severe dysuria.</li>\r\n<li>In this question, you must determine which UTI treatment option is associated with the development of tendon rupture. Commonly used bactericidal fluoroquinolones include ciprofloxacin, norfloxacin, and ofloxacin, among others. These antibiotics act by inhibiting DNA gyrase. Topoisomerases such as DNA gyrase (DNA topoisomerase Il) can insert negative supercoils to relieve the positive supercoiling that occurs as the replication fork proceeds down the length of the chromosome. The fluoroquinolones are associated with the development of tendon rupture and arthropathy in younger children under the age of 18 years as well as phototoxicity, CNS stimulation, and a variety of Gl side effects. The fluoroquinolones are classified as pregnancy category C agents.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Folate synthesis (Option A):</strong> Drugs like sulfonamides and trimethoprim inhibit bacterial folate synthesis by targeting dihydropteroate synthase or dihydrofolate reductase, respectively. These are used in urinary tract infections, but they are not associated with tendon rupture.</p>\r\n<p><strong>Formation of aminoacyl-RNA (Option B):</strong> This step in protein synthesis is inhibited by drugs such as tetracyclines, which block the binding of aminoacyl-tRNA to the ribosomal A-site. Tetracyclines are not linked to tendon rupture.</p>\r\n<p><strong>Formation of initiation complex (Option C):</strong> Aminoglycosides interfere with the initiation complex of protein synthesis, leading to misreading of mRNA. Their adverse effects include nephrotoxicity and ototoxicity, but not tendon rupture.</p>", "options": ["Folate synthesis", "Formation of aminoacyl-RNA", "Formation of initiation complex", "Insertion of negative supercoils in DNA"], "html_options": ["Folate synthesis", "Formation of aminoacyl-RNA", "Formation of initiation complex", "Insertion of negative supercoils in DNA"], "corr_idx": 3}, {"id": "1332361", "html_qtxt": "A 60-year-old man with recurrent urinary tract infections is prescribed an antibiotic. Two weeks later, he presents with complaints of fatigue and mild pallor. Blood tests reveal macrocytic anemia. His serum folate level is low, and supplementation with folinic acid is advised.<br>The prescribed drug is known to be a weak base, achieves tissue concentrations similar to plasma, and can contribute to folate deficiency.<br>Which of the following is the most likely antibiotic responsible for this patient's anemia? Supplementary folinic acid may prevent anemia in folate-deficient persons who use this drug; it is a weak base achieving tissue levels similar to those in plasma.", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Trimethoprim is the only weak base listed (fluoroquinolones and sulfonamides are acidic compounds), and its high lipid solubility at blood pH allows penetration of the drug into prostatic and vaginal fluid to reach levels similar to those in plasma. Leukopenia and thrombocytopenia may occur in folate deficiency when the drug is used alone or in combination with sulfamethoxazole. Fluoroquinolones and linezolid do not exacerbate symptoms of folic acid deficiency.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Ciprofloxacin (Option A):</strong></p>\r\n<p>Ciprofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. Its characteristic adverse effects include gastrointestinal upset, CNS effects, QT prolongation (less commonly), and tendonitis/tendon rupture. It is <strong>not</strong> associated with depletion of folate or producing a true megaloblastic (folate-deficiency) macrocytic anemia; therefore this option is incorrect.</p>\r\n<p><strong>Levofloxacin (Option B):</strong></p>\r\n<p>Levofloxacin is another fluoroquinolone with a mechanism and adverse-effect profile similar to ciprofloxacin (DNA gyrase/topoisomerase IV inhibition, risk of tendon injury). Like ciprofloxacin, it does <strong>not</strong> cause folate deficiency leading to macrocytic anemia. Thus this option is incorrect.</p>\r\n<p><strong>Linezolid (Option C):</strong></p>\r\n<p>Linezolid (an oxazolidinone) inhibits formation of the 70S initiation complex and can cause bone marrow suppression with prolonged use-most commonly thrombocytopenia, and less frequently anemia or neutropenia. When anemia occurs from linezolid it is due to marrow suppression/mitochondrial toxicity rather than folate deficiency; folinic acid supplementation is not the standard remedy. Therefore, while linezolid can cause cytopenias, it does <strong>not</strong> fit the described low serum folate picture and is incorrect here.</p>", "options": ["Ciprofloxacin", "Levofloxacin", "Linezolid", "Trimethoprim"], "html_options": ["Ciprofloxacin", "Levofloxacin", "Linezolid", "Trimethoprim"], "corr_idx": 3}, {"id": "1332364", "html_qtxt": "A 61-year-old woman is suffering from traveler's diarrhea, and her problem has not responded to antidiarrheal drugs. A pathogenic Gram-negative bacillus is suspected. Which drug is most likely to be effective in the treatment of this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>The second-generation fluoroquinolones are very effective in diarrhea caused by bacterial Gram-negative pathogens, including E coli, Shigella, and Salmonella. None of the other drugs listed would be appropriate.</li>\r\n<li>Many coliforms are now resistant to amoxicillin and ampicillin. Although trimethoprim is available as a single drug, resistance emerges rapidly during treatment unless it is used for urinary tract infections, in which high concentrations can be achieved. Vancomycin has no activity against Gram-negative bacilli.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Sulfadiazine (Option B):</strong></p>\r\n<p>Sulfadiazine is a sulfonamide that inhibits dihydropteroate synthase in folate synthesis. It is not typically used as monotherapy for bacterial gastroenteritis, and resistance is common. It is more often combined with pyrimethamine in toxoplasmosis. Hence, not effective for traveler's diarrhea.</p>\r\n<p><strong>Trimethoprim (Option C):</strong></p>\r\n<p>Trimethoprim inhibits dihydrofolate reductase. While it has some urinary tract infection applications, it is not used as a single agent for traveler's diarrhea. It is generally combined with sulfamethoxazole (TMP-SMX), which has some activity against enteric pathogens, but it is not the first-line therapy here.</p>\r\n<p><strong>Vancomycin (Option D):</strong></p>\r\n<p>Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala residues. It is active mainly against <strong>Gram-positive organisms</strong> and is ineffective against Gram-negative bacilli due to poor penetration of the outer membrane. Oral vancomycin is used for <em>Clostridioides difficile</em> colitis, not for traveler's diarrhea due to enterotoxigenic <em>E. coli</em> or other Gram-negative enteric pathogens.</p>", "options": ["Ofloxacin", "Sulfadiazine", "Trimethoprim", "Vancomycin"], "html_options": ["Ofloxacin", "Sulfadiazine", "Trimethoprim", "Vancomycin"], "corr_idx": 0}, {"id": "1332367", "html_qtxt": "A 32-year-old man complains of periodic bouts of diarrhea with lower abdominal cramping and intermittent rectal bleeding. Seen in the clinic, he appears well nourished, with blood pressure in the normal range. Examination reveals moderate abdominal pain and tenderness. His current medications are limited to loperamide for his diarrhea. Sigmoidoscopy reveals mucosal edema, friability, and some pus. Laboratory findings include mild anemia and decreased serum albumin. Microbiologic examination via stool cultures and mucosal biopsies do not reveal any evidence for bacterial, amebic, or cytomegalovirus involvement. The most appropriate drug to use in this patient is", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>In the absence of any evidence pointing toward a definite microbial cause for the colitis in this patient, a drug that decreases inflammation is indicated. Sulfasalazine has significant anti-inflammatory action, and its oral use results in symptomatic improvement in 50-75% of patients suffering from ulcerative colitis. The drug is also used for its anti-inflammatory effects in rheumatoid arthritis.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Ampicillin (Option A):</strong> Ampicillin is a &beta;-lactam antibiotic effective against <em>Enterococcus</em>, <em>Listeria</em>, and some Gram-negative bacilli. It is used in infections such as meningitis, respiratory tract infections, and UTIs. It has no role in the management of inflammatory bowel disease (IBD), as this is not an infectious etiology.</p>\r\n<p><strong>Doxycycline (Option B):</strong> Doxycycline is a tetracycline antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit. It is commonly used in atypical pneumonia, rickettsial infections, chlamydial infections, and some parasitic diseases. It has no therapeutic effect in chronic inflammatory bowel conditions like ulcerative colitis.</p>\r\n<p><strong>Norfloxacin (Option C):</strong> Norfloxacin is a fluoroquinolone with activity against Gram-negative bacilli, often used for urinary tract infections or bacterial gastroenteritis. Since stool cultures and biopsies excluded bacterial or infectious causes, norfloxacin is not appropriate here.</p>", "options": ["Ampicillin", "Doxycycline", "Norfloxacin", "Sulfasalazine"], "html_options": ["Ampicillin", "Doxycycline", "Norfloxacin", "Sulfasalazine"], "corr_idx": 3}, {"id": "1332369", "html_qtxt": "A 28-year-old woman, G1P0 reports that she is allergic to penicillin. Rapid plasma reagin (RPR) test is 1:128 and fluorescent treponemal antibody absorption test (FTA-ABS) is positive. Which of the following is the most appropriate next step in management ?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>There are no proven alternatives to penicillin for the safe and effective treatment of syphilis in pregnant women. Therefore, desensitisation to penicillin should be performed in all patients with penicillin allergies who are diagnosed with syphilis during pregnancy.</li>\r\n<li>The process of desensitisation can be safely performed during pregnancy and does not adversely affect the pregnancy outcome. In conditions for which there are no acceptable alternate drugs (like syphilis in pregnancy), desensitization allows the drug of choice to be used and the complications associated with untreated infection to be avoided (in this case, transplacental infection of the fetus).</li>\r\n<li>An allergy evaluation should be conducted in patients with any history suggesting an allergy. It should include an epicutaneous (prick) test and, if the epicutaneous test is negative, an intradermal test. However, in patients with conditions that can only be treated with penicillin, a possible history of an allergic reaction qualifies the patient for desensitization even if allergy evaluation is not possible or if it delays the required treatment. Desensitization should be initiated (regardless of the allergen test report) because allergen tests are known to have poor sensitivity, and the risk of anaphylaxis is too great to rely on a single allergen test report.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>IV Ceftriaxone (Option A):</strong> Although ceftriaxone has activity against <em>Treponema pallidum</em> and is sometimes used in nonpregnant patients with syphilis who cannot take penicillin, <strong>penicillin remains the only proven therapy during pregnancy</strong> to prevent maternal transmission to the fetus. Ceftriaxone is not the recommended substitute in pregnancy.</p>\r\n<p><strong>Reassurance (Option B):</strong> Syphilis in pregnancy cannot be left untreated. Congenital syphilis can cause severe fetal morbidity and mortality. Simply reassuring the patient without treatment would be inappropriate and unsafe.</p>\r\n<p><strong>Penicillin challenge test (Option D):</strong> A penicillin challenge test is performed to confirm the presence or absence of a true allergy in uncertain cases. However, in this patient, syphilis is confirmed and treatment is urgent. Confirmatory testing of allergy is not appropriate here; desensitization is required so that penicillin can be safely given.</p>", "options": ["IV Ceftriaxone", "Reassurance", "Penicillin desensitization test", "Penicillin challenge test"], "html_options": ["IV Ceftriaxone", "Reassurance", "Penicillin desensitization test", "Penicillin challenge test"], "corr_idx": 2}, {"id": "1332372", "html_qtxt": "A 34-year-old man with painless lesion on his penis presents with diffuse maculopapular rash involving the trunk, extremities, palms, and soles. RPR and FTA-ABS are positive. Next step in the management ?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Secondary syphilis (painless chancre followed by maculopapular rash involving palms and soles, positive serology) is best treated with a <strong>single intramuscular dose of benzathine penicillin G (2.4 million units)</strong>. This provides complete eradication of <em>Treponema pallidum</em> and prevents progression to latent or tertiary syphilis.</p>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Doxycycline (Option A):</strong> Doxycycline is an alternative regimen for syphilis in nonpregnant patients who are allergic to penicillin. However, penicillin remains the drug of choice in all stages of syphilis, especially in patients without allergy. Since this patient has no mention of penicillin allergy, doxycycline is not the first-line option.</p>\r\n<p><strong>IV Penicillin G weekly for 3 weeks (Option C):</strong> This regimen corresponds to <strong>late latent syphilis or tertiary syphilis (non-neurosyphilis)</strong>. The patient here shows signs of <strong>secondary syphilis</strong> (rash on palms and soles, systemic spread). Thus, a single IM dose is sufficient, not prolonged therapy.</p>\r\n<p><strong>Desensitization (Option D):</strong> Penicillin desensitization is required in patients with syphilis <strong>who are allergic to penicillin</strong>(especially pregnant women). Since no allergy is reported in this patient, desensitization is not needed.</p>", "options": ["Doxycycline", "IM Penicillin G single dose", "IV Penicillin G weekly for 3 week", "Desensitization"], "html_options": ["Doxycycline", "IM Penicillin G single dose", "IV Penicillin G weekly for 3 week", "Desensitization"], "corr_idx": 1}, {"id": "1332374", "html_qtxt": "A 33-year-old woman receives a dose of intramuscular benzathine penicillin G. Two hours later, he reports of headache, myalgias, and chills. His temperature is 101.8 F, pulse is 110/min, respirations are 24/min, and blood pressure is 100/70 mm Hg. Which of the following is the most appropriate pharmacotherapy?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>NSAIDs, like ibuprofen, are recommended for the treatment of Jarisch-Herxheimer reaction, which is a common complication of treatment of spirochetal infections such as borreliosis, leptospirosis, and syphilis. After the patient receives antibiotic treatment (usually in the early phases of the secondary stage of syphilis), the release of bacterial endotoxins and pyrogens can elicit the systemic reaction seen in this patient.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Epinephrine (Option A):</strong> Epinephrine is the treatment of choice for anaphylaxis. Anaphylaxis typically presents with urticaria, angioedema, bronchospasm, wheezing, or hypotension soon after drug administration. In this case, symptoms (fever, myalgias, chills) are consistent with <strong>Jarisch-Herxheimer reaction</strong>, not anaphylaxis.</p>\r\n<p><strong>Prednisolone (Option C):</strong> Corticosteroids are sometimes used for severe inflammatory reactions but are <strong>not indicated</strong>for the Jarisch-Herxheimer reaction, which is transient, self-limited, and managed with simple antipyretics.</p>\r\n<p><strong>Ceftriaxone (Option D):</strong> Ceftriaxone is an antibiotic alternative for syphilis in some nonpregnant patients allergic to penicillin. Changing antibiotics does not address this acute reaction since the Jarisch-Herxheimer reaction occurs due to lysis of spirochetes, not from the drug itself.</p>", "options": ["Epinephrine", "Ibuprofen", "Prednisolone", "Ceftriaxone"], "html_options": ["Epinephrine", "Ibuprofen", "Prednisolone", "Ceftriaxone"], "corr_idx": 1}, {"id": "1332377", "html_qtxt": "A 9-year-old girl with sensorineural deafness shows bowing of her anterior tibias, frontal bossing, and a flattened nose. With which of the following drugs should this patient's mother have been treated to prevent this condition in this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>The girl's findings (sensorineural deafness, frontal bossing, saddle nose deformity, and saber shins from tibial bowing) are classic stigmata of <strong>congenital syphilis</strong>. The only drug that prevents transmission of syphilis from mother to fetus is <strong>Penicillin G</strong>, which remains the treatment of choice for all pregnant women with syphilis, regardless of stage. Maternal treatment with penicillin would have prevented these congenital manifestations.</p>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Acyclovir (Option A):</strong> This is an antiviral agent used in HSV and VZV infections. It does not treat <em>Treponema pallidum infection</em> and has no role in preventing congenital syphilis.</p>\r\n<p><strong>Ciprofloxacin (Option B):</strong> A fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, effective against Gram-negative infections. It has no activity against <em>Treponema pallidum</em> and thus cannot prevent congenital syphilis.</p>\r\n<p><strong>Sulfadiazine (Option D):</strong> A sulfonamide that blocks dihydropteroate synthase in folate synthesis. It is mainly used (with pyrimethamine) for toxoplasmosis. It does not treat syphilis and is not effective for congenital prevention.</p>", "options": ["Acyclovir", "Ciprofloxacin", "Penicillin", "Sulfadiazine"], "html_options": ["Acyclovir", "Ciprofloxacin", "Penicillin", "Sulfadiazine"], "corr_idx": 2}, {"id": "1332379", "html_qtxt": "A 27-year-old woman comes with vomiting, urinary frequency, urgency, and burning on urination. Her temperature is 39.2&deg;C and physical examination shows costovertebral angle pain. Her past history is significant for mild GERD for which she takes antacids several times per week. Treatment is begun. She returns 3 days later because of worsening urinary symptoms. Which of the following medications was the patient most likely prescribed?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>The bacterial spectrum of uncomplicated cystitis and pyelonephritis in women primarily consists mainly of E coli (75 to 95 %). Enterobacteriaceae, such as Proteus mirabilis and Klebsiella pneumonia, as well as the gram-positive Staphylococcus saprophyticus may also be found in a much smaller percentage of cases. This patient is presenting with the classical triad of pyelonephritis symptoms: fever, costovertebral angle pain, and nausea and/or vomiting.</li>\r\n<li>Symptoms of cystitis may or may not be present to varying degrees and include urinary frequency, hesitancy, lower abdominal pain, and urgency.</li>\r\n<li>Since the bacteria in most cases of community-acquired infections is usually E. coli or other Enterobacteriaceae, acceptable treatment regimens include fluoroquinolones (i.e., ciprofloxacin), cephalosporins, penicillins, extended-spectrum penicillins, carbapenems, and aminoglycosides. In this case, the physician likely prescribed the fluoroquinolone ciprofloxacin without paying attention to the drug interaction between this drug and antacids, which the patient is taking on a regular basis.</li>\r\n<li>Fluoroquinolones, such as ciprofloxacin, will have a dramatic decrease in bioavailability when taken with antacids, secondary to the binding of the two medications in the intestinal tract. Thus, when taken with antacids, the fluoroquinolones will become ineffective and the patient's symptoms will continue to worsen. The concomitant use of antacids and fluoroquinolones is contraindicated, unless they are taken 2 hr before or 1hr after taking the drug.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Ampicillin (Option A):</strong> Ampicillin is a &beta;-lactam antibiotic effective against some Gram-positive and Gram-negative bacteria, including <em>Enterococcus</em> and <em>Listeria</em>. However, increasing resistance among <em>E. coli</em> strains limits its utility in acute pyelonephritis. This patient's symptoms worsened despite treatment, making ampicillin less likely.</p>\r\n<p><strong>Cephalexin (Option B):</strong> Cephalexin is a first-generation cephalosporin with good activity against some Gram-positive cocci and limited Gram-negative coverage. While it can be used for uncomplicated UTIs, it is <strong>less effective against pyelonephritis</strong>, and failure rates are higher, particularly for resistant <em>E. coli</em>.</p>\r\n<p><strong>Loracarbef (Option D):</strong> Loracarbef is a second-generation carbacephem with activity against Gram-positive and some Gram-negative bacteria. It is <strong>not commonly used for complicated UTIs or pyelonephritis</strong>, and it would not be the first choice for severe febrile UTIs.</p>", "options": ["Ampicillin", "Cephalexin", "Ciprofloxacin", "Loracarbef"], "html_options": ["Ampicillin", "Cephalexin", "Ciprofloxacin", "Loracarbef"], "corr_idx": 2}, {"id": "1332383", "html_qtxt": "A 27-year-old woman presents with fever, vomiting, and painful urination. Physical examination shows pronounced costovertebral angle tenderness. Laboratory studies show 12,000 neutrophils/mL. Blood cultures are positive. Urinalysis shows:<br>A. Leukocyte esterase positive<br>B. Nitrite positive<br>C. Dipstick for blood positive<br>D. Culture positive for 10000 CFUs/mL<br><br>Which of the following is the most appropriate pharmacotherapy for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Acute pyelonephritisis an infectious disease involving the kidney parenchyma and the renal pelvis. This patient is presenting with the classical triad of pyelonephritis symptoms: fever, costovertebral angle pain, and nausea and/or vomiting. Also, symptoms of cystitis, which may or may not be present to varying degrees, include urinary frequency, hesitancy, lower abdominal pain, and urgency.</li>\r\n<li>Gram-negative bacteria, such as Escherichia coli, Proteus, Klebsiella, and Enterobacter, are the most common causative organisms in acute pyelonephritis. Laboratory evaluation will often reveal leukocytosis with a left shift, and urinalysis typically shows pyuria, varying degrees of hematuria, and white cell casts. Since bacteremia is present, this patient should be hospitalized and empirically started on ciprofloxacin, levofloxacin, or ceftriaxone. Extended-spectrum penicillins or carbapenems may also be used. This regimen may need to be changed, however, once the sensitivity results are available.</li>\r\n<li>Azithromycin (A) and doxycycline ( C) are both bacteriostatic antibiotics and would not be recommended in a patient with a severe infection, such as acute pyelonephritis with bacteremia. Both of these drugs are however commonly used in the treatment of STIs such as Chlamydia trachomatis and Neisseria gonorrhoeae.</li>\r\n<li>Vancomycin (D) is primarily used in the treatment of severe gram-positive infections, such as Clostridium difficile and Staphylococcal enterocolitis. Although gentamicin (choice D) is used for the treatment of gram negative-infections, it would not be combined with vancomycin to treat actue gram-negative pyelonephritis.</li>\r\n</ul>", "options": ["Azithromycin", "Ciprofloxacin", "Doxycycline", "Gentamicin and vancomycin"], "html_options": ["Azithromycin", "Ciprofloxacin", "Doxycycline", "Gentamicin and vancomycin"], "corr_idx": 1}, {"id": "1332385", "html_qtxt": "A 14-day-old infant is brought because of decreased alertness and poor feeding. Laboratory studies show an unconjugated bilirubin level of 33 mg/dL. Which of the following drugs taken by the mother during the third trimester is most likely responsible for this patient's condition?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Jaundice is a common condition seen in newborns that requires medical attention. As a result of an accumulation of unconjugated bilirubin, there may be a yellow coloration of the skin and sclera in newborns with jaundice. Neonatal jaundice can result from increased breakdown of fetal erythrocytes coupled with low hepatic excretory capacity.</li>\r\n<li>Thus high levels of unconjugated bilirubin (a breakdown product of hemoglobin) causes can cause jaundice and even kernicterus, which is a complication of neonatal jaundice. Kernicterus is the chronic and permanent neuroloqic sequelae of bilirubin-induced neurologic dysfunction (BIND). Brain regions most commonly affected include the basal ganglia and brainstem nuclei involved in oculomotor and auditory function.</li>\r\n<li>Acute hyperbilirubinemia can lead to decreased alertness, hypotonia and poor feeding. Kernicterus is associated with opisthotonos, a high-pitched cry, an abnormal Moro reflex, and abnormal eye movements. Although kernicterus can occur pathologically, this condition may also occur if the mother takes sulfonamide antibiotics, such as trimethoprim- sulfamethoxazole or sulfisoxazole during the 2nd or 3rd trimester of pregnancy. Sulfonamides can displace bilirubin from itsalbumin-binding site, thereby increasing the serum concentration of free bilirubin available to cross the blood-brain barrier.</li>\r\n<li>Trimethoprim-sulfamethoxazole is not recommended for use in infants less than 2 months old. When hyperbilirubinemia occurs in an infant, the treatment of choice is to remove the bilirubin from the blood by phototherapy or exchange transfusion.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Acetaminophen (Option A):</strong> Acetaminophen is considered safe in pregnancy and does not interfere with bilirubin metabolism in neonates. It is <strong>not associated</strong> with hyperbilirubinemia.</p>\r\n<p><strong>Chloramphenicol (Option B):</strong> Chloramphenicol can cause \"gray baby syndrome\" due to immature UDP-glucuronyl transferase in neonates, leading to toxicity. However, this typically presents <strong>immediately after birth</strong>, not at 14 days, and is associated with hypotension, vomiting, and cyanosis rather than isolated unconjugated hyperbilirubinemia.</p>\r\n<p><strong>Diethylstilbestrol (Option C):</strong> DES is a synthetic estrogen previously used during pregnancy. Its known complications are <strong>clear cell adenocarcinoma of the vagina/cervix</strong> and reproductive tract abnormalities, not neonatal jaundice.</p>", "options": ["Acetaminophen", "Chloramphenicol", "Diethylstilbestrol", "Trimethoprim-sulfamethoxazole"], "html_options": ["Acetaminophen", "Chloramphenicol", "Diethylstilbestrol", "Trimethoprim-sulfamethoxazole"], "corr_idx": 3}, {"id": "1332387", "html_qtxt": "A 26-year-old woman comes with irregular vaginal bleeding and lower abdominal pain over the past 4 days. Physical examination shows a friable cervix, and cervical and adnexal tenderness. You prescribe doxycycline and a second medication. Which of the following best describes the mechanism of action of the most appropriate second drug used to treat this infection?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient has signs of pelvic inflammatory disease, and since distinguishing diagnostic clues are not provided here, the answer should pertain to the most common causes, which include Chlamydia and gonococcal infection.</li>\r\n<li>Infections of the cervix may present as an erythematous, edematous, and friable cervix, but most often are without obvious signs or symptoms. Early signs and symptoms of a chlamydial infection in women tend to be mild and include pain during urination, frequent urination, and low-grade fever.</li>\r\n<li>Later symptoms can be more intense and include nausea, fatigue, and abnormal discharge from the vagina. Other symptoms include abdominal pain, lower back pain, irregular menstrual bleeding or spotting, and pain during sex.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Binding at the D-ala-D-ala muramyl pentapeptide to prevent transglycosylation reactions (Option A):</strong> This describes <strong>vancomycin</strong>, which inhibits peptidoglycan synthesis by preventing elongation of the cell wall glycan chains. While effective against Gram-positive bacteria, it is <strong>not routinely used for pelvic inflammatory disease (PID)</strong>, which often involves <em>Neisseria gonorrhoeae</em> and <em>Chlamydia trachomatis</em>.</p>\r\n<p><strong>Binds to microtubules and causes mitotic arrest in metaphase (Option B):</strong> This describes <strong>colchicine</strong> or some chemotherapeutic agents (e.g., vinca alkaloids). These drugs are <strong>not antimicrobial</strong> and have no role in treating PID.</p>\r\n<p><strong>Inhibits DNA synthesis in virally infected cells (Option C):</strong> This describes antiviral drugs such as acyclovir. Antivirals are <strong>not relevant</strong> for bacterial PID.</p>", "options": ["Binding at the D-ala-D-ala muramyl pentapeptide to prevent transglycosylation reactions", "Binds to microtubules and causes mitotic arrest in metaphase", "Inhibits DNA synthesis in virally infected cells", "Inhibits peptidoglycan synthesis through the blockade of transpeptidation enzymes"], "html_options": ["Binding at the D-ala-D-ala muramyl pentapeptide to prevent transglycosylation reactions", "Binds to microtubules and causes mitotic arrest in metaphase", "Inhibits DNA synthesis in virally infected cells", "Inhibits peptidoglycan synthesis through the blockade of transpeptidation enzymes"], "corr_idx": 3}, {"id": "1332388", "html_qtxt": "A 56-year-old woman presents with productive cough, fever and dyspnea since 2 days. Pulmonary examination shows diffuse crackles. CXR shows a left upper-lobe infiltrate of the lung. Endotracheal aspirate Gram stain shows gram-negative rods that are oxidase-positive. Which of the following is the most appropriate treatment ?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Fever, productive cough, crackles, and an infiltrate on chest x-ray are consistent with community-acquired pneumonia (CAP). Gram negative rods and oxidase-positive rods suggest Pseudomonas aeruginosa is the most likely causative organism</li>\r\n<li>Cefepime and levofloxacin are the first-line treatment for patients with CAP when there is a strong suspicion of P. aeruginosa infection. Other treatment options for CAP with P. aeruginosa include piperacillin/tazobactam, meropenem, or imipenem plus a fluoroquinolone. An aminoglycoside may be added as well.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Amoxiclav (Option B):</strong> Amoxicillin-clavulanate is effective against many Gram-positive and some Gram-negative bacteria but has <strong>limited activity against Pseudomonas and other oxidase-positive Gram-negative rods</strong> commonly causing nosocomial or severe community-acquired pneumonia. It would not be the first choice in this scenario.</p>\r\n<p><strong>Azithromycin (Option C):</strong> Azithromycin is a macrolide effective against atypical bacteria (e.g., <em>Mycoplasma</em>, <em>Chlamydophila</em>) and some Gram-positive cocci. It has <strong>poor coverage against many Gram-negative rods</strong>, particularly oxidase-positive organisms like <em>Pseudomonas aeruginosa</em>.</p>\r\n<p><strong>Ceftriaxone (Option D):</strong> Ceftriaxone is a third-generation cephalosporin with good Gram-negative coverage but <strong>limited activity against Pseudomonas</strong> and other oxidase-positive non-fermenting rods. It is often used for typical community-acquired pneumonia but is less appropriate for severe cases caused by oxidase-positive Gram-negative rods.</p>", "options": ["Levofloxacin", "Amoxiclav", "Azithromycin", "Ceftriaxone"], "html_options": ["Levofloxacin", "Amoxiclav", "Azithromycin", "Ceftriaxone"], "corr_idx": 0}, {"id": "1332391", "html_qtxt": "A 57-year-old man with a history of alcoholism is admitted to the intensive care unit after being involved in a motor vehicle collision. One day later, he develops a fever and a cough productive of purulent sputum. His temperature is 100.6 F, pulse is 98/min, respirations are 22/min, and blood pressure is 128/80 mm Hg. Within hours, the patient's respiratory status declines, with increased work of breathing and cyanosis, necessitating intubation. A Gram stain of sputum shows gram-negative encapsulated rods. A chest X-ray shows right upper lobe consolidation. Which of the following drugs is most appropriate for treatment of this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Cefotaxime is a third-generation cephalosporin with excellent activity against <strong>Gram-negative encapsulated bacteria</strong>, including <em>Klebsiella pneumoniae</em>. Alcoholism is a major risk factor for <em>Klebsiella</em> pneumonia, which often presents with right upper lobe consolidation and rapid respiratory deterioration. Cefotaxime is the <strong>drug of choice</strong> in such community-acquired cases.</p>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Erythromycin (Option B):</strong> Erythromycin is a macrolide effective against atypical pathogens (<em>Mycoplasma</em>, <em>Chlamydophila</em>, <em>Legionella</em>) and some Gram-positive bacteria. It has <strong>poor activity against Gram-negative encapsulated bacilli</strong>, such as <em>Klebsiella pneumoniae</em>, which is the most likely pathogen in an alcoholic patient with right upper lobe pneumonia.</p>\r\n<p><strong>Gentamicin + vancomycin (Option C):</strong> Gentamicin is an aminoglycoside active against many Gram-negative bacteria, and vancomycin covers Gram-positive organisms including MRSA. This combination is <strong>not standard monotherapy for community-acquired pneumonia</strong> caused by encapsulated Gram-negative bacilli.</p>\r\n<p><strong>Ticarcillin-clavulanic acid + vancomycin (Option D):</strong> This combination is often used empirically for <strong>nosocomial pneumonia or hospital-acquired infections</strong> including Pseudomonas and MRSA coverage. In this patient, with community-acquired pneumonia, this regimen is broader than necessary and not first-line.</p>", "options": ["Cefotaxime", "Erythromycin", "Gentamicin + vancomycin", "Ticarcillin-clavulanic acid + vancomycin"], "html_options": ["Cefotaxime", "Erythromycin", "Gentamicin + vancomycin", "Ticarcillin-clavulanic acid + vancomycin"], "corr_idx": 0}, {"id": "1332394", "html_qtxt": "A 46-year-old man comes with fever, perianal pain, and dysuria. Rectal examination shows a boggy, tender prostate. Gram stain of the urine shows gram-negative rods. He is given an oral antibiotic and returns three weeks later complaining of fatigue and shortness of breath. A complete blood count shows a hemoglobin of 12 g/dL and a blood smear stained with methylene blue shows small blue granules located near the periphery of some of the erythrocytes. With which of the following antibiotics was the patient most likely treated?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient has acute prostatitis, which is characterized by fever, chills, and dysuria, with a swollen, extremely tender prostate on rectal exam (this helps distinguish prostatitis from a simple urinary tract infection, which typically presents with dysuria, urinary frequency, and urinary urgency).</li>\r\n<li>The urine Gram stain and culture will generally be positive. The most common pathogens in older men are gram-negatives such as Escherichia coli, Enterobacter, Serratia, Pseudomonas, Enterococcus, and Proteus species. Urinary tract symptoms in young sexually active males may be caused by Neisseria gonorrhoeae or Chlamydia trachomatis.</li>\r\n<li>The treatment regimen for this bacterial infection is typically a 21-day course of ampicillin, a fluoroquinolone (ciprofloxacin, levofloxacin), or trimethoprim/sulfamethoxazole (TMP-SMX).</li>\r\n<li>However, this patient also has symptoms and signs of G6PD deficiency, which is an X-linked recessive disorder. The blood smear describes Heinz bodies in the red cells, which are small aggregates of denatured hemoglobin that can appear in G6PD deficiency-related anemia.</li>\r\n<li>The medications that commonly induce hemolytic anemia in G6PD deficient patients are sulfonamides (TMP-SMX), nitrofurantoin, dapsone, primaquine, and quinine. Fava beans can also have the same effect.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Option:</strong></p>\r\n<p><strong>Ampicillin (Option A):</strong> Ampicillin is a &beta;-lactam antibiotic that inhibits cell wall synthesis. It is used for urinary tract infections and some Gram-negative infections, but it is <strong>not associated with hemolytic anemia or Heinz body formation</strong>, so it does not explain the patient's post-treatment blood findings.</p>\r\n<p><strong>Gentamicin (Option B):</strong> Gentamicin is an aminoglycoside that inhibits bacterial protein synthesis. It can cause nephrotoxicity and ototoxicity but is <strong>not known to cause oxidative hemolysis or formation of Heinz bodies</strong>, so it is an unlikely cause of the methylene blue-staining granules.</p>\r\n<p><strong>Tetracycline (Option C):</strong> Tetracycline inhibits bacterial protein synthesis at the 30S ribosomal subunit. While it has a broad spectrum, it is <strong>not typically associated with oxidative hemolysis or Heinz body anemia</strong>, so this option is incorrect.</p>", "options": ["Ampicillin", "Gentamicin", "Tetracycline", "Trimethoprim/sulfamethoxazole"], "html_options": ["Ampicillin", "Gentamicin", "Tetracycline", "Trimethoprim/sulfamethoxazole"], "corr_idx": 3}]}, {"moduleId": 1013786, "name": "Protein Synthesis Inhibitors", "questions": [{"id": "1332338", "html_qtxt": "Identify the site of action of drug which can cause anaphylactoid reaction caused by rapid IV<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008c8096c68-d638-47db-84bb-e196023c6319.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Red man syndrome</strong>, an anaphylactoid reaction caused by rapid infusion of vancomycin . Caused by nonspecific mast cell degranulation &rarr; rapid release of histamine. Symptoms include diffuse flushing of the skin, pruritus mainly of the upper body, Muscle spasms and pain in the back and chest, Possible hypotension and dyspnea. Red man syndrome can be prevented by slowing the rate of infusion and pretreating with antihistamines</p>", "options": ["A", "B", "C", "E"], "html_options": ["A", "B", "C", "E"], "corr_idx": 3}, {"id": "1332340", "html_qtxt": "Advantage of clarithromycin over erythromycin is:", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Clarithromycin can be administered less frequently than erythromycin, but it is not effective in single doses against susceptible organisms. Organisms resistant to erythromycin, including pneumococci and methicillin-resistant staphylococci, are also resistant to other macrolides. Drug interactions have occurred with clarithromycin, through its ability to inhibit cytochrome P450. Clarithromycin is more active than erythromycin against Maxium complex, Tgondii, and H pylori.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008e5e08452-d103-4d4a-be8f-39f6baa81ac4.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Does not inhibit hepatic microsomal enzymes (Option A):</strong> Clarithromycin, like erythromycin, <strong>can inhibit cytochrome P450 enzymes</strong>, particularly CYP3A4. Therefore, this is not an advantage of clarithromycin.</p>\r\n<p><strong>Eradicate mycoplasma infections in a single dose (Option B):</strong> Both erythromycin and clarithromycin require multi-day courses to effectively treat <em>Mycoplasma pneumoniae</em> infections. Single-dose eradication is <strong>not achievable</strong>, so this is incorrect.</p>\r\n<p><strong>Is active against MRSA (Option D):</strong> Clarithromycin has <strong>limited activity against MRSA</strong>, and erythromycin is similarly ineffective. Therefore, this is not a distinguishing advantage.</p>", "options": ["Does not inhibit hepatic microsomal enzymes", "Eradicate mycoplasma infections in a single dose", "Has greater activity against H.pylori", "Is active against MRSA"], "html_options": ["Does not inhibit hepatic microsomal enzymes", "Eradicate mycoplasma infections in a single dose", "Has greater activity against H.pylori", "Is active against MRSA"], "corr_idx": 2}, {"id": "1332346", "html_qtxt": "Identify the correct match of drug with it's mechanism of resistance<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008e0ba5714-c683-4f55-b8b3-cfec9a0c47fb.png\">\r\n", "html_expl": "<p><strong>Explanation:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100886ef17c9-a78a-49bb-99bb-d6c3bc349e05.png\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008a10e1181-e994-4220-8c1f-5446ee445068.png\">\r\n", "options": ["A", "B", "C", "D"], "html_options": ["A", "B", "C", "D"], "corr_idx": 3}, {"id": "1332348", "html_qtxt": "A 4-year-old girl has most of her teeth have had stains since the time that they erupted. Examination shows brownish-grey discoloration of the teeth. She has lower limb length discrepancy. Which of the following drugs is most likely to have been taken ?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This child has dental and skeletal abnormalities that are likely the result of in utero exposure to a particular antibiotic drug. This drug inhibits bacterial protein synthesis by blocking incoming aminoacyl-tRNA from binding to the ribosome acceptor site.</li>\r\n<li>Tetracycline crosses the placenta and accumulates in developing teeth and bones because of its tendency to form complexes with calcium salts. In utero exposure can lead to discoloration of deciduous teeth and inhibition of bone growth, as seen in this patient. For this reason, tetracyclines are contraindicated during pregnancy and in children < 8 years of age.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Chloramphenicol (Option A):</strong> Chloramphenicol can cause <strong>gray baby syndrome</strong> in neonates and bone marrow suppression but does <strong>not cause permanent teeth discoloration</strong>.</p>\r\n<p><strong>Gentamicin (Option B):</strong> Gentamicin is an aminoglycoside. It can cause <strong>ototoxicity or nephrotoxicity</strong>, but it does not affect teeth or bones in the manner described.</p>\r\n<p><strong>Ciprofloxacin (Option C):</strong> Ciprofloxacin, a fluoroquinolone, can interfere with <strong>cartilage development in growing children</strong>, potentially causing arthropathy, but it does <strong>not cause teeth staining</strong>.</p>", "options": ["Chloramphenicol", "Gentamicin", "Ciprofloxacin", "Tetracycline"], "html_options": ["Chloramphenicol", "Gentamicin", "Ciprofloxacin", "Tetracycline"], "corr_idx": 3}, {"id": "1332349", "html_qtxt": "A 78-year-old man presents with headache and nonproductive cough for 5 days. Results of cold agglutinin titer testing show a 4-fold elevation above normal. CXR shows diffuse, patchy infiltrates bilaterally. Treatment with an antibiotic acts by?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>As per given clinical scenario this man has Mycoplasma pneumonia, which typically manifests with insidious onset and causes headaches and a nonproductive cough with diffuse, patchy infiltrates on chest x-ray. Erythrocyte agglutination is seen as a result of high titers of IgM cold agglutinins.</li>\r\n<li>Macrolides such as erythromycin and azithromycin are often used to treat Mycoplasma pneumonia. These antibiotics inhibit bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit. Doxycycline (which inhibits protein synthesis by binding to the 30S subunit) and fluoroquinolones (which inhibit prokaryotic topoisomerases) are also effective against Mycoplasma pneumoniae.</li>\r\n<li>Option A. Nitroimidazoles create free radicals within bacteria cells, which leads to DNA strand breaks, used to treat infections with anaerobic bacteria. They are not used to treat Mycoplasma pneumoniae.</li>\r\n<li>Sulfonamides inhibit bacterial synthesis of folic acid by DHPS. Sulfamethoxazole is used in combination with trimethoprim (TMP-SMX) to treat Pneumocystis jirovecii pneumonia (In immunocompromised). Sulfonamides are not indicated for Mycoplasma pneumoniae</li>\r\n<li>Rifamycins inhibit bacterial DNA-dependent RNA polymerase, used to treat mycobacterial It is not used to treat Mycoplasma pneumoniae.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Free radical creation within bacterial cells (Option A):</strong> This describes the mechanism of <strong>metronidazole</strong>, which is effective against anaerobic bacteria and some protozoa. It is not effective against <em>Mycoplasma pneumoniae</em>, the likely pathogen here.</p>\r\n<p><strong>Inhibition of folic acid synthesis (Option C):</strong> This mechanism is characteristic of <strong>sulfonamides and trimethoprim</strong>, which inhibit bacterial DNA synthesis indirectly by blocking folate metabolism. These are not first-line agents for atypical pneumonia.</p>\r\n<p><strong>Inhibition of bacterial RNA polymerase (Option D):</strong> This describes the action of <strong>rifampin</strong>, which inhibits transcription in bacteria. Rifampin is not used for treatment of <em>Mycoplasma pneumoniae</em> infections.</p>", "options": ["Free radical creation within bacterial cells", "Inhibition of peptide translocation at the 50S ribosomal subunit", "Inhibition of folic acid synthesis", "Inhibition of bacterial RNA polymerase"], "html_options": ["Free radical creation within bacterial cells", "Inhibition of peptide translocation at the 50S ribosomal subunit", "Inhibition of folic acid synthesis", "Inhibition of bacterial RNA polymerase"], "corr_idx": 1}, {"id": "1332351", "html_qtxt": "A 3-year-old child is presented with violent coughing spells followed by a high pitched inspiratory sound during this time. She also has low-grade fevers and a runny nose. Her only vaccinations were received at birth. Which of the following is treatment ?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>As per given clinical scenario, patient with an incomplete immunisation record, signs of an upper respiratory infection (nasal discharge, low-grade fever) and intense paroxysmal coughing with a high-pitched \"Whooping\" sound indicate pertussis (whooping cough).</li>\r\n<li>Azithromycin is the treatment of choice. Early administration of macrolides can lessen symptoms in the catarrhal and paroxysmal stage. Therefore, oral azithromycin is indicated in this patient.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Option:</strong></p>\r\n<p><strong>Tobramycin (Option B):</strong> Tobramycin is an aminoglycoside used primarily for <strong>Gram-negative bacterial infections</strong>, especially <em>Pseudomonas aeruginosa</em>. It is <strong>not effective against Bordetella pertussis</strong>, the likely pathogen in this child.</p>\r\n<p><strong>Ribavirin (Option C):</strong> Ribavirin is an antiviral agent used for <strong>RSV infection</strong> and some viral hemorrhagic fevers. It has no activity against <em>Bordetella pertussis</em> and is <strong>not indicated for pertussis treatment</strong>.</p>\r\n<p><strong>Oseltamivir (Option D):</strong> Oseltamivir is a neuraminidase inhibitor used for <strong>influenza virus infection</strong>. It does not treat bacterial infections like pertussis.</p>", "options": ["Azithromycin", "Tobramycin", "Ribavirin", "Oseltamivir"], "html_options": ["Azithromycin", "Tobramycin", "Ribavirin", "Oseltamivir"], "corr_idx": 0}, {"id": "1332355", "html_qtxt": "A 2-year-old child has consumed old tablets from his grandparent's cupboard. The child has been vomiting and has had diarrhea with green stools. Representative picture shown below. Other signs and symptoms include hypothermia, hypotension, and abdominal distention. The drug most<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008ac0f42ba-d9a0-4237-8440-ce0f698c5ec7.png\"><br>likely to be the cause of this problem is\r\n", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Chloramphenicol was commonly used outside for treatment of bacillary dysentery. The drug causes a dose-dependent (reversible) suppression of erythropoiesis. Although the gray baby syndrome was initially described in neonates, a similar syndrome has occurred with overdosage of chloramphenicol in older children and adults, especially those with hepatic dysfunction.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Azithromycin (Option A):</strong> Azithromycin is a macrolide antibiotic used for respiratory and atypical bacterial infections. It is generally safe in children and does <strong>not cause gray discoloration, hypotension, or severe toxicity</strong> when ingested.</p>\r\n<p><strong>Doxycycline (Option C):</strong> Doxycycline, a tetracycline derivative, can cause teeth discoloration in young children but does <strong>not cause acute systemic toxicity or gray syndrome</strong>.</p>\r\n<p><strong>Erythromycin (Option D):</strong> Erythromycin is a macrolide that is generally safe in children. Overdose may cause gastrointestinal upset but <strong>does not cause gray baby syndrome or severe systemic toxicity</strong>.</p>", "options": ["Azithromycin", "Chloramphenicol", "Doxycycline", "Erythromycin"], "html_options": ["Azithromycin", "Chloramphenicol", "Doxycycline", "Erythromycin"], "corr_idx": 1}, {"id": "1332357", "html_qtxt": "A 21-year-old woman is prescribed oral doxycycline for chlamydia. She returned to the clinic with a mucopurulent cervicitis after 2 weeks. On questioning she admitted not having the prescription filled. The best course of action at this point would be to", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Cervicitis or urethritis is often caused by Chlamydia trachomatis. Such infections may develop slowly because of the long incubation period of chlamydial infection. Treatment with oral doxycycline for 14 d (as originally prescribed) would have eradicated Chlamydia trachomatis and most other organisms commonly associated with non-gonococcal cervicitis or urethritis. Given the limited compliance of this patient, the best course of action would be the administration (in the clinic) of a single oral dose of azithromycin.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Delay drug treatment until the infecting organism is identified (Option A):</strong> Delaying treatment increases the risk of <strong>complications and transmission</strong>. Empiric therapy is recommended for suspected chlamydial infection based on clinical findings.</p>\r\n<p><strong>Rewrite the original prescription for oral doxycycline (Option B):</strong> While doxycycline is effective, requiring the patient to fill a prescription again may <strong>reduce adherence</strong>. A directly observed single-dose therapy is preferred to ensure completion.</p>\r\n<p><strong>Treat her in the clinic with an intravenous dose of amoxicillin (Option D):</strong> Amoxicillin is <strong>not first-line therapy for chlamydia</strong>. IV administration is unnecessary for uncomplicated genital infection and is not recommended.</p>", "options": ["Delay drug treatment until the infecting organism is identified", "Rewrite the original prescription for oral doxycycline", "Treat her in the clinic with a single oral dose of azithromycin", "Treat her in the clinic with an intravenous dose of amoxicillin"], "html_options": ["Delay drug treatment until the infecting organism is identified", "Rewrite the original prescription for oral doxycycline", "Treat her in the clinic with a single oral dose of azithromycin", "Treat her in the clinic with an intravenous dose of amoxicillin"], "corr_idx": 2}, {"id": "1332359", "html_qtxt": "A 46-year-old man presents with fever and productive cough. He is an alcoholic. CXR shown below. What would be the ideal antibiotic therapy for him ?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008098fef0b-332c-4f4b-a6ea-af83304052d1.png\">", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient with CXR of lung abscess, treated with Clindamycin. It is a bacteriostatic antibiotic that inhibits bacterial protein synthesis by preventing peptide translocation at the 50S (large) ribosomal subunit.</li>\r\n<li>It targets anaerobic organisms and is commonly used for the treatment of aspiration pneumonia and lung abscess, which are typically polymicrobial. Clostridioides difficile colitis is a potential complication of clindamycin.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Azithromycin (Option A):</strong> Azithromycin is a macrolide effective against atypical pathogens and some Gram-positive bacteria. It <strong>does not reliably cover anaerobic bacteria</strong>, which are commonly involved in aspiration pneumonia in alcoholics.</p>\r\n<p><strong>Levofloxacin (Option C):</strong> Levofloxacin is a fluoroquinolone effective against Gram-negative and some Gram-positive bacteria. While it can cover typical respiratory pathogens, it <strong>lacks reliable anaerobic coverage</strong>, making it suboptimal for aspiration pneumonia.</p>\r\n<p><strong>Ceftriaxone (Option D):</strong> Ceftriaxone is a third-generation cephalosporin with good activity against Gram-negative and some Gram-positive bacteria. However, it <strong>does not adequately cover anaerobes</strong>, which are a major component of aspiration pneumonia.</p>", "options": ["Azithromycin", "Clindamycin", "Levofloxacin", "Ceftriaxone"], "html_options": ["Azithromycin", "Clindamycin", "Levofloxacin", "Ceftriaxone"], "corr_idx": 1}, {"id": "1332362", "html_qtxt": "A 67-year-old man develops dysuria, flank pain, and fever. Examination shows marked tenderness in the right costovertebral area. Treatment with an antibiotic is begun, but his symptoms do not improve. Further evaluation shows that the causal organism produces an enzyme that inactivates the antibiotic via phosphorylation. An agent from which of the following classes of antibiotics was most likely administered?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This antibiotic is used to treat infections with gram-negative, aerobic bacteria and acts by irreversibly inhibiting the 30S subunit of the initiation complex.</li>\r\n<li>Aminoglycosides are bactericidal agents that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. Microbial resistance develops when enzymes (e.g., transferases) are produced that inactivate the antibiotic via phosphorylation, acetylation, or adenylation. Aminoglycosides, which are effective against gram-negative bacilli (e.g., E.coli, Klebsiella, Serratia, Proteus, Pseudomonas), can be used instead of fluoroquinolones for the inpatient treatment of complicated pyelonephritis.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Tetracycline (Option B):</strong> Resistance to tetracyclines typically occurs via <strong>efflux pumps or ribosomal protection proteins</strong>, not by enzymatic inactivation through phosphorylation.</p>\r\n<p><strong>Fluoroquinolones (Option C):</strong> Fluoroquinolone resistance usually arises via <strong>mutations in DNA gyrase/topoisomerase IV or efflux mechanisms</strong>, not phosphorylation.</p>\r\n<p><strong>Macrolides (Option D):</strong> Macrolide resistance primarily occurs via <strong>methylation of the 23S rRNA</strong> or efflux pumps, rather than enzymatic inactivation by phosphorylation.</p>", "options": ["Aminoglycosides", "Tetracycline", "Fluoroquinolones", "Macrolides"], "html_options": ["Aminoglycosides", "Tetracycline", "Fluoroquinolones", "Macrolides"], "corr_idx": 0}, {"id": "1332365", "html_qtxt": "72-year-old man with a history of mitral valve replacement is currently taking an oral anticoagulant and also has his prothrombin time monitored on a regular basis. One week after starting treatment for his current condition, he notices blood in his urine. A drug interaction with which of the following medications is most likely responsible for the appearance of hematuria?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Warfarin is the oral anticoagulant the patient was most likely taking. This drug is commonly prescribed for patients with atrial fibrillation to prevent the formation of atrial thrombi. It also prevents thrombus formation in a variety of other situations, such as prosthetic valves. Warfarin increases prothrombin time (PT) and international normalized ratio (INR) because it interferes with the synthesis of the vitamin K-dependent clotting factors of the liver (II, VI, IX, and X) and therefore necessitates regular monitoring of the PT. Here is a summary to differentiate PT from aPTT:</li>\r\n<li>The prothrombin time (PT), which is affected by warfarin, measures factors I (fibrinogen), Il (prothrombin), V, VII, and X. The PT is a measure of the extrinsic pathway of coagulation. The activated partial thromboplastin time (aPTT), which is affected by the heparins, measures the intrinsic pathway and common pathway</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Amoxicillin (Option A):</strong> Amoxicillin can rarely increase INR in patients on warfarin, but this interaction is <strong>much less pronounced</strong> compared to macrolides. It is <strong>less likely</strong> to cause clinically significant hematuria in this scenario.</p>\r\n<p><strong>Rifampin (Option C):</strong> Rifampin is a potent <strong>inducer of hepatic cytochrome P450 enzymes</strong>, which <strong>lowers warfarin levels</strong> and reduces anticoagulant effect. It would be expected to <strong>decrease</strong> bleeding risk, not increase it.</p>\r\n<p><strong>Tetracycline (Option D):</strong> Tetracyclines generally have <strong>minimal effect on warfarin metabolism</strong> and are <strong>unlikely to cause significant bleeding</strong>.</p>", "options": ["Amoxicillin", "Clarithromycin", "Rifampin", "Tetracycline"], "html_options": ["Amoxicillin", "Clarithromycin", "Rifampin", "Tetracycline"], "corr_idx": 1}, {"id": "1332368", "html_qtxt": "A 34-year-old woman diagnosed with infection with Chlamydia urethritis. Treatment with appropriate antibiotic. That is started for a week. Which of the following health maintenance recommendations is most appropriate at this time?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>The patient has chlamydial urethritis. First-line treatment options include azithromycin and doxycycline. While a single dose of azithromycin is usually the preferred treatment, a one-week course of doxycycline is the appropriate treatment in this patient.</li>\r\n<li>Common adverse effect of all tetracyclines, including doxycycline, is an increase in photosensitivity. The drug itself absorbs UV light and releases it to the surrounding tissue, causing damage in areas exposed to sun. Other adverse effects of tetracyclines include deposition in the bones and teeth through complex formation with calcium ions. If administered to children, this may impair growth and cause discolouration of the teeth. Patients should refrain from sexual activity for 1 week after initiation of therapy.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Avoid alcohol (Option A):</strong> While alcohol avoidance is important with some antibiotics (e.g., metronidazole or tinidazole), it is <strong>not generally necessary for doxycycline</strong>, the typical treatment for Chlamydia urethritis.</p>\r\n<p><strong>CBC (Option C):</strong> Routine complete blood count monitoring is <strong>not required</strong> for patients taking doxycycline for uncomplicated chlamydial infection.</p>\r\n<p><strong>LFT (Option D):</strong> Liver function tests are generally <strong>not indicated</strong> in healthy adults receiving a short course of doxycycline for uncomplicated Chlamydia infection.</p>", "options": ["Avoid alcohol", "Avoid sun exposure", "CBC", "LFT"], "html_options": ["Avoid alcohol", "Avoid sun exposure", "CBC", "LFT"], "corr_idx": 1}, {"id": "1332370", "html_qtxt": "A 23-year-old man received intravenous antibiotics for treatment of bacterial meningitis. CBC shows haemoglobin concentration of 9.0 g/dL, a leukocyte count of 1,100/mm3 with 30% segmented neutrophils, and a platelet count of 20,000/mm3. The patient was most likely treated with which of the following antibiotics?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Pancytopenia due to bone marrow suppression is a side effect of therapy with chloramphenicol. It may develop in a dose-dependent, reversible manner or manifest as dose-independent irreversible aplastic anemia with a sudden onset up to several months after treatment. Aplastic anemia is a rare but potentially fatal side effect, so the use of chloramphenicol has been limited in developed countries. However, due to its low cost, it is often still used to treat bacterial meningitis caused by H. influenza, N. meningitidis, or S. pneumoniae in developing countries.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Linezolid (Option A):</strong> Linezolid can cause <strong>myelosuppression</strong>, particularly thrombocytopenia and anemia, usually after <strong>>2 weeks</strong> of therapy. In this case, the patient developed pancytopenia acutely, which is more characteristic of chloramphenicol.</p>\r\n<p><strong>Daptomycin (Option C):</strong> Daptomycin is primarily associated with <strong>myopathy and elevated creatine phosphokinase (CPK)</strong>. It rarely causes significant pancytopenia.</p>\r\n<p><strong>Doxycycline (Option D):</strong> Doxycycline is generally <strong>well tolerated</strong>, with rare hematologic adverse effects. It does not cause acute pancytopenia or bone marrow suppression like chloramphenicol.</p>", "options": ["Linezolid", "Chloramphenicol", "Daptomycin", "Doxycycline"], "html_options": ["Linezolid", "Chloramphenicol", "Daptomycin", "Doxycycline"], "corr_idx": 1}, {"id": "1332371", "html_qtxt": "A 56-year-old man is brought because of fever, chills, and productive cough for the past 4 days. Physical examination shows dullness to percussion, and decreased breath sounds are heard over the left lung base on auscultation of the chest. Gram stain of sputum shows abundant neutrophils and gram-positive diplococci. His past medical history is unremarkable. Which of the following drugs is most appropriate in the treatment of this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Streptococcus pneumonia (pneumococcus) is classified as a gram-positive diplococcus. It is the most likely organism causing this man's pneumonia, based on the clinical presentation as well as the Gram stain results. Since the recommended empiric antibiotic regimen is different for community acquired pneumonia (CAP) in adults being treated in the outpatient vs. inpatient setting you must first determine if the patient requires hospital admission. Criteria for hospital admission are based on the clinical presentation of the patient. CURB-65 prognostic variables for hospitalisation is outlined below:</li>\r\n<li>Confusion (based upon a specific mental test or disorientation to person, place, or time)</li>\r\n<li>Urea (blood urea nitrogen in the United States) >7 mmol/L (20 mg/dL)</li>\r\n<li>Respiratory rate >30 breaths/minute</li>\r\n<li>Blood pressure [BP] (systolic <90 mmHg or diastolic <60 mrHg)</li>\r\n<li>Age >65 years</li>\r\n<li>In this case, the patient can be treated as an outpatient since he does not meet the criteria for admission. Current treatment guidelines for community acquired pneumonia established by the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) mainly rely on macrolides (with or without a beta-lactam) or newer fluoroquinolones for outpatient therapy. The recommendations are as follows:</li>\r\n<li>In previously healthy patients (such as the patient in this vignette) and no use of antimicrobials in the past three months the drugs of choice are a macrolide (azithromycin, clarithromycin or erythromycin) OR doxycycline.</li>\r\n<li>If the patient has an established comorbidity (such as chronic, heart, lung, liver or renal disease, diabetes, or others), the use of a fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin) OR a beta-lactam (such as amoxicillin-clavulanate, cefuroxime or ceftriaxone) PLUS a macrolide is recommended.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Ceftazidime (Option B):</strong> Ceftazidime is a third-generation cephalosporin with <strong>excellent activity against Pseudomonas and Gram-negative bacteria</strong>, but it has <strong>limited activity against Streptococcus pneumoniae</strong>, which is the likely pathogen in this community-acquired pneumonia case.</p>\r\n<p><strong>Gentamicin (Option C):</strong> Gentamicin is an aminoglycoside primarily effective against <strong>Gram-negative bacteria</strong>. It is not appropriate as monotherapy for <strong>pneumococcal pneumonia</strong>.</p>\r\n<p><strong>Penicillin G (Option D):</strong> Penicillin G was historically effective against S. pneumoniae, but <strong>many strains now have intermediate or high-level resistance</strong>, making empiric penicillin monotherapy less reliable for community-acquired pneumonia in adults.</p>", "options": ["Azithromycin", "Ceftazidime", "Gentamicin", "Penicillin G"], "html_options": ["Azithromycin", "Ceftazidime", "Gentamicin", "Penicillin G"], "corr_idx": 0}, {"id": "1332373", "html_qtxt": "A 15-year-old girl is brought low-grade fever, malaise, chills, headache, and a persistent non-productive cough since 1 week. Her temperature is 100.5 &deg;F. Physical examination shows pharyngitis and no findings on chest auscultation. Laboratory studies of serum show the presence of red blood cell agglutinins at 4&deg;C. Which of the following drugs is most appropriate for this patient?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient has primary atypical pneumonia caused by Mycoplasma pneumonia. Low-grade fever, chills, headache, malaise and a persistent, nonproductive cough These organisms are fastidious and difficult to culture in the laboratory; however, serodiagnosis can be most helpful. Patients produce one or two heterophile antibodies during the course of the infection: one agglutinates human O+ red blood cells in the cold (the cold hemagglutinins), and the other causes the agglutination of a strain of Streptococcus salivarius called strain MG (the strep MG agglutinins).</li>\r\n<li>Mycoplasmas are susceptible to the macrolide family of antibiotics (azithromycin, clarithromycin, etc.). These organisms lack a cell wall; hence, they are indifferent to antibiotics that interfere with peptidoglycan synthesis, such as penicillin and cephalosporins.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Ampicillin (Option A):</strong> Ampicillin is a beta-lactam antibiotic effective against many Gram-positive and some Gram-negative bacteria, but it is <strong>not effective against atypical pathogens</strong> like <em>Mycoplasma pneumoniae</em>, which is the likely cause here.</p>\r\n<p><strong>Cephalosporin (Option B):</strong> Cephalosporins (e.g., cefuroxime, ceftriaxone) target <strong>cell wall synthesis</strong> and are ineffective against <strong>cell wall-lacking organisms</strong>, such as <em>Mycoplasma pneumoniae</em>.</p>\r\n<p><strong>Penicillin G (Option D):</strong> Penicillin G is effective against many Gram-positive organisms but <strong>ineffective against atypical pathogens</strong>, including <em>Mycoplasma pneumoniae</em>.</p>", "options": ["Ampicillin", "Cephalosporin", "Clarithromycin", "Penicillin G"], "html_options": ["Ampicillin", "Cephalosporin", "Clarithromycin", "Penicillin G"], "corr_idx": 2}, {"id": "1332376", "html_qtxt": "A 15-year-old girl is brought because of difficulty swallowing, drowsiness, abdominal pain, nausea and vomiting. Physical examination shows dry mucous membranes, peritonsillar abscess, and generalized tenderness of the abdomen. Laboratory studies show blood glucose of 400 mg/dL, anion gap of 15, arterial pH of 7.10, calcium of 9.0 mg/dL, and potassium of 4.0 mg/dL. Urinalysis is positive for ketones. Treatment with insulin is begun. Which of the following drugs or combination of drugs should also be given?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>There are two individual conditions that need to be treated: ketoacidosis and peritonsillar abscess.</li>\r\n<li>Diabetic ketoacidosis (DKA) is associated with nausea, vomiting, abdominal pain, polyuria, and polydipsia. As DKA progresses, neurologic symptoms, such as lethargy, focal deficits, and seizure, may appear. Laboratory studies generally show hyperglycemia (generally > 250 mg/dL), elevated anion gap metabolic acidosis (normal anion gap = 6-12 mEq/L), decreased arterial pH (normal = 7.35-7.45), and dehydration.</li>\r\n<li>Treatment of diabetic ketoacidosis requires more than insulin. Intravascular volume is often depleted, and initial fluids to restore volume should include isotonic saline or lactated Ringer's solution. If arterial blood pH is less than 7.1 or if severe hyperkalemia (> 5.2 mg/dL) is present, bicarbonate supplementation should be used.</li>\r\n<li>IV fluids containing 5-10% dextrose (glucose) should be used when the serum glucose levels fall to 200-300 mg/dL, since high doses of rapidly acting insulin can cause life-threatening hypoglycemia. Additionally, the serum potassium concentration should be watched very carefully, since potassium is co-transported into cells with glucose in the presence of insulin.</li>\r\n<li>It is often the case that hyperkalemia is present. Initially, secondary to decreased cellular uptake of potassium with decreased cellular uptake of glucose. However, this can change rapidly when insulin drives glucose (with potassium) into cells, and a life-threatening hypokalemia can develop.</li>\r\n<li>In the case of this patient, she has a low-normal potassium level. Once the glucose level begins to fall, this patient is very likely to experience hypokalemia. Hence, potassium administration is likely (choices A, B, and C can be eliminated).</li>\r\n<li>The patient also has a peritonsillar abscess, which is most likely caused by anaerobic bacteria (Bacteroides, Fusobacterium, Peptostreptococcus, and Provetella) and aerobic bacteria (Streptococcus, Staphylococcus, and occasionally Hemophilus). Drainage, antimicrobial therapy, and supportive care are the cornerstones of peritonsillar abscess management. In areas where S. aureus remains susceptible to methicillin, the most commonly used antibiotics are ampicillin-sulbactam (IV), amoxicillin-clavulanic acid (PO) or clindamycin (IV or PO).</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Calcium supplementation + IV fluids + levofloxacin (Option A):</strong> Calcium supplementation is unnecessary because serum calcium is normal (9.0 mg/dL). Levofloxacin does not provide adequate anaerobic coverage for a <strong>peritonsillar abscess</strong>.</p>\r\n<p><strong>Calcium supplementation + IV fluids + metronidazole (Option B):</strong> While metronidazole covers anaerobes, calcium supplementation is unnecessary, and metronidazole alone may not cover the typical streptococcal pathogens in peritonsillar abscess.</p>\r\n<p><strong>Metronidazole + IV fluids (Option C):</strong> IV fluids are required for DKA management, and metronidazole alone does not provide adequate coverage for both <strong>streptococci and anaerobes</strong> commonly found in peritonsillar abscesses.</p>", "options": ["Calcium supplementation + IV fluids + levofloxacin", "Calcium supplementation + IV fluids + metronidazole", "Metronidazole + IV fluids", "Potassium supplementation + IV fluids + clindamycin"], "html_options": ["Calcium supplementation + IV fluids + levofloxacin", "Calcium supplementation + IV fluids + metronidazole", "Metronidazole + IV fluids", "Potassium supplementation + IV fluids + clindamycin"], "corr_idx": 3}]}, {"moduleId": 1013787, "name": "Antimycobacterial & Anti-Leprosy Drugs ", "questions": [{"id": "1332339", "html_qtxt": "A 49-year-old woman comes to the office as a new patient. The patient has a history of hypertension and type 2 diabetes mellitus. She was also diagnosed with active pulmonary tuberculosis 4 months ago. She completed 2 months of intensive antituberculosis therapy with 4 drugs and now is on isoniazid and rifampin alone. The patient feels well overall but does have tingling and numbness of the bilateral hands and feet that started a few weeks ago; she has no cough, fever, chills, or night sweats. She does not use tobacco, alcohol, or illicit drugs. Temperature is 37 &deg;C (98.6 &deg;F), blood pressure is 122/82 mm Hg, and pulse is 80/min. Lung auscultation reveals fine crackles in the left upper lung field. Heart sounds are normal and regular. Neurologic examination shows normal motor strength but decreased touch and pain sensation in the bilateral upper and lower extremities. Skin examination shows no abnormalities. Hemoglobin A1C level is 7.4%. Chest x-ray reveals fibrotic changes in the left upper lung. Which of the following is the most likely cause of this patient's current symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Isoniazid is chemically similar to pyridoxine (vitamin B6.). Because of this similarity, isoniazid can compete with vitamin B6, in the synthesis of multiple neurotransmitters (including GABA), resulting in defective end products. Isoniazid also increases the urinary excretion of pyridoxine, and a frank deficiency of this vitamin can eventually develop.</li>\r\n<li>Vitamin B6, deficiency most commonly occurs in patients treated with isoniazid who are elderly, alcoholics, or who have other comorbidities (eg, kidney or liver dysfunction, diabetes mellitus).</li>\r\n<li>When isoniazid neuropathy occurs, it usually clinically manifests as peripheral neuropathy. To prevent these adverse effects, supplemental vitamin B6 is typically prescribed in conjunction with isoniazid.</li>\r\n<li>Other potential adverse effect of isoniazid:</li>\r\n</ul>\r\n<p>Hepatotoxicity, P-450 Inhibition, Drug induced SLE, Anion Gap metabolic acidosis</p>\r\n<p>To Remember: <strong><u>INH</u></strong>(Isoniazid) <strong><u>I</u></strong>njures <strong><u>N</u></strong>eurons and <strong><u>H</u></strong>epatocytes</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Degeneration of the dorsal and lateral spinal columns (Option A):</strong> This is characteristic of <strong>vitamin B12 deficiency</strong>, which typically presents with <strong>loss of vibration and position sense</strong>, spasticity, and sometimes ataxia. This patient has <strong>decreased touch and pain sensation</strong>, not primarily proprioceptive loss, and there is no macrocytic anemia.</p>\r\n<p><strong>Inflammatory demyelination of axons (Option B):</strong> This occurs in conditions like <strong>Guillain-Barr&eacute; syndrome</strong>, which presents with <strong>ascending weakness, areflexia, and sometimes sensory disturbances</strong>, often following infection. This patient has <strong>normal motor strength</strong> and <strong>chronic sensory symptoms</strong>, making acute demyelination unlikely.</p>\r\n<p><strong>Loss of motor neurons (Option D):</strong> Seen in <strong>amyotrophic lateral sclerosis</strong>, characterized by <strong>progressive weakness, muscle wasting, fasciculations</strong>, and minimal sensory deficits. The patient's symptoms are <strong>purely sensory</strong>, ruling this out.</p>", "options": ["Degeneration of the dorsal and lateral spinal columns", "Inflammatory demyelination of axons", "Medication adverse effect", "Loss of motor neurons"], "html_options": ["Degeneration of the dorsal and lateral spinal columns", "Inflammatory demyelination of axons", "Medication adverse effect", "Loss of motor neurons"], "corr_idx": 2}, {"id": "1332342", "html_qtxt": "Patient on anti-tubercular drugs comes to opd with complain of Red urine. He has had no pain or burning on urination. He has infiltrative pulmonary tuberculosis (diagnosed recently). He takes anti M. Tuberculosis drugs. What is the mechanism of action of this drug?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Orange urine (which is nonhazardous), Minor hepatotoxicity and drug interaction (increase cytochrome P-450) are side effects of Rifampin. Mechanism of action of rifampin is inhibiting DNA-Dependent RNA polymerase.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008ad78b7f5-abb8-459c-abaa-b49115f2b702.png\">\r\n<br>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510085881a9cd-b1e7-49a7-b64f-ccbc273762b2.png\">\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Decrease synthesis of mycolic acid (Option B):</strong> This describes the mechanism of <strong>isoniazid</strong>, which inhibits mycolic acid synthesis in the mycobacterial cell wall. Its main side effects include <strong>peripheral neuropathy and hepatotoxicity</strong>, not red/orange urine.</p>\r\n<p><strong>Decrease carbohydrate polymerization of mycobacterium cell wall (Option C):</strong> This is the mechanism of <strong>ethambutol</strong>, which inhibits <strong>arabinosyl transferase</strong>, thereby disrupting cell wall carbohydrate polymerization. Main side effect: <strong>optic neuritis</strong> (red-green color blindness), not discolored urine.</p>\r\n<p><strong>Interferes with 30S component of ribosome (Option D):</strong> This is the mechanism of <strong>streptomycin</strong>, which interferes with protein synthesis at the 30S ribosomal subunit. Side effects: <strong>ototoxicity, nephrotoxicity</strong>, but not red urine.</p>", "options": ["Inhibit DNA-dependent RNA polymerase", "Decrease synthesize of mycolic acid", "Decrease carbohydrate polymerization of mycobacterium cell wall", "Interferes with 30S component of ribosome"], "html_options": ["Inhibit DNA-dependent RNA polymerase", "Decrease synthesize of mycolic acid", "Decrease carbohydrate polymerization of mycobacterium cell wall", "Interferes with 30S component of ribosome"], "corr_idx": 0}, {"id": "1332343", "html_qtxt": "A 41-year-old woman presents to clinic complaining of severe shortness of breath, cough, and hemoptysis. A chest radiograph reveals right upper lobe fibrosis and her sputum is positive for acid-fast bacilli. A diagnosis of active pulmonary tuberculosis is made and she is begun on a regimen of isoniazid, rifampin, ethambutol, and pyrazinamide. She presents for a follow-up visit one month later and says that her symptoms have improved and she feels \"much better.\" Her sputum is now negative for acid-fast bacilli. Laboratory evaluation returns with the following: <br>\r\nLiver studies<br>\r\nAlbumin 4.8 g/dL<br>\r\nTotal bilirubin 0.9 mg/dL<br>\r\nDirect bilirubin 0.2 mg/dL<br>\r\nAlkaline phosphatase 42 U/L<br>\r\nAspartate aminotransferase (AST, SGOT) 75 U/L<br>\r\nAlanine aminotransferase (ALT, SGPT) 97 U/L<br>\r\nWhat is the next best step in the management of this patient?\r\n", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Isoniazid is a bactericidal antibiotic that is particularly effective against replicating Mycobacterium tuberculosis when used in conjunction with other agents such as rifampin, ethambutol, and pyrazinamide.</li>\r\n<li>Isoniazid (INH) is not without adverse effects, however, and has been associated with severe INH hepatitis and a much milder hepatotoxicity. Isoniazid hepatitis presents with clinical manifestations that are similar to those seen with viral hepatitis.</li>\r\n<li>The risk of developing this more ominous form of hepatotoxicity is estimated to be 2.6% for those who drink alcohol daily, already have liver disease, or are age 50 years and older.</li>\r\n<li>If signs and symptoms of INH hepatitis are observed, the drug should be discontinued immediately.</li>\r\n<li>In contrast, it is estimated that 10-20% of patients taking INH will experience mild, subclinical hepatic injury demonstrated only by minor elevations in serum aminotransferases (typically < 10011.1/L).</li>\r\n<li>The prognosis is excellent in these patients and the condition is self-limited, allowing for INH therapy to be maintained with close follow-up.</li>\r\n<li>Because the patient in this question is relatively young and otherwise asymptomatic, she can continue taking INH as long as her liver function tests are regularly monitored and remain only mildly elevated.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Terminate current treatment (Option A):</strong></p>\r\n<p>Stopping therapy would risk <strong>treatment failure and resistance</strong>. Mild asymptomatic transaminitis (<3x ULN) with normal bilirubin <strong>does not require stopping drugs</strong>.</p>\r\n<p><strong>Replace drug with second-line anti-tubercular drugs (Option C):</strong></p>\r\n<p>Second-line drugs are considered only when there is <strong>significant hepatotoxicity</strong> (ALT/AST >5x ULN if asymptomatic, >3x ULN with symptoms, or if bilirubin is elevated). That's not the case here.</p>\r\n<p><strong>Liver biopsy (Option D):</strong></p>\r\n<p>Indicated for <strong>diagnosis of unclear liver disease or persistent, unexplained LFT abnormalities</strong>, not for mild, expected enzyme elevation from anti-TB drugs.</p>", "options": ["Terminate current treatment", "Continue current treatment", "Replace drug with second line anti tubercular drugs", "Liver Biopsy"], "html_options": ["Terminate current treatment", "Continue current treatment", "Replace drug with second line anti tubercular drugs", "Liver Biopsy"], "corr_idx": 1}, {"id": "1332360", "html_qtxt": "A 32-year-old man with HIV is diagnosed with pulmonary tuberculosis and started on a 4-drug combination therapy. On a follow-up visit 3 weeks later, he reports red urine and red staining of his contact lenses. A drug susceptibility test of his sputum isolates of Mycobacterium tuberculosis shows resistance to several antimycobacterial agents. Which of the following best explains the bacterial resistance to the drug responsible for this patient's current symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient with HIV has active pulmonary tuberculosis, typically treated with a 4-drug combination of a rifamycin (eg, rifampin, rifabutin), isoniazid, pyrazinamide, and ethambutol (RIPE therapy).</li>\r\n<li>The Rifamycins commonly cause harmless red-orange discoloration of body fluids (urine, sweat, saliva, tears), which explains this patient's symptoms. They inhibit DNA-dependent RNA polymerase, thereby preventing transcription and leading to a deficiency of proteins necessary for mycobacterial survival.</li>\r\n<li>Structural alteration of this DNA-dependent RNA polymerase induces bacterial resistance. Unlike isoniazid, rifamycins are not specific to mycobacteria.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008cd99c28f-e853-4b99-833a-43eb9d1c1f18.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Altered Structure of enzymes involved in bacterial DNA Winding (Option A):<br /> </strong>Refers to resistance against <strong>fluoroquinolones (DNA gyrase/topoisomerase II inhibitors)</strong>. Not related to rifampin.</p>\r\n<p><strong>Altered Ribosomal Proteins (Option C):<br /> </strong>This mechanism is seen with <strong>aminoglycosides, macrolides, and tetracyclines</strong>. Rifampin does not act on ribosomes.</p>\r\n<p><strong>Decreased Catalase-Peroxidase Activity (Option D):<br /> </strong>This explains resistance to <strong>isoniazid (INH)</strong>, since the drug needs catalase-peroxidase for activation. Not related to rifampin.</p>", "options": ["Altered structure of enzymes involved in bacterial DNA winding-unwinding", "Altered structure of enzymes involved in bacterial RNA synthesis", "Altered structure of bacterial ribosomal proteins", "Decreased activity of bacterial catalase-peroxidase"], "html_options": ["Altered structure of enzymes involved in bacterial DNA winding-unwinding", "Altered structure of enzymes involved in bacterial RNA synthesis", "Altered structure of bacterial ribosomal proteins", "Decreased activity of bacterial catalase-peroxidase"], "corr_idx": 1}, {"id": "1332363", "html_qtxt": "A 31-year-old Woman comes to the emergency department with a 3-week history of fever, night sweats, and productive cough. He has also had a 4-kg weight loss. Chest-x ray reveals a cavitary lesion on the right. Sputum culture is obtained. When exposed to drug A, isolates of the pathogen growing in culture quickly become less resistant to decoloration with an acid-alcohol agent and stop proliferating. Which of the following is drug A most likely to be?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Isoniazid is an antimicrobial agent that is active only against mycobacteria. Its specificity is derived from its inhibition of mycolic acid synthesis.</li>\r\n<li>Mycolic acids form long branched-chain fatty acids in the outer portion of the mycobacterial peptidoglycan cell wall; they are essential for proper cell wall structure and virulence factor synthesis (eg, sulfatides, wax D, cord factor). If mycobacteria are unable to synthesize mycolic acids, they cannot create proper cell walls or divide to form new cells.</li>\r\n<li>Mycolic acids in the cell wall cause mycobacteria to be acid-fast as they retain the carbolfuchsin dye and resist decoloration by an acid-alcohol decolorizing agent.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Ciprofloxacin (Option A):</strong></p>\r\n<p>A fluoroquinolone that inhibits <strong>DNA gyrase (topoisomerase II)</strong>, preventing bacterial DNA replication. It is not specific to <em>Mycobacterium tuberculosis</em> and does not cause increased acid-fast sensitivity.</p>\r\n<p><strong>Rifampin (Option B):</strong></p>\r\n<p>Inhibits <strong>DNA-dependent RNA polymerase</strong>, blocking transcription. While effective against <em>M. tuberculosis</em> and causing red body fluids, it does not directly interfere with <strong>mycolic acid synthesis</strong>, which explains the change in acid-fastness.</p>\r\n<p><strong>Streptomycin (Option D):</strong></p>\r\n<p>An aminoglycoside that binds to the <strong>30S ribosomal subunit</strong>, inhibiting protein synthesis. It is used as a second-line TB drug but does not affect acid-fast cell wall properties.</p>", "options": ["Ciprofloxacin", "Rifampin", "Isoniazid", "Streptomycin"], "html_options": ["Ciprofloxacin", "Rifampin", "Isoniazid", "Streptomycin"], "corr_idx": 2}, {"id": "1332366", "html_qtxt": "A patient diagnosed with tuberculosis 2 months back returns to the office reporting blurring of vision. The patient is on combination therapy with isoniazid, ethambutol, rifampin, pyrazinamide, and pyridoxine. Examination shows bilateral central scotomas. Which of the following is most likely responsible for this patient's visual symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Pulmonary TB is treated with a 4-drug regimen, sometimes referred to as RIPE: rifampin, isoniazid (INH), pyrazinamide, and ethambutol.</li>\r\n<li>The most notable side effect of ethambutol is optic neuropathy, which clinically manifests as decreased visual acuity, central scotoma, or color blindness. It may be reversible with discontinuation of the drug.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510080dadca50-5fc3-4abb-ad65-95529c50b4fc.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Isoniazid (Option B):</strong></p>\r\n<p>Can cause <strong>peripheral neuropathy</strong> (due to pyridoxine deficiency) and <strong>drug-induced hepatitis</strong>, but it does not typically cause optic neuritis or central vision loss.</p>\r\n<p><strong>Pyrazinamide (Option C):</strong></p>\r\n<p>Associated with <strong>hyperuricemia (gouty arthritis)</strong> and <strong>hepatotoxicity</strong>, but visual disturbances are not a recognized side effect.</p>\r\n<p><strong>Rifampin (Option D):</strong></p>\r\n<p>Causes <strong>red-orange discoloration of body fluids</strong> and hepatotoxicity. It does not cause optic neuropathy.</p>", "options": ["Ethambutol", "Isoniazid", "Pyrazinamide", "Rifampin"], "html_options": ["Ethambutol", "Isoniazid", "Pyrazinamide", "Rifampin"], "corr_idx": 0}, {"id": "1332375", "html_qtxt": "A patient presented with a few hypoesthetic, hairless skin plaques. Diagnosis of leprosy confirmed with tissue biopsy. What is the mechanism of action of drugs used to treat this condition? <br>\r\ni) Inhibit dihydropteroate synthase<br>\r\nii) Inhibit DNA-dependent RNA polymerase<br>\r\niii) binding preferentially to mycobacterial DNA and inhibiting replication and growth", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Patient is having presentation of Tuberculoid leprosy. Treatment of tuberculoid leprosy is dapsone and rifampin. Mechanism of action of dapsone and rifampin are inhibit dihydropteroate synthase and Inhibit DNA-dependent RNA polymerase respectively.\r\n<ul>\r\n<li>Lepromatous-presents diffusely over the skin, with leonine (lion-like) facies, and is communicable (high bacterial load); characterized by low cell-mediated immunity with a humoral Th2 response.</li>\r\n<li>Tuberculoid-limited to a few hypo esthetic, hairless skin plaques; characterized by high cell mediated immunity with a largely Th1-type immune response and low bacterial load.</li>\r\n<li>Treatment: dapsone and rifampin for tuberculoid form; clofazimine is added for lepromatous form.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Option A (i):</strong></p>\r\n<p>Refers only to <strong>dapsone</strong>, which inhibits <strong>dihydropteroate synthase</strong> (folate pathway inhibitor, similar to sulfonamides). While correct, this ignores the role of rifampin in standard multidrug therapy.</p>\r\n<p><strong>Option C (i, ii, iii):</strong></p>\r\n<p>Includes <strong>clofazimine (iii)</strong>, which binds to mycobacterial DNA. However, clofazimine is used mainly in <strong>multibacillary leprosy or resistant cases</strong>, not always part of standard first-line multidrug therapy for all patients.</p>\r\n<p><strong>Option D (i, iii):</strong></p>\r\n<p>Excludes rifampin's mechanism (ii). Since rifampin is a cornerstone of therapy, this is incomplete.</p>", "options": ["i)", "i), ii)", "i), ii), iii)", "i), iii)"], "html_options": ["i)", "i), ii)", "i), ii), iii)", "i), iii)"], "corr_idx": 1}, {"id": "1332378", "html_qtxt": "A 64-year-old man comes to the emergency department due to fever, anorexia, and nausea. Several weeks ago, on routine testing, the patient was found to have a positive purified protein derivative test. He had no respiratory symptoms, and a chest x-ray was unremarkable. A month ago, he started isoniazid therapy with pyridoxine supplementation. Currently, temperature is 38.3&deg;C (100.9 &deg;F). On physical examination, there is mild abdominal discomfort. Laboratory studies are pending. Which of the following is the most likely cause of this patient's current symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>This patient with latent tuberculosis infection (positive tuberculin skin test, no symptoms, unremarkable chest x-ray) was started on isoniazid (INH) therapy and now has fever, anorexia, and nausea.</li>\r\n<li>INH is directly hepatotoxic. In 10% - 20% of patients, it causes acute, mild hepatic dysfunction, characterized by transient increases in serum aminotransferases (AST/SGOT, ALT/SGPT). This adverse effect usually occurs during the first 4-6 months of treatment, and, in most cases, liver function tests return to baseline with continued INH therapy.</li>\r\n<li>In rare instances (<1%), frank hepatitis (similar to viral hepatitis with fever, anorexia, nausea, jaundice) can occur (as seen in this patient) and sometimes evolves into a severe form with progressive liver dysfunction and death.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Factitious disorder (Option A):</strong></p>\r\n<p>This is a psychiatric condition in which patients <strong>deliberately produce or feign symptoms</strong> to assume the sick role. It does not explain the temporal relationship between starting isoniazid and the onset of fever, nausea, anorexia, and abdominal discomfort.</p>\r\n<p><strong>Gastric mucosal damage (Option B):</strong></p>\r\n<p>This would be more typical of <strong>NSAIDs</strong> (e.g., aspirin, indomethacin) or alcohol use, leading to epigastric pain and possible bleeding. Isoniazid toxicity is not primarily gastric.</p>\r\n<p><strong>Peripheral nerve damage (Option D):</strong></p>\r\n<p>Isoniazid does cause <strong>peripheral neuropathy</strong> due to pyridoxine (vitamin B6) deficiency. However, this patient is already on <strong>pyridoxine supplementation</strong>, and his presentation (fever, anorexia, abdominal discomfort) is much more consistent with hepatic injury than neuropathy.</p>", "options": ["Factitious disorder", "Gastric mucosal damage", "Hepatocyte damage", "Peripheral nerve damage"], "html_options": ["Factitious disorder", "Gastric mucosal damage", "Hepatocyte damage", "Peripheral nerve damage"], "corr_idx": 2}, {"id": "1332380", "html_qtxt": "Typical adult dose of rifampin?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008d93ea33d-dbf6-43e2-8f4e-831f9c314645.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>300 mg/day (Option A):</strong></p>\r\n<p>This is <strong>too low</strong> for standard adult therapy. Such a dose would be <strong>subtherapeutic</strong>, risking treatment failure and resistance.</p>\r\n<p><strong>25 mg/kg/day (Option B):</strong></p>\r\n<p>This is <strong>much higher</strong> than recommended and would increase the risk of <strong>hepatotoxicity and other adverse effects</strong>.</p>\r\n<p><strong>15 mg/kg/day (Option C):</strong></p>\r\n<p>This corresponds more closely to <strong>pediatric dosing</strong> or weight-based adjustments in children, not typical adult fixed dosing.</p>", "options": ["300 mg/day", "25mg/kg/d", "15mg/kg/d", "600 mg/day"], "html_options": ["300 mg/day", "25mg/kg/d", "15mg/kg/d", "600 mg/day"], "corr_idx": 3}, {"id": "1332381", "html_qtxt": "Which of the following is not mechanism of action of first line agent of tuberculosis?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Interferes with 30s component of ribosome is mechanism of action of Streptomycin , Which is second line drug for tuberculosis.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100899df973e-eea4-4a63-9668-76aaf6d7f132.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Inhibit DNA-dependent RNA polymerase (Option A):</strong></p>\r\n<p>This is the mechanism of <strong>rifampin</strong>, a first-line TB drug.</p>\r\n<p><strong>Decrease synthesis of mycolic acids (Option B):</strong></p>\r\n<p>This is the mechanism of <strong>isoniazid</strong>, another first-line drug.</p>\r\n<p><strong>Decrease carbohydrate polymerization of mycobacterial cell wall (Option D):</strong></p>\r\n<p>This is the mechanism of <strong>ethambutol</strong>, which inhibits arabinosyl transferase.</p>", "options": ["Inhibit DNA-dependent RNA polymerase", "Decrease synthesis of mycolic acids", "Interferes with 30S component of ribosome.", "Decrease carbohydrate polymerization of mycobacterium cell"], "html_options": ["Inhibit DNA-dependent RNA polymerase", "Decrease synthesis of mycolic acids", "Interferes with 30S component of ribosome.", "Decrease carbohydrate polymerization of mycobacterium cell"], "corr_idx": 2}, {"id": "1332382", "html_qtxt": "Drug use in initial treatment of mycobacterium Avium?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Initial regimen for mycobacterium avium:</li>\r\n<li>At least two-antimycobacterial drugs; preferred agents include: Macrolide: clarithromycin (first-line) OR azithromycin AND ethambutol</li>\r\n</ul>", "options": ["Clarithromycin or Azithromycin", "Ethambutol", "A & B Both", "None of the above"], "html_options": ["Clarithromycin or Azithromycin", "Ethambutol", "A & B Both", "None of the above"], "corr_idx": 2}, {"id": "1332384", "html_qtxt": "Which of the following is not an indication of using rifabutin/fluroquinolones in patient having mycobacterium avium infection?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Initial regimen for mycobacterium avium:\r\n<ul>\r\n<li>At least two-antimycobacterial drugs; preferred agents include:</li>\r\n</ul>\r\n</li>\r\n<li>Macrolide: clarithromycin (first-line) ORazithromycin AND ethambutol</li>\r\n<li>Optional third and fourth drugs<sup>[1]</sup></li>\r\n<li>Consider in patients with any of the following:\r\n<ul>\r\n<li>A high risk of mortality (e.g., CD4 count< 50)</li>\r\n<li>Drug resistance</li>\r\n<li>High mycobacterialload</li>\r\n<li>Inadequate response to ART</li>\r\n</ul>\r\n</li>\r\n<li>Agents (any of the following):\r\n<ul>\r\n<li>Rifabutin</li>\r\n<li>Fluoroquinolone: levofloxacin or moxifloxacin</li>\r\n<li>Injectable agent: amikacin or streptomycin</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>High risk of mortality (Option A):</strong></p>\r\n<p>Rifabutin or fluoroquinolones are indicated in <strong>patients with advanced immunosuppression (CD4 < 50)</strong> to reduce the risk of severe MAC disease.</p>\r\n<p><strong>Drug resistance (Option B):</strong></p>\r\n<p>These drugs are considered when there is <strong>resistance to first-line MAC therapy</strong>, making them valid indications.</p>\r\n<p><strong>Inadequate response to ART (Option C):</strong></p>\r\n<p>Rifabutin or fluoroquinolones may be added if <strong>ART alone does not control MAC infection</strong>.</p>", "options": ["A high risk of mortality (e.g., CD4 count < 50)", "Drug resistance", "Inadequate response to ART", "None of the above"], "html_options": ["A high risk of mortality (e.g., CD4 count < 50)", "Drug resistance", "Inadequate response to ART", "None of the above"], "corr_idx": 3}, {"id": "1332386", "html_qtxt": "57-year-old female having tuberculosis comes to the clinic with complain of tinnitus, vertigo. She was on second line drug of anti-tuberculosis because of resistant to some of the first line drug. which of the following is mechanism of action of drug causing patients symptoms?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Below are second line drugs use in treatment of tuberculosis.</li>\r\n<li>Tinnitus, vertigo, ataxia, nephrotoxicity are side effect of streptomycin.</li>\r\n<li>Mechanism of action of streptomycin: Interferes with 30S component of ribosome</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100869ac1a2c-b252-417b-9287-81913381ed94.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Topoisomerase II inhibition (Option B):</strong></p>\r\n<p>Refers to <strong>fluoroquinolones</strong>, which inhibit bacterial DNA gyrase. These do not typically cause <strong>ototoxicity</strong> (tinnitus, vertigo).</p>\r\n<p><strong>50S subunit binding (Option C):</strong></p>\r\n<p>Refers to <strong>macrolides or chloramphenicol</strong>, which inhibit protein synthesis at the 50S subunit. These are not typically associated with <strong>vestibular toxicity</strong>.</p>\r\n<p><strong>None of the above (Option D):</strong></p>\r\n<p>This is incorrect because the patient's symptoms are explained by the known mechanism of <strong>aminoglycosides</strong> (second-line TB drugs like streptomycin, amikacin, kanamycin).</p>", "options": ["Interferes with 30S component of ribosome", "Inhibit prokaryotic enzymes topoisomerase II (DNA gyrase)", "Inhibit protein synthesis by binding to 50S subunit", "None of the above"], "html_options": ["Interferes with 30S component of ribosome", "Inhibit prokaryotic enzymes topoisomerase II (DNA gyrase)", "Inhibit protein synthesis by binding to 50S subunit", "None of the above"], "corr_idx": 0}, {"id": "1332389", "html_qtxt": "Rifampicin increase elimination of all of the following drugs except?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Rifampin strongly induces most cytochrome P450 isoforms (CYP1A2, 2C9, 2C19, 2D6, and 3A4), which increases the elimination of numerous other drugs including methadone, anticoagulants, cyclosporine, some anticonvulsants, protease inhibitors, some nonnucleoside reverse transcriptase inhibitors or integrase strand transfer inhibitors, contraceptives, and a host of others.</li>\r\n</ul>\r\n<p>Coadministration of rifampin results in significantly lower serum levels of these drugs.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Methadone (Option A):</strong></p>\r\n<p>Rifampicin induces <strong>hepatic cytochrome P450 enzymes</strong>, increasing the metabolism of methadone and potentially leading to withdrawal symptoms.</p>\r\n<p><strong>Cyclosporine (Option B):</strong></p>\r\n<p>Rifampicin <strong>induces CYP3A4</strong>, reducing cyclosporine plasma concentrations and risking transplant rejection if not adjusted.</p>\r\n<p><strong>Anticoagulants (Option C):</strong></p>\r\n<p>Rifampicin <strong>accelerates metabolism of warfarin</strong> via CYP induction, decreasing its anticoagulant effect.</p>", "options": ["Methadone", "Cyclosporine", "Anticoagulants", "Captopril"], "html_options": ["Methadone", "Cyclosporine", "Anticoagulants", "Captopril"], "corr_idx": 3}, {"id": "1332390", "html_qtxt": "If a protease inhibitor-based antiretroviral regimen is used to treat his HIV, Then which of the following anti-tuberculosis drug should be avoided?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>If a protease inhibitor-based antiretroviral regimen is used to treat his HIV, rifabutin should replace rifampin because of the serious drug interactions between rifampin and protease inhibitors.</li>\r\n<li>If dolutegravir is chosen, it must be administered twice daily due to the interaction with rifampin; alternatively, rifabutin can be used in place of rifampin, and dolutegravir can be dosed once daily.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Isoniazid (Option B):</strong></p>\r\n<p>Safe to use with protease inhibitors; <strong>no significant CYP450 interaction</strong>.</p>\r\n<p><strong>Ethambutol (Option C):</strong></p>\r\n<p>Safe to use; it is primarily renally excreted and does <strong>not interact significantly</strong> with protease inhibitors.</p>\r\n<p><strong>Rifabutin (Option D):</strong></p>\r\n<p>Can be used as an alternative to rifampin in patients on protease inhibitors; dose adjustment may be required, but it <strong>does not cause the severe drug-drug interactions</strong> seen with rifampin.</p>", "options": ["Rifampin", "Isoniazid", "Ethambutol", "Rifabutin"], "html_options": ["Rifampin", "Isoniazid", "Ethambutol", "Rifabutin"], "corr_idx": 0}, {"id": "1332392", "html_qtxt": "Which of the following first line anti-tubercular drug is not having only hepatic clearance and dose need to be reduced in patient with renal failure?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Rifampin, Isoniazid and Pyrazinamide are cleared by only liver. Ethambutol has mixed clearance (liver and renal) and dose should be reduced in patient with renal failure.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100843f3c7a4-e900-42ed-b3f5-d85a89749740.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Rifampin (Option A):</strong></p>\r\n<p>Almost entirely hepatically metabolized, minimal renal excretion. Dose adjustment is not required in renal failure.</p>\r\n<p><strong>Isoniazid (Option B):</strong></p>\r\n<p>Primarily hepatically metabolized via acetylation. Dose adjustment in renal failure is generally not necessary.</p>\r\n<p><strong>Pyrazinamide (Option D):</strong></p>\r\n<p>Mainly hepatically metabolized, although metabolites are renally excreted. In mild-to-moderate renal failure, dose adjustment is usually not required unless severe impairment exists.</p>", "options": ["Rifampin", "Isoniazid", "Ethambutol", "Pyrazinamide"], "html_options": ["Rifampin", "Isoniazid", "Ethambutol", "Pyrazinamide"], "corr_idx": 2}, {"id": "1332393", "html_qtxt": "Which of the following anti-tuberculosis drug is not bactericidal drug?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Bactericidal drugs: A substance that directly kills bacteria.</li>\r\n<li>Bacteriostatic drugs: A substance that stops bacteria from reproducing (does not directly kill bacteria).</li>\r\n<li>Rifampin, Isoniazid and Streptomycin are bactericidal drugs. Where as ethambutol and Pyrazinamide are bacteriostatic drugs.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Rifampin (Option A):</strong></p>\r\n<p><strong>Bactericidal</strong>; inhibits <strong>DNA-dependent RNA polymerase</strong>, leading to rapid killing of actively dividing mycobacteria.</p>\r\n<p><strong>Isoniazid (Option B):</strong></p>\r\n<p><strong>Bactericidal</strong> against rapidly dividing mycobacteria; inhibits <strong>mycolic acid synthesis</strong>.</p>\r\n<p><strong>Streptomycin (Option D):</strong></p>\r\n<p><strong>Bactericidal</strong>; aminoglycoside that binds to the <strong>30S ribosomal subunit</strong>, disrupting protein synthesis.</p>", "options": ["Rifampin", "Isoniazid", "Ethambutol", "Streptomycin"], "html_options": ["Rifampin", "Isoniazid", "Ethambutol", "Streptomycin"], "corr_idx": 2}, {"id": "1332395", "html_qtxt": "Which of the following anti-tubercular drug contraindicated in pregnancy?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Bactericidal drugs: A substance that directly kills bacteria.</li>\r\n<li>Bacteriostatic drugs: A substance that stops bacteria from reproducing (does not directly kill bacteria).</li>\r\n<li>Rifampin, Isoniazid and Streptomycin are bactericidal drugs. Where as ethambutol and Pyrazinamide are bacteriostatic drugs.</li>\r\n</ul>\r\n<p>The following antituberculosis drugs are contraindicated in pregnant women:</p>\r\n<ul>\r\n<li>Streptomycin</li>\r\n<li>Kanamycin</li>\r\n<li>Amikacin</li>\r\n<li>Capreomycin</li>\r\n<li>Fluoroquinolones</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Rifampin (Option A):</strong></p>\r\n<p>Can be used in pregnancy if indicated. May slightly increase the risk of <strong>hemorrhagic disorders in the newborn</strong> due to vitamin K depletion, but not an absolute contraindication.</p>\r\n<p><strong>Isoniazid (Option B):</strong></p>\r\n<p>Safe in pregnancy; <strong>pyridoxine supplementation</strong> is recommended to prevent neuropathy.</p>\r\n<p><strong>Ethambutol (Option C):</strong></p>\r\n<p>Considered <strong>safe in pregnancy</strong>, with no significant teratogenicity reported.</p>", "options": ["Rifampin", "Isoniazid", "Ethambutol", "Streptomycin"], "html_options": ["Rifampin", "Isoniazid", "Ethambutol", "Streptomycin"], "corr_idx": 3}, {"id": "1332396", "html_qtxt": "Isoniazid is inducer of:", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Isoniazid:</strong></p>\r\n<ul>\r\n<li>Both inducer and inhibitor.</li>\r\n<li>Potent inhibitor of CYP2C19, CYP3A.</li>\r\n<li>Weak inhibitor of CYP2D6.</li>\r\n<li>Inducer of CYP2E1</li>\r\n<li>Other drugs metabolised by CYP2E1 are Paracetamol and Ethanol.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>CYP2D1 (Option A):</strong></p>\r\n<p>This isoenzyme is primarily involved in metabolism of drugs like <strong>beta-blockers and antidepressants</strong>; <strong>isoniazid does not significantly induce it</strong>.</p>\r\n<p><strong>CYP2C19 (Option C):</strong></p>\r\n<p>Metabolizes <strong>proton pump inhibitors and some antiepileptics</strong>; isoniazid does <strong>not induce</strong> this enzyme.</p>\r\n<p><strong>CYP2D6 (Option D):</strong></p>\r\n<p>Metabolizes <strong>opioids, antidepressants, and beta-blockers</strong>; isoniazid is <strong>not an inducer</strong> of CYP2D6.</p>", "options": ["CYP2D1", "CYP2E1", "CYP2C19", "CYP2D6"], "html_options": ["CYP2D1", "CYP2E1", "CYP2C19", "CYP2D6"], "corr_idx": 1}, {"id": "1332397", "html_qtxt": "Daily Dose of pyrazinamide in treatment of tuberculosis?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008403d8977-98cf-4795-a2d6-45e5407faf13.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>5 mg/kg (Option A):</strong></p>\r\n<p>Too low; would be <strong>subtherapeutic</strong>, risking treatment failure and resistance.</p>\r\n<p><strong>10 mg/kg (Option B):</strong></p>\r\n<p>Insufficient for effective <strong>bactericidal activity</strong> against Mycobacterium tuberculosis.</p>\r\n<p><strong>15 mg/kg (Option C):</strong></p>\r\n<p>ed <strong>daily dose</strong>, not optimal for standard treatment regimens.</p>", "options": ["5 mg/ Kg body weight", "10 mg/ Kg body weight", "15 mg/ Kg body weight", "25 mg/ Kg body weight"], "html_options": ["5 mg/ Kg body weight", "10 mg/ Kg body weight", "15 mg/ Kg body weight", "25 mg/ Kg body weight"], "corr_idx": 3}, {"id": "1332398", "html_qtxt": "Which of the following Anti-Tubercular Drug causing Neuro-Psychiatric Side effect?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Cycloserine is associated with Neuro-Psychiatric Side effect.</p>\r\n<p>Adverse effect of 2<sup>nd</sup>&nbsp;line Anti-Tubercular Drug:</p>\r\n<ul>\r\n<li>Thioacetazone (tuberculostatic drug): Hepatitis, bone marrow suppression and Steven Johnson syndrome.</li>\r\n<li>Para amino salicylic acid (PAS) can cause kidney, liver and thyroid dysfunction.</li>\r\n<li>Ethionamide can cause hepatitis, optic neuritis and hypothyroidism.</li>\r\n<li>Cycloserine can cause neuropsychiatric adverse effects.</li>\r\n<li>Kanamycin, Amikacin and Capreomycin can cause ototoxicity, nephrotoxicity, hypokalemia and hypomagnesemia.</li>\r\n<li>Rifabutin commonly causes gastrointestinal adverse effects. Rarely, it can cause anterior uveitis, clostridium difficile-associated diarrhea, diffuse polymyalgia syndrome, yellow skin discoloration (Pseudo-jaundice) and pancytopenia.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Para-aminosalicylic acid (PAS) (Option B):</strong></p>\r\n<p>Mainly causes <strong>gastrointestinal upset</strong> (nausea, diarrhea) and <strong>hypersensitivity reactions</strong>, not neuropsychiatric symptoms.</p>\r\n<p><strong>Thioacetazone (Option C):</strong></p>\r\n<p>Known for <strong>cutaneous reactions</strong> and <strong>hepatotoxicity</strong>, but <strong>neuropsychiatric side effects are rare</strong>.</p>\r\n<p><strong>Ethionamide (Option D):</strong></p>\r\n<p>Can cause <strong>hepatotoxicity, gastrointestinal upset, and peripheral neuropathy</strong>, but <strong>psychiatric manifestations are uncommon</strong>.</p>", "options": ["Cycloserine", "Para amino salicylic acid (PAS)", "Thioacetazone", "Ethionamide"], "html_options": ["Cycloserine", "Para amino salicylic acid (PAS)", "Thioacetazone", "Ethionamide"], "corr_idx": 0}, {"id": "1332399", "html_qtxt": "MDR-TB defined as:", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>(H- ISONIAZID, R- RIFAMPIN, Z- PYRAZINAMIDE, E- ETHAMBUTOL, FQ- FLUROQUINOLONES)</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008e91eb363-cce4-4271-9329-dccb0feb4511.png\">\r\n<p><strong>Explanation of Incorrect Options:</strong></p>\r\n<p><strong>Resistance to any one of H, Z, and E (Option A):</strong></p>\r\n<p>This describes <strong>mono-resistance</strong>, not multidrug resistance.</p>\r\n<p><strong>Resistance to any two or all three of H, Z, and E (Option B):</strong></p>\r\n<p>Partial resistance may include <strong>poly-resistance</strong>, but MDR-TB specifically requires <strong>isoniazid and rifampin resistance</strong>.</p>\r\n<p><strong>Resistance to H and R + any of FQ + any of injections (Option D):</strong></p>\r\n<p>This defines <strong>XDR-TB (extensively drug-resistant TB)</strong>, which is beyond MDR-TB.</p>", "options": ["Resistance to any one of H, Z and E", "Resistance to any two or all 3 of H, Z and E", "Resistance to H and R", "Resistance to H and R + any of FQ + any of injections"], "html_options": ["Resistance to any one of H, Z and E", "Resistance to any two or all 3 of H, Z and E", "Resistance to H and R", "Resistance to H and R + any of FQ + any of injections"], "corr_idx": 2}, {"id": "1332400", "html_qtxt": "Which of the following drug is ineffective in treatment of type 2 lepra reaction?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>All of the drug mentioned in options are effective in treatment of type 2 lepra reaction.</li>\r\n</ul>\r\n<p>[ TT- Tuberculoid Leprosy, LL- Lepromatous Leprosy, Borderline Forms (BT, BB, BL) are between the two ends of the spectrum (TT and LL).]</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20251008f6881bb0-f1ea-4622-bf82-5a19ff3e3bfe.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Corticosteroid (Option A):</strong></p>\r\n<p>Effective in <strong>suppressing inflammation and pain</strong> in type 2 lepra reactions.</p>\r\n<p><strong>Clofazimine (Option B):</strong></p>\r\n<p>Has <strong>anti-inflammatory properties</strong>; used in <strong>prolonged therapy to prevent recurrent ENL episodes</strong>.</p>\r\n<p><strong>Thalidomide (Option C):</strong></p>\r\n<p>Highly effective in <strong>type 2 lepra reactions</strong>, particularly in <strong>severe or corticosteroid-resistant cases</strong>.</p>", "options": ["Corticosteroid", "Clofazimine", "Thalidomide", "None of the above"], "html_options": ["Corticosteroid", "Clofazimine", "Thalidomide", "None of the above"], "corr_idx": 3}, {"id": "1332401", "html_qtxt": "Which of the following best drug for slowly multiplying bacteria?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202510082edb0ae1-fd2f-47fe-b84a-53ba6128da6e.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Isoniazid (Option A):</strong></p>\r\n<p>Highly <strong>bactericidal against rapidly dividing mycobacteria</strong>, but less effective against dormant or slowly replicating bacteria.</p>\r\n<p><strong>Rifampicin (Option B):</strong></p>\r\n<p>Bactericidal against <strong>both rapidly and semi-dormant bacteria</strong>, but <strong>less selective for acidic environments</strong>compared to pyrazinamide.</p>\r\n<p><strong>Ethambutol (Option D):</strong></p>\r\n<p><strong>Bacteriostatic</strong>, mainly prevents cell wall synthesis, not particularly active against slowly multiplying or dormant bacilli.</p>", "options": ["Isoniazid", "Rifampicin", "Pyrazinamide", "Ethambutol"], "html_options": ["Isoniazid", "Rifampicin", "Pyrazinamide", "Ethambutol"], "corr_idx": 2}, {"id": "1332402", "html_qtxt": "Which of the following Anti-Tubercular Drug have maximum CSF \r\nPenetration?\r\n", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p>Isoniazid has maximum CSF penetration. And Streptomycin has minimum CSF penetration.</p>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Rifampicin (Option B):</strong></p>\r\n<p>Penetrates the CSF <strong>moderately</strong>, especially when meninges are inflamed, but less than isoniazid.</p>\r\n<p><strong>Pyrazinamide (Option C):</strong></p>\r\n<p>Good CSF penetration, but still <strong>slightly less than isoniazid</strong>, especially in non-inflamed meninges.</p>\r\n<p><strong>Streptomycin (Option D):</strong></p>\r\n<p>Poor CSF penetration; generally <strong>ineffective for CNS TB</strong> unless meninges are inflamed.</p>", "options": ["Isoniazid", "Rifampicin", "Pyrazinamide", "Streptomycin"], "html_options": ["Isoniazid", "Rifampicin", "Pyrazinamide", "Streptomycin"], "corr_idx": 0}, {"id": "1332403", "html_qtxt": "Which of the following drug used as 'sterilizing' agent which is active against residual intracellular organisms that may cause relapse?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Pyrazinamide is an important front-line drug used in conjunction with isoniazid and rifampin in short-course (i.e., 6-month) regimens as a &ldquo;sterilizing&rdquo; agent active against residual intracellularorganisms that may cause relapse.</li>\r\n<li>Tubercle bacilli develop resistance to pyrazinamide fairly readily, but there is no cross-resistance with isoniazid or other antimycobacterial drugs.</li>\r\n</ul>\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Isoniazid (Option A):</strong></p>\r\n<p>Highly <strong>bactericidal against rapidly dividing mycobacteria</strong>, but less effective against <strong>dormant or slowly multiplying bacilli</strong>, so not the primary sterilizing agent.</p>\r\n<p><strong>Rifampicin (Option B):</strong></p>\r\n<p>Bactericidal and effective against <strong>intracellular bacteria</strong>, but pyrazinamide is considered <strong>more effective as a sterilizing agent in acidic environments</strong>.</p>\r\n<p><strong>Streptomycin (Option D):</strong></p>\r\n<p>Bactericidal aminoglycoside; primarily active against <strong>extracellular organisms</strong>, poor intracellular activity, and not considered a sterilizing agent.</p>", "options": ["Isoniazid", "Rifampicin", "Pyrazinamide", "Streptomycin"], "html_options": ["Isoniazid", "Rifampicin", "Pyrazinamide", "Streptomycin"], "corr_idx": 2}, {"id": "1332404", "html_qtxt": "Type 1 & 2 lepra reaction treated with?", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li>Treatment of choice for type 1 as well as type 2 lepra reaction is corticosteroids.</li>\r\n<li>For severe reaction, prednisolone 40-60mg/day is started immediately and continued till the reaction subsides.</li>\r\n<li>The dose is then tapered over 2-3 months.</li>\r\n<li>For resistant cases of Erythema nodosum leprosum drug of choice is thalidomide.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025100895fe0c11-b180-448d-bb90-ea4b4e435c69.png\">\r\n<p><strong>Explanation of Incorrect Options: </strong></p>\r\n<p><strong>Dapsone (Option B):</strong></p>\r\n<p>Primary drug for <strong>multibacillary leprosy</strong>, but <strong>does not control the inflammatory reactions</strong> seen in type 1 or type 2 lepra reactions.</p>\r\n<p><strong>Minocycline (Option C):</strong></p>\r\n<p>Has <strong>antimicrobial activity against Mycobacterium leprae</strong>, but <strong>not indicated for acute lepra reactions</strong>.</p>\r\n<p><strong>Rifampicin (Option D):</strong></p>\r\n<p>Bactericidal against <strong>Mycobacterium leprae</strong>, part of MDT (multidrug therapy), but <strong>does not treat the immunologic reactions</strong>.</p>", "options": ["Corticosteroid", "Dapsone", "Minocycline", "Rifampicin"], "html_options": ["Corticosteroid", "Dapsone", "Minocycline", "Rifampicin"], "corr_idx": 0}, {"id": "1332405", "html_qtxt": "Which of the following drug given supervised as per national leprosy elimination programme? <br>\r\ni) Rifampicin 600 mg once a month<br>\r\nii) Clofazimine 300 mg once a month<br>\r\niii) Dapsone 100 mg daily<br>\r\niv) Clofazimine 50 mg daily\r\n", "html_expl": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Under NLEP</strong></p>\r\n<ul>\r\n<li>Rifampicin and Clofazimine are given under supervision for both Multibacillary and Paucibacillary Leprosy.</li>\r\n<li>Rifampicin is given 600 mg once a month under supervision.</li>\r\n<li>Clofazimine is given 300 mg once a month under supervision and 50 mg daily unsupervised for 28 days.</li>\r\n<li>Dapsone is given 100 mg once daily unsupervised for 28 days.</li>\r\n<li>Multibacillary Leprosy is treated for 12 months and Paucibacillary Leprosy for 6 months.</li>\r\n</ul>\r\n<p><strong>Under RNTCP, DOTS:</strong></p>\r\n<ul>\r\n<li>Rifampicin, Isoniazid, Pyrazinamide and Ethambutol are administered under supervision.</li>\r\n</ul>\r\n<p><strong>Explanation fo Incorrect Options: </strong></p>\r\n<p><strong>Dapsone 100 mg daily (Option iii):</strong></p>\r\n<p>Taken <strong>daily by the patient at home</strong>, not under supervision.</p>\r\n<p><strong>Clofazimine 50 mg daily (Option iv):</strong></p>\r\n<p>Also taken <strong>daily at home</strong>, not part of the supervised monthly doses.</p>\r\n<p><strong>Option A (i, ii, iii, iv):</strong></p>\r\n<p>Incorrect because <strong>daily doses are not supervised</strong>; only <strong>monthly doses of rifampicin and clofazimine</strong> are supervised.</p>\r\n<p><strong>Option D (i only):</strong></p>\r\n<p>Incorrect because <strong>supervised monthly clofazimine</strong> is also included in the regimen.</p>", "options": ["i), ii), iii), iv)", "i), ii), iii)", "i), ii)", "i)"], "html_options": ["i), ii), iii), iv)", "i), ii), iii)", "i), ii)", "i)"], "corr_idx": 2}]}]}]}]};

    const navListEl = document.getElementById('nav-list');
    const questionsContainerEl = document.getElementById('questions-container');
    const totalQCountEl = document.getElementById('total-q-count');
    const themeToggleBtn = document.getElementById('theme-toggle');
    const progressBar = document.getElementById('progress-bar');
    const breadcrumbEl = document.getElementById('breadcrumb');

    let currentModuleData = null;
    let markedQuestions = new Set();
    let attemptedQuestions = new Set();

    // --- Theme Toggle ---
    themeToggleBtn.addEventListener('click', () => {
        document.body.classList.toggle('dark-mode');
        const isDarkMode = document.body.classList.contains('dark-mode');
        themeToggleBtn.innerHTML = isDarkMode ? '<i class="fas fa-sun"></i>' : '<i class="fas fa-moon"></i>';
        localStorage.setItem('darkMode', isDarkMode);
    });

    function updateProgress() {
        if (!currentModuleData || currentModuleData.id === 'marked') {
            progressBar.style.width = '0%';
            return;
        }
        const total = currentModuleData.questions.length;
        const attempted = attemptedQuestions.size;
        const percentage = total > 0 ? (attempted / total) * 100 : 0;
        progressBar.style.width = `${percentage}%`;
    }

    function updateBreadcrumb(items) {
        breadcrumbEl.innerHTML = '';
        items.forEach((item, index) => {
            const span = document.createElement('span');
            span.className = 'breadcrumb-item';
            span.textContent = item;
            breadcrumbEl.appendChild(span);
        });
    }

    function setupQuestionInteractivity() {
        document.querySelectorAll('.options-list').forEach(list => {
            const correctIndex = parseInt(list.dataset.correctIndex, 10);
            const options = list.querySelectorAll('li');
            const uniqueId = list.dataset.uniqueQId; 
            const card = list.closest('.card');
            const explanationContainer = card.querySelector('.explanation-container');
            const explanationEl = explanationContainer.querySelector('.explanation');
            const showBtn = explanationContainer.querySelector('.show-explanation-btn');
            const markBtn = card.querySelector('.mark-review-btn');

            options.forEach((li, index) => {
                li.addEventListener('click', () => {
                    if (li.classList.contains('locked')) return;
                    
                    options.forEach(opt => opt.classList.add('locked'));
                    attemptedQuestions.add(uniqueId);
                    updateProgress();
                    
                    if (index === correctIndex) {
                        li.classList.add('user-correct');
                    } else {
                        li.classList.add('user-incorrect');
                    }

                    options[correctIndex].classList.add('correct-reveal');
                    
                    if (showBtn) showBtn.style.display = 'inline-block';
                });
            });

            if (showBtn) {
                showBtn.addEventListener('click', () => {
                    const isVisible = explanationEl.style.display === 'block';
                    explanationEl.style.display = isVisible ? 'none' : 'block';
                    showBtn.textContent = isVisible ? 'Show Explanation' : 'Hide Explanation';
                    if (!isVisible) {
                        explanationEl.scrollIntoView({ behavior: 'smooth', block: 'center' });
                    }
                });
            }

            if (markBtn) {
                markBtn.addEventListener('click', () => {
                    if (markedQuestions.has(uniqueId)) {
                        markedQuestions.delete(uniqueId);
                        markBtn.classList.remove('marked');
                        markBtn.textContent = 'Mark for Review';
                    } else {
                        markedQuestions.add(uniqueId);
                        markBtn.classList.add('marked');
                        markBtn.textContent = 'Marked';
                    }
                    updateMarkedCount();
                });
            }
        });

        if (window.MathJax) {
            MathJax.Hub.Queue(["Typeset", MathJax.Hub, questionsContainerEl]);
        }
    }
    
    function updateMarkedCount() {
        const markedLink = document.getElementById('nav-link-marked');
        if (markedLink) {
            markedLink.querySelector('.nav-count').textContent = markedQuestions.size;
        }
    }

    function renderQuestions(questions, title, breadcrumbItems) {
        if (!questions || questions.length === 0) {
            questionsContainerEl.innerHTML = `<p>No questions found for this view.</p>`;
            updateProgress();
            return;
        }

        updateBreadcrumb(breadcrumbItems);

        let html = '';
        questions.forEach((q, i) => {
            const uniqueId = q.uniqueId;
            const isMarked = markedQuestions.has(uniqueId);
            const correctLabel = String.fromCharCode(65 + (q.corr_idx || 0));
            const optionsHtml = q.html_options.map((opt, idx) => `
                <li>
                    <span class="option-label">${String.fromCharCode(65 + idx)}</span>
                    <span>${opt}</span>
                </li>
            `).join('');

            html += `
                <div class="card">
                    <div class="question-header">
                        <div class="question-number">Question ${i + 1}</div>
                        <button class="mark-review-btn ${isMarked ? 'marked' : ''}" data-unique-q-id="${uniqueId}">${isMarked ? 'Marked' : 'Mark for Review'}</button>
                    </div>
                    <div class="question-text">${q.html_qtxt}</div>
                    <ul class="options-list" data-correct-index="${q.corr_idx}" data-unique-q-id="${uniqueId}">
                        ${optionsHtml}
                    </ul>
                    <div class="explanation-container">
                        <button class="show-explanation-btn" style="display: none;">Show Explanation</button>
                        <div class="explanation">
                            <p class="correct-answer-label">Correct Answer: ${correctLabel}</p>
                            ${q.html_expl}
                        </div>
                    </div>
                </div>
            `;
        });

        questionsContainerEl.innerHTML = html;
        setupQuestionInteractivity();
        updateProgress();
    }

    function renderModule(categoryId, subjectId, moduleId) {
        let questionsToRender = [];
        let moduleName = '';
        let breadcrumbItems = ['Home'];

        if (moduleId === 'marked') {
            moduleName = 'Marked for Review';
            breadcrumbItems.push('Marked for Review');
            
            COURSE_DATA.categories.forEach(cat => {
                cat.subjects.forEach(sub => {
                    sub.modules.forEach(mod => {
                        mod.questions.forEach((q, i) => {
                            const potentialUniqueId = `${cat.categoryId}-${sub.subjectId}-${mod.moduleId}-${q.id || i}`;
                            if (markedQuestions.has(potentialUniqueId)) {
                                questionsToRender.push({ 
                                    ...q, 
                                    uniqueId: potentialUniqueId,
                                    _categoryId: cat.categoryId,
                                    _subjectId: sub.subjectId,
                                    _moduleId: mod.moduleId,
                                    _originalIndex: i 
                                });
                            }
                        });
                    });
                });
            });
            currentModuleData = { id: 'marked', name: moduleName, questions: questionsToRender };
        } else {
            let module = null;
            let categoryName = '';
            let subjectName = '';
            
            for (const cat of COURSE_DATA.categories) {
                if (cat.categoryId === categoryId) {
                    categoryName = cat.name;
                    breadcrumbItems.push(cat.name);
                    
                    for (const sub of cat.subjects) {
                        if (sub.subjectId === subjectId) {
                            subjectName = sub.name;
                            breadcrumbItems.push(subjectName);
                            
                            module = sub.modules.find(m => m.moduleId === moduleId);
                            if (module) {
                                moduleName = module.name;
                                breadcrumbItems.push(moduleName);
                                break;
                            }
                        }
                    }
                    if (module) break;
                }
            }
            
            if (!module) {
                questionsContainerEl.innerHTML = '<p>Error: Module not found.</p>';
                currentModuleData = null;
                return;
            }
            
            questionsToRender = module.questions.map((q, i) => ({
                ...q,
                uniqueId: `${categoryId}-${subjectId}-${moduleId}-${q.id || i}`
            }));
            
            currentModuleData = {
                id: moduleId,
                name: moduleName,
                questions: questionsToRender
            };
        }
        
        // Update active state in sidebar
        document.querySelectorAll('.nav-link').forEach(link => link.classList.remove('active'));
        const activeLink = document.getElementById(`nav-link-${moduleId}`);
        if (activeLink) activeLink.classList.add('active');

        renderQuestions(questionsToRender, moduleName, breadcrumbItems);
    }

    function renderSubject(categoryId, subjectId) {
        let questionsToRender = [];
        let subjectName = '';
        let breadcrumbItems = ['Home'];
        
        for (const cat of COURSE_DATA.categories) {
            if (cat.categoryId === categoryId) {
                breadcrumbItems.push(cat.name);
                
                for (const sub of cat.subjects) {
                    if (sub.subjectId === subjectId) {
                        subjectName = sub.name;
                        breadcrumbItems.push(subjectName);
                        
                        sub.modules.forEach(mod => {
                            mod.questions.forEach((q, i) => {
                                questionsToRender.push({
                                    ...q,
                                    uniqueId: `${categoryId}-${subjectId}-${mod.moduleId}-${q.id || i}`,
                                    moduleName: mod.name
                                });
                            });
                        });
                        break;
                    }
                }
                break;
            }
        }
        
        // Update active state in sidebar
        document.querySelectorAll('.nav-link').forEach(link => link.classList.remove('active'));
        const activeLink = document.getElementById(`nav-link-subject-${subjectId}`);
        if (activeLink) activeLink.classList.add('active');
        
        currentModuleData = {
            id: `subject-${subjectId}`,
            name: subjectName,
            questions: questionsToRender
        };
        
        renderQuestions(questionsToRender, subjectName, breadcrumbItems);
    }

    function buildNavigation() {
        navListEl.innerHTML = '';
        
        // Add "Marked for Review" link
        const markedItem = document.createElement('li');
        markedItem.className = 'nav-item';
        markedItem.innerHTML = `
            <div class="nav-link" id="nav-link-marked">
                <i class="fas fa-star nav-icon"></i>
                <span class="nav-text">Marked for Review</span>
                <span class="nav-count">0</span>
            </div>
        `;
        markedItem.querySelector('.nav-link').addEventListener('click', () => renderModule(null, null, 'marked'));
        navListEl.appendChild(markedItem);
        
        COURSE_DATA.categories.forEach(category => {
            const categoryItem = document.createElement('li');
            categoryItem.className = 'nav-item category-item';
            
            const categoryLink = document.createElement('div');
            categoryLink.className = 'nav-link';
            categoryLink.innerHTML = `
                <i class="fas fa-folder nav-icon"></i>
                <span class="nav-text">${category.name}</span>
                <i class="fas fa-chevron-right expand-icon"></i>
            `;
            
            const subNav = document.createElement('div');
            subNav.className = 'sub-nav';
            
            category.subjects.forEach(subject => {
                const subjectItem = document.createElement('li');
                subjectItem.className = 'nav-item subject-item';
                
                const subjectLink = document.createElement('div');
                subjectLink.className = 'nav-link';
                subjectLink.id = `nav-link-subject-${subject.subjectId}`;
                subjectLink.innerHTML = `
                    <i class="fas fa-book nav-icon"></i>
                    <span class="nav-text">${subject.name}</span>
                    <i class="fas fa-chevron-right expand-icon"></i>
                `;
                
                const moduleNav = document.createElement('div');
                moduleNav.className = 'sub-nav';
                
                let subjectQuestionCount = 0;
                
                subject.modules.forEach(module => {
                    subjectQuestionCount += module.questions.length;
                    
                    const moduleItem = document.createElement('li');
                    moduleItem.className = 'nav-item module-item';
                    
                    const moduleLink = document.createElement('div');
                    moduleLink.className = 'nav-link';
                    moduleLink.id = `nav-link-${module.moduleId}`;
                    moduleLink.innerHTML = `
                        <i class="fas fa-file nav-icon"></i>
                        <span class="nav-text">${module.name}</span>
                        <span class="nav-count">${module.questions.length}</span>
                    `;
                    
                    moduleLink.addEventListener('click', (e) => {
                        e.stopPropagation();
                        renderModule(category.categoryId, subject.subjectId, module.moduleId);
                    });
                    
                    moduleItem.appendChild(moduleLink);
                    moduleNav.appendChild(moduleItem);
                });
                
                // Add question count to subject
                subjectLink.innerHTML = `
                    <i class="fas fa-book nav-icon"></i>
                    <span class="nav-text">${subject.name}</span>
                    <span class="nav-count">${subjectQuestionCount}</span>
                    <i class="fas fa-chevron-right expand-icon"></i>
                `;
                
                subjectLink.addEventListener('click', (e) => {
                    e.stopPropagation();
                    subjectItem.classList.toggle('expanded');
                    renderSubject(category.categoryId, subject.subjectId);
                });
                
                subjectItem.appendChild(subjectLink);
                subjectItem.appendChild(moduleNav);
                subNav.appendChild(subjectItem);
            });
            
            categoryLink.addEventListener('click', (e) => {
                e.stopPropagation();
                categoryItem.classList.toggle('expanded');
            });
            
            categoryItem.appendChild(categoryLink);
            categoryItem.appendChild(subNav);
            navListEl.appendChild(categoryItem);
        });
    }

    function normalizeCourseData(courseData) {
        if (!courseData || !Array.isArray(courseData.categories)) {
            return courseData;
        }

        courseData.categories = courseData.categories.map((category) => {
            const normalizedCategory = { ...category };
            normalizedCategory.subjects = Array.isArray(category.subjects)
                ? category.subjects
                : (category.subjects ? [category.subjects] : []);

            normalizedCategory.subjects = normalizedCategory.subjects.map((subject) => {
                const normalizedSubject = { ...subject };
                normalizedSubject.modules = Array.isArray(subject.modules)
                    ? subject.modules
                    : (subject.modules ? [subject.modules] : []);

                normalizedSubject.modules = normalizedSubject.modules.map((module) => {
                    const normalizedModule = { ...module };
                    normalizedModule.questions = Array.isArray(module.questions)
                        ? module.questions
                        : (module.questions ? [module.questions] : []);
                    return normalizedModule;
                });

                return normalizedSubject;
            });

            return normalizedCategory;
        });

        return courseData;
    }

    function init() {
        normalizeCourseData(COURSE_DATA);

        if (!COURSE_DATA || !COURSE_DATA.categories) {
            questionsContainerEl.innerHTML = '<p>Error: Could not load course data.</p>';
            return;
        }

        const darkModePref = localStorage.getItem('darkMode');
        if (darkModePref === 'true') {
            document.body.classList.add('dark-mode');
            themeToggleBtn.innerHTML = '<i class="fas fa-sun"></i>';
        }

        totalQCountEl.textContent = COURSE_DATA.total_questions;
        
        buildNavigation();
    }

    document.addEventListener('DOMContentLoaded', init);
</script>

</body>
</html>
